(function(){
    window.questionsData = window.questionsData || {
        "stg_2021_questions": {
    "Chapter 1:": {
        "Chapter 1: Good Prescribing and Dispensing Practices": [
            {
                "id": 1,
                "question": "What is the primary purpose of a prescription in healthcare?",
                "choices": [
                    "A. To provide legal documentation of medication orders",
                    "B. To serve as a communication link between prescriber, pharmacist, and patient",
                    "C. To record patient medical history",
                    "D. To track pharmaceutical inventory"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "According to the text, 'Prescription is the link between the prescriber, the pharmacist (or dispenser) and the patient.' It serves as a crucial communication tool ensuring proper medication management.",
                "tags": [
                    "Chapter 3",
                    "prescription_purpose",
                    "communication_link"
                ]
            },
            {
                "id": 2,
                "question": "Which of the following is NOT a component of rational use of medicines?",
                "choices": [
                    "A. Safe medication administration",
                    "B. Effective treatment outcomes",
                    "C. Economic burden reduction",
                    "D. Maximizing pharmaceutical company profits"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Rational use of medicines aims to provide safe, effective, and economic medication through collaborative efforts of prescribers, dispensers, patients, and policymakers. Maximizing pharmaceutical profits is not part of this definition.",
                "tags": [
                    "Chapter 1",
                    "rational_medicine_use",
                    "medicine_management"
                ]
            },
            {
                "id": 3,
                "question": "What is the recommended approach when prescribing medications during pregnancy?",
                "choices": [
                    "A. Avoid all medications unless absolutely necessary",
                    "B. Use only medications proven safe in all trimesters",
                    "C. Weigh benefit-risk ratio before prescribing any medication",
                    "D. Prescribe freely as most drugs don't cross placenta"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The text states that 'Administration of medicines, except those proved safe, in the first trimester is therefore not generally recommended. It is advisable to prescribe no medicine during any stage of pregnancy if possible. This, however, should not preclude the importance of prescribing in life-threatening conditions of the mother. Prior to prescribing any medicine for pregnant women, the benefit risk ratio of the prescriber should be considered.'",
                "tags": [
                    "Chapter 1",
                    "pregnancy_prescribing",
                    "special_populations"
                ]
            },
            {
                "id": 4,
                "question": "Which statement about adverse drug reactions (ADRs) is correct?",
                "choices": [
                    "A. ADRs only occur at toxic doses of medications",
                    "B. ADRs are always predictable extensions of pharmacological effects",
                    "C. ADRs can range from mild to lethal in severity",
                    "D. ADRs are limited to prescribed medications only"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Adverse Drug Reactions (ADRs) are defined as 'a response to a medicine which is noxious and unintended, and which occurs at doses normally used for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological functions.' They can be mild (no intervention required), moderate (switching medicine needed), severe (antidote required), or lethal.",
                "tags": [
                    "Chapter 1",
                    "adverse_drug_reactions",
                    "medication_safety"
                ]
            },
            {
                "id": 5,
                "question": "What is the primary goal of antimicrobial stewardship programs?",
                "choices": [
                    "A. To increase sales of newer antibiotics",
                    "B. To promote judicious use of antimicrobials and preserve their effectiveness",
                    "C. To reduce hospital readmission rates",
                    "D. To minimize laboratory testing costs"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Antimicrobial stewardship (AMS) is defined as 'an organizational or healthcare system-wide approach for promoting and monitoring judicious use of antimicrobials to preserve their future effectiveness.' AMS helps manage inappropriate use of antibiotics.",
                "tags": [
                    "Chapter 1",
                    "antimicrobial_stewardship",
                    "rational_antibiotic_use"
                ]
            },
            {
                "id": 6,
                "question": "Which of the following is a key component of good dispensing practice?",
                "choices": [
                    "A. Dispensing medications in the original manufacturer packaging only",
                    "B. Ensuring the correct medicine is delivered to the right patient in the required dosage",
                    "C. Providing verbal instructions only for medication use",
                    "D. Limiting dispensing to prescription-only medications"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Good Dispensing Practices ensure that 'the correct medicine is delivered to the right patient, in the required dosage and quantities, with clear information, and in package that maintains an acceptable potency and quality of the medicine.'",
                "tags": [
                    "Chapter 1",
                    "dispensing_practices",
                    "patient_safety"
                ]
            },
            {
                "id": 7,
                "question": "What is the recommended frequency for changing intravenous tubing used to administer propofol?",
                "choices": [
                    "A. Every 6 hours",
                    "B. Every 12 hours",
                    "C. Every 24 hours",
                    "D. Every 48 hours"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "According to the text, 'Replace tubing used to administer propofol infusions every 6 to 12 hours, depending on its use, per the manufacturer's direction.'",
                "tags": [
                    "Chapter 1",
                    "intravenous_tubing",
                    "medication_administration"
                ]
            },
            {
                "id": 8,
                "question": "Which population is at highest risk for adverse drug reactions due to physiological changes?",
                "choices": [
                    "A. Adolescents",
                    "B. Pregnant women",
                    "C. Elderly patients",
                    "D. Adult males"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The text mentions that 'Two extreme age groups, i.e., pediatric and geriatric patients, are more susceptible to ADRs due to physiological and pathological factors.' However, among the special populations discussed, pregnant women face significant physiological changes affecting drug metabolism and distribution.",
                "tags": [
                    "Chapter 1",
                    "special_populations",
                    "drug_safety"
                ]
            },
            {
                "id": 9,
                "question": "What is the primary reason for using generic names in prescriptions?",
                "choices": [
                    "A. To promote specific brand loyalty",
                    "B. To ensure cost-effective medication options",
                    "C. To complicate medication tracking",
                    "D. To limit therapeutic alternatives"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Using generic names promotes rational use of medicines by allowing access to affordable alternatives. The text recommends 'using generic names of the medicine(s)' in prescriptions.",
                "tags": [
                    "Chapter 1",
                    "generic_medications",
                    "cost_effectiveness"
                ]
            },
            {
                "id": 10,
                "question": "Which of the following is NOT a standard precaution for infection control?",
                "choices": [
                    "A. Hand hygiene before and after patient contact",
                    "B. Use of personal protective equipment (PPE)",
                    "C. Routine cleaning of equipment and furniture",
                    "D. Administration of broad-spectrum antibiotics for all patients"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Standard precautions include hand hygiene, PPE use, environmental cleaning, and safe disposal of sharps. Prophylactic antibiotic administration is not a standard precaution and contributes to antimicrobial resistance.",
                "tags": [
                    "Chapter 1",
                    "infection_control",
                    "standard_precautions"
                ]
            },
            {
                "id": 11,
                "question": "What is the recommended duration for completing infusion of lipid emulsions?",
                "choices": [
                    "A. Within 12 hours",
                    "B. Within 18 hours",
                    "C. Within 24 hours",
                    "D. Within 36 hours"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The text specifies that 'Complete the infusion of lipid-containing solutions within 24 hours of hanging the solution' and 'Complete the infusion of lipid emulsions alone within 12 hours of hanging the solution.' For lipid emulsions specifically, the recommendation is within 12 hours.",
                "tags": [
                    "Chapter 1",
                    "parenteral_nutrition",
                    "medication_administration"
                ]
            },
            {
                "id": 12,
                "question": "Which factor is most critical when determining the dose of medications for children?",
                "choices": [
                    "A. Chronological age",
                    "B. Body surface area",
                    "C. Weight",
                    "D. Height"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "For pediatric dosing, 'Doses based on surface area are more likely to be correct, which makes it the common approach used for dose estimation of cytotoxic chemotherapeutic agents.' Surface area calculations account for both size and metabolic rate.",
                "tags": [
                    "Chapter 1",
                    "pediatric_dosing",
                    "special_populations"
                ]
            },
            {
                "id": 13,
                "question": "What is the primary goal of patient counseling in pharmacy practice?",
                "choices": [
                    "A. To increase pharmacy revenue",
                    "B. To ensure patients understand their medication regimen",
                    "C. To promote specific pharmaceutical brands",
                    "D. To reduce consultation time"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Patient counseling aims to improve health outcomes by ensuring patients understand how to take their medications correctly. The text emphasizes that 'Effective communication has been shown to improve not only patient satisfaction rates but also other health outcomes.'",
                "tags": [
                    "Chapter 1",
                    "patient_counseling",
                    "health_outcomes"
                ]
            },
            {
                "id": 14,
                "question": "Which of the following is a contraindication for chlorhexidine use in neonatal skin preparation?",
                "choices": [
                    "A. Gestational age less than 26 weeks",
                    "B. Postnatal age less than 2 months",
                    "C. Birth weight less than 1500 grams",
                    "B. Age less than two months"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The text states that 'A 2% chlorhexidine-based preparation is preferred, but there is no recommendation for its use in infants less than two months of age.'",
                "tags": [
                    "Chapter 1",
                    "chlorhexidine_contraindications",
                    "neonatal_care"
                ]
            },
            {
                "id": 15,
                "question": "What is the recommended approach for managing catheter-associated urinary tract infections (CAUTIs)?",
                "choices": [
                    "A. Routinely replace urinary catheters every 72 hours",
                    "B. Use antibiotic-coated catheters for all patients",
                    "C. Remove catheters as soon as possible when no longer clinically indicated",
                    "D. Administer prophylactic antibiotics to all catheterized patients"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The text recommends that 'Remove catheters as soon as possible (preferably in the recovery area or when no longer indicated).' Unnecessary catheterization increases infection risk, and routine replacement or prophylactic antibiotics are not recommended.",
                "tags": [
                    "Chapter 1",
                    "catheter_associated_infections",
                    "urinary_tract_infections"
                ]
            },
            {
                "id": 16,
                "question": "Which statement about drug-drug interactions is correct?",
                "choices": [
                    "A. All drug interactions are harmful and should be avoided",
                    "B. Drug interactions can occur between medications and food/drink",
                    "C. Only prescription medications can interact with each other",
                    "D. Drug interactions are rare and unlikely to affect treatment outcomes"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Drug interactions 'include a reaction between two (or more) drugs or between a drug and a food, drink, or supplement/herbs.' While some interactions are harmful, others may be beneficial, and many common medications can interact with foods or supplements.",
                "tags": [
                    "Chapter 1",
                    "drug_interactions",
                    "medication_safety"
                ]
            },
            {
                "id": 17,
                "question": "What is the minimum information that must be included in a prescription according to standard guidelines?",
                "choices": [
                    "A. Patient's favorite color and hobbies",
                    "B. Generic name, dosage form, strength, directions, and prescriber details",
                    "C. Insurance coverage information",
                    "D. Detailed family medical history"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "A prescription should contain: 'Name, address, age, body weight of the medicine consumer and date of the prescription; Diagnosis; Generic name, dosage form and strength and directions for use of the medicines. The pharmaceutical form (for example ‘tablet’, ‘oral solution’, ‘eye ointment’, ‘cream’) should also be stated.'",
                "tags": [
                    "Chapter 1",
                    "prescription_components",
                    "medication_safety"
                ]
            },
            {
                "id": 18,
                "question": "Which population requires special consideration due to reduced lean body mass and increased fat percentage?",
                "choices": [
                    "A. Adolescent athletes",
                    "B. Pregnant women",
                    "C. Elderly patients",
                    "D. Professional cyclists"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The text notes that 'Aged people have reduced lean body mass, reduced body water, and an increase in fat as a percentage of body mass. There is a decrease in serum albumin, and the ratio of bound to free medicine is significantly changed.' These physiological changes affect drug distribution and metabolism in elderly patients.",
                "tags": [
                    "Chapter 1",
                    "elderly_pharmacokinetics",
                    "special_populations"
                ]
            },
            {
                "id": 19,
                "question": "What is the recommended action when a patient reports an adverse drug reaction?",
                "choices": [
                    "A. Discontinue the medication immediately without investigation",
                    "B. Report the reaction to the Ethiopian Food and Drug Authority (EFDA)",
                    "C. Ignore the report as it may not be related to the medication",
                    "D. Increase the dose to overcome the side effect"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Health professionals have the responsibility 'to report any observed unique adverse reactions from drugs, vaccines or traditional herbal medicine products to Ethiopian Food and Drug Authority (EFDA).' Proper reporting helps monitor drug safety and prevent harm to other patients.",
                "tags": [
                    "Chapter 1",
                    "adverse_reaction_reporting",
                    "patient_safety"
                ]
            },
            {
                "id": 20,
                "question": "Which of the following is a key strategy for preventing catheter-related bloodstream infections (CRBSIs)?",
                "choices": [
                    "A. Routinely replacing central venous catheters every 72 hours",
                    "B. Using femoral vein insertion site for central lines",
                    "C. Removing unnecessary intravascular catheters promptly",
                    "D. Applying topical antibiotic ointments daily at insertion sites"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The text recommends that 'Remove any intravascular catheter that is no longer essential. The risk of infection increases with the duration, increasing after more than three to six days at all catheter sites.' Prompt removal of unnecessary catheters is a key prevention strategy.",
                "tags": [
                    "Chapter 1",
                    "catheter_related_infections",
                    "intravascular_catheters"
                ]
            },
            {
                "id": 21,
                "question": "What is the recommended maximum duration for using the same peripheral intravenous catheter?",
                "choices": [
                    "A. 24 hours",
                    "B. 48 hours",
                    "C. 72 hours",
                    "D. 96 hours"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Peripheral intravenous catheters 'be removed or replaced as clinically indicated, rather than routine removal or replacement after a designated time period.' However, they should generally not be used beyond 48 hours unless clinically necessary.",
                "tags": [
                    "Chapter 1",
                    "peripheral_iv_catheters",
                    "intravenous_access"
                ]
            },
            {
                "id": 22,
                "question": "Which of the following is NOT a component of good clinical evaluation in outpatient settings?",
                "choices": [
                    "A. Observing the patient upon entry",
                    "B. Establishing rapport with the patient",
                    "C. Asking closed-ended questions only",
                    "D. Performing a complete physical examination"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Good clinical evaluation includes observing the patient, establishing rapport, listening attentively, asking open-ended questions initially, performing physical exams, and documenting findings. The text emphasizes using both open-ended and close-ended questions as appropriate.",
                "tags": [
                    "Chapter 1",
                    "clinical_evaluation",
                    "outpatient_care"
                ]
            },
            {
                "id": 23,
                "question": "What is the recommended approach for calculating pediatric doses when manufacturer information is unavailable?",
                "choices": [
                    "A. Use adult doses without adjustment",
                    "B. Calculate doses based on surface area",
                    "C. Estimate doses based on chronological age only",
                    "D. Double the adult dose for children under 5 years"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "When pediatric doses aren't provided by manufacturers, 'Calculations of doses based on surface area are more likely to be correct, which makes it the common approach used for dose estimation of cytotoxic chemotherapeutic agents.' Surface area calculations account for developmental differences better than age or weight alone.",
                "tags": [
                    "Chapter 1",
                    "pediatric_dosing",
                    "dose_calculation"
                ]
            },
            {
                "id": 24,
                "question": "Which factor is most important when deciding whether to prescribe antibiotics for a viral respiratory infection?",
                "choices": [
                    "A. Patient demand for medication",
                    "B. Presence of purulent nasal discharge",
                    "C. Recent travel history",
                    "D. Lack of bacterial infection evidence"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Rational prescribing requires considering whether antibiotics are truly necessary. For viral infections, antibiotics are not indicated unless there's evidence of secondary bacterial infection. The text emphasizes avoiding irrational prescribing and dispensing of antimicrobials.",
                "tags": [
                    "Chapter 1",
                    "antibiotic_prescribing",
                    "viral_infections"
                ]
            },
            {
                "id": 25,
                "question": "What is the primary goal of the Access, Watch, and Reserve (AWaRe) classification system?",
                "choices": [
                    "A. To promote the use of newer, more expensive antibiotics",
                    "B. To enhance rational antibiotic use and combat antimicrobial resistance",
                    "C. To simplify hospital formulary management",
                    "D. To increase pharmaceutical industry profits"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The AWaRe classification aims 'to enhance the health facility's ability to contribute to the national antibiotic consumption and to reduce use of the antibiotics most at risk of resistance from the Watch and Reserve groups. Hence this will help to contain antimicrobial resistant by: Strengthening the capacity of the health-care facility's ASP to implement AMS; Aligning empirical antibiotic treatment with ACCESS antibiotics; Targeting WATCH and RESERVE groups for AMS.'",
                "tags": [
                    "Chapter 1",
                    "awarre_classification",
                    "antimicrobial_stewardship"
                ]
            },
            {
                "id": 26,
                "question": "Which of the following is a key component of palliative care according to the guidelines?",
                "choices": [
                    "A. Aggressive life-prolonging treatments",
                    "B. Symptom management and improving quality of life",
                    "C. Focusing exclusively on end-of-life care",
                    "D. Withholding all medications to prevent dependence"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care focuses on 'relieving suffering and improving the quality of life of patients with advanced illness and their families facing problems associated with life-threatening illness.' It involves comprehensive symptom management and support for patients with serious illnesses.",
                "tags": [
                    "Chapter 1",
                    "palliative_care",
                    "symptom_management"
                ]
            },
            {
                "id": 27,
                "question": "What is the recommended approach for managing febrile neutropenia in cancer patients?",
                "choices": [
                    "A. Start empiric antibiotics immediately",
                    "B. Wait for culture results before initiating treatment",
                    "C. Administer antipyretics only without antibiotics",
                    "D. Use narrow-spectrum antibiotics only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "In immunocompromised patients like those with febrile neutropenia, 'Prompt initiation of effective preoperative antibiotics – most important (see 'Antimicrobial prophylaxis in surgery' section)' is emphasized. Empiric broad-spectrum antibiotics should be started immediately due to high risk of serious infection.",
                "tags": [
                    "Chapter 1",
                    "febrile_neutropenia",
                    "immunocompromised_patients"
                ]
            },
            {
                "id": 28,
                "question": "Which of the following is a contraindication for using aminoglycoside antibiotics?",
                "choices": [
                    "A. Pregnancy",
                    "B. Neonatal age",
                    "C. Renal impairment",
                    "D. Viral infections"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Aminoglycosides 'are incompatible with penicillin and heparin.' More importantly, they require dose adjustment in patients with renal impairment and have ototoxicity and nephrotoxicity risks. In neonates, their use requires special consideration due to immature kidney function.",
                "tags": [
                    "Chapter 1",
                    "aminoglycosides",
                    "contraindications",
                    "renal_impairment"
                ]
            },
            {
                "id": 29,
                "question": "What is the primary purpose of the Cockcroft-Gault formula in clinical practice?",
                "choices": [
                    "A. To estimate glomerular filtration rate (GFR) for drug dosing",
                    "B. To diagnose acute kidney injury",
                    "C. To monitor dialysis adequacy",
                    "D. To predict cardiovascular risk"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The Cockcroft-Gault formula is used 'to adjust doses of medications that are eliminated by the kidneys.' It calculates estimated GFR from serum creatinine, age, and weight, helping clinicians determine appropriate drug doses for patients with renal impairment.",
                "tags": [
                    "Chapter 1",
                    "cockcroft_gault_formula",
                    "renal_function",
                    "drug_dosing"
                ]
            },
            {
                "id": 30,
                "question": "Which of the following is a key principle of good prescribing practice?",
                "choices": [
                    "A. Always prescribe the newest medication available",
                    "B. Choose the least expensive option regardless of efficacy",
                    "C. Ensure the benefits outweigh the risks for each medication",
                    "D. Prescribe medications for non-medical reasons"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Rational approaches to therapeutics require careful evaluation of health problems and selecting appropriate strategies. The cornerstone is making the right diagnosis, followed by choosing treatments where 'the benefit-risk ratio of administering the medicine should always be considered prior to prescribing.'",
                "tags": [
                    "Chapter 1",
                    "good_prescribing",
                    "benefit_risk_ratio"
                ]
            },
            {
                "id": 31,
                "question": "What is the recommended maximum duration for using the same administration set for lipid emulsions?",
                "choices": [
                    "A. 12 hours",
                    "B. 24 hours",
                    "C. 72 hours",
                    "D. 96 hours"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The text specifies that 'Replace administration sets, including secondary sets and add-on devices, no more frequently than at 72-hour intervals, unless clinically indicated.' For lipid emulsions specifically, 'Complete the infusion of lipid-containing solutions within 24 hours,' suggesting sets should be changed within 24 hours.",
                "tags": [
                    "Chapter 1",
                    "lipid_emulsions",
                    "administration_sets"
                ]
            },
            {
                "id": 32,
                "question": "Which population is at highest risk for adverse drug reactions due to altered drug metabolism?",
                "choices": [
                    "A. Children",
                    "B. Pregnant women",
                    "C. Elderly patients",
                    "D. Athletes"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The text notes that 'Capacity to significantly metabolize drugs declines with age for some drugs. Phase I reactions carried out by microsomal P450 systems are affected more in elderly patients than phase II reactions.' Elderly patients often have reduced liver function and other age-related changes that affect drug metabolism.",
                "tags": [
                    "Chapter 1",
                    "elderly_pharmacokinetics",
                    "drug_metabolism"
                ]
            },
            {
                "id": 33,
                "question": "What is the recommended approach for managing pain in palliative care patients?",
                "choices": [
                    "A. Use only non-pharmacologic methods",
                    "B. Implement a stepwise analgesic ladder approach",
                    "C. Restrict opioid use to terminal stages only",
                    "D. Use fixed-dose regimens without individual titration"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care follows the WHO analgesic ladder approach, starting with non-opioids for mild pain, progressing to weak opioids for moderate pain, and strong opioids for severe pain. This stepwise approach allows for individualized pain management and regular reassessment.",
                "tags": [
                    "Chapter 1",
                    "palliative_pain_management",
                    "analgesic_ladder"
                ]
            },
            {
                "id": 34,
                "question": "Which of the following is a key component of infection prevention in intensive care units (ICUs)?",
                "choices": [
                    "A. Routine use of broad-spectrum antibiotics for all ICU patients",
                    "B. Strict adherence to hand hygiene protocols",
                    "C. Minimizing visitor access completely",
                    "D. Using hyperbaric oxygen therapy routinely"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "In ICUs, 'Measures to prevent spread of resistant organisms in the ICU include: Infection control measures such as good hand hygiene compliance; contact precautions for patients for drug-resistant organisms, and Minimizing unnecessary hospitalization and interventions.' Hand hygiene is consistently highlighted as the single most important infection control measure.",
                "tags": [
                    "Chapter 1",
                    "icu_infection_control",
                    "hand_hygiene"
                ]
            },
            {
                "id": 35,
                "question": "What is the recommended frequency for changing peripheral intravenous tubing used to administer blood products?",
                "choices": [
                    "A. Every 12 hours",
                    "B. Every 24 hours",
                    "C. Within 24 hours of initiation",
                    "D. Within 4 hours of initiation"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The text specifies that 'Replace tubing used to administer blood, blood products, or lipid emulsions within 24 hours of initiating the infusion.' This applies to tubing used for blood products as well.",
                "tags": [
                    "Chapter 1",
                    "blood_product_infusion",
                    "intravenous_tubing"
                ]
            },
            {
                "id": 36,
                "question": "Which of the following is NOT a recognized type of drug interaction mechanism?",
                "choices": [
                    "A. Pharmacodynamic interactions",
                    "B. Pharmacokinetic interactions",
                    "C. Physicochemical interactions",
                    "D. Psychological interactions"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Drug interactions occur at different levels including: 'Pharmaceutic, which are physicochemical interactions in an IV infusion or in the same solution; Pharmacokinetics, which may take place at the level of absorption, distribution, biotransformation or excretion; Pharmacodynamics, which could occur directly at receptor level.' Psychological interactions are not a recognized mechanism of drug interactions.",
                "tags": [
                    "Chapter 1",
                    "drug_interactions",
                    "interaction_mechanisms"
                ]
            },
            {
                "id": 37,
                "question": "What is the recommended approach for managing nausea and vomiting in palliative care patients?",
                "choices": [
                    "A. Use antiemetics only when vomiting becomes severe",
                    "B. Implement a proactive antiemetic regimen based on cause",
                    "C. Restrict fluid intake to prevent triggering episodes",
                    "D. Use only non-pharmacologic methods like acupressure"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care for gastrointestinal symptoms involves 'Proactive use of antiemetics based on the underlying cause (e.g., bowel obstruction, increased intracranial pressure). Antiemetics should be given regularly rather than on an 'as needed' basis.' A proactive approach prevents suffering and improves quality of life.",
                "tags": [
                    "Chapter 1",
                    "palliative_nausea_vomiting",
                    "antiemetic_management"
                ]
            },
            {
                "id": 38,
                "question": "Which of the following is a contraindication for using tetracycline antibiotics?",
                "choices": [
                    "A. Pregnancy",
                    "B. Children under 8 years old",
                    "C. Patients with hypertension",
                    "D. Individuals with lactose intolerance"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Tetracyclines 'bind to calcium in the plastic containers and tubing' and are known to cause permanent discoloration of teeth when administered to children under 8 years of age. They're generally contraindicated in this population unless no suitable alternatives exist.",
                "tags": [
                    "Chapter 1",
                    "tetracyclines",
                    "contraindications",
                    "pediatric_medication"
                ]
            },
            {
                "id": 39,
                "question": "What is the recommended maximum duration for using the same peripheral intravenous catheter in adults?",
                "choices": [
                    "A. 24 hours",
                    "B. 48 hours",
                    "C. 72 hours",
                    "D. 96 hours"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The text states that 'The risk of infection increases with the duration, increasing after more than three to six days at all catheter sites.' Peripheral intravenous catheters should typically be removed or replaced as clinically indicated, with 48 hours being a commonly referenced timeframe for routine replacement unless clinically necessary.",
                "tags": [
                    "Chapter 1",
                    "peripheral_iv_catheters",
                    "intravenous_access"
                ]
            },
            {
                "id": 40,
                "question": "Which of the following is a key component of good communication in clinical encounters?",
                "choices": [
                    "A. Using complex medical terminology",
                    "B. Maintaining eye contact and active listening",
                    "C. Rushing through the encounter to save time",
                    "D. Focusing solely on the medical chart rather than the patient"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Effective communication in clinical encounters involves 'Sit facing the patient, lean forward, establish eye contact and relax' as noted in the steps for clinical evaluation. Active listening, empathy, and clear explanation of diagnoses and treatment plans are fundamental components of good clinician-patient communication.",
                "tags": [
                    "Chapter 1",
                    "clinical_communication",
                    "patient_interaction"
                ]
            },
            {
                "id": 41,
                "question": "What is the recommended approach for managing dyspnea in palliative care patients?",
                "choices": [
                    "A. Administer oxygen routinely for all patients",
                    "B. Use a stepwise approach including non-pharmacologic and pharmacologic interventions",
                    "C. Restrict fluid intake to prevent pulmonary edema",
                    "D. Avoid using opioids due to respiratory depression concerns"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care for respiratory symptoms involves 'Implementing a stepwise approach to relieve dyspnea, incorporating non-pharmacologic (e.g., fan, positioning) and pharmacologic (e.g., opioids) interventions.' Opioids are often used effectively to manage dyspnea in palliative care when titrated appropriately.",
                "tags": [
                    "Chapter 1",
                    "palliative_dyspnea",
                    "respiratory_symptoms"
                ]
            },
            {
                "id": 42,
                "question": "Which of the following is NOT a recommended component of safe medication storage and handling?",
                "choices": [
                    "A. Storing medications in their original labeled containers",
                    "B. Keeping medications in locked cabinets away from children",
                    "C. Storing liquid medications in direct sunlight",
                    "D. Regularly checking expiration dates"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Safe medication storage involves keeping medications 'in their original labeled containers' and 'in locked cabinets away from children.' Direct sunlight can degrade many medications, so storing them in cool, dry places away from light is recommended. Regularly checking expiration dates ensures medications remain potent and safe to use.",
                "tags": [
                    "Chapter 1",
                    "medication_storage",
                    "patient_safety"
                ]
            },
            {
                "id": 43,
                "question": "What is the recommended approach for managing constipation in palliative care patients?",
                "choices": [
                    "A. Use laxatives only when constipation becomes severe",
                    "B. Implement a proactive bowel regimen including stool softeners and stimulants",
                    "C. Restrict dietary fiber intake to prevent blockages",
                    "D. Use enemas as the primary treatment method"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care for gastrointestinal symptoms involves 'Proactive use of laxatives and stool softeners based on etiology (e.g., opioid-induced constipation, immobility). Bowel regimens should be individualized and adjusted as needed.' A proactive approach prevents complications and maintains patient comfort.",
                "tags": [
                    "Chapter 1",
                    "palliative_constipation",
                    "bowel_regimen"
                ]
            },
            {
                "id": 44,
                "question": "Which of the following is a key principle of rational prescribing?",
                "choices": [
                    "A. Prescribe medications based on patient demand rather than medical need",
                    "B. Consider the total cost of treatment including efficacy, safety, and suitability",
                    "C. Always choose the newest medication available regardless of cost",
                    "D. Restrict prescriptions to specialists only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Rational prescribing requires that 'The process should also consider efficacy, safety, suitability and availability. Medicine treatment should be individualized to the needs of each patient as much as possible.' Cost considerations are important, particularly in resource-limited settings, but should be balanced with efficacy and safety.",
                "tags": [
                    "Chapter 1",
                    "rational_prescribing",
                    "treatment_cost"
                ]
            },
            {
                "id": 45,
                "question": "What is the recommended approach for managing agitation in palliative care patients with delirium?",
                "choices": [
                    "A. Use physical restraints as first-line treatment",
                    "B. Identify and treat underlying causes while using symptomatic management",
                    "C. Administer high-dose sedatives routinely",
                    "D. Ignore behavioral symptoms as they are expected in terminally ill patients"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care for neuropsychiatric symptoms involves 'Identifying reversible causes (e.g., pain, infection, metabolic abnormalities, medications) and treating them while providing symptomatic management.' Physical restraints should be avoided, and sedatives used cautiously with regular assessment.",
                "tags": [
                    "Chapter 1",
                    "palliative_delirium",
                    "agitation_management"
                ]
            },
            {
                "id": 46,
                "question": "Which of the following is a contraindication for using benzodiazepines in elderly patients?",
                "choices": [
                    "A. History of falls",
                    "B. Chronic obstructive pulmonary disease (COPD)",
                    "C. History of substance abuse",
                    "D. Concurrent use of antidepressants"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Benzodiazepines 'increase the risk of falls in the elderly' due to their sedative effects. The text notes that 'There is a change in the sensitivities of receptors to medicines in elderly people,' making them more susceptible to adverse effects including falls, which can lead to serious injuries in this population.",
                "tags": [
                    "Chapter 1",
                    "benzodiazepines",
                    "elderly_patients",
                    "falls_risk"
                ]
            },
            {
                "id": 47,
                "question": "What is the recommended maximum duration for using the same administration set for propofol infusions?",
                "choices": [
                    "A. 6 hours",
                    "B. 12 hours",
                    "C. 24 hours",
                    "D. 48 hours"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "The text specifies that 'Replace tubing used to administer propofol infusions every 6 to 12 hours, depending on its use, per the manufacturer's direction.' This reflects the instability of propofol in solution and the need for frequent changes to maintain potency and safety.",
                "tags": [
                    "Chapter 1",
                    "propofol_infusion",
                    "intravenous_tubing"
                ]
            },
            {
                "id": 48,
                "question": "Which of the following is a key component of good dispensing practice?",
                "choices": [
                    "A. Dispense medications in unmarked containers",
                    "B. Provide clear written instructions for medication use",
                    "C. Dispense only generic medications",
                    "D. Limit dispensing to weekdays only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Good Dispensing Practices ensure that 'Dispensing includes all the activities that occur between the times the prescription or oral request of the patient or care provider is presented and the medicine is issued.' Key components include providing 'clear information' to patients, which should include written instructions reinforced by verbal counseling.",
                "tags": [
                    "Chapter 1",
                    "dispensing_practices",
                    "patient_education"
                ]
            },
            {
                "id": 49,
                "question": "What is the recommended approach for managing pruritus in palliative care patients?",
                "choices": [
                    "A. Use topical steroids as first-line treatment for all cases",
                    "B. Implement a multimodal approach including systemic and topical therapies",
                    "C. Avoid using antihistamines due to sedation concerns",
                    "D. Restrict bathing to once weekly to prevent drying skin"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care for skin symptoms involves 'Considering the cause (e.g., cholestatic vs. uremic) and selecting appropriate topical and/or systemic therapies.' A multimodal approach is often needed, combining moisturizers, topical corticosteroids, antihistamines, and sometimes systemic agents depending on the underlying cause.",
                "tags": [
                    "Chapter 1",
                    "palliative_pruritus",
                    "skin_symptoms"
                ]
            },
            {
                "id": 50,
                "question": "Which of the following is NOT a recommended component of safe medication administration?",
                "choices": [
                    "A. Verify patient identity using two identifiers",
                    "B. Check medication label against order three times",
                    "C. Administer medications quickly to save time",
                    "D. Document administration promptly and accurately"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Safe medication administration requires careful verification and documentation. The text emphasizes the importance of 'Verify patient identity using two identifiers' and 'Document administration promptly and accurately.' Administering medications quickly compromises safety and accuracy.",
                "tags": [
                    "Chapter 1",
                    "medication_administration",
                    "patient_safety"
                ]
            },
            {
                "id": 51,
                "question": "What is the recommended approach for managing xerostomia (dry mouth) in palliative care patients?",
                "choices": [
                    "A. Use alcohol-based mouth rinses regularly",
                    "B. Maintain adequate hydration and use saliva substitutes",
                    "C. Restrict fluid intake to prevent pulmonary edema",
                    "D. Avoid using artificial saliva products"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care for oral symptoms involves 'Maintaining adequate hydration and using saliva substitutes or sugar-free candies/gum to stimulate saliva production.' Alcohol-based products can be drying and irritating, so they should be avoided.",
                "tags": [
                    "Chapter 1",
                    "palliative_xerostomia",
                    "oral_health"
                ]
            },
            {
                "id": 52,
                "question": "Which of the following is a key principle of antimicrobial stewardship?",
                "choices": [
                    "A. Promote indiscriminate use of broad-spectrum antibiotics",
                    "B. Align empirical treatment with ACCESS antibiotics",
                    "C. Focus exclusively on reducing healthcare costs",
                    "D. Restrict all antibiotic use to specialized infectious disease consultants"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Antimicrobial stewardship aims 'to enhance the health facility's ability to contribute to the national antibiotic consumption and to reduce use of the antibiotics most at risk of resistance from the Watch and Reserve groups' by aligning empirical antibiotic treatment with ACCESS antibiotics whenever possible.",
                "tags": [
                    "Chapter 1",
                    "antimicrobial_stewardship",
                    "access_antibiotics"
                ]
            },
            {
                "id": 53,
                "question": "What is the recommended approach for managing insomnia in palliative care patients?",
                "choices": [
                    "A. Use long-acting hypnotics routinely for sleep induction",
                    "B. Address underlying causes and use short-acting hypnotics judiciously",
                    "C. Avoid using any sleep medications due to addiction potential",
                    "D. Recommend over-the-counter antihistamines as first-line treatment"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care for sleep disturbances involves 'Addressing underlying causes (e.g., pain, dyspnea, anxiety) and using short-acting hypnotics judiciously.' Long-acting hypnotics can accumulate and cause excessive sedation, particularly in vulnerable palliative care patients.",
                "tags": [
                    "Chapter 1",
                    "palliative_insomnia",
                    "sleep_disturbances"
                ]
            },
            {
                "id": 54,
                "question": "Which of the following is a contraindication for using nonsteroidal anti-inflammatory drugs (NSAIDs) in elderly patients?",
                "choices": [
                    "A. History of peptic ulcer disease",
                    "B. Congestive heart failure",
                    "C. Mild arthritis",
                    "D. Well-controlled diabetes mellitus"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "NSAIDs 'should be avoided in patients with a history of peptic ulcer disease or GI bleeding.' Elderly patients are at higher risk for NSAID-induced ulcers and bleeding due to age-related changes in gastric mucosal defense mechanisms and comorbidities.",
                "tags": [
                    "Chapter 1",
                    "nsaids",
                    "elderly_patients",
                    "gastrointestinal_risk"
                ]
            },
            {
                "id": 55,
                "question": "What is the recommended approach for managing cachexia in palliative care patients?",
                "choices": [
                    "A. Restrict caloric intake to prevent weight gain",
                    "B. Implement nutritional support with high-calorie, high-protein diet",
                    "C. Use appetite stimulants routinely for all patients",
                    "D. Avoid enteral nutrition due to aspiration risk"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care for cachexia involves 'Implementing nutritional support with high-calorie, high-protein diet and consider pharmacologic interventions (appetite stimulants, progestational agents) when appropriate.' Cachexia represents muscle wasting and requires nutritional support rather than calorie restriction.",
                "tags": [
                    "Chapter 1",
                    "palliative_cachexia",
                    "nutritional_support"
                ]
            },
            {
                "id": 56,
                "question": "Which of the following is a key component of safe intravenous catheter insertion?",
                "choices": [
                    "A. Insert catheters in the femoral vein for easy access",
                    "B. Use maximal barrier precautions including cap, mask, and sterile gloves",
                    "C. Clean the insertion site with an alcohol-based antiseptic",
                    "D. Insert catheters rapidly without regard for sterility"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Safe intravenous catheter insertion requires 'Disinfect clean skin with an appropriate antiseptic before catheter insertion.' The text recommends using '70% alcohol or an iodophor' for disinfection, along with maximal barrier precautions to prevent contamination.",
                "tags": [
                    "Chapter 1",
                    "iv_catheter_insertion",
                    "infection_control"
                ]
            },
            {
                "id": 57,
                "question": "What is the recommended approach for managing depression in palliative care patients?",
                "choices": [
                    "A. Use tricyclic antidepressants as first-line treatment",
                    "B. Screen for depression and use a combination of psychotherapy and antidepressants",
                    "C. Avoid using selective serotonin reuptake inhibitors (SSRIs) due to side effects",
                    "D. Treat with high-dose benzodiazepines for immediate sedation"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care for psychological symptoms involves 'Screening for depression and using a combination of psychotherapy and antidepressants.' SSRIs are often preferred first-line agents due to favorable side effect profiles compared to older antidepressants.",
                "tags": [
                    "Chapter 1",
                    "palliative_depression",
                    "psychological_symptoms"
                ]
            },
            {
                "id": 58,
                "question": "Which of the following is a key principle of good prescribing practice regarding polypharmacy?",
                "choices": [
                    "A. Always prescribe the maximum number of medications to cover all possibilities",
                    "B. Regularly review and deprescribe unnecessary medications",
                    "C. Prescribe medications from different classes for similar indications",
                    "D. Avoid consulting参考资料 when uncertain about drug interactions"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Good prescribing practice involves 'Regularly reviewing and deprescribing unnecessary medications.' Polypharmacy increases the risk of adverse drug reactions and interactions, so regular medication reviews are essential to optimize therapy.",
                "tags": [
                    "Chapter 1",
                    "polypharmacy",
                    "medication_review"
                ]
            },
            {
                "id": 59,
                "question": "What is the recommended approach for managing lymphedema in palliative care patients?",
                "choices": [
                    "A. Use tight-fitting elastic bandages to reduce swelling",
                    "B. Implement gentle manual lymphatic drainage and compression garments",
                    "C. Restrict limb movement to prevent worsening",
                    "D. Avoid skin care to prevent irritation"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care for lymphedema involves 'Implementing gentle manual lymphatic drainage and compression garments.' Tight bandages and restricted movement can worsen symptoms, while proper skin care is important to prevent complications.",
                "tags": [
                    "Chapter 1",
                    "palliative_lymphedema",
                    "swelling_management"
                ]
            },
            {
                "id": 60,
                "question": "Which of the following is NOT a recommended component of safe medication storage in community pharmacies?",
                "choices": [
                    "A. Store medications away from direct sunlight and heat sources",
                    "B. Keep medications in their original labeled containers",
                    "C. Store liquid medications in the refrigerator door compartments",
                    "D. Ensure medications are inaccessible to children"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Medications should be stored 'away from direct sunlight and heat sources' and 'kept in their original labeled containers.' Refrigerator door compartments are subject to temperature fluctuations and should be avoided for medication storage. Medications should be stored in secure locations inaccessible to children.",
                "tags": [
                    "Chapter 1",
                    "medication_storage",
                    "community_pharmacy"
                ]
            },
            {
                "id": 61,
                "question": "What is the recommended approach for managing dysphagia in palliative care patients?",
                "choices": [
                    "A. Withhold all oral intake until formal swallowing evaluation",
                    "B. Implement texture-modified diets and position techniques during meals",
                    "C. Rely solely on parenteral nutrition for all patients",
                    "D. Encourage rapid eating to finish meals quickly"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care for dysphagia involves 'Implementing texture-modified diets and position techniques during meals.' Formal swallowing evaluations may not be feasible in palliative care, and oral intake should be encouraged when safe rather than withheld entirely.",
                "tags": [
                    "Chapter 1",
                    "palliative_dysphagia",
                    "swallowing_disorders"
                ]
            },
            {
                "id": 62,
                "question": "Which of the following is a key principle of rational prescribing regarding cost considerations?",
                "choices": [
                    "A. Always prescribe the most expensive medication available",
                    "B. Consider the total cost of treatment including efficacy, safety, and suitability",
                    "C. Restrict prescriptions to low-cost generics only",
                    "D. Avoid discussing medication costs with patients"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Rational prescribing considers 'the total cost of treatment including efficacy, safety, suitability and availability.' While cost is important, particularly in resource-limited settings, it should be balanced with the medication's effectiveness and safety profile rather than focusing solely on price.",
                "tags": [
                    "Chapter 1",
                    "rational_prescribing",
                    "cost_considerations"
                ]
            },
            {
                "id": 63,
                "question": "What is the recommended approach for managing anxiety in palliative care patients?",
                "choices": [
                    "A. Use high-dose benzodiazepines for immediate sedation",
                    "B. Implement relaxation techniques and consider anxiolytics judiciously",
                    "C. Avoid psychological interventions due to time constraints",
                    "D. Prescribe antipsychotics as first-line treatment"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Palliative care for anxiety involves 'Implementing relaxation techniques and consider anxiolytics judiciously.' High-dose sedation should be avoided, and psychological interventions are valuable complements to pharmacotherapy.",
                "tags": [
                    "Chapter 1",
                    "palliative_anxiety",
                    "psychological_interventions"
                ]
            },
            {
                "id": 64,
                "question": "Which of the following is a contraindication for using metformin in patients with renal impairment?",
                "choices": [
                    "A. Serum creatinine >1.5 mg/dL in men",
                    "B. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m²",
                    "C. Urine albumin-to-creatinine ratio >300 mg/g",
                    "D. Age over 65 years"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Metformin is contraindicated in patients with 'estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m².' The Cockcroft-Gault formula is used to estimate GFR, and metformin should be avoided in severe renal impairment due to risk of lactic acidosis.",
                "tags": [
                    "Chapter 1",
                    "metformin",
                    "renal_impairment",
                    "contraindications"
                ]
            },
            {
                "id": 65,
                "question": "What is the recommended approach for managing constipation in pediatric palliative care patients?",
                "choices": [
                    "A. Use stimulant laxatives as first-line treatment",
                    "B. Implement dietary modifications and osmotic laxatives",
                    "C. Restrict fluid intake to prevent dehydration",
                    "D. Avoid using any laxatives due to concern about dependency"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Pediatric palliative care for constipation involves 'Implementing dietary modifications and osmotic laxatives.' Stimulant laxatives may be used but should be chosen carefully. Adequate hydration is important, and laxatives are often necessary to manage constipation in this population.",
                "tags": [
                    "Chapter 1",
                    "pediatric_constipation",
                    "palliative_care"
                ]
            },
            {
                "id": 66,
                "question": "Which of the following is a key component of safe medication administration via syringe pumps?",
                "choices": [
                    "A. Use the same syringe for multiple medications",
                    "B. Flush the line thoroughly after each medication change",
                    "C. Set the flow rate as fast as possible to complete infusion quickly",
                    "D. Avoid labeling syringes clearly"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Safe medication administration via syringe pumps requires 'Flushing the line thoroughly after each medication change.' This prevents incompatibilities and ensures accurate delivery of subsequent medications. Syringes should be clearly labeled, and flow rates should be set according to recommended guidelines.",
                "tags": [
                    "Chapter 1",
                    "syringe_pump_administration",
                    "medication_safety"
                ]
            },
            {
                "id": 67,
                "question": "What is the recommended approach for managing nausea and vomiting in pediatric palliative care patients?",
                "choices": [
                    "A. Use ondansetron as first-line antiemetic for all ages",
                    "B. Implement age-appropriate antiemetics and address underlying causes",
                    "C. Restrict oral intake completely until symptoms resolve",
                    "D. Avoid using any antiemetics due to concerns about sedation"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Pediatric palliative care for nausea and vomiting involves 'Implementing age-appropriate antiemetics and address underlying causes.' Different antiemetics may be preferred based on the child's age and the underlying cause of symptoms.",
                "tags": [
                    "Chapter 1",
                    "pediatric_nausea_vomiting",
                    "palliative_care"
                ]
            },
            {
                "id": 68,
                "question": "Which of the following is a key principle of rational prescribing regarding drug selection?",
                "choices": [
                    "A. Always choose the newest medication on the market",
                    "B. Select medications based on evidence of efficacy and safety for the condition",
                    "C. Prescribe medications from pharmaceutical companies offering gifts",
                    "D. Avoid using generic medications even when available"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Rational prescribing requires selecting medications 'based on evidence of efficacy and safety for the condition.' Newer medications may not have sufficient safety data, and generic medications are equally effective when bioequivalent.",
                "tags": [
                    "Chapter 1",
                    "rational_prescribing",
                    "drug_selection"
                ]
            },
            {
                "id": 69,
                "question": "What is the recommended approach for managing pain in pediatric palliative care patients?",
                "choices": [
                    "A. Use codeine-containing products as first-line analgesics",
                    "B. Implement a stepwise analgesic ladder approach tailored to the child's age and condition",
                    "C. Restrict opioid use due to concerns about addiction",
                    "D. Avoid using any analgesics until definitive diagnosis is confirmed"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Pediatric palliative care for pain involves 'Implementing a stepwise analgesic ladder approach tailored to the child's age and condition.' Codeine is not recommended as first-line due to metabolism variability, and opioids should be used when needed for pain relief with appropriate monitoring.",
                "tags": [
                    "Chapter 1",
                    "pediatric_pain",
                    "palliative_care"
                ]
            },
            {
                "id": 70,
                "question": "Which of the following is a key component of safe medication storage in home settings?",
                "choices": [
                    "A. Store medications in bathroom cabinets near sinks",
                    "B. Keep medications in their original containers with labels intact",
                    "C. Store medications in direct sunlight to preserve potency",
                    "D. Share medications between family members"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Medications should be stored 'away from direct sunlight and heat sources' and 'kept in their original containers with labels intact.' Bathroom cabinets are often humid environments unsuitable for medication storage, and sharing medications is unsafe and should be avoided.",
                "tags": [
                    "Chapter 1",
                    "home_medication_storage",
                    "patient_safety"
                ]
            },
            {
                "id": 71,
                "question": "What is the recommended approach for managing agitation in pediatric palliative care patients?",
                "choices": [
                    "A. Use physical restraints routinely to prevent movement",
                    "B. Identify and treat underlying causes while using non-pharmacologic interventions",
                    "C. Administer high-dose sedatives as first-line treatment",
                    "D. Avoid any interventions to allow natural behavior expression"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Pediatric palliative care for agitation involves 'Identify and treat underlying causes while using non-pharmacologic interventions.' Physical restraints should be avoided, and sedatives should be used cautiously only when necessary after addressing potential triggers.",
                "tags": [
                    "Chapter 1",
                    "pediatric_agitation",
                    "palliative_care"
                ]
            },
            {
                "id": 72,
                "question": "Which of the following is a key principle of rational prescribing regarding patient education?",
                "choices": [
                    "A. Provide minimal information to avoid overwhelming patients",
                    "B. Explain the purpose and proper use of medications clearly",
                    "C. Avoid discussing potential side effects to prevent anxiety",
                    "D. Rely solely on written instructions without verbal counseling"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Rational prescribing includes 'Explain the purpose and proper use of medications clearly.' Patient education is crucial for adherence to treatment regimens, and both written and verbal counseling should be provided to ensure understanding.",
                "tags": [
                    "Chapter 1",
                    "patient_education",
                    "rational_prescribing"
                ]
            },
            {
                "id": 73,
                "question": "What is the recommended approach for managing diarrhea in pediatric palliative care patients?",
                "choices": [
                    "A. Use antimotility agents routinely for all cases",
                    "B. Implement dietary modifications and address underlying causes",
                    "C. Restrict fluid intake to prevent dehydration",
                    "D. Avoid using any antidiarrheals due to concerns about ileus"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Pediatric palliative care for diarrhea involves 'Implementing dietary modifications and address underlying causes.' Antimotility agents may be used cautiously, and adequate hydration is crucial to prevent dehydration.",
                "tags": [
                    "Chapter 1",
                    "pediatric_diarrhea",
                    "palliative_care"
                ]
            },
            {
                "id": 74,
                "question": "Which of the following is a key component of safe medication administration in long-term care facilities?",
                "choices": [
                    "A. Use medication carts that are left unlocked for convenience",
                    "B. Conduct regular medication reconciliation reviews",
                    "C. Administer all medications at the same time each day regardless of schedule",
                    "D. Avoid documenting administration to save time"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Safe medication administration in long-term care facilities requires 'Conduct regular medication reconciliation reviews.' This helps prevent errors, double-dosing, and interactions. Medication carts should be secured, and administration times should follow prescribed schedules.",
                "tags": [
                    "Chapter 1",
                    "long_term_care_medications",
                    "medication_safety"
                ]
            },
            {
                "id": 75,
                "question": "What is the recommended approach for managing dyspnea in pediatric palliative care patients?",
                "choices": [
                    "A. Use oxygen therapy routinely for all patients",
                    "B. Implement positioning and breathing techniques while addressing underlying causes",
                    "C. Restrict fluids to prevent pulmonary edema",
                    "D. Avoid using bronchodilators due to concerns about side effects"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Pediatric palliative care for dyspnea involves 'Implement positioning and breathing techniques while addressing underlying causes.' Oxygen therapy should be used based on clinical indication rather than routinely, and bronchodilators may be beneficial for reversible airway obstruction.",
                "tags": [
                    "Chapter 1",
                    "pediatric_dyspnea",
                    "palliative_care"
                ]
            },
            {
                "id": 76,
                "question": "Which of the following is a key principle of rational prescribing regarding follow-up?",
                "choices": [
                    "A. Schedule follow-up appointments only when patients request them",
                    "B. Arrange timely follow-up to assess treatment response and modify therapy as needed",
                    "C. Avoid follow-up visits to reduce healthcare costs",
                    "D. Conduct follow-ups only annually regardless of treatment complexity"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Rational prescribing includes 'Arrange timely follow-up to assess treatment response and modify therapy as needed.' Follow-up is essential to ensure treatments are working effectively and to make adjustments as necessary.",
                "tags": [
                    "Chapter 1",
                    "follow_up",
                    "rational_prescribing"
                ]
            },
            {
                "id": 77,
                "question": "What is the recommended approach for managing constipation in pediatric palliative care patients?",
                "choices": [
                    "A. Use stimulant laxatives as first-line treatment",
                    "B. Implement dietary modifications and osmotic laxatives",
                    "C. Restrict fluid intake to prevent dehydration",
                    "D. Avoid using any laxatives due to concerns about dependency"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Pediatric palliative care for constipation involves 'Implement dietary modifications and osmotic laxatives.' Stimulant laxatives may be used but should be chosen carefully based on the child's condition and previous responses.",
                "tags": [
                    "Chapter 1",
                    "pediatric_constipation",
                    "palliative_care"
                ]
            },
            {
                "id": 78,
                "question": "Which of the following is a key component of safe medication storage in tropical climates?",
                "choices": [
                    "A. Store medications in areas with high humidity and fluctuating temperatures",
                    "B. Keep medications in tightly sealed containers away from moisture and heat",
                    "C. Store medications in direct sunlight to prevent fungal growth",
                    "D. Avoid using desiccants or moisture absorbers"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "In tropical climates, medications should be stored 'in tightly sealed containers away from moisture and heat.' High humidity and temperature fluctuations can degrade many medications, so proper storage conditions are especially important.",
                "tags": [
                    "Chapter 1",
                    "medication_storage",
                    "tropical_climates"
                ]
            },
            {
                "id": 79,
                "question": "What is the recommended approach for managing nausea and vomiting in pediatric palliative care patients?",
                "choices": [
                    "A. Use ondansetron as first-line antiemetic for all ages",
                    "B. Implement a stepwise approach tailored to the child's age and condition",
                    "C. Restrict oral intake completely until symptoms resolve",
                    "D. Avoid using any antiemetics due to concerns about sedation"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Pediatric palliative care for nausea and vomiting involves 'Implement a stepwise approach tailored to the child's age and condition.' Different antiemetics may be preferred based on the child's age and the underlying cause of symptoms.",
                "tags": [
                    "Chapter 1",
                    "pediatric_nausea_vomiting",
                    "palliative_care"
                ]
            },
            {
                "id": 80,
                "question": "Which of the following is a key principle of rational prescribing regarding documentation?",
                "choices": [
                    "A. Document only minimal information to save time",
                    "B. Record complete and accurate information about prescriptions and administrations",
                    "C. Use abbreviations extensively to save space",
                    "D. Avoid documenting allergies to prevent liability"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Rational prescribing requires 'Record complete and accurate information about prescriptions and administrations.' Complete documentation is essential for continuity of care, error prevention, and legal protection.",
                "tags": [
                    "Chapter 1",
                    "prescription_documentation",
                    "medical_records"
                ]
            },
            {
                "id": 81,
                "question": "What is the recommended approach for managing agitation in pediatric palliative care patients?",
                "choices": [
                    "A. Use physical restraints routinely to prevent movement",
                    "B. Identify and treat underlying causes while using non-pharmacologic interventions",
                    "C. Administer high-dose sedatives as first-line treatment",
                    "D. Avoid any interventions to allow natural behavior expression"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Pediatric palliative care for agitation involves 'Identify and treat underlying causes while using non-pharmacologic interventions.' Physical restraints should be avoided, and sedatives should be used cautiously only when necessary after addressing potential triggers.",
                "tags": [
                    "Chapter 1",
                    "pediatric_agitation",
                    "palliative_care"
                ]
            },
            {
                "id": 82,
                "question": "Which of the following is a key component of safe medication administration in home health care?",
                "choices": [
                    "A. Allow family members to administer medications without training",
                    "B. Provide thorough patient and caregiver education on medication use",
                    "C. Administer all medications at night to avoid interrupting daily activities",
                    "D. Use verbal instructions only without written materials"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Safe medication administration in home health care requires 'Provide thorough patient and caregiver education on medication use.' Family caregivers should receive proper training, and both verbal and written instructions should be provided to ensure safe and effective medication administration.",
                "tags": [
                    "Chapter 1",
                    "home_healthcare_medications",
                    "patient_education"
                ]
            },
            {
                "id": 83,
                "question": "What is the recommended approach for managing dyspnea in pediatric palliative care patients?",
                "choices": [
                    "A. Use oxygen therapy routinely for all patients",
                    "B. Implement positioning and breathing techniques while addressing underlying causes",
                    "C. Restrict fluids to prevent pulmonary edema",
                    "D. Avoid using bronchodilators due to concerns about side effects"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Pediatric palliative care for dyspnea involves 'Implement positioning and breathing techniques while addressing underlying causes.' Oxygen therapy should be used based on clinical indication rather than routinely, and bronchodilators may be beneficial for reversible airway obstruction.",
                "tags": [
                    "Chapter 1",
                    "pediatric_dyspnea",
                    "palliative_care"
                ]
            },
            {
                "id": 84,
                "question": "Which of the following is a key principle of rational prescribing regarding polypharmacy?",
                "choices": [
                    "A. Always prescribe the maximum number of medications to cover all possibilities",
                    "B. Regularly review and deprescribe unnecessary medications",
                    "C. Prescribe medications from different classes for similar indications",
                    "D. Avoid consulting参考资料 when uncertain about drug interactions"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Rational prescribing involves 'Regularly review and deprescribe unnecessary medications.' Polypharmacy increases the risk of adverse drug reactions and interactions, so regular medication reviews are essential to optimize therapy.",
                "tags": [
                    "Chapter 1",
                    "polypharmacy",
                    "medication_review"
                ]
            },
            {
                "id": 85,
                "question": "What is the recommended approach for managing lymphedema in pediatric palliative care patients?",
                "choices": [
                    "A. Use tight-fitting elastic bandages to reduce swelling",
                    "B. Implement gentle massage and compression garments",
                    "C. Restrict limb movement to prevent worsening",
                    "D. Avoid skin care to prevent irritation"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Pediatric palliative care for lymphedema involves 'Implement gentle massage and compression garments.' Tight bandages and restricted movement can worsen symptoms, while proper skin care is important to prevent complications.",
                "tags": [
                    "Chapter 1",
                    "pediatric_lymphedema",
                    "palliative_care"
                ]
            },
            {
                "id": 86,
                "question": "Which of the following is a key component of safe medication storage in community pharmacies?",
                "choices": [
                    "A. Store medications in areas with high traffic and exposure to elements",
                    "B. Keep medications in their original containers with labels intact",
                    "C. Store medications in direct sunlight to preserve potency",
                    "D. Avoid using desiccants or moisture absorbers"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 1: Good Prescribing and Dispensing Practices",
                "explanation": "Medications should be stored 'in tightly sealed containers away from moisture and",
                "tags": [
                    "Chapter 1",
                    "pediatric_lymphedema",
                    "palliative_care"
                ]
            }
        ]
    },
    "Chapter 6.1": {
        "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease": [
            {
                "id": 307,
                "question": "A 45-year-old male farmer from rural Ethiopia presents with epigastric burning pain for 4 months, relieved by eating and antacids, and often waking him at night. He denies weight loss, vomiting, or melena. Physical examination is unremarkable. What is the most likely diagnosis?",
                "choices": [
                    "A. Gastric ulcer",
                    "B. Duodenal ulcer",
                    "C. Gastroesophageal reflux disease",
                    "D. Gastric cancer"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "The classic presentation of duodenal ulcer includes epigastric pain relieved by food or antacids and nocturnal pain, as described in the Ethiopian STG 2021 (p. 180). Gastric ulcers typically worsen with eating, and alarm symptoms are absent here, making cancer unlikely.",
                "tags": [
                    "Chapter 6.1",
                    "duodenal_ulcer",
                    "dyspepsia",
                    "nocturnal_pain"
                ]
            },
            {
                "id": 308,
                "question": "A 50-year-old woman presents with new-onset epigastric pain, unintentional weight loss of 5 kg over 2 months, early satiety, and occult blood in stool. She has a history of smoking. What is the most appropriate initial management?",
                "choices": [
                    "A. Empirical proton pump inhibitor (PPI) therapy for 4 weeks",
                    "B. Test for Helicobacter pylori and treat if positive",
                    "C. Urgent upper gastrointestinal endoscopy",
                    "D. Abdominal ultrasound"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Alarm features such as age >45 years, unintentional weight loss, early satiety, and evidence of bleeding require urgent upper GI endoscopy to exclude malignancy or complicated ulcer (Ethiopian STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "alarm_features",
                    "endoscopy",
                    "dyspepsia"
                ]
            },
            {
                "id": 309,
                "question": "According to the Ethiopian STG 2021, which of the following is NOT considered an alarm symptom in dyspepsia requiring immediate endoscopy?",
                "choices": [
                    "A. Age over 45 years with new symptoms",
                    "B. Persistent vomiting for more than 2 weeks",
                    "C. Epigastric pain relieved by antacids",
                    "D. Family history of gastric cancer"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Epigastric pain relieved by antacids is a typical feature of uncomplicated peptic ulcer disease and not an alarm symptom. Alarm symptoms include age >45, weight loss, bleeding, dysphagia, persistent vomiting, and family history (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "alarm_symptoms",
                    "peptic_ulcer"
                ]
            },
            {
                "id": 310,
                "question": "A 30-year-old asymptomatic teacher from Addis Ababa is found to have a positive Helicobacter pylori stool antigen test during a routine check-up. According to Ethiopian STG 2021, what is the recommended management?",
                "choices": [
                    "A. No treatment needed as he is asymptomatic",
                    "B. Empirical eradication therapy",
                    "C. Upper GI endoscopy before treatment",
                    "D. Repeat test after 4 weeks"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "In asymptomatic individuals, routine screening and treatment for H. pylori is not recommended unless there are specific risk factors like family history of gastric cancer (STG 2021, p. 181). Treatment is indicated for confirmed peptic ulcer disease or other indications.",
                "tags": [
                    "Chapter 6.1",
                    "H_pylori",
                    "asymptomatic",
                    "screening"
                ]
            },
            {
                "id": 311,
                "question": "A 38-year-old man with confirmed duodenal ulcer tests positive for H. pylori. He has no history of previous antibiotic use. What is the first-line eradication regimen per Ethiopian STG 2021?",
                "choices": [
                    "A. PPI + clarithromycin + amoxicillin for 14 days",
                    "B. PPI + clarithromycin + metronidazole for 7 days",
                    "C. Bismuth subsalicylate + tetracycline + metronidazole + PPI for 14 days",
                    "D. PPI + levofloxacin + amoxicillin for 10 days"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "The first-line regimen for H. pylori eradication in treatment-naïve patients is a 14-day triple therapy: PPI (e.g., omeprazole 20 mg BID) + clarithromycin 500 mg BID + amoxicillin 1 g BID (STG 2021, p. 181). Quadruple therapy is for failures or resistance.",
                "tags": [
                    "Chapter 6.1",
                    "H_pylori_eradication",
                    "triple_therapy",
                    "first_line"
                ]
            },
            {
                "id": 312,
                "question": "A 25-year-old pregnant woman at 16 weeks gestation presents with heartburn and epigastric discomfort. No alarm symptoms. What is the safest initial treatment according to STG 2021?",
                "choices": [
                    "A. Omeprazole 20 mg daily",
                    "B. Ranitidine 150 mg twice daily",
                    "C. Aluminum and magnesium hydroxide antacid as needed",
                    "D. Metoclopramide 10 mg three times daily"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Antacids (aluminum/magnesium hydroxide) are the first-line and safest option in pregnancy for symptomatic relief. PPIs and H2 blockers are used if necessary but with caution (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "pregnancy",
                    "dyspepsia_treatment",
                    "antacids"
                ]
            },
            {
                "id": 313,
                "question": "A 55-year-old diabetic patient on long-term NSAIDs presents with sudden severe epigastric pain radiating to the back, abdominal guarding, and tachycardia. What is the most likely complication of peptic ulcer disease?",
                "choices": [
                    "A. Upper GI bleeding",
                    "B. Gastric outlet obstruction",
                    "C. Perforated ulcer",
                    "D. Penetration into adjacent organs"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Sudden severe pain with signs of peritonitis (guarding, rigidity) indicates perforated peptic ulcer, a surgical emergency, especially in NSAID users (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "perforation",
                    "complications",
                    "NSAIDs"
                ]
            },
            {
                "id": 314,
                "question": "A patient with peptic ulcer disease completed H. pylori eradication therapy. When should confirmation of eradication be performed according to Ethiopian STG 2021?",
                "choices": [
                    "A. Immediately after completing antibiotics",
                    "B. 2 weeks after therapy",
                    "C. At least 4 weeks after therapy and off PPI for 2 weeks",
                    "D. 6 months after therapy"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Eradication is confirmed with non-invasive tests (stool antigen or urea breath test) at least 4 weeks after antibiotics and 2 weeks off PPI to avoid false negatives (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "H_pylori_confirmation",
                    "follow_up",
                    "testing"
                ]
            },
            {
                "id": 315,
                "question": "A 42-year-old man with recurrent duodenal ulcers despite two courses of eradication therapy and ongoing NSAID use for arthritis. What is the next step?",
                "choices": [
                    "A. Repeat triple therapy with different PPI",
                    "B. Endoscopy with biopsy for culture and sensitivity",
                    "C. Long-term high-dose PPI without further testing",
                    "D. Switch to H2 receptor antagonists"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Refractory ulcers require endoscopy and biopsy for H. pylori culture/sensitivity to guide salvage therapy, especially with NSAID continuation (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "refractory_ulcer",
                    "biopsy",
                    "antibiotic_resistance"
                ]
            },
            {
                "id": 316,
                "question": "Which risk factor is most strongly associated with peptic ulcer disease in the Ethiopian context per STG 2021?",
                "choices": [
                    "A. Chronic alcohol consumption",
                    "B. Nonsteroidal anti-inflammatory drugs (NSAIDs)",
                    "C. Spicy food intake",
                    "D. High coffee consumption"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "NSAIDs are a major cause of peptic ulcers, second only to H. pylori in Ethiopia, due to inhibition of prostaglandin synthesis (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "risk_factors",
                    "NSAIDs",
                    "etiology"
                ]
            },
            {
                "id": 317,
                "question": "A 60-year-old patient requiring long-term NSAIDs for rheumatoid arthritis has a history of peptic ulcer. What is the recommended prophylaxis?",
                "choices": [
                    "A. No prophylaxis needed if low-dose aspirin only",
                    "B. Daily PPI (e.g., omeprazole 20 mg)",
                    "C. Misoprostol 200 mcg four times daily",
                    "D. H2 blocker like ranitidine 150 mg at night"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "High-risk patients (history of ulcer) on NSAIDs should receive daily PPI prophylaxis to prevent recurrence (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "NSAID_prophylaxis",
                    "PPI",
                    "high_risk"
                ]
            },
            {
                "id": 318,
                "question": "A 35-year-old man presents with epigastric pain, diarrhea, and symptoms worsening after meals. He has multiple ulcers on endoscopy. What is the suspected diagnosis?",
                "choices": [
                    "A. Zollinger-Ellison syndrome",
                    "B. Crohn's disease",
                    "C. Functional dyspepsia",
                    "D. NSAID-induced ulcer"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Zollinger-Ellison syndrome presents with refractory ulcers, diarrhea due to acid inactivation of enzymes, and postprandial pain (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "Zollinger_Ellison",
                    "refractory_ulcers",
                    "gastrinoma"
                ]
            },
            {
                "id": 319,
                "question": "Following successful H. pylori eradication in a patient with duodenal ulcer, what is the duration of PPI therapy recommended?",
                "choices": [
                    "A. Continue indefinitely",
                    "B. 4-8 weeks total, then stop",
                    "C. 2 weeks after eradication",
                    "D. Lifelong if >60 years"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "After eradication, PPI is given for 4-8 weeks for ulcer healing, then discontinued if symptoms resolve (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "PPI_duration",
                    "ulcer_healing",
                    "follow_up"
                ]
            },
            {
                "id": 320,
                "question": "A 28-year-old woman with dyspepsia tests negative for H. pylori and has normal endoscopy. What is the most likely diagnosis?",
                "choices": [
                    "A. Peptic ulcer disease",
                    "B. Non-ulcer dyspepsia",
                    "C. Esophageal cancer",
                    "D. Biliary colic"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Non-ulcer (functional) dyspepsia is diagnosed after excluding organic causes like H. pylori or ulcers via testing and endoscopy (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "non_ulcer_dyspepsia",
                    "functional",
                    "diagnosis"
                ]
            },
            {
                "id": 321,
                "question": "In a patient with bleeding peptic ulcer confirmed by endoscopy, what is the initial pharmacological management?",
                "choices": [
                    "A. IV PPI bolus followed by infusion",
                    "B. Oral amoxicillin-clavulanate",
                    "C. Transfusion only if Hb <7 g/dL",
                    "D. Surgical ligation immediately"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "High-dose IV PPI (80 mg bolus then 8 mg/hr infusion for 72 hours) reduces rebleeding in high-risk lesions (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "bleeding_ulcer",
                    "PPI_infusion",
                    "endoscopy"
                ]
            },
            {
                "id": 322,
                "question": "Which diagnostic test for H. pylori is most accurate in untreated patients according to STG 2021?",
                "choices": [
                    "A. Serology",
                    "B. Urea breath test or stool antigen",
                    "C. Rapid urease test on biopsy",
                    "D. All are equally accurate"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Urea breath test and stool antigen are non-invasive, highly sensitive/specific for active infection in untreated patients (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "H_pylori_test",
                    "non_invasive",
                    "diagnosis"
                ]
            },
            {
                "id": 323,
                "question": "A 65-year-old man on chronic PPI develops hypomagnesemia. What is the recommended action?",
                "choices": [
                    "A. Continue PPI and monitor",
                    "B. Switch to H2 blocker",
                    "C. Add magnesium supplement and check levels",
                    "D. Stop PPI abruptly"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Long-term PPI use can cause hypomagnesemia; supplement magnesium and monitor levels, considering alternative therapy if persistent (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "PPI_side_effects",
                    "hypomagnesemia",
                    "long_term"
                ]
            },
            {
                "id": 324,
                "question": "For a patient with duodenal ulcer and confirmed clarithromycin resistance, what is the salvage regimen?",
                "choices": [
                    "A. Repeat triple therapy",
                    "B. Bismuth-based quadruple therapy for 14 days",
                    "C. Levofloxacin triple therapy",
                    "D. Metronidazole single agent"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) is recommended for treatment failures due to resistance (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "salvage_therapy",
                    "resistance",
                    "quadruple"
                ]
            },
            {
                "id": 325,
                "question": "A 40-year-old HIV-positive patient with dyspepsia and positive H. pylori. What modification to eradication therapy?",
                "choices": [
                    "A. Standard triple therapy",
                    "B. Avoid metronidazole if recent exposure",
                    "C. Use levofloxacin first-line",
                    "D. No modification needed"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "In HIV patients, avoid metronidazole in quadruple therapy if recent use to prevent resistance; prefer bismuth quadruple or levofloxacin-based (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "HIV",
                    "H_pylori",
                    "resistance"
                ]
            },
            {
                "id": 326,
                "question": "What lifestyle modification is most effective for preventing peptic ulcer recurrence?",
                "choices": [
                    "A. Avoid all dairy products",
                    "B. Stop smoking and limit alcohol",
                    "C. Eat small frequent meals",
                    "D. Raise head of bed"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Smoking cessation and alcohol limitation reduce acid secretion and improve healing; diet has less impact (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "lifestyle",
                    "smoking",
                    "prevention"
                ]
            },
            {
                "id": 327,
                "question": "A patient with giant duodenal ulcer (>2 cm) on endoscopy. What additional evaluation?",
                "choices": [
                    "A. Routine H. pylori test only",
                    "B. Search for malignancy or Crohn's",
                    "C. Immediate surgery",
                    "D. Ignore size"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Giant ulcers require biopsy to rule out malignancy or other etiologies like Crohn's disease (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "giant_ulcer",
                    "biopsy",
                    "differential"
                ]
            },
            {
                "id": 328,
                "question": "In ICU patients on mechanical ventilation, when is stress ulcer prophylaxis indicated?",
                "choices": [
                    "A. All ICU admissions",
                    "B. High-risk patients (coagulopathy, sepsis >1 week)",
                    "C. Only if H. pylori positive",
                    "D. Never in Ethiopia"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Prophylaxis with PPI or H2 blocker for high-risk ICU patients to prevent stress ulcers (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "stress_ulcer",
                    "ICU",
                    "prophylaxis"
                ]
            },
            {
                "id": 329,
                "question": "Which H. pylori test is preferred post-eradication?",
                "choices": [
                    "A. Serology",
                    "B. Stool antigen test",
                    "C. Endoscopy with histology",
                    "D. Blood PCR"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Stool antigen test is non-invasive and reliable for confirming eradication post-therapy (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "post_eradication_test",
                    "stool_antigen",
                    "follow_up"
                ]
            },
            {
                "id": 330,
                "question": "A 32-year-old with dyspepsia in first trimester of pregnancy. What is the approach?",
                "choices": [
                    "A. Routine endoscopy",
                    "B. Avoid medications; use lifestyle measures",
                    "C. Start empirical antibiotics",
                    "D. Full H. pylori workup"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "In pregnancy, especially first trimester, avoid unnecessary drugs and investigations; use antacids and lifestyle advice first (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "pregnancy",
                    "first_trimester",
                    "conservative"
                ]
            },
            {
                "id": 331,
                "question": "Patient with peptic ulcer and gastric outlet obstruction. Initial management?",
                "choices": [
                    "A. Immediate surgery",
                    "B. IV fluids, NG decompression, PPI",
                    "C. H. pylori test only",
                    "D. Oral rehydration"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Conservative management with IV fluids, nasogastric suction, and PPI for edema resolution; surgery if persistent (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "outlet_obstruction",
                    "conservative",
                    "complication"
                ]
            },
            {
                "id": 332,
                "question": "Second-line therapy for H. pylori failure in Ethiopia?",
                "choices": [
                    "A. PPI + amoxicillin + metronidazole 14 days",
                    "B. PPI + bismuth + tetracycline + metronidazole 14 days",
                    "C. PPI + clarithromycin + levofloxacin 10 days",
                    "D. PPI monotherapy"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Bismuth quadruple therapy is second-line for failures (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "second_line",
                    "quadruple_therapy",
                    "failure"
                ]
            },
            {
                "id": 333,
                "question": "A child with epigastric pain and H. pylori positive. Treatment difference from adults?",
                "choices": [
                    "A. Same as adults",
                    "B. Avoid clarithromycin; use amoxicillin + PPI",
                    "C. No antibiotics under 12 years",
                    "D. Surgery preferred"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "In children, due to resistance, use amoxicillin + PPI or quadruple; consult pediatrics (STG 2021, p. 181, cross-referenced to Chapter 16).",
                "tags": [
                    "Chapter 6.1",
                    "pediatric",
                    "H_pylori",
                    "children"
                ]
            },
            {
                "id": 334,
                "question": "Patient with dyspepsia and iron deficiency anemia. Next step?",
                "choices": [
                    "A. Oral iron only",
                    "B. Endoscopy to rule out bleeding ulcer",
                    "C. H. pylori test without endoscopy",
                    "D. Colonoscopy first"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Anemia is an alarm feature requiring endoscopy to exclude occult bleeding from ulcer or malignancy (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "anemia",
                    "alarm",
                    "endoscopy"
                ]
            },
            {
                "id": 335,
                "question": "Role of sucralfate in peptic ulcer treatment?",
                "choices": [
                    "A. First-line acid suppression",
                    "B. Cytoprotective agent for mild cases or adjunct",
                    "C. Eradication of H. pylori",
                    "D. Antiemetic"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Sucralfate coats ulcers for protection; used as adjunct or in mild cases when PPI not available (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "sucralfate",
                    "cytoprotective",
                    "adjunct"
                ]
            },
            {
                "id": 336,
                "question": "A 48-year-old with uninvestigated dyspepsia, age <45, no alarms, high H. pylori area. Approach?",
                "choices": [
                    "A. Endoscopy first",
                    "B. Test and treat H. pylori",
                    "C. Empirical PPI 4 weeks",
                    "D. Reassure"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Test-and-treat strategy for <45 years, no alarms in high-prevalence settings (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "test_treat",
                    "young_patient",
                    "high_prevalence"
                ]
            },
            {
                "id": 337,
                "question": "Complication of untreated H. pylori-associated ulcer?",
                "choices": [
                    "A. Reduced risk of gastric cancer",
                    "B. Increased risk of gastric adenocarcinoma",
                    "C. No long-term risks",
                    "D. Only anemia"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Chronic H. pylori infection increases gastric cancer risk; eradication reduces it (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "H_pylori",
                    "gastric_cancer",
                    "complication"
                ]
            },
            {
                "id": 338,
                "question": "Patient with perforated ulcer. Surgical option?",
                "choices": [
                    "A. Medical management only",
                    "B. Simple closure +/- omental patch",
                    "C. Vagotomy always",
                    "D. Total gastrectomy"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Graham patch (omental) for perforation; definitive surgery if recurrent (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "perforation_surgery",
                    "graham_patch",
                    "emergency"
                ]
            },
            {
                "id": 339,
                "question": "H2 blockers like ranitidine in peptic ulcer?",
                "choices": [
                    "A. Preferred over PPI",
                    "B. Alternative if PPI intolerant",
                    "C. Not recommended",
                    "D. For maintenance only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "H2 blockers are less effective than PPI but useful if intolerant or unavailable (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "H2_blocker",
                    "alternative",
                    "intolerance"
                ]
            },
            {
                "id": 340,
                "question": "Dyspepsia in patient >55 years, no alarms. Approach?",
                "choices": [
                    "A. Test-treat H. pylori",
                    "B. Empirical PPI trial",
                    "C. Endoscopy",
                    "D. Barium meal"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "For >45-55 years, even without alarms, endoscopy is recommended due to malignancy risk (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "older_patient",
                    "endoscopy",
                    "age_risk"
                ]
            },
            {
                "id": 341,
                "question": "Post-endoscopy clean-based ulcer. Management?",
                "choices": [
                    "A. Discharge without therapy",
                    "B. H. pylori test and eradicate if positive; PPI 4 weeks",
                    "C. Surgery",
                    "D. Antibiotics only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Test for H. pylori and treat; PPI for healing (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "clean_ulcer",
                    "H_pylori",
                    "PPI"
                ]
            },
            {
                "id": 342,
                "question": "Role of probiotics in H. pylori therapy?",
                "choices": [
                    "A. Essential component",
                    "B. May improve eradication rates as adjunct",
                    "C. Contraindicated",
                    "D. Replace antibiotics"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Probiotics can reduce side effects and improve compliance, but not standard (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "probiotics",
                    "adjunct",
                    "side_effects"
                ]
            },
            {
                "id": 343,
                "question": "Patient with ulcer and penicillin allergy. Eradication regimen?",
                "choices": [
                    "A. Standard triple with amoxicillin",
                    "B. PPI + clarithromycin + metronidazole",
                    "C. Quadruple without bismuth",
                    "D. Levofloxacin based"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Substitute metronidazole for amoxicillin in allergy (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "penicillin_allergy",
                    "alternative_regimen",
                    "metronidazole"
                ]
            },
            {
                "id": 344,
                "question": "Monitoring for ulcer healing post-therapy?",
                "choices": [
                    "A. Repeat endoscopy routinely",
                    "B. Symptom resolution; endoscopy if persistent",
                    "C. Barium study at 6 weeks",
                    "D. No follow-up needed"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Follow symptoms; endoscopy only if refractory or alarms (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "follow_up",
                    "symptom_based",
                    "healing"
                ]
            },
            {
                "id": 345,
                "question": "H. pylori prevalence in Ethiopian dyspepsia patients?",
                "choices": [
                    "A. <20%",
                    "B. 70-90%",
                    "C. 100%",
                    "D. Declining to 10%"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "High prevalence (70-90%) justifies test-and-treat strategy (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "prevalence",
                    "Ethiopia",
                    "H_pylori"
                ]
            },
            {
                "id": 346,
                "question": "A 70-year-old with dyspepsia, dysphagia, weight loss. Priority?",
                "choices": [
                    "A. H. pylori test",
                    "B. Urgent endoscopy for possible esophageal/gastric cancer",
                    "C. PPI trial",
                    "D. CT abdomen"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Dysphagia and weight loss in elderly are alarms for urgent endoscopy (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "dysphagia",
                    "elderly",
                    "cancer_risk"
                ]
            },
            {
                "id": 347,
                "question": "PPI of choice in Ethiopia for ulcer treatment?",
                "choices": [
                    "A. Omeprazole",
                    "B. Pantoprazole",
                    "C. Esomeprazole",
                    "D. Any equivalent"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Any available PPI (omeprazole preferred due to availability) at standard doses (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "PPI_choice",
                    "omeprazole",
                    "availability"
                ]
            },
            {
                "id": 348,
                "question": "Indication for surgery in peptic ulcer?",
                "choices": [
                    "A. All uncomplicated ulcers",
                    "B. Refractory bleeding after endoscopic therapy",
                    "C. H. pylori positive",
                    "D. Mild pain"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Surgery for complications like uncontrolled bleeding, perforation, or obstruction failing conservative/endoscopic management (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "surgery_indication",
                    "refractory",
                    "complications"
                ]
            },
            {
                "id": 349,
                "question": "False positive H. pylori serology in?",
                "choices": [
                    "A. Active infection only",
                    "B. Past infection (does not distinguish)",
                    "C. Children <5 years",
                    "D. Post-eradication"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Serology detects antibodies, remaining positive post-eradication; not for confirmation (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "serology_limit",
                    "past_infection",
                    "test"
                ]
            },
            {
                "id": 350,
                "question": "Maintenance therapy after complicated ulcer?",
                "choices": [
                    "A. No need after healing",
                    "B. Long-term PPI if high-risk (age >60, NSAID use)",
                    "C. H. pylori retest only",
                    "D. Annual endoscopy"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Long-term PPI for high-risk patients to prevent recurrence (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "maintenance",
                    "high_risk",
                    "PPI"
                ]
            },
            {
                "id": 351,
                "question": "A 55-year-old with epigastric pain, no relief with antacids, bloating. Normal exam. Next?",
                "choices": [
                    "A. Reassure",
                    "B. H. pylori testing",
                    "C. Endoscopy",
                    "D. Ultrasound"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Unrelieved dyspepsia warrants H. pylori testing in <45 no alarms (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "unrelieved",
                    "testing",
                    "bloating"
                ]
            },
            {
                "id": 352,
                "question": "Clarithromycin resistance rate in Ethiopia prompting regimen change?",
                "choices": [
                    "A. <5%",
                    "B. >15%",
                    "C. 50%",
                    "D. Unknown"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "High resistance (>15%) supports bismuth quadruple as alternative, but triple still first-line (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "resistance",
                    "clarithromycin",
                    "Ethiopia"
                ]
            },
            {
                "id": 353,
                "question": "Symptom of gastric vs duodenal ulcer?",
                "choices": [
                    "A. Gastric: pain after meals; duodenal: before meals",
                    "B. Both same",
                    "C. Gastric nocturnal; duodenal daytime",
                    "D. No difference"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Gastric ulcer pain worsens postprandial; duodenal relieved by food (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "gastric_vs_duodenal",
                    "pain_pattern",
                    "symptoms"
                ]
            },
            {
                "id": 354,
                "question": "Patient with ulcer, on warfarin. Bleeding risk management?",
                "choices": [
                    "A. Continue warfarin",
                    "B. Reverse anticoagulation, endoscopic hemostasis",
                    "C. PPI only",
                    "D. Transfuse PRBC"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "In anticoagulated patients with bleeding, reverse and perform endoscopy (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "anticoagulation",
                    "bleeding",
                    "endoscopy"
                ]
            },
            {
                "id": 355,
                "question": "Non-H. pylori, non-NSAID ulcer cause?",
                "choices": [
                    "A. Common in Ethiopia",
                    "B. Rare; investigate for malignancy, Crohn's",
                    "C. Viral infection",
                    "D. Stress only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Idiopathic ulcers are rare; further workup needed (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "idiopathic_ulcer",
                    "investigate",
                    "rare"
                ]
            },
            {
                "id": 356,
                "question": "Duration of triple therapy in confirmed ulcer?",
                "choices": [
                    "A. 7 days",
                    "B. 14 days",
                    "C. 21 days",
                    "D. 28 days"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "14 days for optimal eradication in ulcer patients (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "duration",
                    "triple_therapy",
                    "ulcer"
                ]
            },
            {
                "id": 357,
                "question": "A 29-year-old with dyspepsia, positive UBT. After treatment, repeat UBT negative. Next?",
                "choices": [
                    "A. Continue PPI lifelong",
                    "B. Stop PPI after 4-8 weeks if asymptomatic",
                    "C. Repeat endoscopy",
                    "D. Add H2 blocker"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Discontinue PPI after healing if symptoms resolve (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "post_eradication",
                    "PPI_stop",
                    "asymptomatic"
                ]
            },
            {
                "id": 358,
                "question": "Endoscopic finding in uncomplicated duodenal ulcer?",
                "choices": [
                    "A. Clean base, no stigmata",
                    "B. Visible vessel",
                    "C. Active spurting",
                    "D. Adherent clot"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Uncomplicated: clean base; high-risk stigmata require intervention (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "endoscopy_findings",
                    "clean_base",
                    "low_risk"
                ]
            },
            {
                "id": 359,
                "question": "PPI interaction with clopidogrel?",
                "choices": [
                    "A. No interaction",
                    "B. Omeprazole reduces efficacy; use pantoprazole",
                    "C. Increases bleeding",
                    "D. Dose adjustment needed"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Omeprazole inhibits CYP2C19, reducing clopidogrel activation; prefer pantoprazole (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "drug_interaction",
                    "PPI_clopidogrel",
                    "omeprazole"
                ]
            },
            {
                "id": 360,
                "question": "Symptomatic relief in functional dyspepsia?",
                "choices": [
                    "A. Eradicate H. pylori if positive",
                    "B. Antidepressants first",
                    "C. Surgery",
                    "D. No treatment"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "H. pylori eradication can help even in functional dyspepsia if positive (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "functional_dyspepsia",
                    "H_pylori",
                    "relief"
                ]
            },
            {
                "id": 361,
                "question": "A 62-year-old with melena, hypotension. Initial resuscitation?",
                "choices": [
                    "A. Endoscopy immediately",
                    "B. 2 large-bore IV lines, fluids, blood if needed",
                    "C. PPI oral",
                    "D. NG lavage"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "ABC: secure IV access, fluid resuscitation, transfuse if unstable (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "bleeding_management",
                    "resuscitation",
                    "melena"
                ]
            },
            {
                "id": 362,
                "question": "Urea breath test sensitivity/specificity?",
                "choices": [
                    "A. 90-95% both",
                    "B. 70% sensitivity",
                    "C. 50% specificity",
                    "D. Better than serology"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "UBT has >90% sensitivity/specificity for active infection (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "UBT",
                    "accuracy",
                    "test"
                ]
            },
            {
                "id": 363,
                "question": "In khat chewer with recurrent ulcers, additional risk?",
                "choices": [
                    "A. No association",
                    "B. Increases acid secretion",
                    "C. Protects mucosa",
                    "D. Reduces H. pylori"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Khat may exacerbate by stimulating acid (contextual in Ethiopia, STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "khat",
                    "risk_factor",
                    "Ethiopia"
                ]
            },
            {
                "id": 364,
                "question": "Post-perforation management?",
                "choices": [
                    "A. Early ambulation",
                    "B. IV PPI, antibiotics, NPO, NG tube",
                    "C. Oral feeding day 1",
                    "D. Discharge day 2"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Supportive: NPO, IV PPI, antibiotics for peritonitis (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "post_perforation",
                    "supportive",
                    "care"
                ]
            },
            {
                "id": 365,
                "question": "H. pylori transmission in Ethiopia?",
                "choices": [
                    "A. Airborne",
                    "B. Fecal-oral, waterborne",
                    "C. Sexual",
                    "D. Vector"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Fecal-oral route, poor sanitation contributes to high prevalence (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "transmission",
                    "fecal_oral",
                    "prevention"
                ]
            },
            {
                "id": 366,
                "question": "Elderly patient on multiple meds with dyspepsia. Concern?",
                "choices": [
                    "A. Polypharmacy increasing ulcer risk",
                    "B. Ignore if no pain",
                    "C. Only if diabetic",
                    "D. Diet change sufficient"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Polypharmacy (NSAIDs, steroids) heightens risk; review meds (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "elderly",
                    "polypharmacy",
                    "risk"
                ]
            },
            {
                "id": 367,
                "question": "Forrest classification for bleeding ulcer rebleeding risk?",
                "choices": [
                    "A. Ia (spurting) high risk",
                    "B. III (clean) low risk",
                    "C. IIb medium",
                    "D. All low"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Forrest Ia/Ib high risk for rebleed; III low (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "Forrest",
                    "rebleeding",
                    "classification"
                ]
            },
            {
                "id": 368,
                "question": "Alternative to endoscopy in resource-limited setting for alarms?",
                "choices": [
                    "A. Barium swallow",
                    "B. Not recommended; refer",
                    "C. Ultrasound",
                    "D. CT scan"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Endoscopy is gold standard; if unavailable, urgent referral (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "resource_limited",
                    "referral",
                    "alarms"
                ]
            },
            {
                "id": 369,
                "question": "PPI in renal impairment?",
                "choices": [
                    "A. Contraindicated",
                    "B. Dose reduce",
                    "C. No adjustment",
                    "D. Avoid omeprazole"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "No dose adjustment needed in renal failure (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "renal",
                    "PPI_dose",
                    "adjustment"
                ]
            },
            {
                "id": 370,
                "question": "Symptom-based diagnosis in primary care for dyspepsia?",
                "choices": [
                    "A. Always accurate",
                    "B. Use cautiously; test for H. pylori",
                    "C. Ignore symptoms",
                    "D. Treat all as ulcer"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Symptoms overlap; H. pylori testing helps stratify (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "symptom_diagnosis",
                    "primary_care",
                    "stratify"
                ]
            },
            {
                "id": 371,
                "question": "After successful therapy, recurrence rate if H. pylori eradicated?",
                "choices": [
                    "A. 100%",
                    "B. <5% per year",
                    "C. 50%",
                    "D. Same as untreated"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Eradication reduces recurrence to <5%/year (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "recurrence",
                    "eradication",
                    "low_rate"
                ]
            },
            {
                "id": 372,
                "question": "A 41-year-old with epigastric pain, positive family history of ulcers. Test?",
                "choices": [
                    "A. No test needed",
                    "B. H. pylori stool antigen",
                    "C. Endoscopy",
                    "D. Breath test only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Family history is not alarm but warrants H. pylori testing (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "family_history",
                    "testing",
                    "H_pylori"
                ]
            },
            {
                "id": 373,
                "question": "Metronidazole in quadruple therapy dose?",
                "choices": [
                    "A. 250 mg TID",
                    "B. 500 mg TID",
                    "C. 1 g BID",
                    "D. 400 mg daily"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Standard dose 500 mg TID for 14 days (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "metronidazole_dose",
                    "quadruple",
                    "therapy"
                ]
            },
            {
                "id": 374,
                "question": "Dyspepsia with orthopnea, worse lying down. Differential?",
                "choices": [
                    "A. Only ulcer",
                    "B. Consider cardiac cause like MI",
                    "C. Biliary",
                    "D. Musculoskeletal"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Atypical symptoms may indicate cardiac disease; evaluate accordingly (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "differential",
                    "cardiac",
                    "atypical"
                ]
            },
            {
                "id": 375,
                "question": "Cost-effective strategy in Ethiopia for dyspepsia?",
                "choices": [
                    "A. Routine endoscopy",
                    "B. Test-and-treat H. pylori",
                    "C. All PPI trials",
                    "D. No testing"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Test-and-treat is cost-effective in high-prevalence areas (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "cost_effective",
                    "test_treat",
                    "Ethiopia"
                ]
            },
            {
                "id": 376,
                "question": "Patient with ulcer, cirrhosis. Adjustment?",
                "choices": [
                    "A. Standard therapy",
                    "B. Avoid bismuth (encephalopathy risk)",
                    "C. Increase PPI dose",
                    "D. No antibiotics"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Bismuth contraindicated in liver disease; use non-bismuth regimens (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "cirrhosis",
                    "bismuth",
                    "contraindication"
                ]
            },
            {
                "id": 377,
                "question": "Rapid urease test (CLO test) for H. pylori?",
                "choices": [
                    "A. Non-invasive",
                    "B. Endoscopic biopsy-based",
                    "C. Blood test",
                    "D. Home kit"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "CLO test on gastric biopsy during endoscopy (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "CLO_test",
                    "biopsy",
                    "invasive"
                ]
            },
            {
                "id": 378,
                "question": "Healing time for duodenal ulcer with PPI?",
                "choices": [
                    "A. 1 week",
                    "B. 4-6 weeks",
                    "C. 3 months",
                    "D. 6 months"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Most heal in 4-6 weeks with PPI (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "healing_time",
                    "PPI",
                    "duodenal"
                ]
            },
            {
                "id": 379,
                "question": "Alarm feature: progressive dysphagia in 50-year-old?",
                "choices": [
                    "A. No",
                    "B. Yes, urgent endoscopy",
                    "C. Treat as GERD",
                    "D. Barium first"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Dysphagia suggests possible stricture or cancer (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "dysphagia",
                    "alarm",
                    "urgent"
                ]
            },
            {
                "id": 380,
                "question": "Levofloxacin triple therapy when?",
                "choices": [
                    "A. First-line",
                    "B. Penicillin allergy and failure",
                    "C. Pregnancy",
                    "D. Children"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Salvage for allergy or failure, but resistance emerging (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "levofloxacin",
                    "salvage",
                    "allergy"
                ]
            },
            {
                "id": 381,
                "question": "A 33-year-old with postprandial pain, nausea. Likely gastric ulcer?",
                "choices": [
                    "A. Yes",
                    "B. No, more duodenal",
                    "C. Equal",
                    "D. Functional"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Postprandial pain typical for gastric ulcer (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "gastric_ulcer",
                    "postprandial",
                    "pain"
                ]
            },
            {
                "id": 382,
                "question": "Endoscopic therapy for high-risk bleeding ulcer?",
                "choices": [
                    "A. Epinephrine injection or clips",
                    "B. Observation",
                    "C. Antibiotics only",
                    "D. Balloon tamponade"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Endoscopic hemostasis (injection, thermal, clips) for active bleeding or visible vessel (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "endoscopic_therapy",
                    "hemostasis",
                    "high_risk"
                ]
            },
            {
                "id": 383,
                "question": "Compliance issue in eradication therapy?",
                "choices": [
                    "A. No issue",
                    "B. Side effects reduce; counsel patient",
                    "C. Shorten duration",
                    "D. Use injectable"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Side effects common; emphasize adherence for success (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "compliance",
                    "side_effects",
                    "counseling"
                ]
            },
            {
                "id": 384,
                "question": "H. pylori negative ulcer on NSAIDs. Management?",
                "choices": [
                    "A. Stop NSAID, PPI 8 weeks",
                    "B. Continue NSAID",
                    "C. Add misoprostol only",
                    "D. Surgery"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Discontinue NSAID if possible, PPI for healing (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "NSAID_ulcer",
                    "stop_NSAID",
                    "PPI"
                ]
            },
            {
                "id": 386,
                "question": "Annual retesting for H. pylori in treated patients?",
                "choices": [
                    "A. Yes",
                    "B. No, only if symptoms recur",
                    "C. Every 6 months",
                    "D. Lifelong"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "No routine retesting post-eradication unless recurrence (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "retesting",
                    "symptom_driven",
                    "no_routine"
                ]
            },
            {
                "id": 387,
                "question": "A 27-year-old with dyspepsia, anxiety. Management?",
                "choices": [
                    "A. Rule out organic first",
                    "B. Antidepressants only",
                    "C. Ignore anxiety",
                    "D. Beta blockers"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Exclude organic causes before attributing to functional/psych (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "anxiety",
                    "organic_first",
                    "differential"
                ]
            },
            {
                "id": 388,
                "question": "Bismuth subsalicylate contraindication?",
                "choices": [
                    "A. Allergy to aspirin",
                    "B. Renal failure",
                    "C. Pregnancy",
                    "D. All"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Avoid in salicylate allergy, children (Reye's), severe renal/liver (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "bismuth",
                    "contraindication",
                    "salicylate"
                ]
            },
            {
                "id": 389,
                "question": "Ulcer healing without H. pylori treatment?",
                "choices": [
                    "A. No",
                    "B. Yes with PPI, but recurs",
                    "C. Surgery only",
                    "D. Antibiotics unnecessary"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "PPI heals but eradication prevents recurrence (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "healing_without_eradication",
                    "recurrence",
                    "PPI"
                ]
            },
            {
                "id": 390,
                "question": "Patient with marginal ulcer post-bariatric surgery. Cause?",
                "choices": [
                    "A. H. pylori or NSAID",
                    "B. Infection only",
                    "C. Diet",
                    "D. Rare"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Similar etiology; test and treat (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "marginal_ulcer",
                    "bariatric",
                    "etiology"
                ]
            },
            {
                "id": 391,
                "question": "Dose of omeprazole for active ulcer?",
                "choices": [
                    "A. 20 mg daily",
                    "B. 40 mg daily",
                    "C. 20 mg BID",
                    "D. 80 mg infusion"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "40 mg daily for active disease (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "omeprazole_dose",
                    "active_ulcer",
                    "PPI"
                ]
            },
            {
                "id": 392,
                "question": "Dyspepsia workup in HIV patient?",
                "choices": [
                    "A. Same as general",
                    "B. Consider opportunistic like CMV",
                    "C. No H. pylori",
                    "D. Endoscopy always"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Higher risk for other causes; broader differential (STG 2021, cross Chapter 8).",
                "tags": [
                    "Chapter 6.1",
                    "HIV",
                    "opportunistic",
                    "differential"
                ]
            },
            {
                "id": 393,
                "question": "Success rate of first-line triple therapy?",
                "choices": [
                    "A. >90%",
                    "B. 70-85%",
                    "C. <50%",
                    "D. Variable"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "70-85% in areas with resistance (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "success_rate",
                    "triple_therapy",
                    "resistance"
                ]
            },
            {
                "id": 394,
                "question": "A 36-year-old with pain, no response to PPI. Next?",
                "choices": [
                    "A. Increase PPI dose",
                    "B. Endoscopy",
                    "C. Add antacid",
                    "D. Reassure"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Failure of empirical therapy warrants endoscopy (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "PPI_failure",
                    "endoscopy",
                    "refractory"
                ]
            },
            {
                "id": 395,
                "question": "Role of diet in peptic ulcer?",
                "choices": [
                    "A. Avoid spicy, caffeine; small meals",
                    "B. No specific diet needed",
                    "C. High fiber only",
                    "D. Low carb"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Blunt diet advice: avoid irritants, eat regularly (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "diet",
                    "lifestyle",
                    "advice"
                ]
            },
            {
                "id": 396,
                "question": "Tetracycline dose in quadruple therapy?",
                "choices": [
                    "A. 250 mg QID",
                    "B. 500 mg QID",
                    "C. 1 g BID",
                    "D. 250 mg BID"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "500 mg QID for 14 days (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "tetracycline_dose",
                    "quadruple",
                    "therapy"
                ]
            },
            {
                "id": 397,
                "question": "Alarm in dyspepsia: unexplained anemia?",
                "choices": [
                    "A. No",
                    "B. Yes",
                    "C. Only if severe",
                    "D. Ignore in men"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Iron deficiency anemia is alarm for bleeding (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "anemia",
                    "alarm",
                    "bleeding"
                ]
            },
            {
                "id": 398,
                "question": "Post-treatment, persistent symptoms. Cause?",
                "choices": [
                    "A. Treatment failure",
                    "B. Functional overlay",
                    "C. Both possible",
                    "D. Always cancer"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Recheck eradication or functional dyspepsia (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "persistent_symptoms",
                    "failure",
                    "functional"
                ]
            },
            {
                "id": 399,
                "question": "H. pylori vaccine status?",
                "choices": [
                    "A. Available in Ethiopia",
                    "B. Not available; focus on hygiene",
                    "C. Routine for children",
                    "D. Effective 100%"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "No vaccine; prevention via sanitation (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "vaccine",
                    "prevention",
                    "hygiene"
                ]
            },
            {
                "id": 400,
                "question": "A 49-year-old with epigastric mass on exam. Urgent?",
                "choices": [
                    "A. No",
                    "B. Endoscopy and biopsy",
                    "C. Ultrasound",
                    "D. CT first"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Palpable mass is alarm for malignancy (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "mass",
                    "alarm",
                    "malignancy"
                ]
            },
            {
                "id": 401,
                "question": "Amoxicillin dose in triple therapy?",
                "choices": [
                    "A. 500 mg BID",
                    "B. 1 g BID",
                    "C. 1 g TID",
                    "D. 500 mg QID"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "1 g BID for 14 days (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "amoxicillin_dose",
                    "triple",
                    "therapy"
                ]
            },
            {
                "id": 402,
                "question": "Dyspepsia after viral illness. Likely?",
                "choices": [
                    "A. Post-infectious functional dyspepsia",
                    "B. Ulcer",
                    "C. Cancer",
                    "D. GERD"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Can follow acute gastroenteritis (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "post_infectious",
                    "functional",
                    "dyspepsia"
                ]
            },
            {
                "id": 403,
                "question": "In perforation, free air on X-ray confirms?",
                "choices": [
                    "A. No, ultrasound",
                    "B. Yes, under diaphragm",
                    "C. CT needed",
                    "D. Barium"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Upright chest X-ray shows pneumoperitoneum (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "perforation_diagnosis",
                    "X_ray",
                    "pneumoperitoneum"
                ]
            },
            {
                "id": 404,
                "question": "Long-term PPI risk: osteoporosis?",
                "choices": [
                    "A. No risk",
                    "B. Possible; monitor in elderly",
                    "C. Absolute",
                    "D. Only in men"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Associated with fractures; use lowest dose (STG 2021, p. 180).",
                "tags": [
                    "Chapter 6.1",
                    "PPI_risk",
                    "osteoporosis",
                    "long_term"
                ]
            },
            {
                "id": 405,
                "question": "Eradication confirmation in children?",
                "choices": [
                    "A. UBT >4 weeks post",
                    "B. Serology",
                    "C. No need",
                    "D. Endoscopy always"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Same as adults: UBT or stool antigen (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "children_confirmation",
                    "UBT",
                    "eradication"
                ]
            },
            {
                "id": 406,
                "question": "Final advice for patient post-eradication?",
                "choices": [
                    "A. Annual H. pylori test",
                    "B. Report recurrence; avoid NSAIDs",
                    "C. Daily PPI",
                    "D. No follow-up"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspepsia and Peptic Ulcer Disease",
                "explanation": "Educate on symptoms, risk factors avoidance (STG 2021, p. 182).",
                "tags": [
                    "Chapter 6.1",
                    "patient_education",
                    "recurrence",
                    "avoid_NSAIDs"
                ]
            }
        ],
        "Chapter 6.1 Dyspeptic and Peptic Ulcer Disease": [
            {
                "id": 385,
                "question": "Test of choice during PPI use for H. pylori?",
                "choices": [
                    "A. Stool antigen (false negative)",
                    "B. Histology or culture from biopsy",
                    "C. Serology",
                    "D. UBT (avoid)"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.1 Dyspeptic and Peptic Ulcer Disease",
                "explanation": "PPI suppresses bacteria; use invasive tests like histology (STG 2021, p. 181).",
                "tags": [
                    "Chapter 6.1",
                    "PPI_interference",
                    "histology",
                    "testing"
                ]
            }
        ]
    },
    "Chapter 6.2": {
        "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)": [
            {
                "id": 407,
                "question": "A 38-year-old female teacher presents with heartburn and acid regurgitation for 6 months that worsens when lying down and after heavy meals. Symptoms improve with antacids. No dysphagia or weight loss. What is the most likely diagnosis?",
                "choices": [
                    "A. Peptic ulcer disease",
                    "B. Gastroesophageal reflux disease (GERD)",
                    "C. Achalasia cardia",
                    "D. Esophageal carcinoma"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Typical GERD symptoms: heartburn, acid regurgitation, worse on lying down and after meals, relieved by antacids (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "classic_presentation",
                    "heartburn"
                ]
            },
            {
                "id": 408,
                "question": "A 45-year-old man presents with chronic heartburn and nocturnal cough for 1 year. He has no alarm symptoms. According to Ethiopian STG 2021, what is the initial management?",
                "choices": [
                    "A. Immediate upper GI endoscopy",
                    "B. Lifestyle modification + empirical PPI trial for 4–8 weeks",
                    "C. Barium swallow",
                    "D. 24-hour pH monitoring"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "In uncomplicated GERD (no alarm features), start lifestyle changes and empirical PPI trial (omeprazole 20–40 mg daily) for 4–8 weeks (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "empirical_treatment",
                    "lifestyle"
                ]
            },
            {
                "id": 409,
                "question": "Which of the following is NOT a recommended lifestyle modification for GERD according to Ethiopian STG 2021?",
                "choices": [
                    "A. Elevate head of bed",
                    "B. Avoid meals 3 hours before bedtime",
                    "C. Stop smoking and alcohol",
                    "D. Increase coffee and spicy food intake"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Avoid trigger foods (spicy, fatty, coffee, chocolate, citrus), alcohol, smoking; elevate head of bed; avoid late meals (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "lifestyle_modification",
                    "avoid_triggers"
                ]
            },
            {
                "id": 410,
                "question": "A 52-year-old man with long-standing GERD now presents with progressive dysphagia to solids and 6 kg weight loss in 2 months. What is the most urgent next step?",
                "choices": [
                    "A. Double-dose PPI",
                    "B. Urgent upper GI endoscopy",
                    "C. Barium swallow",
                    "D. Continue current therapy"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "New-onset dysphagia and weight loss in chronic GERD are alarm symptoms indicating possible Barrett’s esophagus or adenocarcinoma → urgent endoscopy (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "alarm_features",
                    "dysphagia",
                    "endoscopy"
                ]
            },
            {
                "id": 411,
                "question": "First-line pharmacological treatment for GERD in Ethiopia per STG 2021 is:",
                "choices": [
                    "A. Ranitidine 150 mg BID",
                    "B. Omeprazole 20–40 mg daily for 4–8 weeks",
                    "C. Domperidone 10 mg TID",
                    "D. Aluminium hydroxide mixture"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Proton pump inhibitors (omeprazole preferred) are the most effective and first-line therapy (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "PPI",
                    "first_line"
                ]
            },
            {
                "id": 412,
                "question": "A 28-year-old pregnant woman at 32 weeks gestation presents with severe heartburn. Safest initial treatment?",
                "choices": [
                    "A. Omeprazole 20 mg daily",
                    "B. Lifestyle modification + antacids (Ca/Mg-based)",
                    "C. Ranitidine 150 mg BID",
                    "D. Metoclopramide"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "In pregnancy, start with lifestyle changes and non-absorbable antacids; PPIs only if severe and unresponsive (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "pregnancy",
                    "antacids",
                    "safe"
                ]
            },
            {
                "id": 413,
                "question": "A 60-year-old man with GERD symptoms unresponsive to 8 weeks of omeprazole 40 mg daily. Next step?",
                "choices": [
                    "A. Switch to ranitidine",
                    "B. Refer for upper GI endoscopy",
                    "C. Add domperidone",
                    "D. Life-long antacids"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Refractory GERD (no response to 8 weeks high-dose PPI) requires endoscopy to rule out erosive esophagitis, Barrett’s, or other pathology (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "refractory",
                    "endoscopy"
                ]
            },
            {
                "id": 414,
                "question": "Which endoscopic finding confirms erosive esophagitis in GERD?",
                "choices": [
                    "A. Normal mucosa",
                    "B. Los Angeles Grade A–D mucosal breaks",
                    "C. Hiatal hernia only",
                    "D. Schatzki ring"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Erosive esophagitis is graded by LA classification (A–D) based on mucosal breaks (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "erosive_esophagitis",
                    "LA_classification"
                ]
            },
            {
                "id": 415,
                "question": "A patient with long-standing GERD is found to have Barrett’s esophagus on biopsy. Most important next step?",
                "choices": [
                    "A. Stop PPI",
                    "B. Continue high-dose PPI + endoscopic surveillance",
                    "C. Immediate surgery",
                    "D. Add H2 blocker"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Barrett’s esophagus requires lifelong high-dose PPI and regular endoscopic surveillance for dysplasia (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "Barretts_esophagus",
                    "surveillance"
                ]
            },
            {
                "id": 416,
                "question": "Most common extra-esophageal manifestation of GERD in Ethiopia?",
                "choices": [
                    "A. Dental erosion",
                    "B. Chronic cough / asthma-like symptoms",
                    "C. Hoarseness",
                    "D. Chest pain"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Chronic cough and asthma exacerbation are common atypical presentations (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "extraesophageal",
                    "cough"
                ]
            },
            {
                "id": 417,
                "question": "A 35-year-old obese man with GERD symptoms. Most effective non-pharmacological advice?",
                "choices": [
                    "A. Increase fiber intake",
                    "B. Weight reduction",
                    "C. Drink milk before bed",
                    "D. Sleep on right side"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Weight loss is the most effective lifestyle intervention in overweight/obese patients (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "obesity",
                    "weight_loss"
                ]
            },
            {
                "id": 418,
                "question": "Maintenance therapy in patient with LA Grade C/D esophagitis after healing?",
                "choices": [
                    "A. Stop PPI",
                    "B. Half-dose PPI long-term",
                    "C. Antacids as needed",
                    "D. H2 blocker"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Severe erosive esophagitis (Grade C/D) usually requires long-term maintenance PPI at lowest effective dose (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "maintenance",
                    "severe_esophagitis"
                ]
            },
            {
                "id": 419,
                "question": "Indication for anti-reflux surgery (fundoplication) in Ethiopia?",
                "choices": [
                    "A. All GERD patients",
                    "B. Young patient with refractory symptoms despite optimal PPI + confirmed reflux",
                    "C. Mild symptoms",
                    "D. Elderly patients"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Surgery reserved for young patients with proven reflux who fail or do not want long-term PPI (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "surgery",
                    "fundoplication"
                ]
            },
            {
                "id": 420,
                "question": "Role of prokinetics (domperidone/metoclopramide) in GERD?",
                "choices": [
                    "A. First-line therapy",
                    "B. Adjunct in patients with delayed gastric emptying",
                    "C. Contraindicated",
                    "D. Replace PPI"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Prokinetics are second-line, used as adjunct when gastroparesis coexists (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "prokinetics",
                    "adjunct"
                ]
            },
            {
                "id": 421,
                "question": "A 55-year-old man with GERD and chronic cough improves dramatically on PPI. Diagnosis?",
                "choices": [
                    "A. Asthma",
                    "B. GERD-related laryngopharyngeal reflux",
                    "C. Tuberculosis",
                    "D. Cardiac disease"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "PPI-responsive chronic cough in non-smoker strongly suggests LPR (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "LPR",
                    "cough",
                    "PPI_trial"
                ]
            },
            {
                "id": 422,
                "question": "Which drug class most commonly worsens GERD symptoms?",
                "choices": [
                    "A. Beta blockers",
                    "B. Calcium channel blockers and nitrates",
                    "C. ACE inhibitors",
                    "D. Statins"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Drugs that relax LES (CCBs, nitrates, benzodiazepines, theophylline) exacerbate reflux (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "drug_induced",
                    "LES_relaxants"
                ]
            },
            {
                "id": 423,
                "question": "Normal finding on endoscopy in up to 70% of GERD patients?",
                "choices": [
                    "A. Erosive esophagitis",
                    "B. Normal esophageal mucosa (NERD)",
                    "C. Barrett’s esophagus",
                    "D. Stricture"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Non-erosive reflux disease (NERD) is the most common endoscopic finding (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "NERD",
                    "normal_endoscopy"
                ]
            },
            {
                "id": 424,
                "question": "Complication of long-standing untreated GERD?",
                "choices": [
                    "A. Peptic ulcer",
                    "B. Barrett’s esophagus → adenocarcinoma",
                    "C. Gastric cancer",
                    "D. Pancreatitis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Chronic reflux → Barrett’s metaplasia → increased risk of esophageal adenocarcinoma (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "Barretts",
                    "adenocarcinoma"
                ]
            },
            {
                "id": 425,
                "question": "Best time to take PPI for optimal effect in GERD?",
                "choices": [
                    "A. At bedtime",
                    "B. 30–60 minutes before breakfast",
                    "C. With meals",
                    "D. Anytime"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "PPIs should be taken 30–60 minutes before the first meal to maximize acid suppression (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "PPI_timing",
                    "before_meal"
                ]
            },
            {
                "id": 426,
                "question": "A 42-year-old with GERD symptoms and iron deficiency anemia. Next step?",
                "choices": [
                    "A. Oral iron only",
                    "B. Urgent endoscopy",
                    "C. Increase PPI dose",
                    "D. Transfusion"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Anemia in GERD may indicate erosive esophagitis or Cameron lesions → alarm symptom (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "anemia",
                    "alarm"
                ]
            },
            {
                "id": 427,
                "question": "Duration of PPI trial in suspected GERD before declaring refractory?",
                "choices": [
                    "A. 2 weeks",
                    "B. 4 weeks",
                    "C. 8 weeks at maximum dose",
                    "D. 12 weeks"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Failure to respond to 8 weeks of high-dose PPI (e.g., omeprazole 40 mg) defines refractory GERD (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "refractory",
                    "PPI_trial"
                ]
            },
            {
                "id": 428,
                "question": "Most common risk factor for GERD in Ethiopia?",
                "choices": [
                    "A. H. pylori infection",
                    "B. Obesity and hiatal hernia",
                    "C. Alcohol",
                    "D. Smoking only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Obesity, hiatal hernia, and delayed gastric emptying are major risk factors (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "risk_factors",
                    "obesity"
                ]
            },
            {
                "id": 429,
                "question": "Patient with GERD develops odynophagia (painful swallowing). Likely cause?",
                "choices": [
                    "A. Erosive esophagitis",
                    "B. Esophageal candidiasis",
                    "C. Pill esophagitis",
                    "D. All possible"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Odynophagia suggests severe esophagitis, infection, or ulceration (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "odynophagia",
                    "complication"
                ]
            },
            {
                "id": 430,
                "question": "Role of H2-receptor antagonists in GERD 2021?",
                "choices": [
                    "A. First-line",
                    "B. Alternative if PPI not tolerated or unavailable",
                    "C. Superior to PPI",
                    "D. Not recommended"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "H2RAs (e.g., ranitidine) are less effective than PPIs but acceptable alternatives (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "H2RA",
                    "alternative"
                ]
            },
            {
                "id": 431,
                "question": "A 30-year-old with heartburn only at night. Best advice?",
                "choices": [
                    "A. Take PPI at night",
                    "B. Elevate head of bed + avoid late meals",
                    "C. Sleep on left side",
                    "D. Take antacid at bedtime"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Nocturnal symptoms respond best to head elevation and avoiding food 3 hours before bed (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "nocturnal",
                    "head_elevation"
                ]
            },
            {
                "id": 432,
                "question": "Alarm symptoms in GERD requiring urgent endoscopy include all EXCEPT:",
                "choices": [
                    "A. Dysphagia",
                    "B. Odynophagia",
                    "C. Weight loss",
                    "D. Heartburn relieved by antacids"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Relief with antacids is typical of uncomplicated GERD; the others are red flags (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "alarm_features"
                ]
            },
            {
                "id": 433,
                "question": "Patient with GERD and known hiatal hernia. Management change?",
                "choices": [
                    "A. Immediate surgery",
                    "B. Same medical management",
                    "C. Avoid PPI",
                    "D. Use only antacids"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Hiatal hernia alone does not change initial medical management (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "hiatal_hernia",
                    "medical"
                ]
            },
            {
                "id": 434,
                "question": "Best diagnostic test for refractory GERD when endoscopy is normal?",
                "choices": [
                    "A. Barium swallow",
                    "B. 24-hour esophageal pH monitoring",
                    "C. Manometry",
                    "D. Repeat endoscopy"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Ambulatory pH monitoring confirms acid reflux in PPI-refractory, endoscopy-negative patients (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "pH_monitoring",
                    "refractory"
                ]
            },
            {
                "id": 435,
                "question": "Long-term PPI use in GERD is indicated in:",
                "choices": [
                    "A. All patients",
                    "B. Severe erosive esophagitis or Barrett’s esophagus",
                    "C. Mild NERD",
                    "D. Only 3 months"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Long-term PPI reserved for complicated or severe disease (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "long_term_PPI",
                    "indication"
                ]
            },
            {
                "id": 436,
                "question": "A 48-year-old with GERD and hoarseness. Likely diagnosis?",
                "choices": [
                    "A. Vocal cord polyp",
                    "B. Laryngopharyngeal reflux (LPR)",
                    "C. Thyroid cancer",
                    "D. Asthma"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "LPR commonly causes hoarseness, throat clearing, globus (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "LPR",
                    "hoarseness"
                ]
            },
            {
                "id": 437,
                "question": "On-demand PPI therapy is appropriate for:",
                "choices": [
                    "A. Severe erosive esophagitis",
                    "B. Mild, infrequent symptoms (NERD)",
                    "C. Barrett’s esophagus",
                    "D. Stricture"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Patients with mild, non-erosive disease can use PPI on-demand (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "on_demand",
                    "mild"
                ]
            },
            {
                "id": 438,
                "question": "Most common complication of chronic GERD requiring dilation?",
                "choices": [
                    "A. Bleeding",
                    "B. Peptic stricture",
                    "C. Perforation",
                    "D. Aspiration"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Long-standing reflux can cause fibrotic peptic stricture → dysphagia (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "stricture",
                    "dilation"
                ]
            },
            {
                "id": 439,
                "question": "Patient with GERD symptoms and normal endoscopy responds to PPI. Diagnosis?",
                "choices": [
                    "A. Functional heartburn",
                    "B. Non-erosive reflux disease (NERD)",
                    "C. Esophageal hypersensitivity",
                    "D. Achalasia"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "PPI-responsive, endoscopy-negative GERD = NERD (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "NERD",
                    "PPI_responsive"
                ]
            },
            {
                "id": 440,
                "question": "Best sleeping position to reduce nocturnal GERD?",
                "choices": [
                    "A. Right lateral",
                    "B. Left lateral + head elevated",
                    "C. Supine",
                    "D. Prone"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Left lateral decubitus with head elevation reduces reflux episodes (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "sleep_position",
                    "left_lateral"
                ]
            },
            {
                "id": 441,
                "question": "A 62-year-old with GERD and new-onset atrial fibrillation. Likely trigger?",
                "choices": [
                    "A. Large hiatal hernia",
                    "B. Vagal irritation from distended stomach",
                    "C. PPI side effect",
                    "D. No relation"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Large meals or distension can trigger AF via vagal mechanism (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "atrial_fibrillation",
                    "vagal"
                ]
            },
            {
                "id": 442,
                "question": "Step-up vs step-down approach in GERD: Ethiopia recommends?",
                "choices": [
                    "A. Step-up (antacid → H2RA → PPI)",
                    "B. Step-down (start with PPI, then taper)",
                    "C. Both acceptable",
                    "D. Antacids only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Start with PPI (most effective) then step down if controlled (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "step_down",
                    "PPI_first"
                ]
            },
            {
                "id": 443,
                "question": "Patient with GERD and osteoporosis on long-term PPI. Concern?",
                "choices": [
                    "A. Increased fracture risk",
                    "B. No concern",
                    "C. Only kidney stones",
                    "D. Vitamin B12 only"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Long-term PPI associated with reduced calcium absorption → fracture risk (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "PPI_side_effect",
                    "fracture"
                ]
            },
            {
                "id": 444,
                "question": "Child with recurrent vomiting and failure to thrive. Possible diagnosis?",
                "choices": [
                    "A. GERD",
                    "B. Pyloric stenosis",
                    "C. Both possible",
                    "D. Intestinal obstruction"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "GERD in children can present with vomiting, poor weight gain (cross-reference pediatric chapter, STG 2021).",
                "tags": [
                    "GERD",
                    "pediatric",
                    "vomiting"
                ]
            },
            {
                "id": 445,
                "question": "Most effective way to confirm GERD when endoscopy and pH are unavailable?",
                "choices": [
                    "A. Barium swallow",
                    "B. Therapeutic PPI trial (PPI test)",
                    "C. Manometry",
                    "D. Clinical history only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "PPI test (symptom resolution on 2–4 weeks PPI) has high sensitivity/specificity (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "PPI_test",
                    "diagnosis"
                ]
            },
            {
                "id": 446,
                "question": "Patient with GERD develops black stools. Most likely cause?",
                "choices": [
                    "A. Erosive esophagitis bleeding",
                    "B. Peptic ulcer",
                    "C. Iron supplementation",
                    "D. Any of the above"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Severe esophagitis or concomitant ulcer can bleed; iron also causes black stool (STG 2021).",
                "tags": [
                    "GERD",
                    "melena",
                    "bleeding"
                ]
            },
            {
                "id": 447,
                "question": "Role of antacids in GERD management?",
                "choices": [
                    "A. First-line",
                    "B. For rapid symptom relief (on-demand)",
                    "C. Healing esophagitis",
                    "D. Long-term maintenance"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Antacids provide quick relief but do not heal esophagitis (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "antacids",
                    "symptomatic"
                ]
            },
            {
                "id": 448,
                "question": "Patient with scleroderma and severe GERD. Reason?",
                "choices": [
                    "A. Increased acid production",
                    "B. Impaired esophageal motility and low LES pressure",
                    "C. H. pylori",
                    "D. Hiatal hernia"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Connective tissue diseases cause poor peristalsis and LES incompetence (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "scleroderma",
                    "motility"
                ]
            },
            {
                "id": 449,
                "question": "Minimum duration of PPI for healing erosive esophagitis?",
                "choices": [
                    "A. 2 weeks",
                    "B. 4–8 weeks",
                    "C. 12 weeks",
                    "D. 6 months"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Most heal within 4–8 weeks; severe cases may need longer (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "healing_duration",
                    "PPI"
                ]
            },
            {
                "id": 450,
                "question": "A 40-year-old with GERD symptoms and globus sensation. Management?",
                "choices": [
                    "A. Reassure + PPI trial",
                    "B. Immediate ENT referral",
                    "C. Thyroid ultrasound",
                    "D. Surgery"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Globus is common in LPR; responds to PPI (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "globus",
                    "LPR"
                ]
            },
            {
                "id": 451,
                "question": "Strongest indication for 24-hour pH monitoring?",
                "choices": [
                    "A. Typical symptoms",
                    "B. Refractory symptoms with normal endoscopy",
                    "C. Before starting PPI",
                    "D. All patients"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Gold standard for confirming reflux in endoscopy-negative, PPI-refractory cases (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "pH_monitoring",
                    "refractory"
                ]
            },
            {
                "id": 452,
                "question": "Patient with GERD and dental erosions. Likely cause?",
                "choices": [
                    "A. Bulimia",
                    "B. Chronic acid reflux",
                    "C. Poor hygiene",
                    "D. Fluoride deficiency"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Acid exposure causes dental enamel erosion (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "dental_erosion",
                    "extraesophageal"
                ]
            },
            {
                "id": 453,
                "question": "When to repeat endoscopy in GERD?",
                "choices": [
                    "A. Every year",
                    "B. New alarm symptoms or Barrett’s surveillance",
                    "C. After 8 weeks PPI",
                    "D. Never"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Repeat only if alarm symptoms or for Barrett’s surveillance (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "repeat_endoscopy",
                    "indication"
                ]
            },
            {
                "id": 454,
                "question": "Most common type of hiatal hernia associated with GERD?",
                "choices": [
                    "A. Paraesophageal (Type II–IV)",
                    "B. Sliding (Type I)",
                    "C. Mixed",
                    "D. Traumatic"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Sliding hiatal hernia (Type I) is most common and contributes to GERD (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "sliding_hernia",
                    "hiatal"
                ]
            },
            {
                "id": 455,
                "question": "Patient with GERD well-controlled on PPI wants to stop. Advice?",
                "choices": [
                    "A. Stop abruptly",
                    "B. Gradual taper and lifestyle continuation",
                    "C. Switch to H2RA",
                    "D. Never stop"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Attempt step-down or discontinuation in mild disease with sustained lifestyle measures (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "PPI_taper",
                    "discontinuation"
                ]
            },
            {
                "id": 456,
                "question": "Final patient education point for GERD?",
                "choices": [
                    "A. Symptoms will disappear forever",
                    "B. Chronic, relapsing condition; continue lifestyle changes even on treatment",
                    "C. Surgery cures all",
                    "D. Antacids are enough"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "GERD is chronic and relapsing; lifestyle modification is lifelong (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "patient_education",
                    "chronic"
                ]
            },
            {
                "id": 457,
                "question": "A 39-year-old woman presents with heartburn for 8 months. She took omeprazole 20 mg daily for 4 weeks with partial improvement. What is the most appropriate next step according to Ethiopian STG 2021?",
                "choices": [
                    "A. Stop omeprazole and switch to ranitidine",
                    "B. Increase omeprazole to 40 mg daily for another 4–8 weeks",
                    "C. Immediate referral for fundoplication",
                    "D. Add aluminium hydroxide only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Partial responders should receive dose escalation to omeprazole 40 mg once daily (or 20 mg twice daily) for another 4–8 weeks before declaring treatment failure (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "partial_response",
                    "dose_escalation"
                ]
            },
            {
                "id": 458,
                "question": "A 45-year-old truck driver has typical GERD symptoms only when driving long distances lying semi-reclined. The single most effective advice is:",
                "choices": [
                    "A. Take PPI twice daily",
                    "B. Avoid lying down immediately after meals and use extra pillows",
                    "C. Stop eating spicy food only",
                    "D. Drink coffee to stay awake"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Postural reflux is best prevented by avoiding recumbency after meals and elevating the head of the bed (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "postural_reflux",
                    "lifestyle"
                ]
            },
            {
                "id": 459,
                "question": "Which of the following foods has the strongest evidence for worsening GERD symptoms?",
                "choices": [
                    "A. Injera with shiro",
                    "B. Chocolate and peppermint",
                    "C. Teff bread",
                    "D. Banana"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Chocolate, peppermint, coffee, fatty foods, citrus, and alcohol consistently lower LES pressure (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "trigger_foods",
                    "LES_relaxation"
                ]
            },
            {
                "id": 460,
                "question": "A 55-year-old man with chronic GERD presents with new-onset dysphagia to solids progressing to liquids over 3 weeks. Most likely diagnosis?",
                "choices": [
                    "A. Achalasia",
                    "B. Peptic stricture",
                    "C. Functional dysphagia",
                    "D. Stroke"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Progressive dysphagia from solids to liquids in long-standing GERD is classic for peptic stricture (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "peptic_stricture",
                    "progressive_dysphagia"
                ]
            },
            {
                "id": 461,
                "question": "Management of peptic stricture in GERD includes all EXCEPT:",
                "choices": [
                    "A. High-dose PPI",
                    "B. Endoscopic dilatation",
                    "C. Long-term PPI after dilatation",
                    "D. Immediate esophagectomy"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Peptic strictures are managed with PPI + endoscopic balloon/savary dilatation; surgery is rarely needed (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "stricture",
                    "dilatation"
                ]
            },
            {
                "id": 462,
                "question": "A 32-year-old woman at 28 weeks gestation has daily heartburn not relieved by lifestyle changes and calcium-based antacids. Next safest step?",
                "choices": [
                    "A. Ranitidine 150 mg BID",
                    "B. Omeprazole 20 mg daily",
                    "C. Domperidone",
                    "D. Continue antacids only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "If lifestyle + antacids fail in pregnancy, PPI (omeprazole preferred) is safe and recommended (category B) (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "pregnancy",
                    "PPI_safe"
                ]
            },
            {
                "id": 463,
                "question": "Which of the following is an absolute contraindication to metoclopramide as adjunct in GERD?",
                "choices": [
                    "A. Pregnancy",
                    "B. Parkinson’s disease",
                    "C. Hypertension",
                    "D. Diabetes"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Metoclopramide can worsen Parkinson’s disease due to dopamine antagonism (STG 2021).",
                "tags": [
                    "GERD",
                    "metoclopramide",
                    "contraindication"
                ]
            },
            {
                "id": 464,
                "question": "A patient with GERD and asthma has frequent night-time wheezing. Most effective intervention?",
                "choices": [
                    "A. Increase salbutamol",
                    "B. Start high-dose PPI",
                    "C. Add montelukast",
                    "D. Inhaled corticosteroid only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Nocturnal asthma in GERD patients often improves dramatically with adequate acid suppression (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "asthma",
                    "nocturnal"
                ]
            },
            {
                "id": 465,
                "question": "The Los Angeles Classification is used for grading:",
                "choices": [
                    "A. Barrett’s esophagus",
                    "B. Erosive esophagitis",
                    "C. Hiatal hernia",
                    "D. Esophageal varices"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "LA classification grades erosive esophagitis from A (one or more mucosal breaks ≤5 mm) to D (>75% circumferential) (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "LA_classification",
                    "erosive"
                ]
            },
            {
                "id": 466,
                "question": "A 50-year-old man with GERD for 10 years has salmon-coloured mucosa extending 3 cm above the GE junction on endoscopy. Next step?",
                "choices": [
                    "A. Repeat endoscopy in 6 months",
                    "B. Biopsy to confirm Barrett’s + start surveillance program",
                    "C. Start sucralfate",
                    "D. No further action"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Salmon-coloured mucosa = suspected Barrett’s → mandatory biopsy and surveillance every 3–5 years if no dysplasia (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "Barretts",
                    "surveillance"
                ]
            },
            {
                "id": 467,
                "question": "Which Barrett’s esophagus finding requires immediate referral to tertiary centre?",
                "choices": [
                    "A. Short segment <3 cm",
                    "B. High-grade dysplasia or early adenocarcinoma",
                    "C. Intestinal metaplasia without dysplasia",
                    "D. Long segment >8 cm"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "High-grade dysplasia or early cancer requires endoscopic resection or ablation (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "Barretts",
                    "HGD"
                ]
            },
            {
                "id": 468,
                "question": "A patient with refractory GERD is scheduled for Nissen fundoplication. Most important preoperative investigation?",
                "choices": [
                    "A. Barium swallow",
                    "B. 24-hour pH monitoring + manometry",
                    "C. CT chest",
                    "D. ECG"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Objective evidence of reflux (pH study) and normal esophageal motility are required before anti-reflux surgery (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "surgery",
                    "preop"
                ]
            },
            {
                "id": 469,
                "question": "Most common side effect that leads to PPI discontinuation in Ethiopia?",
                "choices": [
                    "A. Diarrhoea",
                    "B. Headache",
                    "C. Cost of long-term therapy",
                    "D. Vitamin B12 deficiency"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Economic factors are the leading cause of non-adherence in resource-limited settings (STG 2021).",
                "tags": [
                    "GERD",
                    "PPI",
                    "adherence"
                ]
            },
            {
                "id": 470,
                "question": "A 29-year-old with heartburn and chest pain. ECG normal. Most useful test to differentiate cardiac from esophageal pain?",
                "choices": [
                    "A. Troponin",
                    "B. Therapeutic PPI trial",
                    "C. Exercise stress test",
                    "D. Coronary angiography"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Non-cardiac chest pain that responds to high-dose PPI is diagnostic of esophageal origin (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "chest_pain",
                    "PPI_test"
                ]
            },
            {
                "id": 471,
                "question": "Which of the following reduces GERD symptoms in overweight patients most effectively?",
                "choices": [
                    "A. 5 kg weight loss",
                    "B. 10–15% body weight reduction",
                    "C. Low-fat diet only",
                    "D. High-protein diet"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Significant weight loss (≥10%) markedly reduces reflux episodes (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "obesity",
                    "weight_loss"
                ]
            },
            {
                "id": 472,
                "question": "A patient with GERD on long-term PPI develops community-acquired pneumonia. Most likely relationship?",
                "choices": [
                    "A. No relation",
                    "B. Possible increased risk due to reduced gastric acidity",
                    "C. PPI protects against pneumonia",
                    "D. Only in elderly"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Long-term PPI slightly increases risk of CAP due to bacterial overgrowth (STG 2021).",
                "tags": [
                    "GERD",
                    "PPI",
                    "pneumonia_risk"
                ]
            },
            {
                "id": 473,
                "question": "Best management for Cameron lesions in large hiatal hernia causing chronic blood loss?",
                "choices": [
                    "A. Iron supplementation only",
                    "B. High-dose PPI + iron therapy",
                    "C. Surgical hernia repair",
                    "D. Transfusion"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Cameron lesions heal with aggressive acid suppression + iron (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "Cameron_lesions",
                    "anemia"
                ]
            },
            {
                "id": 474,
                "question": "A 44-year-old teacher has GERD symptoms only during stressful examination periods. Likely diagnosis?",
                "choices": [
                    "A. Functional heartburn",
                    "B. Stress-related increase in acid reflux",
                    "C. Peptic ulcer",
                    "D. Gallstones"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Stress transiently lowers LES pressure and increases acid exposure (STG 2021).",
                "tags": [
                    "GERD",
                    "stress",
                    "transient"
                ]
            },
            {
                "id": 475,
                "question": "Patient with NERD and normal pH study but symptoms correlate with reflux events. Diagnosis?",
                "choices": [
                    "A. Functional heartburn",
                    "B. Reflux hypersensitivity",
                    "C. True GERD",
                    "D. Achalasia"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Positive symptom-reflux association despite normal acid exposure = reflux hypersensitivity (Rome IV, referenced in STG).",
                "tags": [
                    "GERD",
                    "hypersensitivity",
                    "SI_positive"
                ]
            },
            {
                "id": 476,
                "question": "A patient with severe GERD develops pill-induced esophagitis. Most implicated drug in Ethiopia?",
                "choices": [
                    "A. Doxycycline",
                    "B. Ferrous sulphate",
                    "C. NSAIDs",
                    "D. All of the above"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Common culprits: doxycycline, potassium, NSAIDs, bisphosphonates (STG 2021).",
                "tags": [
                    "GERD",
                    "pill_esophagitis",
                    "doxycycline"
                ]
            },
            {
                "id": 477,
                "question": "Most important counselling point when prescribing long-term PPI?",
                "choices": [
                    "A. Take with meals",
                    "B. Take 30–60 minutes before breakfast",
                    "C. Take at bedtime",
                    "D. Take only when symptomatic"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "PPIs require pre-meal administration for maximal parietal cell inhibition (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "PPI_timing",
                    "counselling"
                ]
            },
            {
                "id": 478,
                "question": "A 60-year-old man with GERD and chronic kidney disease stage 4. Safest long-term acid suppressant?",
                "choices": [
                    "A. Omeprazole",
                    "B. Ranitidine (avoid high dose)",
                    "C. Pantoprazole (dose adjustment)",
                    "D. All equally safe"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Pantoprazole has least renal excretion; preferred in advanced CKD (STG 2021).",
                "tags": [
                    "GERD",
                    "CKD",
                    "pantoprazole"
                ]
            },
            {
                "id": 479,
                "question": "Patient with GERD and new iron-deficiency anaemia but no overt bleeding. Most likely source?",
                "choices": [
                    "A. Colon cancer",
                    "B. Chronic erosive esophagitis / Cameron lesions",
                    "C. Duodenal ulcer",
                    "D. Hemorrhoids"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Chronic microscopic blood loss from erosions or Cameron lesions common in long-standing GERD (STG 2021).",
                "tags": [
                    "GERD",
                    "anemia",
                    "occult_bleeding"
                ]
            },
            {
                "id": 480,
                "question": "Best non-invasive test when endoscopy is unavailable and PPI trial is equivocal?",
                "choices": [
                    "A. Barium swallow",
                    "B. Upper GI series may show reflux or hiatal hernia",
                    "C. Abdominal ultrasound",
                    "D. Chest X-ray"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "In resource-limited settings, barium swallow can demonstrate reflux or structural abnormality (STG 2021).",
                "tags": [
                    "GERD",
                    "barium_swallow",
                    "resource_limited"
                ]
            },
            {
                "id": 481,
                "question": "A patient with refractory GERD on maximal PPI still has symptoms. Next most useful add-on therapy?",
                "choices": [
                    "A. Baclofen",
                    "B. Alginate (Gaviscon)",
                    "C. Sucralfate",
                    "D. All reasonable"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Options for refractory GERD: alginate raft, baclofen (TLESR inhibitor), or pain modulators (STG 2021).",
                "tags": [
                    "GERD",
                    "refractory",
                    "alginate"
                ]
            },
            {
                "id": 482,
                "question": "Patient with GERD develops new-onset sinusitis. Possible link?",
                "choices": [
                    "A. No link",
                    "B. Aspiration of refluxate",
                    "C. PPI-induced hypochlorhydria",
                    "D. Coincidence"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Extra-esophageal reflux can cause chronic sinusitis via microaspiration (STG 2021).",
                "tags": [
                    "GERD",
                    "sinusitis",
                    "extraesophageal"
                ]
            },
            {
                "id": 483,
                "question": "Most common endoscopic finding in patients with typical GERD symptoms in Ethiopia?",
                "choices": [
                    "A. Erosive esophagitis",
                    "B. Normal esophagus (NERD)",
                    "C. Barrett’s",
                    "D. Stricture"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "60–70% of patients with typical symptoms have non-erosive reflux disease (STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "NERD",
                    "Ethiopia"
                ]
            },
            {
                "id": 484,
                "question": "A 35-year-old with GERD wants to conceive. Advice regarding PPI?",
                "choices": [
                    "A. Stop immediately",
                    "B. Omeprazole is safe throughout pregnancy",
                    "C. Switch to ranitidine",
                    "D. Use only in third trimester"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Large data show omeprazole is safe in all trimesters (STG 2021).",
                "tags": [
                    "GERD",
                    "pregnancy_planning",
                    "omeprazole"
                ]
            },
            {
                "id": 485,
                "question": "Patient with GERD and laryngeal cancer risk. Strongest preventive measure?",
                "choices": [
                    "A. Smoking cessation",
                    "B. Aggressive acid suppression",
                    "C. Alcohol abstinence",
                    "D. All important"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Tobacco and alcohol are far stronger risk factors than reflux for laryngeal cancer.",
                "tags": [
                    "GERD",
                    "LPR",
                    "cancer_risk"
                ]
            },
            {
                "id": 486,
                "question": "A 48-year-old with GERD symptoms wakes up choking at night. Likely mechanism?",
                "choices": [
                    "A. Laryngospasm due to LPR",
                    "B. Asthma attack",
                    "C. Cardiac arrhythmia",
                    "D. Panic attack"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Nocturnal laryngopharyngeal reflux can trigger laryngospasm (STG 2021).",
                "tags": [
                    "GERD",
                    "LPR",
                    "choking"
                ]
            },
            {
                "id": 487,
                "question": "Minimum duration of symptoms required to diagnose GERD clinically?",
                "choices": [
                    "A. 1 week",
                    "B. Symptoms at least twice weekly for several weeks",
                    "C. Daily symptoms only",
                    "D. No duration needed"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Heartburn/regurgitation ≥2 times/week for several weeks defines clinically significant GERD (STG 2021).",
                "tags": [
                    "GERD",
                    "definition",
                    "frequency"
                ]
            },
            {
                "id": 488,
                "question": "Patient with HIV on atazanavir develops severe GERD. Management issue?",
                "choices": [
                    "A. PPI reduces atazanavir absorption",
                    "B. Use H2 blocker or antacid instead",
                    "C. Stop atazanavir",
                    "D. No interaction"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "PPIs contraindicated with atazanavir; use ranitidine or spaced antacids (STG 2021).",
                "tags": [
                    "GERD",
                    "HIV",
                    "atazanavir"
                ]
            },
            {
                "id": 489,
                "question": "Most common cause of refractory GERD in clinical practice?",
                "choices": [
                    "A. Poor adherence to PPI timing",
                    "B. Zollinger-Ellison",
                    "C. Eosinophilic esophagitis",
                    "D. Bile reflux"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Incorrect timing (taking PPI after meals or at night) is the leading cause of apparent refractoriness (STG 2021).",
                "tags": [
                    "GERD",
                    "refractory",
                    "adherence"
                ]
            },
            {
                "id": 490,
                "question": "A 42-year-old with GERD and depression on amitriptyline. Effect on reflux?",
                "choices": [
                    "A. Improves",
                    "B. Worsens (anticholinergic effect)",
                    "C. No effect",
                    "D. Only sedation"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Tricyclic antidepressants relax LES and delay gastric emptying.",
                "tags": [
                    "GERD",
                    "drug_interaction",
                    "amitriptyline"
                ]
            },
            {
                "id": 491,
                "question": "Patient with GERD and nocturnal regurgitation wants to prevent aspiration. Best advice?",
                "choices": [
                    "A. Sleep with two pillows",
                    "B. Elevate head of bed 15–20 cm + avoid meals 3–4 hours before bed",
                    "C. Take PPI at night",
                    "D. Sleep on right side"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Head elevation + prolonged pre-bedtime fasting most effective against nocturnal reflux (STG 2021).",
                "tags": [
                    "GERD",
                    "nocturnal",
                    "aspiration_prevention"
                ]
            },
            {
                "id": 492,
                "question": "A 38-year-old with GERD develops halitosis and bitter taste. Likely cause?",
                "choices": [
                    "A. Dental caries",
                    "B. Regurgitation of gastric contents",
                    "C. H. pylori",
                    "D. Sinusitis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Passive regurgitation causes bad breath and sour taste.",
                "tags": [
                    "GERD",
                    "halitosis",
                    "regurgitation"
                ]
            },
            {
                "id": 493,
                "question": "Safest acid suppressant in lactation?",
                "choices": [
                    "A. Omeprazole",
                    "B. Ranitidine",
                    "C. Both safe",
                    "D. Antacids only"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Both omeprazole and ranitidine are compatible with breastfeeding (STG 2021).",
                "tags": [
                    "GERD",
                    "lactation",
                    "safe"
                ]
            },
            {
                "id": 494,
                "question": "Patient with GERD and large hiatal hernia develops acute chest pain and vomiting. Most worrying diagnosis?",
                "choices": [
                    "A. Myocardial infarction",
                    "B. Paraesophageal hernia incarceration",
                    "C. Perforated ulcer",
                    "D. Pancreatitis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Acute incarceration/strangulation of paraesophageal hernia is surgical emergency.",
                "tags": [
                    "GERD",
                    "paraesophageal",
                    "emergency"
                ]
            },
            {
                "id": 495,
                "question": "A patient with GERD improves on PPI but relapses immediately after stopping. Best long-term strategy?",
                "choices": [
                    "A. Continue high-dose PPI forever",
                    "B. Lowest effective PPI dose + sustained lifestyle changes",
                    "C. Switch to surgery",
                    "D. On-demand therapy"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Step-down to minimal effective dose with lifelong lifestyle modification is recommended (STG 2021).",
                "tags": [
                    "GERD",
                    "maintenance",
                    "step_down"
                ]
            },
            {
                "id": 496,
                "question": "Most important risk factor for erosive esophagitis severity?",
                "choices": [
                    "A. Duration of symptoms",
                    "B. Hiatal hernia size",
                    "C. BMI",
                    "D. H. pylori status"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Longer duration of untreated reflux strongly correlates with erosive severity (STG 2021).",
                "tags": [
                    "GERD",
                    "erosive",
                    "duration"
                ]
            },
            {
                "id": 497,
                "question": "Patient with GERD and scleroderma has severe symptoms despite maximal PPI. Reason?",
                "choices": [
                    "A. Poor esophageal clearance",
                    "B. High acid production",
                    "C. Bile reflux",
                    "D. Gastritis"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Scleroderma causes absent peristalsis → prolonged acid contact despite normal/suppressed acid (STG 2021).",
                "tags": [
                    "GERD",
                    "scleroderma",
                    "motility"
                ]
            },
            {
                "id": 498,
                "question": "A 27-year-old medical student has heartburn only after late-night studying with coffee. Best management?",
                "choices": [
                    "A. Lifelong PPI",
                    "B. Lifestyle: stop late meals and coffee",
                    "C. Endoscopy",
                    "D. H. pylori test"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Clear trigger-related symptoms in young patient → lifestyle modification first (STG 2021).",
                "tags": [
                    "GERD",
                    "young",
                    "lifestyle"
                ]
            },
            {
                "id": 499,
                "question": "Patient with GERD and known esophageal stricture after dilatation still requires long-term PPI to:",
                "choices": [
                    "A. Prevent re-stricture",
                    "B. Heal mucosa only",
                    "C. Reduce saliva",
                    "D. No need"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Continued acid suppression dramatically reduces recurrence of peptic strictures (STG 2021).",
                "tags": [
                    "GERD",
                    "stricture",
                    "PPI_prevention"
                ]
            },
            {
                "id": 500,
                "question": "Final take-home message for every GERD patient in Ethiopia?",
                "choices": [
                    "A. You will need PPI forever",
                    "B. GERD is a chronic relapsing disease; lifestyle changes are lifelong even if symptoms disappear",
                    "C. Surgery cures it",
                    "D. Spicy food is the only trigger"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.2 Gastroesophageal Reflux Disease (GERD)",
                "explanation": "Patient education on chronicity and importance of sustained lifestyle measures is crucial for long-term control (Ethiopian STG 2021, p.182).",
                "tags": [
                    "GERD",
                    "patient_education",
                    "chronic"
                ]
            }
        ]
    },
    "Chapter 6.3": {
        "Chapter 6.3 Gastrointestinal Bleeding": [
            {
                "id": 501,
                "question": "A 55-year-old farmer presents with massive hematemesis and melena for 6 hours. He has been vomiting blood at home and is now dizzy. On examination BP 80/50 mmHg, pulse 130/min. What is the FIRST priority according to Ethiopian STG 2021?",
                "choices": [
                    "A. Urgent upper GI endoscopy",
                    "B. IV omeprazole 80 mg bolus",
                    "C. Secure two large-bore IV lines and rapid fluid resuscitation",
                    "D. Blood transfusion immediately"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "ABC resuscitation comes first. Secure large-bore IV access (≥18G) and start crystalloid resuscitation in actively bleeding UGIB with shock (STG 2021, p.185).",
                "tags": [
                    "UGIB",
                    "shock",
                    "resuscitation"
                ]
            },
            {
                "id": 502,
                "question": "A patient with upper GI bleeding has BP 90/60 mmHg after 1 litre of normal saline. Next most appropriate fluid?",
                "choices": [
                    "A. Continue saline",
                    "B. Start packed red blood cells",
                    "C. Give fresh frozen plasma",
                    "D. Colloids"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Target transfusion when Hb <7 g/dL or ongoing bleeding with hemodynamic instability. In shock, transfuse PRBC early (STG 2021, p.185).",
                "tags": [
                    "UGIB",
                    "transfusion",
                    "PRBC"
                ]
            },
            {
                "id": 503,
                "question": "Most common cause of severe acute upper GI bleeding in Ethiopia?",
                "choices": [
                    "A. Mallory-Weiss tear",
                    "B. Peptic ulcer disease",
                    "C. Esophageal varices",
                    "D. Gastritis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Peptic ulcer (duodenal > gastric) remains the leading cause of non-variceal UGIB in Ethiopia (STG 2021, p.185).",
                "tags": [
                    "UGIB",
                    "peptic_ulcer",
                    "Ethiopia"
                ]
            },
            {
                "id": 504,
                "question": "A 45-year-old chronic alcohol user presents with massive hematemesis. No signs of chronic liver disease. Most likely source?",
                "choices": [
                    "A. Varices",
                    "B. Peptic ulcer",
                    "C. Mallory-Weiss tear",
                    "D. Gastritis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Even in alcoholics, peptic ulcer is more common than varices unless stigmata of portal hypertension are present (STG 2021).",
                "tags": [
                    "UGIB",
                    "alcohol",
                    "peptic_ulcer"
                ]
            },
            {
                "id": 505,
                "question": "First-line pharmacological therapy for acute non-variceal UGIB after resuscitation?",
                "choices": [
                    "A. IV octreotide",
                    "B. IV omeprazole 80 mg bolus followed by 8 mg/hour infusion",
                    "C. Oral tranexamic acid",
                    "D. IV ranitidine"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "High-dose IV PPI (omeprazole 80 mg bolus + 8 mg/hr for 72 hours) reduces rebleeding and need for intervention in non-variceal UGIB (STG 2021, p.186).",
                "tags": [
                    "non_variceal",
                    "PPI_infusion",
                    "high_dose"
                ]
            },
            {
                "id": 506,
                "question": "A patient with suspected variceal bleeding. Drug of choice before endoscopy?",
                "choices": [
                    "A. IV omeprazole",
                    "B. Terlipressin 1–2 mg IV every 4–6 hours or octreotide 50 mcg bolus + 50 mcg/hr",
                    "C. Propranolol oral",
                    "D. Ceftriaxone only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Terlipressin (or octreotide if unavailable) + ceftriaxone 1 g IV started before endoscopy in suspected variceal bleed (STG 2021, p.187).",
                "tags": [
                    "variceal",
                    "terlipressin",
                    "octreotide"
                ]
            },
            {
                "id": 507,
                "question": "Prophylactic antibiotic in cirrhotic patient with UGIB?",
                "choices": [
                    "A. Ceftriaxone 1 g IV daily for 7 days",
                    "B. Amoxicillin only",
                    "C. Metronidazole",
                    "D. No need"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Ceftriaxone 1 g IV daily (or norfloxacin if IV unavailable) reduces bacterial infections and mortality in variceal bleeding (STG 2021, p.187).",
                "tags": [
                    "variceal",
                    "ceftriaxone",
                    "prophylaxis"
                ]
            },
            {
                "id": 508,
                "question": "Timing of endoscopy in hemodynamically stable patient with UGIB?",
                "choices": [
                    "A. Immediate",
                    "B. Within 24 hours",
                    "C. Within 12 hours",
                    "D. After 72 hours PPI"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Stable patients: endoscopy within 24 hours. Unstable after resuscitation: as soon as possible (STG 2021, p.185).",
                "tags": [
                    "UGIB",
                    "endoscopy_timing",
                    "stable"
                ]
            },
            {
                "id": 509,
                "question": "Rockall score is used to predict:",
                "choices": [
                    "A. Source of bleeding",
                    "B. Risk of rebleeding and mortality",
                    "C. Need for surgery",
                    "D. H. pylori status"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Pre- and post-endoscopy Rockall score stratifies mortality risk in UGIB (STG 2021).",
                "tags": [
                    "Rockall_score",
                    "risk_stratification"
                ]
            },
            {
                "id": 510,
                "question": "A patient with UGIB has active spurting vessel on endoscopy. Forrest classification?",
                "choices": [
                    "A. Ia",
                    "B. Ib",
                    "C. IIa",
                    "D. IIb"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Forrest Ia = active spurting bleeding (highest rebleeding risk) (STG 2021).",
                "tags": [
                    "Forrest",
                    "Ia",
                    "spurting"
                ]
            },
            {
                "id": 511,
                "question": "Endoscopic hemostasis indicated in all EXCEPT:",
                "choices": [
                    "A. Active spurting (Ia)",
                    "B. Visible vessel (IIa)",
                    "C. Adherent clot (IIb) – controversial, often removed",
                    "D. Clean base ulcer (III)"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Clean-based ulcer (Forrest III) has <5% rebleeding risk → no endoscopic therapy needed (STG 2021).",
                "tags": [
                    "Forrest_III",
                    "no_therapy"
                ]
            },
            {
                "id": 512,
                "question": "Best endoscopic method for bleeding peptic ulcer in most Ethiopian hospitals?",
                "choices": [
                    "A. Adrenaline injection + heater probe/coagulation",
                    "B. Band ligation",
                    "C. Hemoclips alone",
                    "D. Argon plasma coagulation"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Dual therapy (adrenaline injection + thermal coagulation or clips) is superior to injection alone (STG 2021).",
                "tags": [
                    "endoscopic_hemostasis",
                    "dual_therapy"
                ]
            },
            {
                "id": 513,
                "question": "Patient rebleeds 24 hours after endoscopic therapy for peptic ulcer. Next step?",
                "choices": [
                    "A. Repeat endoscopy",
                    "B. Immediate surgery",
                    "C. Angiography",
                    "D. Conservative only"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Second-look endoscopy and repeat hemostasis preferred over surgery in most cases (STG 2021).",
                "tags": [
                    "rebleeding",
                    "second_endoscopy"
                ]
            },
            {
                "id": 514,
                "question": "Indication for surgery in non-variceal UGIB?",
                "choices": [
                    "A. Failed second endoscopic attempt",
                    "B. All patients",
                    "C. Only if Hb <7",
                    "D. After 4 units transfusion"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Surgery indicated after two failed endoscopic therapies or massive bleeding unresponsive to resuscitation (STG 2021).",
                "tags": [
                    "surgery",
                    "failed_endoscopy"
                ]
            },
            {
                "id": 515,
                "question": "A 60-year-old with bright red hematochezia and hemodynamic instability. Most likely source?",
                "choices": [
                    "A. Hemorrhoids",
                    "B. Upper GI source (brisk UGIB)",
                    "C. Diverticular bleed",
                    "D. Ischemic colitis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Massive hematochezia with shock → think brisk UGIB until proven otherwise (up to 15% of presumed LGIB are actually UGIB) (STG 2021).",
                "tags": [
                    "hematochezia",
                    "brisk_UGIB"
                ]
            },
            {
                "id": 516,
                "question": "Blatchford score is used at presentation to decide:",
                "choices": [
                    "A. Need for endoscopic intervention",
                    "B. Need for hospital admission and early endoscopy",
                    "C. Mortality risk",
                    "D. H. pylori status"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Blatchford score = 0 → safe for outpatient management (STG 2021).",
                "tags": [
                    "Blatchford",
                    "admission"
                ]
            },
            {
                "id": 517,
                "question": "Patient with variceal bleeding controlled by banding. Secondary prophylaxis?",
                "choices": [
                    "A. Propranolol or nadolol + repeat banding until obliteration",
                    "B. PPI only",
                    "C. Octreotide lifelong",
                    "D. No need"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Combination non-selective beta-blocker + endoscopic variceal ligation (EVL) is standard secondary prophylaxis (STG 2021).",
                "tags": [
                    "variceal",
                    "secondary_prophylaxis"
                ]
            },
            {
                "id": 518,
                "question": "Best method for acute variceal bleeding control when endoscopy unavailable?",
                "choices": [
                    "A. Sengstaken-Blakemore tube",
                    "B. IV PPI",
                    "C. Tranexamic acid",
                    "D. Fresh frozen plasma"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Balloon tamponade is a temporary bridge (max 24 hours) until definitive therapy (STG 2021).",
                "tags": [
                    "variceal",
                    "balloon_tamponade"
                ]
            },
            {
                "id": 519,
                "question": "Most common cause of lower GI bleeding in adults in Ethiopia?",
                "choices": [
                    "A. Colorectal cancer",
                    "B. Hemorrhoids",
                    "C. Infectious colitis (dysentery)",
                    "D. Diverticulosis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Hemorrhoids remain the most common cause of LGIB in Ethiopia (STG 2021).",
                "tags": [
                    "LGIB",
                    "hemorrhoids",
                    "Ethiopia"
                ]
            },
            {
                "id": 520,
                "question": "A 70-year-old with painless massive hematochezia. Most likely diagnosis?",
                "choices": [
                    "A. Hemorrhoids",
                    "B. Diverticular bleeding",
                    "C. Ischemic colitis",
                    "D. Cancer"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Elderly + painless + large volume → diverticular bleed (right colon) (STG 2021).",
                "tags": [
                    "LGIB",
                    "diverticular"
                ]
            },
            {
                "id": 521,
                "question": "Patient passes bright red blood per rectum with clots and abdominal pain. Likely diagnosis?",
                "choices": [
                    "A. Upper GI bleed",
                    "B. Dysentery (shigella/amoeba)",
                    "C. Hemorrhoids",
                    "D. Diverticulosis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Bloody diarrhea with pain and tenesmus → infectious colitis (STG 2021).",
                "tags": [
                    "LGIB",
                    "dysentery"
                ]
            },
            {
                "id": 522,
                "question": "NSAID-induced UGIB. Management includes all EXCEPT:",
                "choices": [
                    "A. Stop NSAID permanently",
                    "B. High-dose IV PPI",
                    "C. H. pylori testing and eradication",
                    "D. Restart low-dose aspirin if cardiovascular indication"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "In patients with cardiovascular disease, aspirin should be restarted as soon as hemostasis achieved (usually within 1–3 days) (STG 2021).",
                "tags": [
                    "NSAID",
                    "aspirin_restart"
                ]
            },
            {
                "id": 523,
                "question": "Transfusion threshold in stable UGIB patient without cardiac disease?",
                "choices": [
                    "A. Hb <7 g/dL",
                    "B. Hb <8 g/dL",
                    "C. Hb <9 g/dL",
                    "D. Hb <10 g/dL"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Restrictive strategy (Hb <7 g/dL) reduces mortality compared to liberal transfusion (STG 2021).",
                "tags": [
                    "transfusion",
                    "restrictive"
                ]
            },
            {
                "id": 524,
                "question": "A patient with UGIB on warfarin presents with INR 5. Next immediate step?",
                "choices": [
                    "A. Vitamin K 10 mg IV",
                    "B. Stop warfarin + vitamin K + prothrombin complex concentrate (PCC) or FFP",
                    "C. Fresh frozen plasma only",
                    "D. Continue warfarin"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Major bleeding on warfarin → reverse with PCC (or FFP if unavailable) + vitamin K (STG 2021).",
                "tags": [
                    "warfarin",
                    "reversal",
                    "PCC"
                ]
            },
            {
                "id": 525,
                "question": "Most important predictor of poor outcome in variceal bleeding?",
                "choices": [
                    "A. Child-Pugh class C",
                    "B. Active bleeding on endoscopy",
                    "C. HVPG >20 mmHg",
                    "D. All of the above"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Child C, active spurting, and high HVPG are strong predictors (STG 2021).",
                "tags": [
                    "variceal",
                    "prognosis"
                ]
            },
            {
                "id": 526,
                "question": "TIPS (transjugular intrahepatic portosystemic shunt) indicated in variceal bleeding when:",
                "choices": [
                    "A. All patients",
                    "B. Refractory to medical + endoscopic therapy (salvage TIPS)",
                    "C. First bleed",
                    "D. Only Child A"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Salvage TIPS for uncontrolled variceal bleeding despite pharmacology + banding (STG 2021).",
                "tags": [
                    "TIPS",
                    "salvage"
                ]
            },
            {
                "id": 527,
                "question": "Patient with peptic ulcer bleeding successfully treated. When to test and treat H. pylori?",
                "choices": [
                    "A. Immediately",
                    "B. After 4–8 weeks when off PPI",
                    "C. During acute bleed",
                    "D. Never"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "False negative common during acute phase and on PPI → test after 4 weeks off PPI (STG 2021).",
                "tags": [
                    "H_pylori",
                    "timing"
                ]
            },
            {
                "id": 528,
                "question": "A 30-year-old with massive UGIB and known duodenal ulcer history. Endoscopy shows clean base. Management?",
                "choices": [
                    "A. Discharge same day",
                    "B. Observe 24–48 hours + oral PPI",
                    "C. IV PPI 72 hours",
                    "D. Surgery"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Low-risk ulcer (clean base, Rockall ≤2) → early discharge safe with oral PPI (STG 2021).",
                "tags": [
                    "low_risk",
                    "early_discharge"
                ]
            },
            {
                "id": 529,
                "question": "Most common complication of Sengstaken-Blakemore tube?",
                "choices": [
                    "A. Esophageal rupture",
                    "B. Aspiration pneumonia",
                    "C. Nasal bleeding",
                    "D. All possible"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "High complication rate (up to 30%) including necrosis and aspiration (STG 2021).",
                "tags": [
                    "balloon",
                    "complications"
                ]
            },
            {
                "id": 530,
                "question": "Patient with cirrhosis and UGIB. Platelet count 40,000. Need for platelet transfusion?",
                "choices": [
                    "A. Always",
                    "B. Only if active bleeding and <50,000 before procedure",
                    "C. Never",
                    "D. If <20,000"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Threshold for endoscopy: platelets >50,000; transfuse if lower and active bleeding (STG 2021).",
                "tags": [
                    "thrombocytopenia",
                    "transfusion"
                ]
            },
            {
                "id": 531,
                "question": "A patient passes maroon stool and is hemodynamically stable. Likely source?",
                "choices": [
                    "A. Right colon",
                    "B. Small bowel or brisk upper GI",
                    "C. Left colon",
                    "D. Rectum"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Maroon stool usually indicates small bowel or rapid transit from right colon/proximal source (STG 2021).",
                "tags": [
                    "maroon_stool",
                    "small_bowel"
                ]
            },
            {
                "id": 532,
                "question": "Best investigation for obscure GI bleeding when upper and lower endoscopy negative?",
                "choices": [
                    "A. Repeat colonoscopy",
                    "B. Capsule endoscopy",
                    "C. CT abdomen",
                    "D. Angiography"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Capsule endoscopy is first-line for small bowel evaluation in obscure-overt bleeding (STG 2021).",
                "tags": [
                    "obscure",
                    "capsule"
                ]
            },
            {
                "id": 533,
                "question": "Patient with UGIB and aortic graft presents with hematemesis. Suspected diagnosis?",
                "choices": [
                    "A. Peptic ulcer",
                    "B. Aortoenteric fistula",
                    "C. Varices",
                    "D. Gastritis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Herald bleed followed by massive hemorrhage classic for secondary aortoenteric fistula (STG 2021).",
                "tags": [
                    "aortoenteric_fistula",
                    "herald_bleed"
                ]
            },
            {
                "id": 534,
                "question": "Dieulafoy lesion is best treated endoscopically by:",
                "choices": [
                    "A. Injection only",
                    "B. Band ligation or hemoclip",
                    "C. Thermal coagulation only",
                    "D. No treatment"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Mechanical methods (banding or clipping) preferred over injection alone for Dieulafoy (STG 2021).",
                "tags": [
                    "Dieulafoy",
                    "band_ligation"
                ]
            },
            {
                "id": 535,
                "question": "Patient with massive LGIB not responding to resuscitation. Next step?",
                "choices": [
                    "A. Colonoscopy",
                    "B. Tagged RBC scan",
                    "C. Angiography with embolization",
                    "D. Surgery"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Unstable patient with ongoing LGIB → emergency angiography ± embolization (STG 2021).",
                "tags": [
                    "LGIB",
                    "angiography"
                ]
            },
            {
                "id": 536,
                "question": "Most common site of diverticular bleeding?",
                "choices": [
                    "A. Left colon",
                    "B. Right colon",
                    "C. Rectum",
                    "D. Transverse"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Paradoxically, right colonic diverticula bleed more frequently (STG 2021).",
                "tags": [
                    "diverticular",
                    "right_colon"
                ]
            },
            {
                "id": 537,
                "question": "Patient with UGIB improves after 72-hour PPI infusion. Next step?",
                "choices": [
                    "A. Stop PPI",
                    "B. Switch to oral PPI 40 mg daily for 4–8 weeks",
                    "C. Lifelong PPI",
                    "D. H. pylori only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "After high-dose IV PPI, step down to oral high-dose PPI for ulcer healing (STG 2021).",
                "tags": [
                    "post_bleed",
                    "oral_PPI"
                ]
            },
            {
                "id": 538,
                "question": "A 28-year-old with bloody diarrhea and fever for 3 days. Most appropriate initial management?",
                "choices": [
                    "A. Upper endoscopy",
                    "B. Stool microscopy/culture + empirical ciprofloxacin + metronidazole",
                    "C. Colonoscopy",
                    "D. IV PPI"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Suspected infectious colitis (dysentery) → stool exam + empirical therapy while awaiting results (STG 2021).",
                "tags": [
                    "dysentery",
                    "empirical"
                ]
            },
            {
                "id": 539,
                "question": "Patient with cirrhosis and ascites presents with hematemesis. First drug to give in ER?",
                "choices": [
                    "A. Ceftriaxone 1 g IV",
                    "B. Terlipressin 2 mg IV",
                    "C. Octreotide 50 mcg bolus",
                    "D. All of the above"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Start vasoactive drug (terlipressin/octreotide) + antibiotic immediately in suspected variceal bleed (STG 2021).",
                "tags": [
                    "variceal",
                    "prehospital"
                ]
            },
            {
                "id": 540,
                "question": "Most sensitive sign of significant UGIB?",
                "choices": [
                    "A. Hematemesis",
                    "B. Melena",
                    "C. Hematochezia",
                    "D. Hypotension"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Melena indicates ≥60 mL blood loss and is the most sensitive clinical sign (STG 2021).",
                "tags": [
                    "melena",
                    "sensitivity"
                ]
            },
            {
                "id": 541,
                "question": "Patient on clopidogrel presents with UGIB. Management of antiplatelet?",
                "choices": [
                    "A. Stop permanently",
                    "B. Stop temporarily, restart when hemostasis achieved",
                    "C. Continue throughout",
                    "D. Switch to aspirin"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Early resumption (within 5–7 days) of antiplatelet in high cardiac risk patients (STG 2021).",
                "tags": [
                    "clopidogrel",
                    "restart"
                ]
            },
            {
                "id": 542,
                "question": "NG tube placement in UGIB is:",
                "choices": [
                    "A. Mandatory in all",
                    "B. Useful for diagnosis and gastric lavage in selected cases",
                    "C. Contraindicated in varices",
                    "D. Diagnostic gold standard"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Not routine, but helpful to confirm active UGIB and clear stomach before endoscopy (STG 2021).",
                "tags": [
                    "NG_tube",
                    "selective"
                ]
            },
            {
                "id": 543,
                "question": "Patient with UGIB has coffee-ground vomitus and stable vitals. Risk category?",
                "choices": [
                    "A. High risk",
                    "B. Low risk",
                    "C. Intermediate",
                    "D. Cannot tell"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Coffee-ground (not bright red) + stable → lower risk than active hematemesis (STG 2021).",
                "tags": [
                    "coffee_ground",
                    "low_risk"
                ]
            },
            {
                "id": 544,
                "question": "Best position for patient with active variceal bleeding during transport?",
                "choices": [
                    "A. Supine",
                    "B. Left lateral decubitus with head elevated",
                    "C. Sitting upright",
                    "D. Trendelenburg"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Reduces aspiration risk while maintaining venous return (STG 2021).",
                "tags": [
                    "position",
                    "aspiration"
                ]
            },
            {
                "id": 545,
                "question": "Child-Pugh score includes all EXCEPT:",
                "choices": [
                    "A. Bilirubin",
                    "B. Albumin",
                    "C. INR",
                    "D. Creatinine"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Child-Pugh: bilirubin, albumin, INR, ascites, encephalopathy (STG 2021).",
                "tags": [
                    "Child_Pugh"
                ]
            },
            {
                "id": 546,
                "question": "Patient with rectal bleeding and history of radiation therapy for cervical cancer. Likely diagnosis?",
                "choices": [
                    "A. Hemorrhoids",
                    "B. Radiation proctitis",
                    "C. Recurrent cancer",
                    "D. Diverticulitis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Chronic radiation proctitis causes telangiectasia and bleeding months to years later (STG 2021).",
                "tags": [
                    "radiation_proctitis"
                ]
            },
            {
                "id": 547,
                "question": "Most effective treatment for bleeding internal hemorrhoids in stable patient?",
                "choices": [
                    "A. Surgery",
                    "B. Rubber band ligation",
                    "C. Sclerotherapy",
                    "D. Conservative (fiber + sitz bath)"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Band ligation is outpatient, effective, and widely available (STG 2021).",
                "tags": [
                    "hemorrhoids",
                    "banding"
                ]
            },
            {
                "id": 548,
                "question": "Patient with UGIB found to have gastric antral vascular ectasia (GAVE). Best endoscopic therapy?",
                "choices": [
                    "A. Band ligation",
                    "B. Argon plasma coagulation (APC)",
                    "C. Injection",
                    "D. Clips"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "APC is treatment of choice for watermelon stomach (GAVE) (STG 2021).",
                "tags": [
                    "GAVE",
                    "APC"
                ]
            },
            {
                "id": 549,
                "question": "Final message to every patient after UGIB due to peptic ulcer?",
                "choices": [
                    "A. Avoid all spicy food forever",
                    "B. Stop NSAIDs, treat H. pylori, continue PPI for at least 4–8 weeks",
                    "C. No need for follow-up",
                    "D. Surgery next time"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Patient education on risk factors and adherence crucial for prevention (STG 2021).",
                "tags": [
                    "patient_education",
                    "prevention"
                ]
            },
            {
                "id": 550,
                "question": "A patient presents with hematochezia 5 days after starting warfarin. INR 8. Most likely source?",
                "choices": [
                    "A. Hemorrhoids",
                    "B. Diverticular bleed exacerbated by anticoagulation",
                    "C. Ischemic colitis",
                    "D. Upper GI source"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Over-anticoagulation can unmask or worsen any bleeding source (STG 2021).",
                "tags": [
                    "warfarin",
                    "INR",
                    "LGIB"
                ]
            },
            {
                "id": 551,
                "question": "A 48-year-old chronic alcohol user with known cirrhosis presents with massive fresh hematemesis and hypotension. After securing two large-bore IV lines and starting fluids, the NEXT most important simultaneous action is:",
                "choices": [
                    "A. Urgent upper GI endoscopy",
                    "B. Start IV ceftriaxone 1 g + terlipressin 2 mg IV stat",
                    "C. Insert Sengstaken-Blakemore tube",
                    "D. Transfuse 4 units PRBC immediately"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "In suspected variceal bleeding in cirrhosis, start vasoactive drug (terlipressin or octreotide) + prophylactic antibiotic (ceftriaxone 1 g) immediately, even before endoscopy (STG 2021, p.187).",
                "tags": [
                    "variceal",
                    "terlipressin",
                    "ceftriaxone",
                    "prehospital"
                ]
            },
            {
                "id": 552,
                "question": "A patient with peptic ulcer bleeding has a visible vessel (Forrest IIa) at endoscopy. Best definitive endoscopic therapy in a general hospital setting in Ethiopia?",
                "choices": [
                    "A. Adrenaline injection alone",
                    "B. Adrenaline injection + thermal coagulation (heater probe or bipolar)",
                    "C. Hemoclip alone",
                    "D. Argon plasma coagulation"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Dual therapy (epinephrine injection + thermal coagulation) is the most widely available and effective method in Ethiopian general hospitals (STG 2021, p.186).",
                "tags": [
                    "Forrest_IIa",
                    "dual_therapy",
                    "Ethiopia"
                ]
            },
            {
                "id": 553,
                "question": "After successful endoscopic banding of esophageal varices, the patient is stable. Duration of IV vasoactive drug (terlipressin/octreotide)?",
                "choices": [
                    "A. 24 hours",
                    "B. 2–5 days",
                    "C. Until discharge",
                    "D. Only stat dose"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Continue vasoactive drugs for 2–5 days after endoscopic control to prevent early rebleeding (STG 2021, p.187).",
                "tags": [
                    "variceal",
                    "vasoactive_duration"
                ]
            },
            {
                "id": 554,
                "question": "A 62-year-old man on aspirin for secondary prevention presents with melena and Hb 7.8 g/dL. He is hemodynamically stable. When should aspirin be restarted?",
                "choices": [
                    "A. Never",
                    "B. After 4 weeks",
                    "C. As soon as hemostasis is achieved (usually within 1–7 days)",
                    "D. After H. pylori eradication"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "In patients with cardiovascular indication, restarting aspirin early (within 1–7 days) reduces cardiovascular events and mortality more than bleeding risk (STG 2021, p.186).",
                "tags": [
                    "aspirin",
                    "restart",
                    "cardiovascular"
                ]
            },
            {
                "id": 555,
                "question": "Most common cause of massive lower GI bleeding requiring hospitalization in elderly Ethiopians?",
                "choices": [
                    "A. Hemorrhoids",
                    "B. Diverticular disease",
                    "C. Colorectal cancer",
                    "D. Ischemic colitis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "With increasing age and dietary westernization, diverticular bleeding is becoming more common in elderly Ethiopians (STG 2021, p.189).",
                "tags": [
                    "LGIB",
                    "diverticular",
                    "elderly"
                ]
            },
            {
                "id": 556,
                "question": "A patient with massive UGIB is intubated for airway protection. Next most important drug to prevent rebleeding?",
                "choices": [
                    "A. IV octreotide",
                    "B. IV omeprazole 80 mg bolus → 8 mg/hour infusion for 72 hours",
                    "C. Oral sucralfate",
                    "D. Tranexamic acid"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "High-dose IV PPI for 72 hours after endoscopy is standard for high-risk non-variceal ulcers (STG 2021, p.186).",
                "tags": [
                    "high_dose_PPI",
                    "72_hours"
                ]
            },
            {
                "id": 557,
                "question": "A cirrhotic patient with variceal bleed is on maximum terlipressin and banding but continues to bleed. Next step?",
                "choices": [
                    "A. Repeat banding",
                    "B. Balloon tamponade as bridge + urgent referral for TIPS/surgery",
                    "C. Increase terlipressin dose",
                    "D. Tranexamic acid"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Refractory variceal bleeding → temporary balloon tamponade + urgent referral for salvage TIPS or shunt surgery (STG 2021, p.187).",
                "tags": [
                    "refractory_variceal",
                    "TIPS"
                ]
            },
            {
                "id": 558,
                "question": "A 35-year-old woman presents with hematochezia 10 days postpartum. Most likely diagnosis?",
                "choices": [
                    "A. Hemorrhoids",
                    "B. Anal fissure",
                    "C. Inflammatory bowel disease",
                    "D. Colorectal cancer"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Perianal conditions (hemorrhoids, fissure) are extremely common postpartum due to constipation and straining (STG 2021).",
                "tags": [
                    "postpartum",
                    "hemorrhoids"
                ]
            },
            {
                "id": 559,
                "question": "Patient with UGIB has Rockall score of 7 post-endoscopy. Predicted mortality?",
                "choices": [
                    "A. <5 Автор%",
                    "B. 10–20%",
                    "C. >40%",
                    "D. 100%"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Complete Rockall score ≥7 → mortality >40% (STG 2021).",
                "tags": [
                    "Rockall",
                    "high_risk"
                ]
            },
            {
                "id": 560,
                "question": "A patient with bleeding duodenal ulcer is on warfarin for atrial fibrillation. INR 6.5. Management of anticoagulation?",
                "choices": [
                    "A. Vitamin K 10 mg IV only",
                    "B. Stop warfarin + vitamin K 5–10 mg IV + PCC (or FFP if unavailable)",
                    "C. Fresh frozen plasma only",
                    "D. Continue warfarin"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Major bleeding + supratherapeutic INR → full reversal with vitamin K + PCC/FFP (STG 2021).",
                "tags": [
                    "warfarin_reversal",
                    "PCC"
                ]
            },
            {
                "id": 561,
                "question": "Most common site of peptic ulcer causing massive UGIB in Ethiopia?",
                "choices": [
                    "A. Gastric antrum",
                    "B. Posterior duodenal bulb",
                    "C. Gastric body",
                    "D. Pre-pyloric"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Posterior duodenal bulb ulcers erode into gastroduodenal artery → severe bleeding (STG 2021).",
                "tags": [
                    "duodenal_ulcer",
                    "gastroduodenal_artery"
                ]
            },
            {
                "id": 562,
                "question": "A 25-year-old with bloody diarrhea, fever, and abdominal pain for 4 days. Stool shows plenty of pus cells. Initial empirical antibiotics?",
                "choices": [
                    "A. Ceftriaxone only",
                    "B. Ciprofloxacin 500 mg BID + metronidazole 400 mg TID",
                    "C. Doxycycline",
                    "D. No antibiotic"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Suspected shigellosis/amoebiasis → ciprofloxacin + metronidazole until culture/sensitivity (STG 2021).",
                "tags": [
                    "dysentery",
                    "empirical"
                ]
            },
            {
                "id": 563,
                "question": "Patient with cirrhosis and variceal bleeding. Target non-selective beta-blocker after discharge?",
                "choices": [
                    "A. Propranolol titrated to heart rate 55–60 or max tolerated",
                    "B. Atenolol",
                    "C. Metoprolol",
                    "D. Carvedilol only"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Propranolol or nadolol for secondary prophylaxis; carvedilol is alternative (STG 2021).",
                "tags": [
                    "propranolol",
                    "secondary_prophylaxis"
                ]
            },
            {
                "id": 564,
                "question": "A patient with melena has Hb 6.2 g/dL but is hemodynamically stable. Transfusion threshold?",
                "choices": [
                    "A. Transfuse to Hb >10",
                    "B. Transfuse to Hb >7–8 g/dL (restrictive strategy)",
                    "C. No transfusion",
                    "D. Transfuse only if symptomatic"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Restrictive transfusion (Hb <7–8 g/dL) is safe and preferred in stable patients (STG 2021).",
                "tags": [
                    "restrictive_transfusion"
                ]
            },
            {
                "id": 565,
                "question": "Most important factor reducing mortality in variceal bleeding in Ethiopia in recent years?",
                "choices": [
                    "A. Endoscopic banding",
                    "B. Early use of antibiotics (ceftriaxone)",
                    "C. TIPS availability",
                    "D. Beta-blockers"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Prophylactic ceftriaxone has dramatically reduced bacterial infections and mortality (STG 2021).",
                "tags": [
                    "antibiotics",
                    "mortality_reduction"
                ]
            },
            {
                "id": 566,
                "question": "A patient with UGIB and known H. pylori-positive duodenal ulcer. When to perform repeat endoscopy to confirm ulcer healing?",
                "choices": [
                    "A. 2 weeks",
                    "B. 4–8 weeks only if symptoms persist or alarm features",
                    "C. Routinely at 4 weeks",
                    "D. Never"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Routine repeat endoscopy not required if symptoms resolve and no alarm features (STG 2021).",
                "tags": [
                    "repeat_endoscopy",
                    "not_routine"
                ]
            },
            {
                "id": 567,
                "question": "Patient with massive LGIB is unstable despite resuscitation. Best next investigation?",
                "choices": [
                    "A. Colonoscopy",
                    "B. CT angiography",
                    "C. Capsule endoscopy",
                    "D. Flexible sigmoidoscopy"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Unstable massive LGIB → CT angiography to localize before embolization or surgery (STG 2021).",
                "tags": [
                    "CT_angiography",
                    "unstable_LGIB"
                ]
            },
            {
                "id": 568,
                "question": "A patient with rectal bleeding has multiple internal hemorrhoids. Best outpatient treatment?",
                "choices": [
                    "A. Hemorrhoidectomy",
                    "B. Rubber band ligation",
                    "C. Infrared coagulation",
                    "D. High fiber + sitz bath only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Rubber band ligation is safe, effective, and widely available in Ethiopia (STG 2021).",
                "tags": [
                    "hemorrhoids",
                    "band_ligation"
                ]
            },
            {
                "id": 569,
                "question": "Patient with UGIB is on dabigatran for AF. Management of anticoagulation?",
                "choices": [
                    "A. Idarucizumab (Praxbind) if available",
                    "B. Stop dabigatran + supportive care + PCC",
                    "C. Vitamin K",
                    "D. Fresh frozen plasma"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Dabigatran-specific reversal agent is idarucizumab; if unavailable, use activated charcoal (if recent ingestion) + supportive care (STG 2021).",
                "tags": [
                    "dabigatran",
                    "idarucizumab"
                ]
            },
            {
                "id": 570,
                "question": "Most common presentation of Meckel’s diverticulum bleeding in children?",
                "choices": [
                    "A. Melena",
                    "B. Painless massive hematochezia",
                    "C. Chronic iron deficiency",
                    "D. Intussusception"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Classic: painless, large-volume, brick-red or maroon bleeding in children/young adults (STG 2021).",
                "tags": [
                    "Meckel",
                    "hematochezia"
                ]
            },
            {
                "id": 571,
                "question": "A patient with cirrhosis and variceal bleed has hepatic encephalopathy grade III. Most important immediate action besides lactulose?",
                "choices": [
                    "A. IV mannitol",
                    "B. Protect airway (intubation if needed)",
                    "C. Rifaximin",
                    "D. Flumazenil"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Grade III–IV encephalopathy in bleeding cirrhotic → high aspiration risk → secure airway (STG 2021).",
                "tags": [
                    "encephalopathy",
                    "intubation"
                ]
            },
            {
                "id": 572,
                "question": "Patient with UGIB has active alcohol withdrawal. Safest drug?",
                "choices": [
                    "A. Diazepam",
                    "B. Lorazepam or oxazepam (no active metabolites)",
                    "C. Phenobarbital",
                    "D. Haloperidol"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Short-acting benzodiazepines without active metabolites preferred in liver disease (STG 2021).",
                "tags": [
                    "alcohol_withdrawal",
                    "liver_safe"
                ]
            },
            {
                "id": 573,
                "question": "A 70-year-old with diverticular bleed stops spontaneously. Discharge advice includes:",
                "choices": [
                    "A. High-fiber diet",
                    "B. Low-fiber diet",
                    "C. Avoid seeds and nuts",
                    "D. Lifelong antibiotics"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "High-fiber diet prevents recurrence of diverticular bleeding (STG 2021).",
                "tags": [
                    "diverticular",
                    "fiber"
                ]
            },
            {
                "id": 574,
                "question": "Patient with UGIB and known chronic kidney disease. Transfusion threshold?",
                "choices": [
                    "A. Hb <7 g/dL",
                    "B. Hb <8–9 g/dL (more liberal)",
                    "C. Hb <10 g/dL",
                    "D. No transfusion"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Patients with cardiovascular disease or CKD may need higher threshold (Hb 8–9 g/dL) (STG 2021).",
                "tags": [
                    "CKD",
                    "transfusion_threshold"
                ]
            },
            {
                "id": 575,
                "question": "Final take-home message for every patient after non-variceal UGIB?",
                "choices": [
                    "A. Avoid all NSAIDs including low-dose aspirin",
                    "B. Eradicate H. pylori, avoid NSAIDs, continue PPI if high risk",
                    "C. Surgery is inevitable",
                    "D. No follow-up needed"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Key prevention: H. pylori eradication + avoid NSAIDs + long-term PPI if ongoing risk (STG 2021, p.186).",
                "tags": [
                    "prevention",
                    "NSAID",
                    "H_pylori"
                ]
            },
            {
                "id": 576,
                "question": "A patient with suspected variceal bleeding arrives in shock. Blood pressure does not respond to 2 liters crystalloid. Next fluid?",
                "choices": [
                    "A. More crystalloid",
                    "B. Uncrosmatched O-negative blood",
                    "C. Wait for type-specific",
                    "D. Albumin"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Life-threatening hemorrhage + shock → give O-negative blood while waiting for crossmatch (STG 2021).",
                "tags": [
                    "O_negative",
                    "massive_transfusion"
                ]
            },
            {
                "id": 577,
                "question": "Patient with UGIB has platelet count 30,000. Need for platelet transfusion before endoscopy?",
                "choices": [
                    "A. Always",
                    "B. Only if active bleeding and platelets <50,000",
                    "C. Never",
                    "D. If <20,000 only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Transfuse platelets if <50,000 and active bleeding or before invasive procedure (STG 2021).",
                "tags": [
                    "platelets",
                    "threshold"
                ]
            },
            {
                "id": 578,
                "question": "Most common cause of obscure-overt GI bleeding in young adults in Ethiopia?",
                "choices": [
                    "A. Meckel’s diverticulum",
                    "B. Small bowel tumors",
                    "C. Crohn’s disease",
                    "D. NSAID enteropathy"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Meckel’s remains the leading cause in patients <40 years (STG 2021).",
                "tags": [
                    "obscure",
                    "Meckel"
                ]
            },
            {
                "id": 579,
                "question": "Patient with bleeding peptic ulcer is on twice-daily clopidogrel. Best long-term strategy after hemostasis?",
                "choices": [
                    "A. Stop clopidogrel forever",
                    "B. Continue clopidogrel alone",
                    "C. Clopidogrel + PPI lifelong",
                    "D. Switch to aspirin + PPI"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "High-risk cardiac patients (e.g., recent stent) need dual antiplatelet; protect with lifelong PPI (STG 2021).",
                "tags": [
                    "DAPT",
                    "PPI_protection"
                ]
            },
            {
                "id": 580,
                "question": "A patient with LGIB is found to have angiodysplasia in the cecum. Best treatment?",
                "choices": [
                    "A. Endoscopic argon plasma coagulation",
                    "B. Surgery",
                    "C. Embolization",
                    "D. Octreotide"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "APC is first-line for vascular lesions like angiodysplasia (STG 2021).",
                "tags": [
                    "angiodysplasia",
                    "APC"
                ]
            },
            {
                "id": 581,
                "question": "Patient presents with sentinel bleed (small hematemesis) followed by massive hemorrhage. History of aortic graft 2 years ago. Diagnosis?",
                "choices": [
                    "A. Peptic ulcer",
                    "B. Aortoenteric fistula",
                    "C. Varices",
                    "D. Mallory-Weiss"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Classic herald/sentinel bleed in patient with aortic graft → secondary aortoenteric fistula (STG 2021).",
                "tags": [
                    "aortoenteric_fistula",
                    "sentinel"
                ]
            },
            {
                "id": 582,
                "question": "Most important nursing instruction for patient with Sengstaken-Blakemore tube?",
                "choices": [
                    "A. Deflate gastric balloon every 4 hours",
                    "B. Keep scissors at bedside for emergency deflation",
                    "C. Inflate esophageal balloon to 100 mmHg",
                    "D. Leave in place for 72 hours"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Risk of esophageal necrosis → scissors must be at bedside to cut tube if respiratory distress (STG 2021).",
                "tags": [
                    "Sengstaken",
                    "scissors"
                ]
            },
            {
                "id": 583,
                "question": "Patient with UGIB and liver cirrhosis has ascites. Fluid of choice for volume expansion?",
                "choices": [
                    "A. Normal saline",
                    "B. Albumin 20–40 g after large-volume paracentesis, but crystalloid initially",
                    "C. Ringer’s lactate",
                    "D. Dextrose 5%"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Crystalloid first; albumin reserved for specific indications in cirrhosis (STG 2021).",
                "tags": [
                    "ascites",
                    "volume_expansion"
                ]
            },
            {
                "id": 584,
                "question": "A 19-year-old presents with sudden painless massive rectal bleeding. Most likely diagnosis?",
                "choices": [
                    "A. Hemorrhoids",
                    "B. Meckel’s diverticulum",
                    "C. IBD",
                    "D. Polyps"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Young patient + painless + large volume → Meckel’s until proven otherwise (STG 2021).",
                "tags": [
                    "Meckel",
                    "young_adult"
                ]
            },
            {
                "id": 585,
                "question": "Patient with variceal bleeding controlled. When to start oral feeding?",
                "choices": [
                    "A. Immediately",
                    "B. After 24–48 hours if no rebleeding",
                    "C. After 5 days",
                    "D. Only parenteral"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Early oral feeding safe after 24–48 hours if hemostasis achieved (STG 2021).",
                "tags": [
                    "oral_feeding",
                    "variceal"
                ]
            },
            {
                "id": 586,
                "question": "Most common cause of GI bleeding in children under 2 years in Ethiopia?",
                "choices": [
                    "A. Meckel’s",
                    "B. Anal fissure",
                    "C. Intussusception",
                    "D. Polyps"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Anal fissure from constipation is extremely common in toddlers (STG 2021).",
                "tags": [
                    "pediatric",
                    "fissure"
                ]
            },
            {
                "id": 587,
                "question": "Patient with UGIB has coffee-ground vomiting only, BP 130/80, HR 88. Blatchford score likely?",
                "choices": [
                    "A. 0–1 (can be managed outpatient)",
                    "B. 2–5",
                    "C. >6 (admit)",
                    "D. Cannot calculate"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Coffee-ground (not fresh blood), stable vitals → low Blatchford → possible outpatient management if reliable follow-up (STG 2021).",
                "tags": [
                    "Blatchford_low"
                ]
            },
            {
                "id": 588,
                "question": "A patient with massive UGIB requires 8 units PRBC in first 24 hours. Next most important blood product?",
                "choices": [
                    "A. FFP and platelets (1:1:1 ratio)",
                    "B. Cryoprecipitate",
                    "C. Albumin",
                    "D. Whole blood"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Massive transfusion protocol → balanced resuscitation with PRBC:FFP:platelets 1:1:1 (STG 2021).",
                "tags": [
                    "massive_transfusion",
                    "1:1:1"
                ]
            },
            {
                "id": 589,
                "question": "Patient with cirrhosis and variceal bleed develops oliguric AKI. Most likely cause?",
                "choices": [
                    "A. Hypovolemia",
                    "B. Abdominal compartment syndrome from ascites",
                    "C. Hepatorenal syndrome",
                    "D. Terlipressin-induced"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Hypovolemia from bleeding is the most common reversible cause of AKI in this setting (STG 2021).",
                "tags": [
                    "AKI",
                    "hypovolemia"
                ]
            },
            {
                "id": 590,
                "question": "Most effective way to prevent recurrent variceal bleeding long-term?",
                "choices": [
                    "A. Repeated banding alone",
                    "B. Beta-blocker + repeated EVL until variceal obliteration",
                    "C. PPI",
                    "D. Shunt surgery"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Combination therapy (non-selective beta-blocker + EVL) is gold standard for secondary prophylaxis (STG 2021).",
                "tags": [
                    "secondary_prophylaxis",
                    "combination"
                ]
            },
            {
                "id": 591,
                "question": "Patient with bleeding peptic ulcer is discharged on oral PPI. Duration of treatment?",
                "choices": [
                    "A. 2 weeks",
                    "B. 4–8 weeks",
                    "C. 3 months",
                    "D. Lifelong"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Standard ulcer healing course 4–8 weeks; longer if giant ulcer or persistent risk factors (STG 2021).",
                "tags": [
                    "PPI_duration",
                    "ulcer_healing"
                ]
            },
            {
                "id": 592,
                "question": "A 65-year-old with ischemic heart disease and recent stent presents with melena. Best antiplatelet management?",
                "choices": [
                    "A. Stop all antiplatelet drugs",
                    "B. Continue dual antiplatelet + high-dose PPI",
                    "C. Stop clopidogrel, continue aspirin",
                    "D. Stop aspirin, continue clopidogrel"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Recent stent (<12 months) → continue DAPT; bleeding risk reduced by PPI (STG 2021).",
                "tags": [
                    "DAPT",
                    "recent_stent"
                ]
            },
            {
                "id": 593,
                "question": "Patient with LGIB has negative colonoscopy. Next investigation if bleeding continues?",
                "choices": [
                    "A. Repeat colonoscopy",
                    "B. CT angiography or tagged RBC scan",
                    "C. Upper endoscopy",
                    "D. Small bowel capsule"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Ongoing overt bleeding with negative colonoscopy → localize with tagged RBC or CT angio (STG 2021).",
                "tags": [
                    "LGIB",
                    "localization"
                ]
            },
            {
                "id": 594,
                "question": "Most common cause of GI bleeding in patients on dual antiplatelet therapy?",
                "choices": [
                    "A. Gastric ulcer",
                    "B. Duodenal ulcer",
                    "C. Erosive gastritis",
                    "D. Hemorrhoids"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Duodenal ulcers remain the most frequent serious bleeding source despite PPI use (STG 2021).",
                "tags": [
                    "DAPT",
                    "duodenal_ulcer"
                ]
            },
            {
                "id": 595,
                "question": "Patient with variceal bleeding has fever on day 3 despite ceftriaxone. Next antibiotic?",
                "choices": [
                    "A. Add metronidazole",
                    "B. Change to piperacillin-tazobactam or meropenem",
                    "C. Vancomycin",
                    "D. Stop antibiotics"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Suspected resistant organism or SBP → broaden coverage (STG 2021).",
                "tags": [
                    "resistant_infection",
                    "cirrhosis"
                ]
            },
            {
                "id": 596,
                "question": "A patient with UGIB is found to have multiple gastric ulcers and is on chronic diclofenac. Management includes:",
                "choices": [
                    "A. Stop NSAID + high-dose PPI + H. pylori treatment",
                    "B. Continue diclofenac + add misoprostol",
                    "C. Switch to celecoxib",
                    "D. Surgery"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Permanent NSAID discontinuation is mandatory after serious bleeding (STG 2021).",
                "tags": [
                    "NSAID_ulcer",
                    "stop_NSAID"
                ]
            },
            {
                "id": 597,
                "question": "Most important prognostic factor in non-variceal UGIB?",
                "choices": [
                    "A. Age >60",
                    "B. Shock on presentation",
                    "C. Comorbidity",
                    "D. All of the above (Rockall score)"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Rockall score incorporates age, shock, comorbidity, diagnosis, and stigmata (STG 2021).",
                "tags": [
                    "Rockall",
                    "prognosis"
                ]
            },
            {
                "id": 598,
                "question": "Patient with cirrhosis and variceal bleed has tense ascites causing respiratory distress. Immediate management?",
                "choices": [
                    "A. Large-volume paracentesis with albumin cover",
                    "B. Spironolactone",
                    "C. Furosemide",
                    "D. Wait"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Tense ascites with respiratory compromise → therapeutic paracentesis + albumin 6–8 g/L removed (STG 2021).",
                "tags": [
                    "tense_ascites",
                    "paracentesis"
                ]
            },
            {
                "id": 599,
                "question": "A patient with obscure recurrent GI bleeding is scheduled for capsule endoscopy. Most important preparation?",
                "choices": [
                    "A. Clear liquids 24 hours",
                    "B. Bowel preparation + prokinetic (if gastroparesis)",
                    "C. Fasting only",
                    "D. Enema"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Good bowel prep improves visualization in small bowel (STG 2021).",
                "tags": [
                    "capsule_endoscopy",
                    "prep"
                ]
            },
            {
                "id": 600,
                "question": "Final key message for prevention of GI bleeding in Ethiopia?",
                "choices": [
                    "A. Avoid all traditional medicines",
                    "B. Eradicate H. pylori, avoid NSAIDs, use PPI when indicated, control portal hypertension",
                    "C. Surgery for all ulcers",
                    "D. Avoid spicy food only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.3 Gastrointestinal Bleeding",
                "explanation": "Comprehensive prevention: H. pylori eradication, rational NSAID use, PPI co-prescription, and variceal prophylaxis are the cornerstones (Ethiopian STG 2021, p.185–189).",
                "tags": [
                    "prevention",
                    "comprehensive"
                ]
            }
        ]
    },
    "Chapter 6.4": {
        "Chapter 6.4 Nausea and Vomiting": [
            {
                "id": 601,
                "question": "A 28-year-old woman at 8 weeks gestation presents with severe vomiting 6–8 times/day, unable to keep any food or water for 3 days. She is dehydrated, urine ketones 3+. According to Ethiopian STG 2021, most appropriate INITIAL management?",
                "choices": [
                    "A. Oral ondansetron 8 mg TID",
                    "B. Admit, IV normal saline + 5% dextrose, thiamine 100 mg IV, then start antiemetic",
                    "C. IM promethazine 25 mg stat",
                    "D. Discharge with oral rehydration solution"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Hyperemesis gravidarum with dehydration and ketonuria requires hospital admission, IV rehydration with dextrose-containing fluids + thiamine to prevent Wernicke’s, then antiemetics (STG 2021, p.193).",
                "tags": [
                    "hyperemesis",
                    "admission",
                    "thiamine"
                ]
            },
            {
                "id": 602,
                "question": "Safest and most effective first-line antiemetic in pregnancy in Ethiopia?",
                "choices": [
                    "A. Metoclopramide",
                    "B. Ondansetron",
                    "C. Doxylamine + pyridoxine (not available) → use promethazine or metoclopramide",
                    "D. Domperidone"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Promethazine and metoclopramide are the most widely available and safe first-line agents in Ethiopian hospitals for hyperemesis (STG 2021, p.193).",
                "tags": [
                    "pregnancy",
                    "promethazine"
                ]
            },
            {
                "id": 603,
                "question": "A 45-year-old man post-laparotomy day 2 has persistent vomiting and abdominal distension. Nasogastric tube drains 1.2 L bilious fluid. Most likely diagnosis?",
                "choices": [
                    "A. Ileus",
                    "B. Mechanical small bowel obstruction",
                    "C. Gastroparesis",
                    "D. Acute gastric dilatation"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Postoperative ileus is the most common cause of nausea/vomiting in the first 72 hours after abdominal surgery (STG 2021, p.194).",
                "tags": [
                    "postoperative_ileus"
                ]
            },
            {
                "id": 604,
                "question": "Best initial management for postoperative ileus?",
                "choices": [
                    "A. IV metoclopramide 10 mg TID",
                    "B. NPO, NG tube if distended, IV fluids, correct electrolytes, encourage early ambulation",
                    "C. Oral erythromycin",
                    "D. Neostigmine IV"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Supportive care (NPO, NG decompression, fluids, electrolytes, ambulation) is the cornerstone; most resolve within 3–5 days (STG 2021, p.194).",
                "tags": [
                    "ileus",
                    "supportive"
                ]
            },
            {
                "id": 605,
                "question": "A 60-year-old diabetic presents with vomiting of undigested food eaten 8 hours ago, succussion splash positive. Most likely diagnosis?",
                "choices": [
                    "A. Peptic ulcer disease",
                    "B. Diabetic gastroparesis",
                    "C. Gastric outlet obstruction",
                    "D. Pancreatic cancer"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Chronic peptic ulcer disease leading to pyloric stenosis is the leading cause of gastric outlet obstruction in Ethiopia (STG 2021, p.194).",
                "tags": [
                    "GOO",
                    "pyloric_stenosis"
                ]
            },
            {
                "id": 606,
                "question": "A patient with suspected cannabinoid hyperemesis syndrome in Addis Ababa. Most characteristic feature?",
                "choices": [
                    "A. Vomiting only at night",
                    "B. Compulsive hot bathing for relief",
                    "C. Weight loss >20 kg",
                    "D. Diarrhoea"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Relief with hot showers/baths is pathognomonic; seen increasingly with khat + cannabis co-use (STG 2021 recognizes this entity).",
                "tags": [
                    "cannabinoid_hyperemesis",
                    "hot_bath"
                ]
            },
            {
                "id": 607,
                "question": "Drug of choice for chemotherapy-induced nausea/vomiting (moderate–high emetogenic risk) in Ethiopia?",
                "choices": [
                    "A. Metoclopramide",
                    "B. Ondansetron 8 mg IV before chemotherapy + dexamethasone",
                    "C. Promethazine",
                    "D. Domperidone"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "5-HT3 antagonist (ondansetron) + dexamethasone is the standard regimen where available (STG 2021, p.195).",
                "tags": [
                    "CINV",
                    "ondansetron_dexa"
                ]
            },
            {
                "id": 608,
                "question": "A 35-year-old with migraine presents to emergency with severe nausea and vomiting. Best acute antiemetic?",
                "choices": [
                    "A. Oral ondansetron",
                    "B. IV metoclopramide 10 mg + IV fluid",
                    "C. Oral domperidone",
                    "D. IM promethazine"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Metoclopramide IV is highly effective in migraine-associated nausea and also treats headache (STG 2021).",
                "tags": [
                    "migraine",
                    "metoclopramide"
                ]
            },
            {
                "id": 609,
                "question": "Most common cause of acute nausea and vomiting in children in Ethiopia?",
                "choices": [
                    "A. Gastroenteritis",
                    "B. Appendicitis",
                    "C. Intussusception",
                    "D. Malaria"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Viral/bacterial gastroenteritis remains the leading cause; use ORS + zinc + ondansetron if severe (STG 2021).",
                "tags": [
                    "pediatric",
                    "gastroenteritis"
                ]
            },
            {
                "id": 610,
                "question": "Safest antiemetic in a 3-year-old child with severe vomiting due to gastroenteritis?",
                "choices": [
                    "A. Metoclopramide",
                    "B. Ondansetron oral dissolving tablet or IV",
                    "C. Domperidone",
                    "D. Promethazine"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Ondansetron is the only antiemetic approved and recommended in children in Ethiopia for severe vomiting (STG 2021).",
                "tags": [
                    "pediatric",
                    "ondansetron"
                ]
            },
            {
                "id": 611,
                "question": "A patient on TB treatment (RHZE) develops daily vomiting 1 hour after taking drugs. Best management?",
                "choices": [
                    "A. Stop all drugs",
                    "B. Give drugs at night + antiemetic (ondansetron or metoclopramide)",
                    "C. Split doses",
                    "D. Change to second-line"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Take TB drugs at bedtime with light meal + add antiemetic; rarely need to stop treatment (STG 2021).",
                "tags": [
                    "TB",
                    "vomiting"
                ]
            },
            {
                "id": 612,
                "question": "Red flag symptom in patient with nausea and vomiting requiring urgent investigation?",
                "choices": [
                    "A. Weight loss >10% + age >50",
                    "B. Early satiety only",
                    "C. Heartburn",
                    "D. Epigastric discomfort"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Age >50 + unintentional weight loss + persistent vomiting → urgent upper endoscopy to rule out gastric cancer (STG 2021, p.193).",
                "tags": [
                    "alarm_symptoms",
                    "gastric_cancer"
                ]
            },
            {
                "id": 613,
                "question": "A 19-year-old student has cyclic vomiting every 2–3 months lasting 3–7 days, normal between attacks, heavy cannabis user. Diagnosis?",
                "choices": [
                    "A. Migraine variant",
                    "B. Cannabinoid hyperemesis syndrome",
                    "C. Gastroparesis",
                    "D. Psychogenic"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Cyclic pattern + cannabis use + relief with hot bathing = classic cannabinoid hyperemesis (STG 2021).",
                "tags": [
                    "cyclic_vomiting",
                    "cannabis"
                ]
            },
            {
                "id": 614,
                "question": "Best treatment for acute attack of cannabinoid hyperemesis?",
                "choices": [
                    "A. IV ondansetron",
                    "B. IV haloperidol 2.5–5 mg + aggressive hydration + topical capsaicin",
                    "C. PPI",
                    "D. Lorazepam"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Haloperidol IV and capsaicin cream are the most effective acute treatments; ondansetron often fails (STG 2021).",
                "tags": [
                    "haloperidol",
                    "capsaicin"
                ]
            },
            {
                "id": 615,
                "question": "A patient with chronic kidney disease stage 5 on dialysis has persistent nausea. Safest long-term antiemetic?",
                "choices": [
                    "A. Metoclopramide",
                    "B. Ondansetron 4–8 mg daily",
                    "C. Domperidone",
                    "D. Promethazine"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Metoclopramide is contraindicated in advanced CKD due to extrapyramidal side effects; ondansetron is safe (STG 2021).",
                "tags": [
                    "CKD",
                    "ondansetron"
                ]
            },
            {
                "id": 616,
                "question": "Most common cause of nausea and vomiting in advanced HIV/AIDS in Ethiopia?",
                "choices": [
                    "A. Cryptococcal meningitis",
                    "B. Drug side effects (ART, cotrimoxazole, TB drugs)",
                    "C. Cerebral toxoplasmosis",
                    "D. Oesophageal candidiasis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Polypharmacy and high pill burden cause most nausea in stable HIV patients (STG 2021).",
                "tags": [
                    "HIV",
                    "ART_nausea"
                ]
            },
            {
                "id": 617,
                "question": "A 55-year-old man with sudden severe headache followed by projectile vomiting. Most likely diagnosis?",
                "choices": [
                    "A. Migraine",
                    "B. Subarachnoid hemorrhage",
                    "C. Gastroenteritis",
                    "D. Meningitis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Thunderclap headache + projectile vomiting = SAH until proven otherwise (STG 2021).",
                "tags": [
                    "SAH",
                    "projectile"
                ]
            },
            {
                "id": 618,
                "question": "Patient with known peptic ulcer disease presents with repeated coffee-ground vomiting and dizziness. Next step?",
                "choices": [
                    "A. Oral PPI",
                    "B. Urgent upper GI endoscopy + resuscitation",
                    "C. IV ondansetron",
                    "D. Wait and observe"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Coffee-ground vomiting in known ulcer patient → suspect UGIB → resuscitate + urgent endoscopy (STG 2021).",
                "tags": [
                    "UGIB",
                    "coffee_ground"
                ]
            },
            {
                "id": 619,
                "question": "Drug most likely to cause nausea and vomiting in Ethiopian patients on treatment for multidrug-resistant TB?",
                "choices": [
                    "A. Levofloxacin",
                    "B. Cycloserine",
                    "C. Ethionamide/prothionamide",
                    "D. Bedaquiline"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Ethionamide/prothionamide frequently cause severe GI intolerance; take at night with antiemetic (STG 2021).",
                "tags": [
                    "MDR_TB",
                    "ethionamide"
                ]
            },
            {
                "id": 620,
                "question": "A 30-year-old woman 2 days post-caesarean section has vomiting and abdominal distension. X-ray shows multiple air-fluid levels. Management?",
                "choices": [
                    "A. Immediate re-laparotomy",
                    "B. Conservative: NPO, NG tube, IV fluids, electrolytes",
                    "C. Oral laxatives",
                    "D. Neostigmine"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Post-caesarean ileus is common and usually resolves with conservative management (STG 2021).",
                "tags": [
                    "post_caesarean_ileus"
                ]
            },
            {
                "id": 621,
                "question": "Best antiemetic for motion sickness in Ethiopia?",
                "choices": [
                    "A. Ondansetron",
                    "B. Promethazine 25 mg 30–60 min before travel",
                    "C. Metoclopramide",
                    "D. Domperidone"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Promethazine and hyoscine are the most effective and available for motion sickness (STG 2021).",
                "tags": [
                    "motion_sickness",
                    "promethazine"
                ]
            },
            {
                "id": 622,
                "question": "Patient with advanced cancer and bowel obstruction has continuous nausea. Best long-term management?",
                "choices": [
                    "A. IV ondansetron",
                    "B. Nasogastric tube + octreotide 100–300 mcg SC TID + haloperidol or levomepromazine",
                    "C. Surgery",
                    "D. PPI only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Malignant bowel obstruction → NG if vomiting large volume + octreotide to reduce secretions + antiemetic (STG 2021 palliative section).",
                "tags": [
                    "malignant_obstruction",
                    "octreotide"
                ]
            },
            {
                "id": 623,
                "question": "A patient with severe vomiting has serum Na 128 mmol/L, K 2.8 mmol/L. Most urgent correction?",
                "choices": [
                    "A. Normal saline",
                    "B. Hypokalemia first (risk of arrhythmia)",
                    "C. 3% saline",
                    "D. Free water"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Severe hypokalemia in vomiting must be corrected before or with sodium to prevent cardiac complications (STG 2021).",
                "tags": [
                    "hypokalemia",
                    "priority"
                ]
            },
            {
                "id": 624,
                "question": "Most common metabolic abnormality in prolonged vomiting?",
                "choices": [
                    "A. Metabolic acidosis",
                    "B. Hypochloremic hypokalemic metabolic alkalosis",
                    "C. Hyperkalemia",
                    "D. Hyponatremia"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Loss of HCl → hypochloremic, hypokalemic, metabolic alkalosis (STG 2021).",
                "tags": [
                    "metabolic_alkalosis"
                ]
            },
            {
                "id": 625,
                "question": "A 22-year-old with bulimia nervosa presents with frequent vomiting. Most likely electrolyte finding?",
                "choices": [
                    "A. Hyperkalemia",
                    "B. Hypokalemia + metabolic alkalosis",
                    "C. Metabolic acidosis",
                    "D. Normal electrolytes"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Self-induced vomiting causes the same alkalosis as pyloric stenosis (STG 2021).",
                "tags": [
                    "bulimia",
                    "alkalosis"
                ]
            },
            {
                "id": 626,
                "question": "Patient with nausea and vertigo, worse on head movement. Diagnosis?",
                "choices": [
                    "A. Vestibular migraine",
                    "B. Benign paroxysmal positional vertigo (BPPV)",
                    "C. Meniere’s disease",
                    "D. Cerebellar stroke"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Positional vertigo + nausea → BPPV; treat with Epley maneuver (STG 2021).",
                "tags": [
                    "BPPV",
                    "Epley"
                ]
            },
            {
                "id": 627,
                "question": "Best antiemetic for opioid-induced nausea?",
                "choices": [
                    "A. Ondansetron",
                    "B. Metoclopramide or haloperidol",
                    "C. Domperidone",
                    "D. Promethazine"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Opioid nausea is centrally mediated → dopamine antagonists (metoclopramide, haloperidol) most effective (STG 2021).",
                "tags": [
                    "opioid_nausea",
                    "dopamine_antagonist"
                ]
            },
            {
                "id": 628,
                "question": "A patient with typhoid fever has persistent vomiting despite ceftriaxone. Best add-on antiemetic?",
                "choices": [
                    "A. Ondansetron 8 mg IV",
                    "B. Metoclopramide",
                    "C. Domperidone",
                    "D. Promethazine"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Ondansetron is safe and effective in systemic infections with vomiting (STG 2021).",
                "tags": [
                    "typhoid",
                    "ondansetron"
                ]
            },
            {
                "id": 629,
                "question": "Most important counselling point for patients with hyperemesis gravidarum at discharge?",
                "choices": [
                    "A. Take PPI lifelong",
                    "B. Small frequent meals, ginger, avoid triggers, return if unable to keep fluids",
                    "C. Bed rest only",
                    "D. Stop prenatal vitamins"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Non-pharmacological measures (small meals, ginger, acupressure) are first-line and continue after discharge (STG 2021).",
                "tags": [
                    "hyperemesis",
                    "counselling"
                ]
            },
            {
                "id": 630,
                "question": "Patient with nausea has vertical nystagmus and ataxia. Most urgent investigation?",
                "choices": [
                    "A. Upper endoscopy",
                    "B. Head CT/MRI (rule out Wernicke’s or posterior fossa lesion)",
                    "C. Abdominal ultrasound",
                    "D. ECG"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Vertical nystagmus + ataxia + vomiting → suspect Wernicke’s encephalopathy → give thiamine immediately + neuroimaging (STG 2021).",
                "tags": [
                    "Wernicke",
                    "vertical_nystagmus"
                ]
            },
            {
                "id": 631,
                "question": "A 40-year-old alcoholic presents with repeated vomiting, hematemesis, and retching. Most likely diagnosis?",
                "choices": [
                    "A. Peptic ulcer",
                    "B. Mallory-Weiss tear",
                    "C. Varices",
                    "D. Gastritis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Forceful retching followed by hematemesis in alcoholic → classic Mallory-Weiss (STG 2021).",
                "tags": [
                    "Mallory_Weiss"
                ]
            },
            {
                "id": 632,
                "question": "Safest route of thiamine administration in vomiting patient with suspected Wernicke’s?",
                "choices": [
                    "A. Oral 100 mg",
                    "B. IV 500 mg TID for 3–5 days (Pabrinex regime if available)",
                    "C. IM 100 mg",
                    "D. No need"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "High-dose parenteral thiamine (IV preferred over IM) for 3–5 days then oral (STG 2021).",
                "tags": [
                    "Wernicke",
                    "high_dose_thiamine"
                ]
            },
            {
                "id": 633,
                "question": "Most common preventable cause of severe nausea in hospitalized patients in Ethiopia?",
                "choices": [
                    "A. Antibiotics",
                    "B. Opioids and poor pain management",
                    "C. Chemotherapy",
                    "D. Anaesthesia"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Inadequate postoperative pain control with opioids is the leading iatrogenic cause (STG 2021).",
                "tags": [
                    "opioids",
                    "postoperative"
                ]
            },
            {
                "id": 634,
                "question": "A patient with nausea and vomiting has serum amylase 1200 U/L. Most likely diagnosis?",
                "choices": [
                    "A. Acute pancreatitis",
                    "B. Intestinal obstruction",
                    "C. Appendicitis",
                    "D. Cholecystitis"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Severe epigastric pain radiating to back + vomiting + elevated amylase/lipase → acute pancreatitis (STG 2021).",
                "tags": [
                    "pancreatitis",
                    "amylase"
                ]
            },
            {
                "id": 635,
                "question": "Best fluid for rehydration in hyperemesis gravidarum?",
                "choices": [
                    "A. Normal saline",
                    "B. 5% dextrose in normal saline or Ringer’s lactate + KCl",
                    "C. Plain 5% dextrose",
                    "D. Hartmann’s solution"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Most patients are hypokalemic; dextrose prevents hypoglycemia and Wernicke’s (STG 2021).",
                "tags": [
                    "hyperemesis",
                    "dextrose_saline"
                ]
            },
            {
                "id": 636,
                "question": "Patient with nausea and vomiting for 3 days has BP 90/60, dry mucosa, urine output 200 mL/day. Classification of dehydration?",
                "choices": [
                    "A. Mild",
                    "B. Moderate",
                    "C. Severe",
                    "D. No dehydration"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Hypotension, oliguria, dry mucosa in adult → severe dehydration → rapid IV rehydration (STG 2021).",
                "tags": [
                    "severe_dehydration"
                ]
            },
            {
                "id": 637,
                "question": "Most effective non-pharmacological measure for pregnancy nausea?",
                "choices": [
                    "A. Ginger 1 g/day or P6 acupressure",
                    "B. Vitamin B6 alone",
                    "C. Avoiding all food",
                    "D. Bed rest"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Ginger and acupressure (wrist bands) have strong evidence and are widely recommended (STG 2021).",
                "tags": [
                    "ginger",
                    "acupressure"
                ]
            },
            {
                "id": 638,
                "question": "A patient with severe vomiting is on furosemide for heart failure. Most likely contributing factor?",
                "choices": [
                    "A. Hypokalemia",
                    "B. Hyponatremia",
                    "C. Hypercalcemia",
                    "D. Hypoglycemia"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Loop diuretics cause hypokalemia → nausea and ileus (STG 2021).",
                "tags": [
                    "furosemide",
                    "hypokalemia"
                ]
            },
            {
                "id": 639,
                "question": "Best antiemetic for radiotherapy-induced nausea?",
                "choices": [
                    "A. Metoclopramide",
                    "B. Ondansetron or granisetron + dexamethasone",
                    "C. Promethazine",
                    "D. Domperidone"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "5-HT3 antagonists are the cornerstone for radiation-induced nausea (STG 2021).",
                "tags": [
                    "RINV",
                    "5HT3"
                ]
            },
            {
                "id": 640,
                "question": "A 25-year-old with nausea and vomiting has wide pulse pressure and collapsing pulse. Most likely diagnosis?",
                "choices": [
                    "A. Pregnancy",
                    "B. Thyrotoxicosis",
                    "C. Anaemia",
                    "D. Adrenal insufficiency"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Hyperthyroidism commonly presents with nausea, vomiting, weight loss, and collapsing pulse (STG 2021).",
                "tags": [
                    "thyrotoxicosis",
                    "collapsing_pulse"
                ]
            },
            {
                "id": 641,
                "question": "Patient with chronic nausea has early satiety and bloating. Most useful investigation in district hospital?",
                "choices": [
                    "A. Upper GI endoscopy",
                    "B. Abdominal ultrasound",
                    "C. Gastric emptying study (not available)",
                    "D. CT abdomen"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Endoscopy is widely available and can rule out gastric outlet obstruction or ulcer disease (STG 2021).",
                "tags": [
                    "chronic_nausea",
                    "endoscopy"
                ]
            },
            {
                "id": 642,
                "question": "Most common cause of nausea in patients taking iron tablets in Ethiopia?",
                "choices": [
                    "A. Gastritis",
                    "B. Direct GI irritation",
                    "C. Constipation",
                    "D. Allergic reaction"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Ferrous sulphate commonly causes nausea; take with meals or at night (STG 2021).",
                "tags": [
                    "iron",
                    "GI_irritation"
                ]
            },
            {
                "id": 643,
                "question": "A patient with nausea and vomiting has blood glucose 28 mmol/L. Most likely diagnosis?",
                "choices": [
                    "A. Diabetic ketoacidosis",
                    "B. Hyperosmolar hyperglycemic state",
                    "C. Lactic acidosis",
                    "D. Sepsis"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "DKA classically presents with nausea, vomiting, abdominal pain, and Kussmaul breathing (STG 2021).",
                "tags": [
                    "DKA",
                    "vomiting"
                ]
            },
            {
                "id": 644,
                "question": "Best antiemetic in raised intracranial pressure?",
                "choices": [
                    "A. Ondansetron",
                    "B. Cyclizine or promethazine (non-sedating preferred)",
                    "C. Metoclopramide (contraindicated)",
                    "D. Dexamethasone + ondansetron"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Metoclopramide contraindicated (lowers seizure threshold); dexamethasone reduces edema and nausea (STG 2021).",
                "tags": [
                    "ICP",
                    "dexamethasone"
                ]
            },
            {
                "id": 645,
                "question": "A 32-year-old with nausea and vomiting has orthostatic hypotension and hyperpigmentation. Diagnosis?",
                "choices": [
                    "A. Pregnancy",
                    "B. Addison’s disease",
                    "C. Hyperthyroidism",
                    "D. Phaeochromocytoma"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Primary adrenal insufficiency presents with chronic nausea, fatigue, hypotension, hyperpigmentation (STG 2021).",
                "tags": [
                    "Addison",
                    "hyperpigmentation"
                ]
            },
            {
                "id": 646,
                "question": "Most important laboratory test in prolonged vomiting?",
                "choices": [
                    "A. Serum amylase",
                    "B. Electrolytes, renal function, glucose",
                    "C. Liver function",
                    "D. Pregnancy test only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Hypokalemia, hyponatremia, elevated urea, metabolic alkalosis are common and guide therapy (STG 2021).",
                "tags": [
                    "electrolytes",
                    "prolonged_vomiting"
                ]
            },
            {
                "id": 647,
                "question": "Patient with nausea and vomiting for 6 weeks has epigastric mass. Most likely diagnosis in Ethiopia?",
                "choices": [
                    "A. Peptic ulcer",
                    "B. Gastric cancer",
                    "C. Pancreatic cancer",
                    "D. Lymphoma"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Age >50 + progressive symptoms + epigastric mass → gastric adenocarcinoma until proven otherwise (STG 2021).",
                "tags": [
                    "gastric_cancer",
                    "epigastric_mass"
                ]
            },
            {
                "id": 648,
                "question": "Best antiemetic combination for breakthrough nausea in palliative care?",
                "choices": [
                    "A. Metoclopramide + ondansetron",
                    "B. Haloperidol 1–2 mg + levomepromazine or olanzapine",
                    "C. Domperidone + PPI",
                    "D. Cyclizine + dexamethasone"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Multiple receptor blockade is needed in complex palliative nausea (STG 2021 palliative guidelines).",
                "tags": [
                    "palliative",
                    "haloperidol"
                ]
            },
            {
                "id": 649,
                "question": "A child with vomiting has sunken eyes, dry mouth, and drinks eagerly. Dehydration category?",
                "choices": [
                    "A. No dehydration",
                    "B. Some dehydration",
                    "C. Severe dehydration",
                    "D. Shock"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "WHO criteria: two of (restless, sunken eyes, drinks eagerly, slow skin pinch) = some dehydration → Plan B (STG 2021).",
                "tags": [
                    "WHO_dehydration",
                    "Plan_B"
                ]
            },
            {
                "id": 650,
                "question": "Final take-home message for every patient with nausea and vomiting in Ethiopia?",
                "choices": [
                    "A. Vomiting is always harmless",
                    "B. Persistent vomiting >48 hours or any red flag symptom needs urgent evaluation and correction of electrolytes",
                    "C. Just take metoclopramide",
                    "D. Fasting cures everything"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.4 Nausea and Vomiting",
                "explanation": "Early recognition of dehydration, electrolyte imbalance, and alarm symptoms prevents mortality (Ethiopian STG 2021, p.193–195).",
                "tags": [
                    "key_message",
                    "red_flags"
                ]
            }
        ]
    },
    "Chapter 6.5": {
        "Chapter 6.5 Chronic Diarrhoea": [
            {
                "id": 651,
                "question": "A 35-year-old HIV-positive man on ART presents with large-volume watery diarrhoea for 6 weeks, weight loss 12 kg, no blood or fever. Most likely diagnosis in Ethiopia?",
                "choices": [
                    "A. Chronic shigellosis",
                    "B. Cryptosporidiosis / Isospora belli infection",
                    "C. Tuberculosis",
                    "D. Lymphoma"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Large-volume watery diarrhoea + severe weight loss in HIV patient = opportunistic protozoal infection (Cryptosporidium or Isospora) until proven otherwise (STG 2021, p.198).",
                "tags": [
                    "HIV",
                    "chronic_diarrhoea",
                    "cryptosporidiosis"
                ]
            },
            {
                "id": 652,
                "question": "First-line treatment for Isospora belli in HIV patient in Ethiopian hospitals?",
                "choices": [
                    "A. Metronidazole",
                    "B. Co-trimoxazole high dose (TMP 5 mg/kg + SMX 25 mg/kg QID) for 10 days then secondary prophylaxis",
                    "C. Ciprofloxacin",
                    "D. Nitazoxanide"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Co-trimoxazole is the drug of choice and widely available in Ethiopia (STG 2021, p.198).",
                "tags": [
                    "Isospora",
                    "co-trimoxazole"
                ]
            },
            {
                "id": 653,
                "question": "A 28-year-old woman has chronic large-volume diarrhoea with greasy, difficult-to-flush stools, weight loss, and bloating. Most likely diagnosis?",
                "choices": [
                    "A. Irritable bowel syndrome",
                    "B. Giardia lamblia chronic infection",
                    "C. Tropical sprue / small bowel bacterial overgrowth",
                    "D. Ulcerative colitis"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Malabsorption features (greasy stool, bloating, weight loss) in tropical area = tropical sprue/SBBO (STG 2021, p.198).",
                "tags": [
                    "tropical_sprue",
                    "malabsorption"
                ]
            },
            {
                "id": 654,
                "question": "Best empirical treatment for tropical sprue in Ethiopia?",
                "choices": [
                    "A. Metronidazole alone",
                    "B. Tetracycline or doxycycline 100 mg QID + folic acid 5 mg daily for 3–6 months",
                    "C. Loperamide",
                    "D. Albendazole"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Long-course tetracycline/doxycycline + folic acid is the cornerstone of treatment (STG 2021, p.198).",
                "tags": [
                    "tropical_sprue",
                    "tetracycline_folic"
                ]
            },
            {
                "id": 655,
                "question": "Most common cause of chronic bloody diarrhoea in adults in Ethiopia?",
                "choices": [
                    "A. Amoebiasis",
                    "B. Schistosoma mansoni",
                    "C. Ulcerative colitis",
                    "D. Colorectal cancer"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "S. mansoni is endemic and frequently causes chronic bloody diarrhoea with hepatosplenomegaly (STG 2021, p.199).",
                "tags": [
                    "schistosomiasis",
                    "bloody_diarrhoea"
                ]
            },
            {
                "id": 656,
                "question": "A 45-year-old farmer from Lake Tana area presents with chronic bloody diarrhoea, tenesmus, and left hypochondrial pain. Stool exam shows S. mansoni eggs. Treatment of choice?",
                "choices": [
                    "A. Metronidazole",
                    "B. Praziquantel 40 mg/kg single dose",
                    "C. Albendazole",
                    "D. Ciprofloxacin"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Praziquantel single dose is curative for intestinal schistosomiasis (STG 2021, p.199).",
                "tags": [
                    "S_mansoni",
                    "praziquantel"
                ]
            },
            {
                "id": 657,
                "question": "A 30-year-old with chronic diarrhoea has CD4 count 80 cells/µL. Stool modified ZN stain shows red coccoid forms. Diagnosis and treatment?",
                "choices": [
                    "A. Cryptosporidium – no specific treatment, start ART",
                    "B. Isospora – high-dose co-trimoxazole",
                    "C. Cyclospora – co-trimoxazole",
                    "D. Mycobacterium avium complex"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Cryptosporidium is acid-fast, appears as small round oocysts; no effective treatment except immune reconstitution with ART (STG 2021, p.198).",
                "tags": [
                    "cryptosporidium",
                    "ART"
                ]
            },
            {
                "id": 658,
                "question": "Red flag symptom in chronic diarrhoea requiring urgent colonoscopy?",
                "choices": [
                    "A. Nocturnal diarrhoea",
                    "B. Age >50 years + weight loss + blood in stool",
                    "C. Abdominal pain only",
                    "D. Alternating constipation"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Age >50 + unintentional weight loss + chronic bloody diarrhoea → rule out colorectal cancer urgently (STG 2021, p.197).",
                "tags": [
                    "alarm_features",
                    "colorectal_cancer"
                ]
            },
            {
                "id": 659,
                "question": "A patient with chronic diarrhoea has macrocytic anaemia and peripheral neuropathy. Most likely diagnosis?",
                "choices": [
                    "A. Tropical sprue (folate/B12 malabsorption)",
                    "B. Celiac disease (rare in Ethiopia)",
                    "C. Chronic pancreatitis",
                    "D. VIPoma"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Tropical sprue commonly causes folate and B12 deficiency leading to macrocytic anaemia and neuropathy (STG 2021).",
                "tags": [
                    "tropical_sprue",
                    "macrocytic"
                ]
            },
            {
                "id": 660,
                "question": "Most common cause of chronic diarrhoea in well-controlled HIV patients on ART in Ethiopia?",
                "choices": [
                    "A. Opportunistic infections",
                    "B. ART side effects (especially protease inhibitors)",
                    "C. IRIS",
                    "D. Lymphoma"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Lopinavir/ritonavir and other PIs frequently cause chronic osmotic diarrhoea (STG 2021).",
                "tags": [
                    "ART",
                    "PI_diarrhoea"
                ]
            },
            {
                "id": 661,
                "question": "A 40-year-old woman has post-prandial diarrhoea, bloating, and weight loss after starting metformin. Most likely mechanism?",
                "choices": [
                    "A. Infectious",
                    "B. Osmotic diarrhoea due to metformin",
                    "C. Bile acid malabsorption",
                    "D. Lactose intolerance"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Metformin commonly causes osmotic diarrhoea; take with meals or switch to extended-release (STG 2021).",
                "tags": [
                    "metformin",
                    "osmotic"
                ]
            },
            {
                "id": 662,
                "question": "Best initial investigation for chronic diarrhoea in district hospital in Ethiopia?",
                "choices": [
                    "A. Colonoscopy",
                    "B. Stool microscopy + occult blood + modified ZN stain (if HIV)",
                    "C. Abdominal CT",
                    "D. Faecal calprotectin"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Stool examination is cheap, widely available, and high yield especially for parasites and AFB (STG 2021, p.197).",
                "tags": [
                    "stool_exam",
                    "first_line"
                ]
            },
            {
                "id": 663,
                "question": "A patient with chronic diarrhoea has stool pH 5.0 and positive reducing substances. Diagnosis?",
                "choices": [
                    "A. Fat malabsorption",
                    "B. Carbohydrate malabsorption (lactose, glucose)",
                    "C. Protein-losing enteropathy",
                    "D. Bacterial overgrowth"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Acidic stool + reducing substances = osmotic diarrhoea from unabsorbed sugars (STG 2021).",
                "tags": [
                    "osmotic",
                    "reducing_substances"
                ]
            },
            {
                "id": 664,
                "question": "Most common intestinal parasite causing chronic diarrhoea in HIV patients in Ethiopia?",
                "choices": [
                    "A. Giardia",
                    "B. Entamoeba histolytica",
                    "C. Strongyloides stercoralis",
                    "D. Isospora belli"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Isospora and Cryptosporidium dominate in advanced HIV; Giardia is common in general population (STG 2021).",
                "tags": [
                    "Isospora",
                    "HIV"
                ]
            },
            {
                "id": 665,
                "question": "A 55-year-old man has chronic diarrhoea, dermatitis herpetiformis-like rash, and iron deficiency. Most likely diagnosis (though rare in Ethiopia)?",
                "choices": [
                    "A. Tropical sprue",
                    "B. Celiac disease",
                    "C. Crohn’s disease",
                    "D. Behcet’s"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Classic triad of celiac: diarrhoea, dermatitis herpetiformis, iron deficiency (STG 2021 mentions it).",
                "tags": [
                    "celiac",
                    "dermatitis_herpetiformis"
                ]
            },
            {
                "id": 666,
                "question": "Patient with chronic diarrhoea improves dramatically on fasting but recurs on eating. Type of diarrhoea?",
                "choices": [
                    "A. Secretory",
                    "B. Osmotic",
                    "C. Inflammatory",
                    "D. Motility-related"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Osmotic diarrhoea stops with fasting; secretory continues (STG 2021, p.197).",
                "tags": [
                    "osmotic",
                    "fasting"
                ]
            },
            {
                "id": 667,
                "question": "A patient with chronic large-volume secretory diarrhoea has normal colonoscopy but low serum K+ and metabolic acidosis. Most likely diagnosis?",
                "choices": [
                    "A. VIPoma (rare)",
                    "B. Laxative abuse (phenolphthalein, bisacodyl)",
                    "C. Bile acid diarrhoea",
                    "D. Microscopic colitis"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "VIPoma causes massive secretory diarrhoea with hypokalemia and acidosis (WDHA syndrome) (STG 2021).",
                "tags": [
                    "VIPoma",
                    "secretory"
                ]
            },
            {
                "id": 668,
                "question": "Most common cause of chronic diarrhoea in diabetic patients with autonomic neuropathy?",
                "choices": [
                    "A. Metformin",
                    "B. Small bowel bacterial overgrowth",
                    "C. Chronic pancreatitis",
                    "D. Celiac disease"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Diabetic enteropathy + stasis → SBBO → treat with rotating antibiotics (STG 2021).",
                "tags": [
                    "diabetic",
                    "SBBO"
                ]
            },
            {
                "id": 669,
                "question": "A 60-year-old with chronic watery diarrhoea has faecal incontinence and perianal excoriation. Most likely mechanism?",
                "choices": [
                    "A. Inflammatory",
                    "B. Overflow diarrhoea from severe constipation",
                    "C. Bile acid malabsorption",
                    "D. Lactose intolerance"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Elderly + incontinence + watery stool → suspect faecal impaction with overflow (STG 2021).",
                "tags": [
                    "overflow",
                    "impaction"
                ]
            },
            {
                "id": 670,
                "question": "Best treatment for chronic diarrhoea due to bile acid malabsorption after ileal resection?",
                "choices": [
                    "A. Loperamide",
                    "B. Cholestyramine or colestipol",
                    "C. Metronidazole",
                    "D. Octreotide"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Bile acid sequestrants are first-line (STG 2021).",
                "tags": [
                    "bile_acid",
                    "cholestyramine"
                ]
            },
            {
                "id": 671,
                "question": "A patient with chronic diarrhoea has stool osmotic gap <50 mOsm/kg. Interpretation?",
                "choices": [
                    "A. Osmotic diarrhoea",
                    "B. Secretory diarrhoea",
                    "C. Fatty diarrhoea",
                    "D. Inflammatory"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Osmotic gap = 290 – 2×(Na + K); <50 = secretory; >50 = osmotic (STG 2021).",
                "tags": [
                    "osmotic_gap",
                    "secretory"
                ]
            },
            {
                "id": 672,
                "question": "Most common cause of chronic bloody diarrhoea in young adults in urban Ethiopia?",
                "choices": [
                    "A. Schistosomiasis",
                    "B. Inflammatory bowel disease (increasing incidence)",
                    "C. Amoebiasis",
                    "D. Cancer"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "IBD (especially ulcerative colitis) is rising rapidly in Addis Ababa and other cities (STG 2021).",
                "tags": [
                    "IBD",
                    "urban"
                ]
            },
            {
                "id": 673,
                "question": "A patient with chronic diarrhoea is on long-term PPI. Most likely contributing factor?",
                "choices": [
                    "A. Hypochlorhydria → small bowel bacterial overgrowth",
                    "B. Direct osmotic effect",
                    "C. Bile acid malabsorption",
                    "D. Lactose intolerance"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Prolonged acid suppression promotes SBBO (STG 2021).",
                "tags": [
                    "PPI",
                    "SBBO"
                ]
            },
            {
                "id": 674,
                "question": "A 25-year-old with chronic diarrhoea has peripheral eosinophilia and history of eating raw beef (kitfo). Most likely diagnosis?",
                "choices": [
                    "A. Taenia saginata",
                    "B. Strongyloides stercoralis",
                    "C. Intestinal flukes",
                    "D. Toxocariasis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Raw meat consumption + eosinophilia + chronic diarrhoea → suspect Strongyloides or other tissue parasites (STG 2021).",
                "tags": [
                    "strongyloides",
                    "kitfo"
                ]
            },
            {
                "id": 675,
                "question": "Patient with chronic diarrhoea and HIV has CMV retinitis. Most likely cause of diarrhoea?",
                "choices": [
                    "A. Cryptosporidium",
                    "B. CMV colitis",
                    "C. MAC",
                    "D. Isospora"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "CMV disease in multiple organs in advanced HIV → treat with ganciclovir/valganciclovir (STG 2021).",
                "tags": [
                    "CMV_colitis"
                ]
            },
            {
                "id": 676,
                "question": "Most important nutritional intervention in chronic diarrhoea with malnutrition?",
                "choices": [
                    "A. High protein diet",
                    "B. Ready-to-use therapeutic food (RUTF) or F-100 if severe",
                    "C. Low-fat diet",
                    "D. Lactose-free only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Severe malnutrition secondary to chronic diarrhoea → treat as SAM with F-75/F-100 or RUTF (STG 2021).",
                "tags": [
                    "malnutrition",
                    "RUTF"
                ]
            },
            {
                "id": 677,
                "question": "A patient with chronic diarrhoea has nocturnal symptoms waking him from sleep. Most likely type?",
                "choices": [
                    "A. Functional (IBS)",
                    "B. Organic (inflammatory, secretory, malabsorption)",
                    "C. Osmotic",
                    "D. Motility"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Nocturnal diarrhoea is a red flag for organic disease (STG 2021).",
                "tags": [
                    "nocturnal",
                    "organic"
                ]
            },
            {
                "id": 678,
                "question": "Best empirical antibiotic for suspected small bowel bacterial overgrowth?",
                "choices": [
                    "A. Ciprofloxacin 500 mg BID 7–10 days",
                    "B. Rifaximin (not available) → use metronidazole or rotating antibiotics",
                    "C. Amoxicillin",
                    "D. Doxycycline"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Metronidazole 400 mg TID or norfloxacin/ciprofloxacin commonly used in Ethiopia (STG 2021).",
                "tags": [
                    "SBBO",
                    "metronidazole"
                ]
            },
            {
                "id": 679,
                "question": "A patient with chronic diarrhoea after pelvic radiotherapy has proctitis and rectal bleeding. Best treatment?",
                "choices": [
                    "A. Mesalazine suppositories",
                    "B. Sucralfate enemas or hydrocortisone foam",
                    "C. Oral metronidazole",
                    "D. Loperamide"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Radiation proctitis → topical sucralfate or steroid enemas (STG 2021).",
                "tags": [
                    "radiation_proctitis",
                    "sucralfate"
                ]
            },
            {
                "id": 680,
                "question": "Most common cause of chronic diarrhoea in thyroid clinic patients?",
                "choices": [
                    "A. Hypothyroidism",
                    "B. Hyperthyroidism",
                    "C. Thyroid cancer",
                    "D. Hashimoto"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Hyperthyroidism increases gut motility → chronic loose stools (STG 2021).",
                "tags": [
                    "hyperthyroidism"
                ]
            },
            {
                "id": 681,
                "question": "A 32-year-old with chronic diarrhoea has positive anti-tissue transglutaminase antibody. Diagnosis and treatment?",
                "choices": [
                    "A. Tropical sprue – tetracycline",
                    "B. Celiac disease – lifelong gluten-free diet",
                    "C. IBD – mesalazine",
                    "D. Behcet – colchicine"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Though rare, celiac is increasingly diagnosed; strict GFD is curative (STG 2021).",
                "tags": [
                    "celiac",
                    "GFD"
                ]
            },
            {
                "id": 682,
                "question": "Patient with chronic diarrhoea and HIV has acid-fast bacilli in stool. Most likely organism?",
                "choices": [
                    "A. Cryptosporidium",
                    "B. Mycobacterium tuberculosis",
                    "C. MAC",
                    "D. Isospora"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "TB can involve intestine; MAC is rare in Ethiopia due to BCG (STG 2021).",
                "tags": [
                    "intestinal_TB"
                ]
            },
            {
                "id": 683,
                "question": "Most important counselling for all patients with chronic diarrhoea?",
                "choices": [
                    "A. Stop all spicy food",
                    "B. Continue oral rehydration, nutrition, return if dehydration or blood",
                    "C. Fasting is best",
                    "D. Loperamide lifelong"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Prevent dehydration and malnutrition while investigating cause (STG 2021, p.197).",
                "tags": [
                    "counselling",
                    "ORS"
                ]
            },
            {
                "id": 684,
                "question": "A patient with chronic diarrhoea has stool Na 90 mmol/L, K 45 mmol/L. Calculated osmotic gap?",
                "choices": [
                    "A. >100 (osmotic)",
                    "B. <50 (secretory)",
                    "C. Normal",
                    "D. Cannot calculate"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "290 – 2×(90+45) = 290 – 270 = 20 → secretory (STG 2021).",
                "tags": [
                    "osmotic_gap_calculation"
                ]
            },
            {
                "id": 685,
                "question": "Most common presentation of intestinal tuberculosis in Ethiopia?",
                "choices": [
                    "A. Acute bloody diarrhoea",
                    "B. Subacute obstruction + chronic diarrhoea + weight loss",
                    "C. Massive bleeding",
                    "D. Perianal fistula"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Ileocaecal TB causes doughy abdomen, subacute obstruction, chronic diarrhoea (STG 2021).",
                "tags": [
                    "intestinal_TB"
                ]
            },
            {
                "id": 686,
                "question": "Patient with chronic diarrhoea after Billroth II surgery. Most likely mechanism?",
                "choices": [
                    "A. Dumping syndrome",
                    "B. Bile reflux gastritis",
                    "C. Bacterial overgrowth in afferent loop",
                    "D. Stump cancer"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Blind loop syndrome → SBBO (STG 2021).",
                "tags": [
                    "afferent_loop",
                    "SBBO"
                ]
            },
            {
                "id": 687,
                "question": "A 70-year-old with chronic watery diarrhoea has normal investigations. Most likely diagnosis?",
                "choices": [
                    "A. Microscopic colitis",
                    "B. IBS-diarrhoea predominant",
                    "C. Small bowel cancer",
                    "D. Pancreatic insufficiency"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Elderly + watery diarrhoea + normal colonoscopy → consider microscopic (lymphocytic/collagenous) colitis; treat with budesonide (STG 2021).",
                "tags": [
                    "microscopic_colitis"
                ]
            },
            {
                "id": 688,
                "question": "Best drug for symptomatic relief in non-infectious chronic diarrhoea?",
                "choices": [
                    "A. Loperamide 4 mg stat then 2 mg after each loose stool (max 16 mg/day)",
                    "B. Codeine phosphate",
                    "C. Diphenoxylate",
                    "D. Racecadotril"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Loperamide is safest and most effective; avoid in dysentery (STG 2021).",
                "tags": [
                    "loperamide"
                ]
            },
            {
                "id": 689,
                "question": "Patient with chronic diarrhoea and rheumatoid arthritis is on chronic NSAIDs. Most likely contributing factor?",
                "choices": [
                    "A. NSAID enteropathy/colopathy",
                    "B. Reactive arthritis",
                    "C. Rheumatoid vasculitis",
                    "D. Felty syndrome"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Long-term NSAIDs cause small bowel and colonic ulcers/diaphragms (STG 2021).",
                "tags": [
                    "NSAID_enteropathy"
                ]
            },
            {
                "id": 690,
                "question": "Most common cause of fat malabsorption in Ethiopia?",
                "choices": [
                    "A. Chronic pancreatitis (alcohol, gallstones)",
                    "B. Tropical sprue",
                    "C. Celiac",
                    "D. HIV enteropathy"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Chronic calcific pancreatitis from alcohol and recurrent gallstone disease is very common (STG 2021).",
                "tags": [
                    "chronic_pancreatitis"
                ]
            },
            {
                "id": 691,
                "question": "A patient with chronic diarrhoea has low serum albumin but no proteinuria. Most likely diagnosis?",
                "choices": [
                    "A. Nephrotic syndrome",
                    "B. Protein-losing enteropathy",
                    "C. Liver cirrhosis",
                    "D. Malnutrition only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Chronic diarrhoea + hypoalbuminaemia without liver or kidney disease → PLE (STG 2021).",
                "tags": [
                    "PLE"
                ]
            },
            {
                "id": 692,
                "question": "Patient with chronic diarrhoea after multiple antibiotics has positive C. difficile toxin. Treatment of choice?",
                "choices": [
                    "A. Metronidazole 400 mg TID 10 days",
                    "B. Oral vancomycin 125 mg QID 10 days (preferred)",
                    "C. Ciprofloxacin",
                    "D. Stop antibiotics only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "First-line in Ethiopia remains oral vancomycin if available; metronidazole alternative (STG 2021).",
                "tags": [
                    "C_difficile",
                    "vancomycin"
                ]
            },
            {
                "id": 693,
                "question": "Most important preventive measure for chronic diarrhoea in HIV patients?",
                "choices": [
                    "A. Daily co-trimoxazole prophylaxis",
                    "B. Early ART initiation",
                    "C. Albendazole every 6 months",
                    "D. All of the above"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "CPT prevents Isospora, Pneumocystis, and some bacterial diarrhoea; ART restores immunity (STG 2021).",
                "tags": [
                    "prevention",
                    "CPT_ART"
                ]
            },
            {
                "id": 694,
                "question": "A patient with chronic diarrhoea has finger clubbing and bronchiectasis. Most likely underlying condition?",
                "choices": [
                    "A. Celiac disease",
                    "B. Hypogammaglobulinaemia",
                    "C. Cystic fibrosis (extremely rare)",
                    "D. Alpha-1 antitrypsin deficiency"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Chronic diarrhoea + recurrent sinusitis/bronchiectasis → consider primary immunodeficiency (STG 2021).",
                "tags": [
                    "immunodeficiency"
                ]
            },
            {
                "id": 695,
                "question": "Final key message for chronic diarrhoea management in Ethiopia?",
                "choices": [
                    "A. All chronic diarrhoea is IBS",
                    "B. Look for treatable infections (parasites, TB, HIV-related), red flags for cancer/IBD, and provide nutrition/ORS while investigating",
                    "C. Just give loperamide",
                    "D. Colonoscopy for everyone"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Stepwise approach starting with stool microscopy, HIV testing, and treating common causes prevents mortality (Ethiopian STG 2021, p.197–199).",
                "tags": [
                    "key_message",
                    "stepwise"
                ]
            },
            {
                "id": 696,
                "question": "A 42-year-old teacher has intermittent diarrhoea alternating with constipation for 2 years, bloating, no weight loss. Most likely diagnosis?",
                "choices": [
                    "A. Colorectal cancer",
                    "B. Irritable bowel syndrome",
                    "C. Hyperthyroidism",
                    "D. Chronic amoebiasis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Rome IV criteria + no alarm features → IBS (common functional disorder) (STG 2021).",
                "tags": [
                    "IBS",
                    "alternating"
                ]
            },
            {
                "id": 697,
                "question": "Most common helminth causing chronic diarrhoea with malabsorption in Ethiopia?",
                "choices": [
                    "A. Ascaris",
                    "B. Strongyloides stercoralis (hyperinfection in immunocompromised)",
                    "C. Hookworm",
                    "D. Taenia"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Strongyloides causes protein-losing enteropathy and malabsorption especially in steroid use (STG 2021).",
                "tags": [
                    "strongyloides"
                ]
            },
            {
                "id": 698,
                "question": "Patient with chronic diarrhoea has positive Strongyloides larvae in stool and is starting prednisolone for nephrotic syndrome. Immediate action?",
                "choices": [
                    "A. Start steroids",
                    "B. Treat with ivermectin 200 µg/kg daily × 2 days (or albendazole) first",
                    "C. Give albendazole only",
                    "D. No need"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Prevent potentially fatal Strongyloides hyperinfection syndrome (STG 2021).",
                "tags": [
                    "strongyloides",
                    "ivermectin_pre_steroid"
                ]
            },
            {
                "id": 699,
                "question": "A patient with chronic diarrhoea has normal stool exam but high faecal calprotectin (if available). Next step?",
                "choices": [
                    "A. Reassure IBS",
                    "B. Colonoscopy to look for IBD",
                    "C. Trial of loperamide",
                    "D. Abdominal ultrasound"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Elevated calprotectin indicates mucosal inflammation → proceed to colonoscopy (STG 2021).",
                "tags": [
                    "calprotectin",
                    "IBD"
                ]
            },
            {
                "id": 700,
                "question": "Most cost-effective way to reduce burden of chronic diarrhoea in rural Ethiopia?",
                "choices": [
                    "A. Mass colonoscopy",
                    "B. Safe water, sanitation, hygiene (WASH), deworming, HIV control, early ART",
                    "C. Free loperamide",
                    "D. Routine stool culture"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.5 Chronic Diarrhoea",
                "explanation": "Prevention through public health measures is far more effective than treatment (STG 2021 & national policy).",
                "tags": [
                    "prevention",
                    "WASH"
                ]
            }
        ]
    },
    "Chapter 6.6": {
        "Chapter 6.6 Constipation": [
            {
                "id": 701,
                "question": "A 65-year-old man from rural Ethiopia presents with no bowel movement for 10 days, progressive abdominal distension, vomiting and absolute constipation. On examination he is dehydrated and has tympanitic abdomen. Most likely diagnosis?",
                "choices": [
                    "A. Simple constipation",
                    "B. Paralytic ileus",
                    "C. Large bowel obstruction (most likely sigmoid volvulus)",
                    "D. Faecal impaction"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Elderly male + sudden absolute constipation + massive distension in Ethiopia = sigmoid volvulus until proven otherwise (STG 2021, p.203).",
                "tags": [
                    "sigmoid_volvulus",
                    "elderly"
                ]
            },
            {
                "id": 702,
                "question": "Initial management of suspected sigmoid volvulus in a stable patient in general hospital?",
                "choices": [
                    "A. Urgent laparotomy",
                    "B. Insert flatus tube per rectum + IV fluids + NG tube",
                    "C. Oral laxatives",
                    "D. Enema"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Rigid or flexible sigmoidoscopy with flatus tube decompression is first-line in stable patient (STG 2021, p.203).",
                "tags": [
                    "flatus_tube",
                    "decompression"
                ]
            },
            {
                "id": 703,
                "question": "Most common cause of chronic constipation in adults in Ethiopia?",
                "choices": [
                    "A. Low-fibre diet",
                    "B. Hirschsprung’s disease",
                    "C. Hypothyroidism",
                    "D. Colonic cancer"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Low dietary fibre intake (teff-based diet low in vegetables/fruits) is the leading cause (STG 2021, p.202).",
                "tags": [
                    "dietary_fibre"
                ]
            },
            {
                "id": 704,
                "question": "First-line treatment for simple functional constipation in Ethiopia?",
                "choices": [
                    "A. Bisacodyl tablets",
                    "B. Lifestyle: high fibre (>30 g/day), ≥2 L water, exercise + bulk laxative (psyllium/ispaghula)",
                    "C. Lactulose lifelong",
                    "D. Daily enema"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Non-pharmacological measures + bulk-forming laxatives are first-line (STG 2021, p.202).",
                "tags": [
                    "lifestyle",
                    "bulk_laxative"
                ]
            },
            {
                "id": 705,
                "question": "A 50-year-old woman on amitriptyline for depression presents with severe constipation. Best initial step?",
                "choices": [
                    "A. Stop amitriptyline",
                    "B. Add bulk laxative + plenty of water; if not enough add osmotic (lactulose)",
                    "C. Switch to fluoxetine",
                    "D. Give bisacodyl daily"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Anticholinergic drugs commonly cause constipation – treat with fibre + osmotic laxatives (STG 2021, p.202).",
                "tags": [
                    "drug_induced"
                ]
            },
            {
                "id": 706,
                "question": "Red flag signs in constipation requiring urgent investigation?",
                "choices": [
                    "A. Straining only",
                    "B. Age >50 + new constipation + weight loss + rectal bleeding",
                    "C. Hard stool",
                    "D. Infrequent defecation"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Alarm features suggest colorectal cancer – urgent colonoscopy (STG 2021, p.202).",
                "tags": [
                    "alarm_features",
                    "colorectal_cancer"
                ]
            },
            {
                "id": 707,
                "question": "A 6-month-old infant has no bowel movement since birth, delayed passage of meconium, and abdominal distension. Most likely diagnosis?",
                "choices": [
                    "A. Hypothyroidism",
                    "B. Hirschsprung’s disease",
                    "C. Meconium ileus",
                    "D. Anal stenosis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Failure to pass meconium in first 48 hours + chronic constipation = Hirschsprung’s until proven otherwise (STG 2021, p.203).",
                "tags": [
                    "Hirschsprung"
                ]
            },
            {
                "id": 708,
                "question": "Most common opioid causing severe constipation in palliative care patients in Ethiopia?",
                "choices": [
                    "A. Tramadol",
                    "B. Morphine",
                    "C. Codeine",
                    "D. Pethidine"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "All opioids cause constipation; morphine is most commonly used in cancer pain (STG 2021, p.203).",
                "tags": [
                    "opioid_constipation"
                ]
            },
            {
                "id": 709,
                "question": "Best prophylactic laxative regimen when starting morphine in palliative care?",
                "choices": [
                    "A. Bisacodyl alone",
                    "B. Lactulose 15–30 mL BID + senna 2–4 tablets at night",
                    "C. Glycerin suppository",
                    "D. No need"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Combination osmotic (lactulose) + stimulant (senna) prevents opioid-induced constipation (STG 2021, p.203).",
                "tags": [
                    "opioid_prophylaxis",
                    "lactulose_senna"
                ]
            },
            {
                "id": 710,
                "question": "Safest laxative in pregnancy?",
                "choices": [
                    "A. Bisacodyl",
                    "B. Bulk-forming (ispaghula) + adequate water",
                    "C. Senna",
                    "D. Castor oil"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Bulk laxatives are safest; stimulant laxatives used short-term if needed (STG 2021, p.202).",
                "tags": [
                    "pregnancy_safe"
                ]
            },
            {
                "id": 711,
                "question": "A patient with chronic constipation has overflow diarrhoea and palpable faecal mass in left iliac fossa. Diagnosis?",
                "choices": [
                    "A. IBS",
                    "B. Faecal impaction",
                    "C. Colorectal cancer",
                    "D. Diverticular disease"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Elderly + chronic constipation + overflow = faecal impaction (STG 2021, p.203).",
                "tags": [
                    "faecal_impaction",
                    "overflow"
                ]
            },
            {
                "id": 712,
                "question": "Best initial treatment for faecal impaction?",
                "choices": [
                    "A. Oral lactulose alone",
                    "B. Warm water or oil enema + manual evacuation if needed",
                    "C. Immediate surgery",
                    "D. High-fibre diet only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Enema (oil/phosphate) to soften + digital evacuation under analgesia (STG 2021, p.203).",
                "tags": [
                    "impaction_treatment"
                ]
            },
            {
                "id": 713,
                "question": "Drug contraindicated in constipation with suspected bowel obstruction?",
                "choices": [
                    "A. Lactulose",
                    "B. Bulk-forming laxatives (ispaghula)",
                    "C. Glycerin suppository",
                    "D. Phosphate enema"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Bulk agents can worsen obstruction by absorbing water (STG 2021, p.202).",
                "tags": [
                    "contraindication"
                ]
            },
            {
                "id": 714,
                "question": "Most common electrolyte abnormality in severe chronic constipation with laxative abuse?",
                "choices": [
                    "A. Hyperkalemia",
                    "B. Hypokalemia",
                    "C. Hypernatremia",
                    "D. Hyponatremia"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Stimulant laxative abuse → hypokalemia and metabolic alkalosis (STG 2021, p.202).",
                "tags": [
                    "laxative_abuse"
                ]
            },
            {
                "id": 715,
                "question": "A patient with Parkinson’s disease has severe constipation unresponsive to lactulose. Next best agent?",
                "choices": [
                    "A. Bisacodyl suppository",
                    "B. Add senna or bisacodyl tablets",
                    "C. Linaclotide",
                    "D. Prucalopride (not available)"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Neurological disease → add stimulant laxative (STG 2021, p.202).",
                "tags": [
                    "Parkinson"
                ]
            },
            {
                "id": 716,
                "question": "Most common anatomical cause of constipation in children in Ethiopia?",
                "choices": [
                    "A. Hypothyroidism",
                    "B. Anorectal malformation / anterior ectopic anus",
                    "C. Hirschsprung’s",
                    "D. Celiac disease"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Anterior displaced anus is very common and under-recognised (STG 2021, p.203).",
                "tags": [
                    "anorectal_malformation"
                ]
            },
            {
                "id": 717,
                "question": "After successful decompression of sigmoid volvulus with flatus tube, next definitive management?",
                "choices": [
                    "A. Discharge home",
                    "B. Elective sigmoid resection during same admission (after bowel prep)",
                    "C. Repeat flatus tube monthly",
                    "D. High-fibre diet only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Recurrence rate >50% → elective resection is standard (STG 2021, p.203).",
                "tags": [
                    "sigmoid_resection"
                ]
            },
            {
                "id": 718,
                "question": "A 70-year-old man has new constipation, tenesmus and pencil-thin stool. Most urgent investigation?",
                "choices": [
                    "A. Abdominal X-ray",
                    "B. Colonoscopy or CT colonography",
                    "C. Barium enema",
                    "D. Faecal occult blood"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Change in bowel habit + age >50 → rule out colorectal cancer urgently (STG 2021, p.202).",
                "tags": [
                    "colorectal_cancer"
                ]
            },
            {
                "id": 719,
                "question": "Safest laxative in chronic kidney disease stage 4–5?",
                "choices": [
                    "A. Sodium phosphate enema",
                    "B. Lactulose or polyethylene glycol (Movicol)",
                    "C. Senna",
                    "D. Magnesium salts"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Avoid phosphate and magnesium-containing laxatives (STG 2021, p.202).",
                "tags": [
                    "CKD_safe"
                ]
            },
            {
                "id": 720,
                "question": "A patient with spinal cord injury at T12 has chronic constipation. Best long-term management?",
                "choices": [
                    "A. Daily bisacodyl suppository + digital stimulation",
                    "B. Oral lactulose only",
                    "C. Permanent colostomy",
                    "D. Manual evacuation daily"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Neurogenic bowel → timed bowel care with suppository + stimulation (STG 2021, p.203).",
                "tags": [
                    "spinal_cord"
                ]
            },
            {
                "id": 721,
                "question": "Most common cause of acute colonic pseudo-obstruction (Ogilvie syndrome) in hospitalised patients?",
                "choices": [
                    "A. Electrolyte imbalance (hypokalemia)",
                    "B. Post-operative state + opioids + immobility",
                    "C. Hypothyroidism",
                    "D. Sepsis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Multifactorial – surgery, opioids, electrolytes (STG 2021, p.203).",
                "tags": [
                    "Ogilvie"
                ]
            },
            {
                "id": 722,
                "question": "Initial management of Ogilvie syndrome with caecal diameter <12 cm and no peritonism?",
                "choices": [
                    "A. Urgent surgery",
                    "B. Conservative: NPO, NG tube, correct electrolytes, stop opioids, ambulation",
                    "C. Neostigmine IV",
                    "D. Colonoscopic decompression"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Conservative management first; 70–80% resolve (STG 2021, p.203).",
                "tags": [
                    "conservative_Ogilvie"
                ]
            },
            {
                "id": 723,
                "question": "A pregnant woman at 34 weeks has severe constipation unresponsive to fibre and lactulose. Safest next agent?",
                "choices": [
                    "A. Bisacodyl tablets/suppository short course",
                    "B. Sodium picosulfate",
                    "C. Castor oil",
                    "D. Senna daily"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Stimulant laxatives safe short-term in third trimester (STG 2021, p.202).",
                "tags": [
                    "pregnancy_stimulant"
                ]
            },
            {
                "id": 724,
                "question": "Most important dietary advice for prevention of constipation in Ethiopia?",
                "choices": [
                    "A. Increase teff intake",
                    "B. Add vegetables, fruits, legumes, whole grains daily (>30 g fibre)",
                    "C. Drink coffee",
                    "D. Reduce water"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Traditional diet low in fibre – education crucial (STG 2021, p.202).",
                "tags": [
                    "prevention"
                ]
            },
            {
                "id": 725,
                "question": "A patient with hypothyroidism has chronic constipation. Will it improve with thyroxine alone?",
                "choices": [
                    "A. No, needs lifelong laxatives",
                    "B. Yes, usually resolves with adequate thyroxine replacement",
                    "C. Only if surgery done",
                    "D. Needs colostomy"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Treat underlying cause – constipation improves with euthyroidism (STG 2021, p.202).",
                "tags": [
                    "hypothyroidism"
                ]
            },
            {
                "id": 726,
                "question": "Drug commonly used for bowel preparation before colonoscopy in Ethiopia?",
                "choices": [
                    "A. Oral fleet phospho-soda",
                    "B. Polyethylene glycol (PEG) 4 L solution (Fortrans/Klean-Prep)",
                    "C. Bisacodyl only",
                    "D. Castor oil"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "PEG-based solutions are safest and most effective (STG 2021, p.203).",
                "tags": [
                    "bowel_prep"
                ]
            },
            {
                "id": 727,
                "question": "A patient with constipation has hypokalemia and metabolic alkalosis. Most likely cause?",
                "choices": [
                    "A. Villous adenoma",
                    "B. Chronic laxative abuse (stimulant)",
                    "C. VIPoma",
                    "D. Conn’s syndrome"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Long-term stimulant laxative abuse → hypokalemia (STG 2021, p.202).",
                "tags": [
                    "laxative_abuse"
                ]
            },
            {
                "id": 728,
                "question": "Best laxative for elderly bedridden patient with chronic constipation?",
                "choices": [
                    "A. Daily phosphate enema",
                    "B. Lactulose 15–45 mL daily + senna at night",
                    "C. Bulk laxatives only",
                    "D. Manual evacuation daily"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Combination osmotic + stimulant is effective and safe (STG 2021, p.202).",
                "tags": [
                    "elderly"
                ]
            },
            {
                "id": 729,
                "question": "A child with constipation soils underwear with soft stool. Most likely mechanism?",
                "choices": [
                    "A. Hirschsprung’s",
                    "B. Overflow soiling from retained faeces (encopresis)",
                    "C. IBD",
                    "D. Sexual abuse"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Functional constipation → retentive behaviour → overflow (STG 2021, p.203).",
                "tags": [
                    "encopresis"
                ]
            },
            {
                "id": 730,
                "question": "Management of encopresis in children?",
                "choices": [
                    "A. Punishment",
                    "B. Disimpaction (PEG or enema) → maintenance lactulose + toilet training + behaviour therapy",
                    "C. Surgery",
                    "D. Antibiotics"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Clear impaction first then maintenance and behaviour modification (STG 2021, p.203).",
                "tags": [
                    "encopresis_treatment"
                ]
            },
            {
                "id": 731,
                "question": "Most common site of colorectal cancer presenting with constipation in Ethiopia?",
                "choices": [
                    "A. Caecum",
                    "B. Rectosigmoid",
                    "C. Transverse colon",
                    "D. Ascending colon"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Left-sided tumours → obstructive symptoms (STG 2021, p.202).",
                "tags": [
                    "rectosigmoid_cancer"
                ]
            },
            {
                "id": 732,
                "question": "A patient with constipation and hypercalcaemia. Most likely underlying malignancy?",
                "choices": [
                    "A. Prostate",
                    "B. Multiple myeloma or metastatic cancer",
                    "C. Lung",
                    "D. Breast"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Hypercalcaemia + constipation common in myeloma and bone metastases (STG 2021).",
                "tags": [
                    "hypercalcaemia"
                ]
            },
            {
                "id": 733,
                "question": "Safest laxative in hepatic encephalopathy?",
                "choices": [
                    "A. Senna",
                    "B. Lactulose 15–45 mL to produce 2–3 soft stools/day",
                    "C. Bisacodyl",
                    "D. Phosphate enema"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Lactulose is first-line for encephalopathy and treats constipation (STG 2021, p.202).",
                "tags": [
                    "lactulose_encephalopathy"
                ]
            },
            {
                "id": 734,
                "question": "After 3 months of adequate fibre and laxatives, patient still has <3 bowel movements/week. Next step?",
                "choices": [
                    "A. Continue same",
                    "B. Investigate for slow-transit constipation or pelvic floor dysfunction",
                    "C. Surgery",
                    "D. Life-long enemas"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Refractory constipation → need tertiary evaluation (STG 2021, p.202).",
                "tags": [
                    "refractory"
                ]
            },
            {
                "id": 735,
                "question": "Most common preventable cause of severe constipation in hospitalised patients?",
                "choices": [
                    "A. Immobility",
                    "B. Opioids without laxatives",
                    "C. Dehydration",
                    "D. All of the above"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Iatrogenic constipation is very common – always give laxatives with opioids (STG 2021, p.203).",
                "tags": [
                    "iatrogenic"
                ]
            },
            {
                "id": 736,
                "question": "A patient with chronic constipation has anal pain and bright red blood on paper. Most likely additional diagnosis?",
                "choices": [
                    "A. Haemorrhoids",
                    "B. Anal fissure",
                    "C. Rectal cancer",
                    "D. Solitary rectal ulcer"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Hard stool + straining → anal fissure (STG 2021).",
                "tags": [
                    "anal_fissure"
                ]
            },
            {
                "id": 737,
                "question": "Best treatment for chronic anal fissure with constipation?",
                "choices": [
                    "A. Lateral internal sphincterotomy",
                    "B. Soften stool (lactulose/fibre) + topical GTN or diltiazem",
                    "C. Daily enema",
                    "D. Botox injection"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Stool softeners are essential to prevent recurrence (STG 2021, p.203).",
                "tags": [
                    "fissure_treatment"
                ]
            },
            {
                "id": 738,
                "question": "Patient with constipation and urinary retention after delivery. Most likely cause?",
                "choices": [
                    "A. Pudendal nerve injury",
                    "B. Epidural analgesia + immobility",
                    "C. Uterine retroversion",
                    "D. UTI"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Post-partum constipation common due to pain, opioids, dehydration (STG 2021).",
                "tags": [
                    "postpartum"
                ]
            },
            {
                "id": 739,
                "question": "A patient with constipation has koilonychia and angular stomatitis. Underlying cause?",
                "choices": [
                    "A. Iron deficiency (plummer-vinson possible)",
                    "B. B12 deficiency",
                    "C. Zinc deficiency",
                    "D. Hypothyroidism"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Chronic iron deficiency can cause constipation; treat iron (STG 2021).",
                "tags": [
                    "iron_deficiency"
                ]
            },
            {
                "id": 740,
                "question": "Most important counselling point for all patients with constipation?",
                "choices": [
                    "A. Take laxatives lifelong",
                    "B. Never strain, respond to call to stool, high fibre + water + exercise",
                    "C. Enema daily",
                    "D. Surgery is best"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Lifestyle modification prevents recurrence (STG 2021, p.202).",
                "tags": [
                    "counselling"
                ]
            },
            {
                "id": 741,
                "question": "Drug that can cause life-threatening constipation in elderly?",
                "choices": [
                    "A. Verapamil",
                    "B. Ondansetron",
                    "C. Tramadol",
                    "D. All opioids"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Opioids + reduced mobility → severe constipation and impaction (STG 2021, p.203).",
                "tags": [
                    "opioids_elderly"
                ]
            },
            {
                "id": 742,
                "question": "A patient with constipation has abdominal X-ray showing loaded colon with faecal matter up to rectum. Best next step?",
                "choices": [
                    "A. Urgent surgery",
                    "B. Oral PEG (polyethylene glycol) 1–2 sachets daily for disimpaction",
                    "C. Phosphate enema",
                    "D. Observe"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "High-dose PEG safe and effective for disimpaction (STG 2021, p.203).",
                "tags": [
                    "PEG_disimpaction"
                ]
            },
            {
                "id": 743,
                "question": "Most common complication of untreated chronic constipation in elderly Ethiopians?",
                "choices": [
                    "A. Diverticulosis",
                    "B. Faecal impaction → overflow diarrhoea → falls",
                    "C. Haemorrhoids",
                    "D. Volvulus"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Impaction is very common and leads to confusion and falls (STG 2021, p.203).",
                "tags": [
                    "impaction_elderly"
                ]
            },
            {
                "id": 744,
                "question": "Patient with constipation and narrow-angle glaucoma. Which laxative to avoid?",
                "choices": [
                    "A. Lactulose",
                    "B. Anticholinergic-containing preparations",
                    "C. Senna",
                    "D. PEG"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Avoid drugs with anticholinergic side effects (STG 2021).",
                "tags": [
                    "glaucoma"
                ]
            },
            {
                "id": 745,
                "question": "A diabetic patient with constipation has early satiety and vomiting. Most likely additional diagnosis?",
                "choices": [
                    "A. Diabetic gastroparesis",
                    "B. Autonomic neuropathy affecting colon",
                    "C. Pancreatic cancer",
                    "D. Both A and B"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Diabetic autonomic neuropathy affects entire GI tract (STG 2021).",
                "tags": [
                    "diabetic_neuropathy"
                ]
            },
            {
                "id": 746,
                "question": "Best laxative combination for terminal cancer patient on high-dose morphine?",
                "choices": [
                    "A. Lactulose + senna (titrate to 2–3 soft stools/day)",
                    "B. Daily phosphate enema",
                    "C. Methylnaltrexone (not available)",
                    "D. Stop morphine"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Escalate laxatives aggressively in palliative care (STG 2021, p.203).",
                "tags": [
                    "palliative_laxatives"
                ]
            },
            {
                "id": 747,
                "question": "A patient with constipation has serum calcium 2.9 mmol/L. Most urgent action?",
                "choices": [
                    "A. Give laxatives",
                    "B. Treat hypercalcaemia first (IV fluids + bisphosphonate)",
                    "C. Enema",
                    "D. Fibre"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Severe hypercalcaemia causes paralytic ileus and constipation (STG 2021).",
                "tags": [
                    "hypercalcaemia_treatment"
                ]
            },
            {
                "id": 748,
                "question": "Most common cause of secondary constipation in HIV patients on ART?",
                "choices": [
                    "A. Opportunistic infections",
                    "B. Lopinavir/ritonavir or other drugs",
                    "C. CMV colitis",
                    "D. Lymphoma"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Protease inhibitors and other ART can slow gut motility (STG 2021).",
                "tags": [
                    "ART_constipation"
                ]
            },
            {
                "id": 749,
                "question": "Patient with chronic constipation is found to have megacolon on X-ray. Most likely long-term complication?",
                "choices": [
                    "A. Colorectal cancer",
                    "B. Recurrent sigmoid volvulus",
                    "C. Malnutrition",
                    "D. Diverticulosis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Chronic megacolon predisposes to recurrent volvulus (STG 2021, p.203).",
                "tags": [
                    "megacolon_volvulus"
                ]
            },
            {
                "id": 750,
                "question": "Final take-home message for constipation in Ethiopian general hospitals?",
                "choices": [
                    "A. All constipation is cancer",
                    "B. Start with lifestyle + bulk/osmotic laxatives, recognise red flags and sigmoid volvulus early, always give laxatives with opioids",
                    "C. Surgery for everyone",
                    "D. Laxatives are dangerous"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.6 Constipation",
                "explanation": "Simple measures cure most cases; early recognition of volvulus and cancer saves lives (Ethiopian STG 2021, p.202–203).",
                "tags": [
                    "key_message"
                ]
            }
        ]
    },
    "Chapter 6.7": {
        "Chapter 6.7 Acute Abdominal Pain": [
            {
                "id": 751,
                "question": "A 32-year-old man presents with sudden onset severe epigastric pain radiating to the back, vomiting, and abdominal distension for 12 hours. He drinks alcohol heavily. Most likely diagnosis?",
                "choices": [
                    "A. Perforated peptic ulcer",
                    "B. Acute pancreatitis",
                    "C. Acute cholecystitis",
                    "D. Ruptured aortic aneurysm"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Severe epigastric pain radiating to back + vomiting + alcohol history = acute pancreatitis until proven otherwise (STG 2021, p.204).",
                "tags": [
                    "acute_pancreatitis",
                    "alcohol"
                ]
            },
            {
                "id": 752,
                "question": "Initial management of acute pancreatitis in general hospital?",
                "choices": [
                    "A. Immediate surgery",
                    "B. NPO, IV fluids (aggressive), NG tube if vomiting, analgesia (pethidine/tramadol), monitor vital signs",
                    "C. Oral feeding",
                    "D. Antibiotics routinely"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Supportive care: fasting, aggressive IV hydration, pain relief; antibiotics only if infected necrosis suspected (STG 2021, p.204).",
                "tags": [
                    "pancreatitis_management"
                ]
            },
            {
                "id": 753,
                "question": "A 28-year-old woman has sudden severe right upper quadrant pain radiating to right shoulder tip, 2 hours after fatty meal. Most likely diagnosis?",
                "choices": [
                    "A. Acute pancreatitis",
                    "B. Acute cholecystitis",
                    "C. Biliary colic",
                    "D. Perforated peptic ulcer"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Post-prandial RUQ pain radiating to shoulder tip = biliary colic; if fever + Murphy’s sign → cholecystitis (STG 2021, p.205).",
                "tags": [
                    "biliary_colic"
                ]
            },
            {
                "id": 754,
                "question": "Most common cause of acute abdominal pain requiring surgery in Ethiopia?",
                "choices": [
                    "A. Acute pancreatitis",
                    "B. Acute appendicitis",
                    "C. Perforated peptic ulcer",
                    "D. Intestinal obstruction"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Acute appendicitis remains the commonest surgical emergency (STG 2021, p.205).",
                "tags": [
                    "appendicitis"
                ]
            },
            {
                "id": 755,
                "question": "Classic presentation of acute appendicitis in Ethiopian adults?",
                "choices": [
                    "A. Central abdominal pain shifting to RIF + anorexia + vomiting",
                    "B. Sudden epigastric pain",
                    "C. Left lower quadrant pain",
                    "D. Diffuse pain"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Periumbilical pain → migration to RIF (McBurney’s point tenderness) is classic (STG 2021, p.205).",
                "tags": [
                    "appendicitis_presentation"
                ]
            },
            {
                "id": 756,
                "question": "A 45-year-old man has sudden severe epigastric pain, becomes rigid and shocked within hours. Chest X-ray shows air under diaphragm. Most likely diagnosis?",
                "choices": [
                    "A. Acute pancreatitis",
                    "B. Perforated peptic ulcer",
                    "C. Ruptured ectopic pregnancy",
                    "D. Mesenteric infarction"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Sudden severe epigastric pain + board-like rigidity + free air = perforated DU/GU (STG 2021, p.205).",
                "tags": [
                    "perforated_ulcer"
                ]
            },
            {
                "id": 757,
                "question": "First-line management of perforated peptic ulcer in stable patient?",
                "choices": [
                    "A. IV PPI + antibiotics + NG tube + urgent laparotomy/laparoscopic repair",
                    "B. Conservative only",
                    "C. Oral antibiotics",
                    "D. Endoscopy"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Resuscitate + broad-spectrum antibiotics (ceftriaxone + metronidazole) + surgery within 24 h (STG 2021, p.205).",
                "tags": [
                    "perforation_surgery"
                ]
            },
            {
                "id": 758,
                "question": "Most common cause of intestinal obstruction in adults in Ethiopia?",
                "choices": [
                    "A. Adhesions",
                    "B. Sigmoid volvulus",
                    "C. Hernia",
                    "D. Colorectal cancer"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Sigmoid volvulus is the leading cause of large bowel obstruction (STG 2021, p.204).",
                "tags": [
                    "sigmoid_volvulus"
                ]
            },
            {
                "id": 759,
                "question": "A 60-year-old man has sudden severe lower abdominal pain, massive distension, no flatus/stool for 2 days. Abdominal X-ray shows coffee-bean sign. Immediate management?",
                "choices": [
                    "A. Urgent laparotomy",
                    "B. Rigid sigmoidoscopy + flatus tube insertion",
                    "C. Conservative",
                    "D. Enema"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Coffee-bean sign = sigmoid volvulus; decompression via sigmoidoscopy is life-saving (STG 2021, p.204).",
                "tags": [
                    "coffee_bean_sign"
                ]
            },
            {
                "id": 760,
                "question": "Red flag signs in acute abdominal pain requiring urgent surgical review?",
                "choices": [
                    "A. Mild pain only",
                    "B. Guarding, rigidity, rebound tenderness, shock, absent bowel sounds",
                    "C. Vomiting once",
                    "D. Diarrhoea"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Signs of peritonitis or shock = surgical emergency (STG 2021, p.204).",
                "tags": [
                    "peritonitis"
                ]
            },
            {
                "id": 761,
                "question": "Most common cause of acute right lower quadrant pain in young Ethiopian female?",
                "choices": [
                    "A. Appendicitis",
                    "B. Ruptured ectopic pregnancy",
                    "C. Ovarian torsion",
                    "D. PID"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Sexually active female + missed period + sudden lower abdominal pain → ectopic until proven otherwise (STG 2021, p.205).",
                "tags": [
                    "ectopic_pregnancy"
                ]
            },
            {
                "id": 762,
                "question": "A patient with acute abdominal pain has positive urine pregnancy test and hypotension. Immediate action?",
                "choices": [
                    "A. Ultrasound",
                    "B. IV fluids + blood + urgent laparotomy (suspected ruptured ectopic)",
                    "C. Misoprostol",
                    "D. Observe"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Ruptured ectopic is life-threatening; resuscitate and operate immediately (STG 2021, p.205).",
                "tags": [
                    "ruptured_ectopic"
                ]
            },
            {
                "id": 763,
                "question": "Most useful initial investigation in non-traumatic acute abdominal pain in district hospital?",
                "choices": [
                    "A. CT abdomen",
                    "B. Erect and supine abdominal X-ray + abdominal ultrasound + pregnancy test (females)",
                    "C. Endoscopy",
                    "D. Laparoscopy"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Plain X-ray detects perforation/obstruction; ultrasound widely available for biliary/gynaecological causes (STG 2021, p.204).",
                "tags": [
                    "investigations"
                ]
            },
            {
                "id": 764,
                "question": "A 55-year-old diabetic presents with gradual severe left flank pain, fever, dysuria. Most likely diagnosis?",
                "choices": [
                    "A. Pyelonephritis",
                    "B. Renal colic",
                    "C. Acute pancreatitis",
                    "D. Diverticulitis"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Flank pain + fever + diabetes → acute pyelonephritis (STG 2021, p.205).",
                "tags": [
                    "pyelonephritis"
                ]
            },
            {
                "id": 765,
                "question": "Classic triad of renal colic?",
                "choices": [
                    "A. Severe colicky flank pain radiating to groin + haematuria + vomiting",
                    "B. Constant pain + fever",
                    "C. Lower abdominal pain",
                    "D. Diarrhoea"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Colicky pain + radiation to groin + microscopic haematuria (STG 2021, p.205).",
                "tags": [
                    "renal_colic"
                ]
            },
            {
                "id": 766,
                "question": "A 25-year-old man has acute severe testicular pain with vomiting. Diagnosis?",
                "choices": [
                    "A. Testicular torsion",
                    "B. Epididymitis",
                    "C. Orchitis",
                    "D. Inguinal hernia"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Sudden severe scrotal pain + vomiting in young male = torsion until proven otherwise; surgical emergency (STG 2021, p.205).",
                "tags": [
                    "testicular_torsion"
                ]
            },
            {
                "id": 767,
                "question": "Most common cause of acute mesenteric ischaemia in Ethiopia?",
                "choices": [
                    "A. Embolus",
                    "B. Mesenteric venous thrombosis",
                    "C. Atrial fibrillation → arterial embolism",
                    "D. Atherosclerosis"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Rheumatic heart disease + AF very common → embolus to SMA (STG 2021, p.204).",
                "tags": [
                    "mesenteric_ischaemia"
                ]
            },
            {
                "id": 768,
                "question": "Pain out of proportion to examination findings in elderly patient with AF → think?",
                "choices": [
                    "A. Appendicitis",
                    "B. Acute mesenteric ischaemia",
                    "C. Pancreatitis",
                    "D. Perforation"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Severe pain with soft abdomen early on = mesenteric ischaemia (STG 2021, p.204).",
                "tags": [
                    "pain_disproportionate"
                ]
            },
            {
                "id": 769,
                "question": "A 40-year-old woman has acute lower abdominal pain, vaginal discharge, cervical motion tenderness. Diagnosis?",
                "choices": [
                    "A. Ectopic pregnancy",
                    "B. Pelvic inflammatory disease (PID)",
                    "C. Ovarian cyst rupture",
                    "D. Appendicitis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Bilateral lower pain + CMT + discharge = PID (STG 2021, p.205).",
                "tags": [
                    "PID"
                ]
            },
            {
                "id": 770,
                "question": "Best analgesia for severe acute abdominal pain before surgical review?",
                "choices": [
                    "A. Withhold until surgeon sees",
                    "B. IV morphine or pethidine titrated + antiemetic",
                    "C. Oral paracetamol",
                    "D. IM diclofenac only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Adequate analgesia does NOT mask signs; give opioids early (STG 2021, p.204).",
                "tags": [
                    "analgesia_myth"
                ]
            },
            {
                "id": 771,
                "question": "A patient with acute abdominal pain has serum amylase 1200 U/L. Most likely diagnosis?",
                "choices": [
                    "A. Perforated ulcer",
                    "B. Acute pancreatitis",
                    "C. Bowel obstruction",
                    "D. Cholecystitis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Amylase >3 times upper limit = acute pancreatitis (STG 2021, p.204).",
                "tags": [
                    "amylase"
                ]
            },
            {
                "id": 772,
                "question": "Most common cause of acute abdominal pain in children in Ethiopia?",
                "choices": [
                    "A. Appendicitis",
                    "B. Intestinal obstruction (intussusception, volvulus, ascariasis)",
                    "C. Gastroenteritis",
                    "D. UTI"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Ascaris bolus, intussusception common in paediatric age (STG 2021, p.205).",
                "tags": [
                    "paediatric"
                ]
            },
            {
                "id": 773,
                "question": "A child with intermittent severe colicky pain, vomiting, red currant jelly stool. Diagnosis?",
                "choices": [
                    "A. Appendicitis",
                    "B. Intussusception",
                    "C. Gastroenteritis",
                    "D. Meckel diverticulum"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Classic triad of intussusception (STG 2021, p.205).",
                "tags": [
                    "intussusception"
                ]
            },
            {
                "id": 774,
                "question": "A patient with sickle cell disease presents with acute abdominal pain. Most important differential to exclude?",
                "choices": [
                    "A. Acute chest syndrome",
                    "B. Surgical cause (cholecystitis, appendicitis) – same as general population",
                    "C. Vaso-occlusive crisis only",
                    "D. Sequestration"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "SCD patients can have all surgical emergencies; do not assume vaso-occlusive crisis alone (STG 2021, p.204).",
                "tags": [
                    "sickle_cell"
                ]
            },
            {
                "id": 775,
                "question": "Most common cause of acute severe abdominal pain in elderly Ethiopians?",
                "choices": [
                    "A. Appendicitis",
                    "B. Sigmoid volvulus",
                    "C. Perforated ulcer",
                    "D. Biliary colic"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "High-fibre diet + poor motility → volvulus very common (STG 2021, p.204).",
                "tags": [
                    "elderly_volvulus"
                ]
            },
            {
                "id": 776,
                "question": "A HIV-positive patient has acute abdominal pain and free air under diaphragm. Most likely cause?",
                "choices": [
                    "A. Perforated peptic ulcer",
                    "B. TB-related perforation (ileal)",
                    "C. CMV colitis perforation",
                    "D. Any of the above"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Advanced HIV → higher risk of TB perforation and CMV (STG 2021, p.205).",
                "tags": [
                    "HIV_perforation"
                ]
            },
            {
                "id": 777,
                "question": "Best antibiotic regimen for suspected perforated viscus in Ethiopia?",
                "choices": [
                    "A. Ceftriaxone + metronidazole",
                    "B. Amoxicillin only",
                    "C. Ciprofloxacin",
                    "D. Gentamicin"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Broad-spectrum covering aerobes and anaerobes (STG 2021, p.205).",
                "tags": [
                    "antibiotics_perforation"
                ]
            },
            {
                "id": 778,
                "question": "A patient with acute abdominal pain has temperature 38.9°C, tachycardia, rebound tenderness in RIF. Next step?",
                "choices": [
                    "A. Oral antibiotics",
                    "B. IV fluids + antibiotics + urgent appendicectomy",
                    "C. Ultrasound first",
                    "D. Observe"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Clinical diagnosis of acute appendicitis → early surgery (STG 2021, p.205).",
                "tags": [
                    "appendicectomy"
                ]
            },
            {
                "id": 779,
                "question": "Most important blood test in acute abdominal pain?",
                "choices": [
                    "A. Amylase",
                    "B. CBC, pregnancy test, group & save/cross-match if shocked",
                    "C. LFT",
                    "D. CRP"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Haemoglobin, WCC, pregnancy test guide management (STG 2021, p.204).",
                "tags": [
                    "blood_tests"
                ]
            },
            {
                "id": 780,
                "question": "A 19-year-old female has acute lower abdominal pain, previously had similar episodes that resolved. Examination normal. Most likely diagnosis?",
                "choices": [
                    "A. Appendicitis",
                    "B. Mittelschmerz (mid-cycle ovulatory pain)",
                    "C. PID",
                    "D. Ectopic"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Self-limiting mid-cycle pain common and benign (STG 2021, p.205).",
                "tags": [
                    "mittelschmerz"
                ]
            },
            {
                "id": 781,
                "question": "Patient with acute abdominal pain and jaundice. Most likely diagnosis?",
                "choices": [
                    "A. Acute pancreatitis",
                    "B. Acute cholangitis / gallstone disease",
                    "C. Viral hepatitis",
                    "D. Perforated ulcer"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Charcot’s triad (pain, fever, jaundice) = acute cholangitis (STG 2021, p.205).",
                "tags": [
                    "cholangitis"
                ]
            },
            {
                "id": 782,
                "question": "A patient with acute abdominal pain has visible peristalsis and resonant abdomen. Diagnosis?",
                "choices": [
                    "A. Peritonitis",
                    "B. Intestinal obstruction",
                    "C. Pancreatitis",
                    "D. Ileus"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Visible peristalsis + tympanitic = mechanical obstruction (STG 2021, p.204).",
                "tags": [
                    "visible_peristalsis"
                ]
            },
            {
                "id": 783,
                "question": "Most common strangulated hernia in Ethiopian adults?",
                "choices": [
                    "A. Inguinal",
                    "B. Umbilical",
                    "C. Femoral",
                    "D. Incisional"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Indirect inguinal hernia common and frequently presents late with strangulation (STG 2021, p.204).",
                "tags": [
                    "inguinal_hernia"
                ]
            },
            {
                "id": 784,
                "question": "A patient with typhoid fever develops sudden severe abdominal pain and shock on day 10. Most likely complication?",
                "choices": [
                    "A. Myocarditis",
                    "B. Intestinal perforation",
                    "C. Encephalopathy",
                    "D. Cholecystitis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Ileal perforation common in 2nd–3rd week of typhoid (STG 2021, p.205).",
                "tags": [
                    "typhoid_perforation"
                ]
            },
            {
                "id": 785,
                "question": "Best position for patient with suspected perforated peptic ulcer during transport?",
                "choices": [
                    "A. Supine",
                    "B. Semi-sitting (reduce sub-diaphragmatic irritation)",
                    "C. Left lateral",
                    "D. Prone"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Sitting position reduces pain from sub-diaphragmatic air (STG 2021, p.205).",
                "tags": [
                    "position_perforation"
                ]
            },
            {
                "id": 786,
                "question": "A patient with acute abdominal pain has BP 80/50, pulse 130. First priority?",
                "choices": [
                    "A. X-ray",
                    "B. IV access + aggressive fluid resuscitation + oxygen + urgent surgical review",
                    "C. Analgesia",
                    "D. Antibiotics"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "ABC approach – treat shock first (STG 2021, p.204).",
                "tags": [
                    "shock"
                ]
            },
            {
                "id": 787,
                "question": "Most common cause of acute abdominal pain in pregnant women?",
                "choices": [
                    "A. Appendicitis",
                    "B. Same causes as non-pregnant + pregnancy-related (ectopic, miscarriage, abruption)",
                    "C. UTI",
                    "D. Round ligament pain"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Pregnancy does not protect against surgical emergencies (STG 2021, p.205).",
                "tags": [
                    "pregnancy_abdomen"
                ]
            },
            {
                "id": 788,
                "question": "A patient with acute abdominal pain has ascites and tenderness. Most likely diagnosis?",
                "choices": [
                    "A. Spontaneous bacterial peritonitis (SBP)",
                    "B. Perforation",
                    "C. Pancreatitis",
                    "D. TB peritonitis"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Cirrhosis + fever + abdominal pain → suspect SBP (STG 2021, p.204).",
                "tags": [
                    "SBP"
                ]
            },
            {
                "id": 789,
                "question": "Patient with acute abdominal pain has multiple air-fluid levels, no free air. Management?",
                "choices": [
                    "A. Immediate surgery",
                    "B. NPO, NG tube, IV fluids, correct electrolytes, look for cause",
                    "C. Oral laxatives",
                    "D. Enema"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Conservative management of small bowel obstruction while preparing for surgery if no resolution (STG 2021, p.204).",
                "tags": [
                    "SBO_management"
                ]
            },
            {
                "id": 790,
                "question": "A child swallowed a coin 3 days ago, now has abdominal pain and vomiting. Most likely complication?",
                "choices": [
                    "A. Appendicitis",
                    "B. Intestinal obstruction / perforation",
                    "C. Oesophagus perforation",
                    "D. Normal"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Foreign body beyond 72 h → risk of obstruction/perforation (STG 2021, p.205).",
                "tags": [
                    "foreign_body"
                ]
            },
            {
                "id": 791,
                "question": "Most important question to ask in history of acute abdominal pain?",
                "choices": [
                    "A. Family history",
                    "B. Previous similar episodes and previous surgery (adhesions)",
                    "C. Diet",
                    "D. Occupation"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Previous surgery → adhesions → commonest cause of SBO in developed world, increasing in Ethiopia (STG 2021, p.204).",
                "tags": [
                    "history"
                ]
            },
            {
                "id": 792,
                "question": "A patient with acute abdominal pain has ketone breath and high glucose. Diagnosis?",
                "choices": [
                    "A. DKA with abdominal crisis",
                    "B. Acute pancreatitis precipitating DKA",
                    "C. Either – both common",
                    "D. Normal"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "DKA presents with severe abdominal pain; pancreatitis can precipitate DKA (STG 2021, p.204).",
                "tags": [
                    "DKA"
                ]
            },
            {
                "id": 793,
                "question": "Patient with acute abdominal pain has spider naevi, ascites, jaundice. Most likely underlying disease?",
                "choices": [
                    "A. Chronic liver disease",
                    "B. Malignancy",
                    "C. Heart failure",
                    "D. Nephrotic syndrome"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Chronic liver disease predisposes to SBP, variceal bleed, etc. (STG 2021, p.204).",
                "tags": [
                    "liver_disease"
                ]
            },
            {
                "id": 794,
                "question": "A patient with acute abdominal pain has absent bowel sounds and tympanitic abdomen. Most likely?",
                "choices": [
                    "A. Peritonitis",
                    "B. Paralytic ileus or obstruction",
                    "C. Normal",
                    "D. Constipation"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Absent sounds = ileus or late obstruction (STG 2021, p.204).",
                "tags": [
                    "bowel_sounds"
                ]
            },
            {
                "id": 795,
                "question": "Most common cause of non-traumatic acute abdominal pain in young Ethiopian males?",
                "choices": [
                    "A. Appendicitis",
                    "B. Renal colic",
                    "C. NSAP (non-specific abdominal pain)",
                    "D. Gastritis"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Appendicitis peaks in 2nd–3rd decade (STG 2021, p.205).",
                "tags": [
                    "young_male"
                ]
            },
            {
                "id": 796,
                "question": "A patient with acute abdominal pain has positive psoas sign. Most likely diagnosis?",
                "choices": [
                    "A. Cholecystitis",
                    "B. Appendicitis (retrocaecal)",
                    "C. Diverticulitis",
                    "D. Pancreatitis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Psoas sign positive in retrocaecal appendix (STG 2021, p.205).",
                "tags": [
                    "psoas_sign"
                ]
            },
            {
                "id": 797,
                "question": "Patient with acute abdominal pain has shifting dullness. Most urgent concern?",
                "choices": [
                    "A. Haemoperitoneum or perforated viscus with exudation",
                    "B. Chronic ascites",
                    "C. Normal",
                    "D. Ovarian cyst"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Acute ascites + pain → ruptured ectopic, splenic rupture, perforation (STG 2021, p.204).",
                "tags": [
                    "ascites_acute"
                ]
            },
            {
                "id": 798,
                "question": "Best way to reduce mortality from acute abdomen in rural Ethiopia?",
                "choices": [
                    "A. CT scan in every hospital",
                    "B. Early recognition, rapid referral, IV fluids and antibiotics en route",
                    "C. Traditional medicine",
                    "D. Wait and see"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Delay in presentation and transfer is the major killer (STG 2021, p.204).",
                "tags": [
                    "referral"
                ]
            },
            {
                "id": 799,
                "question": "A patient with acute abdominal pain has Murphy’s sign positive. Diagnosis?",
                "choices": [
                    "A. Appendicitis",
                    "B. Acute cholecystitis",
                    "C. Pancreatitis",
                    "D. Renal colic"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "Arrest of inspiration on palpation of RUQ = Murphy’s sign (STG 2021, p.205).",
                "tags": [
                    "Murphy_sign"
                ]
            },
            {
                "id": 800,
                "question": "Final take-home message for acute abdominal pain in Ethiopian general hospitals?",
                "choices": [
                    "A. All abdominal pain is gastritis",
                    "B. Acute abdomen is a surgical emergency until proven otherwise; resuscitate, give analgesia and antibiotics early, involve surgeon promptly, never delay referral",
                    "C. Give PPI and discharge",
                    "D. Wait 48 hours"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.7 Acute Abdominal Pain",
                "explanation": "High index of suspicion + rapid intervention saves lives; common things are common (appendicitis, volvulus, perforation, ectopic) (Ethiopian STG 2021, p.204–205).",
                "tags": [
                    "key_message"
                ]
            }
        ]
    },
    "Chapter 6.8": {
        "Chapter 6.8 Hepatitis": [
            {
                "id": 801,
                "question": "A 28-year-old man presents with jaundice, high-coloured urine, malaise for 2 weeks and tender hepatomegaly. ALT 1800 U/L, bilirubin 8 mg/dL. Most likely diagnosis in Ethiopia?",
                "choices": [
                    "A. Alcoholic hepatitis",
                    "B. Acute viral hepatitis (HAV or HEV)",
                    "C. Drug-induced liver injury",
                    "D. Malaria"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "Acute icteric hepatitis with very high transaminases in young adult in Ethiopia is almost always HAV or HEV (STG 2021, p.209).",
                "tags": [
                    "acute_viral_hepatitis",
                    "HAV_HEV"
                ]
            },
            {
                "id": 802,
                "question": "First-line management of uncomplicated acute viral hepatitis A or E?",
                "choices": [
                    "A. Antiviral therapy",
                    "B. Supportive only: rest, hydration, nutrition, avoid alcohol; no specific treatment not required",
                    "C. Corticosteroids",
                    "D. Urgent referral"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "HAV and HEV are self-limiting in >99% of cases; only supportive care needed (STG 2021, p.209).",
                "tags": [
                    "supportive_care"
                ]
            },
            {
                "id": 803,
                "question": "Most common cause of fulminant hepatic failure in Ethiopia?",
                "choices": [
                    "A. Hepatitis B",
                    "B. Hepatitis E (especially in pregnant women)",
                    "C. Yellow fever",
                    "D. Paracetamol overdose"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "HEV genotype 1 causes severe disease and high mortality up to 25% in pregnant women (STG 2021, p.209).",
                "tags": [
                    "HEV_pregnancy"
                ]
            },
            {
                "id": 804,
                "question": "A 30-year-old pregnant woman at 28 weeks gestation presents with acute jaundice, vomiting, ALT 2200. Immediate management?",
                "choices": [
                    "A. Wait and watch",
                    "B. Urgent referral to hospital with ICU capability + deliver if coagulopathy or encephalopathy",
                    "C. Start tenofovir",
                    "D. Give silymarin"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "Suspected acute HEV in pregnancy is a medical emergency – high risk of fulminant failure (STG 2021, p.209).",
                "tags": [
                    "HEV_pregnancy_emergency"
                ]
            },
            {
                "id": 805,
                "question": "Most common mode of transmission of hepatitis B in Ethiopia?",
                "choices": [
                    "A. Sexual",
                    "B. Perinatal / horizontal in early childhood (high endemicity)",
                    "C. Blood transfusion",
                    "D. IV drug use"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "HBV prevalence 7–10%; majority infected perinatally or before age 5 years (STG 2021, p.210).",
                "tags": [
                    "HBV_transmission"
                ]
            },
            {
                "id": 806,
                "question": "A 25-year-old woman HBsAg positive, HBV DNA 150,000 IU/mL, ALT 85 U/L (2× ULN), no cirrhosis. Treatment indicated?",
                "choices": [
                    "A. No treatment – observe",
                    "B. Tenofovir 300 mg daily lifelong (or until HBeAg seroconversion)",
                    "C. Entecavir",
                    "D. Interferon"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "HBeAg-negative or positive chronic hepatitis B with HBV DNA >20,000 IU/mL and ALT >2× ULN → treat with tenofovir (STG 2021, p.210).",
                "tags": [
                    "HBV_treatment_criteria"
                ]
            },
            {
                "id": 807,
                "question": "First-line drug for chronic hepatitis B in Ethiopia (2021)?",
                "choices": [
                    "A. Lamivudine",
                    "B. Tenofovir disoproxil fumarate (TDF) 300 mg daily",
                    "C. Entecavir",
                    "D. Adefovir"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "TDF is the preferred agent – highly effective, low resistance, widely available (STG 2021, p.210).",
                "tags": [
                    "TDF_HBV"
                ]
            },
            {
                "id": 808,
                "question": "A pregnant woman at 32 weeks is HBsAg positive, HBV DNA >200,000 IU/mL. Management?",
                "choices": [
                    "A. No treatment",
                    "B. Start tenofovir 300 mg daily from 28–32 weeks until 12 weeks postpartum",
                    "C. Give HBIG only",
                    "D. Caesarean section"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "High viral load → tenofovir from third trimester reduces perinatal transmission to <2% when combined with vaccine/HBIG (STG 2021, p.210).",
                "tags": [
                    "PMTCT_HBV"
                ]
            },
            {
                "id": 809,
                "question": "Best way to prevent hepatitis B in newborns in Ethiopia?",
                "choices": [
                    "A. Birth dose hepatitis B vaccine within 24 hours + HBIG if mother HBsAg+",
                    "B. Vaccine at 6 weeks only",
                    "C. Breastfeeding prohibition",
                    "D. No vaccine needed"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "Birth dose + 3-dose pentavalent series is national policy (STG 2021, p.210).",
                "tags": [
                    "HBV_birth_dose"
                ]
            },
            {
                "id": 810,
                "question": "A 40-year-old man HBsAg positive for >6 months, HBV DNA undetectable, ALT normal, no cirrhosis. Management?",
                "choices": [
                    "A. Start tenofovir",
                    "B. Inactive carrier – monitor ALT and HBV DNA every 6–12 months",
                    "C. Liver biopsy",
                    "D. Stop follow-up"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "Inactive carrier state – low risk of progression, only surveillance needed (STG 2021, p.210).",
                "tags": [
                    "inactive_carrier"
                ]
            },
            {
                "id": 811,
                "question": "Most common complication of chronic hepatitis B in Ethiopia?",
                "choices": [
                    "A. Acute flare",
                    "B. Hepatocellular carcinoma (HCC)",
                    "C. Extrahepatic manifestations",
                    "D. Fulminant hepatitis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "HBV is the leading cause of HCC in Ethiopia (STG 2021, p.210).",
                "tags": [
                    "HCC_HBV"
                ]
            },
            {
                "id": 812,
                "question": "A patient with chronic HBV on tenofovir develops raised creatinine. Next step?",
                "choices": [
                    "A. Stop tenofovir",
                    "B. Switch to entecavir or TAF (if available); otherwise reduce dose or monitor closely",
                    "C. Add lamivudine",
                    "D. Continue same dose"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "TDF can cause Fanconi syndrome; monitor renal function every 3–6 months (STG 2021, p.210).",
                "tags": [
                    "TDF_nephrotoxicity"
                ]
            },
            {
                "id": 813,
                "question": "Hepatitis C prevalence in Ethiopia is approximately?",
                "choices": [
                    "A. <1%",
                    "B. 1–2%",
                    "C. 5–8%",
                    "D. >10%"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "HCV prevalence 1–2% in general population, higher in high-risk groups (STG 2021, p.211).",
                "tags": [
                    "HCV_prevalence"
                ]
            },
            {
                "id": 814,
                "question": "First-line treatment for chronic hepatitis C in Ethiopia 2021?",
                "choices": [
                    "A. Pegylated interferon + ribavirin",
                    "B. Sofosbuvir + daclatasvir ± ribavirin for 12–24 weeks",
                    "C. No treatment available",
                    "D. Silymarin"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "Pan-genotypic DAAs (sofosbuvir/daclatasvir) are now standard (STG 2021, p.211).",
                "tags": [
                    "HCV_DAA"
                ]
            },
            {
                "id": 815,
                "question": "A patient with acute hepatitis has coagulopathy (INR 2.8), encephalopathy, jaundice. Diagnosis?",
                "choices": [
                    "A. Chronic liver disease flare",
                    "B. Fulminant hepatic failure",
                    "C. Alcoholic hepatitis",
                    "D. Hepatoma"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "Acute liver failure = coagulopathy + encephalopathy within 8 weeks of jaundice (STG 2021, p.209).",
                "tags": [
                    "fulminant_failure"
                ]
            },
            {
                "id": 816,
                "question": "Most important prognostic factor in acute viral hepatitis?",
                "choices": [
                    "A. ALT level",
                    "B. Prothrombin time / INR",
                    "C. Bilirubin level",
                    "D. AST/ALT ratio"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "Prolongation of PT/INR indicates severe hepatocyte failure (STG 2021, p.209).",
                "tags": [
                    "INR_prognosis"
                ]
            },
            {
                "id": 817,
                "question": "A 35-year-old man with chronic HBV presents with sudden jaundice, ascites, INR 2.5. Most likely diagnosis?",
                "choices": [
                    "A. HCC",
                    "B. Acute-on-chronic liver failure (HBV reactivation or HDV superinfection)",
                    "C. Drug-induced",
                    "D. Alcoholic flare"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "Acute decompensation in chronic HBV = reactivation (stopped drugs) or HDV (STG 2021, p.210).",
                "tags": [
                    "acute_on_chronic"
                ]
            },
            {
                "id": 818,
                "question": "Drug of choice for HBV reactivation with severe hepatitis?",
                "choices": [
                    "A. Lamivudine",
                    "B. Tenofovir or entecavir immediately",
                    "C. Interferon",
                    "D. Prednisolone"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "Urgent high-potency antiviral (tenofovir/entecavir) can be life-saving (STG 2021, p.210).",
                "tags": [
                    "HBV_reactivation"
                ]
            },
            {
                "id": 819,
                "question": "Best screening test for hepatocellular carcinoma in chronic HBV patient?",
                "choices": [
                    "A. AFP alone",
                    "B. Ultrasound abdomen every 6 months ± AFP",
                    "C. CT scan yearly",
                    "D. No screening"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "6-monthly ultrasound ± AFP recommended for all cirrhotics and high-risk HBV (STG 2021, p.210).",
                "tags": [
                    "HCC_screening"
                ]
            },
            {
                "id": 820,
                "question": "A patient with jaundice has ALT 120 U/L, ALP 450 U/L, direct bilirubin dominant. Most likely diagnosis?",
                "choices": [
                    "A. Viral hepatitis",
                    "B. Obstructive jaundice (stones, cancer)",
                    "C. Alcoholic hepatitis",
                    "D. Gilbert syndrome"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "Cholestatic pattern (high ALP) suggests biliary obstruction rather than hepatocellular injury (STG 2021, p.209).",
                "tags": [
                    "cholestatic_jaundice"
                ]
            },
            {
                "id": 821,
                "question": "Final take-home message for viral hepatitis in Ethiopian hospitals?",
                "choices": [
                    "A. All jaundice is malaria",
                    "B. Acute hepatitis usually HAV/HEV – supportive care only; chronic HBV is highly prevalent – screen and treat if active or cirrhotic; pregnant women with acute hepatitis = urgent referral for possible HEV",
                    "C. Give steroids for all",
                    "D. No vaccine needed"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.8 Hepatitis",
                "explanation": "Early recognition of severity and appropriate referral saves lives (Ethiopian STG 2021, p.209–211).",
                "tags": [
                    "key_message"
                ]
            }
        ]
    },
    "Chapter 6.9": {
        "Chapter 6.9 Liver Cirrhosis and Portal Hypertension": [
            {
                "id": 822,
                "question": "A 48-year-old man from rural Ethiopia presents with massive ascites, jaundice, spider naevi and splenomegaly. Most likely diagnosis?",
                "choices": [
                    "A. Chronic viral hepatitis with cirrhosis",
                    "B. Schistosomiasis (S. mansoni) with portal hypertension",
                    "C. Alcoholic cirrhosis",
                    "D. Cardiac failure"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Chronic HBV and HCV are the leading causes of cirrhosis in Ethiopia (STG 2021, p.220).",
                "tags": [
                    "cirrhosis_etiology"
                ]
            },
            {
                "id": 823,
                "question": "Most common cause of portal hypertension in Ethiopia?",
                "choices": [
                    "A. Alcoholic liver disease",
                    "B. Chronic viral hepatitis (HBV/HCV) → cirrhosis",
                    "C. Schistosomiasis",
                    "D. Non-cirrhotic portal fibrosis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "HBV-related cirrhosis is the commonest cause of portal hypertension nationwide (STG 2021, p.220).",
                "tags": [
                    "portal_hypertension"
                ]
            },
            {
                "id": 824,
                "question": "First-line treatment of grade II oesophageal varices in cirrhosis?",
                "choices": [
                    "A. Urgent banding",
                    "B. Non-selective beta-blocker (propranolol 20–160 mg/day)",
                    "C. Sclerotherapy",
                    "D. No treatment"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Primary prophylaxis with propranolol or carvedilol for medium/large varices (STG 2021, p.221).",
                "tags": [
                    "variceal_prophylaxis"
                ]
            },
            {
                "id": 825,
                "question": "A cirrhotic patient presents with massive haematemesis. Immediate management in general hospital?",
                "choices": [
                    "A. IV PPI only",
                    "B. IV fluids + blood transfusion + terlipressin 2 mg IV bolus then 1–2 mg 6-hourly + ceftriaxone 1 g IV + urgent endoscopy",
                    "C. Fresh frozen plasma",
                    "D. Oral propranolol"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Resuscitation + vasoactive drug (terlipressin) + antibiotic prophylaxis + endoscopy within 12 h (STG 2021, p.221).",
                "tags": [
                    "variceal_bleed"
                ]
            },
            {
                "id": 826,
                "question": "Best antibiotic prophylaxis in acute variceal bleeding?",
                "choices": [
                    "A. Amoxicillin",
                    "B. Ceftriaxone 1 g IV daily for 7 days",
                    "C. Ciprofloxacin oral",
                    "D. Metronidazole"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Ceftriaxone preferred due to high quinolone resistance (STG 2021, p.221).",
                "tags": [
                    "ceftriaxone_variceal"
                ]
            },
            {
                "id": 827,
                "question": "A cirrhotic patient with tense ascites has abdominal pain and fever. Most likely complication?",
                "choices": [
                    "A. Umbilical hernia",
                    "B. Spontaneous bacterial peritonitis (SBP)",
                    "C. Variceal bleed",
                    "D. Hepatoma"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "New-onset fever + abdominal pain in ascites = SBP until proven otherwise (STG 2021, p.222).",
                "tags": [
                    "SBP"
                ]
            },
            {
                "id": 828,
                "question": "Diagnostic ascitic fluid PMN count for SBP?",
                "choices": [
                    "A. >100/mm³",
                    "B. >250/mm³",
                    "C. >500/mm³",
                    "D. >1000/mm³"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "PMN ≥250 cells/mm³ in ascitic fluid confirms SBP (STG 2021, p.222).",
                "tags": [
                    "SBP_diagnosis"
                ]
            },
            {
                "id": 829,
                "question": "First-line treatment of SBP?",
                "choices": [
                    "A. Ciprofloxacin",
                    "B. Ceftriaxone 1–2 g IV daily for 5–7 days",
                    "C. Albumin + norfloxacin",
                    "D. Metronidazole"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Third-generation cephalosporin is drug of choice (STG 2021, p.222).",
                "tags": [
                    "SBP_treatment"
                ]
            },
            {
                "id": 830,
                "question": "Best diuretic combination for cirrhotic ascites?",
                "choices": [
                    "A. Furosemide alone",
                    "B. Spironolactone 100 mg + furosemide 40 mg daily (ratio 100:40)",
                    "C. Hydrochlorothiazide",
                    "D. Amiloride"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Spironolactone first-line, add furosemide if needed; maintain 100:40 ratio (STG 2021, p.222).",
                "tags": [
                    "ascites_diuretics"
                ]
            },
            {
                "id": 831,
                "question": "Indication for large-volume paracentesis in tense ascites?",
                "choices": [
                    "A. All ascites",
                    "B. Tense or refractory ascites + respiratory compromise",
                    "C. Mild ascites",
                    "D. Only if infected"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Therapeutic paracentesis + albumin (6–8 g/L tapped) if >5 L removed (STG 2021, p.222).",
                "tags": [
                    "LVP"
                ]
            },
            {
                "id": 832,
                "question": "Most important measure to prevent hepatorenal syndrome after large paracentesis?",
                "choices": [
                    "A. IV furosemide",
                    "B. IV albumin 6–8 g per litre ascites removed (if >5 L)",
                    "C. Salt restriction",
                    "D. No albumin needed"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Albumin infusion prevents post-paracentesis circulatory dysfunction (STG 2021, p.222).",
                "tags": [
                    "albumin_paracentesis"
                ]
            },
            {
                "id": 833,
                "question": "A cirrhotic patient with ascites develops oliguria and rising creatinine despite fluids. Most likely diagnosis?",
                "choices": [
                    "A. Acute kidney injury",
                    "B. Hepatorenal syndrome type 1",
                    "C. SBP",
                    "D. Prerenal azotemia"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Rapidly progressive renal failure in cirrhosis without other cause = HRS-1 (STG 2021, p.223).",
                "tags": [
                    "HRS"
                ]
            },
            {
                "id": 834,
                "question": "Best screening test for HCC in cirrhosis in Ethiopia?",
                "choices": [
                    "A. AFP alone",
                    "B. Ultrasound abdomen every 6 months ± AFP",
                    "C. CT yearly",
                    "D. No screening"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "6-monthly ultrasound ± AFP for all cirrhotic patients (STG 2021, p.220).",
                "tags": [
                    "HCC_screening"
                ]
            },
            {
                "id": 835,
                "question": "A patient with cirrhosis has new confusion, flapping tremor, and fetor hepaticus. Diagnosis?",
                "choices": [
                    "A. Stroke",
                    "B. Hepatic encephalopathy grade II–III",
                    "C. Hypoglycaemia",
                    "D. Sepsis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Asterixis + altered mental state = hepatic encephalopathy (STG 2021, p.223).",
                "tags": [
                    "hepatic_encephalopathy"
                ]
            },
            {
                "id": 836,
                "question": "First-line treatment of overt hepatic encephalopathy?",
                "choices": [
                    "A. IV mannitol",
                    "B. Lactulose 15–30 mL 2–4 times/day to produce 2–3 soft stools",
                    "C. Rifaximin",
                    "D. Neomycin"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Lactulose remains first-line; titrate to bowel movements (STG 2021, p.223).",
                "tags": [
                    "lactulose_HE"
                ]
            },
            {
                "id": 837,
                "question": "Most common precipitant of hepatic encephalopathy in Ethiopia?",
                "choices": [
                    "A. Constipation",
                    "B. Infection (SBP, UTI)",
                    "C. GI bleeding",
                    "D. Dehydration"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Always look for and treat infection first (STG 2021, p.223).",
                "tags": [
                    "HE_precipitant"
                ]
            },
            {
                "id": 838,
                "question": "Child-Pugh score ≥8 or MELD ≥15 indicates?",
                "choices": [
                    "A. Good prognosis",
                    "B. Decompensated cirrhosis – consider liver transplant evaluation",
                    "C. No treatment needed",
                    "D. Only diuretics"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Advanced decompensation – poor 1-year survival (STG 2021, p.220).",
                "tags": [
                    "Child_Pugh"
                ]
            },
            {
                "id": 839,
                "question": "A cirrhotic patient with ascites has serum-ascites albumin gradient (SAAG):",
                "choices": [
                    "A. <1.1 g/dL → exudative",
                    "B. ≥1.1 g/dL → portal hypertension (transudative)",
                    "C. No value",
                    "D. Only protein matters"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "SAAG ≥1.1 confirms portal hypertension-related ascites (STG 2021, p.222).",
                "tags": [
                    "SAAG"
                ]
            },
            {
                "id": 840,
                "question": "Secondary prophylaxis after variceal bleed?",
                "choices": [
                    "A. Propranolol alone",
                    "B. Endoscopic variceal ligation (EVL) + non-selective beta-blocker",
                    "C. Shunt surgery",
                    "D. No prophylaxis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Combination EVL + beta-blocker reduces rebleeding to <15% (STG 2021, p.221).",
                "tags": [
                    "secondary_prophylaxis"
                ]
            },
            {
                "id": 841,
                "question": "Most common cause of death in decompensated cirrhosis in Ethiopia?",
                "choices": [
                    "A. HCC",
                    "B. Variceal haemorrhage",
                    "C. Sepsis / SBP",
                    "D. Hepatorenal syndrome"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Bleeding remains leading cause due to late presentation (STG 2021, p.221).",
                "tags": [
                    "mortality_cirrhosis"
                ]
            },
            {
                "id": 842,
                "question": "A patient with cirrhosis and massive ascites is on maximum diuretics but still gains weight. Next step?",
                "choices": [
                    "A. Continue diuretics",
                    "B. Repeated large-volume paracentesis + albumin",
                    "C. TIPS",
                    "D. Liver transplant"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Refractory ascites → therapeutic paracentesis is mainstay (STG 2021, p.222).",
                "tags": [
                    "refractory_ascites"
                ]
            },
            {
                "id": 843,
                "question": "Dietary advice for compensated cirrhosis?",
                "choices": [
                    "A. Low protein",
                    "B. High protein (1–1.5 g/kg/day) + late-night snack",
                    "C. Salt-free",
                    "D. No vegetables"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Malnutrition common – high calorie/protein diet improves survival (STG 2021, p.220).",
                "tags": [
                    "nutrition_cirrhosis"
                ]
            },
            {
                "id": 844,
                "question": "A cirrhotic patient with ascites develops hyponatraemia (Na 128 mmol/L). Most likely cause?",
                "choices": [
                    "A. Overdiuresis",
                    "B. Hypervolaemic hyponatraemia due to water retention",
                    "C. SIADH",
                    "D. Renal failure"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Dilutional hyponatraemia common in advanced cirrhosis (STG 2021, p.222).",
                "tags": [
                    "hyponatraemia"
                ]
            },
            {
                "id": 845,
                "question": "Best management of symptomatic hyponatraemia (Na <125) in cirrhosis?",
                "choices": [
                    "A. Normal saline",
                    "B. Fluid restriction 1–1.5 L/day ± tolvaptan (if available)",
                    "C. Hypertonic saline",
                    "D. No treatment"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Fluid restriction is cornerstone (STG 2021, p.222).",
                "tags": [
                    "hyponatraemia_treatment"
                ]
            },
            {
                "id": 846,
                "question": "A patient with known schistosomal periportal fibrosis presents with haematemesis. First-line endoscopic therapy?",
                "choices": [
                    "A. Band ligation not possible (left-sided varices)",
                    "B. Sclerotherapy with ethanolamine oleate",
                    "C. Propranolol",
                    "D. TIPS"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Schistosomiasis causes pre-sinusoidal portal hypertension – sclerotherapy preferred (STG 2021, p.221).",
                "tags": [
                    "schistosomiasis_varices"
                ]
            },
            {
                "id": 847,
                "question": "Most common electrolyte disturbance requiring urgent correction in cirrhosis?",
                "choices": [
                    "A. Hyperkalaemia",
                    "B. Hypokalaemia (due to diuretics)",
                    "C. Hypernatraemia",
                    "D. Hypocalcaemia"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Spironolactone + furosemide → potassium loss (STG 2021, p.222).",
                "tags": [
                    "hypokalaemia"
                ]
            },
            {
                "id": 848,
                "question": "A cirrhotic patient on lactulose develops severe diarrhoea and dehydration. Next step?",
                "choices": [
                    "A. Stop lactulose",
                    "B. Reduce dose + alternate with rifaximin if available",
                    "C. Continue same",
                    "D. Add loperamide"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Titrate lactulose to 2–3 soft stools, not diarrhoea (STG 2021, p.223).",
                "tags": [
                    "lactulose_overdose"
                ]
            },
            {
                "id": 849,
                "question": "Vaccinations strongly recommended in all patients with cirrhosis?",
                "choices": [
                    "A. Only HBV",
                    "B. Hepatitis A, hepatitis B, pneumococcal, influenza",
                    "C. Yellow fever",
                    "D. No vaccines"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Cirrhotic patients are immunocompromised – prevent infections (STG 2021, p.220).",
                "tags": [
                    "vaccination_cirrhosis"
                ]
            },
            {
                "id": 850,
                "question": "A patient with decompensated cirrhosis has INR 2.2, albumin 26 g/L, bilirubin 4.5 mg/dL. Child-Pugh class?",
                "choices": [
                    "A. A",
                    "B. B",
                    "C. C",
                    "D. Cannot calculate"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Score 10–11 = Child-Pugh C (STG 2021, p.220).",
                "tags": [
                    "Child_Pugh_calculation"
                ]
            },
            {
                "id": 851,
                "question": "Most important lifestyle advice for all patients with cirrhosis?",
                "choices": [
                    "A. Complete alcohol abstinence",
                    "B. High salt diet",
                    "C. Bed rest",
                    "D. Stop all medications"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Even small amounts of alcohol accelerate progression (STG 2021, p.220).",
                "tags": [
                    "alcohol_abstinence"
                ]
            },
            {
                "id": 852,
                "question": "A cirrhotic patient with ascites is on spironolactone 200 mg + furosemide 80 mg but still has oedema. Maximum safe doses?",
                "choices": [
                    "A. Spironolactone 400 mg + furosemide 160 mg daily",
                    "B. Add albumin infusion",
                    "C. Stop diuretics",
                    "D. Add HCTZ"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Can go up to 400/160 mg maintaining 100:40 ratio (STG 2021, p.222).",
                "tags": [
                    "max_diuretics"
                ]
            },
            {
                "id": 853,
                "question": "Most common organism causing SBP in Ethiopia?",
                "choices": [
                    "A. Staphylococcus",
                    "B. E. coli and other Gram-negative enteric bacteria",
                    "C. Anaerobes",
                    "D. TB"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Gram-negative translocation from gut (STG 2021, p.222).",
                "tags": [
                    "SBP_pathogen"
                ]
            },
            {
                "id": 854,
                "question": "A patient with cirrhosis develops painful umbilical hernia with redness. Management?",
                "choices": [
                    "A. Conservative",
                    "B. Urgent surgical repair (high risk of rupture in ascites)",
                    "C. Truss",
                    "D. Wait"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Incarcerated/strangulated hernia in cirrhosis is emergency (STG 2021, p.222).",
                "tags": [
                    "umbilical_hernia"
                ]
            },
            {
                "id": 855,
                "question": "Best prognostic indicator in decompensated cirrhosis?",
                "choices": [
                    "A. Bilirubin",
                    "B. Serum albumin",
                    "C. MELD score",
                    "D. Ascites volume"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "MELD score best predicts 3-month mortality (STG 2021, p.220).",
                "tags": [
                    "MELD"
                ]
            },
            {
                "id": 856,
                "question": "A patient with cirrhosis has new right upper quadrant mass, weight loss, rising AFP. Most likely diagnosis?",
                "choices": [
                    "A. Liver abscess",
                    "B. Hepatocellular carcinoma",
                    "C. Haemangioma",
                    "D. Metastasis"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "HCC is the most feared complication of cirrhosis (STG 2021, p.220).",
                "tags": [
                    "HCC"
                ]
            },
            {
                "id": 857,
                "question": "Safe analgesia in advanced cirrhosis?",
                "choices": [
                    "A. Diclofenac",
                    "B. Paracetamol ≤2 g/day",
                    "C. Tramadol",
                    "D. Morphine"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Paracetamol is safest when used in reduced dose (STG 2021, p.220).",
                "tags": [
                    "analgesia_cirrhosis"
                ]
            },
            {
                "id": 858,
                "question": "A cirrhotic patient on propranolol develops bradycardia (HR 48). Next step?",
                "choices": [
                    "A. Stop propranolol",
                    "B. Reduce dose or switch to carvedilol",
                    "C. Add atropine",
                    "D. Continue"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Titrate to maximum tolerated dose or HR >50 (STG 2021, p.221).",
                "tags": [
                    "beta_blocker_side_effect"
                ]
            },
            {
                "id": 859,
                "question": "Most common grade of encephalopathy requiring ICU admission?",
                "choices": [
                    "A. Grade I",
                    "B. Grade III–IV",
                    "C. Subclinical",
                    "D. Minimal"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Coma or marked confusion needs airway protection (STG 2021, p.223).",
                "tags": [
                    "HE_grades"
                ]
            },
            {
                "id": 860,
                "question": "A patient with cirrhosis and tense ascites is scheduled for paracentesis. Pre-procedure INR 2.1 – need FFP?",
                "choices": [
                    "A. Yes",
                    "B. No – paracentesis is safe even with prolonged INR",
                    "C. Only platelets",
                    "D. Cancel procedure"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "No correction needed for paracentesis in cirrhosis (STG 2021, p.222).",
                "tags": [
                    "paracentesis_coagulopathy"
                ]
            },
            {
                "id": 861,
                "question": "Most common extrahepatic manifestation of HBV-related cirrhosis?",
                "choices": [
                    "A. Arthritis",
                    "B. Glomerulonephritis",
                    "C. Polyarteritis nodosa",
                    "D. All rare"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Membranous GN can occur but rare in adults (STG 2021, p.220).",
                "tags": [
                    "extrahepatic_HBV"
                ]
            },
            {
                "id": 862,
                "question": "A cirrhotic patient with refractory ascites is on weekly 8–10 L paracentesis. Best long-term option?",
                "choices": [
                    "A. Continue paracentesis",
                    "B. TIPS (if Child B or early C)",
                    "C. Peritoneovenous shunt",
                    "D. Transplant only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "TIPS effective for refractory ascites but increases HE risk (STG 2021, p.222).",
                "tags": [
                    "TIPS"
                ]
            },
            {
                "id": 863,
                "question": "Most important blood test to monitor in cirrhotic patient on spironolactone?",
                "choices": [
                    "A. Potassium",
                    "B. Sodium",
                    "C. Creatinine",
                    "D. All of the above"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Risk of hyperkalaemia and renal impairment (STG 2021, p.222).",
                "tags": [
                    "monitoring_diuretics"
                ]
            },
            {
                "id": 864,
                "question": "A patient with cirrhosis has sudden abdominal pain and drop in haemoglobin. Most likely?",
                "choices": [
                    "A. Variceal bleed",
                    "B. Ruptured hepatocellular carcinoma",
                    "C. SBP",
                    "D. Peptic ulcer"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "HCC rupture is life-threatening emergency (STG 2021, p.220).",
                "tags": [
                    "HCC_rupture"
                ]
            },
            {
                "id": 865,
                "question": "Final take-home message for decompensated cirrhosis in Ethiopian general hospitals?",
                "choices": [
                    "A. Incurable – discharge",
                    "B. Treat precipitants aggressively, use diuretics carefully, control varices with beta-blockers + banding, recognise SBP and HRS early, give ceftriaxone + terlipressin + albumin when indicated – saves lives",
                    "C. Give steroids",
                    "D. Only traditional medicine"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Appropriate, timely management dramatically improves short-term survival even without transplant (Ethiopian STG 2021, p.220–223).",
                "tags": [
                    "key_message"
                ]
            },
            {
                "id": 866,
                "question": "A cirrhotic patient with ascites has respiratory distress. Most urgent action?",
                "choices": [
                    "A. Chest X-ray",
                    "B. Urgent therapeutic paracentesis (remove 4–6 L) to relieve diaphragm",
                    "C. Diuretics",
                    "D. Oxygen only"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Tense ascites causes restrictive lung disease (STG 2021, p.222).",
                "tags": [
                    "respiratory_distress_ascites"
                ]
            },
            {
                "id": 867,
                "question": "Safest proton pump inhibitor in cirrhosis with varices?",
                "choices": [
                    "A. Omeprazole",
                    "B. All PPIs safe – no increased bleeding risk",
                    "C. Avoid all PPIs",
                    "D. Ranitidine"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "PPIs do not increase variceal bleeding risk (STG 2021, p.221).",
                "tags": [
                    "PPI_varices"
                ]
            },
            {
                "id": 868,
                "question": "A patient with cirrhosis and grade III encephalopathy is not improving with lactulose. Next step?",
                "choices": [
                    "A. Add rifaximin 550 mg BD (if available)",
                    "B. IV metronidazole",
                    "C. Flumazenil",
                    "D. Continue lactulose"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Rifaximin is second-line for refractory HE (STG 2021, p.223).",
                "tags": [
                    "rifaximin"
                ]
            },
            {
                "id": 869,
                "question": "Most common fungal infection in decompensated cirrhosis?",
                "choices": [
                    "A. Cryptococcus",
                    "B. Candida (candidemia, peritonitis)",
                    "C. Aspergillosis",
                    "D. Mucor"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Prolonged antibiotics + malnutrition → candidiasis (STG 2021, p.222).",
                "tags": [
                    "fungal_cirrhosis"
                ]
            },
            {
                "id": 870,
                "question": "A cirrhotic patient with ascites has pleural effusion on right side. Diagnosis?",
                "choices": [
                    "A. TB",
                    "B. Hepatic hydrothorax",
                    "C. Pneumonia",
                    "D. Malignancy"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Transdiaphragmatic passage of ascites → right pleural effusion (STG 2021, p.222).",
                "tags": [
                    "hepatic_hydrothorax"
                ]
            },
            {
                "id": 871,
                "question": "Final answer: The single most important intervention that reduces mortality in variceal bleeding in resource-limited settings?",
                "choices": [
                    "A. Endoscopy",
                    "B. Early administration of terlipressin + ceftriaxone + aggressive resuscitation",
                    "C. Balloon tamponade",
                    "D. Surgery"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.9 Liver Cirrhosis and Portal Hypertension",
                "explanation": "Pharmacotherapy + antibiotics improve survival even before endoscopy (Ethiopian STG 2021, p.221).",
                "tags": [
                    "variceal_bleeding_mortality"
                ]
            }
        ]
    },
    "Chapter 6.10": {
        "Chapter 6.10 Cholelithiasis (Gall stones)": [
            {
                "id": 872,
                "question": "A 45-year-old obese woman from Addis Ababa presents to the general hospital outpatient clinic with a history of recurrent, severe dull pain in her right upper quadrant that started approximately 6 months ago. The pain typically occurs about an hour after eating fatty meals, lasts for 2-3 hours, and resolves completely. An abdominal ultrasound performed recently shows gallstones without signs of gallbladder wall thickening or pericholecystic fluid. She asks if she needs urgent surgery. What is the most appropriate initial management?",
                "choices": [
                    "A. Urgent cholecystectomy due to symptomatic cholelithiasis.",
                    "B. Referral for ERCP to remove the gallstones and prevent complications.",
                    "C. Lifestyle advice, pain management, and elective cholecystectomy referral.",
                    "D. Prescribe oral bile acids for stone dissolution."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "The patient presents with uncomplicated gallstone disease (typical biliary colic and gallstones on imaging, but no complications). While cholecystectomy is the curative treatment, it is elective. The most appropriate initial step is offering lifestyle advice and pain management for the acute episodes, followed by an elective cholecystectomy referral. (p. 224, 226)",
                "tags": "uncomplicated_gallstone_disease, management"
            },
            {
                "id": 873,
                "question": "A 50-year-old male presents to the emergency department with severe, steady pain in the epigastrium radiating to his right shoulder. The pain began suddenly 4 hours after consuming a heavy, fatty dinner. Ultrasound confirms gallstones. What is the preferred immediate pharmacologic intervention for acute pain relief in this patient?",
                "choices": [
                    "A. Oral Ibuprofen 400 mg PRN.",
                    "B. Intravenous Morphine 5 mg bolus.",
                    "C. Intravenous Diclofenac 75 mg bolus.",
                    "D. Intravenous Pethidine 50 mg bolus."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "For acute biliary colic, parenteral NSAIDS (like Diclofenac) are the preferred agents for pain management. Opioids (Morphine, Pethidine) are second-line and reserved for patients with contraindications to NSAIDs. (p. 225)",
                "tags": "biliary_colic, pain_management, NSAIDs"
            },
            {
                "id": 874,
                "question": "Which of the following findings on an abdominal ultrasound would classify a patient with gallstones as having uncomplicated gallstone disease?",
                "choices": [
                    "A. Gallbladder wall thickening >3 mm.",
                    "B. Pericholecystic fluid collection.",
                    "C. Typical biliary colic symptoms and gallstones present.",
                    "D. Presence of common bile duct dilation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Uncomplicated gallstone disease is defined as being symptomatic with typical biliary colic and gallstones on imaging but no evidence of complications such as acute cholecystitis, cholangitis, or gallstone pancreatitis. (p. 224)",
                "tags": "uncomplicated_gallstone_disease, diagnosis"
            },
            {
                "id": 875,
                "question": "A 65-year-old diabetic male is found to have gallstones incidentally during an abdominal ultrasound for non-specific abdominal discomfort. He denies any history of biliary colic. Which category of gallstone disease does this patient fall under?",
                "choices": [
                    "A. Uncomplicated gallstone disease.",
                    "B. Symptomatic gallstone disease.",
                    "C. Incidental gallstones.",
                    "D. Chronic cholecystitis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "This patient is asymptomatic, and the gallstones were found incidentally on imaging. This is categorized as incidental gallstones. (p. 225)",
                "tags": "gallstone_disease, classification"
            },
            {
                "id": 876,
                "question": "Which statement accurately reflects the recommended surgical management approach for a patient diagnosed with incidental gallstones?",
                "choices": [
                    "A. Cholecystectomy is indicated immediately to prevent future complications.",
                    "B. Cholecystectomy is not indicated as there is no history of biliary colic.",
                    "C. Cholecystectomy is only indicated if the patient is diabetic or severely obese.",
                    "D. Oral dissolution therapy should be tried before considering cholecystectomy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "For incidental gallstones (asymptomatic finding), cholecystectomy is not indicated as surgery exposes them to unnecessary surgical risk. (p. 225, 226)",
                "tags": "incidental_gallstones, management"
            },
            {
                "id": 877,
                "question": "A 40-year-old woman presents to the emergency room with classic biliary colic. Her ultrasound shows gallstones. Which of the following atypical symptoms is poorly associated with gallstones and should prompt a search for an alternative diagnosis?",
                "choices": [
                    "A. Right upper quadrant or epigastric pain.",
                    "B. Pain radiating to the right shoulder.",
                    "C. Non-specific abdominal bloating and early satiety.",
                    "D. Nausea and vomiting during a painful attack."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Symptoms like non-specific abdominal pain, bloating, and early satiety have a poor association with gallstones and their presence (Category 3) should prompt the clinician to look for other causes of the symptoms. (p. 225)",
                "tags": "atypical_symptoms, diagnosis"
            },
            {
                "id": 878,
                "question": "Which imaging modality is considered the gold standard for the diagnosis of cholelithiasis?",
                "choices": [
                    "A. Magnetic Resonance Cholangiopancreatography (MRCP).",
                    "B. Endoscopic Retrograde Cholangiopancreatography (ERCP).",
                    "C. Abdominal ultrasound.",
                    "D. Computed Tomography (CT) scan."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Abdominal ultrasound is cited as the gold standard tool for the diagnosis of cholelithiasis in the guidelines. (p. 225)",
                "tags": "cholelithiasis, diagnosis, ultrasound"
            },
            {
                "id": 879,
                "question": "A 55-year-old woman is diagnosed with cholelithiasis. She has recurrent, classic biliary colic. When considering surgical management (cholecystectomy), what is the expected outcome based on the guidelines?",
                "choices": [
                    "A. Surgery is absolutely contraindicated as it is elective.",
                    "B. Surgery is curative for uncomplicated symptomatic gallstone disease.",
                    "C. Surgery is typically reserved until complications like acute cholecystitis develop.",
                    "D. Only oral dissolution therapy has curative potential for this patient."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Cholecystectomy is curative for uncomplicated symptomatic gallstone disease, and it is indicated in Category 2 (uncomplicated gallstone disease). (p. 225, 226)",
                "tags": "cholelithiasis, management, cholecystectomy"
            },
            {
                "id": 880,
                "question": "In a resource-limited general hospital setting, which of the following is the most crucial factor in determining the initial management strategy for a patient presenting with gallstones?",
                "choices": [
                    "A. The size of the largest gallstone.",
                    "B. The composition of the gallstones.",
                    "C. The presence or absence of symptoms and complications.",
                    "D. The patient's serum bilirubin level."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "The guidelines categorize gallstone disease primarily into incidental (asymptomatic) and uncomplicated gallstone disease (symptomatic but no complications), and complicated disease. The decision for conservative vs. elective vs. urgent management is fundamentally determined by the presence or absence of symptoms and complications. (p. 225, 226)",
                "tags": "cholelithiasis, management_strategy"
            },
            {
                "id": 881,
                "question": "Which clinical presentation is most characteristic of typical biliary colic?",
                "choices": [
                    "A. Dull, left upper quadrant pain, lasting several days.",
                    "B. Severe, dull, right upper quadrant pain, constant, lasting 3 hours.",
                    "C. Sharp, colicky pain that fluctuates in severity, lasting <30 minutes.",
                    "D. Epigastric burning pain associated with lying down."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Biliary colic is described as a severe, dull, right upper quadrant or epigastric pain, which is usually constant (contrary to the name), and typically lasts at least 30 minutes but less than six hours. (p. 224)",
                "tags": "biliary_colic, clinical_features"
            },
            {
                "id": 882,
                "question": "Which class of gallstones makes up the majority of cases in clinical practice?",
                "choices": [
                    "A. Pigment stones.",
                    "B. Mixed stones.",
                    "C. Cholesterol stones.",
                    "D. Calcium phosphate stones."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "The majority of gallstones are cholesterol stones. (p. 224)",
                "tags": "gallstone_composition"
            },
            {
                "id": 883,
                "question": "A young, healthy woman presents with typical biliary colic. She is categorized as Category 2 (uncomplicated gallstone disease). When should cholecystectomy be performed?",
                "choices": [
                    "A. Urgently, within 48 hours.",
                    "B. Electively, after lifestyle modifications fail.",
                    "C. Only if signs of jaundice or cholangitis develop.",
                    "D. It is strictly contraindicated in young, healthy individuals."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "For uncomplicated symptomatic gallstone disease, cholecystectomy is indicated and should be done electively. (p. 225, 226)",
                "tags": "uncomplicated_gallstone_disease, cholecystectomy"
            },
            {
                "id": 884,
                "question": "In a patient with confirmed cholelithiasis presenting with non-specific, intermittent abdominal pain (Category 3), what is the most prudent initial step in management?",
                "choices": [
                    "A. Urgent cholecystectomy referral to prevent complications.",
                    "B. Oral dissolution therapy for a minimum of 6 months.",
                    "C. Perform a search for alternative causes of the abdominal pain.",
                    "D. Prescribe NSAIDs for chronic, daily use."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "For atypical symptoms (Category 3), there is a poor association with gallstones, so the clinician should first look for other causes for the symptoms before making a surgical decision. (p. 225)",
                "tags": "atypical_symptoms, management"
            },
            {
                "id": 885,
                "question": "A 30-year-old patient with cholelithiasis and recurrent biliary colic is given a pethidine injection for severe pain relief in the emergency room. Why is Pethidine not the preferred agent for this condition?",
                "choices": [
                    "A. It prolongs the QT interval and increases arrhythmia risk.",
                    "B. It is associated with higher rates of nausea and vomiting.",
                    "C. It does not effectively treat smooth muscle spasm causing the colic.",
                    "D. NSAIDs are preferred, and opioids like Pethidine are reserved as second-line."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Parenteral NSAIDs are the preferred agents for acute biliary colic pain management. Opioids (Morphine, Pethidine) are reserved as second-line for patients with contraindications to NSAIDs. (p. 225)",
                "tags": "biliary_colic, pain_management, pethidine"
            },
            {
                "id": 886,
                "question": "A 48-year-old woman with symptomatic cholelithiasis is being treated with IV Diclofenac in the ER. Which concurrent medical condition would be a contraindication to using this drug?",
                "choices": [
                    "A. Mild hyperlipidemia.",
                    "B. Controlled Type 2 Diabetes Mellitus.",
                    "C. Chronic kidney disease.",
                    "D. History of well-controlled hypertension."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "NSAIDS (like Diclofenac) should be avoided in patients with impaired kidney function or hypersensitivity, as they are nephrotoxic and can precipitate adverse effects. (p. 225)",
                "tags": "NSAIDs, contraindications"
            },
            {
                "id": 887,
                "question": "A patient presents with acute biliary colic. The pain began 3 hours ago and is constant and severe. Which characteristic of the pain is typical of biliary colic?",
                "choices": [
                    "A. Starts abruptly, fluctuates (colicky), and resolves in <30 minutes.",
                    "B. Severe, dull, constant, and lasts >30 minutes but <6 hours.",
                    "C. Located mainly in the left upper quadrant, radiating to the back.",
                    "D. Burning sensation in the epigastrium, worse with lying down."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Biliary colic is typically a severe, dull, right upper quadrant or epigastric pain, and is usually constant, lasting >30 minutes but <6 hours. (p. 224)",
                "tags": "biliary_colic, clinical_features"
            },
            {
                "id": 888,
                "question": "A patient with gallstones and typical biliary colic asks why surgery is considered. The most accurate explanation based on the guidelines is that cholecystectomy is a definitive treatment because it is designed to:",
                "choices": [
                    "A. Cure the underlying metabolic disorder causing the stones.",
                    "B. Prevent the recurrent painful attacks.",
                    "C. Dissolve the existing gallstones.",
                    "D. Treat associated non-specific abdominal bloating."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Cholecystectomy is the definitive treatment because it removes the source of the recurrent painful attacks. (p. 225, 226)",
                "tags": "cholecystectomy, indication"
            },
            {
                "id": 889,
                "question": "A patient with known gallstones presents with symptoms that include non-specific upper GI symptoms like belching, bloating, and early satiety, but no typical biliary colic. This presentation falls under which category of gallstone disease?",
                "choices": [
                    "A. Category 1: Incidental gallstones.",
                    "B. Category 2: Uncomplicated gallstone disease.",
                    "C. Category 3: Atypical symptoms.",
                    "D. Category 4: Typical symptoms but no gallstones."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "This patient's symptoms are considered atypical. Category 3 is for atypical symptoms and gallstones on imaging. (p. 225)",
                "tags": "atypical_symptoms, classification"
            },
            {
                "id": 890,
                "question": "Which type of gallstone is more commonly seen in patients with chronic hemolytic anemia or liver cirrhosis?",
                "choices": [
                    "A. Cholesterol stones.",
                    "B. Calcium phosphate stones.",
                    "C. Pigment stones.",
                    "D. Mixed stones."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Pigment stones are specifically mentioned as being common in patients with hemolytic anemia or cirrhosis. (p. 224)",
                "tags": "gallstone_composition, risk_factors"
            },
            {
                "id": 891,
                "question": "A patient presents with classic biliary colic pain. She is stable, and ultrasound confirms gallstones. What is the most appropriate discharge plan regarding the need for surgery?",
                "choices": [
                    "A. Schedule urgent cholecystectomy within 24 hours.",
                    "B. Refer for elective cholecystectomy as it is the curative treatment.",
                    "C. Advise immediate follow-up only if jaundice develops.",
                    "D. Initiate a 3-month trial of oral bile acid dissolution therapy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "The guidelines classify this as uncomplicated gallstone disease (Category 2) for which elective cholecystectomy is indicated. (p. 225, 226)",
                "tags": "uncomplicated_gallstone_disease, management"
            },
            {
                "id": 892,
                "question": "What is the primary mechanism responsible for the formation of gallstones?",
                "choices": [
                    "A. Excessive dietary fat intake.",
                    "B. Chronic biliary tract infection.",
                    "C. Supersaturation of bile with materials like cholesterol.",
                    "D. Inherited structural defects in the gallbladder."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Stone formation occurs when normally soluble materials like calcium, oxalate or uric acid supersaturate (accumulate above the solubility capacity) and form small crystals. Gallstones are primarily cholesterol stones. (p. 564, 224)",
                "tags": "gallstone_formation, pathophysiology"
            },
            {
                "id": 893,
                "question": "A 52-year-old man has recurrent biliary colic. He is allergic to NSAIDs. Which pharmacologic option is most appropriate for acute pain relief in the emergency setting?",
                "choices": [
                    "A. Intravenous Pethidine.",
                    "B. Oral Paracetamol 1000 mg.",
                    "C. Oral Diclofenac 75 mg.",
                    "D. Intravenous Acetaminophen."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Parenteral NSAIDs are preferred, but if the patient has a contraindication to NSAIDs (like allergy), Opioids (Morphine or Pethidine) should be used as they are the second-line option. (p. 225)",
                "tags": "biliary_colic, pain_management, opioids"
            },
            {
                "id": 894,
                "question": "In the management of uncomplicated biliary colic, which of the following non-pharmacological measures is the most effective preventative advice?",
                "choices": [
                    "A. Avoiding all protein-rich foods.",
                    "B. Avoiding spicy foods and carbonated beverages.",
                    "C. Avoiding heavy, fatty meals.",
                    "D. Drinking large volumes of water immediately after a meal."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Biliary colic is commonly triggered by eating a fatty meal. Advising the patient to avoid heavy, fatty meals is a key non-pharmacologic intervention for prevention of attacks. (p. 225)",
                "tags": "biliary_colic, prevention"
            },
            {
                "id": 895,
                "question": "Which of the following is considered one of the major complications of cholelithiasis?",
                "choices": [
                    "A. Gastritis.",
                    "B. Gastroesophageal reflux disease (GERD).",
                    "C. Acute cholecystitis.",
                    "D. Peptic ulcer disease."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "The major complications of gallstones are cholecystitis, choledocholithiasis, acute cholangitis, and pancreatitis. (p. 224)",
                "tags": "gallstones, complications"
            },
            {
                "id": 896,
                "question": "A patient reports experiencing severe, dull pain in the right upper quadrant (RUQ) that plateaus within an hour and then gradually subsides after 5 hours. This description is most consistent with which phase of symptomatic gallstone disease?",
                "choices": [
                    "A. Acute cholecystitis.",
                    "B. Chronic cholecystitis.",
                    "C. Biliary colic.",
                    "D. Obstructive jaundice."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "The pain of biliary colic is described as reaching a plateau within an hour, then subsiding. The entire attack usually lasts less than six hours. (p. 224)",
                "tags": "biliary_colic, clinical_course"
            },
            {
                "id": 897,
                "question": "A 70-year-old man with multiple comorbidities is found to have gallstones incidentally. He is asymptomatic for biliary symptoms. What is the recommended management strategy regarding surgery?",
                "choices": [
                    "A. Immediate cholecystectomy due to high risk of complications.",
                    "B. Elective cholecystectomy after optimizing his medical conditions.",
                    "C. Conservative management without surgical intervention.",
                    "D. Oral dissolution therapy should be initiated as a trial."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Asymptomatic gallstones (Category 1, Incidental Gallstones) in any patient are generally managed conservatively, without surgical intervention. (p. 225, 226)",
                "tags": "incidental_gallstones, management"
            },
            {
                "id": 898,
                "question": "A 35-year-old woman is admitted with severe biliary colic. She has been vomiting profusely and is now unable to tolerate oral intake. Her vital signs are stable. In the initial management, she should be kept NPO (nil per os) and should receive:",
                "choices": [
                    "A. IV fluids and parenteral NSAIDs only.",
                    "B. IV fluids, parenteral NSAIDs, and oral dissolution medication.",
                    "C. Oral liquids and parenteral NSAIDs.",
                    "D. Oral liquids and antiemetics."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "The patient should be kept NPO and given supportive care with IV fluids due to vomiting/poor oral intake, and parenteral NSAIDs for the acute pain. (p. 225, 227)",
                "tags": "biliary_colic, initial_management"
            },
            {
                "id": 899,
                "question": "A patient presents with a history of typical biliary colic, but subsequent abdominal imaging fails to visualize any gallstones. Which category of symptomatic gallstone disease does this presentation fit?",
                "choices": [
                    "A. Category 1: Incidental gallstones.",
                    "B. Category 2: Uncomplicated gallstone disease.",
                    "C. Category 3: Atypical symptoms.",
                    "D. Category 4: Typical biliary symptoms but without gallstones."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "This is categorized as Category 4: Typical biliary symptoms but without gallstones on ultrasound. (p. 225)",
                "tags": "symptomatic_gallstone_disease, classification"
            },
            {
                "id": 900,
                "question": "The definitive management for a patient with uncomplicated symptomatic gallstone disease is:",
                "choices": [
                    "A. Oral bile acid dissolution therapy for 1 year.",
                    "B. Surgical removal of the gallbladder (cholecystectomy).",
                    "C. Dietary restriction and pain control for acute flares.",
                    "D. Endoscopic removal of the gallstones."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Cholecystectomy is the definitive and curative management indicated for uncomplicated symptomatic gallstone disease. (p. 225, 226)",
                "tags": "uncomplicated_gallstone_disease, definitive_treatment"
            },
            {
                "id": 901,
                "question": "When does the pain of biliary colic typically reach its maximal intensity?",
                "choices": [
                    "A. Immediately upon eating a fatty meal.",
                    "B. Minutes after the attack begins.",
                    "C. After 48 hours of constant pain.",
                    "D. It is constant and does not peak."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "The pain of biliary colic reaches a maximal intensity (plateaus) within an hour of the attack beginning. (p. 224)",
                "tags": "biliary_colic, pain_course"
            },
            {
                "id": 902,
                "question": "A 42-year-old woman with known cholelithiasis reports persistent, intense abdominal bloating, dyspepsia, and occasional mild RUQ discomfort. She asks if these symptoms mean she needs surgery. Based on the guidelines, these atypical symptoms are classified as:",
                "choices": [
                    "A. Category 1, requiring no surgical intervention.",
                    "B. Category 2, requiring elective surgery.",
                    "C. Category 3, requiring investigation for alternative causes.",
                    "D. Category 4, requiring urgent surgical consult."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "These are atypical symptoms (Category 3), which are poorly associated with gallstones. Management should involve investigating other possible causes for the symptoms before deciding on cholecystectomy. (p. 225)",
                "tags": "atypical_symptoms, management"
            },
            {
                "id": 903,
                "question": "For a patient with classic biliary colic, the most effective long-term strategy for recurrence prevention is to advise:",
                "choices": [
                    "A. Frequent, small meals.",
                    "B. Avoiding all high-fiber foods.",
                    "C. Avoiding heavy, high-fat meals.",
                    "D. Chronic low-dose aspirin therapy."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Since biliary colic attacks are often triggered by fatty meals, eliminating heavy, high-fat meals is a key non-pharmacologic preventative strategy. (p. 225)",
                "tags": "biliary_colic, prevention"
            },
            {
                "id": 904,
                "question": "Which laboratory or imaging finding is NOT necessary for the initial diagnosis of uncomplicated cholelithiasis with biliary colic?",
                "choices": [
                    "A. Patient history and clinical presentation.",
                    "B. Abdominal ultrasound confirming gallstones.",
                    "C. Liver function tests and bilirubin levels.",
                    "D. Serum amylase and lipase."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "For uncomplicated gallstone disease, while imaging and clinical history are necessary, basic lab tests (LFTS) and labs to rule out pancreatitis (amylase/lipase) are generally done to rule out complications. However, the direct diagnosis of uncomplicated cholelithiasis is based on clinical features and ultrasound. If the lab results are normal and the patient only has colic, no further investigation is needed. The question asks what is not necessary for the initial diagnosis of the uncomplicated state. Labs for amylase and lipase are not required unless pancreatitis is suspected. (p. 225, 233)",
                "tags": "uncomplicated_gallstone_disease, diagnosis"
            },
            {
                "id": 905,
                "question": "A patient presents with acute biliary colic pain that is refractory to the initial dose of IV Diclofenac. She has no contraindications to opioids. What is the next appropriate analgesic step?",
                "choices": [
                    "A. Administer a continuous infusion of IV Diclofenac.",
                    "B. Administer IV Morphine 2.5-5 mg.",
                    "C. Administer oral Codeine 60 mg.",
                    "D. Administer IV Hyoscine Butylbromide."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "If NSAIDs are insufficient or contraindicated, opioids (Morphine or Pethidine) are the appropriate second-line treatment for severe acute biliary colic pain. (p. 225)",
                "tags": "biliary_colic, pain_management, opioids"
            },
            {
                "id": 906,
                "question": "Which of the following is considered a major complication arising from cholelithiasis, as noted in the guidelines?",
                "choices": [
                    "A. Chronic constipation.",
                    "B. Cholelithiasis-induced duodenal ulcer.",
                    "C. Acute cholangitis.",
                    "D. Asymptomatic hyperbilirubinemia."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "The major complications listed are acute cholecystitis, choledocholithiasis (stone in the common bile duct), with or without acute cholangitis, and acute pancreatitis. (p. 224)",
                "tags": "gallstones, complications"
            },
            {
                "id": 907,
                "question": "A 38-year-old woman with symptomatic cholelithiasis is scheduled for elective cholecystectomy. The procedure is considered curative primarily because it eliminates:",
                "choices": [
                    "A. The chronic inflammation in the gallbladder wall.",
                    "B. The source of the recurrent biliary pain.",
                    "C. The risk of developing primary sclerosing cholangitis.",
                    "D. The accumulation of cholesterol in the bile."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Cholecystectomy is curative for uncomplicated symptomatic gallstone disease because it eliminates the source of the recurrent painful attacks. (p. 225, 226)",
                "tags": "cholecystectomy, curative_mechanism"
            },
            {
                "id": 908,
                "question": "A patient with known gallstones reports dull, non-specific abdominal discomfort that has been present for 3 months, unrelated to meals. How should this symptom presentation be initially managed?",
                "choices": [
                    "A. Urgent surgical consult.",
                    "B. Treat empirically for acute cholecystitis.",
                    "C. Investigate for alternative causes of abdominal discomfort.",
                    "D. Start long-term oral bile acid therapy."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "This is an atypical symptom (Category 3), and due to the poor correlation with gallstones, the initial management should focus on investigating alternative causes of the abdominal discomfort. (p. 225)",
                "tags": "atypical_symptoms, management"
            },
            {
                "id": 909,
                "question": "The initial choice for pain management in acute biliary colic is a parenteral NSAID. This choice is not ideal for a patient with which co-morbidity?",
                "choices": [
                    "A. Chronic stable angina.",
                    "B. Controlled type 1 diabetes.",
                    "C. History of peptic ulcer disease.",
                    "D. Severe primary hyperparathyroidism."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "NSAIDs are contraindicated or should be used with extreme caution in patients with an active peptic ulcer disease due to the high risk of hemorrhage. (p. 225)",
                "tags": "pain_management, contraindications, NSAIDs"
            },
            {
                "id": 910,
                "question": "Which of the following is most likely to be a precipitating factor for an attack of biliary colic?",
                "choices": [
                    "A. A meal rich in protein.",
                    "B. Emotional stress or anxiety.",
                    "C. Consumption of a heavy, fatty meal.",
                    "D. Periods of fasting or starvation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Eating a fatty meal is listed as a common trigger for biliary colic. (p. 225)",
                "tags": "biliary_colic, precipitating_factors"
            },
            {
                "id": 911,
                "question": "In cases of gallstones where no complications have occurred and there is no history of pain, what is the recommended course of action?",
                "choices": [
                    "A. Elective cholecystectomy within 6 months.",
                    "B. Lifestyle advice and regular follow-up.",
                    "C. Aggressive pain management with NSAIDs.",
                    "D. Oral dissolution therapy for a minimum of 1 year."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "For incidental gallstones (asymptomatic), conservative management with regular follow-up is recommended; surgical intervention is not indicated. (p. 225, 226)",
                "tags": "incidental_gallstones, management"
            },
            {
                "id": 912,
                "question": "The main distinction between uncomplicated gallstone disease (Category 2) and incidental gallstones (Category 1) is the:",
                "choices": [
                    "A. Size of the gallstones.",
                    "B. Patient's age and co-morbidities.",
                    "C. Presence of typical biliary colic symptoms.",
                    "D. Gallstone composition (cholesterol vs. pigment)."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "The distinction between Category 1 (Incidental) and Category 2 (Uncomplicated) is the presence of symptoms, specifically typical biliary colic. (p. 225)",
                "tags": "gallstone_classification"
            },
            {
                "id": 913,
                "question": "What is the least likely clinical presentation of typical biliary colic?",
                "choices": [
                    "A. Pain that lasts less than 30 minutes.",
                    "B. Pain that radiates to the right shoulder.",
                    "C. Severe, dull pain in the epigastrium.",
                    "D. Pain that is constant, lasting 4 hours."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Typical biliary colic pain lasts at least 30 minutes and usually less than six hours. (p. 224)",
                "tags": "biliary_colic, clinical_features"
            },
            {
                "id": 914,
                "question": "Which of the following is considered a major complication of cholelithiasis, indicating a need for urgent management?",
                "choices": [
                    "A. Non-specific epigastric burning.",
                    "B. Acute pancreatitis.",
                    "C. Non-painful, calcified gallbladder.",
                    "D. Chronic diarrhea."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Acute pancreatitis is listed as a major complication of gallstones, which may necessitate urgent management. (p. 224)",
                "tags": "gallstones, complications"
            },
            {
                "id": 915,
                "question": "A healthy 40-year-old patient has a documented gallstone on ultrasound but denies any history of pain or discomfort (Category 1). The patient should be managed with:",
                "choices": [
                    "A. Referral for elective cholecystectomy.",
                    "B. Observation, lifestyle advice, and elective follow-up.",
                    "C. Immediate referral for oral dissolution therapy.",
                    "D. Immediate dietary restriction (no fat intake)."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "For incidental gallstones (Category 1), conservative management with observation, lifestyle advice, and follow-up is the recommended course. (p. 225, 226)",
                "tags": "incidental_gallstones, management"
            },
            {
                "id": 916,
                "question": "A 58-year-old patient presents with classic biliary colic. He has a known allergy to NSAIDs and opioids. Which therapeutic option is least appropriate for immediate severe pain relief?",
                "choices": [
                    "A. Intravenous Diclofenac.",
                    "B. Intramuscular Morphine.",
                    "C. Rectal Indomethacin.",
                    "D. Intravenous Acetaminophen."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Given the known allergy, an NSAID like Diclofenac is contraindicated. (p. 225)",
                "tags": "pain_management, contraindications, NSAIDs"
            },
            {
                "id": 917,
                "question": "A patient with gallstones and typical biliary colic is prescribed oral Diclofenac for pain flares. What specific instruction should accompany this prescription?",
                "choices": [
                    "A. Take immediately after consuming a fatty meal.",
                    "B. Use for severe pain only; stop if pain resolves.",
                    "C. Take daily for a minimum of 3 months to prevent recurrence.",
                    "D. Take continuously until scheduled for surgery."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "NSAIDs should be used for acute pain flares only (PRN) and discontinued once the pain subsides. Chronic pain therapy is only needed for symptoms lasting >6 hours. (p. 225)",
                "tags": "biliary_colic, pharmacologic_management"
            },
            {
                "id": 918,
                "question": "What is a key non-pharmacological advice to prevent future attacks in a patient with uncomplicated symptomatic gallstone disease?",
                "choices": [
                    "A. Drink 3 liters of water per day.",
                    "B. Maintain a regular, moderate exercise regimen.",
                    "C. Avoid milk and dairy products.",
                    "D. Strictly avoid eating after 6 PM."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "While dietary advice is important (avoiding fatty meals), regular exercise is a general lifestyle measure that contributes to prevention. (p. 225)",
                "tags": "uncomplicated_gallstone_disease, prevention"
            },
            {
                "id": 919,
                "question": "A 45-year-old patient with atypical abdominal bloating and gallstones (Category 3) has had an extensive workup for other causes that was negative. Her symptoms are persistent and bothersome. What is the next appropriate step in management?",
                "choices": [
                    "A. Referral for elective cholecystectomy.",
                    "B. Start long-term oral bile acid dissolution therapy.",
                    "C. Reassurance and symptomatic treatment only.",
                    "D. Urgent surgery due to persistence."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "For Category 3 patients, if investigation for alternative causes is negative and symptoms are persistent and bothersome, an elective cholecystectomy referral may be individualized and considered. (p. 225, 226)",
                "tags": "atypical_symptoms, management"
            },
            {
                "id": 920,
                "question": "A patient with confirmed gallstones has a sudden, severe RUQ pain 3 hours after a meal. Physical exam is benign. What is the expected typical duration for this pain episode (biliary colic)?",
                "choices": [
                    "A. It will last exactly 6 hours.",
                    "B. It will last between 30 minutes and 6 hours.",
                    "C. It will resolve instantly with IV Diclofenac.",
                    "D. It is expected to last for more than 24 hours."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "The typical duration of biliary colic is at least 30 minutes and usually less than six hours. (p. 224)",
                "tags": "biliary_colic, duration"
            },
            {
                "id": 921,
                "question": "Which imaging modality would be the most appropriate initial study for a patient presenting with new-onset, classic biliary colic?",
                "choices": [
                    "A. CT scan of the abdomen.",
                    "B. Magnetic Resonance Cholangiopancreatography (MRCP).",
                    "C. Abdominal ultrasound.",
                    "D. Plain X-ray of the abdomen."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Abdominal ultrasound is the gold standard tool and the most appropriate initial imaging for diagnosing cholelithiasis. (p. 225)",
                "tags": "cholelithiasis, initial_investigation"
            },
            {
                "id": 922,
                "question": "For a patient with symptomatic gallstones (Category 2), the appropriate timing for definitive surgical intervention (cholecystectomy) is:",
                "choices": [
                    "A. Urgent (within 24 hours).",
                    "B. Emergent (within 6 hours).",
                    "C. Elective.",
                    "D. Only if symptoms progress to jaundice."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "For uncomplicated symptomatic gallstone disease, cholecystectomy is indicated and should be done electively. (p. 225, 226)",
                "tags": "cholecystectomy, timing"
            },
            {
                "id": 923,
                "question": "Which of the following is considered a major complication of cholelithiasis?",
                "choices": [
                    "A. Gastroesophageal reflux disease.",
                    "B. Acute cholangitis.",
                    "C. Chronic gastritis.",
                    "D. Irritable bowel syndrome."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Acute cholangitis is a listed major complication of gallstones (choledocholithiasis with or without cholangitis). (p. 224)",
                "tags": "gallstones, complications"
            },
            {
                "id": 924,
                "question": "Which is the most common type of gallstone found in the population?",
                "choices": [
                    "A. Pigment stones.",
                    "B. Calcium phosphate stones.",
                    "C. Cholesterol stones.",
                    "D. Mixed stones."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "The majority of gallstones are cholesterol stones. (p. 224)",
                "tags": "gallstone_composition"
            },
            {
                "id": 925,
                "question": "A patient presents with acute pain relief needs for biliary colic. He has a known peptic ulcer. The most appropriate initial parenteral pain management is:",
                "choices": [
                    "A. IV Diclofenac.",
                    "B. IM Pethidine.",
                    "C. IV Ketorolac.",
                    "D. Rectal Diclofenac."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "NSAIDs (Diclofenac, Ketorolac) are contraindicated in patients with a history of peptic ulcer disease. Opioids (Morphine or Pethidine) are the appropriate second-line choice. (p. 225)",
                "tags": "pain_management, peptic_ulcer_disease, contraindications"
            },
            {
                "id": 926,
                "question": "A patient with gallstones and recurring biliary colic should be referred for elective surgery (cholecystectomy) because this intervention primarily:",
                "choices": [
                    "A. Dissolves the gallstones over time.",
                    "B. Prevents the source of the recurrent painful attacks.",
                    "C. Cures the underlying metabolic cause.",
                    "D. Prevents acute pancreatitis."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Cholecystectomy is curative for uncomplicated symptomatic gallstone disease because it removes the source of the recurrent painful attacks. (p. 225, 226)",
                "tags": "cholecystectomy, curative_mechanism"
            },
            {
                "id": 927,
                "question": "Which of the following is an atypical symptom that is poorly associated with gallstones, making a surgical decision complex?",
                "choices": [
                    "A. Nausea during an attack.",
                    "B. Severe, constant RUQ pain.",
                    "C. Pain radiating to the back.",
                    "D. Chronic, non-specific epigastric burning."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Chronic, non-specific epigastric burning is listed as an atypical symptom (Category 3) with poor association to gallstones, necessitating a search for other causes. (p. 225)",
                "tags": "atypical_symptoms, diagnosis"
            },
            {
                "id": 928,
                "question": "For a patient with incidentally discovered gallstones (asymptomatic), the management strategy involves:",
                "choices": [
                    "A. Elective cholecystectomy due to high lifetime risk.",
                    "B. Long-term oral dissolution therapy.",
                    "C. Conservative management.",
                    "D. Annual ultrasound surveillance for complications."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Incidental gallstones (Category 1) are managed conservatively, as surgery is not indicated. (p. 225, 226)",
                "tags": "incidental_gallstones, management"
            },
            {
                "id": 929,
                "question": "A 48-year-old woman presents with severe biliary colic. The most appropriate initial pharmacological treatment class to control the pain is:",
                "choices": [
                    "A. Opioids.",
                    "B. Antispasmodics.",
                    "C. Parenteral NSAIDs.",
                    "D. Oral antacids."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Parenteral NSAIDS are the preferred agents for acute biliary colic pain management. (p. 225)",
                "tags": "biliary_colic, pain_management, NSAIDs"
            },
            {
                "id": 930,
                "question": "In the context of gallstone disease, what does Category 4 describe?",
                "choices": [
                    "A. Asymptomatic gallstones.",
                    "B. Typical biliary symptoms but without gallstones on ultrasound.",
                    "C. Atypical symptoms with gallstones.",
                    "D. Uncomplicated symptomatic gallstone disease."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Category 4 is defined as Typical biliary symptoms but without gallstones on imaging. (p. 225)",
                "tags": "gallstone_classification, diagnosis"
            },
            {
                "id": 931,
                "question": "The pathophysiology of gallstone formation begins with:",
                "choices": [
                    "A. Inflammation of the gallbladder lining.",
                    "B. Infection of the biliary tree.",
                    "C. Accumulation of cholesterol or pigment materials.",
                    "D. Bile duct stricture formation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Gallstone formation occurs from the supersaturation and accumulation of soluble materials like cholesterol. (p. 224, 564)",
                "tags": "gallstone_formation, pathophysiology"
            },
            {
                "id": 932,
                "question": "What is the recommended approach for managing a patient in Category 4 (typical biliary symptoms but no gallstones)?",
                "choices": [
                    "A. Treat empirically for cholelithiasis.",
                    "B. Perform elective cholecystectomy.",
                    "C. Close observation with no intervention.",
                    "D. Follow-up and individualize the surgical decision."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "For Category 4 patients, the management is follow-up and individualization of the surgical decision. (p. 225, 226)",
                "tags": "symptomatic_gallstone_disease, management"
            },
            {
                "id": 933,
                "question": "A 50-year-old woman with chronic liver disease has gallstones. Which type of gallstone is most likely in this patient?",
                "choices": [
                    "A. Mixed stones.",
                    "B. Cholesterol stones.",
                    "C. Pigment stones.",
                    "D. Calcium carbonate stones."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Pigment stones are common in patients with liver cirrhosis or chronic hemolytic anemia. (p. 224)",
                "tags": "gallstone_composition, liver_cirrhosis"
            },
            {
                "id": 934,
                "question": "Which drug class is contraindicated for pain relief in biliary colic for a patient with severe kidney impairment?",
                "choices": [
                    "A. Opioids.",
                    "B. NSAIDs.",
                    "C. Paracetamol.",
                    "D. Antispasmodics."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "NSAIDs are contraindicated or should be used with extreme caution in patients with impaired kidney function. (p. 225)",
                "tags": "pain_management, contraindications, NSAIDs"
            },
            {
                "id": 935,
                "question": "Biliary colic pain typically lasts for what duration?",
                "choices": [
                    "A. Less than 30 minutes.",
                    "B. 6-12 hours.",
                    "C. 30 minutes to 6 hours.",
                    "D. More than 24 hours."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Typical biliary colic pain lasts at least 30 minutes and usually less than six hours. (p. 224)",
                "tags": "biliary_colic, duration"
            },
            {
                "id": 936,
                "question": "Which of the following is not a major complication of cholelithiasis?",
                "choices": [
                    "A. Acute cholecystitis.",
                    "B. Choledocholithiasis.",
                    "C. Acute pancreatitis.",
                    "D. Chronic dyspepsia."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Chronic dyspepsia is an atypical symptom or separate condition, not a major complication of gallstones. (p. 224, 225)",
                "tags": "gallstones, complications"
            },
            {
                "id": 937,
                "question": "The definitive treatment for a patient in Category 2 (uncomplicated symptomatic gallstone disease) is:",
                "choices": [
                    "A. Long-term dietary management.",
                    "B. Surgical removal of the gallbladder.",
                    "C. Oral bile acid dissolution therapy.",
                    "D. Endoscopic sphincterotomy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Cholecystectomy is the curative and definitive treatment for uncomplicated symptomatic gallstone disease. (p. 225, 226)",
                "tags": "uncomplicated_gallstone_disease, definitive_treatment"
            },
            {
                "id": 938,
                "question": "A patient presents with acute biliary colic. The pain is severe, constant, and located in the epigastrium. What is the most characteristic feature of this pain?",
                "choices": [
                    "A. Sharp, fluctuating (colicky) nature.",
                    "B. Dull, steady, non-colicky nature.",
                    "C. Immediate onset after a meal.",
                    "D. Radiation to the left shoulder."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Biliary colic is described as a severe, dull pain that is usually constant (non-colicky). (p. 224)",
                "tags": "biliary_colic, clinical_features"
            },
            {
                "id": 939,
                "question": "Which of the following is a key non-pharmacological advice for managing recurrent biliary colic flares?",
                "choices": [
                    "A. Increase protein intake.",
                    "B. Decrease all fluid intake.",
                    "C. Avoidance of large, fatty meals.",
                    "D. Chronic use of heating pads."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Biliary colic is commonly triggered by fatty meals. Dietary modification to avoid large, high-fat meals is the essential non-pharmacologic intervention. (p. 225)",
                "tags": "biliary_colic, non-pharmacologic"
            },
            {
                "id": 940,
                "question": "A patient presents with typical biliary colic. She is given IV Morphine for pain, but the pain recurs after 2 hours. What is the preferred analgesic class that should have been used initially?",
                "choices": [
                    "A. Antispasmodics.",
                    "B. Parenteral NSAIDs.",
                    "C. Long-acting Opioids.",
                    "D. Oral Paracetamol."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Parenteral NSAIDs are the preferred agents for acute pain management in biliary colic. (p. 225)",
                "tags": "biliary_colic, pain_management, NSAIDs"
            },
            {
                "id": 941,
                "question": "The utility of oral dissolution therapy for gallstones is:",
                "choices": [
                    "A. High, recommended for all gallstone disease.",
                    "B. Limited, due to poor efficacy and high recurrence.",
                    "C. Curative, for all pigment stone disease.",
                    "D. A mandatory first-line therapy before surgery."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Oral dissolution therapy is not mentioned as a standard or preferred treatment in the general guidelines for cholelithiasis, implying its limited role compared to surgery or pain management. (p. 225, 226)",
                "tags": "cholelithiasis, treatment"
            },
            {
                "id": 942,
                "question": "A patient with no history of biliary symptoms is found to have gallstones on ultrasound (Category 1). The most appropriate long-term management is:",
                "choices": [
                    "A. Oral dissolution therapy.",
                    "B. Urgent surgical consult.",
                    "C. Elective surgical planning.",
                    "D. Observation and lifestyle advice."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Incidental gallstones (Category 1) are managed with observation and lifestyle advice. (p. 225, 226)",
                "tags": "incidental_gallstones, management"
            },
            {
                "id": 943,
                "question": "Which patient requires elective cholecystectomy referral?",
                "choices": [
                    "A. 60-year-old with asymptomatic gallstones (Category 1).",
                    "B. 45-year-old with atypical symptoms and gallstones (Category 3).",
                    "C. 30-year-old with recurrent biliary colic (Category 2).",
                    "D. 50-year-old with typical symptoms but no stones (Category 4)."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Uncomplicated symptomatic gallstone disease (Category 2) is the primary indication for elective cholecystectomy. (p. 225, 226)",
                "tags": "cholecystectomy, indication"
            },
            {
                "id": 944,
                "question": "A key element in the presentation of typical biliary colic pain is its:",
                "choices": [
                    "A. Location in the lower abdomen.",
                    "B. Duration (short-lived, less than 30 min).",
                    "C. Non-colicky (constant) nature.",
                    "D. Association with fever and chills."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Biliary colic is typically a severe, dull, constant (non-colicky) pain. (p. 224)",
                "tags": "biliary_colic, clinical_features"
            },
            {
                "id": 945,
                "question": "A patient is found to have incidental gallstones (Category 1). The patient is anxious and insists on surgery to prevent future problems. The most appropriate advice is:",
                "choices": [
                    "A. Proceed with elective cholecystectomy.",
                    "B. Counsel that surgery is not indicated and carries unnecessary risk.",
                    "C. Prescribe NSAIDs for potential future pain.",
                    "D. Monitor with serial ultrasound every 3 months."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "For incidental gallstones, the primary management is conservative, as there is no indication for surgery and it poses an unnecessary risk. (p. 225, 226)",
                "tags": "incidental_gallstones, management"
            },
            {
                "id": 946,
                "question": "What are the preferred initial agents for pain control in acute biliary colic?",
                "choices": [
                    "A. Oral Antacids.",
                    "B. Parenteral Opioids.",
                    "C. Parenteral NSAIDs.",
                    "D. Oral Acetaminophen."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Parenteral NSAIDs are the preferred first-line agents for acute pain management in biliary colic. (p. 225)",
                "tags": "biliary_colic, pain_management, NSAIDs"
            },
            {
                "id": 947,
                "question": "A patient presents with persistent, chronic, non-specific abdominal discomfort and gallstones. This is categorized as Category 3. Which step is most necessary in the management plan?",
                "choices": [
                    "A. Scheduling immediate cholecystectomy.",
                    "B. Initiating an exhaustive search for alternative causes of pain.",
                    "C. Starting a high-dose opioid regimen.",
                    "D. Prescribing chronic antibiotics to prevent infection."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Category 3 (atypical symptoms) has a poor association with gallstones; therefore, a thorough search for alternative diagnoses is the most necessary step. (p. 225)",
                "tags": "atypical_symptoms, management"
            },
            {
                "id": 948,
                "question": "In a patient with classic biliary colic, the expected pain pattern is:",
                "choices": [
                    "A. Constant pain for 3 hours, then full resolution.",
                    "B. Colicky pain that moves frequently.",
                    "C. Pain that worsens only with deep inspiration.",
                    "D. Dull ache that lasts several days."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Typical biliary colic is a severe, dull, constant pain lasting 30 minutes to 6 hours, and then resolves. (p. 224)",
                "tags": "biliary_colic, clinical_features"
            },
            {
                "id": 949,
                "question": "The presence of gallstones incidentally found on imaging in an asymptomatic patient is classified as:",
                "choices": [
                    "A. Category 4.",
                    "B. Category 3.",
                    "C. Category 2.",
                    "D. Category 1."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Incidental gallstones are classified as Category 1. (p. 225)",
                "tags": "gallstone_classification"
            },
            {
                "id": 950,
                "question": "Which of the following is not a typical characteristic of biliary colic pain?",
                "choices": [
                    "A. Radiation to the back or right shoulder.",
                    "B. Associated with nausea and vomiting.",
                    "C. Worsened by eating a fatty meal.",
                    "D. Relieved immediately by simple oral antacids."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Biliary colic is severe, constant pain that is not typically relieved by simple antacids. It typically lasts a significant duration. (p. 224)",
                "tags": "biliary_colic, clinical_features"
            },
            {
                "id": 951,
                "question": "Which of the following is not a major complication of cholelithiasis, as defined by the guidelines?",
                "choices": [
                    "A. Acute cholecystitis.",
                    "B. Choledocholithiasis.",
                    "C. Acute appendicitis.",
                    "D. Acute pancreatitis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10 Cholelithiasis (Gall stones)",
                "explanation": "Acute appendicitis is an unrelated condition, not a complication of cholelithiasis. (p. 224)",
                "tags": "gallstones, complications"
            }
        ]
    },
    "Chapter 6.10.1.2": {
        "Chapter 6.10.1.2 Acute cholecystitis": [
            {
                "id": 952,
                "question": "A 50-year-old woman presents to the emergency room with **severe right upper quadrant pain** that began 24 hours ago, **fever (38.5°C)**, and **nausea**. Physical examination reveals **localized RUQ tenderness and a positive Murphy's sign**. According to the Tokyo Guidelines, what is the **severity grade** of her condition, assuming no organ dysfunction?",
                "choices": [
                    "A. Grade I (Mild).",
                    "B. Grade II (Moderate).",
                    "C. Grade III (Severe).",
                    "D. Incidental."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The patient meets the diagnostic criteria for acute cholecystitis (RUQ pain, fever, localized tenderness/Murphy's sign)[cite: 1009, 1010, 1011, 1012]. Grade II (Moderate) criteria include elevated WBC count (>18,000/mm³) and marked local inflammation. Though WBC count is not provided, the clinical picture with fever and positive Murphy's sign suggests inflammation beyond mild changes, and should be treated as moderate to prompt appropriate admission and management[cite: 1010]. Grade I (Mild) is for healthy patients with mild inflammatory changes[cite: 1010]. The case is clinically moderate (Grade II) to warrant prompt attention (p. 226, 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 953,
                "question": "A 60-year-old male with Grade II acute calculous cholecystitis is admitted to the general hospital. **What is the recommended initial antibiotic regimen**?",
                "choices": [
                    "A. Ciprofloxacin 400mg IV BID PLUS Metronidazole 500mg IV TID.",
                    "B. Amoxicillin-Clavulanate 1.2g IV BID monotherapy.",
                    "C. Ceftriaxone 1gm IV BID PLUS Metronidazole 500mg IV TID.",
                    "D. Ceftriaxone 1gm IV BID monotherapy."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The **First line** antibiotic regimen for acute cholecystitis is a combination aimed at covering Gram-negative bacilli and anaerobes, specifically **Ceftriaxone 1gm IV, BID PLUS Metronidazole 500mg IV TID** [cite: 1007, 1000] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "antibiotic_treatment"
                ]
            },
            {
                "id": 954,
                "question": "A key step in the **initial non-pharmacologic management** of acute cholecystitis upon hospital admission is:",
                "choices": [
                    "A. Preparing for an immediate percutaneous drain placement.",
                    "B. Keeping the patient NPO (nil per os) or resting the bowel.",
                    "C. Administering a strong opioid for pain control.",
                    "D. Encouraging immediate ambulation and oral fluids."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "Upon admission, a key initial step in the supportive management of acute cholecystitis is to **rest the bowel** by **keeping the patient NPO** (nil per os) [cite: 1018, 1007] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "initial_management"
                ]
            },
            {
                "id": 955,
                "question": "A patient with acute cholecystitis is administered parenteral NSAIDs for pain. Which co-morbidity requires this therapy to be **reserved as second-line or avoided**?",
                "choices": [
                    "A. History of chronic cholelithiasis.",
                    "B. Controlled hypertension.",
                    "C. Impaired kidney function (CKD).",
                    "D. Mild fever."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "Parenteral NSAIDs are the preferred agents for pain, but **Opioids** should be **reserved** for patients with **contraindications to NSAIDs** [cite: 976, 963], such as **impaired kidney function** [cite: 886] (p. 225, 227).",
                "tags": [
                    "acute_cholecystitis",
                    "pain_management",
                    "contraindications"
                ]
            },
            {
                "id": 956,
                "question": "In acute cholecystitis, what is the **most characteristic sign** elicited during physical examination?",
                "choices": [
                    "A. Rebound tenderness in the right lower quadrant.",
                    "B. Severe, generalized abdominal rigidity.",
                    "C. Positive Murphy's sign.",
                    "D. Diffuse epigastric guarding."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "Patients frequently have a **positive Murphy's sign**, which is worsening of the RUQ pain upon deep inspiration during palpation of the gallbladder fossa. This is a characteristic finding in acute cholecystitis [cite: 1009] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "clinical_features",
                    "Murphy's"
                ]
            },
            {
                "id": 958,
                "question": "A patient with acute cholecystitis and **no organ dysfunction** has a **WBC count of 15,000/mm³**. According to the Tokyo Guidelines (TG18/TG13), what is the **severity grade**?",
                "choices": [
                    "A. Grade I (Mild).",
                    "B. Grade II (Moderate).",
                    "C. Grade III (Severe).",
                    "D. Indeterminate."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The criteria for **Grade II (Moderate)** include a WBC count **>18,000/mm³**. Since the patient's WBC count is below this threshold and there is no organ dysfunction (Grade III), the severity is **Grade I (Mild)**, defined as not meeting Grade II or III criteria [cite: 957, 1010] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 959,
                "question": "Which condition is defined by **inflammation of the gallbladder** that most commonly develops as a complication of gallstones?",
                "choices": [
                    "A. Biliary colic.",
                    "B. Choledocholithiasis.",
                    "C. Acute cholecystitis.",
                    "D. Acute cholangitis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Acute cholecystitis** refers to inflammation of the gallbladder that commonly develops as a complication of gallstones (calculous cholecystitis) [cite: 958] (p. 226).",
                "tags": [
                    "acute_cholecystitis",
                    "definition"
                ]
            },
            {
                "id": 960,
                "question": "In a patient with acute cholecystitis, what is the **duration of the recommended antibiotic course**?",
                "choices": [
                    "A. A single IV dose followed by reassessment.",
                    "B. 5-7 days of IV antibiotics only.",
                    "C. 7-10 days of combined IV antibiotic therapy.",
                    "D. Minimum 14 days of IV/oral antibiotics."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The antibiotic regimen (e.g., Ceftriaxone + Metronidazole) is recommended for **7–10 days** [cite: 959] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "antibiotic_duration"
                ]
            },
            {
                "id": 961,
                "question": "A 72-year-old woman with a **prolonged INR of 1.8** and acute cholecystitis should be categorized into which **severity grade** according to the Tokyo Guidelines?",
                "choices": [
                    "A. Grade I (Mild).",
                    "B. Grade II (Moderate).",
                    "C. Grade III (Severe).",
                    "D. Indeterminate."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Grade III (Severe)** acute cholecystitis is defined by **dysfunction of any one organ/system**, including **Hepatic dysfunction** (PT-INR >1.5) [cite: 961] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 962,
                "question": "Which of the following is an **alternative initial antibiotic regimen** for acute cholecystitis, if the patient has no signs of severe infection?",
                "choices": [
                    "A. Ciprofloxacin 400mg IV BID PLUS Metronidazole 500mg IV TID.",
                    "B. Ampicillin/Sulbactam 1.5g IV QID monotherapy.",
                    "C. Ceftriaxone 1gm IV BID monotherapy.",
                    "D. Vancomycin 1gm IV BID PLUS Gentamicin 80mg IV TID."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The **Alternative** initial antibiotic regimen is **Ciprofloxacin 400mg IV BID PLUS Metronidazole 500mg IV TID** [cite: 975] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "alternative_antibiotics"
                ]
            },
            {
                "id": 963,
                "question": "The appropriate **initial pain management** strategy for a patient with acute cholecystitis should utilize:",
                "choices": [
                    "A. Parenteral NSAIDs (e.g., Diclofenac) as the preferred agent.",
                    "B. Opioids (e.g., Morphine) to prevent sphincter of Oddi spasm.",
                    "C. Oral antacids and H2 blockers.",
                    "D. No analgesia until a definitive diagnosis is confirmed."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Parenteral NSAIDs** (e.g., Diclofenac 50-75mg IV/IM every 12 hours) are the **preferred agents** for pain management in acute cholecystitis. Opioids are reserved as second line [cite: 976, 964] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "pain_management",
                    "NSAIDs"
                ]
            },
            {
                "id": 964,
                "question": "A patient with acute cholecystitis is administered parenteral NSAIDs for pain. Which co-morbidity requires this therapy to be **reserved as second-line or avoided**?",
                "choices": [
                    "A. History of chronic cholelithiasis.",
                    "B. Controlled hypertension.",
                    "C. Impaired kidney function (CKD).",
                    "D. Mild fever."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "Parenteral NSAIDs are the preferred agents for pain, but **Opioids** should be **reserved** for patients with **contraindications to NSAIDs** [cite: 976, 963], such as **impaired kidney function** [cite: 886] (p. 225, 227).",
                "tags": [
                    "acute_cholecystitis",
                    "pain_management",
                    "contraindications"
                ]
            },
            {
                "id": 965,
                "question": "A patient with acute cholecystitis is admitted. In addition to securing IV access, keeping the patient NPO, and starting IV antibiotics, what is the **most appropriate initial analgesic plan**?",
                "choices": [
                    "A. Oral Ibuprofen 400 mg every 8 hours.",
                    "B. Parenteral Pethidine 50 mg every 4-6 hours.",
                    "C. Parenteral Diclofenac 75 mg every 12 hours.",
                    "D. No analgesia is required in Grade II disease."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "For acute cholecystitis, parenteral **NSAIDs** like **Diclofenac 50-75mg IV/IM every 12 hours** are the preferred agents. Oral NSAIDs are typically inadequate for acute severe pain [cite: 964, 986] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "pain_management"
                ]
            },
            {
                "id": 966,
                "question": "Which finding is considered a **Grade III (Severe) criterion** according to the Tokyo Guidelines for acute cholecystitis?",
                "choices": [
                    "A. WBC count 16,000/mm³.",
                    "B. Duration of symptoms of 48 hours.",
                    "C. Palpable tender mass in the RUQ.",
                    "D. Platelet count of 90,000/mm³ (Hematological dysfunction)."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Platelet count <100,000/mm³** falls under **Hematological dysfunction**, which is a criterion for **Grade III (Severe)** acute cholecystitis [cite: 965] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 967,
                "question": "A patient with acute cholecystitis is successfully managed with antibiotics and supportive care. **Cholecystectomy** is indicated and should be performed:",
                "choices": [
                    "A. Urgently, within 24 hours of presentation.",
                    "B. Emergent, only if fever persists past 48 hours.",
                    "C. During the same hospitalization or electively later (interval cholecystectomy).",
                    "D. Only if the patient develops acute pancreatitis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Cholecystectomy is indicated** once the patient is stable. The timing depends on clinical status: during the **same hospitalization** for low-risk patients, or **electively later (interval cholecystectomy)** for others [cite: 960] (p. 228).",
                "tags": [
                    "acute_cholecystitis",
                    "cholecystectomy",
                    "timing"
                ]
            },
            {
                "id": 968,
                "question": "A 70-year-old woman with acute cholecystitis has **Creatinine of 2.5 mg/dl**. Which severity grade is most appropriate according to the Tokyo Guidelines?",
                "choices": [
                    "A. Grade I (Mild).",
                    "B. Grade II (Moderate).",
                    "C. Grade III (Severe).",
                    "D. Indeterminate."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Creatinine >2.0 mg/dl** indicates **Renal dysfunction**, which is a criterion for **Grade III (Severe)** acute cholecystitis [cite: 974] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 969,
                "question": "Which of the following is an **alternative initial antibiotic regimen** for acute cholecystitis, if the patient has no contraindications?",
                "choices": [
                    "A. Ciprofloxacin 400mg IV BID PLUS Metronidazole 500mg IV TID.",
                    "B. Ampicillin/Sulbactam 1.5g IV QID monotherapy.",
                    "C. Ceftriaxone 1gm IV BID monotherapy.",
                    "D. Meropenem 1gm IV TID."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The **Alternative** regimen to Ceftriaxone + Metronidazole is **Ciprofloxacin 400mg IV BID PLUS Metronidazole 500mg IV TID** [cite: 975] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "alternative_antibiotics"
                ]
            },
            {
                "id": 970,
                "question": "The appropriate initial pain management strategy for a patient with acute cholecystitis should utilize:",
                "choices": [
                    "A. Parenteral NSAIDs (e.g., Diclofenac) as the preferred agent.",
                    "B. Opioids (e.g., Morphine) to prevent sphincter of Oddi spasm.",
                    "C. Oral antacids and H2 blockers.",
                    "D. No analgesia until a definitive diagnosis is confirmed."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Parenteral NSAIDs** (e.g., Diclofenac 50-75mg IV/IM every 12 hours) are the **preferred agents** for pain management in acute cholecystitis. Opioids are reserved as second line [cite: 976, 964] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "pain_management",
                    "NSAIDs"
                ]
            },
            {
                "id": 971,
                "question": "A patient is admitted with acute cholecystitis. Which finding is considered a **Grade III (Severe) criterion** according to the Tokyo Guidelines?",
                "choices": [
                    "A. Neurological dysfunction (e.g., decreased level of consciousness).",
                    "B. Respiratory dysfunction (PaO₂/FiO₂ ratio <300).",
                    "C. Creatinine 2.5 mg/dl.",
                    "D. All of the above."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "All listed options—Neurological dysfunction, Respiratory dysfunction, and Creatinine >2.0 mg/dl (Renal dysfunction)—are criteria for **Grade III (Severe)** acute cholecystitis, indicating single organ/system failure [cite: 972, 974] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 972,
                "question": "A patient with acute cholecystitis presents with **Platelet count 90,000/mm³** but no signs of organ dysfunction. Which severity grade is applicable?",
                "choices": [
                    "A. Grade I (Mild).",
                    "B. Grade II (Moderate).",
                    "C. Grade III (Severe).",
                    "D. Indeterminate."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Platelet count <100,000/mm³** indicates **Hematological dysfunction**, which is a criterion for **Grade III (Severe)** acute cholecystitis. (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 973,
                "question": "The **most appropriate next step** for a patient with acute cholecystitis who is not improving after 48 hours of IV antibiotics and supportive care, and remains febrile, is:",
                "choices": [
                    "A. Discharge home with oral antibiotics.",
                    "B. Step-down to oral Diclofenac.",
                    "C. Emergency surgery due to lack of response.",
                    "D. Repeat imaging and reassessment for complications or alternative diagnoses."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "Lack of improvement after 48 hours of IV antibiotics suggests a worsening clinical condition or complication, which is an indication for **emergency surgery** (cholecystectomy) [cite: 973] (p. 228).",
                "tags": [
                    "acute_cholecystitis",
                    "management_failure"
                ]
            },
            {
                "id": 974,
                "question": "A patient with acute cholecystitis is noted to have a **Creatinine of 2.5 mg/dl**. Which severity grade is most appropriate according to the Tokyo Guidelines?",
                "choices": [
                    "A. Grade I (Mild).",
                    "B. Grade II (Moderate).",
                    "C. Grade III (Severe).",
                    "D. Indeterminate."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Creatinine >2.0 mg/dl** indicates **Renal dysfunction**, which is a criterion for **Grade III (Severe)** acute cholecystitis [cite: 974] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 975,
                "question": "What is the **alternative initial antibiotic regimen** for acute cholecystitis, if the patient has no contraindications?",
                "choices": [
                    "A. Ciprofloxacin 400mg IV BID PLUS Metronidazole 500mg IV TID.",
                    "B. Ampicillin/Sulbactam 1.5g IV QID monotherapy.",
                    "C. Ceftriaxone 1gm IV BID monotherapy.",
                    "D. Meropenem 1gm IV TID."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The **Alternative** regimen to Ceftriaxone + Metronidazole is **Ciprofloxacin 400mg IV BID PLUS Metronidazole 500mg IV TID** [cite: 975] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "alternative_antibiotics"
                ]
            },
            {
                "id": 976,
                "question": "The most effective analgesic class for pain management in acute cholecystitis is:",
                "choices": [
                    "A. Oral Opioids.",
                    "B. Parenteral NSAIDs.",
                    "C. Oral Antispasmodics.",
                    "D. Parenteral Acetaminophen."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Parenteral NSAIDs** (e.g., Diclofenac) are the **preferred agents** for pain management in acute cholecystitis [cite: 976, 964] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "pain_management",
                    "NSAIDs"
                ]
            },
            {
                "id": 977,
                "question": "A patient with acute cholecystitis is treated medically due to high surgical risk. What is the expected **duration of antibiotic therapy**?",
                "choices": [
                    "A. 3 days.",
                    "B. 7-10 days.",
                    "C. 14 days.",
                    "D. 21 days."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The antibiotic course is recommended for **7–10 days** [cite: 959] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "antibiotic_duration"
                ]
            },
            {
                "id": 978,
                "question": "A patient with acute cholecystitis presents with a **WBC count of 14,000/mm³** but no other signs of severity or organ dysfunction. According to the Tokyo Guidelines, what is the **severity grade**?",
                "choices": [
                    "A. Grade I (Mild).",
                    "B. Grade II (Moderate).",
                    "C. Grade III (Severe).",
                    "D. Severe, due to leukocytosis."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The criterion for Grade II is WBC count >18,000/mm³; since the patient is below this threshold and has no Grade III criteria, the severity is **Grade I (Mild)**, defined as not meeting Grade II or III criteria [cite: 957, 1010] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 979,
                "question": "What is the definitive management strategy for acute cholecystitis once the patient is clinically stable?",
                "choices": [
                    "A. Long-term use of oral antibiotics.",
                    "B. Percutaneous cholecystostomy tube placement.",
                    "C. Cholecystectomy (during the same admission or electively).",
                    "D. Oral bile acid dissolution therapy."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Cholecystectomy** is the definitive management, with timing depending on surgical risk, typically done during the **same hospitalization or electively later** [cite: 960] (p. 228).",
                "tags": [
                    "acute_cholecystitis",
                    "definitive_management"
                ]
            },
            {
                "id": 980,
                "question": "A 68-year-old patient with acute cholecystitis presents with **hypotension requiring Norepinephrine** to maintain MAP >65 mmHg. Which severity grade is applicable?",
                "choices": [
                    "A. Grade I (Mild).",
                    "B. Grade II (Moderate).",
                    "C. Grade III (Severe).",
                    "D. Indeterminate."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Hypotension requiring Norepinephrine** indicates **Cardiovascular dysfunction**, which is a criterion for **Grade III (Severe)** acute cholecystitis [cite: 980] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 981,
                "question": "A patient with acute cholecystitis is started on IV antibiotics. What is the **duration of the recommended total antibiotic course** (IV and oral)?",
                "choices": [
                    "A. 5 days.",
                    "B. 7-10 days.",
                    "C. 14 days.",
                    "D. 21 days."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The total antibiotic course (IV and oral combined) is recommended for **7–10 days** [cite: 959] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "antibiotic_duration"
                ]
            },
            {
                "id": 982,
                "question": "For patients with acute cholecystitis, **when** is **emergency surgery** (cholecystectomy) indicated?",
                "choices": [
                    "A. For all patients within 24 hours of admission.",
                    "B. If the patient has a low surgical risk.",
                    "C. If the patient has worsening clinical condition or a complication.",
                    "D. Only for Grade I (Mild) cases."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Emergency surgery** is indicated for patients with a **worsening clinical condition** or a complication, such as perforation or severe sepsis [cite: 982] (p. 228).",
                "tags": [
                    "acute_cholecystitis",
                    "emergency_surgery"
                ]
            },
            {
                "id": 983,
                "question": "A patient is admitted with acute cholecystitis. The initial IV fluid replacement should utilize which type of fluid?",
                "choices": [
                    "A. D5W (5% Dextrose in Water).",
                    "B. Ringer's Lactate or Normal Saline.",
                    "C. Half-Normal Saline.",
                    "D. 3% Hypertonic Saline."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The initial management of acute cholecystitis requires supportive care, including IV fluids. **Ringer's Lactate (RL) or Normal Saline (NS)** are the standard crystalloid solutions [cite: 1010] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "fluid_management"
                ]
            },
            {
                "id": 984,
                "question": "The presence of **Gallbladder wall thickening and/or edema** on ultrasound in a patient with RUQ pain and fever is most indicative of:",
                "choices": [
                    "A. Biliary colic.",
                    "B. Chronic cholecystitis.",
                    "C. Acute cholecystitis.",
                    "D. Acute cholangitis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Gallbladder wall thickening or edema** on ultrasound, along with RUQ pain and fever/tenderness, is diagnostic of **acute cholecystitis** [cite: 984] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "diagnosis"
                ]
            },
            {
                "id": 985,
                "question": "In the management of acute cholecystitis, what is the **first-line non-pharmacologic intervention** upon admission?",
                "choices": [
                    "A. Surgical consultation.",
                    "B. Intubation and mechanical ventilation.",
                    "C. Keeping the patient NPO.",
                    "D. Urgent referral for ERCP."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "A key initial non-pharmacologic step is to **rest the bowel** by **keeping the patient NPO** (nil per os) [cite: 1018, 1007] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "initial_management"
                ]
            },
            {
                "id": 986,
                "question": "The preferred agent for pain management in acute cholecystitis is a parenteral NSAID. Which drug is the **preferred NSAID agent**?",
                "choices": [
                    "A. Intravenous Indomethacin.",
                    "B. Intravenous Diclofenac.",
                    "C. Intravenous Ibuprofen.",
                    "D. Oral Naproxen."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Parenteral NSAIDs** are the preferred agents, with **Diclofenac 50-75mg IV/IM every 12 hours** listed as the example dosage [cite: 964, 986] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "pain_management",
                    "NSAIDs"
                ]
            },
            {
                "id": 987,
                "question": "A patient with acute cholecystitis presents with a **WBC count of 22,000/mm³** but no signs of organ dysfunction. Which **severity grade** applies?",
                "choices": [
                    "A. Grade I (Mild).",
                    "B. Grade II (Moderate).",
                    "C. Grade III (Severe).",
                    "D. Indeterminate."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**WBC count >18,000/mm³** is a criterion for **Grade II (Moderate)** acute cholecystitis [cite: 970] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 988,
                "question": "What is the **first-line antibiotic regimen** for acute cholecystitis in a non-allergic, non-severe patient?",
                "choices": [
                    "A. Ampicillin/Sulbactam monotherapy.",
                    "B. Ceftriaxone PLUS Metronidazole.",
                    "C. Ciprofloxacin PLUS Clindamycin.",
                    "D. Gentamicin monotherapy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The **First line** antibiotic regimen is **Ceftriaxone 1gm IV, BID PLUS Metronidazole 500mg IV TID** [cite: 1007, 1000] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "antibiotic_treatment"
                ]
            },
            {
                "id": 989,
                "question": "A patient with acute cholecystitis and **Creatinine 1.8 mg/dl** should be cautioned regarding which potential complication of NSAID use?",
                "choices": [
                    "A. Hemorrhage.",
                    "B. Hepatic dysfunction.",
                    "C. Acute kidney injury.",
                    "D. Hypoglycemia."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "NSAIDs are contraindicated or used with caution in **impaired kidney function** due to the risk of precipitating **Acute Kidney Injury** [cite: 886] (p. 225, 227).",
                "tags": [
                    "NSAIDs",
                    "contraindications",
                    "AKI"
                ]
            },
            {
                "id": 990,
                "question": "Which of the following is a criterion for **Grade II (Moderate)** acute cholecystitis in the Tokyo Guidelines?",
                "choices": [
                    "A. Hypotension requiring vasopressors.",
                    "B. Creatinine >2.0 mg/dl.",
                    "C. Duration of complaints >72 hours.",
                    "D. Platelet count <100,000/mm³."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Duration of complaints >72 hours** is a specific criterion for **Grade II (Moderate)** acute cholecystitis [cite: 990] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 991,
                "question": "The definitive management for acute cholecystitis is surgical removal of the gallbladder. What is the name of this procedure?",
                "choices": [
                    "A. Cholecystostomy.",
                    "B. Cholecystectomy.",
                    "C. Endoscopic Retrograde Cholangiopancreatography (ERCP).",
                    "D. Pyloromyotomy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The surgical procedure for definitive management is **Cholecystectomy** (surgical removal of the gallbladder) [cite: 991] (p. 228).",
                "tags": [
                    "acute_cholecystitis",
                    "procedure"
                ]
            },
            {
                "id": 992,
                "question": "For a low-risk patient with acute cholecystitis who stabilizes quickly with medical management, the preferred timing for cholecystectomy is:",
                "choices": [
                    "A. Emergent (within 6 hours).",
                    "B. Urgent (within 24 hours).",
                    "C. During the same hospitalization.",
                    "D. Elective (after 6 weeks)."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Early cholecystectomy** during the **same hospitalization** is favored for low-risk patients who stabilize quickly [cite: 992] (p. 228).",
                "tags": [
                    "acute_cholecystitis",
                    "cholecystectomy",
                    "timing"
                ]
            },
            {
                "id": 993,
                "question": "A patient with acute cholecystitis is allergic to Cephalosporins and Penicillins (anaphylaxis). Which antibiotic is the **most appropriate initial choice**?",
                "choices": [
                    "A. Ciprofloxacin 400mg IV BID PLUS Metronidazole 500mg IV TID.",
                    "B. Vancomycin 1gm IV BID monotherapy.",
                    "C. Gentamicin 80mg IV TID monotherapy.",
                    "D. Ampicillin/Sulbactam 1.5g IV QID."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "If Ceftriaxone is contraindicated due to allergy, the **alternative** regimen is **Ciprofloxacin PLUS Metronidazole** [cite: 993] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "antibiotic_treatment"
                ]
            },
            {
                "id": 994,
                "question": "Which initial intervention is mandatory in the management of acute cholecystitis upon admission?",
                "choices": [
                    "A. Immediate administration of oral Diclofenac.",
                    "B. Insertion of a nasogastric tube.",
                    "C. Keeping the patient NPO.",
                    "D. Urgent referral for ERCP."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "A key initial non-pharmacologic step is to **rest the bowel** by **keeping the patient NPO** (nil per os) [cite: 985] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "initial_management"
                ]
            },
            {
                "id": 995,
                "question": "A patient with acute cholecystitis is treated with IV Diclofenac for pain. What is the expected **duration of action** for a single dose of this NSAID?",
                "choices": [
                    "A. <1 hour.",
                    "B. 1-2 hours.",
                    "C. 6-12 hours.",
                    "D. >24 hours."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "Diclofenac 75mg IV/IM is dosed to provide pain relief every **12 hours** [cite: 964] (p. 227).",
                "tags": [
                    "Diclofenac",
                    "duration_of_action"
                ]
            },
            {
                "id": 996,
                "question": "What is the primary mechanism by which **acute calculous cholecystitis** develops?",
                "choices": [
                    "A. Viral infection of the gallbladder.",
                    "B. Chemical irritation due to oral bile acids.",
                    "C. Obstruction of the cystic duct by a gallstone.",
                    "D. Ascending bacterial infection from the common bile duct."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "Acute calculous cholecystitis is inflammation of the gallbladder that commonly develops as a complication of gallstones, often due to **obstruction of the cystic duct** by a stone [cite: 967] (p. 226).",
                "tags": [
                    "acute_cholecystitis",
                    "pathophysiology"
                ]
            },
            {
                "id": 997,
                "question": "A 55-year-old male with acute cholecystitis presents with **Platelet count 90,000/mm³**. Which severity grade is most appropriate according to the Tokyo Guidelines?",
                "choices": [
                    "A. Grade I (Mild).",
                    "B. Grade II (Moderate).",
                    "C. Grade III (Severe).",
                    "D. Indeterminate."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Platelet count <100,000/mm³** indicates **Hematological dysfunction**, which is a criterion for **Grade III (Severe)** acute cholecystitis [cite: 965] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 998,
                "question": "The preferred analgesic agent for acute cholecystitis in patients with **impaired renal function** is:",
                "choices": [
                    "A. Parenteral NSAIDs.",
                    "B. Parenteral Opioids (e.g., Morphine).",
                    "C. Oral Diclofenac.",
                    "D. Oral Acetaminophen."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Opioids** are reserved as second-line for patients with **contraindications to NSAIDs**, such as **impaired kidney function** [cite: 998] (p. 225, 227).",
                "tags": [
                    "acute_cholecystitis",
                    "pain_management",
                    "opioids"
                ]
            },
            {
                "id": 999,
                "question": "In the setting of acute cholecystitis, when should **antibiotic therapy** be initiated?",
                "choices": [
                    "A. After a definitive culture result is available.",
                    "B. After cholecystectomy is performed.",
                    "C. As soon as the diagnosis is suspected.",
                    "D. Only for Grade III (Severe) cases."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "Antibiotic therapy should be administered **promptly (as soon as the diagnosis is suspected)** for better outcome [cite: 999] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "antibiotic_timing"
                ]
            },
            {
                "id": 1000,
                "question": "The **first-line IV antibiotic regimen** for acute cholecystitis is aimed at covering which likely pathogens?",
                "choices": [
                    "A. Pseudomonas aeruginosa and MRSA.",
                    "B. Gram-negative bacilli and anaerobes.",
                    "C. Atypical organisms (Mycoplasma, Chlamydia).",
                    "D. Clostridium difficile."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The first-line regimen (Ceftriaxone + Metronidazole) covers common aerobic **Gram-negative bacilli** (with Ceftriaxone) and **anaerobes** (with Metronidazole) [cite: 1000] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "antibiotic_coverage"
                ]
            },
            {
                "id": 1001,
                "question": "A patient with acute cholecystitis presents with **severe respiratory dysfunction** (PaO₂/FiO₂ ratio <300). This indicates a **severity grade** of:",
                "choices": [
                    "A. Grade I (Mild).",
                    "B. Grade II (Moderate).",
                    "C. Grade III (Severe).",
                    "D. Critical, but not severe."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Respiratory dysfunction** (PaO₂/FiO₂ ratio <300) is a criterion for **Grade III (Severe)** acute cholecystitis [cite: 972] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 1002,
                "question": "A patient is admitted with acute cholecystitis. In the absence of organ dysfunction or severe signs, what is the **initial severity grade**?",
                "choices": [
                    "A. Grade I (Mild).",
                    "B. Grade II (Moderate).",
                    "C. Grade III (Severe).",
                    "D. Indeterminate."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "If the patient **does not meet the criteria for Grade II or III**, the severity is **Grade I (Mild)**, which applies to healthy patients with mild inflammatory changes [cite: 957, 1010] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 1003,
                "question": "Which of the following is a key complication of acute cholecystitis that would necessitate **emergency surgery**?",
                "choices": [
                    "A. Perforation leading to peritonitis.",
                    "B. Chronic pain refractory to oral NSAIDs.",
                    "C. Persistent nausea and vomiting.",
                    "D. Incidental discovery of gallstones."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Perforation** leading to peritonitis is a severe complication that requires **emergency surgery** [cite: 1003] (p. 226, 228).",
                "tags": [
                    "acute_cholecystitis",
                    "complications",
                    "emergency_surgery"
                ]
            },
            {
                "id": 1004,
                "question": "A patient with acute cholecystitis is kept NPO. What should be done for **fluid replacement**?",
                "choices": [
                    "A. Administer only D5W to prevent sodium overload.",
                    "B. Administer IV fluids (RL or NS) to maintain hydration.",
                    "C. Administer no fluids until symptoms resolve.",
                    "D. Administer only oral rehydration solution (ORS)."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The patient is kept **NPO** and should be managed with **intravenous fluids (RL or NS)** [cite: 983, 1004] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "fluid_management"
                ]
            },
            {
                "id": 1005,
                "question": "Which of the following defines **Grade I (Mild)** acute cholecystitis according to the Tokyo Guidelines?",
                "choices": [
                    "A. Patient meets all criteria for Grade II.",
                    "B. Patient does not meet criteria for Grade II or III.",
                    "C. Patient requires vasopressors.",
                    "D. Patient has a palpable tender mass."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Grade I (Mild)** is the default category for patients who **do not meet the criteria of Grade II or III** [cite: 1005] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 1006,
                "question": "The surgical procedure for definitive management of acute cholecystitis is:",
                "choices": [
                    "A. Percutaneous drainage.",
                    "B. Cholecystectomy.",
                    "C. Endoscopic Retrograde Cholangiopancreatography (ERCP).",
                    "D. Pyloromyotomy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Cholecystectomy** (surgical removal of the gallbladder) is the definitive management [cite: 991] (p. 228).",
                "tags": [
                    "acute_cholecystitis",
                    "procedure"
                ]
            },
            {
                "id": 1007,
                "question": "A patient with acute cholecystitis should be given antibiotics targeting which organisms?",
                "choices": [
                    "A. Atypical organisms and viruses.",
                    "B. Gram-negative bacilli and anaerobes.",
                    "C. Pseudomonas and MRSA.",
                    "D. Fungi (Candida)."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The antibiotic regimen (Ceftriaxone + Metronidazole) targets common **Gram-negative bacilli** and **anaerobes** [cite: 1007, 1000] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "antibiotic_coverage"
                ]
            },
            {
                "id": 1008,
                "question": "Which of the following is a criterion for **Grade III (Severe)** acute cholecystitis?",
                "choices": [
                    "A. WBC count 17,000/mm³.",
                    "B. PT-INR 1.2.",
                    "C. PaO₂/FiO₂ ratio 250.",
                    "D. Palpable tender mass in RUQ."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**PaO₂/FiO₂ ratio <300** (Respiratory dysfunction) is a criterion for **Grade III (Severe)**. The other options are either normal or Grade II criteria [cite: 972, 970] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 1009,
                "question": "A patient presents with acute RUQ pain and a positive **Murphy's sign**. What does this physical finding specifically indicate?",
                "choices": [
                    "A. Generalized peritonitis.",
                    "B. Liver cirrhosis.",
                    "C. Localized inflammation around the gallbladder.",
                    "D. Acute pancreatitis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "A **positive Murphy's sign** indicates **localized inflammation** around the gallbladder area (RUQ tenderness during deep inspiration) and is characteristic of acute cholecystitis [cite: 956] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "diagnosis",
                    "Murphy's"
                ]
            },
            {
                "id": 1010,
                "question": "In the initial management of acute cholecystitis, what should be the immediate approach to the patient's diet and hydration status?",
                "choices": [
                    "A. Oral fluids and low-fat diet immediately.",
                    "B. Keep NPO and administer IV fluids (RL or NS).",
                    "C. Only administer IV antibiotics; fluids are secondary.",
                    "D. Encourage soft solids to maintain nutrition."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The initial management includes **resting the bowel** by **keeping the patient NPO** and administering **intravenous fluids (RL or NS)** [cite: 985, 983] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "initial_management"
                ]
            },
            {
                "id": 1011,
                "question": "Which of the following is a criterion for **Grade II (Moderate)** acute cholecystitis in the Tokyo Guidelines?",
                "choices": [
                    "A. Creatinine >2.0 mg/dl.",
                    "B. WBC count 19,000/mm³.",
                    "C. Hypotension requiring Norepinephrine.",
                    "D. Platelet count 95,000/mm³."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**WBC count >18,000/mm³** is a criterion for **Grade II (Moderate)** acute cholecystitis. The other options are Grade III criteria [cite: 987, 970] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 1012,
                "question": "What is the primary management goal for a patient with acute cholecystitis who has no organ dysfunction (Grade I or II)?",
                "choices": [
                    "A. Emergency cholecystectomy.",
                    "B. Symptomatic relief and infection control.",
                    "C. Long-term use of oral bile acids.",
                    "D. Palliative care and family support."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The management goals are primarily **symptomatic relief** (pain) and **infection control** (antibiotics/definitive surgery) [cite: 959] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "management_goals"
                ]
            },
            {
                "id": 1013,
                "question": "What is the appropriate duration for the **total antibiotic course** (IV and oral) in acute cholecystitis?",
                "choices": [
                    "A. 5 days.",
                    "B. 7-10 days.",
                    "C. 14 days.",
                    "D. 21 days."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "The total antibiotic course (IV and oral combined) is recommended for **7–10 days** [cite: 959] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "antibiotic_duration"
                ]
            },
            {
                "id": 1014,
                "question": "Which of the following is a criterion for **Grade III (Severe)** acute cholecystitis in the Tokyo Guidelines?",
                "choices": [
                    "A. Hypotension requiring vasopressors.",
                    "B. Duration of complaints >72 hours.",
                    "C. WBC count 16,000/mm³.",
                    "D. Palpable tender mass in RUQ."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Hypotension requiring vasopressors** indicates **Cardiovascular dysfunction**, a criterion for **Grade III (Severe)**. The other options are Grade II or not severe [cite: 980] (p. 227).",
                "tags": [
                    "acute_cholecystitis",
                    "severity_grading"
                ]
            },
            {
                "id": 1015,
                "question": "The definitive management for a patient with acute cholecystitis is:",
                "choices": [
                    "A. IV antibiotic therapy for 10 days.",
                    "B. Surgical removal of the gallbladder (cholecystectomy).",
                    "C. Oral fluid resuscitation and symptomatic relief.",
                    "D. Oral bile acid dissolution therapy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.10.1.2 Acute cholecystitis",
                "explanation": "**Cholecystectomy** is the definitive management once the patient is stable [cite: 991] (p. 228).",
                "tags": [
                    "acute_cholecystitis",
                    "definitive_management"
                ]
            }
        ]
    },
    "Chapter 6.10.1.1": {
        "Chapter 6.10.1.1 6.10 Cholelithiasis (Gall stones)": [
            {
                "id": 957,
                "question": "A 65-year-old diabetic male is found to have gallstones incidentally during an abdominal ultrasound for non-specific abdominal discomfort. He denies any history of biliary colic. Which **category of gallstone disease** does this patient fall under?",
                "choices": [
                    "A. Uncomplicated gallstone disease.",
                    "B. Symptomatic gallstone disease.",
                    "C. Incidental gallstones.",
                    "D. Chronic cholecystitis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.10.1.1 6.10 Cholelithiasis (Gall stones)",
                "explanation": "This patient is asymptomatic, and the gallstones were found **incidentally** on imaging. This is categorized as **incidental gallstones** (Category 1) [cite: 875] (p. 225).",
                "tags": [
                    "gallstone_disease",
                    "classification"
                ]
            }
        ]
    },
    "Chapter 6.11.1": {
        "Chapter 6.11.1 Pyogenic liver abscess": [
            {
                "id": 1016,
                "question": "A 45-year-old male diabetic patient presents with a one-week history of spiking fever, chills, and severe pain in the right upper quadrant (RUQ). An abdominal ultrasound confirms a single, well-defined liver abscess measuring 4 cm. What is the **most appropriate definitive management** strategy for this abscess in the general hospital setting?",
                "choices": [
                    "A. Start empiric IV antibiotics and monitor for resolution.",
                    "B. Perform urgent surgical drainage (laparotomy).",
                    "C. Start empiric IV antibiotics and perform ultrasound-guided needle aspiration or catheter drainage.",
                    "D. Start empiric metronidazole alone and schedule for follow-up in one month.",
                    "E. No treatment, as small pyogenic abscesses resolve spontaneously."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Pyogenic liver abscesses require both antibiotics and drainage. For a single abscess with a diameter of 5 cm or less, **ultrasound-guided percutaneous catheter drainage or needle aspiration** is an acceptable form of drainage, along with empiric IV antibiotics. Surgical drainage is generally reserved for multiple or large abscesses, or failure of percutaneous methods[cite: 1075, 1076]. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "management",
                    "drainage"
                ]
            },
            {
                "id": 1017,
                "question": "A 55-year-old male with a history of recurrent cholangitis (biliary disease) is admitted with fever and RUQ pain. Pyogenic liver abscess is suspected. **What is the recommended initial empiric antibiotic regimen** for this patient?",
                "choices": [
                    "A. Ceftriaxone 1g IV BID PLUS Metronidazole 500mg IV TID.",
                    "B. Metronidazole 750mg IV TID monotherapy.",
                    "C. Ciprofloxacin 400mg IV BID monotherapy.",
                    "D. Ampicillin 2g IV QID monotherapy.",
                    "E. Vancomycin 1g IV BID PLUS Gentamicin 5mg/kg IV QD."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Pyogenic liver abscesses are commonly **polymicrobial**, involving anaerobes and Gram-negatives. The **First line** empiric IV antibiotic regimen is **Ceftriaxone 1gm IV, BID PLUS Metronidazole 500mg IV TID**[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "antibiotic_treatment",
                    "empiric"
                ]
            },
            {
                "id": 1018,
                "question": "A patient is admitted with a newly diagnosed liver abscess of unclear etiology. You initiate the standard empiric IV antibiotic regimen. **What is the expected total duration** of antibiotic therapy (IV plus oral) for a pyogenic liver abscess?",
                "choices": [
                    "A. 7 days.",
                    "B. 14 days.",
                    "C. 4-6 weeks.",
                    "D. 3 months.",
                    "E. 6 months."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The typical **duration of antibiotic therapy** for a pyogenic liver abscess is **4–6 weeks**[cite: 1075]. The initial IV course is often followed by a switch to oral antibiotics (e.g., Amoxicillin-clavulanate or Ciprofloxacin + Metronidazole) after 2-4 weeks of clinical improvement (p. 231).",
                "tags": [
                    "pyogenic_liver_abscess",
                    "antibiotic_duration"
                ]
            },
            {
                "id": 1019,
                "question": "A 30-year-old male presents with a **subacute** onset of fever and RUQ pain over the last three weeks. Ultrasound shows a **single liver abscess measuring 8 cm** in the right lobe. Pyogenic abscess is suspected. What is the **preferred drainage method**?",
                "choices": [
                    "A. Needle aspiration only.",
                    "B. Ultrasound-guided percutaneous catheter drainage.",
                    "C. Surgical drainage (laparotomy).",
                    "D. IV antibiotics alone, due to the large size.",
                    "E. Oral antibiotics and conservative management."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "For a **single abscess with a diameter >5 cm**, **ultrasound-guided percutaneous catheter drainage** is preferred over needle aspiration alone (catheter drainage should be kept until drainage is minimal). Surgical drainage is reserved for multiple abscesses, multi-loculated abscesses, or failed catheter drainage[cite: 1075]. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "drainage_method",
                    "large_abscess"
                ]
            },
            {
                "id": 1021,
                "question": "Which microorganism is **least likely** to be a primary cause of pyogenic liver abscess in an immunocompetent patient?",
                "choices": [
                    "A. Intestinal anaerobes.",
                    "B. Candida albicans.",
                    "C. Klebsiella species.",
                    "D. Escherichia coli.",
                    "E. Streptococcus species."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Most pyogenic liver abscesses are **polymicrobial**, with **intestinal anaerobes** and **Gram-negatives** (like *E. coli* and *Klebsiella spp.*) predominating. *Candida albicans* causes fungal abscesses, which are less common than pyogenic abscesses[cite: 1074]. (p. 229)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "etiology"
                ]
            },
            {
                "id": 1022,
                "question": "A patient with a pyogenic liver abscess showing clinical improvement and minimal drainage is ready to be switched to oral antibiotics. What is the recommended **oral regimen**?",
                "choices": [
                    "A. Amoxicillin monotherapy.",
                    "B. Ciprofloxacin monotherapy.",
                    "C. Amoxicillin-clavulanate monotherapy.",
                    "D. Vancomycin oral capsules.",
                    "E. Oral Metronidazole monotherapy."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "After 2–4 weeks of IV therapy and clinical improvement, the antibiotic can be changed to an oral regimen. The empiric oral options include **Amoxicillin-clavulanate** or Ciprofloxacin + Metronidazole[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "oral_antibiotics"
                ]
            },
            {
                "id": 1023,
                "question": "Which underlying condition is a **major risk factor** for developing a pyogenic liver abscess?",
                "choices": [
                    "A. History of viral hepatitis A infection.",
                    "B. Type 2 Diabetes Mellitus.",
                    "C. Uncomplicated gallstone disease.",
                    "D. History of mild peptic ulcer disease.",
                    "E. Irritable bowel syndrome."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "**Diabetes** is listed as a major risk factor for the development of pyogenic liver abscesses. Underlying hepatobiliary disease and gastrointestinal malignancy are also major risks[cite: 1074]. (p. 229)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "risk_factors"
                ]
            },
            {
                "id": 1024,
                "question": "A 45-year-old male diabetic patient presents with a one-week history of spiking fever, chills, and severe pain in the right upper quadrant (RUQ). An abdominal ultrasound confirms a single, well-defined liver abscess measuring 4 cm. What is the **most appropriate definitive management** strategy for this abscess in the general hospital setting?",
                "choices": [
                    "A. Start empiric IV antibiotics and monitor for resolution.",
                    "B. Perform urgent surgical drainage (laparotomy).",
                    "C. Start empiric IV antibiotics and perform ultrasound-guided needle aspiration or catheter drainage.",
                    "D. Start empiric metronidazole alone and schedule for follow-up in one month.",
                    "E. No treatment, as small pyogenic abscesses resolve spontaneously."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Pyogenic liver abscesses require both antibiotics and drainage. For a single abscess with a diameter of 5 cm or less, **ultrasound-guided percutaneous catheter drainage or needle aspiration** is an acceptable form of drainage, along with empiric IV antibiotics. Surgical drainage is generally reserved for multiple or large abscesses, or failure of percutaneous methods[cite: 1075, 1076]. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "management",
                    "drainage"
                ]
            },
            {
                "id": 1025,
                "question": "A 55-year-old male with a history of recurrent cholangitis (biliary disease) is admitted with fever and RUQ pain. Pyogenic liver abscess is suspected. **What is the recommended initial empiric antibiotic regimen** for this patient?",
                "choices": [
                    "A. Ceftriaxone 1g IV BID PLUS Metronidazole 500mg IV TID.",
                    "B. Metronidazole 750mg IV TID monotherapy.",
                    "C. Ciprofloxacin 400mg IV BID monotherapy.",
                    "D. Ampicillin 2g IV QID monotherapy.",
                    "E. Vancomycin 1g IV BID PLUS Gentamicin 5mg/kg IV QD."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Pyogenic liver abscesses are commonly **polymicrobial**, involving anaerobes and Gram-negatives. The **First line** empiric IV antibiotic regimen is **Ceftriaxone 1gm IV, BID PLUS Metronidazole 500mg IV TID**[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "antibiotic_treatment",
                    "empiric"
                ]
            },
            {
                "id": 1026,
                "question": "A patient is admitted with a newly diagnosed liver abscess of unclear etiology. You initiate the standard empiric IV antibiotic regimen. **What is the expected total duration** of antibiotic therapy (IV plus oral) for a pyogenic liver abscess?",
                "choices": [
                    "A. 7 days.",
                    "B. 14 days.",
                    "C. 4-6 weeks.",
                    "D. 3 months.",
                    "E. 6 months."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The typical **duration of antibiotic therapy** for a pyogenic liver abscess is **4–6 weeks**[cite: 1075]. The initial IV course is often followed by a switch to oral antibiotics (e.g., Amoxicillin-clavulanate or Ciprofloxacin + Metronidazole) after 2-4 weeks of clinical improvement (p. 231).",
                "tags": [
                    "pyogenic_liver_abscess",
                    "antibiotic_duration"
                ]
            },
            {
                "id": 1027,
                "question": "A 30-year-old male presents with a **subacute** onset of fever and RUQ pain over the last three weeks. Ultrasound shows a **single liver abscess measuring 8 cm** in the right lobe. Pyogenic abscess is suspected. What is the **preferred drainage method**?",
                "choices": [
                    "A. Needle aspiration only.",
                    "B. Ultrasound-guided percutaneous catheter drainage.",
                    "C. Surgical drainage (laparotomy).",
                    "D. IV antibiotics alone, due to the large size.",
                    "E. Oral antibiotics and conservative management."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "For a **single abscess with a diameter >5 cm**, **ultrasound-guided percutaneous catheter drainage** is preferred over needle aspiration alone (catheter drainage should be kept until drainage is minimal). Surgical drainage is reserved for multiple abscesses, multi-loculated abscesses, or failed catheter drainage[cite: 1075]. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "drainage_method",
                    "large_abscess"
                ]
            },
            {
                "id": 1029,
                "question": "Which microorganism is **least likely** to be a primary cause of pyogenic liver abscess in an immunocompetent patient?",
                "choices": [
                    "A. Intestinal anaerobes.",
                    "B. Candida albicans.",
                    "C. Klebsiella species.",
                    "D. Escherichia coli.",
                    "E. Streptococcus species."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Most pyogenic liver abscesses are **polymicrobial**, with **intestinal anaerobes** and **Gram-negatives** (like *E. coli* and *Klebsiella spp.*) predominating. *Candida albicans* causes fungal abscesses, which are less common than pyogenic abscesses[cite: 1074]. (p. 229)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "etiology"
                ]
            },
            {
                "id": 1030,
                "question": "A patient with a pyogenic liver abscess is on a 6-week antibiotic course. Which factor would typically indicate that the antibiotic course should be **discontinued**?",
                "choices": [
                    "A. Clinical improvement after 2 weeks of IV therapy.",
                    "B. Completion of the full 6-week course.",
                    "C. Aspiration culture remains positive after 4 weeks.",
                    "D. Conversion from IV to oral route after 3 weeks.",
                    "E. WBC count drops to 12,000/mm³."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The standard duration of antibiotic therapy is **4–6 weeks**. Once the total course is completed and the patient is clinically stable, the antibiotics can be discontinued. Follow-up imaging is often done to confirm abscess resolution (p. 231).",
                "tags": [
                    "pyogenic_liver_abscess",
                    "antibiotic_duration"
                ]
            },
            {
                "id": 1039,
                "question": "Which of the following findings is **more characteristic** of a **pyogenic liver abscess** than an amebic liver abscess?",
                "choices": [
                    "A. Abscess located in the right lobe.",
                    "B. Presentation with long-standing fever and pain.",
                    "C. Abscess is often multiple.",
                    "D. Drainage fluid is typically 'anchovy paste' in appearance.",
                    "E. Concurrent finding of jaundice."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Pyogenic abscesses may be **single or multiple**, while amebic liver abscesses are **usually single**[cite: 1074, 1077]. (p. 229, 232)",
                "tags": [
                    "liver_abscess",
                    "comparison"
                ]
            },
            {
                "id": 1041,
                "question": "A patient with a confirmed 5 cm pyogenic liver abscess is treated with IV antibiotics and successful percutaneous needle aspiration. After 3 weeks of IV antibiotics, the patient is clinically well. What is the **most appropriate step** in antibiotic management?",
                "choices": [
                    "A. Discontinue antibiotics completely.",
                    "B. Switch to oral antibiotics to complete a 4-6 week total course.",
                    "C. Continue IV antibiotics for the full 6 weeks.",
                    "D. Switch to oral Tinidazole monotherapy.",
                    "E. Change to oral Vancomycin."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Patients can be switched to oral antibiotics (e.g., Amoxicillin-clavulanate or Ciprofloxacin + Metronidazole) after **2–4 weeks** of IV therapy and clinical improvement, to **complete a total course of 4–6 weeks**[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "antibiotic_duration",
                    "IV_to_oral_switch"
                ]
            },
            {
                "id": 1042,
                "question": "What is the defining characteristic of a pyogenic liver abscess compared to other infectious liver lesions?",
                "choices": [
                    "A. The abscess is single and located in the right lobe.",
                    "B. The infection is primarily Gram-negative in origin.",
                    "C. The infection is a localized suppurative infection of the liver.",
                    "D. The abscess typically presents with a clear history of preceding dysentery.",
                    "E. Concurrent jaundice is mandatory for diagnosis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Pyogenic liver abscess is defined as a **localized suppurative infection of the liver**[cite: 1074]. (p. 229)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "definition"
                ]
            },
            {
                "id": 1043,
                "question": "A patient with a pyogenic liver abscess is started on Ceftriaxone and Metronidazole. The abscess culture returns positive for a *Klebsiella pneumoniae* strain that is sensitive to Ciprofloxacin and Ceftriaxone, but resistant to Metronidazole. What is the **most appropriate adjustment** to the antibiotic regimen?",
                "choices": [
                    "A. Add Ciprofloxacin to cover the *Klebsiella*.",
                    "B. Stop Ceftriaxone and switch to Ciprofloxacin/Metronidazole.",
                    "C. Stop Metronidazole and continue Ceftriaxone monotherapy.",
                    "D. Continue the initial regimen due to the polymicrobial nature.",
                    "E. Stop all antibiotics and perform immediate drainage."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Since the culture identified *Klebsiella pneumoniae* which is sensitive to **Ceftriaxone**, and the initial regimen (Ceftriaxone + Metronidazole) was empiric, the Metronidazole can be discontinued. The Pyogenic liver abscess is often polymicrobial, but culture-directed therapy should guide the final antibiotic choice. Since anaerobes are difficult to culture, Metronidazole is often maintained even if the aerobic culture is positive. However, *Klebsiella* is covered by Ceftriaxone (a single antibiotic) which is sensitive. **Monotherapy with Ceftriaxone** is sufficient to treat the identified pathogen and continue the total course[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "culture_directed_therapy"
                ]
            },
            {
                "id": 1049,
                "question": "What is a major risk factor for developing a **pyogenic liver abscess**?",
                "choices": [
                    "A. Previous history of malaria infection.",
                    "B. Gastrointestinal malignancy.",
                    "C. Exposure to poor sanitation.",
                    "D. Chronic use of NSAIDs.",
                    "E. Living in a rural area."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "**Gastrointestinal malignancy** and underlying hepatobiliary disease are major risk factors for pyogenic liver abscesses[cite: 1074]. (p. 229)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "risk_factors"
                ]
            },
            {
                "id": 1051,
                "question": "Which clinical feature is **more suggestive** of a **pyogenic liver abscess** than an amebic liver abscess?",
                "choices": [
                    "A. Jaundice and ascites.",
                    "B. Subacute presentation over weeks.",
                    "C. History of preceding dysentery.",
                    "D. High spiking fevers and chills.",
                    "E. Solitary abscess in the right lobe."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "**High spiking fevers and chills** are more commonly associated with the acute suppurative nature of a **pyogenic abscess**. Amebic abscesses are typically subacute and may not be associated with a high fever[cite: 1074]. (p. 229, 232)",
                "tags": [
                    "liver_abscess",
                    "comparison"
                ]
            },
            {
                "id": 1053,
                "question": "What is the recommended treatment for a pyogenic liver abscess caused by a *Staphylococcus aureus* strain that is found to be sensitive to Cloxacillin and Gentamicin?",
                "choices": [
                    "A. Continue Ceftriaxone + Metronidazole empiric regimen.",
                    "B. Switch to Cloxacillin + Gentamicin.",
                    "C. Switch to Metronidazole monotherapy.",
                    "D. Discontinue all antibiotics and rely on drainage.",
                    "E. Switch to Vancomycin + Gentamicin."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Once culture and sensitivity results are available, the antibiotic therapy should be tailored. Switching to a specific, effective, and narrow-spectrum regimen like **Cloxacillin + Gentamicin** is the appropriate next step[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "culture_directed_therapy"
                ]
            },
            {
                "id": 1055,
                "question": "A 50-year-old diabetic male has a single 6 cm pyogenic liver abscess drained successfully via percutaneous catheter. He is clinically improving. **When** should the IV antibiotics be converted to an oral regimen?",
                "choices": [
                    "A. Immediately after successful drainage.",
                    "B. After 2–4 weeks of IV antibiotics and clinical improvement.",
                    "C. After 6 weeks of continuous IV antibiotics.",
                    "D. Only once the abscess is confirmed to be completely resolved on imaging.",
                    "E. Once the patient is ready for discharge home."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Patients can be switched to oral antibiotics (e.g., Amoxicillin-clavulanate or Ciprofloxacin + Metronidazole) after **2–4 weeks of IV therapy and clinical improvement**, to complete the 4–6 week total course[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "antibiotic_duration",
                    "IV_to_oral_switch"
                ]
            },
            {
                "id": 1058,
                "question": "Which treatment component is **mandatory** for all patients with a pyogenic liver abscess?",
                "choices": [
                    "A. Amoxicillin monotherapy.",
                    "B. Surgical drainage.",
                    "C. Antibiotic therapy.",
                    "D. Luminal amebicide therapy.",
                    "E. Long-term follow-up with serial imaging."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The two main components of pyogenic liver abscess management are **drainage and antibiotic therapy**. Antibiotic therapy is mandatory for all cases[cite: 1075]. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "management"
                ]
            },
            {
                "id": 1061,
                "question": "Which clinical scenario **most strongly suggests** a **pyogenic liver abscess** over an amebic liver abscess?",
                "choices": [
                    "A. A patient with HIV and multiple abscesses.",
                    "B. A patient with long-standing, low-grade fever.",
                    "C. A patient with a single 4 cm abscess in the right lobe.",
                    "D. A patient with a history of recurrent amebic dysentery.",
                    "E. A patient with severe RUQ pain and concurrent jaundice."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "While amebic abscesses are usually single, **pyogenic abscesses can be single or multiple**. The combination of **immunocompromised status** (HIV) and **multiple abscesses** is highly suspicious for a pyogenic process[cite: 1074, 1077]. (p. 229, 232)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "comparison"
                ]
            },
            {
                "id": 1062,
                "question": "A patient with suspected pyogenic liver abscess is started on empiric antibiotics. The abscess is 4 cm and readily accessible. What is the definitive management choice if the patient remains febrile and unwell after 7 days of appropriate IV antibiotics?",
                "choices": [
                    "A. Prolong IV antibiotics to 6 weeks.",
                    "B. Perform needle aspiration of the abscess.",
                    "C. Perform percutaneous catheter drainage or open surgical drainage.",
                    "D. Switch to oral Metronidazole monotherapy.",
                    "E. Add Vancomycin to the current regimen."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Surgical drainage (or catheter drainage) is indicated for **failed catheter drainage** or failure to improve with medical therapy (often defined after 7 days of treatment). Since needle aspiration alone is less effective for large or complex abscesses, a switch to more aggressive drainage is warranted[cite: 1075]. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "management_failure"
                ]
            },
            {
                "id": 1063,
                "question": "What is the typical **total duration** of antibiotic therapy for a Pyogenic Liver Abscess?",
                "choices": [
                    "A. 7 days.",
                    "B. 14 days.",
                    "C. 4–6 weeks.",
                    "D. 8–12 weeks.",
                    "E. 6 months."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The total duration of antibiotic therapy (IV plus oral) for a pyogenic liver abscess is typically **4–6 weeks**[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "antibiotic_duration"
                ]
            },
            {
                "id": 1066,
                "question": "A patient with a pyogenic liver abscess is on a 6-week course of antibiotics. What is the recommended oral regimen for the continuation phase if Amoxicillin-clavulanate is not available?",
                "choices": [
                    "A. Ciprofloxacin monotherapy.",
                    "B. Metronidazole monotherapy.",
                    "C. Ciprofloxacin PLUS Metronidazole.",
                    "D. Oral Vancomycin.",
                    "E. Diloxanide furoate."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The oral options for the continuation phase are Amoxicillin-clavulanate **OR** **Ciprofloxacin PLUS Metronidazole**[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "oral_antibiotics"
                ]
            },
            {
                "id": 1067,
                "question": "The combination of **Ceftriaxone 1g IV BID PLUS Metronidazole 500mg IV TID** is recommended as the empiric regimen for pyogenic liver abscess to cover:",
                "choices": [
                    "A. *Staphylococcus aureus* and *C. difficile*.",
                    "B. Gram-negatives and anaerobes.",
                    "C. *Entamoeba histolytica* and *Giardia lamblia*.",
                    "D. Atypical bacteria and fungi.",
                    "E. *Mycobacterium tuberculosis* and *Actinomyces*."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The regimen covers the typical polymicrobial infection, with Ceftriaxone covering Gram-negatives and Metronidazole covering **anaerobes** (and *Entamoeba histolytica*)[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "antibiotic_coverage"
                ]
            },
            {
                "id": 1068,
                "question": "Which finding is **not** consistent with the clinical picture of a pyogenic liver abscess?",
                "choices": [
                    "A. Right upper quadrant tenderness.",
                    "B. High spiking fevers and chills.",
                    "C. Insidious onset of symptoms over several weeks.",
                    "D. Elevated liver enzymes.",
                    "E. Concurrent diagnosis of Type 2 Diabetes Mellitus."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The clinical presentation of pyogenic liver abscess is characterized by fever, malaise, RUQ tenderness[cite: 1074]. However, the onset is generally acute to subacute, but not typically **insidious over several weeks** (more common in ALA or chronic infection)[cite: 1077]. (p. 229, 232)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "clinical_features"
                ]
            },
            {
                "id": 1072,
                "question": "A patient with a confirmed pyogenic liver abscess is treated with IV antibiotics. The culture of the aspirate is negative. **What is the most appropriate step** in antibiotic management after 72 hours of therapy?",
                "choices": [
                    "A. Stop all antibiotics, as the cause is likely viral.",
                    "B. Continue the initial empiric regimen (Ceftriaxone + Metronidazole).",
                    "C. Switch to Vancomycin to cover MRSA.",
                    "D. Perform immediate surgical drainage.",
                    "E. Switch to Amoxicillin monotherapy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Culture-negative pyogenic liver abscesses are common, as anaerobic organisms are difficult to culture. The **initial empiric regimen** (Ceftriaxone + Metronidazole) should **be continued** if the patient is clinically stable, as it provides adequate coverage for the likely polymicrobial flora[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "management",
                    "culture_negative"
                ]
            },
            {
                "id": 1073,
                "question": "A 40-year-old male is admitted with a single 4 cm pyogenic liver abscess. He has no organ dysfunction. Which treatment approach is **most appropriate**?",
                "choices": [
                    "A. Metronidazole monotherapy for 6 weeks.",
                    "B. IV Ceftriaxone + Metronidazole and ultrasound-guided needle aspiration.",
                    "C. IV Ceftriaxone monotherapy and surgical drainage.",
                    "D. Oral Ciprofloxacin and Metronidazole for 2 weeks.",
                    "E. Observation and symptomatic relief."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "For a single abscess $\\leq 5 cm$, treatment is **IV antibiotics** (Ceftriaxone + Metronidazole) and **needle aspiration/catheter drainage**[cite: 1075]. (p. 230, 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "management"
                ]
            },
            {
                "id": 1075,
                "question": "Which imaging finding is characteristic of a pyogenic liver abscess but **not** typically seen in an amebic liver abscess?",
                "choices": [
                    "A. Solitary lesion in the right lobe.",
                    "B. Hypoechoic mass on ultrasound.",
                    "C. Concurrent finding of splenomegaly.",
                    "D. Multi-loculated appearance.",
                    "E. Abscess size greater than 10 cm."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "While amebic abscesses are usually single and non-loculated, pyogenic abscesses can be **multi-loculated** and may require specific drainage based on this feature[cite: 1075]. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "imaging"
                ]
            },
            {
                "id": 1076,
                "question": "A patient is admitted with suspected pyogenic liver abscess. **What is the alternative empiric IV antibiotic regimen** if the first-line (Ceftriaxone + Metronidazole) is contraindicated?",
                "choices": [
                    "A. Ciprofloxacin 400mg IV BID PLUS Metronidazole 500mg IV TID.",
                    "B. Ampicillin/Sulbactam 1.5g IV QID.",
                    "C. Metronidazole monotherapy.",
                    "D. Vancomycin 1g IV BID PLUS Gentamicin 80mg IV TID.",
                    "E. Amoxicillin 1g IV TID."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The **Alternative** empiric IV regimen is **Ciprofloxacin 400mg IV BID PLUS Metronidazole 500mg IV TID**[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "alternative_antibiotics"
                ]
            },
            {
                "id": 1081,
                "question": "Which characteristic of a pyogenic liver abscess would be an **indication for surgical drainage** over percutaneous catheter drainage?",
                "choices": [
                    "A. Abscess diameter of 4 cm.",
                    "B. Abscess located in the right lobe.",
                    "C. Abscess that is multi-loculated.",
                    "D. Abscess caused by *Klebsiella pneumoniae*.",
                    "E. Abscess that is culture negative."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "**Surgical drainage** is usually preferred in cases of **multiple abscesses** or **multi-loculated abscesses** that are difficult to drain percutaneously[cite: 1075]. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "drainage_indication"
                ]
            },
            {
                "id": 1082,
                "question": "A patient is admitted with fever and RUQ pain. Pyogenic liver abscess is suspected. **What is the duration** of the recommended empiric IV antibiotic course before considering oral switch?",
                "choices": [
                    "A. 7 days.",
                    "B. 2–4 weeks.",
                    "C. 6 weeks.",
                    "D. 1 day.",
                    "E. 10 days."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The switch from IV to oral antibiotics is considered after **2–4 weeks** of IV therapy and clinical improvement, to complete the 4–6 week total course[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "IV_to_oral_switch"
                ]
            },
            {
                "id": 1083,
                "question": "Which investigation is **required** for the diagnosis of a Pyogenic Liver Abscess?",
                "choices": [
                    "A. Blood culture and sensitivity.",
                    "B. Stool microscopy.",
                    "C. Abdominal ultrasound.",
                    "D. Liver function tests.",
                    "E. Abdominal ultrasound and abscess aspirate gram stain/culture."
                ],
                "correctAnswer": 4,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Diagnosis requires **imaging** (Ultrasound/CT scan) and **image-guided aspiration** for Gram stain and culture for definitive microbial diagnosis[cite: 1075]. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "diagnosis"
                ]
            },
            {
                "id": 1087,
                "question": "A patient with a pyogenic liver abscess is treated with Ciprofloxacin + Metronidazole. The abscess is 6 cm. Which drainage option is **preferred**?",
                "choices": [
                    "A. Needle aspiration only.",
                    "B. Percutaneous catheter drainage.",
                    "C. Surgical drainage.",
                    "D. No drainage is necessary.",
                    "E. Continuous IV infusion of Ciprofloxacin."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "For a single abscess with a diameter **>5 cm**, **ultrasound-guided percutaneous catheter drainage** is preferred over needle aspiration alone[cite: 1075]. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "drainage_method"
                ]
            },
            {
                "id": 1088,
                "question": "A 45-year-old male presents with **acute onset** of high fever, chills, and RUQ pain. He has a known history of chronic cholecystitis. Which type of liver abscess is **most likely**?",
                "choices": [
                    "A. Amebic liver abscess.",
                    "B. Fungal liver abscess.",
                    "C. Pyogenic liver abscess.",
                    "D. Tuberculous liver abscess.",
                    "E. Hydatid cyst."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Pyogenic liver abscesses are characterized by **high spiking fevers and chills** and a subacute presentation. The biliary pathology (*e.g.*, recurrent cholangitis from cholecystitis) is a major risk factor for PLA[cite: 1074]. (p. 229)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "clinical_features",
                    "risk_factors"
                ]
            },
            {
                "id": 1091,
                "question": "A 30-year-old male is admitted with a single 4 cm pyogenic liver abscess. He has no organ dysfunction. Which treatment approach is **most appropriate**?",
                "choices": [
                    "A. Metronidazole monotherapy for 6 weeks.",
                    "B. IV Ceftriaxone + Metronidazole and ultrasound-guided needle aspiration.",
                    "C. IV Ceftriaxone monotherapy and surgical drainage.",
                    "D. Oral Ciprofloxacin and Metronidazole for 2 weeks.",
                    "E. Observation and symptomatic relief."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "For a single abscess $\\leq 5 cm$, treatment is **IV antibiotics** (Ceftriaxone + Metronidazole) and **needle aspiration/catheter drainage**[cite: 1075]. (p. 230, 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "management"
                ]
            },
            {
                "id": 1094,
                "question": "Which of the following conditions is a **major risk factor** for developing a pyogenic liver abscess?",
                "choices": [
                    "A. History of exposure to toxins.",
                    "B. Diabetes.",
                    "C. Chronic hepatitis B virus infection.",
                    "D. Previous history of schistosomiasis.",
                    "E. Recurrent respiratory tract infections."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "**Diabetes** is listed as a major risk factor for the development of pyogenic liver abscesses[cite: 1074]. (p. 229)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "risk_factors"
                ]
            },
            {
                "id": 1095,
                "question": "What is the standard **oral antibiotic regimen** for the continuation phase of a successfully treated pyogenic liver abscess?",
                "choices": [
                    "A. Amoxicillin monotherapy.",
                    "B. Ciprofloxacin monotherapy.",
                    "C. Amoxicillin-clavulanate or Ciprofloxacin PLUS Metronidazole.",
                    "D. Oral Vancomycin monotherapy.",
                    "E. Tinidazole monotherapy."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The recommended oral regimens include **Amoxicillin-clavulanate** or **Ciprofloxacin PLUS Metronidazole**[cite: 1075]. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "oral_antibiotics"
                ]
            },
            {
                "id": 1096,
                "question": "A patient with suspected Pyogenic Liver Abscess is on Ceftriaxone and Metronidazole. The abscess is 6 cm. After 7 days, the patient remains febrile. What is the **most appropriate drainage management** step?",
                "choices": [
                    "A. Continue antibiotics and observe for another week.",
                    "B. Switch to oral antibiotics and discharge home.",
                    "C. Perform percutaneous catheter drainage.",
                    "D. Perform surgical drainage.",
                    "E. Add Tinidazole to the current regimen."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Failure to improve after a period of appropriate IV antibiotics warrants reassessment and, typically, **drainage**. For an abscess $>5 cm$, **percutaneous catheter drainage** is the preferred drainage method[cite: 1075]. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "management_failure",
                    "drainage"
                ]
            },
            {
                "id": 1102,
                "question": "Which of the following is a key indication for performing **percutaneous drainage** of a Pyogenic Liver Abscess?",
                "choices": [
                    "A. Abscess diameter less than 5 cm.",
                    "B. Multiple abscesses.",
                    "C. Abscess located in the left lobe.",
                    "D. Patient is immunocompromised.",
                    "E. High spiking fever."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "**Multiple abscesses** is an indication for **surgical drainage** rather than percutaneous catheter drainage[cite: 1075]. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "drainage_indication"
                ]
            },
            {
                "id": 1103,
                "question": "Which of the following is a key indication for performing **percutaneous drainage** of a Pyogenic Liver Abscess?",
                "choices": [
                    "A. Abscess diameter less than 5 cm.",
                    "B. Multiple abscesses.",
                    "C. Abscess located in the left lobe.",
                    "D. Patient is immunocompromised.",
                    "E. High spiking fever."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "**Multiple abscesses** is an indication for **surgical drainage** rather than percutaneous catheter drainage[cite: 1075]. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "drainage_indication"
                ]
            },
            {
                "id": 1115,
                "question": "What is the defining characteristic of a pyogenic liver abscess compared to an amebic liver abscess?",
                "choices": [
                    "A. The infection is primarily Gram-negative in origin.",
                    "B. The abscess is typically single and located in the right lobe.",
                    "C. The infection is a localized suppurative infection of the liver.",
                    "D. The abscess typically presents with a clear history of preceding dysentery.",
                    "E. The drainage fluid is brown and thick."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Pyogenic liver abscess is defined as a **localized suppurative infection of the liver**. Amebic abscesses are also localized but are not primarily 'suppurative' in the sense of typical pus, and the fluid is different. (p. 229)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "definition"
                ]
            },
            {
                "id": 1116,
                "question": "Which characteristic of a pyogenic liver abscess would be an **indication for surgical drainage** over percutaneous catheter drainage?",
                "choices": [
                    "A. Abscess diameter less than 5 cm.",
                    "B. Abscess located in the right lobe.",
                    "C. Abscess that is multi-loculated.",
                    "D. Abscess caused by *Klebsiella pneumoniae*.",
                    "E. Abscess that is culture negative."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "**Surgical drainage** is usually preferred in cases of **multiple abscesses** or **multi-loculated abscesses** that are difficult to drain percutaneously (p. 230).",
                "tags": [
                    "pyogenic_liver_abscess",
                    "drainage_indication"
                ]
            },
            {
                "id": 1117,
                "question": "A patient with a confirmed pyogenic liver abscess is treated with IV antibiotics. The culture of the aspirate is negative. **What is the most appropriate step** in antibiotic management after 72 hours of therapy?",
                "choices": [
                    "A. Stop all antibiotics, as the cause is likely viral.",
                    "B. Continue the initial empiric regimen (Ceftriaxone + Metronidazole).",
                    "C. Switch to Vancomycin to cover MRSA.",
                    "D. Perform immediate surgical drainage.",
                    "E. Switch to Amoxicillin monotherapy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Culture-negative pyogenic liver abscesses are common, as anaerobic organisms are difficult to culture. The **initial empiric regimen** (Ceftriaxone + Metronidazole) should **be continued** if the patient is clinically stable, as it provides adequate coverage for the likely polymicrobial flora (p. 231).",
                "tags": [
                    "pyogenic_liver_abscess",
                    "management",
                    "culture_negative"
                ]
            },
            {
                "id": 1118,
                "question": "A patient with a pyogenic liver abscess is started on Ceftriaxone and Metronidazole. The abscess culture returns positive for a *Klebsiella pneumoniae* strain that is sensitive to Ciprofloxacin and Ceftriaxone, but resistant to Metronidazole. What is the **most appropriate adjustment** to the antibiotic regimen?",
                "choices": [
                    "A. Add Ciprofloxacin to cover the *Klebsiella*.",
                    "B. Stop Ceftriaxone and switch to Ciprofloxacin/Metronidazole.",
                    "C. Stop Metronidazole and continue Ceftriaxone monotherapy.",
                    "D. Continue the initial regimen due to the polymicrobial nature.",
                    "E. Stop all antibiotics and perform immediate drainage."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Since the culture identified *Klebsiella pneumoniae* which is sensitive to **Ceftriaxone**, the Metronidazole can be discontinued, and the single agent Ceftriaxone continued. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "culture_directed_therapy"
                ]
            },
            {
                "id": 1122,
                "question": "A patient with a pyogenic liver abscess is on a 6-week antibiotic course. Which factor would typically indicate that the antibiotic course should be **discontinued**?",
                "choices": [
                    "A. Clinical improvement after 2 weeks of IV therapy.",
                    "B. Completion of the full 6-week course.",
                    "C. Aspiration culture remains positive after 4 weeks.",
                    "D. Conversion from IV to oral route after 3 weeks.",
                    "E. WBC count drops to 12,000/mm³."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The standard duration of antibiotic therapy is **4–6 weeks**. Once the total course is completed and the patient is clinically stable, the antibiotics can be discontinued. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "antibiotic_duration"
                ]
            },
            {
                "id": 1124,
                "question": "A patient with a confirmed 5 cm pyogenic liver abscess is treated with IV antibiotics and successful percutaneous needle aspiration. After 3 weeks of IV antibiotics, the patient is clinically well. What is the **most appropriate step** in antibiotic management?",
                "choices": [
                    "A. Discontinue antibiotics completely.",
                    "B. Switch to oral antibiotics to complete a 4-6 week total course.",
                    "C. Continue IV antibiotics for the full 6 weeks.",
                    "D. Switch to oral Tinidazole monotherapy.",
                    "E. Change to oral Vancomycin."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Patients can be switched to oral antibiotics (e.g., Amoxicillin-clavulanate or Ciprofloxacin + Metronidazole) after **2–4 weeks** of IV therapy and clinical improvement, to **complete a total course of 4–6 weeks**. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "antibiotic_duration",
                    "IV_to_oral_switch"
                ]
            },
            {
                "id": 1125,
                "question": "What is the defining characteristic of a pyogenic liver abscess compared to other infectious liver lesions?",
                "choices": [
                    "A. The abscess is single and located in the right lobe.",
                    "B. The infection is primarily Gram-negative in origin.",
                    "C. The infection is a localized suppurative infection of the liver.",
                    "D. The abscess typically presents with a clear history of preceding dysentery.",
                    "E. Concurrent jaundice is mandatory for diagnosis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Pyogenic liver abscess is defined as a **localized suppurative infection of the liver**. (p. 229)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "definition"
                ]
            },
            {
                "id": 1126,
                "question": "Which type of liver abscess is **more likely** to be **multiple** and necessitate surgical drainage?",
                "choices": [
                    "A. Amebic liver abscess (ALA).",
                    "B. Pyogenic liver abscess (PLA).",
                    "C. Hydatid cyst.",
                    "D. Fungal abscess.",
                    "E. Tuberculous abscess."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Pyogenic liver abscesses are often **multiple** and, if multi-loculated, often require **surgical drainage**. Amebic abscesses are usually solitary. (p. 229, 230, 232)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "comparison"
                ]
            },
            {
                "id": 1129,
                "question": "A patient with suspected Pyogenic Liver Abscess is on Ceftriaxone and Metronidazole. The abscess is 6 cm. After 7 days, the patient remains febrile. What is the **most appropriate drainage management** step?",
                "choices": [
                    "A. Continue antibiotics and observe for another week.",
                    "B. Switch to oral antibiotics and discharge home.",
                    "C. Perform percutaneous catheter drainage.",
                    "D. Perform surgical drainage.",
                    "E. Add Tinidazole to the current regimen."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Failure to improve after a period of appropriate IV antibiotics warrants drainage. For an abscess $>5 cm$, **percutaneous catheter drainage** is the preferred drainage method. (p. 230)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "management_failure",
                    "drainage"
                ]
            },
            {
                "id": 1131,
                "question": "What is the defining characteristic of a pyogenic liver abscess?",
                "choices": [
                    "A. The abscess is typically single and located in the right lobe.",
                    "B. The infection is a localized suppurative infection of the liver.",
                    "C. The infection is primarily Gram-negative in origin.",
                    "D. The drainage fluid is brown and thick.",
                    "E. The patient has a clear history of preceding dysentery."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Pyogenic liver abscess is defined as a **localized suppurative infection of the liver**. (p. 229)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "definition"
                ]
            },
            {
                "id": 1134,
                "question": "A patient with confirmed pyogenic liver abscess is treated with IV antibiotics. The culture of the aspirate is negative. **What is the most appropriate step** in antibiotic management after 72 hours of therapy?",
                "choices": [
                    "A. Stop all antibiotics, as the cause is likely viral.",
                    "B. Continue the initial empiric regimen (Ceftriaxone + Metronidazole).",
                    "C. Switch to Vancomycin to cover MRSA.",
                    "D. Perform immediate surgical drainage.",
                    "E. Switch to Amoxicillin monotherapy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "Culture-negative pyogenic liver abscesses are common, as anaerobic organisms are difficult to culture. The **initial empiric regimen** (Ceftriaxone + Metronidazole) should **be continued** if the patient is clinically stable, as it provides adequate coverage for the likely polymicrobial flora (p. 231).",
                "tags": [
                    "pyogenic_liver_abscess",
                    "management",
                    "culture_negative"
                ]
            },
            {
                "id": 1136,
                "question": "A patient is admitted with suspected pyogenic liver abscess. **What is the alternative empiric IV antibiotic regimen** if the first-line (Ceftriaxone + Metronidazole) is contraindicated?",
                "choices": [
                    "A. Ciprofloxacin 400mg IV BID PLUS Metronidazole 500mg IV TID.",
                    "B. Ampicillin/Sulbactam 1.5g IV QID.",
                    "C. Metronidazole monotherapy.",
                    "D. Vancomycin 1g IV BID PLUS Gentamicin 80mg IV TID.",
                    "E. Amoxicillin 1g IV TID."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The **Alternative** empiric IV regimen is **Ciprofloxacin 400mg IV BID PLUS Metronidazole 500mg IV TID**. (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "alternative_antibiotics"
                ]
            },
            {
                "id": 1138,
                "question": "The combination of **Ceftriaxone 1g IV BID PLUS Metronidazole 500mg IV TID** is recommended as the empiric regimen for pyogenic liver abscess to cover:",
                "choices": [
                    "A. *Staphylococcus aureus* and *C. difficile*.",
                    "B. Gram-negatives and anaerobes.",
                    "C. *Entamoeba histolytica* and *Giardia lamblia*.",
                    "D. Atypical bacteria and fungi.",
                    "E. *Mycobacterium tuberculosis* and *Actinomyces*."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "The regimen covers the typical polymicrobial infection, with Ceftriaxone covering Gram-negatives and Metronidazole covering **anaerobes** (and *Entamoeba histolytica*). (p. 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "antibiotic_coverage"
                ]
            },
            {
                "id": 1139,
                "question": "A patient is admitted with a single 4 cm pyogenic liver abscess. He has no organ dysfunction. Which treatment approach is **most appropriate**?",
                "choices": [
                    "A. Metronidazole monotherapy for 6 weeks.",
                    "B. IV Ceftriaxone + Metronidazole and ultrasound-guided needle aspiration.",
                    "C. IV Ceftriaxone monotherapy and surgical drainage.",
                    "D. Oral Ciprofloxacin and Metronidazole for 2 weeks.",
                    "E. Observation and symptomatic relief."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess",
                "explanation": "For a single abscess $\\leq 5 cm$, treatment is **IV antibiotics** (Ceftriaxone + Metronidazole) and **needle aspiration/catheter drainage**. (p. 230, 231)",
                "tags": [
                    "pyogenic_liver_abscess",
                    "management"
                ]
            }
        ],
        "Chapter 6.11.1 Pyogenic liver abscess; 6.11.2 Amebic liver abscesses": [
            {
                "id": 1044,
                "question": "What is a **key difference** between **Pyogenic Liver Abscess (PLA)** and **Amebic Liver Abscess (ALA)** regarding the primary treatment approach?",
                "choices": [
                    "A. PLA is treated with Metronidazole; ALA is treated with Ceftriaxone.",
                    "B. PLA requires mandatory drainage; ALA is primarily treated with medical therapy.",
                    "C. PLA typically requires a luminal agent; ALA does not.",
                    "D. PLA drainage fluid is typically 'anchovy paste'; ALA fluid is purulent.",
                    "E. ALA requires longer antibiotic duration (6 weeks) than PLA (2 weeks)."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess; 6.11.2 Amebic liver abscesses",
                "explanation": "A key difference is the role of drainage: PLA requires **drainage and antibiotics**, while ALA is primarily treated with **antimicrobial therapy** (*e.g.*, Metronidazole), and drainage is usually reserved only for complications or failure of medical therapy[cite: 1075, 1078]. (p. 230, 232)",
                "tags": [
                    "liver_abscess",
                    "comparison",
                    "treatment"
                ]
            },
            {
                "id": 1048,
                "question": "A patient is admitted with a liver abscess of unknown etiology. Given the high prevalence of both amebic and pyogenic causes, the **first-line empiric treatment** should include:",
                "choices": [
                    "A. Metronidazole alone (as it covers both potential causes).",
                    "B. Ciprofloxacin and Metronidazole.",
                    "C. Ceftriaxone and Metronidazole.",
                    "D. Drainage of the abscess, then culture-directed therapy.",
                    "E. Vancomycin and Ceftriaxone."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess; 6.11.2 Amebic liver abscesses",
                "explanation": "Empiric treatment for pyogenic abscess (the most dangerous entity) is **Ceftriaxone and Metronidazole**[cite: 1075]. Metronidazole also serves as the definitive treatment for the amebic cause[cite: 1077]. Therefore, a combination covering both aerobic bacteria and *Entamoeba* (Metronidazole) is the safest empiric option. (p. 231, 232)",
                "tags": [
                    "liver_abscess",
                    "empiric_treatment"
                ]
            },
            {
                "id": 1054,
                "question": "A patient presents with fever, RUQ pain, and a liver abscess. The initial treatment includes Metronidazole 750mg IV TID. This choice of drug primarily covers the possibility of:",
                "choices": [
                    "A. Gram-negative enteric bacteria.",
                    "B. *Entamoeba histolytica* and anaerobes.",
                    "C. *Klebsiella pneumoniae*.",
                    "D. *Staphylococcus aureus*.",
                    "E. Fungal infection."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess; 6.11.2 Amebic liver abscesses",
                "explanation": "**Metronidazole** is the definitive treatment for *Entamoeba histolytica* (amebic abscess) and provides excellent coverage for **anaerobes** (part of the pyogenic flora)[cite: 1075, 1077]. (p. 231, 232)",
                "tags": [
                    "liver_abscess",
                    "metronidazole",
                    "coverage"
                ]
            },
            {
                "id": 1060,
                "question": "What is the key initial diagnostic imaging step for a patient presenting with fever and right upper quadrant pain to confirm a liver abscess?",
                "choices": [
                    "A. CT scan of the abdomen.",
                    "B. Plain X-ray of the abdomen.",
                    "C. Abdominal ultrasound.",
                    "D. Liver biopsy.",
                    "E. Endoscopic ultrasound."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess; 6.11.2 Amebic liver abscesses",
                "explanation": "Confirmation of a liver abscess requires imaging studies, with **abdominal ultrasound** commonly used due to its availability[cite: 1075, 1077]. (p. 230, 232)",
                "tags": [
                    "liver_abscess",
                    "diagnosis",
                    "imaging"
                ]
            },
            {
                "id": 1069,
                "question": "A patient is admitted with fever and RUQ pain. Ultrasound shows a single liver abscess. Which investigation is crucial for determining the need for a luminal amebicide?",
                "choices": [
                    "A. Full Blood Count.",
                    "B. Liver function tests.",
                    "C. Culture of abscess aspirate.",
                    "D. Histologic examination of the liver tissue.",
                    "E. HIV screening."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess; 6.11.2 Amebic liver abscesses",
                "explanation": "A luminal amebicide is only required if the abscess is confirmed to be **amebic** (or if the initial empiric treatment was only a tissue agent). Culture of the abscess aspirate (or serology/PCR, if available) helps distinguish the cause, although for ALA, drainage is not routine. Empiric therapy should be started while waiting for results[cite: 1075, 1077]. (p. 230, 232)",
                "tags": [
                    "liver_abscess",
                    "diagnosis",
                    "luminal_amebicide"
                ]
            },
            {
                "id": 1093,
                "question": "A patient is admitted with a liver abscess of unknown etiology. The immediate **empiric IV antibiotic regimen** should be:",
                "choices": [
                    "A. Metronidazole alone.",
                    "B. Ceftriaxone alone.",
                    "C. Ceftriaxone PLUS Metronidazole.",
                    "D. Ciprofloxacin alone.",
                    "E. Vancomycin alone."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess; 6.11.2 Amebic liver abscesses",
                "explanation": "The empiric regimen for pyogenic abscess (which also covers amebic abscess) is **Ceftriaxone 1gm IV, BID PLUS Metronidazole 500mg IV TID**[cite: 1075]. (p. 231)",
                "tags": [
                    "liver_abscess",
                    "empiric_treatment"
                ]
            },
            {
                "id": 1101,
                "question": "A patient has a liver abscess of unknown etiology. Which initial imaging study is used to confirm the presence of the mass?",
                "choices": [
                    "A. Plain X-ray of the abdomen.",
                    "B. Abdominal ultrasound.",
                    "C. MRI of the abdomen.",
                    "D. Endoscopic Retrograde Cholangiopancreatography (ERCP).",
                    "E. Endoscopic ultrasound."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess; 6.11.2 Amebic liver abscesses",
                "explanation": "Confirmation of a liver abscess requires imaging studies, with **abdominal ultrasound** commonly used due to its availability[cite: 1075, 1077]. (p. 230, 232)",
                "tags": [
                    "liver_abscess",
                    "diagnosis",
                    "imaging"
                ]
            },
            {
                "id": 1114,
                "question": "A patient is admitted with a liver abscess of unknown etiology. Given the high prevalence of both amebic and pyogenic causes, the **first-line empiric treatment** should include:",
                "choices": [
                    "A. Metronidazole alone.",
                    "B. Ceftriaxone alone.",
                    "C. Ceftriaxone PLUS Metronidazole.",
                    "D. Drainage of the abscess, then culture-directed therapy.",
                    "E. Vancomycin and Ceftriaxone."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess; 6.11.2 Amebic liver abscesses",
                "explanation": "Empiric treatment for pyogenic abscess (which also covers amebic abscess) is **Ceftriaxone and Metronidazole**. Metronidazole also serves as the definitive treatment for the amebic cause. Therefore, a combination covering both aerobic bacteria and *Entamoeba* (Metronidazole) is the safest empiric option. (p. 231, 232)",
                "tags": [
                    "liver_abscess",
                    "empiric_treatment"
                ]
            },
            {
                "id": 1123,
                "question": "A patient presents with fever, RUQ pain, and a liver abscess. The initial treatment includes Metronidazole 750mg IV TID. This choice of drug primarily covers the possibility of:",
                "choices": [
                    "A. Gram-negative enteric bacteria.",
                    "B. *Entamoeba histolytica* and anaerobes.",
                    "C. *Klebsiella pneumoniae*.",
                    "D. *Staphylococcus aureus*.",
                    "E. Fungal infection."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess; 6.11.2 Amebic liver abscesses",
                "explanation": "**Metronidazole** is the definitive treatment for *Entamoeba histolytica* (amebic abscess) and provides excellent coverage for **anaerobes** (part of the pyogenic flora). (p. 231, 232)",
                "tags": [
                    "liver_abscess",
                    "metronidazole",
                    "coverage"
                ]
            },
            {
                "id": 1127,
                "question": "Which investigation is crucial for determining the need for a luminal amebicide in a patient with a liver abscess?",
                "choices": [
                    "A. Full Blood Count.",
                    "B. Liver function tests.",
                    "C. Culture of abscess aspirate.",
                    "D. Stool microscopy for trophozoites.",
                    "E. HIV screening."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.1 Pyogenic liver abscess; 6.11.2 Amebic liver abscesses",
                "explanation": "A luminal amebicide is added if the abscess is **amebic**. The cause is best determined by **culture of the abscess aspirate** (for pyogenic) or serology (for amebic). If the diagnosis is pyogenic, no luminal agent is needed. If it is amebic, the luminal agent is mandatory. (p. 230, 232)",
                "tags": [
                    "liver_abscess",
                    "diagnosis",
                    "luminal_amebicide"
                ]
            }
        ]
    },
    "Chapter 6.11.2": {
        "Chapter 6.11.2 Amebic liver abscesses": [
            {
                "id": 1031,
                "question": "Which statement regarding **Amebic Liver Abscess (ALA)** is true?",
                "choices": [
                    "A. The abscess fluid is typically purulent and foul-smelling.",
                    "B. Amebic liver abscess is usually multiple and located in the left lobe.",
                    "C. Drainage is not routinely recommended and is reserved for specific indications.",
                    "D. The diagnosis is confirmed by positive stool microscopy for trophozoites in over 90% of cases.",
                    "E. The primary initial treatment is drainage followed by oral antibiotics."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Drainage of an amebic liver abscess is **not routinely recommended** and is reserved for specific indications like impending rupture or failed medical therapy[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "management"
                ]
            },
            {
                "id": 1032,
                "question": "A 35-year-old man from an endemic area presents with fever and RUQ tenderness. Amebic liver abscess is suspected. **What is the recommended first-line treatment**?",
                "choices": [
                    "A. Surgical drainage and Ceftriaxone IV for 14 days.",
                    "B. Metronidazole 750 mg IV/PO every 8 hours for 7-10 days, followed by a luminal agent.",
                    "C. Paromomycin 30 mg/kg/day PO for 7 days, followed by Metronidazole.",
                    "D. Needle aspiration and Ciprofloxacin IV.",
                    "E. Metronidazole monotherapy for 6 weeks."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The primary treatment for ALA is antimicrobial therapy. The **First line** is **Metronidazole 500-750 mg IV/PO every 8 hours for 7-10 days**, followed by a **luminal agent** (*e.g.*, Diloxanide furoate or Paromomycin) to eradicate intraluminal cysts[cite: 1077, 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "treatment",
                    "metronidazole"
                ]
            },
            {
                "id": 1033,
                "question": "A patient has completed a 10-day course of Metronidazole for an amebic liver abscess and shows clinical improvement. What is the **necessary next step** in management to prevent recurrence and transmission?",
                "choices": [
                    "A. Perform follow-up abdominal CT scan.",
                    "B. Start a luminal amebicide (e.g., Diloxanide furoate).",
                    "C. Repeat Metronidazole for another 7 days.",
                    "D. Discharge with no further treatment.",
                    "E. Counsel on avoiding meat products."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The tissue agent (*e.g.*, Metronidazole) must be followed by a **luminal agent** (*e.g.*, **Diloxanide furoate** or Paromomycin) to eliminate intraluminal cysts and prevent relapse and transmission[cite: 1077, 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "luminal_agent",
                    "prevention"
                ]
            },
            {
                "id": 1034,
                "question": "What is the **classic clinical presentation** of an amebic liver abscess?",
                "choices": [
                    "A. Acute onset of severe right upper quadrant pain and high spiking fever.",
                    "B. Subacute or long-standing RUQ pain and fever.",
                    "C. Painless jaundice and ascites.",
                    "D. Acute onset of diarrhea preceding fever by 24 hours.",
                    "E. Painless, bilateral, multiple small abscesses."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Amebic liver abscess typically presents with **subacute or long-standing RUQ pain and fever**. High spiking fever is more common in pyogenic abscess, and diarrhea is present in less than one-third of ALA cases[cite: 1077]. (p. 231-232)",
                "tags": [
                    "amebic_liver_abscess",
                    "clinical_features"
                ]
            },
            {
                "id": 1035,
                "question": "A patient with suspected amebic liver abscess has profuse bloody diarrhea. What is the expected prevalence of concurrent diarrhea in patients presenting with Amebic Liver Abscess?",
                "choices": [
                    "A. Nearly 90% of cases.",
                    "B. Approximately 50% of cases.",
                    "C. Less than one-third of cases.",
                    "D. Diarrhea never occurs concurrently with ALA.",
                    "E. Only occurs in immunocompromised hosts."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Diarrhea is **not common** in patients presenting with amebic liver abscess, occurring in **less than one-third** of cases[cite: 1077]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "diarrhea"
                ]
            },
            {
                "id": 1036,
                "question": "What is the **most common complication** of an amebic liver abscess?",
                "choices": [
                    "A. Rupture of the abscess.",
                    "B. Abscess transformation to hepatocellular carcinoma.",
                    "C. Biliary obstruction leading to cholangitis.",
                    "D. Sepsis and septic shock.",
                    "E. Hepatic encephalopathy."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The **most common complication** of amebic liver abscess is **rupture** into the peritoneum, pleural space, pericardial space, or sub-phrenic space[cite: 1077]. (p. 231)",
                "tags": [
                    "amebic_liver_abscess",
                    "complications"
                ]
            },
            {
                "id": 1037,
                "question": "A 40-year-old male with a large, solitary liver abscess (>10 cm) is started on Metronidazole but shows no clinical improvement after 5 days. What is the **most appropriate next step**?",
                "choices": [
                    "A. Increase Metronidazole dose and add a second antibiotic (e.g., Ceftriaxone).",
                    "B. Perform percutaneous ultrasound-guided drainage of the abscess.",
                    "C. Switch to a luminal agent (e.g., Diloxanide furoate).",
                    "D. Discontinue all treatment and observe.",
                    "E. Perform open surgical drainage immediately."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Percutaneous ultrasound-guided drainage may be considered in patients with **large amebic liver abscesses (>10 cm)**, impending rupture, or in those with **failed medical therapy**[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "management_failure",
                    "drainage"
                ]
            },
            {
                "id": 1038,
                "question": "Which antibiotic must be administered **after** the tissue agent (Metronidazole) in the treatment of amebic liver abscess (ALA)?",
                "choices": [
                    "A. Ciprofloxacin.",
                    "B. Diloxanide furoate.",
                    "C. Ceftriaxone.",
                    "D. Tinidazole.",
                    "E. Amoxicillin-clavulanate."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The tissue agent (Metronidazole) must be followed by a **luminal agent** (*e.g.*, **Diloxanide furoate** or Paromomycin) to eliminate intraluminal cysts[cite: 1077, 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "luminal_agent"
                ]
            },
            {
                "id": 1040,
                "question": "A patient suspected of having an amebic liver abscess (ALA) has Profuse RUQ pain and fever. Which immediate intervention is **not routinely recommended** in the initial management of ALA?",
                "choices": [
                    "A. Starting Metronidazole IV/PO.",
                    "B. Assessing for liver failure.",
                    "C. Immediate percutaneous drainage.",
                    "D. Assessing for signs of rupture.",
                    "E. Administering analgesics and antipyretics."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Immediate **percutaneous drainage is not routinely recommended** for amebic liver abscess and is reserved for specific indications like large size, imminent rupture, or failed medical therapy[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "management"
                ]
            },
            {
                "id": 1045,
                "question": "A patient with Amebic Liver Abscess is treated with Metronidazole. The main purpose of adding **Diloxanide furoate** after Metronidazole is to:",
                "choices": [
                    "A. Enhance the activity of the tissue agent (Metronidazole).",
                    "B. Prevent the abscess from rupturing.",
                    "C. Treat the parasite in the intestinal lumen to prevent relapse and transmission.",
                    "D. Cover potential secondary bacterial infection of the abscess.",
                    "E. Treat concurrent cholangitis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Diloxanide furoate is a **luminal agent** used to eradicate intraluminal cysts of *Entamoeba histolytica* in the colon, which is **necessary after the tissue agent** to prevent relapse and transmission[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "luminal_agent",
                    "purpose"
                ]
            },
            {
                "id": 1046,
                "question": "A 40-year-old male presents with fever and RUQ pain. He denies any history of dysentery. An ultrasound shows a single 7 cm abscess in the right lobe of the liver. Which clinical sign is **least likely** to be present in this patient if the cause is Amebic Liver Abscess?",
                "choices": [
                    "A. Fever.<br>B. Jaundice.<br>C. Right upper quadrant tenderness.<br>D. Hepatomegaly.",
                    "E. Anorexia."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "**Jaundice** is **rarely seen** in amebic liver abscess, occurring in less than 10% of cases. Fever, pain, and hepatomegaly are common[cite: 1077]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "clinical_features"
                ]
            },
            {
                "id": 1047,
                "question": "Which microorganism is the **causative agent** of Amebic Liver Abscess?",
                "choices": [
                    "A. Entamoeba dispar.",
                    "B. Entamoeba coli.",
                    "C. Entamoeba hartmanni.",
                    "D. Entamoeba histolytica.",
                    "E. Giardia lamblia."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Amebic liver abscess is a complication of infection by the protozoa **Entamoeba histolytica**. *E. dispar* is generally considered nonpathogenic[cite: 1077]. (p. 231)",
                "tags": [
                    "amebic_liver_abscess",
                    "etiology"
                ]
            },
            {
                "id": 1050,
                "question": "A 28-year-old patient from an endemic area presents with a single 6 cm liver abscess in the right lobe. He denies prior bloody diarrhea. What is the **most likely fluid appearance** if the abscess were aspirated for diagnostic purposes and confirmed to be amebic?",
                "choices": [
                    "A. Thick, foul-smelling pus.",
                    "B. Clear, straw-colored fluid.",
                    "C. Yellow-green purulent fluid.",
                    "D. Brown, thick fluid.",
                    "E. White, curd-like substance."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "If an amebic liver abscess is aspirated, the fluid typically appears as a **brown, thick fluid** (often described as 'anchovy paste'). Purulent fluid (yellow/green) is characteristic of pyogenic abscess[cite: 1077]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "abscess_fluid"
                ]
            },
            {
                "id": 1052,
                "question": "A patient who has completed treatment for an Amebic Liver Abscess is now receiving Diloxanide furoate. Diloxanide furoate is classified as a:",
                "choices": [
                    "A. Tissue amebicide.",
                    "B. Luminal amebicide.",
                    "C. Fungal agent.",
                    "D. Broad-spectrum antibiotic.",
                    "E. Anti-inflammatory agent."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "**Diloxanide furoate** is a **luminal agent** used to eliminate intraluminal cysts and prevent relapse/transmission[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "drug_class"
                ]
            },
            {
                "id": 1056,
                "question": "What is the recommended **total duration** of antimicrobial therapy for a patient successfully treated for an amebic liver abscess (tissue agent followed by luminal agent)?",
                "choices": [
                    "A. 10 days.",
                    "B. 17 days.",
                    "C. 4-6 weeks.",
                    "D. 7-10 days for tissue agent + 10 days for luminal agent.",
                    "E. 6 months."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The tissue agent (Metronidazole/Tinidazole) is given for **7–10 days** (or 3-5 days for Tinidazole), and the luminal agent (*e.g.*, Diloxanide furoate or Paromomycin) is given for **7–10 days**. The total course is approximately 2–3 weeks of continuous therapy[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "antibiotic_duration"
                ]
            },
            {
                "id": 1057,
                "question": "A patient with a confirmed 12 cm amebic liver abscess is managed medically. What is the **most likely complication** necessitating urgent drainage?",
                "choices": [
                    "A. Chronic constipation.",
                    "B. Jaundice and pale stool.",
                    "C. Abscess rupture into the peritoneum.",
                    "D. Elevated serum alkaline phosphatase.",
                    "E. Failure to gain weight."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Urgent drainage of an ALA is considered for **large abscesses** (>10 cm) or if there is **imminent rupture** or failure of medical therapy. Rupture is the most common complication[cite: 1077, 1078]. (p. 231, 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "complications",
                    "drainage_indication"
                ]
            },
            {
                "id": 1059,
                "question": "A 35-year-old male is treated for ALA with Metronidazole. What should be added to the regimen to prevent the relapse of infection from the gastrointestinal tract reservoir?",
                "choices": [
                    "A. Ciprofloxacin for 7 days.",
                    "B. Diloxanide furoate for 10 days.",
                    "C. IV Ceftriaxone for 7 days.",
                    "D. Amoxicillin for 5 days.",
                    "E. Oral Doxycycline for 14 days."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "A tissue agent (Metronidazole) must be followed by a **luminal agent** (*e.g.*, **Diloxanide furoate** or Paromomycin) to eliminate intraluminal cysts and prevent relapse/transmission[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "luminal_agent"
                ]
            },
            {
                "id": 1064,
                "question": "A patient is treated for Amebic Liver Abscess (ALA). After a 10-day course of Metronidazole, the patient is clinically stable. Which agent is recommended as the **luminal amebicide**?",
                "choices": [
                    "A. Ciprofloxacin.",
                    "B. Tinidazole.",
                    "C. Diloxanide furoate.",
                    "D. Ceftriaxone.",
                    "E. Fluconazole."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "After the tissue agent (*e.g.*, Metronidazole), a **luminal agent** (*e.g.*, **Diloxanide furoate** or Paromomycin) is necessary[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "luminal_agent"
                ]
            },
            {
                "id": 1065,
                "question": "A key indication for performing **percutaneous drainage** of an amebic liver abscess is:",
                "choices": [
                    "A. Concurrent finding of Gram-negative rods on blood culture.",
                    "B. Abscess diameter less than 5 cm.",
                    "C. Failure of medical therapy after 5 days of Metronidazole.",
                    "D. Concurrent finding of bloody diarrhea.",
                    "E. Abscess located in the left lobe."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Drainage is not routine for ALA but is considered in cases of **failed medical therapy** (lack of clinical improvement after 3–5 days) or abscesses larger than 10 cm[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "drainage_indication"
                ]
            },
            {
                "id": 1070,
                "question": "What is the recommended treatment for a patient diagnosed with an amebic liver abscess that is complicated by impending rupture?",
                "choices": [
                    "A. Surgical drainage alone.",
                    "B. Oral Metronidazole monotherapy.",
                    "C. Metronidazole IV/PO PLUS percutaneous drainage.",
                    "D. Luminal amebicide alone.",
                    "E. Ciprofloxacin IV and observation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The cornerstone of ALA treatment is the tissue agent (*e.g.*, Metronidazole). However, in cases of **impending rupture** (a major complication), **percutaneous drainage** must be added to the medical regimen[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "management",
                    "complication"
                ]
            },
            {
                "id": 1071,
                "question": "Which finding is characteristic of the **fluid** obtained from an **amebic liver abscess**?",
                "choices": [
                    "A. Clear, serous fluid.",
                    "B. Yellow-green purulent fluid.",
                    "C. Brown, thick fluid.",
                    "D. Foul-smelling pus.",
                    "E. White, sticky exudate."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Amebic liver abscess fluid is classically described as **brown, thick fluid** (anchovy paste)[cite: 1077]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "abscess_fluid"
                ]
            },
            {
                "id": 1074,
                "question": "What is the recommended treatment duration for the **tissue agent** (Metronidazole) in Amebic Liver Abscess (ALA)?",
                "choices": [
                    "A. A single 2g dose.",
                    "B. 3-5 days.",
                    "C. 7-10 days.",
                    "D. 14 days.",
                    "E. 6 weeks."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The tissue agent **Metronidazole** is given for **7–10 days**. Tinidazole is an alternative given for 3–5 days[cite: 1077]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "treatment",
                    "duration"
                ]
            },
            {
                "id": 1077,
                "question": "A patient with suspected Amebic Liver Abscess has profuse bloody diarrhea. What is the expected prevalence of concurrent diarrhea in patients presenting with Amebic Liver Abscess?",
                "choices": [
                    "A. Nearly 90% of cases.",
                    "B. Approximately 50% of cases.",
                    "C. Less than one-third of cases.",
                    "D. Diarrhea never occurs concurrently with ALA.",
                    "E. Only occurs in immunocompromised hosts."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Diarrhea is **not common** in patients presenting with amebic liver abscess, occurring in **less than one-third** of cases[cite: 1077]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "diarrhea"
                ]
            },
            {
                "id": 1078,
                "question": "What is the recommended treatment for a patient diagnosed with an amebic liver abscess that is complicated by impending rupture?",
                "choices": [
                    "A. Surgical drainage alone.",
                    "B. Oral Metronidazole monotherapy.",
                    "C. Metronidazole IV/PO PLUS percutaneous drainage.",
                    "D. Luminal amebicide alone.",
                    "E. Ciprofloxacin IV and observation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The cornerstone of ALA treatment is the tissue agent (*e.g.*, Metronidazole). However, in cases of **impending rupture** (a major complication), **percutaneous drainage** must be added to the medical regimen[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "management",
                    "complication"
                ]
            },
            {
                "id": 1079,
                "question": "Which antibiotic must be administered **after** the tissue agent (Metronidazole) in the treatment of amebic liver abscess (ALA)?",
                "choices": [
                    "A. Ciprofloxacin.",
                    "B. Diloxanide furoate.",
                    "C. Ceftriaxone.",
                    "D. Tinidazole.",
                    "E. Amoxicillin-clavulanate."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The tissue agent (Metronidazole) must be followed by a **luminal agent** (*e.g.*, **Diloxanide furoate** or Paromomycin) to eliminate intraluminal cysts and prevent relapse and transmission[cite: 1077, 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "luminal_agent"
                ]
            },
            {
                "id": 1080,
                "question": "A patient presents with subacute fever and RUQ pain. Ultrasound shows a single 7 cm liver abscess. Jaundice is absent. What is the **most appropriate initial therapeutic agent**?",
                "choices": [
                    "A. Ciprofloxacin monotherapy.",
                    "B. Metronidazole 750 mg IV/PO every 8 hours.",
                    "C. Ceftriaxone monotherapy.",
                    "D. Surgical drainage immediately.",
                    "E. Oral Amoxicillin-clavulanate."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Given the subacute presentation, a single abscess, and a single agent option, the presumptive diagnosis is **amebic liver abscess**. The **First line** is **Metronidazole 500-750 mg IV/PO every 8 hours** for 7-10 days[cite: 1077]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "treatment"
                ]
            },
            {
                "id": 1084,
                "question": "A patient with a confirmed amebic liver abscess is treated with Metronidazole. What is the name of the **luminal agent** that must be added to the regimen?",
                "choices": [
                    "A. Ciprofloxacin.",
                    "B. Diloxanide furoate.",
                    "C. Ceftriaxone.",
                    "D. Tinidazole.",
                    "E. Amoxicillin-clavulanate."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The treatment of ALA must include a tissue agent (Metronidazole) followed by a **luminal agent** (*e.g.*, **Diloxanide furoate** or Paromomycin) to prevent relapse[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "luminal_agent"
                ]
            },
            {
                "id": 1085,
                "question": "A patient with Amebic Liver Abscess shows clinical improvement after 5 days of Metronidazole. What is the correct next step in therapy?",
                "choices": [
                    "A. Discontinue Metronidazole and start Diloxanide furoate.",
                    "B. Continue Metronidazole to complete 7-10 days, then add a luminal agent.",
                    "C. Perform percutaneous drainage to hasten resolution.",
                    "D. Switch to oral Ciprofloxacin and Metronidazole.",
                    "E. Add a second tissue agent (e.g., Tinidazole)."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The tissue agent (Metronidazole) should be continued to complete the **7–10 day course**, and then the **luminal agent** is added[cite: 1077]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "treatment_sequence"
                ]
            },
            {
                "id": 1086,
                "question": "What is the recommended treatment duration for the **luminal agent** (Diloxanide furoate) in Amebic Liver Abscess (ALA)?",
                "choices": [
                    "A. A single 2g dose.",
                    "B. 3-5 days.",
                    "C. 7-10 days.",
                    "D. 14 days.",
                    "E. 6 weeks."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The luminal agent, **Diloxanide furoate** or Paromomycin, is given for **10 days** and **7 days**, respectively[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "treatment",
                    "duration"
                ]
            },
            {
                "id": 1089,
                "question": "Which of the following is a criterion for considering **percutaneous drainage** of an Amebic Liver Abscess?",
                "choices": [
                    "A. Abscess diameter less than 5 cm.",
                    "B. Jaundice and fever.",
                    "C. Failure of medical therapy after 5 days.",
                    "D. Previous history of dysentery.",
                    "E. Abscess located in the right lobe."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Drainage is considered for ALA if there is **failure of medical therapy** (lack of clinical improvement after 3–5 days) or abscesses larger than 10 cm[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "drainage_indication"
                ]
            },
            {
                "id": 1090,
                "question": "The definitive treatment for Amebic Liver Abscess is primarily based on:",
                "choices": [
                    "A. Percutaneous drainage and long-term observation.",
                    "B. Surgical excision of the abscess.",
                    "C. Antimicrobial therapy (tissue and luminal agents).",
                    "D. High-dose oral corticosteroids.",
                    "E. Antibiotics targeting enteric Gram-negatives."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The management of ALA is primarily **antimicrobial therapy** using a tissue agent (*e.g.*, Metronidazole) followed by a luminal agent (*e.g.*, Diloxanide furoate)[cite: 1077, 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "management"
                ]
            },
            {
                "id": 1092,
                "question": "What is the primary role of the **luminal amebicide** in the treatment of Amebic Liver Abscess?",
                "choices": [
                    "A. Treat the abscess wall inflammation.",
                    "B. Kill *E. histolytica* cysts in the colon.",
                    "C. Prevent bacterial superinfection of the abscess.",
                    "D. Decrease the size of the abscess rapidly.",
                    "E. Enhance the absorption of Metronidazole."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The luminal agent (*e.g.*, Diloxanide furoate) is given to **eliminate intraluminal cysts** of *Entamoeba histolytica* in the colon to prevent relapse and transmission[cite: 1078]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "luminal_agent",
                    "role"
                ]
            },
            {
                "id": 1097,
                "question": "A key indication for initiating Metronidazole treatment for an Amebic Liver Abscess is:",
                "choices": [
                    "A. Abscess size less than 5 cm.",
                    "B. Preceding symptoms of bloody diarrhea.",
                    "C. Clinical suspicion of ALA.",
                    "D. Negative serology for *Entamoeba histolytica*.",
                    "E. Concurrent finding of jaundice."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Metronidazole treatment for ALA is initiated based on **clinical suspicion** (fever, RUQ pain, single abscess in endemic area) supported by imaging, as serology is often used later for confirmation[cite: 1077]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "treatment",
                    "timing"
                ]
            },
            {
                "id": 1098,
                "question": "What is the recommended treatment for a patient with a confirmed amebic liver abscess that has ruptured into the pleural space?",
                "choices": [
                    "A. Metronidazole IV/PO monotherapy.",
                    "B. Surgical repair and Metronidazole IV/PO.",
                    "C. Percutaneous drainage and Tinidazole PO.",
                    "D. Ciprofloxacin and Metronidazole IV/PO.",
                    "E. Drainage of the abscess alone."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Rupture of an abscess requires drainage of the fluid/pus (e.g., chest tube for pleural rupture) plus the tissue agent, **Metronidazole IV/PO**[cite: 1077]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "complication_management"
                ]
            },
            {
                "id": 1099,
                "question": "Which microorganism is the **causative agent** of Amebic Liver Abscess?",
                "choices": [
                    "A. *Entamoeba dispar*.",
                    "B. *Entamoeba coli*.",
                    "C. *Entamoeba histolytica*.",
                    "D. *Giardia lamblia*.",
                    "E. *Schistosoma mansoni*."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Amebic liver abscess is a complication of infection by the protozoa **Entamoeba histolytica**[cite: 1077]. (p. 231)",
                "tags": [
                    "amebic_liver_abscess",
                    "etiology"
                ]
            },
            {
                "id": 1100,
                "question": "What is the recommended duration for the tissue agent **Metronidazole** in the treatment of Amebic Liver Abscess (ALA)?",
                "choices": [
                    "A. 3 days.",
                    "B. 7-10 days.",
                    "C. 14 days.",
                    "D. 21 days.",
                    "E. 6 weeks."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The tissue agent **Metronidazole** is given for **7–10 days**[cite: 1077]. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "treatment",
                    "duration"
                ]
            },
            {
                "id": 1104,
                "question": "A 35-year-old male is treated for Amebic Liver Abscess (ALA) with Metronidazole. After a 10-day course, the patient is clinically stable. What is the **necessary next step** in management to prevent recurrence and transmission?",
                "choices": [
                    "A. Perform follow-up abdominal CT scan.",
                    "B. Start a luminal amebicide (e.g., Diloxanide furoate or Paromomycin).",
                    "C. Repeat Metronidazole for another 7 days.",
                    "D. Discharge with no further treatment.",
                    "E. Counsel on avoiding meat products."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The tissue agent (Metronidazole) must be followed by a **luminal agent** (*e.g.*, **Diloxanide furoate** or Paromomycin) to eliminate intraluminal cysts and prevent relapse and transmission. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "management",
                    "luminal_agent"
                ]
            },
            {
                "id": 1105,
                "question": "A patient has completed a 10-day course of Metronidazole for an amebic liver abscess. The patient asks why another medicine (a luminal agent) is needed. What is the **primary purpose** of the luminal agent?",
                "choices": [
                    "A. To enhance the abscess drainage rate.",
                    "B. To treat *Entamoeba histolytica* cysts in the intestinal lumen.",
                    "C. To accelerate the healing of the liver abscess.",
                    "D. To cover potential secondary bacterial infection.",
                    "E. To prevent the amebic organism from spreading to the brain."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The tissue agent kills the motile trophozoites, but a **luminal agent** (like Diloxanide furoate or Paromomycin) is necessary to **eradicate intraluminal cysts** of *Entamoeba histolytica* in the colon, thereby preventing recurrence and transmission. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "luminal_agent",
                    "purpose"
                ]
            },
            {
                "id": 1106,
                "question": "Which microorganism is the **causative agent** of Amebic Liver Abscess?",
                "choices": [
                    "A. *Entamoeba dispar*.",
                    "B. *Entamoeba coli*.",
                    "C. *Entamoeba histolytica*.",
                    "D. *Giardia lamblia*.",
                    "E. *Schistosoma mansoni*."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Amebic liver abscess is a complication of infection by the protozoa **Entamoeba histolytica**. (p. 231)",
                "tags": [
                    "amebic_liver_abscess",
                    "etiology"
                ]
            },
            {
                "id": 1107,
                "question": "A 40-year-old male is admitted with a single 7 cm abscess in the right lobe of the liver. He denies prior bloody diarrhea. What is the **most likely fluid appearance** if the abscess were aspirated for diagnostic purposes and confirmed to be amebic?",
                "choices": [
                    "A. Thick, foul-smelling pus.",
                    "B. Clear, straw-colored fluid.",
                    "C. Yellow-green purulent fluid.",
                    "D. Brown, thick fluid.",
                    "E. White, curd-like substance."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "If an amebic liver abscess is aspirated, the fluid typically appears as a **brown, thick fluid** (often described as 'anchovy paste'). (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "abscess_fluid"
                ]
            },
            {
                "id": 1108,
                "question": "A patient presents with fever and RUQ tenderness. Amebic liver abscess is suspected. **What is the recommended duration** for the tissue agent, Metronidazole?",
                "choices": [
                    "A. 3 days.",
                    "B. 7-10 days.",
                    "C. 14 days.",
                    "D. 21 days.",
                    "E. 6 weeks."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The tissue agent **Metronidazole** is given for **7–10 days**. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "treatment",
                    "duration"
                ]
            },
            {
                "id": 1109,
                "question": "Which clinical feature is **least common** in patients presenting with Amebic Liver Abscess (ALA)?",
                "choices": [
                    "A. Fever.",
                    "B. Right upper quadrant tenderness.",
                    "C. Jaundice.",
                    "D. Subacute presentation over weeks.",
                    "E. Hepatomegaly."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "**Jaundice** is **rarely seen** in amebic liver abscess, occurring in less than 10% of cases. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "clinical_features"
                ]
            },
            {
                "id": 1110,
                "question": "A patient with confirmed ALA is treated with Metronidazole. What is the recommended **alternative luminal amebicide** if Diloxanide furoate is unavailable?",
                "choices": [
                    "A. Ciprofloxacin.",
                    "B. Tinidazole.",
                    "C. Paromomycin.",
                    "D. Ceftriaxone.",
                    "E. Oral Amoxicillin-clavulanate."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The alternative options for the luminal agent are **Diloxanide furoate** or **Paromomycin**. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "luminal_agent"
                ]
            },
            {
                "id": 1111,
                "question": "A 55-year-old male with a large, solitary liver abscess (>10 cm) is started on Metronidazole but shows no clinical improvement after 5 days. What is the **most appropriate next step** in management?",
                "choices": [
                    "A. Increase Metronidazole dose and add a second antibiotic (e.g., Ceftriaxone).",
                    "B. Perform percutaneous ultrasound-guided drainage of the abscess.",
                    "C. Switch to a luminal agent (e.g., Diloxanide furoate).",
                    "D. Discontinue all treatment and observe.",
                    "E. Perform open surgical drainage immediately."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Percutaneous ultrasound-guided drainage may be considered in patients with **large amebic liver abscesses (>10 cm)**, impending rupture, or in those with **failed medical therapy** (lack of improvement after 3-5 days). (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "management_failure",
                    "drainage"
                ]
            },
            {
                "id": 1112,
                "question": "What is the **most common complication** of an amebic liver abscess?",
                "choices": [
                    "A. Abscess transformation to hepatocellular carcinoma.",
                    "B. Rupture of the abscess.",
                    "C. Biliary obstruction leading to cholangitis.",
                    "D. Sepsis and septic shock.",
                    "E. Hepatic encephalopathy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The **most common complication** of amebic liver abscess is **rupture** into the peritoneum, pleural space, pericardial space, or sub-phrenic space. (p. 231)",
                "tags": [
                    "amebic_liver_abscess",
                    "complications"
                ]
            },
            {
                "id": 1113,
                "question": "A patient with suspected Amebic Liver Abscess has profuse bloody diarrhea. What is the expected prevalence of concurrent diarrhea in patients presenting with Amebic Liver Abscess?",
                "choices": [
                    "A. Nearly 90% of cases.",
                    "B. Approximately 50% of cases.",
                    "C. Less than one-third of cases.",
                    "D. Diarrhea never occurs concurrently with ALA.",
                    "E. Only occurs in immunocompromised hosts."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Diarrhea is **not common** in patients presenting with amebic liver abscess, occurring in **less than one-third** of cases. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "diarrhea"
                ]
            },
            {
                "id": 1119,
                "question": "What is the recommended treatment for a patient with a confirmed amebic liver abscess that has ruptured into the pleural space?",
                "choices": [
                    "A. Metronidazole IV/PO monotherapy.",
                    "B. Surgical repair and Metronidazole IV/PO.",
                    "C. Percutaneous drainage and Tinidazole PO.",
                    "D. Ciprofloxacin and Metronidazole IV/PO.",
                    "E. Drainage of the abscess alone."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Rupture of an abscess (a major complication) requires drainage of the fluid/pus (e.g., chest tube for pleural rupture) plus the tissue agent, **Metronidazole IV/PO**. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "complication_management"
                ]
            },
            {
                "id": 1120,
                "question": "A 30-year-old male is admitted with a single 7 cm abscess in the right lobe of the liver. He denies prior bloody diarrhea. What is the **most appropriate initial therapeutic agent**?",
                "choices": [
                    "A. Ciprofloxacin monotherapy.",
                    "B. Metronidazole 750 mg IV/PO every 8 hours.",
                    "C. Ceftriaxone monotherapy.",
                    "D. Surgical drainage immediately.",
                    "E. Oral Amoxicillin-clavulanate."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Given the subacute presentation, a single abscess, and a single agent option, the presumptive diagnosis is **amebic liver abscess**. The **First line** is **Metronidazole 500-750 mg IV/PO every 8 hours** for 7-10 days. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "treatment"
                ]
            },
            {
                "id": 1121,
                "question": "What is the recommended treatment duration for the **tissue agent** (Metronidazole) in Amebic Liver Abscess (ALA)?",
                "choices": [
                    "A. 3 days.",
                    "B. 7-10 days.",
                    "C. 14 days.",
                    "D. 21 days.",
                    "E. 6 weeks."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The tissue agent **Metronidazole** is given for **7–10 days**. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "treatment",
                    "duration"
                ]
            },
            {
                "id": 1128,
                "question": "What is the recommended duration for the tissue agent **Metronidazole** in the treatment of Amebic Liver Abscess (ALA)?",
                "choices": [
                    "A. 3 days.",
                    "B. 7-10 days.",
                    "C. 14 days.",
                    "D. 21 days.",
                    "E. 6 weeks."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The tissue agent **Metronidazole** is given for **7–10 days**. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "treatment",
                    "duration"
                ]
            },
            {
                "id": 1130,
                "question": "A patient with Amebic Liver Abscess is treated with Metronidazole. The main purpose of adding **Diloxanide furoate** after Metronidazole is to:",
                "choices": [
                    "A. Enhance the activity of the tissue agent (Metronidazole).",
                    "B. Treat *Entamoeba histolytica* cysts in the intestinal lumen.",
                    "C. Accelerate the healing of the liver abscess.",
                    "D. Cover potential secondary bacterial infection of the abscess.",
                    "E. Treat concurrent cholangitis."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Diloxanide furoate is a **luminal agent** used to eradicate intraluminal cysts of *Entamoeba histolytica* in the colon, which is **necessary after the tissue agent** to prevent relapse and transmission. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "luminal_agent",
                    "purpose"
                ]
            },
            {
                "id": 1132,
                "question": "A patient presents with subacute fever and RUQ pain. Ultrasound shows a single 7 cm liver abscess. Jaundice is absent. What is the **most appropriate initial therapeutic agent**?",
                "choices": [
                    "A. Ciprofloxacin monotherapy.",
                    "B. Metronidazole 750 mg IV/PO every 8 hours.",
                    "C. Ceftriaxone monotherapy.",
                    "D. Surgical drainage immediately.",
                    "E. Oral Amoxicillin-clavulanate."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Given the subacute presentation, a single abscess, and a single agent option, the presumptive diagnosis is **amebic liver abscess**. The **First line** is **Metronidazole 500-750 mg IV/PO every 8 hours** for 7-10 days. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "treatment"
                ]
            },
            {
                "id": 1133,
                "question": "Which microorganism is the **causative agent** of Amebic Liver Abscess?",
                "choices": [
                    "A. *Entamoeba dispar*.",
                    "B. *Entamoeba coli*.",
                    "C. *Entamoeba histolytica*.",
                    "D. *Giardia lamblia*.",
                    "E. *Schistosoma mansoni*."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Amebic liver abscess is a complication of infection by the protozoa **Entamoeba histolytica**. (p. 231)",
                "tags": [
                    "amebic_liver_abscess",
                    "etiology"
                ]
            },
            {
                "id": 1135,
                "question": "What is the primary role of the **luminal amebicide** in the treatment of Amebic Liver Abscess?",
                "choices": [
                    "A. Treat the abscess wall inflammation.",
                    "B. Kill *E. histolytica* cysts in the colon.",
                    "C. Prevent bacterial superinfection of the abscess.",
                    "D. Decrease the size of the abscess rapidly.",
                    "E. Enhance the absorption of Metronidazole."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The luminal agent (*e.g.*, Diloxanide furoate) is given to **eliminate intraluminal cysts** of *Entamoeba histolytica* in the colon to prevent relapse and transmission. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "luminal_agent",
                    "role"
                ]
            },
            {
                "id": 1137,
                "question": "Which of the following is a criterion for considering **percutaneous drainage** of an Amebic Liver Abscess?",
                "choices": [
                    "A. Abscess diameter less than 5 cm.",
                    "B. Jaundice and fever.",
                    "C. Failure of medical therapy after 5 days.",
                    "D. Previous history of dysentery.",
                    "E. Abscess located in the right lobe."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Drainage is considered for ALA if there is **failure of medical therapy** (lack of clinical improvement after 3–5 days) or abscesses larger than 10 cm. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "drainage_indication"
                ]
            },
            {
                "id": 1140,
                "question": "What is the recommended treatment for a patient with a confirmed amebic liver abscess that has ruptured into the pleural space?",
                "choices": [
                    "A. Metronidazole IV/PO monotherapy.",
                    "B. Surgical repair and Metronidazole IV/PO.",
                    "C. Percutaneous drainage and Tinidazole PO.",
                    "D. Ciprofloxacin and Metronidazole IV/PO.",
                    "E. Drainage of the abscess alone."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "Rupture of an abscess (a major complication) requires drainage of the fluid/pus (e.g., chest tube for pleural rupture) plus the tissue agent, **Metronidazole IV/PO**. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "complication_management"
                ]
            },
            {
                "id": 1141,
                "question": "A patient with confirmed ALA is treated with Metronidazole. What is the necessary next step in management to prevent recurrence and transmission?",
                "choices": [
                    "A. Perform follow-up abdominal CT scan.",
                    "B. Start a luminal amebicide (e.g., Diloxanide furoate or Paromomycin).",
                    "C. Repeat Metronidazole for another 7 days.",
                    "D. Discharge with no further treatment.",
                    "E. Counsel on avoiding meat products."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.11.2 Amebic liver abscesses",
                "explanation": "The tissue agent (Metronidazole) must be followed by a **luminal agent** (*e.g.*, **Diloxanide furoate** or Paromomycin) to eliminate intraluminal cysts and prevent relapse and transmission. (p. 232)",
                "tags": [
                    "amebic_liver_abscess",
                    "management",
                    "luminal_agent"
                ]
            }
        ]
    },
    "Chapter 6.12": {
        "Chapter 6.12 Acute Pancreatitis": [
            {
                "id": 1142,
                "question": "A 40-year-old male is admitted to the general hospital with acute, severe, persistent **epigastric pain that radiates to the back**. He reports heavy alcohol consumption. Serum lipase is over three times the upper limit of normal. What is the **most likely diagnosis** and the **primary goal of immediate treatment**?",
                "choices": [
                    "A. Acute cholecystitis; Immediate surgery.",
                    "B. Acute pancreatitis; Aggressive fluid resuscitation and pain control.",
                    "C. Peptic ulcer disease; Urgent endoscopy and proton pump inhibitor therapy.",
                    "D. Biliary colic; Pain control with oral NSAIDs and discharge.",
                    "E. Acute coronary syndrome; Cardiac workup and antiplatelet therapy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "The clinical presentation (severe epigastric pain radiating to the back) and laboratory findings (serum lipase > 3x normal) are diagnostic of **Acute Pancreatitis**[cite: 708]. The primary goals of management are **pain control, and fluid, electrolyte, and nutritional abnormality prevention and correction**[cite: 708]. (p. 233-234)",
                "tags": [
                    "acute_pancreatitis",
                    "diagnosis",
                    "management"
                ]
            },
            {
                "id": 1143,
                "question": "A patient with acute pancreatitis is being assessed for fluid needs. Which fluid type is explicitly mentioned in the guidelines as preferred for the initial phase of fluid resuscitation?",
                "choices": [
                    "A. 5% Dextrose in Water (D5W).",
                    "B. Normal Saline (NS).",
                    "C. Ringer's Lactate (RL).",
                    "D. Half-Normal Saline.",
                    "E. Hydroxyethyl starch solution."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "The guidelines state that for fluid and electrolyte correction, **Ringer's Lactate (RL) or Normal Saline (NS)** should be used, with an emphasis on avoiding volume depletion[cite: 707, 708]. RL is often favored in pancreatitis to prevent acidosis. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "fluid_resuscitation"
                ]
            },
            {
                "id": 1144,
                "question": "A 60-year-old female with acute pancreatitis is in severe pain. What is the **preferred initial drug class** for managing the acute, severe pain?",
                "choices": [
                    "A. NSAIDs (e.g., Diclofenac).",
                    "B. Oral non-opioid analgesics (e.g., Paracetamol).",
                    "C. Opioids (e.g., Morphine or Pethidine).",
                    "D. Antispasmodics (e.g., Hyoscine).",
                    "E. Corticosteroids (e.g., Dexamethasone)."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "For pain control in acute pancreatitis, **Opioids** (Morphine or Pethidine) are the mainstay. The guidelines explicitly advise to **Avoid NSAIDs** such as Diclofenac[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "pain_management",
                    "opioids"
                ]
            },
            {
                "id": 1145,
                "question": "A patient with severe acute pancreatitis has been kept NPO for 48 hours due to paralytic ileus. Given that their condition is stabilizing, what is the **recommended time frame** for reintroducing enteral nutrition (feeding)?",
                "choices": [
                    "A. Wait until serum amylase and lipase normalize.",
                    "B. Wait until abdominal pain completely resolves.",
                    "C. Start early (within 24 hours) if tolerated, or as soon as possible thereafter.",
                    "D. Start parenteral nutrition immediately.",
                    "E. Wait for 7 days (one week) for bowel rest."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "Management guidelines recommend to **Start early (within 24 hours) oral re-feeding**. If not tolerated (due to pain/ileus), feeding should be delayed, but the patient should try to restart as soon as possible[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "nutrition",
                    "enteral_feeding"
                ]
            },
            {
                "id": 1146,
                "question": "A patient is admitted with a severe attack of acute pancreatitis. Which finding is **least likely** to be observed during the physical examination?",
                "choices": [
                    "A. Epigastric tenderness.",
                    "B. High-grade fever.",
                    "C. Tachycardia.",
                    "D. Signs of fluid overload (rales, edema).",
                    "E. Gaseous abdominal distension."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "Acute pancreatitis typically causes **fluid sequestration/loss** (third spacing), which often leads to hypovolemia or shock, not fluid overload. Signs like fever, tachycardia, and epigastric tenderness are common[cite: 707]. (p. 233)",
                "tags": [
                    "acute_pancreatitis",
                    "clinical_features",
                    "fluid_status"
                ]
            },
            {
                "id": 1147,
                "question": "Which of the following laboratory findings is **most specific** for the diagnosis of acute pancreatitis?",
                "choices": [
                    "A. Elevated serum amylase.",
                    "B. Elevated serum lipase.",
                    "C. Leukocytosis.",
                    "D. Elevated C-reactive protein (CRP).",
                    "E. Hyperglycemia."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "The diagnosis is based on clinical presentation and elevated serum enzymes. **Serum lipase** is generally considered **more specific** for the diagnosis of acute pancreatitis than serum amylase[cite: 707, 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "diagnosis",
                    "laboratory"
                ]
            },
            {
                "id": 1148,
                "question": "A patient with acute pancreatitis has persistent vomiting and developing signs of paralytic ileus. What is the appropriate **management step** for this complication?",
                "choices": [
                    "A. Surgical exploration for intestinal obstruction.",
                    "B. Aggressive antiemetic therapy with metoclopramide and ondansetron.",
                    "C. Nasogastric (NG) tube placement for suction.",
                    "D. Immediate initiation of total parenteral nutrition (TPN).",
                    "E. Withholding all fluid resuscitation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "In cases of **persistent vomiting** or evidence of **paralytic ileus**, **NG tube placement for suction** is indicated[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "complications",
                    "management"
                ]
            },
            {
                "id": 1149,
                "question": "Acute pancreatitis is diagnosed if a patient presents with acute, severe epigastric pain and at least one other criterion. What are the **two key diagnostic criteria** for acute pancreatitis, besides the clinical pain syndrome?",
                "choices": [
                    "A. Elevated WBC count and fever.",
                    "B. Elevated serum amylase/lipase (>3x ULN) or characteristic imaging findings.",
                    "C. Elevated serum bilirubin and liver enzymes.",
                    "D. Presence of gallstones on ultrasound or history of alcohol abuse.",
                    "E. Hypotension and tachycardia."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "Diagnosis requires the presence of two of the following three: acute onset of typical pain, **elevation in serum lipase or amylase (at least three times the upper limit of normal)**, or **characteristic imaging findings** (CT scan or abdominal ultrasound)[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "diagnosis",
                    "triad"
                ]
            },
            {
                "id": 1150,
                "question": "Which imaging study is considered the **choice for the diagnosis** of acute pancreatitis?",
                "choices": [
                    "A. Plain abdominal X-ray.",
                    "B. Abdominal ultrasound.",
                    "C. Computed Tomography (CT) scan of the abdomen.",
                    "D. Magnetic Resonance Imaging (MRI).",
                    "E. Endoscopic Retrograde Cholangiopancreatography (ERCP)."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "Although ultrasound is useful, the **Abdominal CT scan** is cited as the **imaging choice for the diagnosis** of acute pancreatitis[cite: 707, 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "investigation",
                    "imaging"
                ]
            },
            {
                "id": 1151,
                "question": "A patient with acute pancreatitis develops signs of clinical deterioration and persistent fevers after 7 days of hospitalization. What should be the **primary concern** and appropriate management action?",
                "choices": [
                    "A. Pancreatic pseudocyst formation; Observe only.",
                    "B. Infected pancreatic necrosis; Initiate broad-spectrum antibiotics.",
                    "C. Hemorrhage; Transfuse blood and perform urgent angiography.",
                    "D. Recurrent gallstone passage; Immediate ERCP.",
                    "E. Drug-induced pancreatitis; Stop all non-essential medication."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Infected pancreatic necrosis** is indicated by clinical deterioration, increasing WBC count, fevers, or failure to improve after 7-10 days. **Initiating antibiotics** is the appropriate step to treat this complication[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "complications",
                    "antibiotics"
                ]
            },
            {
                "id": 1152,
                "question": "In the management of acute pancreatitis, the role of **prophylactic antibiotics** is:",
                "choices": [
                    "A. Recommended for all patients with severe disease.",
                    "B. Recommended only for patients undergoing fine-needle aspiration.",
                    "C. Not indicated, unless there is evidence of infected necrosis.",
                    "D. Mandated if the etiology is gallstones.",
                    "E. Given for a minimum of 7 days to prevent infection."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "Management guidelines explicitly state that **Prophylactic antibiotics are not indicated** and should only be initiated if there is **evidence of infected pancreatic necrosis**[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "antibiotics",
                    "prophylaxis"
                ]
            },
            {
                "id": 1153,
                "question": "A patient with acute pancreatitis is in severe pain. You decide to administer parenteral Pethidine. What is the recommended **initial IV dose**?",
                "choices": [
                    "A. 10 mg/kg bolus.",
                    "B. 50-100 mg bolus.",
                    "C. 1-3 mg bolus.",
                    "D. 200 mg bolus.",
                    "E. 10 mg every 12 hours."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "For pain control, the initial dose for **Pethidine** is $25-100 \text{ mg}$ (IV/SC/IM) or **Morphine** $1-3 \text{ mg}$ (IV)[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "pain_management",
                    "opioids"
                ]
            },
            {
                "id": 1154,
                "question": "A 50-year-old male is admitted with acute pancreatitis secondary to heavy alcohol consumption. What is the recommended strategy for **analgesia**?",
                "choices": [
                    "A. Oral NSAIDs (Diclofenac) PRN.",
                    "B. Morphine or Pethidine IV bolus or infusion.",
                    "C. Acetaminophen (Paracetamol) monotherapy.",
                    "D. Tramadol IV/PO monotherapy.",
                    "E. Continuous epidural block only."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Opioids** (Morphine IV, 1-3 mg every 4 hour OR Pethidine 25-100 mg SC or IM) are the agents used for pain control. The guidelines explicitly state to **Avoid NSAIDs** such as Diclofenac[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "pain_management",
                    "opioids"
                ]
            },
            {
                "id": 1155,
                "question": "A patient with acute pancreatitis is admitted. What is the recommended approach to **fluid and electrolyte correction** in the initial phase?",
                "choices": [
                    "A. Restrict fluids to prevent pulmonary edema.",
                    "B. Administer fluids slowly (50 mL/hour) over 24 hours.",
                    "C. Aggressively correct volume depletion with IV crystalloids (RL or NS).",
                    "D. Administer only D5W to prevent hypoglycemia.",
                    "E. Give only oral rehydration solutions."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "The initial management should focus on correcting volume depletion aggressively with **IV crystalloids (RL or NS)** to avoid worsening the condition[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "fluid_resuscitation"
                ]
            },
            {
                "id": 1156,
                "question": "Which of the following is considered a **leading cause** of acute pancreatitis?",
                "choices": [
                    "A. Type 2 Diabetes Mellitus.",
                    "B. Viral infection (e.g., mumps).",
                    "C. Gallstones.",
                    "D. Peptic ulcer disease.",
                    "E. Hypertriglyceridemia."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Gallstones** and **chronic alcohol abuse** are cited as the **leading causes** of acute pancreatitis[cite: 707]. (p. 233)",
                "tags": [
                    "acute_pancreatitis",
                    "etiology"
                ]
            },
            {
                "id": 1157,
                "question": "A patient with acute pancreatitis is being assessed for severity. Which classification uses transient or persistent organ failure as a key differentiating factor?",
                "choices": [
                    "A. Ranson's Criteria.",
                    "B. Glasgow Criteria.",
                    "C. Modified Marshall Score.",
                    "D. Atlanta Classification (Mild, Moderately Severe, Severe).",
                    "E. APACHE II Score."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "Acute pancreatitis is divided into **Mild, Moderately severe, and Severe** severity classes based on the presence of **organ dysfunction** (transient or persistent) and local complications[cite: 707]. (p. 233)",
                "tags": [
                    "acute_pancreatitis",
                    "severity_classification"
                ]
            },
            {
                "id": 1158,
                "question": "A patient presents with classic symptoms and lab findings for acute pancreatitis. What is the recommended approach to **enteral feeding**?",
                "choices": [
                    "A. Total parenteral nutrition (TPN) for 7 days.",
                    "B. NPO for 7 days, then slow reintroduction of liquids.",
                    "C. Start early (within 24 hours) oral re-feeding if tolerated.",
                    "D. Start high-fat enteral tube feeding within 48 hours.",
                    "E. Delay feeding until CRP normalizes."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "The guidelines recommend to **Start early (within 24 hours) oral re-feeding** if tolerated, or as soon as possible thereafter, as part of supportive care[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "nutrition"
                ]
            },
            {
                "id": 1159,
                "question": "What is the key difference between **Severe acute pancreatitis** and **Moderately severe acute pancreatitis** in the classification system?",
                "choices": [
                    "A. Severe has no organ failure; Moderately Severe has organ failure.",
                    "B. Severe has transient organ failure; Moderately Severe has no organ failure.",
                    "C. Severe has persistent organ failure; Moderately Severe has transient organ failure.",
                    "D. Severe has local complications only; Moderately Severe has systemic complications.",
                    "E. Severity is solely based on serum lipase levels."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Severe acute pancreatitis** involves **persistent organ failure**. **Moderately severe acute pancreatitis** involves **transient organ failure** (resolves within 48 hours) or complications without persistent organ failure[cite: 707]. (p. 233)",
                "tags": [
                    "acute_pancreatitis",
                    "severity_classification"
                ]
            },
            {
                "id": 1160,
                "question": "A 45-year-old female with acute pancreatitis is admitted. She is allergic to all opioids. Which agent is explicitly advised to be **Avoided** for pain management in this condition?",
                "choices": [
                    "A. Oral Paracetamol (Acetaminophen).",
                    "B. Parenteral Morphine.",
                    "C. Diclofenac.",
                    "D. Pethidine.",
                    "E. Codeine."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "The guidelines explicitly advise to **Avoid NSAIDs** such as **Diclofenac** in the pain management of acute pancreatitis[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "pain_management",
                    "contraindications"
                ]
            },
            {
                "id": 1161,
                "question": "Which complication of acute pancreatitis is an indication for initiating **broad-spectrum antibiotics**?",
                "choices": [
                    "A. Formation of a pancreatic pseudocyst.",
                    "B. Development of paralytic ileus.",
                    "C. Evidence of infected pancreatic necrosis.",
                    "D. Persistent vomiting after 24 hours.",
                    "E. Serum lipase level exceeding 10x the upper limit of normal."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Antibiotics are indicated in patients with evidence of infected pancreatic necrosis**; otherwise, they are not used prophylactically[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "antibiotics",
                    "indication"
                ]
            },
            {
                "id": 1162,
                "question": "A patient with acute pancreatitis has persistent vomiting. Which supportive measure is indicated to prevent the complications of vomiting?",
                "choices": [
                    "A. Immediate surgical drainage.",
                    "B. Insertion of a Nasogastric (NG) tube for suction.",
                    "C. Prophylactic antibiotic administration.",
                    "D. High-dose oral NSAIDs.",
                    "E. Administering oral refeeding within 24 hours."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "For **persistent vomiting**, placement of an **NG tube for suction** is indicated[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "complications",
                    "management"
                ]
            },
            {
                "id": 1163,
                "question": "What are the two most common causes of acute pancreatitis?",
                "choices": [
                    "A. Alcohol and viral infection.",
                    "B. Trauma and hypercalcemia.",
                    "C. Gallstones and chronic alcohol abuse.",
                    "D. Hypertriglyceridemia and peptic ulcer disease.",
                    "E. Drugs and diabetes mellitus."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Gallstones** and **chronic alcohol abuse** are cited as the **leading causes** of acute pancreatitis[cite: 707]. (p. 233)",
                "tags": [
                    "acute_pancreatitis",
                    "etiology"
                ]
            },
            {
                "id": 1164,
                "question": "The primary goal of managing acute pancreatitis is to provide supportive care. This includes **all** of the following EXCEPT:",
                "choices": [
                    "A. Pain control.",
                    "B. Prompt initiation of prophylactic antibiotics.",
                    "C. Fluid, electrolyte, and nutritional support.",
                    "D. Early oral re-feeding when tolerated.",
                    "E. Close monitoring for complications."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Prophylactic antibiotics are not indicated** in the management of acute pancreatitis unless there is evidence of infected necrosis[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "management",
                    "antibiotics"
                ]
            },
            {
                "id": 1165,
                "question": "A patient is admitted with a mild case of acute pancreatitis. They should be placed in which environment for the best outcome?",
                "choices": [
                    "A. General Medical Ward.",
                    "B. Surgical Ward.",
                    "C. Intensive Care Unit (ICU).",
                    "D. Day Care Clinic.",
                    "E. Isolation Unit."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Mild acute pancreatitis** does not require intensive care, but **Moderately severe and Severe** cases need to be managed in an **ICU setting**[cite: 708]. (p. 234, 233)",
                "tags": [
                    "acute_pancreatitis",
                    "setting_of_care"
                ]
            },
            {
                "id": 1166,
                "question": "A patient with acute pancreatitis is hypotensive and tachycardic. What is the recommended approach to immediate fluid resuscitation?",
                "choices": [
                    "A. Restrict fluids to 500 mL over 8 hours.",
                    "B. Administer IV fluid bolus rapidly and aggressively (RL or NS).",
                    "C. Give only oral fluids until symptoms improve.",
                    "D. Start only D5W at a slow rate.",
                    "E. Administer only colloid solutions (Albumin)."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "In the initial phase, the management should **aggressively correct volume depletion** (which causes hypotension/tachycardia) with **IV crystalloids (RL or NS)**[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "fluid_resuscitation"
                ]
            },
            {
                "id": 1167,
                "question": "Which analgesic drug is specifically advised to be **Avoided** in the pain management of acute pancreatitis?",
                "choices": [
                    "A. Pethidine.",
                    "B. Morphine.",
                    "C. Diclofenac.",
                    "D. Paracetamol.",
                    "E. Tramadol."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "The guidelines explicitly advise to **Avoid NSAIDs** such as **Diclofenac**[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "pain_management",
                    "contraindications"
                ]
            },
            {
                "id": 1168,
                "question": "The primary cause of the severe abdominal pain characteristic of acute pancreatitis is:",
                "choices": [
                    "A. Inflammation and autodigestion of the pancreas.",
                    "B. Perforation of the duodenum.",
                    "C. Ischemia of the pancreatic tail.",
                    "D. Secondary gastritis from vomiting.",
                    "E. Biliary colic from gallstones."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "The pain is caused by the acute **inflammation** of the pancreas and the secondary effects of enzyme release. (p. 233)",
                "tags": [
                    "acute_pancreatitis",
                    "pathophysiology"
                ]
            },
            {
                "id": 1169,
                "question": "A 55-year-old female presents with acute severe epigastric pain. Blood tests reveal serum lipase is four times the upper limit of normal. This finding, combined with the pain, fulfills the diagnostic criteria for:",
                "choices": [
                    "A. Severe acute pancreatitis.",
                    "B. Moderately severe acute pancreatitis.",
                    "C. Acute pancreatitis.",
                    "D. Chronic pancreatitis.",
                    "E. Hyperlipasemia of unknown significance."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "Diagnosis requires the acute typical pain and **elevation in serum lipase or amylase (at least three times the upper limit of normal)**, or characteristic imaging findings[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "diagnosis",
                    "laboratory"
                ]
            },
            {
                "id": 1170,
                "question": "A patient with acute pancreatitis develops severe hypotension that is refractory to initial fluid boluses. This patient should be referred for management in the:",
                "choices": [
                    "A. General Medical Ward.",
                    "B. Gastroenterology Clinic.",
                    "C. Intensive Care Unit (ICU).",
                    "D. Surgical Ward.",
                    "E. Oncology Unit."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "Patients with **Severe** and **Moderately severe** pancreatitis (which includes shock/refractory hypotension) need to be managed in an **ICU setting**[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "setting_of_care",
                    "severity"
                ]
            },
            {
                "id": 1171,
                "question": "What is the recommended initial IV dose of Morphine for a patient with severe pain from acute pancreatitis?",
                "choices": [
                    "A. 1-3 mg.",
                    "B. 5-10 mg.",
                    "C. 20 mg.",
                    "D. 1 mg/kg.",
                    "E. 10 mg every 4 hours."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "The recommended dose for **Morphine** is **$1-3 \text{ mg}$ IV every 4 hour**[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "pain_management",
                    "opioids"
                ]
            },
            {
                "id": 1172,
                "question": "A patient with acute pancreatitis has persistent vomiting and developing signs of paralytic ileus. What is the appropriate management step for this complication?",
                "choices": [
                    "A. Surgical exploration for intestinal obstruction.",
                    "B. Aggressive antiemetic therapy with metoclopramide and ondansetron.",
                    "C. Nasogastric (NG) tube placement for suction.",
                    "D. Immediate initiation of total parenteral nutrition (TPN).",
                    "E. Withholding all fluid resuscitation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "In cases of **persistent vomiting** or evidence of **paralytic ileus**, **NG tube placement for suction** is indicated[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "complications",
                    "management"
                ]
            },
            {
                "id": 1173,
                "question": "The definitive diagnosis of acute pancreatitis requires the presence of acute, severe pain and:",
                "choices": [
                    "A. Normal serum amylase and lipase.",
                    "B. Elevation of serum lipase or amylase (>3x ULN) or characteristic imaging.",
                    "C. Only characteristic imaging findings (CT scan).",
                    "D. Only elevation of serum amylase (lipase is non-specific).",
                    "E. Hyperglycemia (RBS > 200 mg/dl)."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "Diagnosis requires the acute typical pain and **elevation in serum lipase or amylase (at least three times the upper limit of normal)**, or **characteristic imaging findings**[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "diagnosis",
                    "laboratory"
                ]
            },
            {
                "id": 1174,
                "question": "A patient with acute pancreatitis is stable after 72 hours of admission. When should **antibiotics** be initiated?",
                "choices": [
                    "A. Immediately on admission.",
                    "B. After 7 days of hospitalization.",
                    "C. Only if evidence of infected necrosis develops.",
                    "D. Only if the etiology is gallstones.",
                    "E. Prophylactically for 5 days."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Antibiotics are not indicated prophylactically**. They should only be initiated if there is **evidence of infected pancreatic necrosis**[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "antibiotics",
                    "indication"
                ]
            },
            {
                "id": 1175,
                "question": "The primary goal of managing acute pancreatitis is to provide supportive care. This includes **all** of the following EXCEPT:",
                "choices": [
                    "A. Pain control.",
                    "B. Prompt initiation of prophylactic antibiotics.",
                    "C. Fluid, electrolyte, and nutritional support.",
                    "D. Early oral re-feeding when tolerated.",
                    "E. Close monitoring for complications."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Prophylactic antibiotics are not indicated** in the management of acute pancreatitis unless there is evidence of infected necrosis[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "management",
                    "antibiotics"
                ]
            },
            {
                "id": 1176,
                "question": "Which classification uses transient or persistent organ failure as a key differentiating factor for severity?",
                "choices": [
                    "A. Ranson's Criteria.",
                    "B. Glasgow Criteria.",
                    "C. Modified Marshall Score.",
                    "D. Atlanta Classification (Mild, Moderately Severe, Severe).",
                    "E. APACHE II Score."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Acute pancreatitis** is divided into **Mild, Moderately severe, and Severe** severity classes based on the presence of **organ dysfunction** (transient or persistent) and local complications[cite: 707]. (p. 233)",
                "tags": [
                    "acute_pancreatitis",
                    "severity_classification"
                ]
            },
            {
                "id": 1177,
                "question": "A patient with acute pancreatitis develops signs of clinical deterioration and persistent fevers after 7 days of hospitalization. What should be the **primary concern** and appropriate management action?",
                "choices": [
                    "A. Pancreatic pseudocyst formation; Observe only.",
                    "B. Infected pancreatic necrosis; Initiate broad-spectrum antibiotics.",
                    "C. Hemorrhage; Transfuse blood and perform urgent angiography.",
                    "D. Recurrent gallstone passage; Immediate ERCP.",
                    "E. Drug-induced pancreatitis; Stop all non-essential medication."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Infected pancreatic necrosis** is indicated by clinical deterioration, increasing WBC count, fevers, or failure to improve after 7-10 days. **Initiating antibiotics** is the appropriate step to treat this complication[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "complications",
                    "antibiotics"
                ]
            },
            {
                "id": 1178,
                "question": "What is the recommended initial IV dose of Morphine for a patient with severe pain from acute pancreatitis?",
                "choices": [
                    "A. 1-3 mg.",
                    "B. 5-10 mg.",
                    "C. 20 mg.",
                    "D. 1 mg/kg.",
                    "E. 10 mg every 4 hours."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "The recommended dose for **Morphine** is **$1-3 \text{ mg}$ IV every 4 hour**[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "pain_management",
                    "opioids"
                ]
            },
            {
                "id": 1179,
                "question": "Which analgesic drug is specifically advised to be **Avoided** in the pain management of acute pancreatitis?",
                "choices": [
                    "A. Pethidine.",
                    "B. Morphine.",
                    "C. Diclofenac.",
                    "D. Paracetamol.",
                    "E. Codeine."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "The guidelines explicitly advise to **Avoid NSAIDs** such as **Diclofenac** in the pain management of acute pancreatitis[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "pain_management",
                    "contraindications"
                ]
            },
            {
                "id": 1180,
                "question": "The primary goal of managing acute pancreatitis is to provide supportive care. This includes **all** of the following EXCEPT:",
                "choices": [
                    "A. Pain control.",
                    "B. Prompt initiation of prophylactic antibiotics.",
                    "C. Fluid, electrolyte, and nutritional support.",
                    "D. Early oral re-feeding when tolerated.",
                    "E. Close monitoring for complications."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Prophylactic antibiotics are not indicated** in the management of acute pancreatitis unless there is evidence of infected necrosis[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "management",
                    "antibiotics"
                ]
            },
            {
                "id": 1181,
                "question": "A patient with acute pancreatitis is hypotensive and tachycardic. What is the recommended approach to immediate fluid resuscitation?",
                "choices": [
                    "A. Restrict fluids to 500 mL over 8 hours.",
                    "B. Administer IV fluid bolus rapidly and aggressively (RL or NS).",
                    "C. Give only oral fluids until symptoms improve.",
                    "D. Start only D5W at a slow rate.",
                    "E. Administer only colloid solutions (Albumin)."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "The initial management should focus on correcting volume depletion aggressively with **IV crystalloids (RL or NS)**[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "fluid_resuscitation"
                ]
            },
            {
                "id": 1182,
                "question": "What are the two most common causes of acute pancreatitis?",
                "choices": [
                    "A. Alcohol and viral infection.",
                    "B. Trauma and hypercalcemia.",
                    "C. Gallstones and chronic alcohol abuse.",
                    "D. Hypertriglyceridemia and peptic ulcer disease.",
                    "E. Drugs and diabetes mellitus."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Gallstones** and **chronic alcohol abuse** are cited as the **leading causes** of acute pancreatitis[cite: 707]. (p. 233)",
                "tags": [
                    "acute_pancreatitis",
                    "etiology"
                ]
            },
            {
                "id": 1183,
                "question": "A patient is admitted with a mild case of acute pancreatitis. They should be placed in which environment for the best outcome?",
                "choices": [
                    "A. General Medical Ward.",
                    "B. Surgical Ward.",
                    "C. Intensive Care Unit (ICU).",
                    "D. Day Care Clinic.",
                    "E. Isolation Unit."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Mild acute pancreatitis** does not require intensive care, but **Moderately severe and Severe** cases need to be managed in an **ICU setting**[cite: 708]. (p. 234, 233)",
                "tags": [
                    "acute_pancreatitis",
                    "setting_of_care"
                ]
            },
            {
                "id": 1184,
                "question": "A patient with acute pancreatitis is stable after 72 hours of admission. When should **antibiotics** be initiated?",
                "choices": [
                    "A. Immediately on admission.",
                    "B. After 7 days of hospitalization.",
                    "C. Only if evidence of infected necrosis develops.",
                    "D. Only if the etiology is gallstones.",
                    "E. Prophylactically for 5 days."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Antibiotics are not indicated prophylactically**. They should only be initiated if there is **evidence of infected necrosis**[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "antibiotics",
                    "indication"
                ]
            },
            {
                "id": 1185,
                "question": "The primary goal of managing acute pancreatitis is to provide supportive care. This includes **all** of the following EXCEPT:",
                "choices": [
                    "A. Pain control.",
                    "B. Prompt initiation of prophylactic antibiotics.",
                    "C. Fluid, electrolyte, and nutritional support.",
                    "D. Early oral re-feeding when tolerated.",
                    "E. Close monitoring for complications."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Prophylactic antibiotics are not indicated** in the management of acute pancreatitis unless there is evidence of infected necrosis[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "management",
                    "antibiotics"
                ]
            },
            {
                "id": 1186,
                "question": "The primary goal of managing acute pancreatitis is to provide supportive care. This includes **all** of the following EXCEPT:",
                "choices": [
                    "A. Pain control.",
                    "B. Prompt initiation of prophylactic antibiotics.",
                    "C. Fluid, electrolyte, and nutritional support.",
                    "D. Early oral re-feeding when tolerated.",
                    "E. Close monitoring for complications."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Prophylactic antibiotics are not indicated** in the management of acute pancreatitis unless there is evidence of infected necrosis[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "management",
                    "antibiotics"
                ]
            },
            {
                "id": 1187,
                "question": "The primary goal of managing acute pancreatitis is to provide supportive care. This includes **all** of the following EXCEPT:",
                "choices": [
                    "A. Pain control.",
                    "B. Prompt initiation of prophylactic antibiotics.",
                    "C. Fluid, electrolyte, and nutritional support.",
                    "D. Early oral re-feeding when tolerated.",
                    "E. Close monitoring for complications."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Prophylactic antibiotics are not indicated** in the management of acute pancreatitis unless there is evidence of infected necrosis[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "management",
                    "antibiotics"
                ]
            },
            {
                "id": 1188,
                "question": "The primary goal of managing acute pancreatitis is to provide supportive care. This includes **all** of the following EXCEPT:",
                "choices": [
                    "A. Pain control.",
                    "B. Prompt initiation of prophylactic antibiotics.",
                    "C. Fluid, electrolyte, and nutritional support.",
                    "D. Early oral re-feeding when tolerated.",
                    "E. Close monitoring for complications."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Prophylactic antibiotics are not indicated** in the management of acute pancreatitis unless there is evidence of infected necrosis[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "management",
                    "antibiotics"
                ]
            },
            {
                "id": 1189,
                "question": "The primary goal of managing acute pancreatitis is to provide supportive care. This includes **all** of the following EXCEPT:",
                "choices": [
                    "A. Pain control.",
                    "B. Prompt initiation of prophylactic antibiotics.",
                    "C. Fluid, electrolyte, and nutritional support.",
                    "D. Early oral re-feeding when tolerated.",
                    "E. Close monitoring for complications."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Prophylactic antibiotics are not indicated** in the management of acute pancreatitis unless there is evidence of infected necrosis[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "management",
                    "antibiotics"
                ]
            },
            {
                "id": 1190,
                "question": "The primary goal of managing acute pancreatitis is to provide supportive care. This includes **all** of the following EXCEPT:",
                "choices": [
                    "A. Pain control.",
                    "B. Prompt initiation of prophylactic antibiotics.",
                    "C. Fluid, electrolyte, and nutritional support.",
                    "D. Early oral re-feeding when tolerated.",
                    "E. Close monitoring for complications."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Prophylactic antibiotics are not indicated** in the management of acute pancreatitis unless there is evidence of infected necrosis[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "management",
                    "antibiotics"
                ]
            },
            {
                "id": 1191,
                "question": "The primary goal of managing acute pancreatitis is to provide supportive care. This includes **all** of the following EXCEPT:",
                "choices": [
                    "A. Pain control.",
                    "B. Prompt initiation of prophylactic antibiotics.",
                    "C. Fluid, electrolyte, and nutritional support.",
                    "D. Early oral re-feeding when tolerated.",
                    "E. Close monitoring for complications."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Prophylactic antibiotics are not indicated** in the management of acute pancreatitis unless there is evidence of infected necrosis[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "management",
                    "antibiotics"
                ]
            },
            {
                "id": 1192,
                "question": "The primary goal of managing acute pancreatitis is to provide supportive care. This includes **all** of the following EXCEPT:",
                "choices": [
                    "A. Pain control.",
                    "B. Prompt initiation of prophylactic antibiotics.",
                    "C. Fluid, electrolyte, and nutritional support.",
                    "D. Early oral re-feeding when tolerated.",
                    "E. Close monitoring for complications."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 6.12 Acute Pancreatitis",
                "explanation": "**Prophylactic antibiotics are not indicated** in the management of acute pancreatitis unless there is evidence of infected necrosis[cite: 708]. (p. 234)",
                "tags": [
                    "acute_pancreatitis",
                    "management",
                    "antibiotics"
                ]
            }
        ]
    },
    "Chapter 7.1.2": {
        "Chapter 7.1.2 Iron deficiency anemia": [
            {
                "id": 1193,
                "question": "A 45-year-old male with chronic kidney disease (CKD) presents with fatigue and dyspnea. His hemoglobin (Hb) is $9.0 \text{ g/dl}$. Iron studies show a Transferrin Saturation (TSAT) of $15%$ (low). Which treatment is **most appropriate** for his anemia, based on his renal and iron status?",
                "choices": [
                    "A. Start oral ferrous sulfate monotherapy.",
                    "B. Start Epoetin (ESA) therapy immediately.",
                    "C. Start IV iron (Iron Sucrose).",
                    "D. Transfuse packed RBCs immediately.",
                    "E. High-dose Folic Acid therapy."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "The patient has anemia of CKD with concurrent iron deficiency (TSAT $<20%$). **IV iron** (Iron Sucrose) is the **preferred treatment** option in CKD patients, regardless of dialysis status, to correct iron deficiency, which is often refractory to oral iron and is necessary before initiating ESA therapy. (p. 519)",
                "tags": [
                    "iron_deficiency_anemia",
                    "CKD",
                    "IV_iron"
                ]
            },
            {
                "id": 1194,
                "question": "A 28-year-old pregnant woman in her **third trimester** is diagnosed with **severe iron deficiency anemia** ($Hb 6.5 \text{ g/dl}$). She is unable to tolerate oral iron due to severe nausea. What is the **most appropriate** and timely intervention to correct her iron deficit?",
                "choices": [
                    "A. Transfuse 2 units of packed RBCs.",
                    "B. Initiate a high dose of oral ferrous gluconate.",
                    "C. Initiate IV iron therapy (e.g., Iron Sucrose).",
                    "D. Prescribe a prokinetic agent (e.g., Metoclopramide) to improve oral tolerance.",
                    "E. Weekly oral iron with weekly vitamin C administration."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "**IV iron therapy** is indicated in pregnant women with **severe anemia during late second or third trimester** and for those with **intolerance to oral iron therapy** to rapidly correct the iron deficit before delivery. (p. 240)",
                "tags": [
                    "iron_deficiency_anemia",
                    "pregnancy",
                    "IV_iron"
                ]
            },
            {
                "id": 1195,
                "question": "A 60-year-old male presents with fatigue. Lab results show $\text{Hb } 8.5 \text{ g/dl}$, $\text{MCV } 72 \text{ fl}$ (Microcytic), $\text{MCH } 24 \text{ pg}$. Initial workup reveals a positive stool occult blood test. What is the **immediate priority** following the diagnosis of iron deficiency anemia in this setting?",
                "choices": [
                    "A. Initiate oral Ferrous Sulfate $325 \text{ mg}$ TID.",
                    "B. Perform a bone marrow aspiration to confirm diagnosis.",
                    "C. Investigate the cause of chronic blood loss (GI workup).",
                    "D. Start high-dose Vitamin $\text{B}_{12}$ and Folic Acid empirically.",
                    "E. Transfuse packed RBCs immediately to raise Hb."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "In adults, iron deficiency anemia should be assumed to be due to **chronic blood loss (usually GI)** until proven otherwise. The immediate priority, after confirming the microcytic anemia, is to **investigate the underlying cause of bleeding** (GI workup) rather than just treating the deficiency. (p. 238)",
                "tags": [
                    "iron_deficiency_anemia",
                    "diagnosis",
                    "etiology"
                ]
            },
            {
                "id": 1196,
                "question": "A 35-year-old female is started on oral Ferrous Sulfate $325 \text{ mg}$ TID for iron deficiency anemia. She reports severe abdominal discomfort and constipation. What is the **most appropriate initial modification** to improve drug tolerance?",
                "choices": [
                    "A. Switch to intravenous iron (Iron Sucrose).",
                    "B. Advise taking the tablet with meals or reducing the dose.",
                    "C. Change to an oral opioid analgesic for the pain.",
                    "D. Increase the dose of the iron supplement to speed up recovery.",
                    "E. Switch to high-dose oral Vitamin $\text{C}$ to enhance absorption."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "The major side effects of oral iron are **gastrointestinal intolerance** (e.g., pain, constipation). The patient should be advised to **take the medication with meals** to reduce GI distress, or to try a **smaller dose**, which are appropriate first steps before switching to IV iron. (p. 239, 240)",
                "tags": [
                    "iron_deficiency_anemia",
                    "treatment",
                    "side_effects"
                ]
            },
            {
                "id": 1197,
                "question": "An 8-year-old child from a rural area presents with microcytic anemia and Pica (craving for soil). Stool microscopy confirms **hookworm infestation**. What is the **definitive initial management** for this anemia?",
                "choices": [
                    "A. Iron therapy alone for 6 months.",
                    "B. Treatment with an anti-helminthic agent (e.g., Albendazole) alone.",
                    "C. Iron therapy and an anti-helminthic agent.",
                    "D. Blood transfusion immediately.",
                    "E. High-dose Vitamin $\text{B}_{12}$ therapy."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "The anemia is caused by chronic blood loss from the hookworm. The definitive management requires **treating the underlying cause** (Albendazole) **and replacing the iron deficit** with oral iron therapy. (p. 238)",
                "tags": [
                    "iron_deficiency_anemia",
                    "hookworm",
                    "management"
                ]
            },
            {
                "id": 1198,
                "question": "A 55-year-old male is started on oral iron for anemia. When should the oral iron therapy typically be **discontinued**?",
                "choices": [
                    "A. After 7 days of treatment.",
                    "B. After 4 weeks, if the Hb has increased by $2 \text{ g/dl}$.",
                    "C. After 3 months following the correction of anemia.",
                    "D. After normalization of serum iron, regardless of Hb level.",
                    "E. When the patient reports resolution of fatigue."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "Oral iron therapy should be continued for at least **3 months following the correction of anemia** to adequately replenish the body's iron stores. (p. 238)",
                "tags": [
                    "iron_deficiency_anemia",
                    "treatment_duration"
                ]
            },
            {
                "id": 1199,
                "question": "Which finding in a patient with microcytic anemia is **most indicative** of chronic inflammation (Anemia of Chronic Disease) rather than Iron Deficiency Anemia?",
                "choices": [
                    "A. High Transferrin Saturation (TSAT).",
                    "B. High Total Iron Binding Capacity (TIBC).",
                    "C. Low Serum Ferritin.",
                    "D. High Serum Ferritin.",
                    "E. High Reticulocyte Count."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "In **Iron Deficiency Anemia**, **Serum Ferritin is usually low**. In **Anemia of Chronic Disease** (ACD), ferritin is typically **high** because it is an acute phase reactant, even if there is functional iron deficiency. (p. 238)",
                "tags": [
                    "anemia_of_chronic_disease",
                    "iron_studies",
                    "ferritin"
                ]
            },
            {
                "id": 1200,
                "question": "A patient with iron deficiency anemia is started on Ferrous Sulfate. What advice should be given to **enhance** the absorption of the iron supplement?",
                "choices": [
                    "A. Take the tablet with milk or tea.",
                    "B. Take the tablet 2 hours before or 4 hours after meals.",
                    "C. Take the tablet with a meal high in saturated fat.",
                    "D. Take a double dose every morning.",
                    "E. Take the tablet just before bedtime."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "Iron is best absorbed when the stomach is empty; thus, it should preferably be taken **2 hours before or 4 hours after a meal**. (p. 239, 240)",
                "tags": [
                    "iron_deficiency_anemia",
                    "absorption"
                ]
            },
            {
                "id": 1201,
                "question": "Which of the following is a key **indication** for switching an iron-deficient patient from **oral iron therapy to IV iron** (e.g., Iron Sucrose)?",
                "choices": [
                    "A. Patient reports mild constipation.",
                    "B. Patient is anemic and pregnant in the first trimester.",
                    "C. No improvement in hemoglobin after 4 weeks of compliant oral iron therapy.",
                    "D. Concomitant history of controlled hypertension.",
                    "E. Patient is on maintenance hemodialysis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "Key indications for IV iron include **Intolerance to oral iron**, **No improvement in hemoglobin after 4 weeks** of oral iron, **CKD on EPO/dialysis**, and **Severe anemia** in late pregnancy. (p. 240)",
                "tags": [
                    "iron_deficiency_anemia",
                    "IV_iron",
                    "indication"
                ]
            },
            {
                "id": 1202,
                "question": "A 70-year-old man presents with fatigue. $\text{Hb } 9.5 \text{ g/dl}$, $\text{MCV } 75 \text{ fl}$. He reports no melena, hematochezia, or iron loss. Given the microcytic anemia, what is the **mandatory next diagnostic step**?",
                "choices": [
                    "A. Colonoscopy and EGD.",
                    "B. Serum iron studies (Ferritin, TIBC).",
                    "C. Bone marrow biopsy.",
                    "D. Trial of oral iron for 4 weeks.",
                    "E. Genetic testing for thalassemia."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "In microcytic anemia, iron studies (Ferritin, TIBC, TSAT) are necessary to confirm iron deficiency before proceeding with the likely **GI investigation** (which is mandatory if iron deficiency is confirmed). (p. 238)",
                "tags": [
                    "iron_deficiency_anemia",
                    "diagnosis",
                    "investigation"
                ]
            },
            {
                "id": 1203,
                "question": "Which symptom in a child with microcytic anemia is a **specific clinical feature** of severe iron deficiency?",
                "choices": [
                    "A. Fatigue and pallor.",
                    "B. Koilonychia (spoon-shaped nails).",
                    "C. Dyspnea on exertion.",
                    "D. Glossitis.",
                    "E. Pica."
                ],
                "correctAnswer": 4,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "**Pica** (craving to eat unusual substances like soil or ice), Koilonychia, and Glossitis/Angular stomatitis are **unique clinical features** of severe iron deficiency anemia. (p. 238)",
                "tags": [
                    "iron_deficiency_anemia",
                    "clinical_features"
                ]
            },
            {
                "id": 1205,
                "question": "A 60-year-old male with microcytic anemia ($\text{Hb } 9.0 \text{ g/dl}$, $\text{MCV } 70 \text{ fl}$) has serum ferritin $\text{5 ng/ml}$ (low) and positive stool occult blood. What is the **most crucial next step** for management?",
                "choices": [
                    "A. Start high-dose oral iron with a vitamin $\text{C}$ supplement.",
                    "B. Refer urgently for colonoscopy and upper GI endoscopy.",
                    "C. Transfuse 2 units of packed RBCs.",
                    "D. Start empiric Metronidazole and Albendazole.",
                    "E. Administer IV Iron Sucrose."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "Confirmed iron deficiency anemia in an adult with occult GI bleeding requires immediate investigation of the **underlying cause (GI malignancy/polyp)** with **colonoscopy and EGD** (Upper GI endoscopy). (p. 238)",
                "tags": [
                    "iron_deficiency_anemia",
                    "GI_workup"
                ]
            },
            {
                "id": 1206,
                "question": "A patient is on intravenous Iron Sucrose for refractory iron deficiency anemia. How should the dose be administered for a non-dialysis dependent patient?",
                "choices": [
                    "A. $1000 \text{ mg}$ IV push over 1 minute.",
                    "B. $200 \text{ mg}$ IV over 30 minutes, repeated every 3 days for a total of 5 doses.",
                    "C. $500 \text{ mg}$ IV once weekly for 4 weeks.",
                    "D. $100 \text{ mg}$ IV during the first hour of dialysis.",
                    "E. $20 \text{ mg}$ IV slowly, once daily for 7 days."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "For non-dialysis patients, the typical regimen is $200 \text{ mg}$ IV (diluted in $100 \text{ ml}$ NS) administered over **30 minutes**, repeated every **3 days for a total of 5 doses** ($1000 \text{ mg}$ total). (p. 240)",
                "tags": [
                    "iron_deficiency_anemia",
                    "IV_iron",
                    "dosing"
                ]
            },
            {
                "id": 1207,
                "question": "A patient with iron deficiency anemia reports severe constipation and abdominal pain with oral iron. You switch him to IV iron. What is the **duration of antibiotic therapy** for this patient?",
                "choices": [
                    "A. The question is flawed; IV iron is not an antibiotic.",
                    "B. 7 days.",
                    "C. 14 days.",
                    "D. 4 weeks.",
                    "E. 6 months."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "**IV iron** (Iron Sucrose) is a mineral replacement, **not an antibiotic**. The duration of therapy depends on the total deficit needed to be replaced. (p. 240)",
                "tags": [
                    "iron_deficiency_anemia",
                    "IV_iron",
                    "pharmacology"
                ]
            },
            {
                "id": 1208,
                "question": "A 25-year-old female is diagnosed with microcytic anemia due to excessive menstrual bleeding. She is started on oral iron. Which adverse effect should she be **counseled about as being common**?",
                "choices": [
                    "A. Diarrhea and constipation.",
                    "B. Headache and dizziness.",
                    "C. Skin rash and allergy.",
                    "D. Numbness in her feet.",
                    "E. Darkening of the urine."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "**GI side effects** are very common with oral iron, including **epigastric pain, nausea, vomiting, constipation, or diarrhea**. (p. 239)",
                "tags": [
                    "iron_deficiency_anemia",
                    "side_effects"
                ]
            },
            {
                "id": 1213,
                "question": "A patient is on maintenance hemodialysis for End Stage Renal Disease. His $\text{Hb}$ is $9.5 \text{ g/dl}$. Iron studies show TSAT $18%$. What is the **preferred first-line treatment** to correct the iron deficiency in this patient?",
                "choices": [
                    "A. Oral Ferrous Sulfate $325 \text{ mg}$ daily.",
                    "B. IV Iron Sucrose $100 \text{ mg}$ during the first hour of dialysis.",
                    "C. Epoetin (ESA) therapy alone.",
                    "D. Blood transfusion.",
                    "E. Oral iron with Vitamin $\text{C}$ supplements."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "**IV iron** (Iron Sucrose) is indicated for CKD patients on hemodialysis with iron deficiency (TSAT $<20%$). The typical dose is **$100 \text{ mg}$ IV during the first hour of dialysis** until the deficiency is corrected. (p. 240)",
                "tags": [
                    "iron_deficiency_anemia",
                    "CKD",
                    "IV_iron",
                    "hemodialysis"
                ]
            },
            {
                "id": 1214,
                "question": "A patient with iron deficiency anemia reports that taking her oral iron supplement with her morning tea minimizes her abdominal upset. What is the drawback of taking oral iron with tea?",
                "choices": [
                    "A. Tea causes secondary constipation.",
                    "B. Tea increases iron toxicity.",
                    "C. Tea significantly **interferes with iron absorption**.",
                    "D. Tea has no effect on iron absorption or side effects.",
                    "E. Tea causes gastric irritation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "Foods that significantly interfere with iron absorption, such as **tea, coffee, milk, and eggs**, should be avoided when oral iron is administered. (p. 239, 240)",
                "tags": [
                    "iron_deficiency_anemia",
                    "absorption",
                    "dietary_interaction"
                ]
            },
            {
                "id": 1228,
                "question": "A patient with microcytic anemia ($\text{MCV } 72 \text{ fl}$) has serum ferritin $20 \text{ ng/ml}$. After 4 weeks of compliant oral iron therapy, her $\text{Hb}$ remains unchanged. Which intervention is indicated?",
                "choices": [
                    "A. Continue oral iron for 3 more months.",
                    "B. Switch to IV Iron Sucrose.",
                    "C. Start Folic Acid $5 \text{ mg}$ daily.",
                    "D. Transfuse packed $\text{RBCs}$.",
                    "E. Increase oral iron dose by $50%$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "**No improvement in hemoglobin after 4 weeks** of compliant oral iron therapy is a key **indication for switching to IV iron** therapy. (p. 240)",
                "tags": [
                    "iron_deficiency_anemia",
                    "treatment_failure",
                    "IV_iron"
                ]
            },
            {
                "id": 1233,
                "question": "A 28-year-old female is diagnosed with microcytic anemia ($\text{MCV } 75 \text{ fl}$) due to heavy menstrual bleeding. She is started on oral iron. Which adverse effect should she be **counseled about as being common**?",
                "choices": [
                    "A. Headache.",
                    "B. Constipation.",
                    "C. Peripheral neuropathy.",
                    "D. Hyperglycemia.",
                    "E. Fever."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "**Constipation** is a common **GI side effect** of oral iron therapy. (p. 239)",
                "tags": [
                    "iron_deficiency_anemia",
                    "side_effects"
                ]
            },
            {
                "id": 1238,
                "question": "A patient with confirmed iron deficiency anemia is advised to take her tablets **2 hours before meals**. Why is this timing preferred?",
                "choices": [
                    "A. To prevent GI side effects.",
                    "B. To avoid interaction with antacids.",
                    "C. To enhance absorption on an empty stomach.",
                    "D. To coordinate with her dialysis schedule.",
                    "E. To ensure she remembers the dose."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "Iron is best absorbed when the stomach is empty; thus, taking the supplement **2 hours before or 4 hours after meals** is preferred to **enhance absorption**. (p. 239, 240)",
                "tags": [
                    "iron_deficiency_anemia",
                    "absorption",
                    "dosing"
                ]
            },
            {
                "id": 1240,
                "question": "A 30-year-old female presents with $\text{Hb } 11.5 \text{ g/dl}$, $\text{MCV } 75 \text{ fl}$. She is diagnosed with mild iron deficiency anemia. She has a history of severe gastritis. What is the **most appropriate initial therapeutic choice**?",
                "choices": [
                    "A. Oral Ferrous Sulfate $325 \text{ mg}$ TID.",
                    "B. IV Iron Sucrose.",
                    "C. Folic Acid $5 \text{ mg}$ PO daily.",
                    "D. Blood transfusion.",
                    "E. Oral iron with antacid therapy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "While oral iron is generally first line, **IV iron therapy** is indicated for patients with conditions that **interfere with absorption** from the GI tract (e.g., severe gastritis, gastrectomy). (p. 240)",
                "tags": [
                    "iron_deficiency_anemia",
                    "IV_iron",
                    "gastritis"
                ]
            },
            {
                "id": 1242,
                "question": "The most common etiology of anemia in the general population of developing countries is:",
                "choices": [
                    "A. Hemolytic anemia.",
                    "B. Megaloblastic anemia.",
                    "C. Iron deficiency anemia.",
                    "D. Anemia of chronic disease.",
                    "E. Aplastic anemia."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "**Iron deficiency anemia** is explicitly stated as a **common cause of anemia worldwide** and is the most prevalent nutritional anemia. (p. 238)",
                "tags": [
                    "iron_deficiency_anemia",
                    "epidemiology"
                ]
            },
            {
                "id": 1244,
                "question": "What is the recommended total dose of **Ferrous Sulfate** ($325 \text{ mg}$) to be taken daily for an adult being treated for iron deficiency anemia?",
                "choices": [
                    "A. One tablet daily.",
                    "B. One tablet BID.",
                    "C. One tablet TID.",
                    "D. Two tablets BID.",
                    "E. Four tablets daily."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "The recommended dose for Ferrous Sulfate is $325 \text{ mg}$ PO **TID** (three times daily). (p. 238)",
                "tags": [
                    "iron_deficiency_anemia",
                    "dosing"
                ]
            },
            {
                "id": 1276,
                "question": "The most common etiology of anemia in the general population of developing countries is:",
                "choices": [
                    "A. Hemolytic anemia.",
                    "B. Megaloblastic anemia.",
                    "C. Iron deficiency anemia.",
                    "D. Anemia of chronic disease.",
                    "E. Aplastic anemia."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "**Iron deficiency anemia** is explicitly stated as a **common cause of anemia worldwide** and is the most prevalent nutritional anemia. (p. 238)",
                "tags": [
                    "iron_deficiency_anemia",
                    "epidemiology"
                ]
            },
            {
                "id": 1280,
                "question": "What is the recommended total dose of **Ferrous Sulfate** ($325 \text{ mg}$) to be taken daily for an adult being treated for iron deficiency anemia?",
                "choices": [
                    "A. One tablet daily.",
                    "B. One tablet BID.",
                    "C. One tablet TID.",
                    "D. Two tablets BID.",
                    "E. Four tablets daily."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.2 Iron deficiency anemia",
                "explanation": "The recommended dose for Ferrous Sulfate is $325 \text{ mg}$ PO **TID** (three times daily). (p. 238)",
                "tags": [
                    "iron_deficiency_anemia",
                    "dosing"
                ]
            }
        ]
    },
    "Chapter 7.1.1": {
        "Chapter 7.1.1 Approach to adults with anemia": [
            {
                "id": 1204,
                "question": "What is the key difference in the definition of anemia for a child aged 8 years versus an adult male aged 45 years, according to WHO criteria?",
                "choices": [
                    "A. The cut-off is Hb $<10.0 \text{ g/dl}$ for both.",
                    "B. Child: Hb $<11.5 \text{ g/dl}$; Adult: Hb $<13 \text{ g/dl}$.",
                    "C. Child: Hb $<12 \text{ g/dl}$; Adult: Hb $<14 \text{ g/dl}$.",
                    "D. The cut-off is the same for all age groups.",
                    "E. Only the MCV defines anemia in children."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "WHO criteria for diagnosing anemia are $\text{Hb } <13 \text{ g/dl}$ in adult men and **Hb $<11.5 \text{ g/dl}$ in children** (5-12 years). (p. 236, 817)",
                "tags": [
                    "anemia",
                    "WHO_criteria",
                    "pediatrics"
                ]
            },
            {
                "id": 1209,
                "question": "A patient presents with extreme fatigue. $\text{Hb } 6.0 \text{ g/dl}$, $\text{MCV } 78 \text{ fl}$. She is hemodynamically stable. What is the appropriate management decision regarding **blood transfusion**?",
                "choices": [
                    "A. Transfuse immediately due to $\text{Hb } <7.0 \text{ g/dl}$.",
                    "B. Transfuse only if she develops hemodynamic instability or cardiac symptoms.",
                    "C. Transfuse only if IV iron fails after 4 weeks.",
                    "D. Transfuse only if $\text{Hb } <5.0 \text{ g/dl}$.",
                    "E. Transfuse only after the cause of anemia is found."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "For **hospitalized medical patients**, transfusion is generally indicated at $\text{Hb } <7.0 \text{ g/dl}$. However, for **ambulatory patients with chronic anemia**, transfusion may not be needed even at $\text{Hb } <7 \text{ g/dl}$ **unless they have severe symptoms** (e.g., heart failure, chest pain). Since she is stable, transfusion is based on symptoms. (p. 237)",
                "tags": [
                    "anemia",
                    "transfusion_indication"
                ]
            },
            {
                "id": 1210,
                "question": "In the general workup of anemia, what is the **primary purpose** of obtaining the Mean Corpuscular Volume (MCV)?",
                "choices": [
                    "A. To calculate the Reticulocyte Index.",
                    "B. To distinguish between Iron Deficiency Anemia and Anemia of Chronic Disease.",
                    "C. To classify anemia based on **RBC morphology (size)**.",
                    "D. To confirm the diagnosis of anemia ($\text{Hb } <13 \text{ g/dl}$).",
                    "E. To determine the need for blood transfusion."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "Anemia is classified based on **RBC morphology (size)**, as measured by **MCV**. This classification (Microcytic, Normocytic, Macrocytic) is useful for considering possible causes. (p. 236)",
                "tags": [
                    "anemia",
                    "MCV",
                    "classification"
                ]
            },
            {
                "id": 1211,
                "question": "A 40-year-old male with microcytic anemia ($\text{MCV } 75 \text{ fl}$) has normal serum ferritin. Which other category of anemia should be considered in the differential diagnosis?",
                "choices": [
                    "A. Hemolytic anemia.",
                    "B. Megaloblastic anemia.",
                    "C. Anemia of Chronic Disease (ACD) or Thalassemia.",
                    "D. Aplastic anemia.",
                    "E. Polycythemia Vera."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "Microcytic anemia ($\text{MCV } <80 \text{ fl}$) is typically caused by **Iron Deficiency Anemia** or **Anemia of Chronic Disease (ACD)**. Since ferritin is a positive acute phase reactant, it can be normal or high in ACD despite functional iron deficiency. **Thalassemia** is also a cause of microcytic anemia with normal or high ferritin. (p. 236, 238)",
                "tags": [
                    "anemia",
                    "MCV",
                    "differential_diagnosis"
                ]
            },
            {
                "id": 1212,
                "question": "Which of the following conditions is generally **not** a cause of **Macrocytic Anemia** ($\text{MCV } >100 \text{ fl}$)?",
                "choices": [
                    "A. Folic acid deficiency.",
                    "B. Alcohol abuse.",
                    "C. Chronic liver disease.",
                    "D. Vitamin $\text{B}_{12}$ deficiency.",
                    "E. Chronic blood loss from GI malignancy."
                ],
                "correctAnswer": 4,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "Macrocytic anemia is commonly caused by **Vitamin $\text{B}_{12}$ or folate deficiency**, **alcohol abuse**, or **chronic liver disease**. Chronic blood loss from GI malignancy typically causes **microcytic** (iron deficiency) anemia. (p. 236)",
                "tags": [
                    "anemia",
                    "MCV",
                    "macrocytic"
                ]
            },
            {
                "id": 1223,
                "question": "A patient with known megaloblastic anemia is brought to the $\text{ER}$ with signs of heart failure. Her $\text{Hb}$ is $5.5 \text{ g/dl}$. What is the immediate priority for management?",
                "choices": [
                    "A. High-dose oral folic acid and vitamin $\text{B}_{12}$.",
                    "B. Transfusion of packed $\text{RBCs}$ with slow rate and IV diuretics.",
                    "C. Immediate administration of IV iron.",
                    "D. Immediate LP to rule out neurosyphilis.",
                    "E. $100 \text{ mcg}$ Vitamin $\text{B}_{12}$ IM and $5 \text{ mg}$ Folic Acid PO."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "Severe anemia complicated by **heart failure** is an indication for **blood transfusion**. The transfusion must be done cautiously with a **slow rate and concomitant use of IV diuretics** to prevent fluid overload and worsening cardiac function. (p. 237)",
                "tags": [
                    "anemia",
                    "transfusion_indication",
                    "heart_failure"
                ]
            },
            {
                "id": 1226,
                "question": "What is the hematologic definition of **Anemia** for an **adult male**?",
                "choices": [
                    "A. $\text{Hb } <11.0 \text{ g/dl}$ or $\text{Hct } <33%$",
                    "B. $\text{Hb } <12 \text{ g/dl}$ or $\text{Hct } <36%$",
                    "C. $\text{Hb } <13 \text{ g/dl}$ or $\text{Hct } <39%$",
                    "D. $\text{Hb } <14 \text{ g/dl}$ or $\text{Hct } <42%$",
                    "E. $\text{Hb } <10.0 \text{ g/dl}$ regardless of $\text{Hct}$"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "WHO criteria define anemia in adult males as **$\text{Hb } <13 \text{ g/dl}$** or $\text{Hct } <39%$. (p. 236)",
                "tags": [
                    "anemia",
                    "WHO_criteria",
                    "hematology"
                ]
            },
            {
                "id": 1230,
                "question": "A 35-year-old male presents with fatigue. $\text{Hb } 12.5 \text{ g/dl}$, $\text{MCV } 78 \text{ fl}$. He has a family history of microcytic anemia. Serum ferritin is high. What is the most likely diagnosis among the common causes of microcytic anemia?",
                "choices": [
                    "A. Iron Deficiency Anemia (IDA).",
                    "B. Anemia of Chronic Disease (ACD).",
                    "C. Thalassemia Trait.",
                    "D. Lead Poisoning.",
                    "E. Sideroblastic Anemia."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "Microcytic anemia ($\text{MCV } <80 \text{ fl}$) with **high/normal serum ferritin** suggests ACD or **Thalassemia**. Given the family history and the presence of microcytosis without severe anemia, **Thalassemia Trait** is a strong differential. (p. 236, 238)",
                "tags": [
                    "anemia",
                    "MCV",
                    "differential_diagnosis"
                ]
            },
            {
                "id": 1231,
                "question": "Which condition is a recognized cause of macrocytic anemia ($\text{MCV } >100 \text{ fl}$)?",
                "choices": [
                    "A. $\text{H. pylori}$ infection.",
                    "B. Chronic alcohol abuse.",
                    "C. Chronic parasitic infection.",
                    "D. Rheumatoid arthritis.",
                    "E. Chronic menorrhagia."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "**Chronic alcohol abuse** is explicitly listed as a cause of macrocytic anemia. (p. 236)",
                "tags": [
                    "anemia",
                    "MCV",
                    "macrocytic"
                ]
            },
            {
                "id": 1234,
                "question": "In the management of chronic stable anemia in an ambulatory patient with $\text{Hb } 6.5 \text{ g/dl}$, what is the **primary determinant** for the decision to transfuse packed $\text{RBCs}$?",
                "choices": [
                    "A. $\text{Hb}$ value alone.",
                    "B. Underlying etiology of anemia.",
                    "C. Patient's age.",
                    "D. Presence of severe symptoms (e.g., cardiac symptoms).",
                    "E. MCV value."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "For **ambulatory patients with chronic anemia**, transfusion is usually determined by the **presence of severe symptoms** (e.g., cardiac symptoms, severe dyspnea) and not just the $\text{Hb}$ level. (p. 237)",
                "tags": [
                    "anemia",
                    "transfusion_indication",
                    "symptom_status"
                ]
            },
            {
                "id": 1235,
                "question": "What is the required $\text{Hb}$ level for an **adult female** to be considered non-anemic, according to WHO criteria?",
                "choices": [
                    "A. $\text{Hb } ge 11.0 \text{ g/dl}$.",
                    "B. $\text{Hb } ge 12 \text{ g/dl}$.",
                    "C. $\text{Hb } ge 12.5 \text{ g/dl}$.",
                    "D. $\text{Hb } ge 13 \text{ g/dl}$.",
                    "E. $\text{Hb } ge 14 \text{ g/dl}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "WHO criteria define anemia in adult women as $\text{Hb } <12 \text{ g/dl}$. Therefore, $\text{Hb } ge 12 \text{ g/dl}$ is considered non-anemic. (p. 236)",
                "tags": [
                    "anemia",
                    "WHO_criteria"
                ]
            },
            {
                "id": 1245,
                "question": "In the workup for anemia, the finding of an $\text{MCV}$ of $112 \text{ fl}$ is generally considered indicative of:",
                "choices": [
                    "A. Microcytic anemia.",
                    "B. Normocytic anemia.",
                    "C. Macrocytic anemia.",
                    "D. Hemolytic anemia.",
                    "E. Sideroblastic anemia."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "An $\text{MCV}$ **$>100 \text{ fl}$** indicates **Macrocytic Anemia**. (p. 236)",
                "tags": [
                    "anemia",
                    "MCV",
                    "classification"
                ]
            },
            {
                "id": 1248,
                "question": "What is the hematologic definition of Anemia for an **adult female**?",
                "choices": [
                    "A. $\text{Hb } <11.0 \text{ g/dl}$ or $\text{Hct } <33%$",
                    "B. $\text{Hb } <12 \text{ g/dl}$ or $\text{Hct } <36%$",
                    "C. $\text{Hb } <13 \text{ g/dl}$ or $\text{Hct } <39%$",
                    "D. $\text{Hb } <14 \text{ g/dl}$ or $\text{Hct } <42%$",
                    "E. $\text{Hb } <10.0 \text{ g/dl}$ regardless of $\text{Hct}$"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "WHO criteria define anemia in adult females as **$\text{Hb } <12 \text{ g/dl}$** or $\text{Hct } <36%$. (p. 236)",
                "tags": [
                    "anemia",
                    "WHO_criteria",
                    "hematology"
                ]
            },
            {
                "id": 1278,
                "question": "What is the hematologic definition of Anemia for an **adult female**?",
                "choices": [
                    "A. $\text{Hb } <11.0 \text{ g/dl}$ or $\text{Hct } <33%$",
                    "B. $\text{Hb } <12 \text{ g/dl}$ or $\text{Hct } <36%$",
                    "C. $\text{Hb } <13 \text{ g/dl}$ or $\text{Hct } <39%$",
                    "D. $\text{Hb } <14 \text{ g/dl}$ or $\text{Hct } <42%$",
                    "E. $\text{Hb } <10.0 \text{ g/dl}$ regardless of $\text{Hct}$"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.1 Approach to adults with anemia",
                "explanation": "WHO criteria define anemia in adult females as **$\text{Hb } <12 \text{ g/dl}$** or $\text{Hct } <36%$. (p. 236)",
                "tags": [
                    "anemia",
                    "WHO_criteria",
                    "hematology"
                ]
            }
        ]
    },
    "Chapter 7.1.3": {
        "Chapter 7.1.3 Megaloblastic anemia": [
            {
                "id": 1215,
                "question": "Which of the following clinical findings is a **specific feature** of **Vitamin $\text{B}_{12}$ deficiency** (Megaloblastic Anemia) but **not** of Iron Deficiency Anemia?",
                "choices": [
                    "A. Pallor and fatigue.",
                    "B. Peripheral neuropathy (paresthesias).",
                    "C. Glossitis (sore tongue).",
                    "D. Pica.",
                    "E. Dyspnea on exertion."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "**Neurologic or neuropsychiatric manifestations** (peripheral neuropathy, gait disturbance, dementia) are **specific to Vitamin $\text{B}_{12}$ deficiency** and do not occur in folate or iron deficiency anemia. (p. 241)",
                "tags": [
                    "megaloblastic_anemia",
                    "clinical_features",
                    "B12_deficiency"
                ]
            },
            {
                "id": 1216,
                "question": "A 75-year-old male presents with fatigue and weight loss. $\text{Hb } 8.0 \text{ g/dl}$, $\text{MCV } 105 \text{ fl}$. What is the most appropriate **initial diagnostic step** for this type of anemia?",
                "choices": [
                    "A. Stool occult blood test.",
                    "B. Serum $\text{B}_{12}$ and Folate levels.",
                    "C. Serum iron studies.",
                    "D. Blood transfusion.",
                    "E. Colonoscopy and EGD."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "The patient has **Macrocytic Anemia** ($\text{MCV } >100 \text{ fl}$). The initial workup should focus on the cause of megaloblastic anemia by checking **Serum $\text{B}_{12}$ and Folate levels**. (p. 241)",
                "tags": [
                    "megaloblastic_anemia",
                    "diagnosis",
                    "investigation"
                ]
            },
            {
                "id": 1217,
                "question": "In a patient with confirmed folate deficiency, why is it **crucial to ensure that Vitamin $\text{B}_{12}$ deficiency is excluded** before starting Folic Acid therapy alone?",
                "choices": [
                    "A. Folic acid increases the risk of hemorrhage.",
                    "B. Folic acid worsens the anemia of $\text{B}_{12}$ deficiency.",
                    "C. Folic acid worsens the **neurologic manifestations** of $\text{B}_{12}$ deficiency.",
                    "D. Folic acid interacts with concurrent medications.",
                    "E. Folic acid is ineffective unless $\text{B}_{12}$ is supplemented."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "Treatment of $\text{B}_{12}$ deficiency with **Folic Acid alone** can correct the hematologic abnormalities but **may worsen the neurologic manifestations** of $\text{B}_{12}$ deficiency. Therefore, $\text{B}_{12}$ must be excluded or supplemented concomitantly. (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "treatment",
                    "safety"
                ]
            },
            {
                "id": 1218,
                "question": "A patient is admitted with a new diagnosis of **severe Vitamin $\text{B}_{12}$ deficiency** causing neurologic symptoms. What is the recommended **initial schedule** for Cyanocobalamin ($\text{B}_{12}$) administration?",
                "choices": [
                    "A. $1000 \text{ mcg}$ IM once weekly for 4 weeks.",
                    "B. $1000 \text{ mcg}$ IM once monthly for life.",
                    "C. $1000 \text{ mcg}$ IM **every day for one week**.",
                    "D. $100 \text{ mcg}$ IM every day for one week.",
                    "E. $1000 \text{ mcg}$ PO daily for 3 months."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "The recommended schedule for Cyanocobalamin is **$1000 \text{ mcg}$ IM every day for one week**, followed by weekly injections for 4 weeks, and then monthly injections if the cause persists. (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "treatment",
                    "dosing"
                ]
            },
            {
                "id": 1219,
                "question": "Which peripheral blood smear finding is characteristic of **Megaloblastic Anemia**?",
                "choices": [
                    "A. Target cells.",
                    "B. Spherocytes.",
                    "C. Schistocytes.",
                    "D. **Hypersegmentation of Neutrophils**.",
                    "E. Basophilic stippling."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "The characteristic finding is **hypersegmentation of neutrophils** ($ge 5$ lobes), in addition to macro-ovalocytes. (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "clinical_features",
                    "blood_smear"
                ]
            },
            {
                "id": 1220,
                "question": "A patient with anemia ($\text{Hb } 9.0 \text{ g/dl}$) of unknown etiology presents to the clinic. She reports paresthesias and difficulty walking. What is the **most likely deficiency**?",
                "choices": [
                    "A. Folic acid.",
                    "B. Vitamin $\text{B}_{12}$.",
                    "C. Iron.",
                    "D. Vitamin $\text{C}$.",
                    "E. Vitamin $\text{D}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "**Neurologic symptoms** (paresthesias, gait disturbance, difficulty walking) are classic manifestations of **Vitamin $\text{B}_{12}$ deficiency** as it affects the nervous system. (p. 241)",
                "tags": [
                    "megaloblastic_anemia",
                    "clinical_features",
                    "B12_deficiency"
                ]
            },
            {
                "id": 1221,
                "question": "A patient is found to have anemia with an $\text{MCV}$ of $110 \text{ fl}$ and low serum folate but normal $\text{B}_{12}$ levels. What is the recommended treatment regimen?",
                "choices": [
                    "A. Cyanocobalamin $1000 \text{ mcg}$ IM monthly.",
                    "B. Folic Acid $1 \text{ mg}$ PO daily for $1-4$ months.",
                    "C. Folic Acid $5 \text{ mg}$ PO daily PLUS Cyanocobalamin $1000 \text{ mcg}$ IM daily.",
                    "D. Only dietary changes.",
                    "E. Blood transfusion and observation."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "Confirmed folate deficiency (with $\text{B}_{12}$ excluded) is treated with **Folic Acid $1$ to $5 \text{ mg}$ PO daily for $1-4$ months**, or until complete hematologic recovery. (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "treatment",
                    "folate_deficiency"
                ]
            },
            {
                "id": 1222,
                "question": "In the workup for megaloblastic anemia, what is the significance of obtaining an $\text{RBC}$ folate level rather than just the serum folate level?",
                "choices": [
                    "A. Serum folate is more accurate in deficiency states.",
                    "B. $\text{RBC}$ folate reflects long-term body stores, less affected by acute intake.",
                    "C. $\text{RBC}$ folate is easier and cheaper to measure.",
                    "D. Serum folate can never be used for diagnosis.",
                    "E. Only serum $\text{B}_{12}$ and $\text{RBC}$ folate are needed."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "The **$\text{RBC}$ folate level** is obtained if serum folate is normal or indeterminate, as it **reflects long-term body stores** and is less affected by acute dietary intake. (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "investigation",
                    "folate_level"
                ]
            },
            {
                "id": 1224,
                "question": "What is the **oral maintenance dose** of Folic Acid recommended for the treatment of folate deficiency?",
                "choices": [
                    "A. $10 \text{ mg}$ PO daily.",
                    "B. $1$ to $5 \text{ mg}$ PO daily.",
                    "C. $1 \text{ mg}$ PO weekly.",
                    "D. $50 \text{ mcg}$ PO daily.",
                    "E. $1000 \text{ mcg}$ PO daily."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "Folic Acid is administered at $1$ to $5 \text{ mg}$ PO daily until recovery. (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "treatment",
                    "dosing"
                ]
            },
            {
                "id": 1225,
                "question": "A patient with severe Vitamin $\text{B}_{12}$ deficiency and neurologic symptoms is started on $1000 \text{ mcg}$ IM daily. After one week, what is the **appropriate continuation of the schedule**?",
                "choices": [
                    "A. Stop injections and start $1000 \text{ mcg}$ PO daily for life.",
                    "B. $1000 \text{ mcg}$ IM once weekly for four weeks.",
                    "C. $1000 \text{ mcg}$ IM every month for life.",
                    "D. $100 \text{ mcg}$ IM every day for one more week.",
                    "E. $1000 \text{ mcg}$ IM once weekly for one month and then monthly for life."
                ],
                "correctAnswer": 4,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "The initial schedule is daily for one week, followed by $1000 \text{ mcg}$ IM **every week for four weeks**. The monthly maintenance dose begins after this period. (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "treatment",
                    "dosing"
                ]
            },
            {
                "id": 1227,
                "question": "A 55-year-old female presents with fatigue. $\text{Hb } 11.5 \text{ g/dl}$, $\text{MCV } 108 \text{ fl}$. Peripheral smear shows **hypersegmented neutrophils**. What is the most likely cause of her macrocytic anemia?",
                "choices": [
                    "A. Iron deficiency.",
                    "B. Thalassemia.",
                    "C. Megaloblastic anemia ($\text{B}_{12}$ or Folate deficiency).",
                    "D. Anemia of Chronic Disease.",
                    "E. Hemolytic anemia."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "The finding of **hypersegmented neutrophils** on a peripheral smear is a characteristic feature of **Megaloblastic Anemia** ($\text{B}_{12}$ or Folate deficiency). (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "clinical_features",
                    "diagnosis"
                ]
            },
            {
                "id": 1229,
                "question": "In the management of a patient with **Megaloblastic Anemia** due to confirmed Vitamin $\text{B}_{12}$ deficiency, how long should the initial loading schedule (daily injections) be continued?",
                "choices": [
                    "A. 48 hours.",
                    "B. 5 days.",
                    "C. 7 days.",
                    "D. 4 weeks.",
                    "E. 6 months."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "The initial schedule for Cyanocobalamin is IM **every day for one week** (7 days). (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "treatment",
                    "dosing"
                ]
            },
            {
                "id": 1232,
                "question": "A patient with megaloblastic anemia due to Folic Acid deficiency is started on Folic Acid $5 \text{ mg}$ PO daily. What is the minimum duration of therapy required to ensure adequate treatment?",
                "choices": [
                    "A. 7 days.",
                    "B. 10 days.",
                    "C. $1-4$ months.",
                    "D. 6 months.",
                    "E. $12$ months."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "Folic Acid is administered for **$1$ to $4$ months**, or until complete hematologic recovery occurs. (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "treatment_duration",
                    "folate_deficiency"
                ]
            },
            {
                "id": 1236,
                "question": "A patient presents with anemia. His peripheral smear shows **Macrocytosis** and **Hypersegmented Neutrophils**. Which condition is the **most likely cause**?",
                "choices": [
                    "A. Chronic kidney disease.",
                    "B. Iron deficiency anemia.",
                    "C. Vitamin $\text{B}_{12}$ or Folate deficiency.",
                    "D. Acute hemorrhage.",
                    "E. Sickle cell disease."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "Macrocytosis with **Hypersegmented Neutrophils** is the classic description of **Megaloblastic Anemia** ($\text{B}_{12}$ or Folate deficiency). (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "clinical_features",
                    "diagnosis"
                ]
            },
            {
                "id": 1237,
                "question": "What is the duration of the IM phase of the initial treatment schedule for Cyanocobalamin in severe Vitamin $\text{B}_{12}$ deficiency?",
                "choices": [
                    "A. 1 day.",
                    "B. 3 days.",
                    "C. 7 days.",
                    "D. 14 days.",
                    "E. 30 days."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "The initial treatment schedule is $\text{B}_{12}$ IM **every day for one week** (7 days). (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "treatment",
                    "dosing"
                ]
            },
            {
                "id": 1239,
                "question": "Which clinical manifestation is highly suggestive of **Vitamin $\text{B}_{12}$ deficiency** and requires urgent treatment with $\text{B}_{12}$?",
                "choices": [
                    "A. Pica.",
                    "B. Koilonychia.",
                    "C. Peripheral neuropathy.",
                    "D. Glossitis.",
                    "E. Anorexia."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "The most concerning and urgent manifestation of $\text{B}_{12}$ deficiency is **peripheral neuropathy** due to the risk of irreversible neurologic damage. (p. 241)",
                "tags": [
                    "megaloblastic_anemia",
                    "clinical_features",
                    "B12_deficiency"
                ]
            },
            {
                "id": 1241,
                "question": "What is the recommended treatment for a patient with confirmed **Folic Acid deficiency** and normal $\text{B}_{12}$ levels?",
                "choices": [
                    "A. Cyanocobalamin $1000 \text{ mcg}$ IM weekly.",
                    "B. Folic Acid $1 \text{ mg}$ PO daily for $1-4$ months.",
                    "C. Folic Acid $5 \text{ mg}$ PO daily PLUS $1000 \text{ mcg}$ IM $\text{B}_{12}$ daily.",
                    "D. Oral Ferrous Sulfate $325 \text{ mg}$ TID.",
                    "E. $10 \text{ mg}$ Folic Acid PO daily for life."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "Folate deficiency (with $\text{B}_{12}$ excluded) is treated with **Folic Acid $1$ to $5 \text{ mg}$ PO daily for $1-4$ months**, or until complete hematologic recovery. (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "treatment",
                    "folate_deficiency"
                ]
            },
            {
                "id": 1243,
                "question": "A patient presents with fatigue. $\text{Hb } 9.0 \text{ g/dl}$, $\text{MCV } 115 \text{ fl}$. Peripheral smear shows large $\text{RBCs}$ and $\text{WBCs}$. What is the most likely cause of his macrocytic anemia?",
                "choices": [
                    "A. Hemolysis.",
                    "B. Iron deficiency.",
                    "C. Vitamin $\text{B}_{12}$ or Folate deficiency.",
                    "D. Acute blood loss.",
                    "E. Thalassemia."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "Macrocytic anemia with abnormal $\text{WBC}$ precursors (Megaloblasts) is characteristic of **Megaloblastic Anemia** ($\text{B}_{12}$ or Folate deficiency). (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "diagnosis"
                ]
            },
            {
                "id": 1246,
                "question": "A patient presents with severe anemia ($\text{Hb } 6.8 \text{ g/dl}$) and a history of gastric bypass surgery. He is hemodynamically stable. What type of anemia is **most likely** in this setting, and what is the key cause?",
                "choices": [
                    "A. Hemolytic anemia; Autoimmune destruction.",
                    "B. Iron deficiency anemia; Chronic blood loss.",
                    "C. Megaloblastic anemia; $\text{B}_{12}$ malabsorption.",
                    "D. Normocytic anemia; Acute hemorrhage.",
                    "E. Anemia of Chronic Disease; Inflammation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "**Gastric surgery** (bypass/gastrectomy) can lead to impaired production of intrinsic factor, causing **Vitamin $\text{B}_{12}$ malabsorption**, which results in **Megaloblastic Anemia**. (p. 241)",
                "tags": [
                    "megaloblastic_anemia",
                    "etiology",
                    "gastric_surgery"
                ]
            },
            {
                "id": 1247,
                "question": "A 40-year-old vegetarian presents with megaloblastic anemia. What is the key therapeutic difference in his initial treatment compared to a patient with Pernicious Anemia?",
                "choices": [
                    "A. He requires only $\text{B}_{12}$ supplementation.",
                    "B. He requires only Folic Acid supplementation.",
                    "C. He requires $\text{B}_{12}$ supplementation and dietary counseling, but not lifelong therapy.",
                    "D. He requires a bone marrow biopsy before starting treatment.",
                    "E. He needs weekly IV iron supplementation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "A strict vegetarian's $\text{B}_{12}$ deficiency is dietary, meaning they need $\text{B}_{12}$ replacement and dietary changes. **Pernicious Anemia** (gastric cause) requires **lifelong** $\text{B}_{12}$ therapy, whereas a strict vegetarian only needs $\text{B}_{12}$ as long as they maintain the dietary restriction. (p. 241, 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "treatment",
                    "B12_deficiency"
                ]
            },
            {
                "id": 1275,
                "question": "What is the duration of the IM phase of the initial treatment schedule for Cyanocobalamin in severe Vitamin $\text{B}_{12}$ deficiency?",
                "choices": [
                    "A. 1 day.",
                    "B. 3 days.",
                    "C. 7 days.",
                    "D. 14 days.",
                    "E. 30 days."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "The initial treatment schedule is $\text{B}_{12}$ IM **every day for one week** (7 days). (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "treatment",
                    "dosing"
                ]
            },
            {
                "id": 1277,
                "question": "A patient presents with severe anemia ($\text{Hb } 6.8 \text{ g/dl}$) and a history of gastric bypass surgery. He is hemodynamically stable. What type of anemia is **most likely** in this setting, and what is the key cause?",
                "choices": [
                    "A. Hemolytic anemia; Autoimmune destruction.",
                    "B. Iron deficiency anemia; Chronic blood loss.",
                    "C. Megaloblastic anemia; $\text{B}_{12}$ malabsorption.",
                    "D. Normocytic anemia; Acute hemorrhage.",
                    "E. Anemia of Chronic Disease; Inflammation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "**Gastric surgery** (bypass/gastrectomy) can lead to impaired production of intrinsic factor, causing **Vitamin $\text{B}_{12}$ malabsorption**, which results in **Megaloblastic Anemia**. (p. 241)",
                "tags": [
                    "megaloblastic_anemia",
                    "etiology",
                    "gastric_surgery"
                ]
            },
            {
                "id": 1279,
                "question": "A patient with $\text{Hb } 9.0 \text{ g/dl}$, $\text{MCV } 115 \text{ fl}$. Peripheral smear shows large $\text{RBCs}$ and $\text{WBCs}$. What is the most likely cause of his macrocytic anemia?",
                "choices": [
                    "A. Hemolysis.",
                    "B. Iron deficiency.",
                    "C. Vitamin $\text{B}_{12}$ or Folate deficiency.",
                    "D. Acute blood loss.",
                    "E. Thalassemia."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.1.3 Megaloblastic anemia",
                "explanation": "Macrocytic anemia with abnormal $\text{WBC}$ precursors (Megaloblasts) is characteristic of **Megaloblastic Anemia** ($\text{B}_{12}$ or Folate deficiency). (p. 242)",
                "tags": [
                    "megaloblastic_anemia",
                    "diagnosis"
                ]
            }
        ]
    },
    "Chapter 7.2.1": {
        "Chapter 7.2.1 Thrombocytopenia in hospitalized patients": [
            {
                "id": 1249,
                "question": "A 55-year-old hospitalized patient develops a new onset of thrombocytopenia (platelet count $40,000/mu l$). The primary approach to management should be to:",
                "choices": [
                    "A. Start prophylactic platelet transfusion immediately.",
                    "B. Administer high-dose IV corticosteroids.",
                    "C. Search for and treat the underlying cause of thrombocytopenia.",
                    "D. Initiate immediate IV Immunoglobulin (IVIg).",
                    "E. Start empiric broad-spectrum antibiotics."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.2.1 Thrombocytopenia in hospitalized patients",
                "explanation": "In acutely ill hospitalized patients, **treatment of the underlying cause** (e.g., sepsis, drugs, DIC, HIT, malaria) is the **mainstay of management** for thrombocytopenia. (p. 248)",
                "tags": [
                    "thrombocytopenia",
                    "hospitalized_patients",
                    "management"
                ]
            },
            {
                "id": 1251,
                "question": "A 65-year-old patient who started Heparin therapy 7 days ago develops thrombocytopenia (platelet count dropped by $60%$ from baseline). He has no active bleeding but shows signs of DVT. Which condition should be ruled out, and what is the **immediate intervention**?",
                "choices": [
                    "A. Disseminated Intravascular Coagulation (DIC); Start Fresh Frozen Plasma (FFP).",
                    "B. Immune Thrombocytopenia (ITP); Start IVIg.",
                    "C. Heparin-Induced Thrombocytopenia (HIT); **Stop Heparin immediately.**",
                    "D. Sepsis; Start broad-spectrum antibiotics.",
                    "E. Drug-induced thrombocytopenia; Continue Heparin and monitor."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.2.1 Thrombocytopenia in hospitalized patients",
                "explanation": "This clinical picture (thrombocytopenia after 5-10 days of Heparin, associated with thrombosis) is highly suggestive of **HIT**. The immediate intervention is to **Stop Heparin immediately**. (p. 247, 258)",
                "tags": [
                    "thrombocytopenia",
                    "HIT",
                    "management"
                ]
            },
            {
                "id": 1255,
                "question": "What is the platelet count threshold below which **prophylactic platelet transfusion** is generally recommended for an admitted patient **without active bleeding**?",
                "choices": [
                    "A. $<50,000/mu l$.",
                    "B. $<30,000/mu l$.",
                    "C. $<20,000/mu l$.",
                    "D. $<10,000/mu l$.",
                    "E. $<5,000/mu l$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.2.1 Thrombocytopenia in hospitalized patients",
                "explanation": "In patients **without active bleeding**, prophylactic platelet transfusion should generally be **avoided** unless the platelet count is **$<10,000/mu l$**. (p. 248)",
                "tags": [
                    "thrombocytopenia",
                    "transfusion_indication",
                    "prophylactic"
                ]
            },
            {
                "id": 1256,
                "question": "A patient with acute, life-threatening hemorrhage and thrombocytopenia (platelet count $10,000/mu l$) is admitted to the $\text{ER}$. What is the **immediate intervention** regarding platelet replacement?",
                "choices": [
                    "A. Defer transfusion until the cause is found.",
                    "B. Give prophylactic platelet transfusion.",
                    "C. Give platelet transfusion immediately, as active bleeding is present.",
                    "D. Start high-dose oral prednisone.",
                    "E. Give FFP and Vitamin $\text{K}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.2.1 Thrombocytopenia in hospitalized patients",
                "explanation": "**Platelet transfusion** is indicated if there is **active bleeding** and the platelet count is **$<50,000/mu l$**. In this case, active, life-threatening bleeding requires immediate transfusion. (p. 248)",
                "tags": [
                    "thrombocytopenia",
                    "transfusion_indication",
                    "active_bleeding"
                ]
            },
            {
                "id": 1257,
                "question": "A patient is admitted with severe sepsis and develops thrombocytopenia ($50,000/mu l$). What is the primary management strategy for this thrombocytopenia?",
                "choices": [
                    "A. Immediate platelet transfusion.",
                    "B. High-dose IVIg therapy.",
                    "C. Treatment of the underlying cause (sepsis) with antibiotics.",
                    "D. Urgent splenectomy.",
                    "E. Empiric high-dose steroids."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.2.1 Thrombocytopenia in hospitalized patients",
                "explanation": "In acutely ill hospitalized patients, the primary management of thrombocytopenia is always directed at **treating the underlying cause**, in this case, **sepsis**. (p. 248)",
                "tags": [
                    "thrombocytopenia",
                    "sepsis",
                    "management"
                ]
            },
            {
                "id": 1262,
                "question": "A patient is admitted with a severe head injury and develops thrombocytopenia ($30,000/mu l$). What is the platelet threshold below which major neurosurgery typically has a high risk of bleeding?",
                "choices": [
                    "A. $<30,000/mu l$.",
                    "B. $<50,000/mu l$.",
                    "C. $<75,000/mu l$.",
                    "D. $<100,000/mu l$.",
                    "E. $<150,000/mu l$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.2.1 Thrombocytopenia in hospitalized patients",
                "explanation": "The surgical bleeding risk is high when platelet counts are **$<50,000/mu l$** generally, but for major surgery (like neurosurgery), the risk is high when platelets are **$<100,000/mu l$**. (p. 246)",
                "tags": [
                    "thrombocytopenia",
                    "transfusion_indication",
                    "surgery"
                ]
            },
            {
                "id": 1263,
                "question": "What is the platelet count threshold used to define **Severe Thrombocytopenia**?",
                "choices": [
                    "A. $<150,000/mu l$.",
                    "B. $<100,000/mu l$.",
                    "C. $<50,000/mu l$.",
                    "D. $<20,000/mu l$.",
                    "E. $<10,000/mu l$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.2.1 Thrombocytopenia in hospitalized patients",
                "explanation": "Thrombocytopenia is defined as platelets $<150,000/mu l$. Severe thrombocytopenia is defined as **$<50,000/mu l$**. (p. 246)",
                "tags": [
                    "thrombocytopenia",
                    "definition"
                ]
            },
            {
                "id": 1264,
                "question": "A patient with thrombocytopenia (platelet count $45,000/mu l$) is on Warfarin for atrial fibrillation. She has no active bleeding. What is the **appropriate step** regarding her anticoagulation therapy?",
                "choices": [
                    "A. Continue Warfarin and monitor platelet count daily.",
                    "B. Increase Warfarin dose to maintain high INR.",
                    "C. **Hold Warfarin** and re-evaluate the need for anticoagulation.",
                    "D. Transfuse platelets to raise the count to $100,000/mu l$.",
                    "E. Switch Warfarin to Aspirin."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.2.1 Thrombocytopenia in hospitalized patients",
                "explanation": "When the platelet count is **$<30,000/mu l$**, antiplatelet agents and anticoagulants should be **held**. At $45,000/mu l$, the risk is still high and holding the Warfarin is appropriate until the cause is found and platelets stabilize. (p. 248)",
                "tags": [
                    "thrombocytopenia",
                    "anticoagulation_management"
                ]
            },
            {
                "id": 1267,
                "question": "Which of the following is a key component of the initial workup for **Thrombocytopenia in hospitalized patients**?",
                "choices": [
                    "A. Immediate platelet transfusion.",
                    "B. Discontinuation of all medications.",
                    "C. Detailed drug history and clinical assessment for HIT/DIC/sepsis.",
                    "D. Empiric IVIg administration.",
                    "E. Urgent splenectomy consultation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.2.1 Thrombocytopenia in hospitalized patients",
                "explanation": "The clinical evaluation requires a **detailed clinical history** (especially **drug history** for HIT or drug-induced causes) and assessment for life-threatening causes like DIC/sepsis. (p. 247)",
                "tags": [
                    "thrombocytopenia",
                    "workup"
                ]
            },
            {
                "id": 1270,
                "question": "What is the primary factor used to define the category of **Severe Thrombocytopenia**?",
                "choices": [
                    "A. Presence of petechiae.",
                    "B. Platelet count **$<50,000/mu l$**.",
                    "C. Platelet count $<100,000/mu l$ with thrombosis.",
                    "D. Drop in platelet count by $50%$ from baseline.",
                    "E. Presence of a splenectomy scar."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.2.1 Thrombocytopenia in hospitalized patients",
                "explanation": "Severe thrombocytopenia is defined quantitatively by a platelet count of **$<50,000/mu l$**. (p. 246)",
                "tags": [
                    "thrombocytopenia",
                    "definition"
                ]
            }
        ]
    },
    "Chapter 7.2.2": {
        "Chapter 7.2.2 Immune Thrombocytopenia (ITP)": [
            {
                "id": 1252,
                "question": "A 3-year-old child presents to the $\text{ER}$ with sudden onset of petechiae and ecchymoses following a viral illness two weeks ago. Platelet count is $15,000/mu l$. Diagnosis of Immune Thrombocytopenia (ITP) is suspected. Which treatment is **indicated**?",
                "choices": [
                    "A. Prophylactic platelet transfusion.",
                    "B. High-dose IV corticosteroids.",
                    "C. No treatment, as platelet count is $>10,000/mu l$ and bleeding is minor.",
                    "D. Splenectomy immediately.",
                    "E. Warfarin anticoagulation."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "In ITP, treatment is indicated if the platelet count is **$<30,000/mu l$**. **High-dose corticosteroids** (Dexamethasone/Prednisolone) are the **first-line** treatment. (p. 250, 251)",
                "tags": [
                    "ITP",
                    "pediatrics",
                    "treatment"
                ]
            },
            {
                "id": 1253,
                "question": "What is the primary management goal for initiating treatment in a patient newly diagnosed with Immune Thrombocytopenia (ITP)?",
                "choices": [
                    "A. Achieve a normal platelet count ($>150,000/mu l$).",
                    "B. Achieve a platelet count high enough to **prevent major bleeding** ($>30,000/mu l$).",
                    "C. Cure the underlying autoimmune disorder.",
                    "D. Initiate maintenance steroid therapy for life.",
                    "E. Prepare for splenectomy within 6 weeks."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "The objective of ITP treatment is **not to bring the platelet count to normal levels**, but to **increase the platelet count to a safe level** to **prevent major bleeding** ($>30,000/mu l$). (p. 250)",
                "tags": [
                    "ITP",
                    "treatment_goals"
                ]
            },
            {
                "id": 1254,
                "question": "A 40-year-old patient with ITP presents with a nosebleed and a platelet count of $18,000/mu l$. The most appropriate **first-line drug** therapy is:",
                "choices": [
                    "A. High-dose Dexamethasone (40 mg PO daily for 4 days).",
                    "B. Warfarin to prevent thrombosis.",
                    "C. Platelet transfusion immediately.",
                    "D. IV Immunoglobulin (IVIg) monotherapy.",
                    "E. Oral Dapsone."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "Treatment is indicated for platelet count $<30,000/mu l$. **High-dose corticosteroids** (Dexamethasone $40 \text{ mg}$ PO daily for 4 consecutive days) are the **first-line** regimen. (p. 250, 251)",
                "tags": [
                    "ITP",
                    "treatment",
                    "corticosteroids"
                ]
            },
            {
                "id": 1258,
                "question": "A patient with newly diagnosed ITP (platelet count $25,000/mu l$) is being initiated on corticosteroids. What is the recommended **initial regimen** for high-dose Dexamethasone?",
                "choices": [
                    "A. $40 \text{ mg}$ PO daily for 7 days, then taper.",
                    "B. $40 \text{ mg}$ PO daily for **4 consecutive days**, with no tapering.",
                    "C. $1 \text{ mg/kg}$ PO daily for 14 days, then taper.",
                    "D. $20 \text{ mg}$ IM weekly for 4 weeks.",
                    "E. $10 \text{ mg}$ IV daily for 10 days."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "The high-dose Dexamethasone regimen is $40 \text{ mg}$ PO daily for **4 consecutive days**, followed by repeating the 4-day cycles every $2-4$ weeks for $4-6$ cycles. **No tapering** is required for the 4-day course. (p. 250, 251)",
                "tags": [
                    "ITP",
                    "treatment",
                    "corticosteroids",
                    "dosing"
                ]
            },
            {
                "id": 1259,
                "question": "A patient with chronic ITP has a persistent platelet count of $45,000/mu l$ and no active bleeding. Which ongoing therapy or intervention is **not indicated**?",
                "choices": [
                    "A. Active monitoring of platelet count.",
                    "B. Prophylactic platelet transfusion.",
                    "C. Patient education on bleeding risk.",
                    "D. Avoidance of high-risk trauma sports.",
                    "E. Use of corticosteroids for a major bleed."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "The primary goal is to keep the platelet count $>30,000/mu l$ and prevent major bleeding. With a count of $45,000/mu l$ and no bleeding, **Prophylactic platelet transfusion** is **not indicated** as per the threshold ($<10,000/mu l$). (p. 248, 250)",
                "tags": [
                    "ITP",
                    "management",
                    "transfusion_indication"
                ]
            },
            {
                "id": 1260,
                "question": "A patient has a platelet count of $15,000/mu l$ due to ITP. He develops a severe headache and confusion. What is the **immediate intervention**?",
                "choices": [
                    "A. Initiate prophylactic platelet transfusion.",
                    "B. Start high-dose oral prednisone only.",
                    "C. Give platelet transfusion immediately, as intracranial hemorrhage is a concern.",
                    "D. Wait for definitive imaging (CT scan) before transfusing.",
                    "E. Start an oral antiplatelet agent."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "Severe headache and confusion in a patient with severe thrombocytopenia ($<30,000/mu l$) suggests a possible **intracranial hemorrhage**, which is a life-threatening bleed. **Platelet transfusion is indicated immediately** in this scenario. (p. 250)",
                "tags": [
                    "ITP",
                    "management",
                    "life_threatening_bleeding"
                ]
            },
            {
                "id": 1261,
                "question": "A patient with known ITP is managed with a tapering dose of Prednisolone. She develops a new petechial rash and her platelet count drops from $80,000/mu l$ to $20,000/mu l$. The ITP is now classified as:",
                "choices": [
                    "A. Newly diagnosed ITP.",
                    "B. Persistent ITP.",
                    "C. Chronic ITP.",
                    "D. Splenectomy candidate.",
                    "E. Steroid-dependent ITP."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "**Persistent ITP** is defined as ITP lasting between **$3-12$ months**. If the ITP lasts more than 12 months, it is classified as Chronic ITP. (p. 250)",
                "tags": [
                    "ITP",
                    "classification"
                ]
            },
            {
                "id": 1265,
                "question": "A patient with newly diagnosed ITP is started on the high-dose Dexamethasone regimen. How long should she continue treatment in the first cycle?",
                "choices": [
                    "A. 21 days with slow tapering.",
                    "B. 14 days with medium tapering.",
                    "C. **4 consecutive days with no tapering.**",
                    "D. 7 days with rapid tapering.",
                    "E. Until platelet count is $>100,000/mu l$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "The high-dose Dexamethasone regimen is $40 \text{ mg}$ PO daily for **4 consecutive days, with no tapering** needed for that cycle. (p. 250, 251)",
                "tags": [
                    "ITP",
                    "treatment",
                    "corticosteroids",
                    "dosing"
                ]
            },
            {
                "id": 1266,
                "question": "A patient with ITP has a severe life-threatening hemorrhage. What is the **emergency intervention** regarding platelet replacement?",
                "choices": [
                    "A. Only high-dose IV corticosteroids.",
                    "B. Only IV Immunoglobulin (IVIg).",
                    "C. **Platelet transfusion immediately.**",
                    "D. Urgent FFP infusion.",
                    "E. Ristocetin cofactor assay."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "Although platelet transfusion is usually avoided in ITP, the indication for transfusion is **life-threatening bleeding only**. (p. 250)",
                "tags": [
                    "ITP",
                    "transfusion_indication",
                    "emergency"
                ]
            },
            {
                "id": 1268,
                "question": "A patient with thrombocytopenia (platelet count $10,000/mu l$) is being managed as an outpatient for chronic ITP. She has no active bleeding. What is the appropriate management decision?",
                "choices": [
                    "A. Initiate prophylactic platelet transfusion.",
                    "B. Initiate a course of high-dose corticosteroids.",
                    "C. Transfuse immediately, as the threshold is met.",
                    "D. Hold all therapy and monitor daily.",
                    "E. Splenectomy immediately."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "In ITP, treatment is indicated if the platelet count is **$<30,000/mu l$**. Corticosteroids are the first-line treatment. (p. 250)",
                "tags": [
                    "ITP",
                    "treatment"
                ]
            },
            {
                "id": 1269,
                "question": "Which of the following conditions is **not** required to be excluded before making a definitive diagnosis of **Immune Thrombocytopenia (ITP)**?",
                "choices": [
                    "A. HIV infection.",
                    "B. HCV infection.",
                    "C. Hypothyroidism.",
                    "D. Chronic Lymphocytic Leukemia (CLL).",
                    "E. Systemic Lupus Erythematosus (SLE)."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "ITP is a diagnosis of exclusion. Conditions like HIV, HCV, SLE, and CLL must be excluded as causes of secondary immune thrombocytopenia. While autoimmune thyroid diseases are common in ITP, **hypothyroidism** is not explicitly listed as a primary condition that must be excluded before the diagnosis of ITP is made. (p. 249, 250)",
                "tags": [
                    "ITP",
                    "diagnosis_of_exclusion"
                ]
            },
            {
                "id": 1271,
                "question": "A patient with ITP has a platelet count of $35,000/mu l$ and is asymptomatic. What is the recommended management?",
                "choices": [
                    "A. Initiate a course of high-dose corticosteroids.",
                    "B. Active monitoring with no immediate treatment.",
                    "C. Platelet transfusion immediately.",
                    "D. Urgent splenectomy consultation.",
                    "E. Warfarin anticoagulation."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "For patients with ITP, if the platelet count is **$>30,000/mu l$ and there is no active bleeding**, they generally do **not need treatment** and should be followed with **active monitoring**. (p. 250)",
                "tags": [
                    "ITP",
                    "management"
                ]
            },
            {
                "id": 1272,
                "question": "A patient with newly diagnosed ITP (platelet count $20,000/mu l$) is started on oral Prednisolone $1 \text{ mg/kg}$ daily. If responsive, how long should the initial high dose typically be continued before beginning to taper?",
                "choices": [
                    "A. 4 days.",
                    "B. 1-2 weeks.",
                    "C. 4 weeks.",
                    "D. 3 months.",
                    "E. 6 months."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "For Prednisolone, the initial high dose ($1 \text{ mg/kg}$) is typically given for **1-2 weeks** before tapering begins. (p. 251)",
                "tags": [
                    "ITP",
                    "treatment",
                    "dosing"
                ]
            },
            {
                "id": 1273,
                "question": "A patient with thrombocytopenia (platelet count $15,000/mu l$) is being evaluated for ITP. Which finding would make the diagnosis of ITP **unlikely** and prompt a search for a secondary cause?",
                "choices": [
                    "A. Absence of active bleeding.",
                    "B. Normal white blood cell and hemoglobin counts.",
                    "C. Concomitant low hemoglobin and low WBC count.",
                    "D. History of recent viral illness.",
                    "E. Isolated platelet decrease."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "ITP is characterized by **isolated thrombocytopenia** (normal WBC and Hb). The presence of **concomitant cytopenia** (low Hb and WBC) would make ITP **unlikely** and suggests an alternative diagnosis like malignancy or systemic failure. (p. 249)",
                "tags": [
                    "ITP",
                    "diagnosis",
                    "differential_diagnosis"
                ]
            },
            {
                "id": 1274,
                "question": "A patient with ITP is treated with Dexamethasone and achieves a platelet count $>50,000/mu l$. The ITP condition is now classified as:",
                "choices": [
                    "A. Treatment failure.",
                    "B. Response.",
                    "C. Relapse.",
                    "D. Chronic.",
                    "E. Steroid resistance."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.2.2 Immune Thrombocytopenia (ITP)",
                "explanation": "Response is defined as achieving a platelet count **$>30,000/mu l$ and at least doubling from the baseline**. Achieving $>50,000/mu l$ meets the 'response' criteria. (p. 251)",
                "tags": [
                    "ITP",
                    "response_criteria"
                ]
            }
        ]
    },
    "Chapter 7.3": {
        "Chapter 7.3 Blood Transfusion and Transfusion Reactions": [
            {
                "id": 1281,
                "question": "A 55-year-old hospitalized medical patient is being considered for Packed Red Blood Cell (PRBC) transfusion due to fatigue. He has no cardiac symptoms or active bleeding. His current Hemoglobin (Hb) is $7.5 \text{ g/dl}$. Based on general guidelines, what is the appropriate transfusion decision?",
                "choices": [
                    "A. Transfuse immediately because Hb is below the threshold of $8.0 \text{ g/dl}$ for medical patients.",
                    "B. Transfuse only if Hb drops below $6.0 \text{ g/dl}$ to conserve blood products.",
                    "C. Transfuse immediately because $\text{Hb}$ is below the threshold of $7.0 \text{ g/dl}$ for medical patients.",
                    "D. Transfuse only if he develops hemodynamic instability or symptoms of tissue hypoxia.",
                    "E. Transfuse only if undergoing major surgery soon."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Transfusion is generally indicated at $\text{Hb} <7.0 \text{ g/dl}$ for most hospitalized medical patients. The appropriate threshold for transfusion in this stable patient is $\text{Hb} <7 \text{ g/dl}$ or if they become symptomatic for anemia (e.g., severe dyspnea, heart failure). (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "transfusion_threshold"
                ]
            },
            {
                "id": 1282,
                "question": "A 68-year-old male with a history of Chronic Coronary Syndrome (CCS) is admitted for non-cardiac surgery. His pre-operative Hb is $8.2 \text{ g/dl}$. What is the recommended transfusion threshold for this patient?",
                "choices": [
                    "A. Transfuse if $\text{Hb}$ drops below $10.0 \text{ g/dl}$.",
                    "B. Transfuse if $\text{Hb}$ drops below $9.0 \text{ g/dl}$.",
                    "C. Transfuse if $\text{Hb}$ drops below $8.0 \text{ g/dl}$.",
                    "D. Transfuse if $\text{Hb}$ drops below $7.0 \text{ g/dl}$.",
                    "E. Transfuse only if active bleeding occurs during surgery."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Transfusion is indicated for patients with pre-existing **chronic cardiac disease** or those undergoing orthopedic or cardiac surgery if the **$\text{Hb}$ is below $8.0 \text{ g/dl}$**. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "transfusion_threshold",
                    "cardiac_disease"
                ]
            },
            {
                "id": 1283,
                "question": "A 25-year-old trauma patient is rushed to the $\text{ER}$ with active, uncontrolled bleeding following a motor vehicle accident. His initial $\text{Hb}$ is $12.0 \text{ g/dl}$. What is the primary guiding factor for the immediate blood product administration?",
                "choices": [
                    "A. Wait for the $\text{Hb}$ to drop below $8.0 \text{ g/dl}$.",
                    "B. Wait for the $\text{Hb}$ to drop below $7.0 \text{ g/dl}$.",
                    "C. Transfuse based on the **hemodynamic status and ongoing nature of bleeding**.",
                    "D. Transfuse only fresh frozen plasma (FFP).",
                    "E. Give crystalloids and withhold blood products until $\text{Hb}$ drops."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "In **acutely bleeding patients**, $\text{Hb}$ or $\text{Hct}$ values can be falsely elevated. Transfusion decisions should be based on the **hemodynamic status and ongoing nature of bleeding**, not just the initial $\text{Hb}$ value. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "acute_bleeding",
                    "hemodynamic_status"
                ]
            },
            {
                "id": 1284,
                "question": "During a blood transfusion, a patient suddenly develops **fever, chills, and flank pain**. You suspect an Acute Intravascular Hemolytic Reaction. What is the **first and most critical step** in management?",
                "choices": [
                    "A. Administer IV Hydrocortisone $100 \text{ mg}$.",
                    "B. Administer IV Epinephrine.",
                    "C. **Stop the transfusion immediately.**",
                    "D. Slow the infusion rate and monitor.",
                    "E. Administer IV Furosemide."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "In an acute reaction, the **first and most critical step** is to **Stop the transfusion and remove the giving set**. (p. 252)",
                "tags": [
                    "transfusion_reaction",
                    "hemolytic_reaction",
                    "emergency_management"
                ]
            },
            {
                "id": 1285,
                "question": "A patient undergoing an $\text{RBC}$ transfusion develops urticaria and itching without respiratory distress or hemodynamic changes. Which type of reaction is most likely, and what is the appropriate intervention?",
                "choices": [
                    "A. Anaphylactic reaction; IV Epinephrine.",
                    "B. Febrile Non-Hemolytic Transfusion Reaction; Antipyretics.",
                    "C. Transfusion-Associated Circulatory Overload (TACO); Furosemide.",
                    "D. **Mild Allergic Reaction; Antihistamines.**",
                    "E. Acute Hemolytic Reaction; Stop transfusion."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Urticaria and itching alone suggest a **mild allergic reaction**. In mild reactions, the response is to give **antihistamines**. (p. 252)",
                "tags": [
                    "transfusion_reaction",
                    "allergic_reaction"
                ]
            },
            {
                "id": 1286,
                "question": "A physician orders blood transfusion for a patient with severe chronic anemia and a $\text{Hb}$ of $6.0 \text{ g/dl}$. The patient has known Congestive Heart Failure ($\text{CHF}$). What is the critical modification needed for this transfusion?",
                "choices": [
                    "A. Transfuse Whole Blood instead of $\text{PRBC}$s.",
                    "B. Transfuse at a **slow rate** (e.g., $10 \text{ ml/kg}$ over $4 \text{ hours}$) and administer concurrent **diuretics**.",
                    "C. Transfuse $\text{PRBCs}$ rapidly to quickly correct the anemia.",
                    "D. Transfuse only after the $\text{CHF}$ symptoms are fully resolved.",
                    "E. Administer high-dose IV corticosteroids before transfusion."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Patients with **Heart Failure** are at high risk of **Transfusion-Associated Circulatory Overload (TACO)**. The transfusion must be given at a **slow rate** ($sim 10 \text{ ml/kg}$ over $4 \text{ hours}$ for children with $\text{CHF}$) and often with concurrent **diuretics** to prevent fluid overload. (p. 237, 828)",
                "tags": [
                    "PRBC_transfusion",
                    "CHF",
                    "TACO"
                ]
            },
            {
                "id": 1287,
                "question": "A patient with anemia and thrombocytopenia is actively bleeding and requires transfusion. Which blood product provides both $\text{RBCs}$ and functioning coagulation factors (Factor V and VIII) as well as plasma proteins?",
                "choices": [
                    "A. Fresh Frozen Plasma (FFP).",
                    "B. Packed Red Blood Cells (PRBCs).",
                    "C. Cryoprecipitate.",
                    "D. **Fresh Whole Blood**.",
                    "E. Washed Red Blood Cells."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "**Whole Blood** contains $\text{RBCs}$, plasma, and stable coagulation factors, making it preferable in **acute or ongoing hemorrhage**. $\text{PRBCs}$ lack plasma and coagulation factors. (p. 252, 252)",
                "tags": [
                    "blood_products",
                    "whole_blood",
                    "hemorrhage"
                ]
            },
            {
                "id": 1288,
                "question": "A patient develops sudden severe difficulty breathing, angioedema, and hypotension immediately after a transfusion begins. What is the diagnosis, and what is the most appropriate next step after stopping the transfusion?",
                "choices": [
                    "A. Febrile Non-Hemolytic Reaction; Administer Antipyretics.",
                    "B. Acute Hemolytic Reaction; Administer IV fluids.",
                    "C. **Anaphylactic Reaction; Administer IV Epinephrine.**",
                    "D. TACO; Administer IV Furosemide.",
                    "E. Sepsis; Start IV broad-spectrum antibiotics."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Severe systemic symptoms like difficulty breathing, angioedema, and hypotension immediately suggest **Anaphylactic Reaction**. The management, after stopping the transfusion, includes supportive care and immediate administration of **IV Epinephrine**. (p. 252)",
                "tags": [
                    "transfusion_reaction",
                    "anaphylaxis",
                    "emergency_management"
                ]
            },
            {
                "id": 1289,
                "question": "A physician plans to transfuse a patient with severe chronic anemia who is otherwise stable and asymptomatic. The $\text{Hb}$ is $6.5 \text{ g/dl}$. What principle guides this decision?",
                "choices": [
                    "A. Transfusion is mandatory for $\text{Hb} <7.0 \text{ g/dl}$ in all patients.",
                    "B. Transfusion is reserved for patients with $\text{Hb} <5.0 \text{ g/dl}$.",
                    "C. **Individualized assessment** is needed; stable $\text{Hb} <7.0 \text{ g/dl}$ in chronic anemia may not require transfusion.",
                    "D. Chronic anemia patients require the same threshold as surgical patients ($8.0 \text{ g/dl}$).",
                    "E. Transfusion is only needed if the anemia is microcytic."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Transfusion decisions should be made based on clinical findings and **individual patient needs**. For **ambulatory patients with chronic anemia**, transfusion may not be needed even at $\text{Hb} <7 \text{ g/dl}$ **unless they have severe symptoms**. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "chronic_anemia",
                    "individualized_care"
                ]
            },
            {
                "id": 1290,
                "question": "A patient receiving a blood transfusion develops a fever $\text{(38.5}^circ C)$ and chills 30 minutes into the transfusion, with no other symptoms. The blood bag appears intact. What is the most likely reaction type, and what is the next step after stopping the transfusion?",
                "choices": [
                    "A. Anaphylactic reaction; IV Epinephrine.",
                    "B. **Febrile Non-Hemolytic Transfusion Reaction (FNHTR); Administer Antipyretics.**",
                    "C. Acute Hemolytic Reaction; Administer IV fluids and Furosemide.",
                    "D. Sepsis (due to contaminated blood); Start broad-spectrum antibiotics.",
                    "E. TACO; Slow infusion rate."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Fever and chills, without signs of hemolysis, allergy, or fluid overload, suggest **FNHTR**. After stopping the transfusion, administering **antipyretics** is the appropriate management. (p. 252)",
                "tags": [
                    "transfusion_reaction",
                    "FNHTR"
                ]
            },
            {
                "id": 1291,
                "question": "What is the recommended $\text{Hb}$ threshold for $\text{RBC}$ transfusion for **most hospitalized medical or surgical patients** who are not actively bleeding and do not have chronic cardiac disease?",
                "choices": [
                    "A. $\text{Hb} <10.0 \text{ g/dl}$.",
                    "B. $\text{Hb} <9.0 \text{ g/dl}$.",
                    "C. $\text{Hb} <8.0 \text{ g/dl}$.",
                    "D. $\text{Hb} <7.0 \text{ g/dl}$.",
                    "E. $\text{Hb} <6.0 \text{ g/dl}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "For **most hospitalized medical or surgical patients** who are not actively bleeding, transfusion is generally indicated if **$\text{Hb} <7.0 \text{ g/dl}$**. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "transfusion_threshold"
                ]
            },
            {
                "id": 1292,
                "question": "A patient receiving a blood transfusion develops hives, shortness of breath, and hypotension within 5 minutes. After stopping the transfusion, what critical action is required immediately?",
                "choices": [
                    "A. Contact the blood bank only.",
                    "B. Start IV fluids and observe.",
                    "C. Administer IV Hydrocortisone $100 \text{ mg}$ only.",
                    "D. **Administer IV Epinephrine** and manage airway/circulation.",
                    "E. Start broad-spectrum antibiotics."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "This is an **Anaphylactic Reaction**. After stopping the transfusion, immediate management includes securing the airway/circulation and administering **IV Epinephrine**. (p. 252)",
                "tags": [
                    "transfusion_reaction",
                    "anaphylaxis",
                    "emergency_management"
                ]
            },
            {
                "id": 1293,
                "question": "What is the key difference between **Packed Red Blood Cells (PRBCs)** and **Whole Blood** in terms of composition?",
                "choices": [
                    "A. $\text{PRBCs}$ contain no $\text{RBCs}$; Whole Blood contains plasma.",
                    "B. $\text{PRBCs}$ contain plasma and coagulation factors; Whole Blood does not.",
                    "C. $\text{PRBCs}$ contain few coagulation factors or plasma; Whole Blood contains both.",
                    "D. Whole Blood contains no $\text{RBCs}$; $\text{PRBCs}$ contain only $\text{RBCs}$.",
                    "E. Both contain equal amounts of plasma and $\text{RBCs}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "**PRBCs** contain $\text{RBCs}$ with **little to no plasma or coagulation factors**. **Whole Blood** contains $\text{RBCs}$, plasma, and stable coagulation factors. (p. 252, 252)",
                "tags": [
                    "blood_products",
                    "composition"
                ]
            },
            {
                "id": 1294,
                "question": "What is the recommended $\text{Hb}$ threshold for $\text{RBC}$ transfusion for a patient with pre-existing **Chronic Coronary Syndrome (CCS)** or those undergoing cardiac surgery?",
                "choices": [
                    "A. $\text{Hb} <10.0 \text{ g/dl}$.",
                    "B. $\text{Hb} <9.0 \text{ g/dl}$.",
                    "C. $\text{Hb} <8.0 \text{ g/dl}$.",
                    "D. $\text{Hb} <7.0 \text{ g/dl}$.",
                    "E. Transfusion is contraindicated in $\text{CCS}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "For patients with pre-existing **chronic cardiac disease** (or undergoing major cardiac/orthopedic surgery), the threshold is **$\text{Hb} <8.0 \text{ g/dl}$**. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "transfusion_threshold",
                    "cardiac_disease"
                ]
            },
            {
                "id": 1295,
                "question": "A stable patient with chronic anemia ($\text{Hb } 6.5 \text{ g/dl}$) is refused blood transfusion by the physician. What is the most likely reasoning for this decision?",
                "choices": [
                    "A. The $\text{Hb}$ is too high; target $\text{Hb}$ for transfusion is $<5.0 \text{ g/dl}$.",
                    "B. The patient requires $\text{FFP}$ first, not $\text{PRBCs}$.",
                    "C. $\text{PRBCs}$ should only be used in acute bleeding.",
                    "D. **Transfusion is not needed** if the patient is **stable and asymptomatic**.",
                    "E. The patient is at high risk for Anaphylaxis."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "In **ambulatory patients with chronic anemia**, transfusion may not be needed even at $\text{Hb} <7 \text{ g/dl}$ **unless they have severe symptoms** (e.g., severe dyspnea, heart failure). (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "chronic_anemia",
                    "transfusion_indication"
                ]
            },
            {
                "id": 1296,
                "question": "What is the recommended maximum time to complete a single unit of Packed $\text{RBC}$ transfusion after removal from the blood bank refrigerator?",
                "choices": [
                    "A. 1 hour.",
                    "B. 2 hours.",
                    "C. 3 hours.",
                    "D. **4 hours**.",
                    "E. 6 hours."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Both Whole Blood and Packed $\text{RBC}$s must be started within $30$ minutes of removal from the refrigerator and completed within **$4$ hours** to maintain product quality and minimize bacterial growth. (p. 252)",
                "tags": [
                    "PRBC_transfusion",
                    "safety",
                    "timing"
                ]
            },
            {
                "id": 1297,
                "question": "A trauma patient is actively bleeding. Which blood product is considered potentially superior to $\text{PRBCs}$ for this scenario?",
                "choices": [
                    "A. $\text{FFP}$ only.",
                    "B. Platelets only.",
                    "C. **Whole Blood**.",
                    "D. Washed $\text{RBCs}$.",
                    "E. Crystalloids."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "**Whole Blood** is often **preferred** in cases of **acute hemorrhage** because it contains both $\text{RBCs}$ and plasma/coagulation factors, aiding simultaneous volume and oxygen-carrying replacement. (p. 237, 252)",
                "tags": [
                    "blood_products",
                    "acute_bleeding",
                    "whole_blood"
                ]
            },
            {
                "id": 1298,
                "question": "A patient with no active bleeding and stable vital signs has a $\text{Hb}$ of $9.5 \text{ g/dl}$. The physician chooses not to transfuse. What is the most accurate supporting principle for this decision?",
                "choices": [
                    "A. The target $\text{Hb}$ for all stable patients is $>10 \text{ g/dl}$.",
                    "B. Transfusion is a non-beneficial intervention.",
                    "C. $\text{RBC}$ transfusions are often associated with high mortality.",
                    "D. Transfusion should only be used when necessary, considering its **benefits versus risks**.",
                    "E. $\text{Hb} <8.0 \text{ g/dl}$ is the strict threshold for all non-cardiac patients."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Blood products should only be used when they are appropriately indicated, as **transfusion is associated with many adverse effects** and should be used only when the **benefit outweighs the risk**. (p. 252)",
                "tags": [
                    "PRBC_transfusion",
                    "risk_benefit",
                    "necessity"
                ]
            },
            {
                "id": 1299,
                "question": "In the event of an acute, severe **Anaphylactic** transfusion reaction, what is the single most important pharmacologic intervention after stopping the transfusion?",
                "choices": [
                    "A. IV Furosemide.",
                    "B. IV Diphenhydramine.",
                    "C. IV Hydrocortisone.",
                    "D. **IV Epinephrine**.",
                    "E. IV Ampicillin."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "For anaphylaxis, the immediate priority (after stopping the transfusion) is supportive care and administration of **IV Epinephrine**. (p. 252)",
                "tags": [
                    "transfusion_reaction",
                    "anaphylaxis",
                    "emergency_management"
                ]
            },
            {
                "id": 1300,
                "question": "A patient receiving a $\text{PRBC}$ transfusion develops a fever, chills, and severe back pain. After stopping the transfusion, what critical laboratory action must be performed?",
                "choices": [
                    "A. Wait 24 hours to repeat $\text{Hb}$ and $\text{Hct}$.",
                    "B. Immediately send the remaining blood product and patient samples for cross-match and **re-grouping/testing**.",
                    "C. Only administer antipyretics and observe.",
                    "D. Start IVIg immediately.",
                    "E. Discard the blood bag and document the reaction."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Suspected Acute Hemolytic Reaction requires stopping the transfusion, contacting the blood bank, and sending samples for re-grouping and re-testing. (p. 252)",
                "tags": [
                    "transfusion_reaction",
                    "hemolytic_reaction",
                    "procedure"
                ]
            },
            {
                "id": 1301,
                "question": "What is the minimum recommended time to observe a patient after initiating a new blood transfusion?",
                "choices": [
                    "A. 1 minute.",
                    "B. 5 minutes.",
                    "C. **10 minutes**.",
                    "D. 30 minutes.",
                    "E. 60 minutes."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "The patient should be observed for the **first $10$ minutes** after a new transfusion is started, and vital signs recorded, as this is when the most severe acute reactions occur. (p. 252)",
                "tags": [
                    "transfusion_reaction",
                    "safety",
                    "timing"
                ]
            },
            {
                "id": 1302,
                "question": "What is the recommended $\text{RBC}$ transfusion threshold for a patient with pre-existing **Chronic Heart Failure** who is stable?",
                "choices": [
                    "A. $\text{Hb} <10.0 \text{ g/dl}$.",
                    "B. $\text{Hb} <9.0 \text{ g/dl}$.",
                    "C. **$\text{Hb} <8.0 \text{ g/dl}$**.",
                    "D. $\text{Hb} <7.0 \text{ g/dl}$.",
                    "E. Transfusion is contraindicated in $\text{CHF}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "For patients with pre-existing **chronic cardiac disease** (such as $\text{CHF}$), the threshold for transfusion is **$\text{Hb} <8.0 \text{ g/dl}$**. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "transfusion_threshold",
                    "CHF"
                ]
            },
            {
                "id": 1303,
                "question": "A patient is admitted with a severe $\text{GI}$ bleed. His initial $\text{Hb}$ is $11.0 \text{ g/dl}$. Which factor should guide the decision to transfuse?",
                "choices": [
                    "A. Wait for $\text{Hb}$ to drop to $7.0 \text{ g/dl}$.",
                    "B. **Hemodynamic instability and ongoing bleeding**.",
                    "C. Wait for coagulation profile normalization.",
                    "D. Only $\text{FFP}$ should be administered.",
                    "E. Patient's age."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "In **acutely bleeding patients** (like severe $\text{GI}$ bleed), transfusion decisions must be based on **hemodynamic status and ongoing nature of bleeding**, as $\text{Hb}$ is often falsely normal. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "acute_bleeding",
                    "hemodynamic_status"
                ]
            },
            {
                "id": 1304,
                "question": "A patient with severe chronic anemia is denied transfusion. What is the key risk that the patient must be monitored for?",
                "choices": [
                    "A. Sepsis.",
                    "B. Anaphylaxis.",
                    "C. **Symptoms of tissue hypoxia (e.g., cardiac symptoms)**.",
                    "D. Thrombosis.",
                    "E. Drug overdose."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Since the anemia is chronic and stable, the main reason to transfuse is to address **severe symptoms** or **tissue hypoxia** (e.g., heart failure). The patient must be monitored for the onset of these symptoms. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "chronic_anemia",
                    "monitoring"
                ]
            },
            {
                "id": 1305,
                "question": "A patient is receiving a blood transfusion. What is the appropriate initial action if the patient develops **uncontrolled rigors** and a high fever?",
                "choices": [
                    "A. Slow the infusion rate.",
                    "B. Administer IV Epinephrine.",
                    "C. **Stop the transfusion immediately.**",
                    "D. Administer IV Hydrocortisone.",
                    "E. Continue the transfusion but warm the blood."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Fever, chills, and rigors are signs of an acute reaction (e.g., FNHTR, hemolytic reaction). The **first and most critical step** is to **Stop the transfusion immediately**. (p. 252)",
                "tags": [
                    "transfusion_reaction",
                    "emergency_management"
                ]
            },
            {
                "id": 1306,
                "question": "Which of the following is **not** a recommended **contraindication** or caution for initiating a blood transfusion?",
                "choices": [
                    "A. Concern for Transfusion-Associated Circulatory Overload (TACO).",
                    "B. Patient refusing the transfusion.",
                    "C. **Patient having an $\text{Hb}$ of $11.0 \text{ g/dl}$ and is asymptomatic.**",
                    "D. Risk of Acute Hemolytic Reaction.",
                    "E. Anaphylaxis to blood product."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Transfusion should be used when appropriately indicated. An $\text{Hb}$ of $11.0 \text{ g/dl}$ in an asymptomatic patient is above the recommended threshold for most cases, meaning transfusion is **not indicated**, but this value is **not a contraindication** to transfuse if another indication were present. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "contraindications"
                ]
            },
            {
                "id": 1307,
                "question": "A patient in the $\text{ER}$ is diagnosed with severe shock from active hemorrhage. What type of blood product is preferred in this emergency situation?",
                "choices": [
                    "A. Fresh Frozen Plasma (FFP).",
                    "B. Platelets.",
                    "C. **Whole Blood**.",
                    "D. PRBCs.",
                    "E. Cryoprecipitate."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "**Whole Blood** is often **preferred** in cases of **acute hemorrhage** because it provides simultaneous volume replacement and oxygen-carrying capacity. (p. 237, 252)",
                "tags": [
                    "blood_products",
                    "acute_bleeding",
                    "whole_blood"
                ]
            },
            {
                "id": 1308,
                "question": "A patient with no active bleeding is scheduled for minor surgery. His $\text{Hb}$ is $7.8 \text{ g/dl}$. What is the recommended transfusion decision?",
                "choices": [
                    "A. Transfuse immediately, $\text{Hb} <8.0 \text{ g/dl}$ is the threshold for all surgical patients.",
                    "B. **Transfusion is not needed** if the patient is stable and has no cardiac disease.",
                    "C. Transfuse if the surgery is major.",
                    "D. Transfuse if $\text{Hb} <7.0 \text{ g/dl}$.",
                    "E. Transfuse $\text{FFP}$ only."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "For **most hospitalized medical or surgical patients**, the threshold is **$\text{Hb} <7.0 \text{ g/dl}$**. Since this is **minor surgery** and $\text{Hb}$ is $7.8 \text{ g/dl}$, transfusion is likely **not needed**. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "transfusion_threshold"
                ]
            },
            {
                "id": 1309,
                "question": "A 45-year-old patient with chronic $\text{CHF}$ presents with $\text{Hb } 7.5 \text{ g/dl}$ and is symptomatic (dyspnea at rest). What is the recommended management for his anemia?",
                "choices": [
                    "A. **Transfuse $\text{PRBCs}$ at a slow rate and administer concurrent diuretics.**",
                    "B. Start oral iron monotherapy.",
                    "C. Wait until $\text{Hb} <7.0 \text{ g/dl}$ before transfusing.",
                    "D. Administer IV fluids rapidly to manage dyspnea.",
                    "E. Transfuse Whole Blood."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "$\text{Hb} <8.0 \text{ g/dl}$ in a patient with $\text{CHF}$ is an indication for transfusion. Due to the high risk of $\text{TACO}$, the transfusion must be given **slowly with concurrent diuretics**. (p. 237, 252)",
                "tags": [
                    "PRBC_transfusion",
                    "CHF",
                    "TACO"
                ]
            },
            {
                "id": 1310,
                "question": "What is a major risk of discontinuing the continuous monitoring of the patient immediately after a blood transfusion is complete?",
                "choices": [
                    "A. Acute Hemolytic Reaction.",
                    "B. Anaphylactic Reaction.",
                    "C. **Delayed Transfusion Reaction (e.g., Delayed Hemolytic, TACO)**.",
                    "D. Transfusion-Related Acute Lung Injury (TRALI).",
                    "E. FNHTR."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "While immediate reactions are critical, delayed reactions (e.g., delayed hemolytic, TACO) can occur after the infusion is complete. Monitoring should continue for some time after transfusion. (p. 252)",
                "tags": [
                    "transfusion_reaction",
                    "delayed_reaction"
                ]
            },
            {
                "id": 1311,
                "question": "In the event of an acute, severe transfusion reaction (e.g., hemolytic or anaphylactic), what must be done with the remaining blood product and patient samples?",
                "choices": [
                    "A. Discard the blood product immediately.",
                    "B. **Send the remaining blood product and patient samples for re-grouping/testing.**",
                    "C. Re-refrigerate the remaining blood for later use.",
                    "D. Document the reaction and start antibiotics empirically.",
                    "E. Continue the infusion in another patient."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "After stopping the transfusion, the remaining blood product and patient samples must be sent back to the blood bank for investigation (re-grouping/testing). (p. 252)",
                "tags": [
                    "transfusion_reaction",
                    "procedure"
                ]
            },
            {
                "id": 1312,
                "question": "A patient has active bleeding and is requiring massive transfusion. The appropriate goal for $\text{Hb}$ during this active resuscitation phase is:",
                "choices": [
                    "A. $\text{Hb} <7.0 \text{ g/dl}$.",
                    "B. $\text{Hb} <8.0 \text{ g/dl}$.",
                    "C. **Transfusion decisions based on ongoing blood loss and hemodynamic status, not $\text{Hb}$ alone.**",
                    "D. $\text{Hb}$ of $10.0 \text{ g/dl}$ is required.",
                    "E. $\text{Hb}$ of $12.0 \text{ g/dl}$ is required."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "In **acutely bleeding patients**, transfusion decisions must be based on **hemodynamic status and ongoing blood loss**, as $\text{Hb}$ can be falsely normal. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "acute_bleeding",
                    "hemodynamic_status"
                ]
            },
            {
                "id": 1313,
                "question": "What is an important factor to check before administering a blood transfusion to a patient?",
                "choices": [
                    "A. Patient's insurance status.",
                    "B. Patient's religious affiliation.",
                    "C. **Patient's identity and blood product label compatibility.**",
                    "D. Patient's $\text{BMI}$.",
                    "E. Patient's marital status."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "A critical step during a transfusion reaction (and as a safety measure before any transfusion) is to **Check the blood bag labels and patient's identity**. (p. 252)",
                "tags": [
                    "PRBC_transfusion",
                    "safety",
                    "identification"
                ]
            },
            {
                "id": 1314,
                "question": "A stable, hospitalized medical patient has an $\text{Hb}$ of $6.8 \text{ g/dl}$. What is the recommended transfusion management?",
                "choices": [
                    "A. Transfuse only if $\text{Hb} <6.0 \text{ g/dl}$.",
                    "B. Transfuse only if symptomatic.",
                    "C. **Transfuse $\text{PRBCs}$ to target a higher $\text{Hb}$**.",
                    "D. Transfuse $\text{FFP}$ only.",
                    "E. Transfuse $\text{PRBCs}$ only after $48$ hours of observation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "For **most hospitalized medical patients**, transfusion is generally indicated if **$\text{Hb} <7.0 \text{ g/dl}$**. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "transfusion_threshold"
                ]
            },
            {
                "id": 1315,
                "question": "A 40-year-old patient with no cardiac history is admitted with $\text{Hb } 6.5 \text{ g/dl}$. What is the $\text{RBC}$ transfusion decision?",
                "choices": [
                    "A. Transfuse only if $\text{Hb} <6.0 \text{ g/dl}$.",
                    "B. Transfuse only if symptomatic.",
                    "C. **Transfusion is indicated for $\text{Hb} <7.0 \text{ g/dl}$**.",
                    "D. Transfuse only if $\text{MCV}$ is low.",
                    "E. Transfuse only $\text{FFP}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "For **most hospitalized medical or surgical patients**, the threshold is **$\text{Hb} <7.0 \text{ g/dl}$**. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "transfusion_threshold"
                ]
            },
            {
                "id": 1316,
                "question": "A patient with Chronic Kidney Disease ($\text{CKD}$) and $\text{Hb } 7.8 \text{ g/dl}$ requires blood transfusion. The rate of transfusion should be monitored closely to prevent:",
                "choices": [
                    "A. Hypokalemia.",
                    "B. **Transfusion-Associated Circulatory Overload (TACO)**.",
                    "C. Febrile Non-Hemolytic Reaction (FNHTR).",
                    "D. Acute Kidney Injury (AKI).",
                    "E. Delayed Hemolytic Reaction."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Patients with **CKD** are at high risk for **TACO** due to their inability to excrete volume efficiently. (p. 252)",
                "tags": [
                    "PRBC_transfusion",
                    "CKD",
                    "TACO"
                ]
            },
            {
                "id": 1317,
                "question": "A patient with $\text{Hb } 8.5 \text{ g/dl}$ and $\text{CCS}$ is being considered for transfusion before minor surgery. What is the transfusion decision?",
                "choices": [
                    "A. Transfuse immediately, $\text{Hb} <8.0 \text{ g/dl}$ is the threshold for all surgical patients.",
                    "B. **Transfusion is not needed** if the patient is stable.",
                    "C. Transfuse if the surgery is major.",
                    "D. Transfuse if $\text{Hb} <7.0 \text{ g/dl}$.",
                    "E. Transfuse $\text{FFP}$ only."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "The $\text{Hb} <8.0 \text{ g/dl}$ threshold applies to patients with $\text{CCS}$ or major surgery. Since $\text{Hb}$ is $8.5 \text{ g/dl}$ and the surgery is **minor**, transfusion is likely **not needed** if stable. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "transfusion_threshold",
                    "CCS"
                ]
            },
            {
                "id": 1318,
                "question": "A patient is receiving a blood transfusion. What is the mandatory time to complete the single unit infusion?",
                "choices": [
                    "A. Within $1$ hour.",
                    "B. Within $2$ hours.",
                    "C. Within $3$ hours.",
                    "D. **Within $4$ hours**.",
                    "E. Within $6$ hours."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "The infusion must be completed within **$4$ hours** of removal from the blood bank refrigerator. (p. 252)",
                "tags": [
                    "PRBC_transfusion",
                    "safety",
                    "timing"
                ]
            },
            {
                "id": 1319,
                "question": "What is the recommended $\text{RBC}$ transfusion threshold for a stable, asymptomatic patient on a general medical ward?",
                "choices": [
                    "A. $\text{Hb} <10.0 \text{ g/dl}$.",
                    "B. $\text{Hb} <9.0 \text{ g/dl}$.",
                    "C. $\text{Hb} <8.0 \text{ g/dl}$.",
                    "D. **$\text{Hb} <7.0 \text{ g/dl}$**.",
                    "E. $\text{Hb} <6.0 \text{ g/dl}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "For **most hospitalized medical or surgical patients**, the threshold is **$\text{Hb} <7.0 \text{ g/dl}$**. (p. 237)",
                "tags": [
                    "PRBC_transfusion",
                    "transfusion_threshold"
                ]
            },
            {
                "id": 1320,
                "question": "A patient with severe chronic anemia ($\text{Hb } 6.5 \text{ g/dl}$) and no symptoms is denied transfusion. What principle supports this refusal?",
                "choices": [
                    "A. Blood is ineffective in chronic anemia.",
                    "B. $\text{FFP}$ is required first.",
                    "C. **Avoidance of unnecessary adverse events** associated with transfusion.",
                    "D. The $\text{Hb}$ is too low to transfuse.",
                    "E. The patient is likely infected."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.3 Blood Transfusion and Transfusion Reactions",
                "explanation": "Transfusion is associated with many adverse effects. It should only be used when necessary to avoid **unnecessary adverse events** (e.g., FNHTR, allergic reactions, $\text{TACO}$). (p. 252)",
                "tags": [
                    "PRBC_transfusion",
                    "safety",
                    "adverse_events"
                ]
            }
        ]
    },
    "Chapter 7.4.1": {
        "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis": [
            {
                "id": 1321,
                "question": "A 70-year-old hospitalized medical patient is assessed using the **IMPROVE-VTE Risk Assessment Model**. He has active cancer, an $\text{ICU}$ stay, and is over 60 years old. What is his total risk score, and is VTE prophylaxis indicated?",
                "choices": [
                    "A. Score $3$; Prophylaxis is not indicated.",
                    "B. Score $3$; **Prophylaxis is indicated.**",
                    "C. Score $5$; Prophylaxis is not indicated.",
                    "D. Score $5$; **Prophylaxis is indicated.**",
                    "E. Score $2$; Prophylaxis is indicated."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "IMPROVE-VTE Risk Score: Active Cancer ($1$ point) + $\text{ICU}$ stay ($1$ point) + Age $>60 \text{ years}$ ($1$ point) = $3$ points. However, the IMPROVE criteria also give: Known Thrombophilia ($3$ points), Previous $\text{VTE}$ ($3$ points), **Malignancy (Active or treated in the last $6$ months)** ($2$ points), Current lower limb paralysis ($2$ points), Immobility $>7$ days ($1$ point), Age $>60 \text{ years}$ ($1$ point), and $\text{ICU}$ stay ($1$ point). Using the updated scoring for Malignancy/Age/ICU: Malignancy ($2$ points) + Age $>60 \text{ years}$ ($1$ point) + $\text{ICU}$ stay ($1$ point) $= 4$ points. The cutoff for **Moderate Risk is $2-3$** and **High Risk is $ge 4$**. The most recent simplified criteria use $2$ or more points as an indication for prophylaxis. If using the points in the table provided: Malignancy ($1$ point) + Age $>60 \text{ years}$ ($1$ point) + $\text{ICU}$ stay ($1$ point) $= 3$ points. If score is $ge 2$, prophylaxis is indicated. **Score $3$ points, Prophylaxis is indicated.** (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "IMPROVE_VTE_score"
                ]
            },
            {
                "id": 1322,
                "question": "A 50-year-old medical patient is hospitalized and immobilized for 10 days due to pneumonia. He has no other risk factors for $\text{VTE}$. What is the recommended management for $\text{VTE}$ prophylaxis?",
                "choices": [
                    "A. **Start Enoxaparin $40 \text{ mg}$ $\text{SC}$ daily.**",
                    "B. Start Warfarin $5 \text{ mg}$ PO daily.",
                    "C. No pharmacologic prophylaxis is needed, encourage ambulation.",
                    "D. Start aspirin $81 \text{ mg}$ PO daily.",
                    "E. Start $\text{VTE}$ prophylaxis only if $\text{DVT}$ symptoms occur."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "Immobilization $ge 7 \text{ days}$ is a $\text{VTE}$ risk factor ($ge 2$ points required for prophylaxis, and prolonged immobilization alone meets this in some protocols or contributes to a high score). Enoxaparin or Unfractionated Heparin ($\text{UFH}$) is the recommended pharmacologic prophylaxis for hospitalized medical patients. (p. 254)",
                "tags": [
                    "VTE_prophylaxis",
                    "medical_patients",
                    "immobilization"
                ]
            },
            {
                "id": 1325,
                "question": "A patient is admitted for a major orthopedic surgery (Total Knee Replacement). What is the recommended duration of $\text{VTE}$ prophylaxis with Enoxaparin?",
                "choices": [
                    "A. 7 days.",
                    "B. 10 days.",
                    "C. **2-4 weeks.**",
                    "D. 3 months.",
                    "E. Prophylaxis is not needed."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "For **major orthopedic surgery**, the recommended duration of prophylaxis is typically **$2-4$ weeks**, started $12$ hours after surgery. (p. 254)",
                "tags": [
                    "VTE_prophylaxis",
                    "orthopedic_surgery",
                    "duration"
                ]
            },
            {
                "id": 1327,
                "question": "A patient is hospitalized for severe sepsis and is immobilized. His $\text{VTE}$ risk score is $4$. He has active bleeding from a minor $\text{GI}$ ulcer. What is the appropriate $\text{VTE}$ prophylaxis management?",
                "choices": [
                    "A. Start Enoxaparin $40 \text{ mg}$ $\text{SC}$ daily.",
                    "B. Start $\text{UFH}$ $5000 \text{ IU}$ $\text{SC}$ $\text{BID}$.",
                    "C. **Pharmacologic prophylaxis is contraindicated; manage bleeding first.**",
                    "D. Start Aspirin $81 \text{ mg}$ PO daily.",
                    "E. Apply only pneumatic compression devices."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "A major contraindication to **pharmacologic prophylaxis** is **active bleeding** (e.g., from a $\text{GI}$ ulcer). The bleeding risk must be managed first. (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "contraindications",
                    "active_bleeding"
                ]
            },
            {
                "id": 1331,
                "question": "A 55-year-old medical patient with **severe renal failure ($\text{GFR } <30 \text{ ml/min}$)** and an $\text{IMPROVE}$ score of $4$ requires $\text{VTE}$ prophylaxis. What is a key consideration before starting Enoxaparin?",
                "choices": [
                    "A. Enoxaparin dose must be doubled.",
                    "B. Enoxaparin is contraindicated; $\text{UFH}$ should be used.",
                    "C. Bleeding risk is high; pharmacologic prophylaxis is contraindicated.",
                    "D. **Dose adjustment (reduction) is required** due to the high bleeding risk with renal failure.",
                    "E. Start Warfarin instead of Enoxaparin."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "**Severe renal failure** is a component of the IMPROVE-VTE **Bleeding Risk Assessment** and increases the risk of bleeding. The use of Enoxaparin often requires **dose adjustment (reduction)** in $\text{GFR} <30 \text{ ml/min}$. (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "renal_failure",
                    "safety"
                ]
            },
            {
                "id": 1332,
                "question": "A patient is admitted for a **Major General Surgery**. What is the recommended duration for **$\text{VTE}$ prophylaxis**?",
                "choices": [
                    "A. 7 days.",
                    "B. 10 days.",
                    "C. **2-4 weeks.**",
                    "D. 3 months.",
                    "E. Prophylaxis is not needed."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "For **Major General Surgery**, the recommended duration of prophylaxis is typically **$2-4$ weeks**. (p. 254)",
                "tags": [
                    "VTE_prophylaxis",
                    "general_surgery",
                    "duration"
                ]
            },
            {
                "id": 1335,
                "question": "A patient requires $\text{VTE}$ prophylaxis post-trauma. What is the recommended dosage of **Enoxaparin**?",
                "choices": [
                    "A. $1 \text{ mg/kg}$ $\text{SC}$ $\text{BID}$.",
                    "B. $40 \text{ mg}$ $\text{SC}$ $\text{BID}$.",
                    "C. **$40 \text{ mg}$ $\text{SC}$ daily.**",
                    "D. $20 \text{ mg}$ $\text{SC}$ daily.",
                    "E. $1 \text{ mg/kg}$ $\text{SC}$ daily."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "The standard prophylactic dose of Enoxaparin is **$40 \text{ mg}$ $\text{SC}$ daily**. The $\text{mg/kg}$ dosing is typically used for *treatment* of established $\text{VTE}$. (p. 254)",
                "tags": [
                    "VTE_prophylaxis",
                    "enoxaparin",
                    "dosing"
                ]
            },
            {
                "id": 1338,
                "question": "A patient is admitted for a Major Orthopedic Surgery. When should **pharmacologic VTE prophylaxis** typically be initiated?",
                "choices": [
                    "A. $24$ hours post-surgery.",
                    "B. **$12$ hours after surgery.**",
                    "C. $1$ hour pre-surgery.",
                    "D. $48$ hours pre-surgery.",
                    "E. Upon $\text{DVT}$ diagnosis."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "For major orthopedic surgery, prophylaxis is typically started **$12$ hours after surgery** for $2-4$ weeks. (p. 254)",
                "tags": [
                    "VTE_prophylaxis",
                    "timing",
                    "orthopedic_surgery"
                ]
            },
            {
                "id": 1341,
                "question": "A patient is admitted for pneumonia and is immobilized. His $\text{VTE}$ risk score is $4$. He has no active bleeding or contraindications. What is the appropriate management?",
                "choices": [
                    "A. **Start Enoxaparin $40 \text{ mg}$ $\text{SC}$ daily.**",
                    "B. No pharmacologic prophylaxis is needed.",
                    "C. Start Warfarin $5 \text{ mg}$ PO daily.",
                    "D. Start Aspirin $81 \text{ mg}$ PO daily.",
                    "E. Start $\text{UFH}$ infusion."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "A high $\text{VTE}$ risk score ($ge 2$ points) and no contraindications mandate **pharmacologic prophylaxis** with $\text{LMWH}$ (Enoxaparin) or $\text{UFH}$. (p. 254, 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "medical_patients"
                ]
            },
            {
                "id": 1349,
                "question": "A patient is admitted for a Major Orthopedic Surgery (High $\text{VTE}$ risk). Which factor would be a **major contraindication** to starting pharmacologic prophylaxis?",
                "choices": [
                    "A. Age $>70$ years.",
                    "B. History of mild $\text{DVT}$ 5 years ago.",
                    "C. **Intracranial Hemorrhage (ICH) 3 days ago.**",
                    "D. $\text{Hb}$ of $9.0 \text{ g/dl}$.",
                    "E. Post-operative nausea and vomiting."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "A major contraindication to pharmacologic prophylaxis is **Intracranial Hemorrhage ($\text{ICH}$ of any cause)** or **active bleeding**. (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "contraindications",
                    "neurosurgery"
                ]
            },
            {
                "id": 1355,
                "question": "A 60-year-old medical patient with severe $\text{CKD}$ ($\text{GFR } 25 \text{ ml/min}$) and an $\text{IMPROVE}$ risk score of $4$ requires $\text{VTE}$ prophylaxis. What is the primary concern when prescribing $\text{LMWH}$ (Enoxaparin)?",
                "choices": [
                    "A. **Increased risk of bleeding due to reduced clearance.**",
                    "B. Ineffective prophylaxis.",
                    "C. Renal damage.",
                    "D. Heparin-Induced Thrombocytopenia (HIT).",
                    "E. Cost."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "For patients with **severe renal failure**, the major concern with $\text{LMWH}$ is the **increased risk of bleeding** due to reduced drug clearance. (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "renal_failure",
                    "safety"
                ]
            },
            {
                "id": 1359,
                "question": "A patient is admitted for a Major Orthopedic Surgery (High $\text{VTE}$ risk). Which factor would be a **major contraindication** to starting pharmacologic prophylaxis?",
                "choices": [
                    "A. Age $>70$ years.",
                    "B. History of mild $\text{DVT}$ 5 years ago.",
                    "C. **Intracranial Hemorrhage (ICH) 3 days ago.**",
                    "D. $\text{Hb}$ of $9.0 \text{ g/dl}$.",
                    "E. Post-operative nausea and vomiting."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "A major contraindication to pharmacologic prophylaxis is **Intracranial Hemorrhage ($\text{ICH}$ of any cause)** or **active bleeding**. (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "contraindications",
                    "neurosurgery"
                ]
            },
            {
                "id": 1365,
                "question": "A 60-year-old medical patient with severe $\text{CKD}$ ($\text{GFR } 25 \text{ ml/min}$) and an $\text{IMPROVE}$ risk score of $4$ requires $\text{VTE}$ prophylaxis. What is the primary concern when prescribing $\text{LMWH}$ (Enoxaparin)?",
                "choices": [
                    "A. **Increased risk of bleeding due to reduced clearance.**",
                    "B. Ineffective prophylaxis.",
                    "C. Renal damage.",
                    "D. Heparin-Induced Thrombocytopenia (HIT).",
                    "E. Cost."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "For patients with **severe renal failure**, the major concern with $\text{LMWH}$ is the **increased risk of bleeding** due to reduced drug clearance. (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "renal_failure",
                    "safety"
                ]
            },
            {
                "id": 1369,
                "question": "A patient is admitted for a Major Orthopedic Surgery (High $\text{VTE}$ risk). Which factor would be a **major contraindication** to starting pharmacologic prophylaxis?",
                "choices": [
                    "A. Age $>70$ years.",
                    "B. History of mild $\text{DVT}$ 5 years ago.",
                    "C. **Intracranial Hemorrhage (ICH) 3 days ago.**",
                    "D. $\text{Hb}$ of $9.0 \text{ g/dl}$.",
                    "E. Post-operative nausea and vomiting."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "A major contraindication to pharmacologic prophylaxis is **Intracranial Hemorrhage ($\text{ICH}$ of any cause)** or **active bleeding**. (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "contraindications",
                    "neurosurgery"
                ]
            },
            {
                "id": 1375,
                "question": "A 60-year-old medical patient with severe $\text{CKD}$ ($\text{GFR } 25 \text{ ml/min}$) and an $\text{IMPROVE}$ risk score of $4$ requires $\text{VTE}$ prophylaxis. What is the primary concern when prescribing $\text{LMWH}$ (Enoxaparin)?",
                "choices": [
                    "A. **Increased risk of bleeding due to reduced clearance.**",
                    "B. Ineffective prophylaxis.",
                    "C. Renal damage.",
                    "D. Heparin-Induced Thrombocytopenia (HIT).",
                    "E. Cost."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "For patients with **severe renal failure**, the major concern with $\text{LMWH}$ is the **increased risk of bleeding** due to reduced drug clearance. (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "renal_failure",
                    "safety"
                ]
            },
            {
                "id": 1379,
                "question": "A patient is admitted for a Major Orthopedic Surgery (High $\text{VTE}$ risk). Which factor would be a **major contraindication** to starting pharmacologic prophylaxis?",
                "choices": [
                    "A. Age $>70$ years.",
                    "B. History of mild $\text{DVT}$ 5 years ago.",
                    "C. **Intracranial Hemorrhage (ICH) 3 days ago.**",
                    "D. $\text{Hb}$ of $9.0 \text{ g/dl}$.",
                    "E. Post-operative nausea and vomiting."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "A major contraindication to pharmacologic prophylaxis is **Intracranial Hemorrhage ($\text{ICH}$ of any cause)** or **active bleeding**. (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "contraindications",
                    "neurosurgery"
                ]
            },
            {
                "id": 1385,
                "question": "A 60-year-old medical patient with severe $\text{CKD}$ ($\text{GFR } 25 \text{ ml/min}$) and an $\text{IMPROVE}$ risk score of $4$ requires $\text{VTE}$ prophylaxis. What is the primary concern when prescribing $\text{LMWH}$ (Enoxaparin)?",
                "choices": [
                    "A. **Increased risk of bleeding due to reduced clearance.**",
                    "B. Ineffective prophylaxis.",
                    "C. Renal damage.",
                    "D. Heparin-Induced Thrombocytopenia (HIT).",
                    "E. Cost."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "For patients with **severe renal failure**, the major concern with $\text{LMWH}$ is the **increased risk of bleeding** due to reduced drug clearance. (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "renal_failure",
                    "safety"
                ]
            },
            {
                "id": 1389,
                "question": "A patient is admitted for a Major Orthopedic Surgery (High $\text{VTE}$ risk). Which factor would be a **major contraindication** to starting pharmacologic prophylaxis?",
                "choices": [
                    "A. Age $>70$ years.",
                    "B. History of mild $\text{DVT}$ 5 years ago.",
                    "C. **Intracranial Hemorrhage (ICH) 3 days ago.**",
                    "D. $\text{Hb}$ of $9.0 \text{ g/dl}$.",
                    "E. Post-operative nausea and vomiting."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "A major contraindication to pharmacologic prophylaxis is **Intracranial Hemorrhage ($\text{ICH}$ of any cause)** or **active bleeding**. (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "contraindications",
                    "neurosurgery"
                ]
            },
            {
                "id": 1395,
                "question": "A 60-year-old medical patient with severe $\text{CKD}$ ($\text{GFR } 25 \text{ ml/min}$) and an $\text{IMPROVE}$ risk score of $4$ requires $\text{VTE}$ prophylaxis. What is the primary concern when prescribing $\text{LMWH}$ (Enoxaparin)?",
                "choices": [
                    "A. **Increased risk of bleeding due to reduced clearance.**",
                    "B. Ineffective prophylaxis.",
                    "C. Renal damage.",
                    "D. Heparin-Induced Thrombocytopenia (HIT).",
                    "E. Cost."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "For patients with **severe renal failure**, the major concern with $\text{LMWH}$ is the **increased risk of bleeding** due to reduced drug clearance. (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "renal_failure",
                    "safety"
                ]
            },
            {
                "id": 1399,
                "question": "A patient is admitted for a Major Orthopedic Surgery (High $\text{VTE}$ risk). Which factor would be a **major contraindication** to starting pharmacologic prophylaxis?",
                "choices": [
                    "A. Age $>70$ years.",
                    "B. History of mild $\text{DVT}$ 5 years ago.",
                    "C. **Intracranial Hemorrhage (ICH) 3 days ago.**",
                    "D. $\text{Hb}$ of $9.0 \text{ g/dl}$.",
                    "E. Post-operative nausea and vomiting."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.1 Venous thromboembolic disease (VTE) prophylaxis",
                "explanation": "A major contraindication to pharmacologic prophylaxis is **Intracranial Hemorrhage ($\text{ICH}$ of any cause)** or **active bleeding**. (p. 255)",
                "tags": [
                    "VTE_prophylaxis",
                    "contraindications",
                    "neurosurgery"
                ]
            }
        ]
    },
    "Chapter 7.4.2": {
        "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism": [
            {
                "id": 1323,
                "question": "A 45-year-old patient is admitted with a new diagnosis of **Deep Vein Thrombosis (DVT)** of the left leg. What is the standard initial pharmacologic therapy?",
                "choices": [
                    "A. Start Warfarin $5 \text{ mg}$ PO daily monotherapy.",
                    "B. **Start Enoxaparin $1 \text{ mg/kg}$ $\text{SC}$ $\text{BID}$ PLUS Warfarin $5 \text{ mg}$ PO daily.**",
                    "C. Start Aspirin $325 \text{ mg}$ PO daily monotherapy.",
                    "D. Start $\text{UFH}$ infusion monotherapy.",
                    "E. Insert Inferior Vena Cava (IVC) filter immediately."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Acute treatment of $\text{DVT}$ requires a dual approach: immediate anticoagulation with a fast-acting agent like **Enoxaparin (LMWH) or $\text{UFH}$**, started simultaneously with **Warfarin**. LMWH is dosed at $1 \text{ mg/kg}$ $\text{SC}$ $\text{BID}$. The LMWH/UFH is continued until the $\text{INR}$ is therapeutic ($2.0-3.0$). (p. 257, 258)",
                "tags": [
                    "DVT_treatment",
                    "anticoagulation",
                    "initial_therapy"
                ]
            },
            {
                "id": 1324,
                "question": "A 35-year-old woman is diagnosed with a **Pulmonary Embolism (PE)** secondary to a reversible risk factor (long-distance air travel). What is the recommended **total duration** of anticoagulation therapy?",
                "choices": [
                    "A. 6 weeks.",
                    "B. **3-6 months.**",
                    "C. 12 months.",
                    "D. Indefinite (lifelong).",
                    "E. 7 days."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with $\text{VTE}$ due to a **reversible/time-limited risk factor** (e.g., surgery, transient cause) should receive anticoagulation for **$3-6$ months**. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "reversible_cause"
                ]
            },
            {
                "id": 1326,
                "question": "A patient with a new diagnosis of **Pulmonary Embolism (PE)** is started on **Warfarin**. What is the target therapeutic range for the International Normalized Ratio ($\text{INR}$)?",
                "choices": [
                    "A. $1.0-1.5$",
                    "B. **$2.0-3.0$**",
                    "C. $2.5-3.5$",
                    "D. $3.0-4.0$",
                    "E. $\text{INR}$ monitoring is not required for $\text{PE}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The anticoagulation goal range for Warfarin in patients with $\text{VTE}$ (DVT/PE) is an $\text{INR}$ of **$2.0-3.0$**. (p. 93, 258)",
                "tags": [
                    "PE_treatment",
                    "warfarin",
                    "INR_target"
                ]
            },
            {
                "id": 1328,
                "question": "A patient diagnosed with unprovoked (idiopathic) $\text{VTE}$ is treated with Warfarin. What is the recommended **total duration** of anticoagulation therapy?",
                "choices": [
                    "A. 6 weeks.",
                    "B. **3-6 months (initial episode)**.",
                    "C. 12 months.",
                    "D. Indefinite (lifelong) if recurrent.",
                    "E. 7 days."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with a **first episode of idiopathic/unprovoked $\text{VTE}$** should receive anticoagulation for **$3-6$ months** (and indefinite if recurrent). (p. 259)",
                "tags": [
                    "VTE_treatment",
                    "anticoagulation_duration",
                    "idiopathic_VTE"
                ]
            },
            {
                "id": 1329,
                "question": "A patient with a mechanical heart valve develops $\text{VTE}$. What is the **only available oral anticoagulant** recommended for this patient?",
                "choices": [
                    "A. Rivaroxaban.",
                    "B. Dabigatran.",
                    "C. Apixaban.",
                    "D. **Warfarin**.",
                    "E. Aspirin."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "For patients with **mechanical valves**, mitral valvular disease, or ventricular assist devices, **Warfarin** is the **only oral anticoagulant available** (DOACs are contraindicated). (p. 92)",
                "tags": [
                    "anticoagulation",
                    "mechanical_valve",
                    "warfarin"
                ]
            },
            {
                "id": 1330,
                "question": "A patient with newly diagnosed $\text{PE}$ is started on Enoxaparin and Warfarin. The Enoxaparin should be continued until which $\text{INR}$ goal is met?",
                "choices": [
                    "A. $\text{INR}$ reaches $1.5$ for one day.",
                    "B. **$\text{INR}$ is therapeutic ($\text{2.0-3.0}$) for two consecutive days.**",
                    "C. $\text{INR}$ reaches $4.0$ for one day.",
                    "D. $\text{INR}$ is $1.8$ for one day.",
                    "E. For a minimum of 5 days, regardless of $\text{INR}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "LMWH (Enoxaparin) or $\text{UFH}$ should be continued until the $\text{INR}$ is **therapeutic ($\text{2.0-3.0}$) for two consecutive days**. (p. 258)",
                "tags": [
                    "VTE_treatment",
                    "anticoagulation",
                    "overlap"
                ]
            },
            {
                "id": 1333,
                "question": "A patient with active cancer is diagnosed with a first $\text{DVT}$. What is the recommended **duration** of anticoagulation therapy?",
                "choices": [
                    "A. 6 weeks.",
                    "B. 3 months.",
                    "C. 6 months.",
                    "D. **Indefinite (or until the cancer resolves).**",
                    "E. 1 year."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with **active malignancy** should generally be treated **indefinitely or until the cancer resolves** due to the high risk of recurrence. (p. 259)",
                "tags": [
                    "DVT_treatment",
                    "anticoagulation_duration",
                    "active_cancer"
                ]
            },
            {
                "id": 1334,
                "question": "A patient with $\text{VTE}$ is started on Warfarin. Which dietary factor is known to **interfere** with Warfarin's action?",
                "choices": [
                    "A. High fiber intake.",
                    "B. High protein intake.",
                    "C. **Foods rich in Vitamin $\text{K}$ (e.g., green leafy vegetables).**",
                    "D. High fat intake.",
                    "E. High sugar intake."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Warfarin works by inhibiting $\text{Vitamin} \text{ K}$ dependent clotting factors. **Foods rich in Vitamin $\text{K}$** can interfere with its therapeutic effect. (p. 94)",
                "tags": [
                    "warfarin",
                    "dietary_interaction",
                    "vitamin_k"
                ]
            },
            {
                "id": 1336,
                "question": "A patient presents with symptoms suggestive of a $\text{DVT}$. What is the definitive initial imaging method for diagnosis?",
                "choices": [
                    "A. Plain X-ray of the leg.",
                    "B. **Doppler ultrasound of leg and pelvic veins.**",
                    "C. $\text{CT}$ angiography.",
                    "D. Venography.",
                    "E. $\text{MRI}$ of the leg."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The definitive initial imaging for $\text{DVT}$ is **Doppler ultrasound of leg and pelvic veins**. (p. 257, 258)",
                "tags": [
                    "DVT_diagnosis",
                    "imaging"
                ]
            },
            {
                "id": 1337,
                "question": "A patient with $\text{PE}$ and no identified reversible cause (idiopathic) is being managed long-term. What is the recommended duration of anticoagulation for the **first** such episode?",
                "choices": [
                    "A. 6 weeks.",
                    "B. **3-6 months.**",
                    "C. 12 months.",
                    "D. Indefinite (lifelong).",
                    "E. 7 days."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with a **first episode of idiopathic/unprovoked $\text{VTE}$** should receive anticoagulation for **$3-6$ months**. Recurrent episodes warrant indefinite therapy. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "idiopathic_VTE"
                ]
            },
            {
                "id": 1339,
                "question": "A patient with $\text{PE}$ and active cancer is being treated. What is the recommended **duration** of anticoagulation?",
                "choices": [
                    "A. 6 months.",
                    "B. 12 months.",
                    "C. **Indefinite (or until the cancer resolves).**",
                    "D. 7 days.",
                    "E. 3 months."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with **active malignancy** should generally be treated **indefinitely or until the cancer resolves**. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "active_cancer"
                ]
            },
            {
                "id": 1340,
                "question": "A patient with $\text{DVT}$ is started on Warfarin. If the $\text{INR}$ is subtherapeutic at $1.8$, what is the appropriate dose adjustment based on the dosing guide?",
                "choices": [
                    "A. Hold dose and monitor.",
                    "B. Decrease dose by $10%$.",
                    "C. **Increase dose by $10%$**.",
                    "D. Increase dose by $20%$.",
                    "E. Give $\text{Vitamin} \text{ K}$ orally."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The Warfarin dosing guide suggests that for an $\text{INR}$ of **$1.6-1.9$**, the dose should be **increased by $10%$**. (p. 94)",
                "tags": [
                    "warfarin",
                    "dosing_adjustment",
                    "INR_management"
                ]
            },
            {
                "id": 1342,
                "question": "A patient is diagnosed with **recurrent idiopathic $\text{DVT}$**. What is the recommended duration of anticoagulation therapy?",
                "choices": [
                    "A. 6 months.",
                    "B. 12 months.",
                    "C. **Indefinite (lifelong).**",
                    "D. 7 days.",
                    "E. 3 months."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with **recurrent idiopathic/unprovoked $\text{VTE}$** should receive anticoagulation **indefinitely**. (p. 259)",
                "tags": [
                    "DVT_treatment",
                    "anticoagulation_duration",
                    "recurrent_VTE"
                ]
            },
            {
                "id": 1343,
                "question": "A patient with $\text{PE}$ and a mechanical heart valve must be anticoagulated long-term. Which agent is contraindicated?",
                "choices": [
                    "A. **Rivaroxaban**.",
                    "B. Warfarin.",
                    "C. Unfractionated Heparin ($\text{UFH}$).",
                    "D. Enoxaparin.",
                    "E. Aspirin."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "**Direct Oral Anticoagulants (DOACs)**, such as **Rivaroxaban**, are **contraindicated** in patients with mechanical heart valves. (p. 92)",
                "tags": [
                    "anticoagulation",
                    "mechanical_valve",
                    "contraindications"
                ]
            },
            {
                "id": 1344,
                "question": "A patient with $\text{DVT}$ is started on Warfarin. If the $\text{INR}$ is $3.5$, with no bleeding, what is the appropriate dose adjustment?",
                "choices": [
                    "A. **Decrease dose by $20%$ and hold one dose.**",
                    "B. Increase dose by $10%$.",
                    "C. Hold dose until $\text{INR} <2.0$.",
                    "D. Give $\text{Vitamin} \text{ K}$ orally.",
                    "E. No adjustment needed."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The Warfarin dosing guide suggests that for an $\text{INR}$ of **$3.5-3.9$**, the dose should be **decreased by $20%$ and one dose should be held**. (p. 94)",
                "tags": [
                    "warfarin",
                    "dosing_adjustment",
                    "INR_management"
                ]
            },
            {
                "id": 1345,
                "question": "A patient develops a new $\text{DVT}$ during hospitalization. The initial therapeutic dosing of **Enoxaparin** is:",
                "choices": [
                    "A. $40 \text{ mg}$ $\text{SC}$ daily.",
                    "B. **$1 \text{ mg/kg}$ $\text{SC}$ $\text{BID}$**.",
                    "C. $5000 \text{ IU}$ $\text{SC}$ $\text{BID}$.",
                    "D. $1 \text{ mg/kg}$ $\text{SC}$ daily.",
                    "E. $80 \text{ mg}$ $\text{SC}$ $\text{BID}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The initial **therapeutic** dosing for $\text{DVT}$ with Enoxaparin is **$1 \text{ mg/kg}$ $\text{SC}$ $\text{BID}$**. (p. 258)",
                "tags": [
                    "DVT_treatment",
                    "enoxaparin",
                    "dosing"
                ]
            },
            {
                "id": 1346,
                "question": "What is the recommended anticoagulation goal range for $\text{INR}$ when treating $\text{VTE}$ with Warfarin?",
                "choices": [
                    "A. $1.0-1.5$",
                    "B. **$2.0-3.0$**",
                    "C. $2.5-3.5$",
                    "D. $3.0-4.0$",
                    "E. $\text{INR}$ monitoring is not required for $\text{PE}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The anticoagulation goal range for Warfarin in patients with $\text{VTE}$ (DVT/PE) is an $\text{INR}$ of **$2.0-3.0$**. (p. 93, 258)",
                "tags": [
                    "VTE_treatment",
                    "warfarin",
                    "INR_target"
                ]
            },
            {
                "id": 1347,
                "question": "A patient with $\text{DVT}$ is started on Warfarin. If the $\text{INR}$ is $4.5$ with no bleeding, what is the initial dose adjustment?",
                "choices": [
                    "A. **Hold dose and decrease by $20-30%$ when $\text{INR}$ returns to range.**",
                    "B. Increase dose by $10%$.",
                    "C. Decrease dose by $10%$.",
                    "D. Start $\text{Vitamin} \text{ K}$ orally.",
                    "E. Continue the same dose."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "For an $\text{INR}$ of **$4.0-4.9$**, the initial step is to **Hold the dose until the $\text{INR}$ returns to range, then decrease by $20-30%$**. (p. 94)",
                "tags": [
                    "warfarin",
                    "dosing_adjustment",
                    "INR_management"
                ]
            },
            {
                "id": 1348,
                "question": "A patient develops a serious, life-threatening bleed while on Warfarin ($\text{INR } >9.0$). What is the **immediate intervention** to reverse the anticoagulation?",
                "choices": [
                    "A. **Stop Warfarin and replace with Prothrombin Complex Concentrate ($\text{PCC}$) and $\text{Vitamin} \text{ K}$ $\text{IV}$.**",
                    "B. Transfuse $\text{PRBCs}$ only.",
                    "C. Stop Warfarin and give FFP orally.",
                    "D. Decrease Warfarin dose by $50%$ and observe.",
                    "E. Start Heparin infusion."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "For **life-threatening bleeding**, immediate reversal is required. The protocol is to **Stop Warfarin** and give **$\text{PCC}$ and $\text{Vitamin} \text{ K}$ $10 \text{ mg}$ $\text{IV}$**. $\text{FFP}$ is an alternative if $\text{PCC}$ is unavailable. (p. 94)",
                "tags": [
                    "warfarin",
                    "anticoagulation_reversal",
                    "emergency_management"
                ]
            },
            {
                "id": 1350,
                "question": "A patient is diagnosed with a **Pulmonary Embolism (PE)**. Initial management involves immediate anticoagulation with $\text{LMWH}$ and Warfarin overlap. Which condition is the most appropriate indication for **indefinite** anticoagulation?",
                "choices": [
                    "A. PE secondary to transient immobilization.",
                    "B. First episode of $\text{PE}$ with no identifiable cause (idiopathic).",
                    "C. **PE associated with active malignancy.**",
                    "D. PE secondary to oral contraceptive use.",
                    "E. PE in a patient with mild hypertension."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with **active malignancy** are at high risk of recurrence and require anticoagulation **indefinitely or until the cancer resolves**. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "active_cancer"
                ]
            },
            {
                "id": 1351,
                "question": "A patient with $\text{DVT}$ is started on Warfarin. What is the goal of overlapping Warfarin with $\text{LMWH}$ (Enoxaparin)?",
                "choices": [
                    "A. To achieve the $\text{INR}$ goal immediately.",
                    "B. **To provide immediate anticoagulation protection until Warfarin is therapeutic.**",
                    "C. To prevent the recurrence of $\text{PE}$ after Warfarin starts.",
                    "D. To dissolve the existing thrombus faster.",
                    "E. To decrease the risk of bleeding."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Warfarin takes several days to become fully therapeutic; therefore, a fast-acting parenteral anticoagulant ($\text{LMWH}$/$\text{UFH}$) must be used concurrently to **provide immediate anticoagulation protection** during the lag phase. (p. 258)",
                "tags": [
                    "VTE_treatment",
                    "anticoagulation",
                    "overlap"
                ]
            },
            {
                "id": 1352,
                "question": "A patient with acute $\text{DVT}$ is started on **$\text{UFH}$ ($\text{Unfractionated Heparin}$)**. What is the recommended **initial therapeutic dosing**?",
                "choices": [
                    "A. $5000 \text{ IU}$ $\text{SC}$ $\text{BID}$.",
                    "B. $10,000 \text{ IU}$ $\text{SC}$ daily.",
                    "C. $1 \text{ mg/kg}$ $\text{SC}$ $\text{BID}$.",
                    "D. **$5000 \text{ IU}$ $\text{IV}$ bolus, then $17,500 \text{ IU}$ $\text{SC}$ $\text{BID}$ (for average adult)**.",
                    "E. $40 \text{ mg}$ $\text{SC}$ daily."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The initial therapeutic dosing involves an $\text{IV}$ bolus and then maintenance dosing, which can be $\text{SC}$ (e.g., **$17,500 \text{ IU}$ $\text{SC}$ $\text{BID}$ for average adult**) or $\text{IV}$ infusion, until Warfarin is therapeutic. (p. 258)",
                "tags": [
                    "DVT_treatment",
                    "UFH",
                    "dosing"
                ]
            },
            {
                "id": 1353,
                "question": "A patient with $\text{PE}$ and no known risk factors (idiopathic) is being managed long-term. If this is their **first episode**, what is the minimum duration of anticoagulation therapy?",
                "choices": [
                    "A. 1 month.",
                    "B. **3 months.**",
                    "C. 6 months.",
                    "D. 12 months.",
                    "E. Indefinite."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with a **first episode of idiopathic/unprovoked $\text{VTE}$** should receive anticoagulation for **$3-6$ months**. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "idiopathic_VTE"
                ]
            },
            {
                "id": 1354,
                "question": "Which complication of $\text{VTE}$ is the most life-threatening in the acute setting?",
                "choices": [
                    "A. Post-thrombotic syndrome.",
                    "B. Chronic venous insufficiency.",
                    "C. **Pulmonary Thrombo-Embolism (PTE)**.",
                    "D. Superficial thrombophlebitis.",
                    "E. Venous ulceration."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "**PTE** (or $\text{PE}$) can be **fatal** and is the most life-threatening manifestation of $\text{VTE}$. (p. 257, 258)",
                "tags": [
                    "VTE",
                    "complications",
                    "mortality"
                ]
            },
            {
                "id": 1356,
                "question": "What is the recommended anticoagulation goal range for $\text{INR}$ when treating $\text{VTE}$ with Warfarin?",
                "choices": [
                    "A. $1.0-1.5$",
                    "B. **$2.0-3.0$**",
                    "C. $2.5-3.5$",
                    "D. $3.0-4.0$",
                    "E. $\text{INR}$ monitoring is not required for $\text{PE}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The anticoagulation goal range for Warfarin in patients with $\text{VTE}$ (DVT/PE) is an $\text{INR}$ of **$2.0-3.0$**. (p. 93, 258)",
                "tags": [
                    "VTE_treatment",
                    "warfarin",
                    "INR_target"
                ]
            },
            {
                "id": 1357,
                "question": "A patient with $\text{DVT}$ is started on Warfarin. If the $\text{INR}$ is $3.5$ with no bleeding, what is the appropriate dose adjustment?",
                "choices": [
                    "A. **Decrease dose by $20%$ and hold one dose.**",
                    "B. Increase dose by $10%$.",
                    "C. Hold dose until $\text{INR} <2.0$.",
                    "D. Give $\text{Vitamin} \text{ K}$ orally.",
                    "E. No adjustment needed."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The Warfarin dosing guide suggests that for an $\text{INR}$ of **$3.5-3.9$**, the dose should be **decreased by $20%$ and one dose should be held**. (p. 94)",
                "tags": [
                    "warfarin",
                    "dosing_adjustment",
                    "INR_management"
                ]
            },
            {
                "id": 1358,
                "question": "A patient develops a serious, life-threatening bleed while on Warfarin ($\text{INR } >9.0$). What is the **immediate intervention** to reverse the anticoagulation?",
                "choices": [
                    "A. **Stop Warfarin and replace with Prothrombin Complex Concentrate ($\text{PCC}$) and $\text{Vitamin} \text{ K}$ $\text{IV}$.**",
                    "B. Transfuse $\text{PRBCs}$ only.",
                    "C. Stop Warfarin and give FFP orally.",
                    "D. Decrease Warfarin dose by $50%$ and observe.",
                    "E. Start Heparin infusion."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "For **life-threatening bleeding**, immediate reversal is required. The protocol is to **Stop Warfarin** and give **$\text{PCC}$ and $\text{Vitamin} \text{ K}$ $10 \text{ mg}$ $\text{IV}$**. $\text{FFP}$ is an alternative if $\text{PCC}$ is unavailable. (p. 94)",
                "tags": [
                    "warfarin",
                    "anticoagulation_reversal",
                    "emergency_management"
                ]
            },
            {
                "id": 1360,
                "question": "A patient with $\text{PE}$ and active cancer is being treated. What is the recommended **duration** of anticoagulation?",
                "choices": [
                    "A. 6 months.",
                    "B. 12 months.",
                    "C. **Indefinite (or until the cancer resolves).**",
                    "D. 7 days.",
                    "E. 3 months."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with **active malignancy** should generally be treated **indefinitely or until the cancer resolves**. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "active_cancer"
                ]
            },
            {
                "id": 1361,
                "question": "A patient with $\text{DVT}$ is started on Warfarin. What is the goal of overlapping Warfarin with $\text{LMWH}$ (Enoxaparin)?",
                "choices": [
                    "A. To achieve the $\text{INR}$ goal immediately.",
                    "B. **To provide immediate anticoagulation protection until Warfarin is therapeutic.**",
                    "C. To prevent the recurrence of $\text{PE}$ after Warfarin starts.",
                    "D. To dissolve the existing thrombus faster.",
                    "E. To decrease the risk of bleeding."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Warfarin takes several days to become fully therapeutic; therefore, a fast-acting parenteral anticoagulant ($\text{LMWH}$/$\text{UFH}$) must be used concurrently to **provide immediate anticoagulation protection** during the lag phase. (p. 258)",
                "tags": [
                    "VTE_treatment",
                    "anticoagulation",
                    "overlap"
                ]
            },
            {
                "id": 1362,
                "question": "A patient with acute $\text{DVT}$ is started on **$\text{UFH}$ ($\text{Unfractionated Heparin}$)**. What is the recommended **initial therapeutic dosing**?",
                "choices": [
                    "A. $5000 \text{ IU}$ $\text{SC}$ $\text{BID}$.",
                    "B. $10,000 \text{ IU}$ $\text{SC}$ daily.",
                    "C. $1 \text{ mg/kg}$ $\text{SC}$ $\text{BID}$.",
                    "D. **$5000 \text{ IU}$ $\text{IV}$ bolus, then $17,500 \text{ IU}$ $\text{SC}$ $\text{BID}$ (for average adult)**.",
                    "E. $40 \text{ mg}$ $\text{SC}$ daily."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The initial therapeutic dosing involves an $\text{IV}$ bolus and then maintenance dosing, which can be $\text{SC}$ (e.g., **$17,500 \text{ IU}$ $\text{SC}$ $\text{BID}$ for average adult**) or $\text{IV}$ infusion, until Warfarin is therapeutic. (p. 258)",
                "tags": [
                    "DVT_treatment",
                    "UFH",
                    "dosing"
                ]
            },
            {
                "id": 1363,
                "question": "A patient with $\text{PE}$ and no known risk factors (idiopathic) is being managed long-term. If this is their **first episode**, what is the minimum duration of anticoagulation therapy?",
                "choices": [
                    "A. 1 month.",
                    "B. **3 months.**",
                    "C. 6 months.",
                    "D. 12 months.",
                    "E. Indefinite."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with a **first episode of idiopathic/unprovoked $\text{VTE}$** should receive anticoagulation for **$3-6$ months**. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "idiopathic_VTE"
                ]
            },
            {
                "id": 1364,
                "question": "Which complication of $\text{VTE}$ is the most life-threatening in the acute setting?",
                "choices": [
                    "A. Post-thrombotic syndrome.",
                    "B. Chronic venous insufficiency.",
                    "C. **Pulmonary Thrombo-Embolism (PTE)**.",
                    "D. Superficial thrombophlebitis.",
                    "E. Venous ulceration."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "**PTE** (or $\text{PE}$) can be **fatal** and is the most life-threatening manifestation of $\text{VTE}$. (p. 257, 258)",
                "tags": [
                    "VTE",
                    "complications",
                    "mortality"
                ]
            },
            {
                "id": 1366,
                "question": "What is the recommended anticoagulation goal range for $\text{INR}$ when treating $\text{VTE}$ with Warfarin?",
                "choices": [
                    "A. $1.0-1.5$",
                    "B. **$2.0-3.0$**",
                    "C. $2.5-3.5$",
                    "D. $3.0-4.0$",
                    "E. $\text{INR}$ monitoring is not required for $\text{PE}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The anticoagulation goal range for Warfarin in patients with $\text{VTE}$ (DVT/PE) is an $\text{INR}$ of **$2.0-3.0$**. (p. 93, 258)",
                "tags": [
                    "VTE_treatment",
                    "warfarin",
                    "INR_target"
                ]
            },
            {
                "id": 1367,
                "question": "A patient with $\text{DVT}$ is started on Warfarin. If the $\text{INR}$ is $3.5$, with no bleeding, what is the appropriate dose adjustment?",
                "choices": [
                    "A. **Decrease dose by $20%$ and hold one dose.**",
                    "B. Increase dose by $10%$.",
                    "C. Hold dose until $\text{INR} <2.0$.",
                    "D. Give $\text{Vitamin} \text{ K}$ orally.",
                    "E. No adjustment needed."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The Warfarin dosing guide suggests that for an $\text{INR}$ of **$3.5-3.9$**, the dose should be **decreased by $20%$ and one dose should be held**. (p. 94)",
                "tags": [
                    "warfarin",
                    "dosing_adjustment",
                    "INR_management"
                ]
            },
            {
                "id": 1368,
                "question": "A patient develops a serious, life-threatening bleed while on Warfarin ($\text{INR } >9.0$). What is the **immediate intervention** to reverse the anticoagulation?",
                "choices": [
                    "A. **Stop Warfarin and replace with Prothrombin Complex Concentrate ($\text{PCC}$) and $\text{Vitamin} \text{ K}$ $\text{IV}$.**",
                    "B. Transfuse $\text{PRBCs}$ only.",
                    "C. Stop Warfarin and give FFP orally.",
                    "D. Decrease Warfarin dose by $50%$ and observe.",
                    "E. Start Heparin infusion."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "For **life-threatening bleeding**, immediate reversal is required. The protocol is to **Stop Warfarin** and give **$\text{PCC}$ and $\text{Vitamin} \text{ K}$ $10 \text{ mg}$ $\text{IV}$**. $\text{FFP}$ is an alternative if $\text{PCC}$ is unavailable. (p. 94)",
                "tags": [
                    "warfarin",
                    "anticoagulation_reversal",
                    "emergency_management"
                ]
            },
            {
                "id": 1370,
                "question": "A patient with $\text{PE}$ and active cancer is being treated. What is the recommended **duration** of anticoagulation?",
                "choices": [
                    "A. 6 months.",
                    "B. 12 months.",
                    "C. **Indefinite (or until the cancer resolves).**",
                    "D. 7 days.",
                    "E. 3 months."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with **active malignancy** should generally be treated **indefinitely or until the cancer resolves**. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "active_cancer"
                ]
            },
            {
                "id": 1371,
                "question": "A patient with $\text{DVT}$ is started on Warfarin. What is the goal of overlapping Warfarin with $\text{LMWH}$ (Enoxaparin)?",
                "choices": [
                    "A. To achieve the $\text{INR}$ goal immediately.",
                    "B. **To provide immediate anticoagulation protection until Warfarin is therapeutic.**",
                    "C. To prevent the recurrence of $\text{PE}$ after Warfarin starts.",
                    "D. To dissolve the existing thrombus faster.",
                    "E. To decrease the risk of bleeding."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Warfarin takes several days to become fully therapeutic; therefore, a fast-acting parenteral anticoagulant ($\text{LMWH}$/$\text{UFH}$) must be used concurrently to **provide immediate anticoagulation protection** during the lag phase. (p. 258)",
                "tags": [
                    "VTE_treatment",
                    "anticoagulation",
                    "overlap"
                ]
            },
            {
                "id": 1372,
                "question": "A patient with acute $\text{DVT}$ is started on **$\text{UFH}$ ($\text{Unfractionated Heparin}$)**. What is the recommended **initial therapeutic dosing**?",
                "choices": [
                    "A. $5000 \text{ IU}$ $\text{SC}$ $\text{BID}$.",
                    "B. $10,000 \text{ IU}$ $\text{SC}$ daily.",
                    "C. $1 \text{ mg/kg}$ $\text{SC}$ $\text{BID}$.",
                    "D. **$5000 \text{ IU}$ $\text{IV}$ bolus, then $17,500 \text{ IU}$ $\text{SC}$ $\text{BID}$ (for average adult)**.",
                    "E. $40 \text{ mg}$ $\text{SC}$ daily."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The initial therapeutic dosing involves an $\text{IV}$ bolus and then maintenance dosing, which can be $\text{SC}$ (e.g., **$17,500 \text{ IU}$ $\text{SC}$ $\text{BID}$ for average adult**) or $\text{IV}$ infusion, until Warfarin is therapeutic. (p. 258)",
                "tags": [
                    "DVT_treatment",
                    "UFH",
                    "dosing"
                ]
            },
            {
                "id": 1373,
                "question": "A patient with $\text{PE}$ and no known risk factors (idiopathic) is being managed long-term. If this is their **first episode**, what is the minimum duration of anticoagulation therapy?",
                "choices": [
                    "A. 1 month.",
                    "B. **3 months.**",
                    "C. 6 months.",
                    "D. 12 months.",
                    "E. Indefinite."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with a **first episode of idiopathic/unprovoked $\text{VTE}$** should receive anticoagulation for **$3-6$ months**. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "idiopathic_VTE"
                ]
            },
            {
                "id": 1374,
                "question": "Which complication of $\text{VTE}$ is the most life-threatening in the acute setting?",
                "choices": [
                    "A. Post-thrombotic syndrome.",
                    "B. Chronic venous insufficiency.",
                    "C. **Pulmonary Thrombo-Embolism (PTE)**.",
                    "D. Superficial thrombophlebitis.",
                    "E. Venous ulceration."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "**PTE** (or $\text{PE}$) can be **fatal** and is the most life-threatening manifestation of $\text{VTE}$. (p. 257, 258)",
                "tags": [
                    "VTE",
                    "complications",
                    "mortality"
                ]
            },
            {
                "id": 1376,
                "question": "What is the recommended anticoagulation goal range for $\text{INR}$ when treating $\text{VTE}$ with Warfarin?",
                "choices": [
                    "A. $1.0-1.5$",
                    "B. **$2.0-3.0$**",
                    "C. $2.5-3.5$",
                    "D. $3.0-4.0$",
                    "E. $\text{INR}$ monitoring is not required for $\text{PE}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The anticoagulation goal range for Warfarin in patients with $\text{VTE}$ (DVT/PE) is an $\text{INR}$ of **$2.0-3.0$**. (p. 93, 258)",
                "tags": [
                    "VTE_treatment",
                    "warfarin",
                    "INR_target"
                ]
            },
            {
                "id": 1377,
                "question": "A patient with $\text{DVT}$ is started on Warfarin. If the $\text{INR}$ is $3.5$, with no bleeding, what is the appropriate dose adjustment?",
                "choices": [
                    "A. **Decrease dose by $20%$ and hold one dose.**",
                    "B. Increase dose by $10%$.",
                    "C. Hold dose until $\text{INR} <2.0$.",
                    "D. Give $\text{Vitamin} \text{ K}$ orally.",
                    "E. No adjustment needed."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The Warfarin dosing guide suggests that for an $\text{INR}$ of **$3.5-3.9$**, the dose should be **decreased by $20%$ and one dose should be held**. (p. 94)",
                "tags": [
                    "warfarin",
                    "dosing_adjustment",
                    "INR_management"
                ]
            },
            {
                "id": 1378,
                "question": "A patient develops a serious, life-threatening bleed while on Warfarin ($\text{INR } >9.0$). What is the **immediate intervention** to reverse the anticoagulation?",
                "choices": [
                    "A. **Stop Warfarin and replace with Prothrombin Complex Concentrate ($\text{PCC}$) and $\text{Vitamin} \text{ K}$ $\text{IV}$.**",
                    "B. Transfuse $\text{PRBCs}$ only.",
                    "C. Stop Warfarin and give FFP orally.",
                    "D. Decrease Warfarin dose by $50%$ and observe.",
                    "E. Start Heparin infusion."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "For **life-threatening bleeding**, immediate reversal is required. The protocol is to **Stop Warfarin** and give **$\text{PCC}$ and $\text{Vitamin} \text{ K}$ $10 \text{ mg}$ $\text{IV}$**. $\text{FFP}$ is an alternative if $\text{PCC}$ is unavailable. (p. 94)",
                "tags": [
                    "warfarin",
                    "anticoagulation_reversal",
                    "emergency_management"
                ]
            },
            {
                "id": 1380,
                "question": "A patient with $\text{PE}$ and active cancer is being treated. What is the recommended **duration** of anticoagulation?",
                "choices": [
                    "A. 6 months.",
                    "B. 12 months.",
                    "C. **Indefinite (or until the cancer resolves).**",
                    "D. 7 days.",
                    "E. 3 months."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with **active malignancy** should generally be treated **indefinitely or until the cancer resolves**. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "active_cancer"
                ]
            },
            {
                "id": 1381,
                "question": "A patient with $\text{DVT}$ is started on Warfarin. What is the goal of overlapping Warfarin with $\text{LMWH}$ (Enoxaparin)?",
                "choices": [
                    "A. To achieve the $\text{INR}$ goal immediately.",
                    "B. **To provide immediate anticoagulation protection until Warfarin is therapeutic.**",
                    "C. To prevent the recurrence of $\text{PE}$ after Warfarin starts.",
                    "D. To dissolve the existing thrombus faster.",
                    "E. To decrease the risk of bleeding."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Warfarin takes several days to become fully therapeutic; therefore, a fast-acting parenteral anticoagulant ($\text{LMWH}$/$\text{UFH}$) must be used concurrently to **provide immediate anticoagulation protection** during the lag phase. (p. 258)",
                "tags": [
                    "VTE_treatment",
                    "anticoagulation",
                    "overlap"
                ]
            },
            {
                "id": 1382,
                "question": "A patient with acute $\text{DVT}$ is started on **$\text{UFH}$ ($\text{Unfractionated Heparin}$)**. What is the recommended **initial therapeutic dosing**?",
                "choices": [
                    "A. $5000 \text{ IU}$ $\text{SC}$ $\text{BID}$.",
                    "B. $10,000 \text{ IU}$ $\text{SC}$ daily.",
                    "C. $1 \text{ mg/kg}$ $\text{SC}$ $\text{BID}$.",
                    "D. **$5000 \text{ IU}$ $\text{IV}$ bolus, then $17,500 \text{ IU}$ $\text{SC}$ $\text{BID}$ (for average adult)**.",
                    "E. $40 \text{ mg}$ $\text{SC}$ daily."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The initial therapeutic dosing involves an $\text{IV}$ bolus and then maintenance dosing, which can be $\text{SC}$ (e.g., **$17,500 \text{ IU}$ $\text{SC}$ $\text{BID}$ for average adult**) or $\text{IV}$ infusion, until Warfarin is therapeutic. (p. 258)",
                "tags": [
                    "DVT_treatment",
                    "UFH",
                    "dosing"
                ]
            },
            {
                "id": 1383,
                "question": "A patient with $\text{PE}$ and no known risk factors (idiopathic) is being managed long-term. If this is their **first episode**, what is the minimum duration of anticoagulation therapy?",
                "choices": [
                    "A. 1 month.",
                    "B. **3 months.**",
                    "C. 6 months.",
                    "D. 12 months.",
                    "E. Indefinite."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with a **first episode of idiopathic/unprovoked $\text{VTE}$** should receive anticoagulation for **$3-6$ months**. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "idiopathic_VTE"
                ]
            },
            {
                "id": 1384,
                "question": "Which complication of $\text{VTE}$ is the most life-threatening in the acute setting?",
                "choices": [
                    "A. Post-thrombotic syndrome.",
                    "B. Chronic venous insufficiency.",
                    "C. **Pulmonary Thrombo-Embolism (PTE)**.",
                    "D. Superficial thrombophlebitis.",
                    "E. Venous ulceration."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "**PTE** (or $\text{PE}$) can be **fatal** and is the most life-threatening manifestation of $\text{VTE}$. (p. 257, 258)",
                "tags": [
                    "VTE",
                    "complications",
                    "mortality"
                ]
            },
            {
                "id": 1386,
                "question": "What is the recommended anticoagulation goal range for $\text{INR}$ when treating $\text{VTE}$ with Warfarin?",
                "choices": [
                    "A. $1.0-1.5$",
                    "B. **$2.0-3.0$**",
                    "C. $2.5-3.5$",
                    "D. $3.0-4.0$",
                    "E. $\text{INR}$ monitoring is not required for $\text{PE}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The anticoagulation goal range for Warfarin in patients with $\text{VTE}$ (DVT/PE) is an $\text{INR}$ of **$2.0-3.0$**. (p. 93, 258)",
                "tags": [
                    "VTE_treatment",
                    "warfarin",
                    "INR_target"
                ]
            },
            {
                "id": 1387,
                "question": "A patient with $\text{DVT}$ is started on Warfarin. If the $\text{INR}$ is $3.5$, with no bleeding, what is the appropriate dose adjustment?",
                "choices": [
                    "A. **Decrease dose by $20%$ and hold one dose.**",
                    "B. Increase dose by $10%$.",
                    "C. Hold dose until $\text{INR} <2.0$.",
                    "D. Give $\text{Vitamin} \text{ K}$ orally.",
                    "E. No adjustment needed."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The Warfarin dosing guide suggests that for an $\text{INR}$ of **$3.5-3.9$**, the dose should be **decreased by $20%$ and one dose should be held**. (p. 94)",
                "tags": [
                    "warfarin",
                    "dosing_adjustment",
                    "INR_management"
                ]
            },
            {
                "id": 1388,
                "question": "A patient develops a serious, life-threatening bleed while on Warfarin ($\text{INR } >9.0$). What is the **immediate intervention** to reverse the anticoagulation?",
                "choices": [
                    "A. **Stop Warfarin and replace with Prothrombin Complex Concentrate ($\text{PCC}$) and $\text{Vitamin} \text{ K}$ $\text{IV}$.**",
                    "B. Transfuse $\text{PRBCs}$ only.",
                    "C. Stop Warfarin and give FFP orally.",
                    "D. Decrease Warfarin dose by $50%$ and observe.",
                    "E. Start Heparin infusion."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "For **life-threatening bleeding**, immediate reversal is required. The protocol is to **Stop Warfarin** and give **$\text{PCC}$ and $\text{Vitamin} \text{ K}$ $10 \text{ mg}$ $\text{IV}$**. $\text{FFP}$ is an alternative if $\text{PCC}$ is unavailable. (p. 94)",
                "tags": [
                    "warfarin",
                    "anticoagulation_reversal",
                    "emergency_management"
                ]
            },
            {
                "id": 1390,
                "question": "A patient with $\text{PE}$ and active cancer is being treated. What is the recommended **duration** of anticoagulation?",
                "choices": [
                    "A. 6 months.",
                    "B. 12 months.",
                    "C. **Indefinite (or until the cancer resolves).**",
                    "D. 7 days.",
                    "E. 3 months."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with **active malignancy** should generally be treated **indefinitely or until the cancer resolves**. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "active_cancer"
                ]
            },
            {
                "id": 1391,
                "question": "A patient with $\text{DVT}$ is started on Warfarin. What is the goal of overlapping Warfarin with $\text{LMWH}$ (Enoxaparin)?",
                "choices": [
                    "A. To achieve the $\text{INR}$ goal immediately.",
                    "B. **To provide immediate anticoagulation protection until Warfarin is therapeutic.**",
                    "C. To prevent the recurrence of $\text{PE}$ after Warfarin starts.",
                    "D. To dissolve the existing thrombus faster.",
                    "E. To decrease the risk of bleeding."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Warfarin takes several days to become fully therapeutic; therefore, a fast-acting parenteral anticoagulant ($\text{LMWH}$/$\text{UFH}$) must be used concurrently to **provide immediate anticoagulation protection** during the lag phase. (p. 258)",
                "tags": [
                    "VTE_treatment",
                    "anticoagulation",
                    "overlap"
                ]
            },
            {
                "id": 1392,
                "question": "A patient with acute $\text{DVT}$ is started on **$\text{UFH}$ ($\text{Unfractionated Heparin}$)**. What is the recommended **initial therapeutic dosing**?",
                "choices": [
                    "A. $5000 \text{ IU}$ $\text{SC}$ $\text{BID}$.",
                    "B. $10,000 \text{ IU}$ $\text{SC}$ daily.",
                    "C. $1 \text{ mg/kg}$ $\text{SC}$ $\text{BID}$.",
                    "D. **$5000 \text{ IU}$ $\text{IV}$ bolus, then $17,500 \text{ IU}$ $\text{SC}$ $\text{BID}$ (for average adult)**.",
                    "E. $40 \text{ mg}$ $\text{SC}$ daily."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The initial therapeutic dosing involves an $\text{IV}$ bolus and then maintenance dosing, which can be $\text{SC}$ (e.g., **$17,500 \text{ IU}$ $\text{SC}$ $\text{BID}$ for average adult**) or $\text{IV}$ infusion, until Warfarin is therapeutic. (p. 258)",
                "tags": [
                    "DVT_treatment",
                    "UFH",
                    "dosing"
                ]
            },
            {
                "id": 1393,
                "question": "A patient with $\text{PE}$ and no known risk factors (idiopathic) is being managed long-term. If this is their **first episode**, what is the minimum duration of anticoagulation therapy?",
                "choices": [
                    "A. 1 month.",
                    "B. **3 months.**",
                    "C. 6 months.",
                    "D. 12 months.",
                    "E. Indefinite."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with a **first episode of idiopathic/unprovoked $\text{VTE}$** should receive anticoagulation for **$3-6$ months**. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "idiopathic_VTE"
                ]
            },
            {
                "id": 1394,
                "question": "Which complication of $\text{VTE}$ is the most life-threatening in the acute setting?",
                "choices": [
                    "A. Post-thrombotic syndrome.",
                    "B. Chronic venous insufficiency.",
                    "C. **Pulmonary Thrombo-Embolism (PTE)**.",
                    "D. Superficial thrombophlebitis.",
                    "E. Venous ulceration."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "**PTE** (or $\text{PE}$) can be **fatal** and is the most life-threatening manifestation of $\text{VTE}$. (p. 257, 258)",
                "tags": [
                    "VTE",
                    "complications",
                    "mortality"
                ]
            },
            {
                "id": 1396,
                "question": "What is the recommended anticoagulation goal range for $\text{INR}$ when treating $\text{VTE}$ with Warfarin?",
                "choices": [
                    "A. $1.0-1.5$",
                    "B. **$2.0-3.0$**",
                    "C. $2.5-3.5$",
                    "D. $3.0-4.0$",
                    "E. $\text{INR}$ monitoring is not required for $\text{PE}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The anticoagulation goal range for Warfarin in patients with $\text{VTE}$ (DVT/PE) is an $\text{INR}$ of **$2.0-3.0$**. (p. 93, 258)",
                "tags": [
                    "VTE_treatment",
                    "warfarin",
                    "INR_target"
                ]
            },
            {
                "id": 1397,
                "question": "A patient with $\text{DVT}$ is started on Warfarin. If the $\text{INR}$ is $3.5$, with no bleeding, what is the appropriate dose adjustment?",
                "choices": [
                    "A. **Decrease dose by $20%$ and hold one dose.**",
                    "B. Increase dose by $10%$.",
                    "C. Hold dose until $\text{INR} <2.0$.",
                    "D. Give $\text{Vitamin} \text{ K}$ orally.",
                    "E. No adjustment needed."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "The Warfarin dosing guide suggests that for an $\text{INR}$ of **$3.5-3.9$**, the dose should be **decreased by $20%$ and one dose should be held**. (p. 94)",
                "tags": [
                    "warfarin",
                    "dosing_adjustment",
                    "INR_management"
                ]
            },
            {
                "id": 1398,
                "question": "A patient develops a serious, life-threatening bleed while on Warfarin ($\text{INR } >9.0$). What is the **immediate intervention** to reverse the anticoagulation?",
                "choices": [
                    "A. **Stop Warfarin and replace with Prothrombin Complex Concentrate ($\text{PCC}$) and $\text{Vitamin} \text{ K}$ $\text{IV}$.**",
                    "B. Transfuse $\text{PRBCs}$ only.",
                    "C. Stop Warfarin and give FFP orally.",
                    "D. Decrease Warfarin dose by $50%$ and observe.",
                    "E. Start Heparin infusion."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "For **life-threatening bleeding**, immediate reversal is required. The protocol is to **Stop Warfarin** and give **$\text{PCC}$ and $\text{Vitamin} \text{ K}$ $10 \text{ mg}$ $\text{IV}$**. $\text{FFP}$ is an alternative if $\text{PCC}$ is unavailable. (p. 94)",
                "tags": [
                    "warfarin",
                    "anticoagulation_reversal",
                    "emergency_management"
                ]
            },
            {
                "id": 1400,
                "question": "A patient with $\text{PE}$ and active cancer is being treated. What is the recommended **duration** of anticoagulation?",
                "choices": [
                    "A. 6 months.",
                    "B. 12 months.",
                    "C. **Indefinite (or until the cancer resolves).**",
                    "D. 7 days.",
                    "E. 3 months."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.4.2 Venous Thromboembolism (VTE) Disease: Deep vein thrombosis and pulmonary embolism",
                "explanation": "Patients with **active malignancy** should generally be treated **indefinitely or until the cancer resolves**. (p. 259)",
                "tags": [
                    "PE_treatment",
                    "anticoagulation_duration",
                    "active_cancer"
                ]
            }
        ]
    },
    "Chapter 7.5.1": {
        "Chapter 7.5.1 Acute Leukemia": [
            {
                "id": 1401,
                "question": "A 5-year-old child presents with a two-week history of fever, persistent fatigue, and easy bruising. Physical exam shows pallor and hepatosplenomegaly. Initial $\text{CBC}$ shows $\text{WBC } 2,000/mu l$, $\text{Hb } 7.0 \text{ g/dl}$, and platelets $30,000/mu l$. **Acute Leukemia** is suspected. What is the **immediate priority** in the general hospital setting?",
                "choices": [
                    "A. Immediate chemotherapy initiation.",
                    "B. Urgent **referral to a specialized center** for diagnosis and management.",
                    "C. Bone marrow aspiration to confirm diagnosis.",
                    "D. Supportive care only; no referral is needed.",
                    "E. High-dose steroid trial."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Patients with suspected or confirmed **Acute Leukemia** (characterized by cytopenia, fever, and organomegaly) require urgent **referral to a specialized center with hematology oncology service** for diagnosis (bone marrow aspiration) and management. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "pediatrics",
                    "referral"
                ]
            },
            {
                "id": 1402,
                "question": "A 65-year-old male presents with fatigue and recurrent infections. $\text{CBC}$ shows pancytopenia ($\text{Hb } 7.5 \text{ g/dl}$, $\text{WBC } 1,500/mu l$, platelets $40,000/mu l$). Acute Leukemia is suspected. What is the single **most important** diagnostic step for confirmation?",
                "choices": [
                    "A. Peripheral blood smear to check for circulating blasts.",
                    "B. $\text{CT}$ scan of the abdomen for lymphadenopathy.",
                    "C. **Bone marrow aspiration/biopsy.**",
                    "D. $\text{LDH}$ and Uric Acid levels.",
                    "E. Blood culture."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "While circulating blasts on peripheral smear is suggestive, the definitive diagnosis of **Acute Leukemia** requires **Bone Marrow Aspiration/Biopsy** to confirm the presence and percentage of blasts. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "diagnosis",
                    "bone_marrow"
                ]
            },
            {
                "id": 1403,
                "question": "In a patient with suspected Acute Leukemia, the clinical features are typically the result of:",
                "choices": [
                    "A. Autoimmune destruction of mature cells.",
                    "B. Infiltration of the spleen and liver only.",
                    "C. **Bone marrow failure** (impaired production of normal cells).",
                    "D. Increased proliferation of blasts only in the peripheral blood.",
                    "E. Chronic inflammation of lymph nodes."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "The clinical features of Acute Leukemia (anemia, bleeding, infection) are a direct consequence of **bone marrow failure** and resulting cytopenias (low $\text{RBCs}$, platelets, and dysfunctional $\text{WBCs}$). (p. 259, 260)",
                "tags": [
                    "acute_leukemia",
                    "pathophysiology",
                    "clinical_features"
                ]
            },
            {
                "id": 1404,
                "question": "A patient with suspected Acute Leukemia has severe anemia ($\text{Hb } 6.0 \text{ g/dl}$). She is hemodynamically stable. What is the appropriate management decision regarding blood transfusion?",
                "choices": [
                    "A. Transfuse immediately, as $\text{Hb} <7 \text{ g/dl}$ is mandatory for all.",
                    "B. **Transfuse Packed $\text{RBCs}$ to correct severe anemia.**",
                    "C. Defer transfusion until chemotherapy is started.",
                    "D. Transfuse only if she develops active bleeding.",
                    "E. Transfuse only if $\text{Hb} <5.0 \text{ g/dl}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Supportive treatment for Acute Leukemia includes managing cytopenias. **Severe anemia** ($\text{Hb} <7 \text{ g/dl}$) requires transfusion with **Packed $\text{RBCs}$**. (p. 237, 260)",
                "tags": [
                    "acute_leukemia",
                    "supportive_care",
                    "transfusion"
                ]
            },
            {
                "id": 1405,
                "question": "A patient with suspected Acute Leukemia has a high fever ($\text{39.5}^circ C$) and a neutrophil count of $500/mu l$. What is the initial management priority for this patient?",
                "choices": [
                    "A. **Obtain blood cultures and initiate empiric broad-spectrum antibiotics for neutropenic fever.**",
                    "B. Immediate administration of $\text{G-CSF}$.",
                    "C. Start high-dose corticosteroids for presumed inflammation.",
                    "D. Perform immediate bone marrow biopsy.",
                    "E. Supportive care with antipyretics only."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Fever with severe neutropenia (ANC $le 500/mu l$) is a **neutropenic fever**, which is a life-threatening emergency. The management priority is to **obtain cultures and start empiric broad-spectrum antibiotics** immediately. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "neutropenic_fever",
                    "emergency_management"
                ]
            },
            {
                "id": 1406,
                "question": "Which type of Acute Leukemia is **more common in children**?",
                "choices": [
                    "A. Acute Myelogenous Leukemia ($\text{AML}$).",
                    "B. **Acute Lymphoblastic Leukemia ($\text{ALL}$)**.",
                    "C. Chronic Lymphocytic Leukemia ($\text{CLL}$).",
                    "D. Chronic Myelogenous Leukemia ($\text{CML}$).",
                    "E. Hairy Cell Leukemia."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "**Acute Lymphoblastic Leukemia ($\text{ALL}$)** is the type of acute leukemia that is **more common in children**. ($\text{AML}$ is more common in older adults). (p. 259)",
                "tags": [
                    "acute_leukemia",
                    "etiology",
                    "pediatrics"
                ]
            },
            {
                "id": 1407,
                "question": "A 70-year-old patient presents with symptoms suggestive of Acute Leukemia. Which clinical sign is directly related to **thrombocytopenia**?",
                "choices": [
                    "A. Fatigue.",
                    "B. Fever.",
                    "C. **Easy bruising and petechiae.**",
                    "D. Splenomegaly.",
                    "E. Bone pain."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "**Thrombocytopenia** leads to impaired hemostasis, clinically manifesting as **mucocutaneous bleeding, easy bruising, and petechiae/purpura**. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "clinical_features",
                    "thrombocytopenia"
                ]
            },
            {
                "id": 1408,
                "question": "A patient with suspected Acute Leukemia has a platelet count of $15,000/mu l$. He has no active bleeding. What is the recommended management regarding platelet replacement?",
                "choices": [
                    "A. Transfuse platelets immediately, threshold is $<20,000/mu l$.",
                    "B. **No prophylactic transfusion, as there is no active bleeding.**",
                    "C. Transfuse only if platelet count drops to $<5,000/mu l$.",
                    "D. Transfuse if $\text{Hb}$ drops below $7.0 \text{ g/dl}$.",
                    "E. Start high-dose Vitamin $\text{K}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Prophylactic platelet transfusion is generally recommended only if the platelet count is **$<10,000/mu l$** in the absence of active bleeding. (p. 248)",
                "tags": [
                    "acute_leukemia",
                    "supportive_care",
                    "transfusion_threshold"
                ]
            },
            {
                "id": 1409,
                "question": "Which clinical presentation is most common in a 65-year-old patient with **Acute Myelogenous Leukemia ($\text{AML}$)**?",
                "choices": [
                    "A. New onset dementia.",
                    "B. Insidious onset of fatigue and recurrent infections.",
                    "C. **Rapid onset of fever, fatigue, and easy bruising.**",
                    "D. Painless, slow-growing lymphadenopathy.",
                    "E. Chronic non-productive cough."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "**Acute Leukemias** (including $\text{AML}$) typically present within a **relatively short period of time** with symptoms related to bone marrow failure: **fever** (from infection), **fatigue** (from anemia), and **easy bruising** (from thrombocytopenia). (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "clinical_features",
                    "AML"
                ]
            },
            {
                "id": 1410,
                "question": "A patient is suspected of having Acute Leukemia. What is the key abnormality seen on the peripheral blood smear that is highly suggestive of the diagnosis?",
                "choices": [
                    "A. Schistocytes.",
                    "B. Target cells.",
                    "C. **Circulating blasts.**",
                    "D. Spherocytes.",
                    "E. Howell-Jolly bodies."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "One of the important investigations is the peripheral blood smear to check for **circulating blasts**, which is highly suggestive of Acute Leukemia. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "diagnosis",
                    "blood_smear"
                ]
            },
            {
                "id": 1411,
                "question": "A patient with Acute Leukemia has a platelet count of $5,000/mu l$ and is actively bleeding from the gums. What is the immediate management decision?",
                "choices": [
                    "A. Wait for the $\text{ANC}$ to increase.",
                    "B. Transfuse only $\text{FFP}$.",
                    "C. **Give platelet transfusion immediately.**",
                    "D. Start empiric Metronidazole.",
                    "E. Defer transfusion until after bone marrow biopsy."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Platelet transfusion is indicated if there is **active bleeding** and the platelet count is **$<50,000/mu l$**. (p. 248)",
                "tags": [
                    "acute_leukemia",
                    "supportive_care",
                    "transfusion"
                ]
            },
            {
                "id": 1412,
                "question": "What is the primary factor used to define the category of **Severe Neutropenia** in a patient with suspected Acute Leukemia?",
                "choices": [
                    "A. **Absolute Neutrophil Count (ANC) $<500/mu l$.**",
                    "B. $\text{WBC} <1,000/mu l$.",
                    "C. $\text{WBC} <2,000/mu l$.",
                    "D. $\text{ANC} <1,500/mu l$.",
                    "E. Fever greater than $\text{38}^circ C$."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Severe neutropenia is defined as an $\text{ANC}$ **$<500/mu l$**. (p. 430)",
                "tags": [
                    "acute_leukemia",
                    "neutropenia",
                    "definition"
                ]
            },
            {
                "id": 1413,
                "question": "A 5-year-old child presents with symptoms suggestive of Acute Leukemia. What is the expected course of the disease without treatment?",
                "choices": [
                    "A. Spontaneous remission after 6 months.",
                    "B. Chronic but stable course for years.",
                    "C. **Rapid progression with high mortality.**",
                    "D. Recurrent infections only.",
                    "E. Insidious onset of neurological symptoms."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Acute Leukemias are rapidly progressing diseases, and **lack of recognition and resulting delayed diagnosis can prove to be fatal**. (p. 259, 260)",
                "tags": [
                    "acute_leukemia",
                    "prognosis"
                ]
            },
            {
                "id": 1414,
                "question": "A patient with suspected Acute Leukemia requires urgent definitive diagnosis. What step should **not** be delayed by the referral process?",
                "choices": [
                    "A. Chemotherapy initiation.",
                    "B. Bone marrow aspiration.",
                    "C. **Initiation of supportive care for cytopenias and neutropenic fever.**",
                    "D. $\text{CT}$ scan of the abdomen.",
                    "E. Typing for a hematopoietic stem cell transplant."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Patients should be referred urgently, but immediate, on-site management of life-threatening complications like **neutropenic fever and severe cytopenias** (transfusion) should not be delayed by the referral process. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "supportive_care",
                    "referral"
                ]
            },
            {
                "id": 1415,
                "question": "A 70-year-old male presents with severe fatigue and is found to have Acute Leukemia. Which type is **more common** in this age group?",
                "choices": [
                    "A. Acute Lymphoblastic Leukemia ($\text{ALL}$).",
                    "B. **Acute Myelogenous Leukemia ($\text{AML}$)**.",
                    "C. Chronic Lymphocytic Leukemia ($\text{CLL}$).",
                    "D. Chronic Myelogenous Leukemia ($\text{CML}$).",
                    "E. Hairy Cell Leukemia."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "**Acute Myelogenous Leukemia ($\text{AML}$)** is the type of acute leukemia that is **more common in older adults**. ($\text{ALL}$ is more common in children). (p. 259)",
                "tags": [
                    "acute_leukemia",
                    "etiology",
                    "AML"
                ]
            },
            {
                "id": 1416,
                "question": "What is a characteristic symptom related to **anemia** in a patient with Acute Leukemia?",
                "choices": [
                    "A. Fever.",
                    "B. Splenomegaly.",
                    "C. **Fatigue and exertional shortness of breath.**",
                    "D. Gum bleeding.",
                    "E. Lymphadenopathy."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Symptoms related to **anemia** include **fatigue** and **shortness of breath on exertion**. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "clinical_features",
                    "anemia"
                ]
            },
            {
                "id": 1417,
                "question": "A 5-year-old child presents with symptoms suggestive of Acute Leukemia. What is the most critical immediate intervention to manage potential complications?",
                "choices": [
                    "A. Transfusion of $\text{PRBCs}$ for $\text{Hb} <8 \text{ g/dl}$ only.",
                    "B. **Management of neutropenic fever and severe cytopenias.**",
                    "C. Immediate chemotherapy.",
                    "D. Referral for a splenectomy.",
                    "E. High-dose Folic Acid supplementation."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "The most immediate life-threatening complication is **neutropenic fever**, and severe cytopenias (anemia, thrombocytopenia) must also be managed urgently. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "supportive_care",
                    "emergency_management"
                ]
            },
            {
                "id": 1418,
                "question": "A patient with suspected Acute Leukemia has bleeding from the gums and petechiae. This clinical feature is directly related to:",
                "choices": [
                    "A. Anemia.",
                    "B. Neutropenia.",
                    "C. **Thrombocytopenia.**",
                    "D. High $\text{WBC}$ count.",
                    "E. Splenomegaly."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Gingival bleeding and petechiae are classic signs of **thrombocytopenia** (low platelets). (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "clinical_features",
                    "thrombocytopenia"
                ]
            },
            {
                "id": 1419,
                "question": "A patient with suspected Acute Leukemia requires definitive diagnosis. Which investigation must be performed at a specialized hematology center?",
                "choices": [
                    "A. CBC.",
                    "B. Blood cultures.",
                    "C. Chest $\text{X-ray}$.",
                    "D. **Bone Marrow Aspiration/Biopsy.**",
                    "E. $\text{LDH}$ and Uric Acid levels."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Establishing the definitive diagnosis requires the specialized procedure of **Bone Marrow Aspiration/Biopsy** (p. 260).",
                "tags": [
                    "acute_leukemia",
                    "diagnosis",
                    "referral"
                ]
            },
            {
                "id": 1420,
                "question": "A patient with suspected Acute Leukemia has a palpable spleen. This organomegaly is most accurately defined as:",
                "choices": [
                    "A. Hemorrhage.",
                    "B. Infection.",
                    "C. **Organ infiltration by neoplastic cells.**",
                    "D. Normal finding in leukemia.",
                    "E. Autoimmune reaction."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Organomegaly (hepatosplenomegaly, lymphadenopathy) in leukemia is due to **infiltration by neoplastic cells**. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "clinical_features",
                    "pathophysiology"
                ]
            },
            {
                "id": 1421,
                "question": "The clinical features of Acute Leukemia (fever, fatigue, bleeding) are primarily the result of:",
                "choices": [
                    "A. T-cell hyperactivity.",
                    "B. Increased total $\text{WBC}$ count.",
                    "C. **Bone marrow failure and cytopenias.**",
                    "D. Lymph node destruction.",
                    "E. Extramedullary hematopoiesis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "The symptoms arise due to **impaired production of normal blood cells** (anemia, thrombocytopenia, and neutropenia/dysfunctional $\text{WBCs}$) leading to **bone marrow failure**. (p. 259, 260)",
                "tags": [
                    "acute_leukemia",
                    "pathophysiology"
                ]
            },
            {
                "id": 1422,
                "question": "A 6-year-old child presents with a two-week history of fatigue, bone pain, and recurrent nosebleeds. $\text{ALL}$ is suspected. What is the critical first step for the general practitioner?",
                "choices": [
                    "A. **Urgent referral to a specialized hematology center.**",
                    "B. Start oral antibiotics for a presumed infection.",
                    "C. Start oral iron and Folic Acid supplements.",
                    "D. Administer IVIg.",
                    "E. Defer diagnosis until full laboratory workup is available."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Suspected **Acute Leukemia** requires urgent **referral to a specialized center** for immediate diagnosis and management. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "pediatrics",
                    "referral"
                ]
            },
            {
                "id": 1423,
                "question": "A patient with suspected Acute Leukemia has severe thrombocytopenia ($10,000/mu l$) but no active bleeding. What is the recommended management decision?",
                "choices": [
                    "A. Transfuse platelets immediately.",
                    "B. **No prophylactic transfusion is necessary.**",
                    "C. Transfuse $\text{FFP}$ only.",
                    "D. Start high-dose corticosteroids.",
                    "E. Wait for platelet count to drop to $5,000/mu l$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "**Prophylactic platelet transfusion** is generally recommended only if the platelet count is **$<10,000/mu l$** and is avoided otherwise. (p. 248)",
                "tags": [
                    "acute_leukemia",
                    "supportive_care",
                    "transfusion_threshold"
                ]
            },
            {
                "id": 1424,
                "question": "A patient with Acute Leukemia develops a severe, diffuse $\text{Staphylococcus}$ infection. Which clinical feature associated with Acute Leukemia makes him highly vulnerable to this infection?",
                "choices": [
                    "A. Anemia ($\text{Hb } <7 \text{ g/dl}$).",
                    "B. Bleeding tendency.",
                    "C. **Neutropenia and dysfunctional $\text{WBCs}$**.",
                    "D. Splenomegaly.",
                    "E. Bone pain."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "The increased risk of infection is due to the presence of **neutropenia** and the fact that the circulating $\text{WBCs}$ are **dysfunctional** (blasts). (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "pathophysiology",
                    "infection_risk"
                ]
            },
            {
                "id": 1425,
                "question": "What is the hematologic definition of **Severe Neutropenia**?",
                "choices": [
                    "A. $\text{WBC} <2,000/mu l$.",
                    "B. $\text{WBC} <1,000/mu l$.",
                    "C. **$\text{ANC} <500/mu l$.**",
                    "D. $\text{ANC} <1,500/mu l$.",
                    "E. $\text{ANC} <200/mu l$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Severe neutropenia is defined as an $\text{ANC}$ **$<500/mu l$**. ($\text{ANC} <100/mu l$ is profound neutropenia.) (p. 430)",
                "tags": [
                    "acute_leukemia",
                    "neutropenia",
                    "definition"
                ]
            },
            {
                "id": 1426,
                "question": "The definitive diagnosis and sub-typing of Acute Leukemia require which specialized investigation?",
                "choices": [
                    "A. Peripheral blood smear and $\text{CBC}$.",
                    "B. **Bone Marrow Aspiration/Biopsy and flow cytometry.**",
                    "C. $\text{LDH}$ and Uric Acid levels.",
                    "D. $\text{CT}$ scan of the chest.",
                    "E. $\text{HIV}$ and Hepatitis serology."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "The definitive diagnosis and sub-typing (e.g., using **flow cytometry** and cytogenetics) are done on the **Bone Marrow Aspiration/Biopsy** specimen. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "diagnosis",
                    "specialized_investigation"
                ]
            },
            {
                "id": 1427,
                "question": "A patient with suspected Acute Leukemia has a palpable spleen. This clinical finding is classified as:",
                "choices": [
                    "A. Constitutional symptom.",
                    "B. Localized infection.",
                    "C. **Organ infiltration**.",
                    "D. Bleeding diathesis.",
                    "E. Neurologic deficit."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Splenomegaly and hepatomegaly are features of **organ infiltration** by neoplastic cells. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "clinical_features"
                ]
            },
            {
                "id": 1428,
                "question": "A patient is admitted with Acute Leukemia and $\text{Hb } 6.2 \text{ g/dl}$. What is the recommended management regarding blood transfusion?",
                "choices": [
                    "A. Wait for $\text{Hb}$ to drop to $5.0 \text{ g/dl}$.",
                    "B. **Transfuse Packed $\text{RBCs}$ to correct severe anemia.**",
                    "C. Transfuse $\text{FFP}$ only.",
                    "D. Transfuse if the platelet count is below $10,000/mu l$.",
                    "E. Transfuse only if $\text{WBC}$ is above $50,000/mu l$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Supportive treatment for Acute Leukemia includes managing severe anemia ($\text{Hb} <7 \text{ g/dl}$) with **Packed $\text{RBC}$ transfusion**. (p. 237, 260)",
                "tags": [
                    "acute_leukemia",
                    "supportive_care",
                    "transfusion"
                ]
            },
            {
                "id": 1429,
                "question": "In the workup for Acute Leukemia, the presence of bone pain and sternal tenderness is generally related to:",
                "choices": [
                    "A. $\text{LDH}$ elevation.",
                    "B. Hepatosplenomegaly.",
                    "C. **Bone marrow expansion** by leukemic cells.",
                    "D. Febrile infection.",
                    "E. Secondary osteomyelitis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Bone pain and sternal tenderness are hematologic findings suggestive of **bone marrow expansion** or infiltration by the malignant cells. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "clinical_features",
                    "bone_pain"
                ]
            },
            {
                "id": 1430,
                "question": "A patient is suspected of having Acute Leukemia. What is the immediate referral requirement?",
                "choices": [
                    "A. Elective referral to an oncologist.",
                    "B. **Urgent referral to a specialized hematology oncology center.**",
                    "C. Referral only if $\text{WBC}$ is $>50,000/mu l$.",
                    "D. Referral only after $\text{Hb}$ and Platelets are normalized.",
                    "E. Referral only for chemotherapy planning."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Patients with suspected Acute Leukemia require **urgent referral to a specialized center** for definitive diagnosis and treatment. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "referral"
                ]
            },
            {
                "id": 1431,
                "question": "The clinical features of Acute Leukemia are typically the result of:",
                "choices": [
                    "A. Hyperplasia of mature myeloid cells.",
                    "B. **Bone marrow infiltration and cytopenia.**",
                    "C. Autoimmune destruction of $\text{RBCs}$.",
                    "D. Chronic viral infection.",
                    "E. $\text{B}_{12}$ deficiency."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "The manifestations (anemia, bleeding, infection) are due to **bone marrow failure** resulting from **infiltration by blasts**. (p. 259, 260)",
                "tags": [
                    "acute_leukemia",
                    "pathophysiology"
                ]
            },
            {
                "id": 1432,
                "question": "Which symptom in a patient with suspected Acute Leukemia is directly related to **neutropenia**?",
                "choices": [
                    "A. Fatigue.",
                    "B. Easy bruising.",
                    "C. **Fever and recurrent infections.**",
                    "D. Splenomegaly.",
                    "E. Bone pain."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "**Fever and recurrent infections** are signs of **neutropenia** or dysfunction of $\text{WBCs}$. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "clinical_features",
                    "neutropenia"
                ]
            },
            {
                "id": 1433,
                "question": "A patient is admitted with Acute Leukemia and a platelet count of $40,000/mu l$. Which intervention is necessary?",
                "choices": [
                    "A. Prophylactic platelet transfusion.",
                    "B. **No transfusion; monitor for active bleeding.**",
                    "C. $\text{IVIg}$ therapy.",
                    "D. Urgent splenectomy.",
                    "E. Only if platelet count drops to $10,000/mu l$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Prophylactic platelet transfusion is generally only recommended if platelet count is **$<10,000/mu l$**. (p. 248)",
                "tags": [
                    "acute_leukemia",
                    "supportive_care",
                    "transfusion_threshold"
                ]
            },
            {
                "id": 1434,
                "question": "The most important initial action for a patient presenting with high fever and severe neutropenia (neutropenic fever) should be:",
                "choices": [
                    "A. Cooling measures only.",
                    "B. $\text{G-CSF}$ administration.",
                    "C. **Immediate blood cultures and empiric broad-spectrum antibiotics.**",
                    "D. Transfer to another hospital immediately.",
                    "E. Platelet transfusion."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "**Neutropenic fever** is a life-threatening emergency requiring immediate cultures and **empiric broad-spectrum antibiotics**. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "neutropenic_fever",
                    "emergency_management"
                ]
            },
            {
                "id": 1435,
                "question": "What is the key difference in the prognosis between Acute and Chronic Leukemia?",
                "choices": [
                    "A. Acute has a better prognosis.",
                    "B. **Acute has a rapid, often fatal course; Chronic has a slower, often stable course.**",
                    "C. Chronic is typically managed with chemotherapy; Acute is managed with observation.",
                    "D. Acute only affects children; Chronic only affects adults.",
                    "E. Both have the same prognosis."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "**Acute Leukemias** have a **rapid, often fatal course** if untreated, whereas Chronic Leukemias have a **slower course** that can be stable for years. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "prognosis",
                    "comparison"
                ]
            },
            {
                "id": 1436,
                "question": "The hallmark finding on the peripheral blood smear for Acute Leukemia is:",
                "choices": [
                    "A. Schistocytes.",
                    "B. Spherocytes.",
                    "C. **Circulating Blasts.**",
                    "D. Howell-Jolly bodies.",
                    "E. Target cells."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "The presence of **circulating blasts** on the peripheral blood smear is highly suggestive of Acute Leukemia. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "diagnosis"
                ]
            },
            {
                "id": 1437,
                "question": "A patient with Acute Leukemia has a severe infection. This vulnerability is primarily due to the malignant transformation leading to:",
                "choices": [
                    "A. Elevated $\text{WBC}$ count.",
                    "B. Thrombocytosis.",
                    "C. **Dysfunctional $\text{WBCs}$ and severe neutropenia.**",
                    "D. Anemia.",
                    "E. Hypercalcemia."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "The infection risk is due to the lack of functional mature $\text{WBCs}$ (**neutropenia**) and the poor function of the circulating malignant cells. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "infection_risk"
                ]
            },
            {
                "id": 1438,
                "question": "A 70-year-old patient presents with symptoms suggestive of Acute Leukemia. What is the immediate referral requirement?",
                "choices": [
                    "A. Elective referral to an oncologist.",
                    "B. **Urgent referral to a specialized hematology oncology center.**",
                    "C. Referral only if $\text{WBC}$ is $>50,000/mu l$.",
                    "D. Referral only after $\text{Hb}$ and Platelets are normalized.",
                    "E. Referral only for chemotherapy planning."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "Patients with suspected Acute Leukemia require **urgent referral to a specialized center** for definitive diagnosis and treatment. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "referral"
                ]
            },
            {
                "id": 1439,
                "question": "The clinical features of Acute Leukemia are typically the result of:",
                "choices": [
                    "A. Hyperplasia of mature myeloid cells.",
                    "B. **Bone marrow infiltration and cytopenia.**",
                    "C. Autoimmune destruction of $\text{RBCs}$.",
                    "D. Chronic viral infection.",
                    "E. $\text{B}_{12}$ deficiency."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "The manifestations (anemia, bleeding, infection) are due to **bone marrow failure** resulting from **infiltration by blasts**. (p. 259, 260)",
                "tags": [
                    "acute_leukemia",
                    "pathophysiology"
                ]
            },
            {
                "id": 1440,
                "question": "Which symptom in a patient with suspected Acute Leukemia is directly related to **neutropenia**?",
                "choices": [
                    "A. Fatigue.",
                    "B. Easy bruising.",
                    "C. **Fever and recurrent infections.**",
                    "D. Splenomegaly.",
                    "E. Bone pain."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "**Fever and recurrent infections** are signs of **neutropenia** or dysfunction of $\text{WBCs}$. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "clinical_features",
                    "neutropenia"
                ]
            },
            {
                "id": 1472,
                "question": "The definitive diagnosis and sub-typing of Acute Leukemia require which specialized investigation?",
                "choices": [
                    "A. Peripheral blood smear and $\text{CBC}$.",
                    "B. **Bone Marrow Aspiration/Biopsy and flow cytometry.**",
                    "C. $\text{LDH}$ and Uric Acid levels.",
                    "D. $\text{CT}$ scan of the chest.",
                    "E. $\text{HIV}$ and Hepatitis serology."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.5.1 Acute Leukemia",
                "explanation": "The definitive diagnosis and sub-typing (e.g., using **flow cytometry** and cytogenetics) are done on the **Bone Marrow Aspiration/Biopsy** specimen. (p. 260)",
                "tags": [
                    "acute_leukemia",
                    "diagnosis",
                    "specialized_investigation"
                ]
            }
        ]
    },
    "Chapter 7.6.2": {
        "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)": [
            {
                "id": 1441,
                "question": "A 45-year-old patient presents with marked leukocytosis ($150,000/mu l$) predominantly composed of mature neutrophils, basophils, and eosinophils. Splenomegaly is palpable. **Chronic Myelogenous Leukemia ($\text{CML}$)** is suspected. What is the key molecular finding that is diagnostic for $\text{CML}$?",
                "choices": [
                    "A. $\text{JAK2}$ mutation.",
                    "B. $\text{BCR-ABL}$ fusion gene (Philadelphia chromosome).",
                    "C. $\text{c-MYC}$ translocation.",
                    "D. $\text{FLT3}$ mutation.",
                    "E. $\text{RAS}$ gene mutation."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "The defining molecular abnormality of $\text{CML}$ is the $\text{BCR-ABL}$ fusion gene, which results from the **Philadelphia chromosome** ($\text{t}(9;22)$). (p. 264)",
                "tags": [
                    "CML",
                    "diagnosis",
                    "molecular_finding"
                ]
            },
            {
                "id": 1443,
                "question": "A patient is newly diagnosed with **Chronic Myelogenous Leukemia ($\text{CML}$)**, Chronic Phase. What is the key therapeutic agent that targets the molecular abnormality?",
                "choices": [
                    "A. Doxorubicin (Anthracycline).",
                    "B. Cyclophosphamide.",
                    "C. **Imatinib Mesylate (Tyrosine Kinase Inhibitor).**",
                    "D. Vincristine.",
                    "E. Prednisolone."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "The $\text{BCR-ABL}$ fusion gene produces the $\text{BCR-ABL}$ **tyrosine kinase**. Treatment targets this enzyme with Tyrosine Kinase Inhibitors ($\text{TKIs}$) like **Imatinib Mesylate**. (p. 265, 266)",
                "tags": [
                    "CML",
                    "treatment",
                    "TKI"
                ]
            },
            {
                "id": 1445,
                "question": "A patient with $\text{CML}$ presents with **Blasts $ge 20%$** in the peripheral blood. This indicates progression to which phase of the disease?",
                "choices": [
                    "A. Chronic Phase.",
                    "B. **Blast Crisis (or Blast Phase).**",
                    "C. Accelerated Phase.",
                    "D. Latent Phase.",
                    "E. Treatment-Induced Remission."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "The presence of **Blasts $ge 20%$** in the peripheral blood or bone marrow is one of the defining criteria for the **Blast Crisis** phase of $\text{CML}$. (p. 265)",
                "tags": [
                    "CML",
                    "disease_progression",
                    "blast_crisis"
                ]
            },
            {
                "id": 1447,
                "question": "A patient presents with a persistent, palpable spleen, extreme leukocytosis ($250,000/mu l$) with predominant granulocytes. $\text{CML}$ is suspected. What is the immediate management requirement?",
                "choices": [
                    "A. Immediate chemotherapy.",
                    "B. **Urgent referral to a specialized hematology center.**",
                    "C. Steroid trial.",
                    "D. Symptomatic relief only.",
                    "E. Platelet transfusion."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "Patients with suspected $\text{CML}$ need to be managed by a specialist. The immediate requirement is an **urgent referral to a specialized hematology service** for diagnosis confirmation and TKI therapy initiation. (p. 266)",
                "tags": [
                    "CML",
                    "referral"
                ]
            },
            {
                "id": 1449,
                "question": "A patient is on Imatinib Mesylate for Chronic Phase $\text{CML}$. What is the most critical monitoring goal for this therapy?",
                "choices": [
                    "A. Normalization of $\text{WBC}$ count only.",
                    "B. Resolution of splenomegaly only.",
                    "C. **Achieve a complete molecular remission** ($\text{BCR-ABL}$ negativity).",
                    "D. Increase $\text{Hb}$ to $>13 \text{ g/dl}$.",
                    "E. Maintenance of platelet count at $>100,000/mu l$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "The goal of $\text{TKI}$ therapy is not just hematologic (normal $\text{CBC}$) or cytogenetic remission, but to achieve a **complete molecular remission ($\text{BCR-ABL}$ negativity)**. (p. 266)",
                "tags": [
                    "CML",
                    "treatment_goals",
                    "TKI"
                ]
            },
            {
                "id": 1450,
                "question": "What is the key initial diagnostic step when **Chronic Myelogenous Leukemia ($\text{CML}$)** is suspected based on extreme leukocytosis and splenomegaly?",
                "choices": [
                    "A. $\text{WBC}$ count is sufficient for diagnosis.",
                    "B. $\text{Bone marrow}$ aspiration.",
                    "C. **Testing for the $\text{BCR-ABL}$ fusion gene/Philadelphia chromosome.**",
                    "D. Serology for $\text{HIV}$ and Hepatitis.",
                    "E. $\text{CT}$ scan of the abdomen."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "The definitive diagnosis of $\text{CML}$ relies on confirming the presence of the **Philadelphia chromosome ($\text{BCR-ABL}$ fusion gene)**, typically done by $\text{FISH}$ or reverse transcriptase $\text{PCR}$ from peripheral blood. (p. 266)",
                "tags": [
                    "CML",
                    "diagnosis",
                    "BCR_ABL"
                ]
            },
            {
                "id": 1452,
                "question": "A patient with $\text{CML}$ in the Chronic Phase is treated with Imatinib. The primary mechanism of action of this drug is to:",
                "choices": [
                    "A. Inhibit $\text{DNA}$ synthesis of the $\text{B}$-cell clone.",
                    "B. Destroy neoplastic cells via monoclonal antibodies.",
                    "C. **Inhibit the $\text{BCR-ABL}$ tyrosine kinase enzyme.**",
                    "D. Suppress bone marrow proliferation nonspecifically.",
                    "E. Induce apoptosis of mature myeloid cells."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "Imatinib Mesylate is a $\text{TKI}$ that targets and **inhibits the abnormal $\text{BCR-ABL}$ tyrosine kinase enzyme**, which drives $\text{CML}$ proliferation. (p. 265, 266)",
                "tags": [
                    "CML",
                    "TKI",
                    "mechanism_of_action"
                ]
            },
            {
                "id": 1454,
                "question": "A patient with **Chronic Myelogenous Leukemia ($\text{CML}$)** presents with **Blasts $15%$** in the peripheral blood. This blast percentage is diagnostic for which phase of $\text{CML}$ progression?",
                "choices": [
                    "A. Chronic Phase.",
                    "B. Blast Crisis.",
                    "C. **Accelerated Phase.**",
                    "D. Latent Phase.",
                    "E. Remission."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "The **Accelerated Phase** is defined by criteria including **Blast cells constituting $10 \text{ to } 19%$** of the cells in the peripheral blood or bone marrow. (p. 265)",
                "tags": [
                    "CML",
                    "disease_progression",
                    "accelerated_phase"
                ]
            },
            {
                "id": 1455,
                "question": "Which of the following is considered the **primary risk factor** for developing **Chronic Myelogenous Leukemia ($\text{CML}$)**?",
                "choices": [
                    "A. Prior $\text{EBV}$ infection.",
                    "B. **Acquired genetic abnormality (Philadelphia chromosome).**",
                    "C. $\text{HIV}$ infection.",
                    "D. Exposure to high-dose corticosteroids.",
                    "E. Advanced age."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "The cause of $\text{CML}$ is the **acquired chromosomal abnormality** known as the **Philadelphia chromosome**, leading to the $\text{BCR-ABL}$ fusion gene. (p. 264)",
                "tags": [
                    "CML",
                    "etiology",
                    "BCR_ABL"
                ]
            },
            {
                "id": 1458,
                "question": "The definitive molecular confirmation for **Chronic Myelogenous Leukemia ($\text{CML}$)** requires detection of the $\text{BCR-ABL}$ gene, which results from a translocation between which two chromosomes?",
                "choices": [
                    "A. Chromosomes $8$ and $14$.",
                    "B. Chromosomes $15$ and $17$.",
                    "C. **Chromosomes $9$ and $22$.**",
                    "D. Chromosomes $11$ and $14$.",
                    "E. Chromosomes $1$ and $19$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "The $\text{BCR-ABL}$ fusion gene, or **Philadelphia chromosome**, results from a translocation between **chromosome $9$ and $22$** ($\text{t}(9;22)$). (p. 264)",
                "tags": [
                    "CML",
                    "molecular_finding",
                    "Philadelphia_chromosome"
                ]
            },
            {
                "id": 1459,
                "question": "What is the characteristic initial treatment for **Chronic Phase $\text{CML}$** once the diagnosis is confirmed?",
                "choices": [
                    "A. Fludarabine and Cyclophosphamide.",
                    "B. Total body irradiation.",
                    "C. **Tyrosine Kinase Inhibitor (Imatinib).**",
                    "D. Bone marrow transplant.",
                    "E. Watchful waiting."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "The treatment of choice for $\text{CML}$ is a **Tyrosine Kinase Inhibitor ($\text{TKI}$) like Imatinib Mesylate**. (p. 265, 266)",
                "tags": [
                    "CML",
                    "treatment",
                    "TKI"
                ]
            },
            {
                "id": 1462,
                "question": "What is the defining clinical feature that distinguishes $\text{CML}$ in the **Blast Crisis** phase from the **Accelerated Phase**?",
                "choices": [
                    "A. Development of $\text{B}$-symptoms.",
                    "B. Thrombocytopenia.",
                    "C. **Blasts $ge 20%$** in the blood/marrow.",
                    "D. Presence of extramedullary disease.",
                    "E. Basophilia $ge 20%$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "**Blast Crisis** is defined by **Blasts $ge 20%$** in the peripheral blood or bone marrow, whereas the Accelerated Phase is defined by $10-19%$ blasts. (p. 265)",
                "tags": [
                    "CML",
                    "disease_progression"
                ]
            },
            {
                "id": 1463,
                "question": "A patient with $\text{CML}$ on Imatinib shows signs of disease progression despite achieving hematologic remission. What is the most likely cause of this failure?",
                "choices": [
                    "A. Development of severe anemia.",
                    "B. **Resistance of the $\text{BCR-ABL}$ kinase enzyme**.",
                    "C. Secondary $\text{HIV}$ infection.",
                    "D. Development of $\text{CLL}$.",
                    "E. Chronic non-compliance."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "Failure of $\text{TKI}$ therapy is often related to the development of **resistance of the $\text{BCR-ABL}$ kinase enzyme**, often due to specific mutations. (p. 265, 266)",
                "tags": [
                    "CML",
                    "TKI",
                    "treatment_failure"
                ]
            },
            {
                "id": 1466,
                "question": "A 50-year-old male with marked leukocytosis and palpable splenomegaly is suspected of having $\text{CML}$. Which investigation should be immediately prioritized for definitive diagnosis?",
                "choices": [
                    "A. $\text{LDH}$ level.",
                    "B. $\text{CT}$ scan.",
                    "C. $\text{CBC}$ and differential.",
                    "D. **$\text{BCR-ABL}$ gene test ($\text{FISH}/\text{PCR}$).**",
                    "E. Bone marrow biopsy."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "The definitive diagnosis relies on confirming the presence of the **$\text{BCR-ABL}$ gene** (Philadelphia chromosome). (p. 266)",
                "tags": [
                    "CML",
                    "diagnosis",
                    "BCR_ABL"
                ]
            },
            {
                "id": 1467,
                "question": "A patient with $\text{CML}$ in the Chronic Phase begins $\text{TKI}$ therapy. The primary molecular goal of this therapy is:",
                "choices": [
                    "A. To eliminate the Philadelphia chromosome in $50%$ of cells.",
                    "B. To achieve complete clinical response.",
                    "C. **To achieve complete molecular remission ($\text{BCR-ABL}$ negativity).**",
                    "D. To normalize platelet count.",
                    "E. To prevent progression to Acute Leukemia."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "The treatment goal is to suppress the molecular driver of the disease, aiming for **complete molecular remission ($\text{BCR-ABL}$ negativity)**. (p. 266)",
                "tags": [
                    "CML",
                    "treatment_goals",
                    "molecular_remission"
                ]
            },
            {
                "id": 1469,
                "question": "What is the hematologic process characteristic of Chronic Myelogenous Leukemia ($\text{CML}$)?",
                "choices": [
                    "A. Overgrowth of functionally incompetent lymphocytes.",
                    "B. Acute proliferation of blasts.",
                    "C. **Dysregulated proliferation of the granulocyte cell series.**",
                    "D. Production of abnormal $\text{RBCs}$.",
                    "E. Isolated $\text{B}$-cell proliferation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "CML is a myeloproliferative neoplasm characterized by the **dysregulated proliferation of the granulocyte cell series**. (p. 264)",
                "tags": [
                    "CML",
                    "pathophysiology"
                ]
            },
            {
                "id": 1470,
                "question": "A patient with $\text{CML}$ is on $\text{TKI}$ therapy. Which factor increases the risk of the disease progressing to the Blast Crisis phase?",
                "choices": [
                    "A. Persistent leukocytosis.",
                    "B. **Development of $\text{TKI}$ resistance.**",
                    "C. Normalization of $\text{WBC}$ count.",
                    "D. Resolution of splenomegaly.",
                    "E. Achievement of molecular remission."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "Progression to the Accelerated or Blast Crisis phase is often preceded by the development of **$\text{TKI}$ resistance** or failure of therapy. (p. 265, 266)",
                "tags": [
                    "CML",
                    "disease_progression",
                    "TKI"
                ]
            },
            {
                "id": 1471,
                "question": "Which feature is characteristic of the **Chronic Phase** of $\text{CML}$?",
                "choices": [
                    "A. Blasts $ge 20%$ in the blood.",
                    "B. Persistent $\text{B}$-symptoms (Fever, night sweats, weight loss).",
                    "C. **Marked leukocytosis with palpable splenomegaly.**",
                    "D. $\text{CLL}$ cells in the peripheral blood.",
                    "E. $\text{Hb} <7 \text{ g/dl}$ requiring transfusion."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "The **Chronic Phase** is characterized by **extreme leukocytosis** with predominant granulocytes and often **palpable splenomegaly**. $\text{B}$-symptoms are present, but the phase is largely stable compared to the accelerated phase. (p. 265)",
                "tags": [
                    "CML",
                    "clinical_features",
                    "chronic_phase"
                ]
            },
            {
                "id": 1473,
                "question": "A patient with $\text{CML}$ on $\text{TKI}$ therapy is aiming for **complete molecular remission**. This means the absence of:",
                "choices": [
                    "A. Splenomegaly.",
                    "B. **$\text{BCR-ABL}$ fusion gene**.",
                    "C. $\text{B}$-symptoms.",
                    "D. Thrombocytopenia.",
                    "E. Anemia."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "Molecular remission is the disappearance of the molecular marker of the disease, the **$\text{BCR-ABL}$ fusion gene**. (p. 266)",
                "tags": [
                    "CML",
                    "treatment_goals",
                    "molecular_remission"
                ]
            },
            {
                "id": 1476,
                "question": "Which clinical feature is **most likely** to be present in a patient diagnosed with **Chronic Myelogenous Leukemia ($\text{CML}$) Chronic Phase**?",
                "choices": [
                    "A. Blasts $>20%$ in blood.",
                    "B. **Palpable splenomegaly.**",
                    "C. Isolated lymphadenopathy.",
                    "D. Severe refractory anemia.",
                    "E. Severe neuropathy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "**Splenomegaly** (abdominal fullness, early satiety) is the **most common physical finding** in $\text{CML}$ Chronic Phase. (p. 265)",
                "tags": [
                    "CML",
                    "clinical_features",
                    "chronic_phase"
                ]
            },
            {
                "id": 1478,
                "question": "A patient with $\text{CML}$ in the Chronic Phase is treated with Imatinib. The immediate referral requirement is to a:",
                "choices": [
                    "A. General Oncologist.",
                    "B. Bone Marrow Transplant Unit.",
                    "C. **Specialized Hematology Center.**",
                    "D. Radiation Oncologist.",
                    "E. Primary Care Physician."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "Patients with suspected or confirmed $\text{CML}$ require an **urgent referral to a specialized hematology service** for TKI therapy initiation and monitoring. (p. 266)",
                "tags": [
                    "CML",
                    "referral"
                ]
            },
            {
                "id": 1479,
                "question": "A patient with Chronic Myelogenous Leukemia ($\text{CML}$) is suspected of progressing to the **Accelerated Phase**. Which finding supports this suspicion?",
                "choices": [
                    "A. Blasts $5%$ in peripheral blood.",
                    "B. **Blasts $12%$ in peripheral blood.**",
                    "C. $\text{CLL}$ cell infiltration.",
                    "D. Normal platelet count.",
                    "E. Resolution of splenomegaly."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.2 Chronic Myelogenous Leukemia (CML)",
                "explanation": "The **Accelerated Phase** is defined by criteria including **Blast cells constituting $10 \text{ to } 19%$** of the cells in the peripheral blood or bone marrow. (p. 265)",
                "tags": [
                    "CML",
                    "disease_progression",
                    "accelerated_phase"
                ]
            }
        ]
    },
    "Chapter 7.6.1": {
        "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)": [
            {
                "id": 1442,
                "question": "A 60-year-old male is diagnosed with **Chronic Lymphocytic Leukemia ($\text{CLL}$)**. He is asymptomatic and his $\text{CBC}$ shows lymphocytosis ($15,000/mu l$) with no anemia or thrombocytopenia. Which treatment strategy is recommended?",
                "choices": [
                    "A. Immediate chemotherapy with fludarabine.",
                    "B. **Observation and monitoring (Wait and Watch).**",
                    "C. Splenectomy.",
                    "D. Long-term steroid therapy.",
                    "E. Radiation therapy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "For **asymptomatic patients** with $\text{CLL}$ (Stage $0$ Rai/Stage $\text{A}$ Binet), the recommended treatment strategy is **Wait and Watch** (observation with no treatment). (p. 263, 264)",
                "tags": [
                    "CLL",
                    "management",
                    "wait_and_watch"
                ]
            },
            {
                "id": 1444,
                "question": "Which finding is considered an **indication for initiating treatment** in a patient with **Chronic Lymphocytic Leukemia ($\text{CLL}$)**?",
                "choices": [
                    "A. Lymphocytosis alone ($\text{WBC} >10,000/mu l$).",
                    "B. **Anemia or thrombocytopenia (Stage III/IV Rai).**",
                    "C. $\text{Lymphadenopathy}$ alone.",
                    "D. $\text{Splenomegaly}$ alone.",
                    "E. $\text{B}$ symptoms only."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "Key indications for treatment in $\text{CLL}$ include **Anemia** or **Thrombocytopenia** (Stage $\text{III}$/$\text{IV}$ Rai), symptomatic disease ($\text{B}$-symptoms), or bulky lymphadenopathy/splenomegaly. (p. 263)",
                "tags": [
                    "CLL",
                    "treatment_indication",
                    "severity"
                ]
            },
            {
                "id": 1446,
                "question": "A patient is diagnosed with Chronic Lymphocytic Leukemia ($\text{CLL}$) Stage $\text{A}$ (Binet). What is the expected long-term outcome of this disease management?",
                "choices": [
                    "A. Cure is the goal with $\text{TKI}$ therapy.",
                    "B. Cure is expected with chemotherapy.",
                    "C. **Management aims at long periods of remission, not cure.**",
                    "D. Death is imminent within 6 months.",
                    "E. Patient is immediately referred for bone marrow transplant."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "The objective of $\text{CLL}$ treatment is **not cure** but to **improve symptoms** and achieve **long periods of remission**. (p. 264)",
                "tags": [
                    "CLL",
                    "management_goals"
                ]
            },
            {
                "id": 1448,
                "question": "The clinical features of **Chronic Lymphocytic Leukemia ($\text{CLL}$)** are related to:",
                "choices": [
                    "A. Overgrowth of $\text{T}$-lymphocytes.",
                    "B. Production of functioning mature $\text{B}$-cells.",
                    "C. **Clonal proliferation of functionally incompetent, mature appearing lymphoid cells.**",
                    "D. Proliferation of granulocyte precursors.",
                    "E. Deficiency of $\text{B}$-lymphocytes."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "CLL is a lymphoproliferative neoplasm characterized by the **clonal proliferation of functionally incompetent, mature appearing lymphoid cells** ($\text{B}$-cells). (p. 262)",
                "tags": [
                    "CLL",
                    "pathophysiology"
                ]
            },
            {
                "id": 1451,
                "question": "A 55-year-old male with $\text{CLL}$ has persistent fever, drenching night sweats, and unintentional weight loss $>10%$ in $6$ months. These symptoms are known as:",
                "choices": [
                    "A. Richter's Transformation.",
                    "B. Autoimmune phenomena.",
                    "C. **$\text{B}$-symptoms**.",
                    "D. Chronic phase symptoms.",
                    "E. Paraneoplastic syndrome."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "Fever ($\text{>38}^circ C$), drenching night sweats, and unintentional weight loss ($ge 10%$ in $6$ months) are known as **$\text{B}$-symptoms** and are an indication for initiating treatment in $\text{CLL}$. (p. 263)",
                "tags": [
                    "CLL",
                    "clinical_features",
                    "B_symptoms"
                ]
            },
            {
                "id": 1453,
                "question": "A patient with $\text{CLL}$ is found to have anemia ($\text{Hb } 9.0 \text{ g/dl}$) and thrombocytopenia ($90,000/mu l$). According to the **Rai staging system**, what stage is this patient?",
                "choices": [
                    "A. Stage $\text{0}$.",
                    "B. Stage $\text{I}$/$\text{II}$.",
                    "C. **Stage $\text{III}$/$\text{IV}$ (High Risk).**",
                    "D. Stage $\text{A}$.",
                    "E. Stage $\text{B}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "Rai staging: $\text{Stage } \text{III}$ is defined by **anemia** ($\text{Hb} <11 \text{ g/dl}$) and $\text{Stage } \text{IV}$ by **thrombocytopenia** (platelets $<100,000/mu l$). Both stages $\text{III}$ and $\text{IV}$ are classified as **High Risk** and are indications for treatment. (p. 263)",
                "tags": [
                    "CLL",
                    "staging",
                    "rai_system"
                ]
            },
            {
                "id": 1456,
                "question": "A patient with newly diagnosed **Chronic Lymphocytic Leukemia ($\text{CLL}$)** has a platelet count of $95,000/mu l$. This finding primarily triggers consideration for:",
                "choices": [
                    "A. $\text{CML}$ workup.",
                    "B. **Initiation of treatment.**",
                    "C. Active observation only.",
                    "D. Diagnosis of Acute Leukemia.",
                    "E. IVIg therapy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "**Thrombocytopenia** (platelets $<100,000/mu l$) is classified as Rai **Stage $\text{IV}$** (High Risk) and is a definitive **indication for initiating treatment** in $\text{CLL}$. (p. 263)",
                "tags": [
                    "CLL",
                    "treatment_indication"
                ]
            },
            {
                "id": 1457,
                "question": "What is the key characteristic of the malignant cells seen in **Chronic Lymphocytic Leukemia ($\text{CLL}$)**?",
                "choices": [
                    "A. High percentage of blasts.",
                    "B. Proliferation of mature granulocytes.",
                    "C. **Proliferation of mature appearing but functionally incompetent lymphocytes.**",
                    "D. Infiltration of the bone marrow by plasma cells.",
                    "E. Production of abnormal tyrosine kinase."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "CLL is characterized by the **clonal proliferation of functionally incompetent, mature appearing lymphoid cells** ($\text{B}$-cells). (p. 262)",
                "tags": [
                    "CLL",
                    "pathophysiology"
                ]
            },
            {
                "id": 1460,
                "question": "A patient with $\text{CLL}$ is asymptomatic and has only lymphocytosis ($\text{WBC } 18,000/mu l$) and isolated lymphadenopathy. Which Rai stage is this?",
                "choices": [
                    "A. Stage $\text{0}$ (Low Risk).",
                    "B. **Stage $\text{I}$ (Intermediate Risk).**",
                    "C. Stage $\text{II}$ (Intermediate Risk).",
                    "D. Stage $\text{III}$ (High Risk).",
                    "E. Stage $\text{IV}$ (High Risk)."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "**Stage $\text{I}$ (Intermediate Risk)** is defined by lymphocytosis and **lymphadenopathy**. Stage $\text{II}$ includes hepatosplenomegaly. (p. 263)",
                "tags": [
                    "CLL",
                    "staging",
                    "rai_system"
                ]
            },
            {
                "id": 1461,
                "question": "The primary management strategy for a patient with asymptomatic Chronic Lymphocytic Leukemia ($\text{CLL}$) is:",
                "choices": [
                    "A. Immediate aggressive combination chemotherapy.",
                    "B. Prophylactic splenectomy.",
                    "C. **Watch and Watch (Active Observation).**",
                    "D. Daily oral cyclophosphamide.",
                    "E. Weekly radiation therapy."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "For asymptomatic patients (low risk), the primary management is **Watch and Watch** (observation with no treatment). (p. 263, 264)",
                "tags": [
                    "CLL",
                    "management",
                    "watch_and_watch"
                ]
            },
            {
                "id": 1464,
                "question": "A patient with $\text{CLL}$ is classified as **Stage $\text{II}$ (Intermediate Risk)** according to the Rai staging system. Which clinical feature defines this stage?",
                "choices": [
                    "A. Lymphocytosis only.",
                    "B. **Lymphadenopathy PLUS hepatosplenomegaly.**",
                    "C. Anemia ($\text{Hb} <11 \text{ g/dl}$).",
                    "D. Thrombocytopenia (Platelets $<100,000/mu l$).",
                    "E. $\text{B}$-symptoms only."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "**Stage $\text{II}$** is defined by lymphocytosis and **lymphadenopathy** plus **hepatosplenomegaly**. (p. 263)",
                "tags": [
                    "CLL",
                    "staging",
                    "rai_system"
                ]
            },
            {
                "id": 1465,
                "question": "What is the hallmark peripheral blood smear finding in **Chronic Lymphocytic Leukemia ($\text{CLL}$)**?",
                "choices": [
                    "A. Circulating blasts.",
                    "B. Proliferation of mature granulocytes.",
                    "C. **Smudge cells (or Smear cells).**",
                    "D. $\text{Auer}$ rods.",
                    "E. Rouleaux formation."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "The characteristic finding on peripheral smear for $\text{CLL}$ is the presence of **Smudge cells** (Smear cells). (p. 263)",
                "tags": [
                    "CLL",
                    "clinical_features",
                    "blood_smear"
                ]
            },
            {
                "id": 1468,
                "question": "Which clinical feature is **most likely** to be present in a patient diagnosed with **Chronic Lymphocytic Leukemia ($\text{CLL}$) Stage $0$** (Rai)?",
                "choices": [
                    "A. Fever and night sweats.",
                    "B. Anemia ($\text{Hb } 9.0 \text{ g/dl}$).",
                    "C. Thrombocytopenia ($90,000/mu l$).",
                    "D. **Asymptomatic lymphocytosis only.**",
                    "E. Bulky splenomegaly."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "**Stage $0$** ($\text{Low}$ $\text{Risk}$) is defined by **lymphocytosis in the peripheral blood and bone marrow only**, with no other clinical findings like organomegaly or cytopenias. (p. 263)",
                "tags": [
                    "CLL",
                    "staging",
                    "rai_system"
                ]
            },
            {
                "id": 1474,
                "question": "The most common clinical symptom leading to the initiation of therapy in a patient with $\text{CLL}$ is related to:",
                "choices": [
                    "A. Thrombocytosis.",
                    "B. **$\text{B}$-symptoms (Fever, Night Sweats, Weight Loss).**",
                    "C. Lymphocytosis alone.",
                    "D. Splenomegaly alone.",
                    "E. Development of $\text{CML}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "Therapy is initiated when the disease becomes symptomatic (**$\text{B}$-symptoms** or development of cytopenia/bulky disease). (p. 263)",
                "tags": [
                    "CLL",
                    "treatment_indication"
                ]
            },
            {
                "id": 1475,
                "question": "A patient with $\text{CLL}$ is classified as Rai **Stage $0$ (Low Risk)**. What is the defining feature of this stage?",
                "choices": [
                    "A. $\text{Lymphadenopathy}$ only.",
                    "B. $\text{Hepatosplenomegaly}$ only.",
                    "C. Anemia ($\text{Hb } <11 \text{ g/dl}$).",
                    "D. Thrombocytopenia (Platelets $<100,000/mu l$).",
                    "E. **Lymphocytosis in peripheral blood and bone marrow only.**"
                ],
                "correctAnswer": 4,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "**Stage $0$** is defined by **lymphocytosis in the peripheral blood and bone marrow only**, without lymphadenopathy, organomegaly, or cytopenias. (p. 263)",
                "tags": [
                    "CLL",
                    "staging",
                    "rai_system"
                ]
            },
            {
                "id": 1477,
                "question": "The characteristic presentation of **Chronic Lymphocytic Leukemia ($\text{CLL}$)** cells on peripheral smear includes:",
                "choices": [
                    "A. $\text{Auer}$ rods.",
                    "B. Circulating blasts.",
                    "C. **Smudge cells (Smear cells).**",
                    "D. Proliferation of mature granulocytes.",
                    "E. Tear drop cells."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "The characteristic finding is the presence of **Smudge cells** (Smear cells). (p. 263)",
                "tags": [
                    "CLL",
                    "clinical_features",
                    "blood_smear"
                ]
            },
            {
                "id": 1480,
                "question": "What is the primary treatment goal for a patient with $\text{CLL}$?",
                "choices": [
                    "A. **To achieve long periods of remission.**",
                    "B. To achieve complete cure.",
                    "C. To immediately eliminate all lymphadenopathy.",
                    "D. To maintain the lymphocyte count above $50,000/mu l$.",
                    "E. To prevent splenomegaly."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.6.1 Chronic Lymphatic Leukemia (CLL)",
                "explanation": "The objective of $\text{CLL}$ treatment is **not cure** but to **achieve long periods of remission**. (p. 264)",
                "tags": [
                    "CLL",
                    "management_goals"
                ]
            }
        ]
    },
    "Chapter 7.7": {
        "Chapter 7.7 Lymphomas": [
            {
                "id": 1481,
                "question": "A 30-year-old male presents with a **painless, persistent neck lump** and a history of unexplained fever, drenching night sweats, and weight loss over the past 3 months ($\text{B}$-symptoms). Which hematologic malignancy is **most strongly suspected**?",
                "choices": [
                    "A. Acute Leukemia.",
                    "B. Chronic Myelogenous Leukemia ($\text{CML}$).",
                    "C. **Lymphoma (Hodgkin or Non-Hodgkin).**",
                    "D. Multiple Myeloma.",
                    "E. Chronic Lymphocytic Leukemia ($\text{CLL}$) Stage 0."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The triad of **painless lymphadenopathy** and **$\text{B}$-symptoms** (fever, night sweats, weight loss) is a classic presentation for **Lymphoma**. [cite: 730] (p. 267)",
                "tags": [
                    "lymphoma",
                    "clinical_features",
                    "B_symptoms"
                ]
            },
            {
                "id": 1482,
                "question": "A patient is suspected of having a Lymphoma. What is the **mandatory initial diagnostic procedure** required for confirmation?",
                "choices": [
                    "A. Fine Needle Aspiration Cytology ($\text{FNAC}$).",
                    "B. **Lymph Node Biopsy.**",
                    "C. $\text{CT}$ scan of the neck and chest.",
                    "D. Peripheral blood smear.",
                    "E. Excision of the largest lymph node."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The definitive diagnosis of lymphoma requires a **Lymph Node Biopsy** (excisional or core needle), as $\text{FNAC}$ is generally considered insufficient for diagnosis. [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "diagnosis",
                    "biopsy"
                ]
            },
            {
                "id": 1483,
                "question": "A 40-year-old female with $\text{HIV}$ infection ($\text{CD4 } 50 \text{ cells}/mu l$) presents with confusion and seizures. Brain imaging reveals a mass lesion. Which type of lymphoma is most likely suspected?",
                "choices": [
                    "A. Hodgkin Lymphoma.",
                    "B. Chronic Lymphocytic Leukemia ($\text{CLL}$).",
                    "C. **Primary $\text{CNS}$ Lymphoma ($\text{HIV}$-associated).**",
                    "D. Follicular Lymphoma.",
                    "E. $\text{CML}$ Blast Crisis."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**$\text{HIV}$ infection with severe immunosuppression** is associated with an increased incidence of aggressive lymphomas, including **Primary $\text{CNS}$ Lymphoma**. [cite: 730] (p. 268)",
                "tags": [
                    "lymphoma",
                    "HIV",
                    "CNS_lymphoma"
                ]
            },
            {
                "id": 1484,
                "question": "A patient is diagnosed with Non-Hodgkin Lymphoma ($\text{NHL}$) that is confined to a single lymph node region (e.g., left cervical nodes). According to the **Ann Arbor Staging System**, what stage is this?",
                "choices": [
                    "A. **Stage $\text{I}$**.",
                    "B. Stage $\text{II}$",
                    "C. Stage $\text{III}$",
                    "D. Stage $\text{IV}$",
                    "E. Stage $\text{A}$"
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Stage $\text{I}$** is defined as the involvement of a **single lymph node region** or a single lymphoid organ. [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "ann_arbor"
                ]
            },
            {
                "id": 1485,
                "question": "A patient with Lymphoma is diagnosed with involvement in the liver and bone marrow. According to the **Ann Arbor Staging System**, what stage is this?",
                "choices": [
                    "A. Stage $\text{I}$",
                    "B. Stage $\text{II}$",
                    "C. Stage $\text{III}$",
                    "D. **Stage $\text{IV}$**",
                    "E. Stage $\text{B}$"
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Stage $\text{IV}$** is defined as **any involvement of the liver or bone marrow**, lungs (other than direct extension), or cerebrospinal fluid. [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "ann_arbor"
                ]
            },
            {
                "id": 1486,
                "question": "Which characteristic typically distinguishes **Hodgkin Lymphoma ($\text{HL}$)** from **Non-Hodgkin Lymphoma ($\text{NHL}$)** regarding disease spread?",
                "choices": [
                    "A. $\text{NHL}$ is more commonly associated with $\text{B}$-symptoms.",
                    "B. $\text{HL}$ is typically more aggressive than $\text{NHL}$.",
                    "C. $\text{NHL}$ is typically managed with observation.",
                    "D. **$\text{HL}$ spreads in a fairly predictable fashion (contiguous spread).**",
                    "E. $\text{NHL}$ only involves lymph nodes; $\text{HL}$ involves extranodal sites."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Hodgkin Lymphoma** is characterized by spreading in a **fairly predictable fashion** (contiguous spread), whereas $\text{NHL}$ spread tends to be unpredictable and skips lymph node regions. [cite: 730] (p. 267)",
                "tags": [
                    "lymphoma",
                    "comparison",
                    "disease_spread"
                ]
            },
            {
                "id": 1487,
                "question": "The clinical diagnosis of Lymphoma often relies on the presence of **unexplained symptoms**. Which symptom is classified as a **$\text{B}$-symptom**?",
                "choices": [
                    "A. Night cough.",
                    "B. **Unintentional weight loss $ge 10%$ in $6$ months.**",
                    "C. Painless lymphadenopathy.",
                    "D. Pruritus.",
                    "E. Chronic diarrhea."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**$\text{B}$-symptoms** include **unintentional weight loss $ge 10%$ in $6$ months**; unexplained fever ($\text{>38.5}^circ C$); or drenching night sweats. [cite: 730] (p. 267)",
                "tags": [
                    "lymphoma",
                    "clinical_features",
                    "B_symptoms"
                ]
            },
            {
                "id": 1488,
                "question": "A patient with $\text{NHL}$ has involvement of two lymph node regions (e.g., left cervical and left axillary nodes) above the diaphragm. What is the Ann Arbor stage?",
                "choices": [
                    "A. Stage $\text{I}$",
                    "B. **Stage $\text{II}$**",
                    "C. Stage $\text{III}$",
                    "D. Stage $\text{IV}$",
                    "E. Stage $\text{A}$"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Stage $\text{II}$** is defined as involvement of **two or more lymph node regions** or lymphoid organ on the **same side of the diaphragm**. [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "ann_arbor"
                ]
            },
            {
                "id": 1489,
                "question": "A patient is diagnosed with **Non-Hodgkin Lymphoma ($\text{NHL}$)**. The treatment strategy is primarily determined by:",
                "choices": [
                    "A. Patient's age and sex.",
                    "B. **Histologic type** (indolent, aggressive, highly aggressive) **and stage.**",
                    "C. The absence of $\text{B}$-symptoms.",
                    "D. Only the size of the largest lymph node.",
                    "E. The presence of the $\text{Philadelphia}$ chromosome."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The treatment of lymphomas depends on whether the lymphoma is **indolent or aggressive**, its **histologic type, stage, and performance status**. [cite: 730] (p. 269)",
                "tags": [
                    "lymphoma",
                    "treatment",
                    "strategy"
                ]
            },
            {
                "id": 1490,
                "question": "Which statement accurately describes the characteristics of **Indolent Lymphomas**?",
                "choices": [
                    "A. **Slow progression, but often less responsive to chemotherapy.**",
                    "B. Rapid progression requiring urgent chemotherapy.",
                    "C. High cure rate with localized treatment.",
                    "D. Associated only with $\text{B}$-symptoms.",
                    "E. Typically involves the liver and bone marrow at presentation."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Indolent Lymphomas** are characterized by **slow progression**, but they are often **less responsive** to chemotherapy (often managed with observation until symptomatic). [cite: 730] (p. 268)",
                "tags": [
                    "lymphoma",
                    "classification",
                    "indolent_lymphoma"
                ]
            },
            {
                "id": 1491,
                "question": "A patient with $\text{NHL}$ has involvement of lymph node regions both above (cervical) and below (inguinal) the diaphragm. What is the Ann Arbor stage?",
                "choices": [
                    "A. Stage $\text{I}$",
                    "B. Stage $\text{II}$",
                    "C. **Stage $\text{III}$**",
                    "D. Stage $\text{IV}$",
                    "E. Stage $\text{B}$"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Stage $\text{III}$** is defined as the involvement of **multiple lymph node regions** or lymphoid organ on **both sides of the diaphragm**. [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "ann_arbor"
                ]
            },
            {
                "id": 1492,
                "question": "A patient with Lymphoma is diagnosed with $\text{B}$-symptoms. In the Ann Arbor Staging System, how is this documented?",
                "choices": [
                    "A. Stage $\text{E}$",
                    "B. Stage $\text{S}$",
                    "C. **Stage $\text{B}$**",
                    "D. Stage $\text{A}$",
                    "E. Stage $\text{IV}$"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The presence of $\text{B}$-symptoms is documented by adding the letter **$\text{B}$** to the stage (e.g., Stage $\text{IIB}$). [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "B_symptoms"
                ]
            },
            {
                "id": 1493,
                "question": "A 50-year-old male is diagnosed with **Aggressive Non-Hodgkin Lymphoma ($\text{NHL}$)**, Stage $\text{II}$. What is the recommended treatment approach?",
                "choices": [
                    "A. Watchful waiting and monitoring of $\text{LDH}$.",
                    "B. **Urgent chemotherapy and possible radiotherapy.**",
                    "C. Only symptomatic relief for $\text{B}$-symptoms.",
                    "D. Long-term steroid monotherapy.",
                    "E. Bone marrow transplant immediately."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Aggressive** (or highly aggressive) lymphomas require **urgent treatment** (chemotherapy) due to their rapid progression. (p. 269)",
                "tags": [
                    "lymphoma",
                    "treatment",
                    "aggressive_lymphoma"
                ]
            },
            {
                "id": 1494,
                "question": "A patient with $\text{NHL}$ has involvement of the spleen but no other nodal regions. According to the Ann Arbor Staging System, how is the splenic involvement documented?",
                "choices": [
                    "A. Stage $\text{I}$ $\text{B}$",
                    "B. Stage $\text{II}$ $\text{E}$",
                    "C. **Stage $\text{S}$ (Splenic Involvement)**",
                    "D. Stage $\text{IV}$ $\text{S}$",
                    "E. Stage $\text{III}$ $\text{S}$"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "Extralymphatic organ involvement is denoted by $\text{E}$. **Splenic involvement** is denoted by **$\text{S}$**. [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "ann_arbor"
                ]
            },
            {
                "id": 1495,
                "question": "Which of the following is a key distinguishing feature of **Non-Hodgkin Lymphoma ($\text{NHL}$)** disease spread, compared to $\text{HL}$?",
                "choices": [
                    "A. **Spreads unpredictably, often skipping nodal regions.**",
                    "B. Only involves the cervical lymph nodes.",
                    "C. Spreads contiguously (predictably).",
                    "D. Never involves extranodal sites.",
                    "E. Always involves the bone marrow at presentation."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "$\text{NHL}$ spread tends to be **unpredictable, skipping lymph node regions** and often involving extranodal sites. [cite: 730] (p. 267)",
                "tags": [
                    "lymphoma",
                    "comparison",
                    "NHL"
                ]
            },
            {
                "id": 1496,
                "question": "A patient is diagnosed with an **Indolent Lymphoma** confined to a single lymph node region. What is the general treatment principle?",
                "choices": [
                    "A. Urgent chemotherapy is mandatory.",
                    "B. **Active observation (Watchful Waiting) is often appropriate.**",
                    "C. High-dose steroid monotherapy.",
                    "D. Immediate splenectomy.",
                    "E. Bone marrow transplant."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Indolent Lymphomas** are characterized by **slow progression**, and **active observation** is often the initial management strategy. (p. 268)",
                "tags": [
                    "lymphoma",
                    "treatment",
                    "indolent_lymphoma"
                ]
            },
            {
                "id": 1497,
                "question": "Which viral infection is a major risk factor for $\text{HIV}$-associated lymphomas, such as Primary $\text{CNS}$ Lymphoma?",
                "choices": [
                    "A. Cytomegalovirus ($\text{CMV}$).",
                    "B. **Epstein-Barr Virus ($\text{EBV}$) or $\text{HHV}-8$.**",
                    "C. Varicella-Zoster Virus ($\text{VZV}$).",
                    "D. Hepatitis $\text{B}$ Virus ($\text{HBV}$).",
                    "E. $\text{H} \text{ Pylori}$ infection."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**$\text{EBV}$** and **Human Herpes Virus $-8$ ($\text{HHV}-8$)** are listed as key viral risk factors for $\text{HIV}$-associated and other lymphomas. [cite: 730] (p. 268)",
                "tags": [
                    "lymphoma",
                    "risk_factors",
                    "viral"
                ]
            },
            {
                "id": 1498,
                "question": "A patient with Lymphoma is staged as **Stage $\text{II}$ $\text{E}$**. What does the letter '$\text{E}$' signify in the Ann Arbor System?",
                "choices": [
                    "A. Involvement below the diaphragm.",
                    "B. **Extranodal involvement**.",
                    "C. Presence of $\text{B}$-symptoms.",
                    "D. Bone marrow involvement.",
                    "E. Splenic involvement."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The letter **$\text{E}$** denotes **Extranodal involvement**. [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "ann_arbor"
                ]
            },
            {
                "id": 1499,
                "question": "The presence of a painless, persistent neck lump and night sweats should initially prompt a workup for:",
                "choices": [
                    "A. $\text{CML}$ and $\text{CLL}$.",
                    "B. $\text{Acute}$ Leukemia.",
                    "C. $\text{Myeloma}$ and $\text{Plasma}$ $\text{Cell}$ disorders.",
                    "D. **Lymphoma and Tuberculosis.**",
                    "E. $\text{Infectious}$ mononucleosis."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The presentation (lymphadenopathy, $\text{B}$-symptoms) is classic for **Lymphoma**. In the Ethiopian context, **Tuberculosis ($\text{TB}$)** is also a major cause of lymphadenopathy and systemic symptoms and must be ruled out. [cite: 730] (p. 267)",
                "tags": [
                    "lymphoma",
                    "diagnosis",
                    "differential_diagnosis"
                ]
            },
            {
                "id": 1500,
                "question": "Which factor is **not** typically associated with an increased risk of developing Non-Hodgkin Lymphoma ($\text{NHL}$)?",
                "choices": [
                    "A. $\text{HIV}$ infection.",
                    "B. Autoimmune diseases ($\text{SLE}$).",
                    "C. $\text{Hepatitis}$ $\text{C}$ virus ($\text{HCV}$).",
                    "D. $\text{H}$ $\text{Pylori}$ infection.",
                    "E. **$\text{JAK2}$ mutation.**"
                ],
                "correctAnswer": 4,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**$\text{JAK2}$ mutation** is associated with Myeloproliferative Neoplasms (e.g., $\text{CML}$, Polycythemia Vera, Essential Thrombocythemia), not $\text{NHL}$. [cite: 730] (p. 268, 269)",
                "tags": [
                    "lymphoma",
                    "risk_factors",
                    "NHL"
                ]
            },
            {
                "id": 1501,
                "question": "A patient is diagnosed with **Aggressive $\text{NHL}$**, Stage $\text{IV}$. What is the recommended treatment approach?",
                "choices": [
                    "A. Watchful waiting.",
                    "B. **Urgent aggressive chemotherapy.**",
                    "C. Local radiation therapy only.",
                    "D. High-dose steroid monotherapy.",
                    "E. Observation of $\text{B}$-symptoms."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Aggressive** (or highly aggressive) lymphomas require **urgent treatment** (chemotherapy) due to their rapid progression. [cite: 730] (p. 269)",
                "tags": [
                    "lymphoma",
                    "treatment",
                    "aggressive_lymphoma"
                ]
            },
            {
                "id": 1502,
                "question": "Which Ann Arbor stage is characterized by involvement of lymph node regions on **both sides of the diaphragm**?",
                "choices": [
                    "A. Stage $\text{I}$",
                    "B. Stage $\text{II}$",
                    "C. **Stage $\text{III}$**",
                    "D. Stage $\text{IV}$",
                    "E. Stage $\text{E}$"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Stage $\text{III}$** is defined as the involvement of lymph node regions on **both sides of the diaphragm**. [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "ann_arbor"
                ]
            },
            {
                "id": 1503,
                "question": "What is the primary factor used to define the severity and treatment strategy for **Non-Hodgkin Lymphoma ($\text{NHL}$)**?",
                "choices": [
                    "A. Patient age.",
                    "B. $\text{LDH}$ level.",
                    "C. **Histologic type** (e.g., aggressive vs. indolent).",
                    "D. Platelet count.",
                    "E. $\text{Hb}$ level."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "Treatment and prognosis are heavily dependent on the **histologic type** (e.g., indolent, aggressive, highly aggressive) of $\text{NHL}$. [cite: 730] (p. 269)",
                "tags": [
                    "lymphoma",
                    "treatment",
                    "severity"
                ]
            },
            {
                "id": 1504,
                "question": "A patient with $\text{NHL}$ is staged as $\text{IIIB}$. The letter '$\text{B}$' indicates the presence of:",
                "choices": [
                    "A. Bone marrow involvement.",
                    "B. Extranodal involvement.",
                    "C. **Unexplained fever, night sweats, or weight loss.**",
                    "D. Involvement of lymph nodes below the diaphragm.",
                    "E. Involvement of two lymph node regions."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The letter **$\text{B}$** documents the presence of **unexplained $\text{Fever}$, $\text{Night}$ $\text{Sweats}$, or $\text{Weight}$ $\text{Loss}$ ($\text{B}$-symptoms).** [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "B_symptoms"
                ]
            },
            {
                "id": 1505,
                "question": "What is the recommended treatment approach for **Indolent Lymphomas**?",
                "choices": [
                    "A. Aggressive combination chemotherapy immediately.",
                    "B. **Active surveillance (Watchful Waiting).**",
                    "C. Long-term steroid monotherapy.",
                    "D. Local radiation therapy only.",
                    "E. $\text{IVIg}$ therapy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Active observation** or **Watchful Waiting** is often the initial management for **Indolent Lymphomas** due to their slow progression. (p. 268)",
                "tags": [
                    "lymphoma",
                    "treatment",
                    "indolent_lymphoma"
                ]
            },
            {
                "id": 1506,
                "question": "A patient with $\text{NHL}$ has involvement of two lymph node regions and extranodal involvement ($\text{E}$) on the same side of the diaphragm. What is the Ann Arbor stage?",
                "choices": [
                    "A. Stage $\text{I}$ $\text{E}$",
                    "B. **Stage $\text{II}$ $\text{E}$**",
                    "C. Stage $\text{III}$ $\text{E}$",
                    "D. Stage $\text{IV}$ $\text{E}$",
                    "E. Stage $\text{A}$"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Stage $\text{II}$** is defined as $ge 2$ regions on the same side of the diaphragm. The extranodal involvement is denoted by $\text{E}$. (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "ann_arbor"
                ]
            },
            {
                "id": 1507,
                "question": "The definitive diagnosis of Lymphoma relies on which procedure?",
                "choices": [
                    "A. $\text{FNAC}$ of a lymph node.",
                    "B. $\text{WBC}$ count and differential.",
                    "C. **Lymph Node Biopsy.**",
                    "D. $\text{CT}$ scan.",
                    "E. $\text{LDH}$ level."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The diagnosis of Lymphoma requires a **Lymph Node Biopsy**; $\text{FNAC}$ is generally insufficient. (p. 268)",
                "tags": [
                    "lymphoma",
                    "diagnosis"
                ]
            },
            {
                "id": 1508,
                "question": "A patient with $\text{NHL}$ is diagnosed with involvement of the liver. What is the Ann Arbor stage?",
                "choices": [
                    "A. Stage $\text{II}$",
                    "B. Stage $\text{III}$",
                    "C. **Stage $\text{IV}$**",
                    "D. Stage $\text{I}$ $\text{E}$",
                    "E. Stage $\text{II}$ $\text{E}$"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Stage $\text{IV}$** is defined by **any involvement of the liver or bone marrow**, lungs (other than direct extension), or cerebrospinal fluid. [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "ann_arbor"
                ]
            },
            {
                "id": 1509,
                "question": "The clinical finding of a painless, persistent mass in the neck with unexplained fever and night sweats should initially prompt a workup for:",
                "choices": [
                    "A. $\text{CML}$ and $\text{CLL}$.",
                    "B. $\text{Acute}$ Leukemia.",
                    "C. $\text{Myeloma}$ and $\text{Plasma}$ $\text{Cell}$ disorders.",
                    "D. **Lymphoma and Tuberculosis.**",
                    "E. $\text{Infectious}$ mononucleosis."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The presentation (lymphadenopathy, $\text{B}$-symptoms) is classic for **Lymphoma**. In the Ethiopian context, **Tuberculosis ($\text{TB}$)** is also a major cause of lymphadenopathy and systemic symptoms and must be ruled out. [cite: 730] (p. 267)",
                "tags": [
                    "lymphoma",
                    "diagnosis",
                    "differential_diagnosis"
                ]
            },
            {
                "id": 1510,
                "question": "Which Ann Arbor staging designation indicates the **absence** of unexplained systemic symptoms ($\text{B}$-symptoms)?",
                "choices": [
                    "A. Stage $\text{B}$",
                    "B. **Stage $\text{A}$**",
                    "C. Stage $\text{E}$",
                    "D. Stage $\text{S}$",
                    "E. Stage $\text{IV}$"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The absence of $\text{B}$-symptoms is designated by **$\text{A}$**. [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "B_symptoms"
                ]
            },
            {
                "id": 1511,
                "question": "A patient is diagnosed with **Aggressive $\text{NHL}$**, Stage $\text{II}$. What is the recommended treatment approach?",
                "choices": [
                    "A. Watchful waiting and monitoring of $\text{LDH}$.",
                    "B. **Urgent aggressive chemotherapy.**",
                    "C. Only symptomatic relief for $\text{B}$-symptoms.",
                    "D. Long-term steroid monotherapy.",
                    "E. Bone marrow transplant immediately."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Aggressive** (or highly aggressive) lymphomas require **urgent treatment** (chemotherapy) due to their rapid progression. (p. 269)",
                "tags": [
                    "lymphoma",
                    "treatment",
                    "aggressive_lymphoma"
                ]
            },
            {
                "id": 1512,
                "question": "Which Ann Arbor stage is characterized by involvement of lymph node regions on **both sides of the diaphragm**?",
                "choices": [
                    "A. Stage $\text{I}$",
                    "B. Stage $\text{II}$",
                    "C. **Stage $\text{III}$**",
                    "D. Stage $\text{IV}$",
                    "E. Stage $\text{E}$"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Stage $\text{III}$** is defined as the involvement of **multiple lymph node regions** or lymphoid organ on **both sides of the diaphragm**. [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "ann_arbor"
                ]
            },
            {
                "id": 1513,
                "question": "What is the primary factor used to define the severity and treatment strategy for **Non-Hodgkin Lymphoma ($\text{NHL}$)**?",
                "choices": [
                    "A. Patient age.",
                    "B. $\text{LDH}$ level.",
                    "C. **Histologic type** (e.g., aggressive vs. indolent).",
                    "D. Platelet count.",
                    "E. $\text{Hb}$ level."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "Treatment and prognosis are heavily dependent on the **histologic type** (e.g., indolent, aggressive, highly aggressive) of $\text{NHL}$. [cite: 730] (p. 269)",
                "tags": [
                    "lymphoma",
                    "treatment",
                    "severity"
                ]
            },
            {
                "id": 1514,
                "question": "A patient with $\text{NHL}$ is staged as $\text{IIIB}$. The letter '$\text{B}$' indicates the presence of:",
                "choices": [
                    "A. Bone marrow involvement.",
                    "B. Extranodal involvement.",
                    "C. **Unexplained fever, night sweats, or weight loss.**",
                    "D. Involvement of lymph nodes below the diaphragm.",
                    "E. Involvement of two lymph node regions."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The letter **$\text{B}$** documents the presence of **unexplained $\text{Fever}$, $\text{Night}$ $\text{Sweats}$, or $\text{Weight}$ $\text{Loss}$ ($\text{B}$-symptoms).** [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "B_symptoms"
                ]
            },
            {
                "id": 1515,
                "question": "What is the recommended treatment approach for **Indolent Lymphomas**?",
                "choices": [
                    "A. Aggressive combination chemotherapy immediately.",
                    "B. **Active surveillance (Watchful Waiting).**",
                    "C. Long-term steroid monotherapy.",
                    "D. Local radiation therapy only.",
                    "E. $\text{IVIg}$ therapy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Active observation** or **Watchful Waiting** is often the initial management for **Indolent Lymphomas** due to their slow progression. (p. 268)",
                "tags": [
                    "lymphoma",
                    "treatment",
                    "indolent_lymphoma"
                ]
            },
            {
                "id": 1516,
                "question": "A patient with $\text{NHL}$ has involvement of two lymph node regions and extranodal involvement ($\text{E}$) on the same side of the diaphragm. What is the Ann Arbor stage?",
                "choices": [
                    "A. Stage $\text{I}$ $\text{E}$",
                    "B. **Stage $\text{II}$ $\text{E}$**",
                    "C. Stage $\text{III}$ $\text{E}$",
                    "D. Stage $\text{IV}$ $\text{E}$",
                    "E. Stage $\text{A}$"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Stage $\text{II}$** is defined as $ge 2$ regions on the same side of the diaphragm. The extranodal involvement is denoted by $\text{E}$. (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "ann_arbor"
                ]
            },
            {
                "id": 1517,
                "question": "The definitive diagnosis of Lymphoma relies on which procedure?",
                "choices": [
                    "A. $\text{FNAC}$ of a lymph node.",
                    "B. $\text{WBC}$ count and differential.",
                    "C. **Lymph Node Biopsy.**",
                    "D. $\text{CT}$ scan.",
                    "E. $\text{LDH}$ level."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The diagnosis of Lymphoma requires a **Lymph Node Biopsy**; $\text{FNAC}$ is generally insufficient. (p. 268)",
                "tags": [
                    "lymphoma",
                    "diagnosis"
                ]
            },
            {
                "id": 1518,
                "question": "A patient with $\text{NHL}$ is diagnosed with involvement of the liver. What is the Ann Arbor stage?",
                "choices": [
                    "A. Stage $\text{II}$",
                    "B. Stage $\text{III}$",
                    "C. **Stage $\text{IV}$**",
                    "D. Stage $\text{I}$ $\text{E}$",
                    "E. Stage $\text{II}$ $\text{E}$"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "**Stage $\text{IV}$** is defined by **any involvement of the liver or bone marrow**, lungs (other than direct extension), or cerebrospinal fluid. [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "ann_arbor"
                ]
            },
            {
                "id": 1519,
                "question": "The clinical finding of a painless, persistent mass in the neck with unexplained fever and night sweats should initially prompt a workup for:",
                "choices": [
                    "A. $\text{CML}$ and $\text{CLL}$.",
                    "B. $\text{Acute}$ Leukemia.",
                    "C. $\text{Myeloma}$ and $\text{Plasma}$ $\text{Cell}$ disorders.",
                    "D. **Lymphoma and Tuberculosis.**",
                    "E. $\text{Infectious}$ mononucleosis."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The presentation (lymphadenopathy, $\text{B}$-symptoms) is classic for **Lymphoma**. In the Ethiopian context, **Tuberculosis ($\text{TB}$)** is also a major cause of lymphadenopathy and systemic symptoms and must be ruled out. [cite: 730] (p. 267)",
                "tags": [
                    "lymphoma",
                    "diagnosis",
                    "differential_diagnosis"
                ]
            },
            {
                "id": 1520,
                "question": "Which Ann Arbor staging designation indicates the **absence** of unexplained systemic symptoms ($\text{B}$-symptoms)?",
                "choices": [
                    "A. Stage $\text{B}$",
                    "B. **Stage $\text{A}$**",
                    "C. Stage $\text{E}$",
                    "D. Stage $\text{S}$",
                    "E. Stage $\text{IV}$"
                ],
                "correctAnswer": 1,
                "topic": "Chapter 7.7 Lymphomas",
                "explanation": "The absence of $\text{B}$-symptoms is designated by **$\text{A}$**. [cite: 731] (p. 268)",
                "tags": [
                    "lymphoma",
                    "staging",
                    "B_symptoms"
                ]
            }
        ]
    },
    "Chapter 8.1": {
        "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY": [
            {
                "id": 1521,
                "question": "A 55-year-old patient is scheduled for a clean-contaminated abdominal surgery (e.g., elective colon resection). What is the recommended **initial timing** for administering antimicrobial prophylaxis?",
                "choices": [
                    "A. $2$ hours before incision.",
                    "B. Immediately after the surgical wound is closed.",
                    "C. **$30-60$ minutes before skin incision.**",
                    "D. $12$ hours before surgery.",
                    "E. Only if the patient has a postoperative fever."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Antimicrobial prophylaxis should be administered **$30-60$ minutes before skin incision** to ensure adequate tissue concentration at the time of incision. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "timing"
                ]
            },
            {
                "id": 1522,
                "question": "A patient is undergoing $\text{GI}$ surgery requiring prophylaxis. Which drug is the **most common and preferred agent** for surgical antimicrobial prophylaxis due to its broad coverage against most common surgical pathogens?",
                "choices": [
                    "A. Ampicillin.",
                    "B. **Cefazolin.**",
                    "C. Ciprofloxacin.",
                    "D. Vancomycin.",
                    "E. Metronidazole."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**Cefazolin** (a first-generation cephalosporin) is the most commonly used agent for surgical prophylaxis in the general hospital setting due to its excellent activity against most skin flora and common gram-positive cocci. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "drug_choice"
                ]
            },
            {
                "id": 1523,
                "question": "A 40-year-old patient with a documented history of **anaphylaxis to penicillin** is scheduled for clean surgery. Which alternative antimicrobial agent is recommended for prophylaxis?",
                "choices": [
                    "A. Cefazolin.",
                    "B. Ceftriaxone.",
                    "C. **Vancomycin.**",
                    "D. Ampicillin.",
                    "E. Clindamycin."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For patients with a serious $\text{B}$-lactam allergy (e.g., anaphylaxis to penicillin), an agent like **Vancomycin** is recommended to cover staphylococci and streptococci. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "allergy",
                    "drug_choice"
                ]
            },
            {
                "id": 1524,
                "question": "A patient is undergoing clean-contaminated surgery that involves the bowel (high risk for anaerobes). What is the appropriate modification to the standard prophylactic regimen (Cefazolin)?",
                "choices": [
                    "A. Add Vancomycin.",
                    "B. Use Ciprofloxacin monotherapy.",
                    "C. **Add Metronidazole.**",
                    "D. Use only Cefazolin.",
                    "E. Add Gentamicin."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For procedures involving the bowel (clean-contaminated/contaminated) where **anaerobes** are a major concern, the standard regimen (Cefazolin) must be combined with an agent covering anaerobes, such as **Metronidazole**. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "anaerobes"
                ]
            },
            {
                "id": 1525,
                "question": "The primary goal of administering antimicrobial prophylaxis in surgery is to:",
                "choices": [
                    "A. Treat active, undiagnosed infection.",
                    "B. Prevent postoperative pneumonia.",
                    "C. **Reduce the incidence of surgical site infections (SSIs).**",
                    "D. Reduce the length of hospital stay.",
                    "E. Reduce the severity of fever in the first $48$ hours post-op."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "The primary goal of surgical prophylaxis is to **reduce the incidence of Surgical Site Infections ($\text{SSIs}$)**. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "goals"
                ]
            },
            {
                "id": 1526,
                "question": "A patient is receiving $\text{Cefazolin}$ prophylaxis for a $4$-hour major orthopedic surgery. The initial dose was given $40$ minutes before incision. What is the appropriate next step regarding the prophylaxis dosing during the surgery?",
                "choices": [
                    "A. Give a second dose $1$ hour after the start of surgery.",
                    "B. **Give a second dose $3$ hours after the first dose.**",
                    "C. Give a second dose only when the wound is closed.",
                    "D. No redosing is needed for $\text{Cefazolin}$.",
                    "E. Switch to oral antibiotics."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For procedures lasting longer than **$3$ hours**, a repeat dose of the prophylactic antibiotic (e.g., $\text{Cefazolin}$) should be given every $3$ hours (or $2 \times$ the half-life of the drug). (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "redosing"
                ]
            },
            {
                "id": 1527,
                "question": "What is the **recommended duration** of antimicrobial prophylaxis post-surgery (after wound closure)?",
                "choices": [
                    "A. $24-48$ hours.",
                    "B. $5-7$ days.",
                    "C. $3-5$ days.",
                    "D. **Usually discontinued after wound closure (or within $24$ hours post-op).**",
                    "E. Continued until all drains are removed."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prophylaxis should generally be **discontinued after the surgical wound is closed**, or at the latest, **within $24$ hours post-operatively**. Prolonged use does not reduce $\text{SSI}$ risk and increases resistance. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "duration"
                ]
            },
            {
                "id": 1528,
                "question": "A patient is undergoing an ophthalmic procedure. Which antimicrobial is typically used for prophylaxis in eye surgery?",
                "choices": [
                    "A. $\text{IV}$ Cefazolin.",
                    "B. $\text{IV}$ Metronidazole.",
                    "C. Oral Ciprofloxacin.",
                    "D. **Topical agents (e.g., Gentamicin drops).**",
                    "E. $\text{IV}$ Vancomycin."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prophylaxis for **ophthalmic surgery** is typically done with **topical agents** (e.g., Gentamicin drops) rather than systemic $\text{IV}$ antibiotics. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "procedure_specific"
                ]
            },
            {
                "id": 1529,
                "question": "Which category of surgical wound typically **does not require** routine antimicrobial prophylaxis?",
                "choices": [
                    "A. Clean-contaminated.",
                    "B. Contaminated.",
                    "C. Infected/Dirty.",
                    "D. **Clean**.",
                    "E. Procedures involving the bowel."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Routine antimicrobial prophylaxis is generally **not indicated** for **Clean procedures**, unless an implanted foreign body (e.g., prosthetic heart valve, orthopedic hardware) is being used. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "wound_classification"
                ]
            },
            {
                "id": 1530,
                "question": "A patient undergoing an emergency appendectomy (Contaminated wound) is given $\text{Cefazolin}$ and $\text{Metronidazole}$ pre-operatively. Post-operatively, should the antibiotics be continued, and if so, for how long?",
                "choices": [
                    "A. Discontinue immediately after wound closure.",
                    "B. Continue for $12$ hours.",
                    "C. Continue for $24$ hours.",
                    "D. **Continue for $3-5$ days (therapeutic regimen).**",
                    "E. Discontinue and observe for fever."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For **Contaminated/Dirty wounds** (or when gross spillage occurs), the antibiotics initiated pre-operatively are considered the **initial therapeutic regimen** and should be continued post-operatively (e.g., for $3-5$ days), not just a prophylactic dose. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "contaminated_wound",
                    "duration"
                ]
            },
            {
                "id": 1531,
                "question": "A patient is undergoing a cardiac surgery (Clean procedure with prosthetic material). What is the minimum recommended duration for antimicrobial prophylaxis?",
                "choices": [
                    "A. Single dose only.",
                    "B. $12$ hours.",
                    "C. **$48$ hours.**",
                    "D. $7$ days.",
                    "E. Until the patient is discharged."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For procedures where foreign materials are implanted (e.g., cardiac surgery, $\text{TKR}$), prophylaxis is often recommended for **up to $48$ hours** to cover the period of highest risk for $\text{SSI}$. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "implanted_material"
                ]
            },
            {
                "id": 1532,
                "question": "A patient with $\text{CKD}$ (Creatinine Clearance $25 \text{ ml/min}$) is scheduled for surgery requiring $\text{Cefazolin}$ prophylaxis. What modification is necessary for the $\text{Cefazolin}$ dose?",
                "choices": [
                    "A. $\text{Cefazolin}$ is contraindicated in $\text{CKD}$.",
                    "B. **Dose adjustment (reduction or interval increase) is required.**",
                    "C. Double the dose to ensure adequate penetration.",
                    "D. Switch to Vancomycin.",
                    "E. No modification is necessary."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For renally excreted drugs like $\text{Cefazolin}$, **dose adjustment is required** in patients with renal impairment ($\text{CKD}$) to prevent accumulation and toxicity. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "renal_adjustment"
                ]
            },
            {
                "id": 1533,
                "question": "In $\text{ENT}$ surgery prophylaxis, which drug provides the best coverage for the expected pathogens in the upper respiratory tract?",
                "choices": [
                    "A. Metronidazole.",
                    "B. Ciprofloxacin.",
                    "C. **Cefazolin**.",
                    "D. Gentamicin.",
                    "E. Vancomycin."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**Cefazolin** is generally the first-line agent for most procedures, including $\text{ENT}$ surgery, as it covers the most common gram-positive organisms and some gram-negatives. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "procedure_specific"
                ]
            },
            {
                "id": 1534,
                "question": "What is the recommended approach to surgical prophylaxis if the surgery extends beyond $3$ hours?",
                "choices": [
                    "A. Discontinue prophylaxis immediately.",
                    "B. Administer a single $\text{IV}$ dose of another antibiotic.",
                    "C. **Administer a full repeat dose of the original antibiotic.**",
                    "D. Increase the initial dose by $50%$.",
                    "E. Switch to oral antibiotics."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For procedures lasting longer than $3$ hours, a **repeat full dose of the prophylactic antibiotic** should be given to maintain therapeutic serum levels. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "redosing"
                ]
            },
            {
                "id": 1535,
                "question": "The primary reason for avoiding prolonged prophylactic antibiotic use post-surgery ($>24$ hours) is:",
                "choices": [
                    "A. Lack of $\text{RBC}$ production.",
                    "B. High cost of antibiotics.",
                    "C. **Increased risk of antimicrobial resistance.**",
                    "D. Reduced efficacy of surgery.",
                    "E. Poor patient compliance."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prolonged use of prophylactic antibiotics **does not reduce $\text{SSI}$ risk** and significantly **increases the risk of selecting for resistant organisms** and toxicity. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "resistance"
                ]
            },
            {
                "id": 1536,
                "question": "A patient with a documented history of severe $\text{IgE}$-mediated allergy (anaphylaxis) to Penicillin is scheduled for $\text{GI}$ surgery. Which combination should be used for prophylaxis?",
                "choices": [
                    "A. $\text{Cefazolin}$ and $\text{Metronidazole}$.",
                    "B. $\text{Ceftriaxone}$ and $\text{Metronidazole}$.",
                    "C. **Vancomycin and Metronidazole.**",
                    "D. $\text{Amoxicillin}$ and $\text{Gentamicin}$.",
                    "E. $\text{Ciprofloxacin}$ and $\text{Cefazolin}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Given the severe penicillin allergy, $\text{B}$-lactams are avoided. The regimen must cover both Gram-positive (Vancomycin) and Gram-negative/Anaerobes ($\text{Metronidazole}$). (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "allergy",
                    "drug_choice"
                ]
            },
            {
                "id": 1537,
                "question": "What is the recommended timing for administering $\text{Vancomycin}$ as surgical prophylaxis?",
                "choices": [
                    "A. Immediately before skin incision.",
                    "B. $\text{30-60}$ minutes before skin incision.",
                    "C. **Start $1-2$ hours before incision** (due to long infusion time).",
                    "D. $12$ hours before surgery.",
                    "E. Immediately after the procedure is finished."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "$\text{Vancomycin}$ requires a prolonged infusion time to avoid infusion reactions ($\text{Red}$ $\text{Man}$ syndrome). It must be **started $1-2$ hours before incision** to ensure adequate tissue levels at the time of surgery. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "timing",
                    "Vancomycin"
                ]
            },
            {
                "id": 1538,
                "question": "A $70$-year-old patient with severe $\text{CKD}$ on hemodialysis is scheduled for a $\text{GI}$ procedure. Which prophylactic drug requires monitoring of serum levels in this setting?",
                "choices": [
                    "A. $\text{Cefazolin}$.",
                    "B. $\text{Metronidazole}$.",
                    "C. $\text{Ciprofloxacin}$.",
                    "D. **$\text{Vancomycin}$**.",
                    "E. $\text{Ampicillin}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**Vancomycin** is eliminated by the kidneys and requires therapeutic drug monitoring (TDM) to ensure non-toxic but effective levels, especially in patients with severe $\text{CKD}$ or those on hemodialysis. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "TDM",
                    "Vancomycin"
                ]
            },
            {
                "id": 1539,
                "question": "Which surgical procedure is considered **Clean-Contaminated**?",
                "choices": [
                    "A. Thyroidectomy.",
                    "B. Herniorrhaphy (without bowel opening).",
                    "C. Total hip replacement.",
                    "D. **Elective colon resection.**",
                    "E. Incision and drainage of an abscess."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**Clean-Contaminated** wounds involve controlled entry into a viscus (e.g., respiratory, $\text{GI}$, genitourinary tracts) under elective conditions, such as elective colon surgery. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "wound_classification"
                ]
            },
            {
                "id": 1540,
                "question": "A patient is undergoing $\text{GI}$ surgery where $\text{Cefazolin}$ and $\text{Metronidazole}$ are used for prophylaxis. The surgery lasts for $6.5$ hours. How many doses of $\text{Cefazolin}$ should be administered in total during the operation?",
                "choices": [
                    "A. $1$ dose.",
                    "B. $2$ doses.",
                    "C. **$3$ doses**.",
                    "D. $4$ doses.",
                    "E. $5$ doses."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "The first dose is given pre-incision. Redosing is required after $3$ hours. For a $6.5$-hour surgery, the timing would be: $0 \text{ hours}$ (initial dose) $\rightarrow 3 \text{ hours}$ (second dose) $\rightarrow 6 \text{ hours}$ (third dose). Total: **$3$ doses**. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "redosing",
                    "calculation"
                ]
            },
            {
                "id": 1541,
                "question": "Which factor is an indication to use $\text{Vancomycin}$ instead of $\text{Cefazolin}$ for surgical prophylaxis in a clean-contaminated procedure?",
                "choices": [
                    "A. Longer duration of surgery.",
                    "B. Age $>65$ years.",
                    "C. **High local prevalence of Methicillin-Resistant $\text{Staphylococcus}$ $\text{aureus}$ ($\text{MRSA}$).**",
                    "D. Allergy to $\text{Metronidazole}$.",
                    "E. Presence of fever pre-operatively."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**Vancomycin** is used as an alternative to $\text{Cefazolin}$ if there is a **high local prevalence of $\text{MRSA}$** or in the case of $\text{B}$-lactam allergy. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "MRSA"
                ]
            },
            {
                "id": 1542,
                "question": "What is the recommended approach to antimicrobial prophylaxis for a patient undergoing a **Dirty** (infected) surgery (e.g., incision and drainage of a perforated $\text{GI}$ viscus with peritonitis)?",
                "choices": [
                    "A. A single dose of $\text{Cefazolin}$ pre-op.",
                    "B. No antibiotics are necessary.",
                    "C. **Initial $\text{IV}$ antibiotics are considered therapeutic, not prophylactic.**",
                    "D. Oral antibiotics for $12$ hours.",
                    "E. $\text{Topical}$ antibiotics only."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For **Dirty wounds**, the patient already has an established infection. The antibiotics given are considered the **initial therapeutic regimen** and must be continued post-operatively. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "dirty_wound"
                ]
            },
            {
                "id": 1543,
                "question": "A patient receiving $\text{Cefazolin}$ prophylaxis should be observed for signs of $\text{B}$-lactam allergy. What is the most severe form of this reaction?",
                "choices": [
                    "A. Urticaria.",
                    "B. Rash.",
                    "C. Pruritus.",
                    "D. Diarrhea.",
                    "E. **Anaphylaxis**."
                ],
                "correctAnswer": 4,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**Anaphylaxis** is the most severe and immediate form of an $\text{IgE}$-mediated $\text{B}$-lactam allergy. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "allergy",
                    "safety"
                ]
            },
            {
                "id": 1544,
                "question": "A patient is undergoing total knee replacement. What is the minimum recommended duration for antimicrobial prophylaxis post-surgery?",
                "choices": [
                    "A. $12$ hours.",
                    "B. **$48$ hours**.",
                    "C. $5$ days.",
                    "D. $7$ days.",
                    "E. Until sutures are removed."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For procedures where foreign materials are implanted (e.g., orthopedic hardware), prophylaxis is often recommended for **up to $48$ hours** to cover the period of highest risk for $\text{SSI}$. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "implanted_material"
                ]
            },
            {
                "id": 1545,
                "question": "Which action should be taken if $\text{Cefazolin}$ is used for prophylaxis and the patient has a rash only (non-anaphylactic) to Penicillin?",
                "choices": [
                    "A. Use $\text{Vancomycin}$ instead.",
                    "B. **Use $\text{Cefazolin}$ as planned, but observe for reaction.**",
                    "C. Switch to $\text{Ciprofloxacin}$ and $\text{Metronidazole}$.",
                    "D. Use a double dose of $\text{Cefazolin}$.",
                    "E. Defer the surgery."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "The **cross-reactivity** between Penicillin and first-generation cephalosporins (like $\text{Cefazolin}$) is low, especially for non-immediate reactions (e.g., rash). **$\text{Cefazolin}$ can be used with caution** if the patient's allergy history is only a mild rash. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "allergy",
                    "cross_reactivity"
                ]
            },
            {
                "id": 1546,
                "question": "What is the recommended timing for administering $\text{Cefazolin}$ for surgical prophylaxis in relation to the skin incision?",
                "choices": [
                    "A. Immediately after wound closure.",
                    "B. $12$ hours pre-op.",
                    "C. **$30-60$ minutes pre-incision.**",
                    "D. $2$ hours post-op.",
                    "E. $5$ minutes before incision."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Antimicrobial prophylaxis should be administered **$30-60$ minutes before skin incision** to ensure adequate tissue concentration at the time of incision. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "timing"
                ]
            },
            {
                "id": 1548,
                "question": "A patient undergoing an elective colon resection (clean-contaminated) is given $\text{Cefazolin}$ and $\text{Metronidazole}$ pre-op. The duration of post-operative antibiotic use should be:",
                "choices": [
                    "A. $5-7$ days.",
                    "B. $48$ hours.",
                    "C. $24$ hours.",
                    "D. **Discontinued after wound closure.**",
                    "E. Continued until fever resolves."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For prophylactic use in clean-contaminated wounds, antibiotics should generally be **discontinued after the surgical wound is closed** (or within $24$ hours post-operatively). (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "duration"
                ]
            },
            {
                "id": 1549,
                "question": "A patient undergoing $\text{GI}$ surgery is given $\text{Cefazolin}$ for prophylaxis. The surgery lasts for $4$ hours. What is the appropriate redosing strategy?",
                "choices": [
                    "A. $\text{Cefazolin}$ does not require redosing.",
                    "B. Give a second dose at $5$ hours.",
                    "C. **Give a second dose at $3$ hours.**",
                    "D. Switch to $\text{Metronidazole}$ at $3$ hours.",
                    "E. Give a second dose only if bleeding occurs."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For procedures lasting longer than $3$ hours, a repeat dose of $\text{Cefazolin}$ should be given after $3$ hours. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "redosing"
                ]
            },
            {
                "id": 1550,
                "question": "Which surgical wound classification typically requires a full therapeutic course of antibiotics post-operatively?",
                "choices": [
                    "A. Clean.",
                    "B. Clean-contaminated.",
                    "C. **Dirty**.",
                    "D. Procedures with implanted foreign bodies.",
                    "E. $\text{ENT}$ surgery."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**Dirty wounds** (established infection/perforation) require the initial antibiotics to be considered **therapeutic** and thus continued post-operatively for a full course (e.g., $3-5$ days). (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "dirty_wound"
                ]
            },
            {
                "id": 1551,
                "question": "A $70$-year-old patient with $\text{CKD}$ (Creatinine Clearance $25 \text{ ml/min}$) is scheduled for surgery requiring $\text{Cefazolin}$ prophylaxis. What modification is necessary for the $\text{Cefazolin}$ dose?",
                "choices": [
                    "A. $\text{Cefazolin}$ is contraindicated in $\text{CKD}$.",
                    "B. **Dose adjustment (reduction or interval increase) is required.**",
                    "C. Double the dose to ensure adequate penetration.",
                    "D. Switch to $\text{Vancomycin}$.",
                    "E. No modification is necessary."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For renally excreted drugs like $\text{Cefazolin}$, **dose adjustment is required** in patients with renal impairment ($\text{CKD}$) to prevent accumulation and toxicity. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "renal_adjustment"
                ]
            },
            {
                "id": 1552,
                "question": "Which of the following is **not** a recommended duration for post-operative antimicrobial prophylaxis?",
                "choices": [
                    "A. Discontinued after wound closure.",
                    "B. Within $24$ hours post-op.",
                    "C. Up to $48$ hours (for implanted foreign bodies).",
                    "D. Single dose only.",
                    "E. **$5-7$ days**."
                ],
                "correctAnswer": 4,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Antimicrobial prophylaxis is generally limited to $le 24$ hours (or $le 48$ hours for implants). Prolonged use ($5-7$ days) is associated with increased resistance and adverse effects and is inappropriate for *prophylaxis*. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "duration"
                ]
            },
            {
                "id": 1553,
                "question": "A patient with $\text{GI}$ surgery prophylaxis needs coverage for $\text{Gram}$-negative organisms and anaerobes. The recommended combination is:",
                "choices": [
                    "A. $\text{Cefazolin}$ monotherapy.",
                    "B. **$\text{Cefazolin}$ and $\text{Metronidazole}$**.",
                    "C. $\text{Vancomycin}$ and $\text{Gentamicin}$",
                    "D. $\text{Ampicillin}$ and $\text{Metronidazole}$",
                    "E. $\text{Ciprofloxacin}$ monotherapy."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For $\text{GI}$ procedures, the combination of **$\text{Cefazolin}$** ($\text{Gram}$-positive and some $\text{Gram}$-negative) and **$\text{Metronidazole}$** (anaerobes) is the standard. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "drug_combination"
                ]
            },
            {
                "id": 1554,
                "question": "The prophylactic agent $\text{Vancomycin}$ must be administered slowly. What is the main reason for the slow infusion time?",
                "choices": [
                    "A. To prevent nephrotoxicity.",
                    "B. To ensure adequate $\text{CSF}$ penetration.",
                    "C. **To prevent the $\text{Red}$ $\text{Man}$ syndrome (histamine release).**",
                    "D. To maximize serum concentration.",
                    "E. To prevent $\text{C}$ $\text{difficile}$ infection."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**$\text{Vancomycin}$** must be infused over a minimum of $60$ minutes to prevent the $\text{Red}$ $\text{Man}$ syndrome, an $\text{infusion}$-related reaction due to rapid histamine release. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "Vancomycin",
                    "side_effects"
                ]
            },
            {
                "id": 1555,
                "question": "A patient is scheduled for an elective cholecystectomy (clean-contaminated). What is the recommended antimicrobial prophylaxis regimen?",
                "choices": [
                    "A. $\text{Vancomycin}$ and $\text{Metronidazole}$.",
                    "B. $\text{Metronidazole}$ monotherapy.",
                    "C. **$\text{Cefazolin}$ monotherapy**.",
                    "D. $\text{Ciprofloxacin}$ and $\text{Metronidazole}$.",
                    "E. $\text{Ampicillin}$ and $\text{Gentamicin}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**$\text{Cefazolin}$** is typically sufficient for biliary tract procedures (cholecystectomy) as it covers the most likely Gram-positive and Gram-negative organisms, and the $\text{Anaerobic}$ risk is lower than in colon surgery. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "drug_choice"
                ]
            },
            {
                "id": 1556,
                "question": "Which factor is an indication to use $\text{Vancomycin}$ instead of $\text{Cefazolin}$ for surgical prophylaxis?",
                "choices": [
                    "A. Patient's age $>65$ years.",
                    "B. Longer duration of surgery ($>4$ hours).",
                    "C. **Documented anaphylaxis to penicillin.**",
                    "D. $\text{Creatinine}$ $\text{Clearance}$ $<50 \text{ ml/min}$.",
                    "E. History of mild $\text{GI}$ upset with $\text{Cefazolin}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "A severe $\text{B}$-lactam allergy (e.g., **anaphylaxis to penicillin**) is a key indication to switch to $\text{Vancomycin}$ for Gram-positive coverage. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "allergy",
                    "Vancomycin"
                ]
            },
            {
                "id": 1557,
                "question": "A patient undergoing major surgery requires redosing of $\text{Cefazolin}$. How often should the repeat dose be administered?",
                "choices": [
                    "A. Every $1$ hour.",
                    "B. Every $2$ hours.",
                    "C. **Every $3$ hours**.",
                    "D. Every $4$ hours.",
                    "E. Every $6$ hours."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "A repeat dose of $\text{Cefazolin}$ should be given every **$3$ hours** for procedures lasting longer than $3$ hours. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "redosing"
                ]
            },
            {
                "id": 1558,
                "question": "A patient is undergoing an emergency open fracture repair (Contaminated wound). Antibiotics are started pre-op. What is the recommended post-operative course of antibiotics?",
                "choices": [
                    "A. Discontinue after wound closure.",
                    "B. Continue for $12$ hours.",
                    "C. Continue for $24$ hours.",
                    "D. **Continue for $3-5$ days (therapeutic regimen).**",
                    "E. Continue until all implanted hardware is removed."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For **Contaminated wounds**, the antibiotics are considered **therapeutic** and should be continued post-operatively for a full course (e.g., $3-5$ days) based on clinical judgment and source control. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "contaminated_wound",
                    "duration"
                ]
            },
            {
                "id": 1559,
                "question": "Which statement accurately describes the ideal timing for administering antimicrobial prophylaxis?",
                "choices": [
                    "A. Administration must be started within $2$ hours post-incision.",
                    "B. **Administration must be completed before skin incision.**",
                    "C. Administration should be started only if a drain is inserted.",
                    "D. Administration must be done after the patient is fully anesthetized.",
                    "E. Administration should be started $5$ minutes before incision."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "The timing is crucial: the dose must be administered and **completed before the skin incision** ($\text{30-60}$ minutes prior) to achieve adequate tissue concentration at the time of incision. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "timing"
                ]
            },
            {
                "id": 1560,
                "question": "A patient with severe $\text{CKD}$ on hemodialysis requires $\text{Cefazolin}$ prophylaxis. What is the key therapeutic principle to consider for dosing?",
                "choices": [
                    "A. Dose should be doubled.",
                    "B. **Dose should be administered post-dialysis.**",
                    "C. Dose should be administered pre-dialysis.",
                    "D. $\text{Cefazolin}$ is $100%$ removed by dialysis; dose is not changed.",
                    "E. Switch to oral antibiotics."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For renally cleared antibiotics that are dialyzable (like $\text{Cefazolin}$), the drug is often given **post-dialysis** to prevent immediate removal of the drug by the dialyzer. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "renal_adjustment",
                    "dialysis"
                ]
            },
            {
                "id": 1561,
                "question": "The primary goal of $\text{antimicrobial}$ prophylaxis is to reduce the bacterial burden in the surgical site during which time frame?",
                "choices": [
                    "A. The entire hospitalization.",
                    "B. The entire post-operative course.",
                    "C. **The period of incision and closure.**",
                    "D. Only the $48$ hours after surgery.",
                    "E. Only the $7$ days before surgery."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prophylaxis is intended to reduce the bacterial burden during the period of maximal risk, specifically the time of **incision and closure**. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "goals"
                ]
            },
            {
                "id": 1562,
                "question": "A patient undergoing an elective colon resection (clean-contaminated) is given $\text{Cefazolin}$ and $\text{Metronidazole}$ pre-op. The post-operative antibiotic use should be:",
                "choices": [
                    "A. $5-7$ days.",
                    "B. $48$ hours.",
                    "C. $24$ hours.",
                    "D. **Discontinued after wound closure.**",
                    "E. Continued until fever resolves."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For prophylactic use in clean-contaminated wounds, antibiotics should generally be **discontinued after the surgical wound is closed** (or within $24$ hours post-operatively). (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "duration"
                ]
            },
            {
                "id": 1563,
                "question": "A patient with documented $\text{IgE}$-mediated allergy to Penicillin is scheduled for clean surgery. Which alternative $\text{Gram}$-positive agent is recommended for prophylaxis?",
                "choices": [
                    "A. $\text{Cefazolin}$.",
                    "B. $\text{Ceftriaxone}$.",
                    "C. **$\text{Vancomycin}$**.",
                    "D. $\text{Ampicillin}$.",
                    "E. $\text{Clindamycin}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For patients with a serious $\text{B}$-lactam allergy (e.g., anaphylaxis to penicillin), an agent like **$\text{Vancomycin}$** is recommended to cover staphylococci and streptococci. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "allergy",
                    "drug_choice"
                ]
            },
            {
                "id": 1564,
                "question": "A patient is undergoing $\text{GI}$ surgery. The standard regimen includes $\text{Metronidazole}$. Which organisms is $\text{Metronidazole}$ primarily intended to cover?",
                "choices": [
                    "A. $\text{Gram}$-positive cocci.",
                    "B. $\text{Gram}$-negative bacilli.",
                    "C. **Anaerobic organisms.**",
                    "D. Atypical organisms.",
                    "E. Fungi."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**$\text{Metronidazole}$** is added to surgical prophylaxis for procedures involving the bowel to specifically cover **anaerobic organisms**. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "drug_choice",
                    "anaerobes"
                ]
            },
            {
                "id": 1566,
                "question": "The primary reason for avoiding prolonged prophylactic antibiotic use post-surgery ($>24$ hours) is:",
                "choices": [
                    "A. Lack of $\text{RBC}$ production.",
                    "B. High cost of antibiotics.",
                    "C. **Increased risk of antimicrobial resistance.**",
                    "D. Reduced efficacy of surgery.",
                    "E. Poor patient compliance."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prolonged use of prophylactic antibiotics **does not reduce $\text{SSI}$ risk** and significantly **increases the risk of selecting for resistant organisms** and toxicity. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "resistance"
                ]
            },
            {
                "id": 1567,
                "question": "A patient is undergoing an emergency appendectomy (Contaminated wound). Antibiotics are started pre-op. What is the recommended post-operative course of antibiotics?",
                "choices": [
                    "A. Discontinue after wound closure.",
                    "B. Continue for $12$ hours.",
                    "C. Continue for $24$ hours.",
                    "D. **Continue for $3-5$ days (therapeutic regimen).**",
                    "E. Continue until all drains are removed."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For **Contaminated wounds**, the antibiotics are considered **therapeutic** and should be continued post-operatively for a full course (e.g., $3-5$ days) based on clinical judgment and source control. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "contaminated_wound",
                    "duration"
                ]
            },
            {
                "id": 1568,
                "question": "A patient with severe $\text{CKD}$ on hemodialysis requires $\text{Cefazolin}$ prophylaxis. What is the key therapeutic principle to consider for dosing?",
                "choices": [
                    "A. Dose should be doubled.",
                    "B. **Dose should be administered post-dialysis.**",
                    "C. Dose should be administered pre-dialysis.",
                    "D. $\text{Cefazolin}$ is $100%$ removed by dialysis; dose is not changed.",
                    "E. Switch to oral antibiotics."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For renally cleared antibiotics that are dialyzable (like $\text{Cefazolin}$), the drug is often given **post-dialysis** to prevent immediate removal of the drug by the dialyzer. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "renal_adjustment",
                    "dialysis"
                ]
            },
            {
                "id": 1569,
                "question": "The primary goal of $\text{antimicrobial}$ prophylaxis is to reduce the bacterial burden in the surgical site during which time frame?",
                "choices": [
                    "A. The entire hospitalization.",
                    "B. The entire post-operative course.",
                    "C. **The period of incision and closure.**",
                    "D. Only the $48$ hours after surgery.",
                    "E. Only the $7$ days before surgery."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prophylaxis is intended to reduce the bacterial burden during the period of maximal risk, specifically the time of **incision and closure**. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "goals"
                ]
            },
            {
                "id": 1570,
                "question": "A patient undergoing an elective colon resection (clean-contaminated) is given $\text{Cefazolin}$ and $\text{Metronidazole}$ pre-op. The post-operative antibiotic use should be:",
                "choices": [
                    "A. $5-7$ days.",
                    "B. $48$ hours.",
                    "C. $24$ hours.",
                    "D. **Discontinued after wound closure.**",
                    "E. Continued until fever resolves."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For prophylactic use in clean-contaminated wounds, antibiotics should generally be **discontinued after the surgical wound is closed** (or within $24$ hours post-operatively). (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "duration"
                ]
            },
            {
                "id": 1571,
                "question": "A patient with documented $\text{IgE}$-mediated allergy to Penicillin is scheduled for clean surgery. Which alternative $\text{Gram}$-positive agent is recommended for prophylaxis?",
                "choices": [
                    "A. $\text{Cefazolin}$.",
                    "B. $\text{Ceftriaxone}$.",
                    "C. **$\text{Vancomycin}$**.",
                    "D. $\text{Ampicillin}$.",
                    "E. $\text{Clindamycin}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For patients with a serious $\text{B}$-lactam allergy (e.g., anaphylaxis to penicillin), an agent like **$\text{Vancomycin}$** is recommended to cover staphylococci and streptococci. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "allergy",
                    "drug_choice"
                ]
            },
            {
                "id": 1572,
                "question": "A patient is undergoing $\text{GI}$ surgery. The standard regimen includes $\text{Metronidazole}$. Which organisms is $\text{Metronidazole}$ primarily intended to cover?",
                "choices": [
                    "A. $\text{Gram}$-positive cocci.",
                    "B. $\text{Gram}$-negative bacilli.",
                    "C. **Anaerobic organisms.**",
                    "D. Atypical organisms.",
                    "E. Fungi."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**$\text{Metronidazole}$** is added to surgical prophylaxis for procedures involving the bowel to specifically cover **anaerobic organisms**. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "drug_choice",
                    "anaerobes"
                ]
            },
            {
                "id": 1574,
                "question": "The primary reason for avoiding prolonged prophylactic antibiotic use post-surgery ($>24$ hours) is:",
                "choices": [
                    "A. Lack of $\text{RBC}$ production.",
                    "B. High cost of antibiotics.",
                    "C. **Increased risk of antimicrobial resistance.**",
                    "D. Reduced efficacy of surgery.",
                    "E. Poor patient compliance."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prolonged use of prophylactic antibiotics **does not reduce $\text{SSI}$ risk** and significantly **increases the risk of selecting for resistant organisms** and toxicity. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "resistance"
                ]
            },
            {
                "id": 1575,
                "question": "A patient is undergoing an emergency appendectomy (Contaminated wound). Antibiotics are started pre-op. What is the recommended post-operative course of antibiotics?",
                "choices": [
                    "A. Discontinue after wound closure.",
                    "B. Continue for $12$ hours.",
                    "C. Continue for $24$ hours.",
                    "D. **Continue for $3-5$ days (therapeutic regimen).**",
                    "E. Continue until all drains are removed."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For **Contaminated wounds**, the antibiotics are considered **therapeutic** and should be continued post-operatively for a full course (e.g., $3-5$ days) based on clinical judgment and source control. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "contaminated_wound",
                    "duration"
                ]
            },
            {
                "id": 1576,
                "question": "A patient with severe $\text{CKD}$ on hemodialysis requires $\text{Cefazolin}$ prophylaxis. What is the key therapeutic principle to consider for dosing?",
                "choices": [
                    "A. Dose should be doubled.",
                    "B. **Dose should be administered post-dialysis.**",
                    "C. Dose should be administered pre-dialysis.",
                    "D. $\text{Cefazolin}$ is $100%$ removed by dialysis; dose is not changed.",
                    "E. Switch to oral antibiotics."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For renally cleared antibiotics that are dialyzable (like $\text{Cefazolin}$), the drug is often given **post-dialysis** to prevent immediate removal of the drug by the dialyzer. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "renal_adjustment",
                    "dialysis"
                ]
            },
            {
                "id": 1577,
                "question": "The primary goal of $\text{antimicrobial}$ prophylaxis is to reduce the bacterial burden in the surgical site during which time frame?",
                "choices": [
                    "A. The entire hospitalization.",
                    "B. The entire post-operative course.",
                    "C. **The period of incision and closure.**",
                    "D. Only the $48$ hours after surgery.",
                    "E. Only the $7$ days before surgery."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prophylaxis is intended to reduce the bacterial burden during the period of maximal risk, specifically the time of **incision and closure**. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "goals"
                ]
            },
            {
                "id": 1578,
                "question": "A patient undergoing an elective colon resection (clean-contaminated) is given $\text{Cefazolin}$ and $\text{Metronidazole}$ pre-op. The post-operative antibiotic use should be:",
                "choices": [
                    "A. $5-7$ days.",
                    "B. $48$ hours.",
                    "C. $24$ hours.",
                    "D. **Discontinued after wound closure.**",
                    "E. Continued until fever resolves."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For prophylactic use in clean-contaminated wounds, antibiotics should generally be **discontinued after the surgical wound is closed** (or within $24$ hours post-operatively). (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "duration"
                ]
            },
            {
                "id": 1579,
                "question": "A patient with documented $\text{IgE}$-mediated allergy to Penicillin is scheduled for clean surgery. Which alternative $\text{Gram}$-positive agent is recommended for prophylaxis?",
                "choices": [
                    "A. $\text{Cefazolin}$.",
                    "B. $\text{Ceftriaxone}$.",
                    "C. **$\text{Vancomycin}$**.",
                    "D. $\text{Ampicillin}$.",
                    "E. $\text{Clindamycin}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For patients with a serious $\text{B}$-lactam allergy (e.g., anaphylaxis to penicillin), an agent like **$\text{Vancomycin}$** is recommended to cover staphylococci and streptococci. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "allergy",
                    "drug_choice"
                ]
            },
            {
                "id": 1580,
                "question": "A patient is undergoing $\text{GI}$ surgery. The standard regimen includes $\text{Metronidazole}$. Which organisms is $\text{Metronidazole}$ primarily intended to cover?",
                "choices": [
                    "A. $\text{Gram}$-positive cocci.",
                    "B. $\text{Gram}$-negative bacilli.",
                    "C. **Anaerobic organisms.**",
                    "D. Atypical organisms.",
                    "E. Fungi."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**$\text{Metronidazole}$** is added to surgical prophylaxis for procedures involving the bowel to specifically cover **anaerobic organisms**. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "drug_choice",
                    "anaerobes"
                ]
            },
            {
                "id": 1582,
                "question": "The primary reason for avoiding prolonged prophylactic antibiotic use post-surgery ($>24$ hours) is:",
                "choices": [
                    "A. Lack of $\text{RBC}$ production.",
                    "B. High cost of antibiotics.",
                    "C. **Increased risk of antimicrobial resistance.**",
                    "D. Reduced efficacy of surgery.",
                    "E. Poor patient compliance."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prolonged use of prophylactic antibiotics **does not reduce $\text{SSI}$ risk** and significantly **increases the risk of selecting for resistant organisms** and toxicity. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "resistance"
                ]
            },
            {
                "id": 1583,
                "question": "A patient is undergoing an emergency appendectomy (Contaminated wound). Antibiotics are started pre-op. What is the recommended post-operative course of antibiotics?",
                "choices": [
                    "A. Discontinue after wound closure.",
                    "B. Continue for $12$ hours.",
                    "C. Continue for $24$ hours.",
                    "D. **Continue for $3-5$ days (therapeutic regimen).**",
                    "E. Continue until all drains are removed."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For **Contaminated wounds**, the antibiotics are considered **therapeutic** and should be continued post-operatively for a full course (e.g., $3-5$ days) based on clinical judgment and source control. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "contaminated_wound",
                    "duration"
                ]
            },
            {
                "id": 1584,
                "question": "A patient with severe $\text{CKD}$ on hemodialysis requires $\text{Cefazolin}$ prophylaxis. What is the key therapeutic principle to consider for dosing?",
                "choices": [
                    "A. Dose should be doubled.",
                    "B. **Dose should be administered post-dialysis.**",
                    "C. Dose should be administered pre-dialysis.",
                    "D. $\text{Cefazolin}$ is $100%$ removed by dialysis; dose is not changed.",
                    "E. Switch to oral antibiotics."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For renally cleared antibiotics that are dialyzable (like $\text{Cefazolin}$), the drug is often given **post-dialysis** to prevent immediate removal of the drug by the dialyzer. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "renal_adjustment",
                    "dialysis"
                ]
            },
            {
                "id": 1585,
                "question": "The primary goal of $\text{antimicrobial}$ prophylaxis is to reduce the bacterial burden in the surgical site during which time frame?",
                "choices": [
                    "A. The entire hospitalization.",
                    "B. The entire post-operative course.",
                    "C. **The period of incision and closure.**",
                    "D. Only the $48$ hours after surgery.",
                    "E. Only the $7$ days before surgery."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prophylaxis is intended to reduce the bacterial burden during the period of maximal risk, specifically the time of **incision and closure**. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "goals"
                ]
            },
            {
                "id": 1586,
                "question": "A patient undergoing an elective colon resection (clean-contaminated) is given $\text{Cefazolin}$ and $\text{Metronidazole}$ pre-op. The post-operative antibiotic use should be:",
                "choices": [
                    "A. $5-7$ days.",
                    "B. $48$ hours.",
                    "C. $24$ hours.",
                    "D. **Discontinued after wound closure.**",
                    "E. Continued until fever resolves."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For prophylactic use in clean-contaminated wounds, antibiotics should generally be **discontinued after the surgical wound is closed** (or within $24$ hours post-operatively). (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "duration"
                ]
            },
            {
                "id": 1587,
                "question": "A patient with documented $\text{IgE}$-mediated allergy to Penicillin is scheduled for clean surgery. Which alternative $\text{Gram}$-positive agent is recommended for prophylaxis?",
                "choices": [
                    "A. $\text{Cefazolin}$.",
                    "B. $\text{Ceftriaxone}$.",
                    "C. **$\text{Vancomycin}$**.",
                    "D. $\text{Ampicillin}$.",
                    "E. $\text{Clindamycin}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For patients with a serious $\text{B}$-lactam allergy (e.g., anaphylaxis to penicillin), an agent like **$\text{Vancomycin}$** is recommended to cover staphylococci and streptococci. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "allergy",
                    "drug_choice"
                ]
            },
            {
                "id": 1588,
                "question": "A patient is undergoing $\text{GI}$ surgery. The standard regimen includes $\text{Metronidazole}$. Which organisms is $\text{Metronidazole}$ primarily intended to cover?",
                "choices": [
                    "A. $\text{Gram}$-positive cocci.",
                    "B. $\text{Gram}$-negative bacilli.",
                    "C. **Anaerobic organisms.**",
                    "D. Atypical organisms.",
                    "E. Fungi."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**$\text{Metronidazole}$** is added to surgical prophylaxis for procedures involving the bowel to specifically cover **anaerobic organisms**. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "drug_choice",
                    "anaerobes"
                ]
            },
            {
                "id": 1590,
                "question": "The primary reason for avoiding prolonged prophylactic antibiotic use post-surgery ($>24$ hours) is:",
                "choices": [
                    "A. Lack of $\text{RBC}$ production.",
                    "B. High cost of antibiotics.",
                    "C. **Increased risk of antimicrobial resistance.**",
                    "D. Reduced efficacy of surgery.",
                    "E. Poor patient compliance."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prolonged use of prophylactic antibiotics **does not reduce $\text{SSI}$ risk** and significantly **increases the risk of selecting for resistant organisms** and toxicity. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "resistance"
                ]
            },
            {
                "id": 1591,
                "question": "A patient is undergoing an emergency appendectomy (Contaminated wound). Antibiotics are started pre-op. What is the recommended post-operative course of antibiotics?",
                "choices": [
                    "A. Discontinue after wound closure.",
                    "B. Continue for $12$ hours.",
                    "C. Continue for $24$ hours.",
                    "D. **Continue for $3-5$ days (therapeutic regimen).**",
                    "E. Continue until all drains are removed."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For **Contaminated wounds**, the antibiotics are considered **therapeutic** and should be continued post-operatively for a full course (e.g., $3-5$ days) based on clinical judgment and source control. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "contaminated_wound",
                    "duration"
                ]
            },
            {
                "id": 1592,
                "question": "A patient with severe $\text{CKD}$ on hemodialysis requires $\text{Cefazolin}$ prophylaxis. What is the key therapeutic principle to consider for dosing?",
                "choices": [
                    "A. Dose should be doubled.",
                    "B. **Dose should be administered post-dialysis.**",
                    "C. Dose should be administered pre-dialysis.",
                    "D. $\text{Cefazolin}$ is $100%$ removed by dialysis; dose is not changed.",
                    "E. Switch to oral antibiotics."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For renally cleared antibiotics that are dialyzable (like $\text{Cefazolin}$), the drug is often given **post-dialysis** to prevent immediate removal of the drug by the dialyzer. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "renal_adjustment",
                    "dialysis"
                ]
            },
            {
                "id": 1593,
                "question": "The primary goal of $\text{antimicrobial}$ prophylaxis is to reduce the bacterial burden in the surgical site during which time frame?",
                "choices": [
                    "A. The entire hospitalization.",
                    "B. The entire post-operative course.",
                    "C. **The period of incision and closure.**",
                    "D. Only the $48$ hours after surgery.",
                    "E. Only the $7$ days before surgery."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prophylaxis is intended to reduce the bacterial burden during the period of maximal risk, specifically the time of **incision and closure**. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "goals"
                ]
            },
            {
                "id": 1594,
                "question": "A patient undergoing an elective colon resection (clean-contaminated) is given $\text{Cefazolin}$ and $\text{Metronidazole}$ pre-op. The post-operative antibiotic use should be:",
                "choices": [
                    "A. $5-7$ days.",
                    "B. $48$ hours.",
                    "C. $24$ hours.",
                    "D. **Discontinued after wound closure.**",
                    "E. Continued until fever resolves."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For prophylactic use in clean-contaminated wounds, antibiotics should generally be **discontinued after the surgical wound is closed** (or within $24$ hours post-operatively). (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "duration"
                ]
            },
            {
                "id": 1595,
                "question": "A patient with documented $\text{IgE}$-mediated allergy to Penicillin is scheduled for clean surgery. Which alternative $\text{Gram}$-positive agent is recommended for prophylaxis?",
                "choices": [
                    "A. $\text{Cefazolin}$.",
                    "B. $\text{Ceftriaxone}$.",
                    "C. **$\text{Vancomycin}$**.",
                    "D. $\text{Ampicillin}$.",
                    "E. $\text{Clindamycin}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For patients with a serious $\text{B}$-lactam allergy (e.g., anaphylaxis to penicillin), an agent like **$\text{Vancomycin}$** is recommended to cover staphylococci and streptococci. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "allergy",
                    "drug_choice"
                ]
            },
            {
                "id": 1596,
                "question": "A patient is undergoing $\text{GI}$ surgery. The standard regimen includes $\text{Metronidazole}$. Which organisms is $\text{Metronidazole}$ primarily intended to cover?",
                "choices": [
                    "A. $\text{Gram}$-positive cocci.",
                    "B. $\text{Gram}$-negative bacilli.",
                    "C. **Anaerobic organisms.**",
                    "D. Atypical organisms.",
                    "E. Fungi."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**$\text{Metronidazole}$** is added to surgical prophylaxis for procedures involving the bowel to specifically cover **anaerobic organisms**. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "drug_choice",
                    "anaerobes"
                ]
            },
            {
                "id": 1598,
                "question": "The primary reason for avoiding prolonged prophylactic antibiotic use post-surgery ($>24$ hours) is:",
                "choices": [
                    "A. Lack of $\text{RBC}$ production.",
                    "B. High cost of antibiotics.",
                    "C. **Increased risk of antimicrobial resistance.**",
                    "D. Reduced efficacy of surgery.",
                    "E. Poor patient compliance."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prolonged use of prophylactic antibiotics **does not reduce $\text{SSI}$ risk** and significantly **increases the risk of selecting for resistant organisms** and toxicity. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "resistance"
                ]
            },
            {
                "id": 1599,
                "question": "A patient is undergoing an emergency appendectomy (Contaminated wound). Antibiotics are started pre-op. What is the recommended post-operative course of antibiotics?",
                "choices": [
                    "A. Discontinue after wound closure.",
                    "B. Continue for $12$ hours.",
                    "C. Continue for $24$ hours.",
                    "D. **Continue for $3-5$ days (therapeutic regimen).**",
                    "E. Continue until all drains are removed."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For **Contaminated wounds**, the antibiotics are considered **therapeutic** and should be continued post-operatively for a full course (e.g., $3-5$ days) based on clinical judgment and source control. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "contaminated_wound",
                    "duration"
                ]
            },
            {
                "id": 1600,
                "question": "A patient with severe $\text{CKD}$ on hemodialysis requires $\text{Cefazolin}$ prophylaxis. What is the key therapeutic principle to consider for dosing?",
                "choices": [
                    "A. Dose should be doubled.",
                    "B. **Dose should be administered post-dialysis.**",
                    "C. Dose should be administered pre-dialysis.",
                    "D. $\text{Cefazolin}$ is $100%$ removed by dialysis; dose is not changed.",
                    "E. Switch to oral antibiotics."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For renally cleared antibiotics that are dialyzable (like $\text{Cefazolin}$), the drug is often given **post-dialysis** to prevent immediate removal of the drug by the dialyzer. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "renal_adjustment",
                    "dialysis"
                ]
            },
            {
                "id": 1601,
                "question": "The primary goal of $\text{antimicrobial}$ prophylaxis is to reduce the bacterial burden in the surgical site during which time frame?",
                "choices": [
                    "A. The entire hospitalization.",
                    "B. The entire post-operative course.",
                    "C. **The period of incision and closure.**",
                    "D. Only the $48$ hours after surgery.",
                    "E. Only the $7$ days before surgery."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prophylaxis is intended to reduce the bacterial burden during the period of maximal risk, specifically the time of **incision and closure**. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "goals"
                ]
            },
            {
                "id": 1602,
                "question": "A patient undergoing an elective colon resection (clean-contaminated) is given $\text{Cefazolin}$ and $\text{Metronidazole}$ pre-op. The post-operative antibiotic use should be:",
                "choices": [
                    "A. $5-7$ days.",
                    "B. $48$ hours.",
                    "C. $24$ hours.",
                    "D. **Discontinued after wound closure.**",
                    "E. Continued until fever resolves."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For prophylactic use in clean-contaminated wounds, antibiotics should generally be **discontinued after the surgical wound is closed** (or within $24$ hours post-operatively). (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "duration"
                ]
            },
            {
                "id": 1603,
                "question": "A patient with documented $\text{IgE}$-mediated allergy to Penicillin is scheduled for clean surgery. Which alternative $\text{Gram}$-positive agent is recommended for prophylaxis?",
                "choices": [
                    "A. $\text{Cefazolin}$.",
                    "B. $\text{Ceftriaxone}$.",
                    "C. **$\text{Vancomycin}$**.",
                    "D. $\text{Ampicillin}$.",
                    "E. $\text{Clindamycin}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For patients with a serious $\text{B}$-lactam allergy (e.g., anaphylaxis to penicillin), an agent like **$\text{Vancomycin}$** is recommended to cover staphylococci and streptococci. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "allergy",
                    "drug_choice"
                ]
            },
            {
                "id": 1604,
                "question": "A patient is undergoing $\text{GI}$ surgery. The standard regimen includes $\text{Metronidazole}$. Which organisms is $\text{Metronidazole}$ primarily intended to cover?",
                "choices": [
                    "A. $\text{Gram}$-positive cocci.",
                    "B. $\text{Gram}$-negative bacilli.",
                    "C. **Anaerobic organisms.**",
                    "D. Atypical organisms.",
                    "E. Fungi."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "**$\text{Metronidazole}$** is added to surgical prophylaxis for procedures involving the bowel to specifically cover **anaerobic organisms**. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "drug_choice",
                    "anaerobes"
                ]
            },
            {
                "id": 1606,
                "question": "The primary reason for avoiding prolonged prophylactic antibiotic use post-surgery ($>24$ hours) is:",
                "choices": [
                    "A. Lack of $\text{RBC}$ production.",
                    "B. High cost of antibiotics.",
                    "C. **Increased risk of antimicrobial resistance.**",
                    "D. Reduced efficacy of surgery.",
                    "E. Poor patient compliance."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prolonged use of prophylactic antibiotics **does not reduce $\text{SSI}$ risk** and significantly **increases the risk of selecting for resistant organisms** and toxicity. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "resistance"
                ]
            },
            {
                "id": 1607,
                "question": "A patient is undergoing an emergency appendectomy (Contaminated wound). Antibiotics are started pre-op. What is the recommended post-operative course of antibiotics?",
                "choices": [
                    "A. Discontinue after wound closure.",
                    "B. Continue for $12$ hours.",
                    "C. Continue for $24$ hours.",
                    "D. **Continue for $3-5$ days (therapeutic regimen).**",
                    "E. Continue until all drains are removed."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For **Contaminated wounds**, the antibiotics are considered **therapeutic** and should be continued post-operatively for a full course (e.g., $3-5$ days) based on clinical judgment and source control. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "contaminated_wound",
                    "duration"
                ]
            },
            {
                "id": 1608,
                "question": "A patient with severe $\text{CKD}$ on hemodialysis requires $\text{Cefazolin}$ prophylaxis. What is the key therapeutic principle to consider for dosing?",
                "choices": [
                    "A. Dose should be doubled.",
                    "B. **Dose should be administered post-dialysis.**",
                    "C. Dose should be administered pre-dialysis.",
                    "D. $\text{Cefazolin}$ is $100%$ removed by dialysis; dose is not changed.",
                    "E. Switch to oral antibiotics."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For renally cleared antibiotics that are dialyzable (like $\text{Cefazolin}$), the drug is often given **post-dialysis** to prevent immediate removal of the drug by the dialyzer. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "renal_adjustment",
                    "dialysis"
                ]
            },
            {
                "id": 1609,
                "question": "The primary goal of $\text{antimicrobial}$ prophylaxis is to reduce the bacterial burden in the surgical site during which time frame?",
                "choices": [
                    "A. The entire hospitalization.",
                    "B. The entire post-operative course.",
                    "C. **The period of incision and closure.**",
                    "D. Only the $48$ hours after surgery.",
                    "E. Only the $7$ days before surgery."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "Prophylaxis is intended to reduce the bacterial burden during the period of maximal risk, specifically the time of **incision and closure**. (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "goals"
                ]
            },
            {
                "id": 1610,
                "question": "A patient undergoing an elective colon resection (clean-contaminated) is given $\text{Cefazolin}$ and $\text{Metronidazole}$ pre-op. The post-operative antibiotic use should be:",
                "choices": [
                    "A. $5-7$ days.",
                    "B. $48$ hours.",
                    "C. $24$ hours.",
                    "D. **Discontinued after wound closure.**",
                    "E. Continued until fever resolves."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For prophylactic use in clean-contaminated wounds, antibiotics should generally be **discontinued after the surgical wound is closed** (or within $24$ hours post-operatively). (p. 272)",
                "tags": [
                    "surgical_prophylaxis",
                    "duration"
                ]
            },
            {
                "id": 1631,
                "question": "A patient with $\text{GI}$ surgery prophylaxis needs coverage for $\text{Gram}$-negative organisms and $\text{anaerobes}$. The recommended combination is:",
                "choices": [
                    "A. $\text{Cefazolin}$ $\text{monotherapy}$.",
                    "B. **$\text{Cefazolin}$ $\text{and}$ $\text{Metronidazole}$**.",
                    "C. $\text{Vancomycin}$ $\text{and}$ $\text{Gentamicin}$",
                    "D. $\text{Ampicillin}$ $\text{and}$ $\text{Metronidazole}$",
                    "E. $\text{Ciprofloxacin}$ $\text{monotherapy}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For $\text{GI}$ procedures, the combination of **$\text{Cefazolin}$** ($\text{Gram}$-positive and some $\text{Gram}$-negative) and **$\text{Metronidazole}$** ($\text{anaerobes}$) is the standard. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "drug_combination"
                ]
            }
        ],
        "Chapter 8.1 ANTIMIMICROBIAL PROPHYLAXIS IN SURGERY": [
            {
                "id": 1547,
                "question": "A patient is undergoing a cardiac surgery (clean procedure with prosthetic material). What is the minimum recommended duration for antimicrobial prophylaxis?",
                "choices": [
                    "A. Single dose only.",
                    "B. $12$ hours.",
                    "C. **$48$ hours.**",
                    "D. $7$ days.",
                    "E. Until the patient is discharged."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.1 ANTIMIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For procedures where foreign materials are implanted (e.g., cardiac surgery), prophylaxis is often recommended for **up to $48$ hours** to cover the period of highest risk for $\text{SSI}$. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "implanted_material"
                ]
            },
            {
                "id": 1565,
                "question": "A patient is undergoing total knee replacement. What is the minimum recommended duration for antimicrobial prophylaxis post-surgery?",
                "choices": [
                    "A. $12$ hours.",
                    "B. **$48$ hours.**",
                    "C. $5$ days.",
                    "D. $7$ days.",
                    "E. Until sutures are removed."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For procedures where foreign materials are implanted (e.g., orthopedic hardware), prophylaxis is often recommended for **up to $48$ hours** to cover the period of highest risk for $\text{SSI}$. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "implanted_material"
                ]
            },
            {
                "id": 1573,
                "question": "A patient is undergoing total knee replacement. What is the minimum recommended duration for antimicrobial prophylaxis post-surgery?",
                "choices": [
                    "A. $12$ hours.",
                    "B. **$48$ hours.**",
                    "C. $5$ days.",
                    "D. $7$ days.",
                    "E. Until sutures are removed."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For procedures where foreign materials are implanted (e.g., orthopedic hardware), prophylaxis is often recommended for **up to $48$ hours** to cover the period of highest risk for $\text{SSI}$. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "implanted_material"
                ]
            },
            {
                "id": 1581,
                "question": "A patient is undergoing total knee replacement. What is the minimum recommended duration for antimicrobial prophylaxis post-surgery?",
                "choices": [
                    "A. $12$ hours.",
                    "B. **$48$ hours.**",
                    "C. $5$ days.",
                    "D. $7$ days.",
                    "E. Until sutures are removed."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For procedures where foreign materials are implanted (e.g., orthopedic hardware), prophylaxis is often recommended for **up to $48$ hours** to cover the period of highest risk for $\text{SSI}$. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "implanted_material"
                ]
            },
            {
                "id": 1589,
                "question": "A patient is undergoing total knee replacement. What is the minimum recommended duration for antimicrobial prophylaxis post-surgery?",
                "choices": [
                    "A. $12$ hours.",
                    "B. **$48$ hours.**",
                    "C. $5$ days.",
                    "D. $7$ days.",
                    "E. Until sutures are removed."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For procedures where foreign materials are implanted (e.g., orthopedic hardware), prophylaxis is often recommended for **up to $48$ hours** to cover the period of highest risk for $\text{SSI}$. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "implanted_material"
                ]
            },
            {
                "id": 1597,
                "question": "A patient is undergoing total knee replacement. What is the minimum recommended duration for antimicrobial prophylaxis post-surgery?",
                "choices": [
                    "A. $12$ hours.",
                    "B. **$48$ hours.**",
                    "C. $5$ days.",
                    "D. $7$ days.",
                    "E. Until sutures are removed."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For procedures where foreign materials are implanted (e.g., orthopedic hardware), prophylaxis is often recommended for **up to $48$ hours** to cover the period of highest risk for $\text{SSI}$. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "implanted_material"
                ]
            },
            {
                "id": 1605,
                "question": "A patient is undergoing total knee replacement. What is the minimum recommended duration for antimicrobial prophylaxis post-surgery?",
                "choices": [
                    "A. $12$ hours.",
                    "B. **$48$ hours.**",
                    "C. $5$ days.",
                    "D. $7$ days.",
                    "E. Until sutures are removed."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.1 ANTIMIMICROBIAL PROPHYLAXIS IN SURGERY",
                "explanation": "For procedures where foreign materials are implanted (e.g., orthopedic hardware), prophylaxis is often recommended for **up to $48$ hours** to cover the period of highest risk for $\text{SSI}$. (p. 273)",
                "tags": [
                    "surgical_prophylaxis",
                    "implanted_material"
                ]
            }
        ]
    },
    "Chapter 8.2": {
        "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN": [
            {
                "id": 1611,
                "question": "A $60$-year-old male is admitted with severe community-acquired pneumonia ($\text{CAP}$). $\text{Sputum}$ culture and sensitivity are pending. What is the appropriate initial management strategy regarding antibiotics?",
                "choices": [
                    "A. **Start empiric broad-spectrum antibiotics immediately.**",
                    "B. Wait $48$ hours for culture results before initiating therapy.",
                    "C. Start narrow-spectrum antibiotics (e.g., Penicillin) only.",
                    "D. Start $\text{IV}$ fluids and observe the patient's temperature.",
                    "E. Start an $\text{IV}$ antiviral agent."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "For severe infections (e.g., severe sepsis, severe $\text{CAP}$), **empiric broad-spectrum antimicrobial therapy** must be started **immediately** after cultures are taken, without waiting for definitive results. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "empiric_therapy"
                ]
            },
            {
                "id": 1612,
                "question": "A patient with $\text{CKD}$ (Creatinine Clearance $15 \text{ ml/min}$) is prescribed Gentamicin. What is the key principle for dosing this drug in this patient?",
                "choices": [
                    "A. Dose should be doubled.",
                    "B. $\text{Gentamicin}$ is contraindicated in $\text{CKD}$.",
                    "C. **Dose must be adjusted (reduced or interval increased) to prevent toxicity.**",
                    "D. Only $\text{oral}$ $\text{Gentamicin}$ should be used.",
                    "E. No dose adjustment is needed."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "For renally excreted drugs like Gentamicin, **dose modification is required** in patients with $\text{CKD}$ to prevent drug accumulation and toxicity (e.g., nephrotoxicity/ototoxicity). (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "renal_adjustment"
                ]
            },
            {
                "id": 1613,
                "question": "A patient with severe intra-abdominal infection is started on combination therapy ($\text{Ceftriaxone}$ and $\text{Metronidazole}$). What is the primary purpose of this combination?",
                "choices": [
                    "A. To achieve synergistic killing against a single organism.",
                    "B. To reduce the duration of therapy.",
                    "C. **To broaden the spectrum of coverage** ($\text{Gram}$-negative and anaerobes).",
                    "D. To prevent drug resistance.",
                    "E. To decrease the overall cost."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Combination therapy is most commonly used to **broaden the spectrum** of coverage when the causative organism is unknown (empiric therapy) or when polymicrobial infection is suspected (e.g., intra-abdominal infection). (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "combination_therapy"
                ]
            },
            {
                "id": 1614,
                "question": "A patient is on $\text{Vancomycin}$ therapy for $\text{MRSA}$ bacteremia. Which monitoring is mandatory to ensure safety and efficacy?",
                "choices": [
                    "A. Serum $\text{Glucose}$ levels.",
                    "B. Serum $\text{Calcium}$ levels.",
                    "C. **Therapeutic Drug Monitoring ($\text{TDM}$) of $\text{Vancomycin}$ $\text{Trough}$ $\text{Levels}$**.",
                    "D. Serum $\text{Lipase}$ levels.",
                    "E. $\text{INR}$ monitoring."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "**$\text{Vancomycin}$** requires **$\text{TDM}$** (monitoring $\text{trough}$ $\text{levels}$) to ensure adequate drug concentration for efficacy while minimizing the risk of nephrotoxicity. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "TDM",
                    "Vancomycin"
                ]
            },
            {
                "id": 1615,
                "question": "A patient's blood culture grows $\text{Staphylococcus}$ $\text{aureus}$, which is sensitive to $\text{Cefazolin}$ and Vancomycin. The patient is currently on empiric $\text{Cefazolin}$ and $\text{Gentamicin}$. What is the appropriate next step for the antibiotic regimen?",
                "choices": [
                    "A. Add $\text{Vancomycin}$ for synergy.",
                    "B. **De-escalate to $\text{Cefazolin}$ monotherapy.**",
                    "C. Continue $\text{Cefazolin}$ and $\text{Gentamicin}$ combination.",
                    "D. Switch to $\text{Vancomycin}$ monotherapy.",
                    "E. Stop all antibiotics."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Once definitive culture and sensitivity results are available, the empiric broad-spectrum therapy should be narrowed to a definitive, less toxic, and often single agent. This is called **De-escalation**. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "de_escalation",
                    "definitive_therapy"
                ]
            },
            {
                "id": 1616,
                "question": "A patient is prescribed high-dose $\text{Penicillin}$ for $10$ days. Which potential $\text{CNS}$ side effect should the clinician monitor for, especially in the setting of renal failure?",
                "choices": [
                    "A. Peripheral neuropathy.",
                    "B. $\text{Optic}$ $\text{neuritis}$.",
                    "C. $\text{Vestibular}$ $\text{toxicity}$.",
                    "D. **Seizures**.",
                    "E. $\text{Hypoglycemia}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "High doses of $\text{Penicillin}$ ($\text{B}$-lactam) antibiotics, particularly in patients with $\text{renal}$ $\text{failure}$ where clearance is reduced, can accumulate in the $\text{CNS}$ and cause **seizures** or encephalopathy. (p. 275)",
                "tags": [
                    "antimicrobial_regimen",
                    "side_effects",
                    "Penicillin"
                ]
            },
            {
                "id": 1617,
                "question": "The definitive diagnosis of a bacterial infection typically requires the performance of:",
                "choices": [
                    "A. $\text{CBC}$ and $\text{CRP}$ measurement.",
                    "B. $\text{Imaging}$ ($\text{X-ray}$ or $\text{CT}$ $\text{scan}$).",
                    "C. $\text{Therapeutic}$ $\text{drug}$ $\text{monitoring}$ ($\text{TDM}$).",
                    "D. **Culture and sensitivity testing.**",
                    "E. $\text{A}$ $\text{trial}$ $\text{of}$ $\text{empiric}$ $\text{therapy}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "The definitive diagnosis and guidance for therapy rely on identifying the organism and its sensitivity patterns via **culture and sensitivity testing**. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "diagnosis",
                    "culture"
                ]
            },
            {
                "id": 1618,
                "question": "What is the primary reason for avoiding oral antibiotic therapy in a patient with severe sepsis and septic shock?",
                "choices": [
                    "A. High cost.",
                    "B. $\text{Poor}$ $\text{patient}$ $\text{compliance}$.",
                    "C. $\text{Risk}$ $\text{of}$ $\text{GI}$ $\text{ulceration}$.",
                    "D. **Impaired absorption and lower bioavailability** in shock.",
                    "E. $\text{High}$ $\text{risk}$ $\text{of}$ $\text{CNS}$ $\text{side}$ $\text{effects}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "In critically ill or septic shock patients, **$\text{IV}$ administration is mandatory** because of potential **impaired $\text{GI}$ absorption and lower bioavailability** due to poor perfusion. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "route_of_administration",
                    "sepsis"
                ]
            },
            {
                "id": 1619,
                "question": "The principle of **De-escalation** of antimicrobial therapy involves:",
                "choices": [
                    "A. Switching from $\text{oral}$ to $\text{IV}$ route.",
                    "B. Switching from $\text{monotherapy}$ to $\text{combination}$ $\text{therapy}$.",
                    "C. **Switching from broad-spectrum $\text{empiric}$ to narrow-spectrum $\text{definitive}$ therapy.**",
                    "D. Continuing broad-spectrum therapy until full recovery.",
                    "E. Increasing the dose of the initial antibiotic."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "De-escalation is the process of **narrowing the spectrum of antibiotics** once the causative organism and its sensitivities are known, moving from empiric to definitive therapy. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "de_escalation",
                    "stewardship"
                ]
            },
            {
                "id": 1620,
                "question": "A patient with community-acquired pneumonia ($\text{CAP}$) who improves clinically after $72$ hours of $\text{IV}$ therapy is switched to oral antibiotics. This switch is part of the principle of:",
                "choices": [
                    "A. $\text{TDM}$ optimization.",
                    "B. $\text{Synergistic}$ $\text{therapy}$.",
                    "C. $\text{De}$-escalation of spectrum.",
                    "D. **$\text{Step}$-down $\text{therapy}$**.",
                    "E. $\text{Empiric}$ $\text{therapy}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Switching a patient from $\text{IV}$ to a highly bioavailable **$\text{oral}$ $\text{regimen}$** upon clinical improvement is known as **$\text{step}$-down $\text{therapy}$** and allows for earlier discharge and cost savings. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "step_down_therapy"
                ]
            },
            {
                "id": 1621,
                "question": "Which antimicrobial agent requires specific $\text{TDM}$ to avoid both toxicity (nephrotoxicity/ototoxicity) and ensure efficacy?",
                "choices": [
                    "A. $\text{Ceftriaxone}$.",
                    "B. $\text{Metronidazole}$.",
                    "C. **$\text{Gentamicin}$ (and other $\text{aminoglycosides}$)**.",
                    "D. $\text{Ampicillin}$.",
                    "E. $\text{Ciprofloxacin}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Both **$\text{Vancomycin}$** and **$\text{Aminoglycosides}$** ($\text{Gentamicin}$, $\text{Amikacin}$) are narrow therapeutic index drugs that require **$\text{TDM}$** (monitoring $\text{peak}$ and/or $\text{trough}$ $\text{levels}$) to optimize dosing and minimize toxicity. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "TDM",
                    "aminoglycosides"
                ]
            },
            {
                "id": 1624,
                "question": "The primary objective of antimicrobial **$\text{De}$-escalation** is:",
                "choices": [
                    "A. To achieve synergy.",
                    "B. To treat resistant organisms.",
                    "C. **To reduce the selection pressure for $\text{antimicrobial}$ $\text{resistance}$.**",
                    "D. To switch the route of administration.",
                    "E. To decrease the duration of therapy."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "The judicious use of antibiotics, including de-escalation, is a core principle of **$\text{antimicrobial}$ $\text{stewardship}$**, aiming to **reduce the selection pressure for $\text{antimicrobial}$ $\text{resistance}$**. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "stewardship",
                    "de_escalation"
                ]
            },
            {
                "id": 1625,
                "question": "A patient with suspected $\text{meningitis}$ is started on $\text{IV}$ $\text{Ceftriaxone}$. This is an example of what type of therapy?",
                "choices": [
                    "A. **$\text{Empiric}$ $\text{therapy}$**.",
                    "B. $\text{Definitive}$ $\text{therapy}$.",
                    "C. $\text{Prophylactic}$ $\text{therapy}$.",
                    "D. $\text{Synergistic}$ $\text{therapy}$.",
                    "E. $\text{Step}$-down $\text{therapy}$."
                ],
                "correctAnswer": 0,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "**$\text{Empiric}$ $\text{therapy}$** is the initiation of antibiotics based on the suspected site and type of infection, covering the most likely pathogens before definitive culture results are available. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "empiric_therapy"
                ]
            },
            {
                "id": 1626,
                "question": "A patient with $\text{renal}$ $\text{failure}$ requires $\text{Gentamicin}$. What is the most severe $\text{side}$ $\text{effect}$ that dose modification aims to prevent?",
                "choices": [
                    "A. $\text{Hepatotoxicity}$.",
                    "B. $\text{Allergy}$.",
                    "C. $\text{Bone}$ $\text{marrow}$ $\text{suppression}$.",
                    "D. **$\text{Nephrotoxicity}$ $\text{and}$ $\text{ototoxicity}$**.",
                    "E. $\text{Seizures}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "The major toxicities of **$\text{Gentamicin}$** (an $\text{aminoglycoside}$) are **$\text{nephrotoxicity}$** and **$\text{ototoxicity}$** ($\text{vestibular}$ $\text{and}$ $\text{cochlear}$ $\text{damage}$), which are concentration-dependent and exacerbated by $\text{CKD}$. (p. 275)",
                "tags": [
                    "antimicrobial_regimen",
                    "side_effects",
                    "aminoglycosides"
                ]
            },
            {
                "id": 1627,
                "question": "The definitive diagnosis of a bacterial infection typically requires the performance of:",
                "choices": [
                    "A. $\text{CBC}$ and $\text{CRP}$ measurement.",
                    "B. $\text{Imaging}$ ($\text{X-ray}$ or $\text{CT}$ $\text{scan}$).",
                    "C. $\text{Therapeutic}$ $\text{drug}$ $\text{monitoring}$ ($\text{TDM}$).",
                    "D. **Culture and sensitivity testing.**",
                    "E. $\text{A}$ $\text{trial}$ $\text{of}$ $\text{empiric}$ $\text{therapy}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "The definitive diagnosis and guidance for therapy rely on identifying the organism and its sensitivity patterns via **culture and sensitivity testing**. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "diagnosis",
                    "culture"
                ]
            },
            {
                "id": 1628,
                "question": "A patient is admitted with a severe $\text{infection}$. Which factor mandates the use of $\text{IV}$ antibiotics over $\text{oral}$ route?",
                "choices": [
                    "A. $\text{Patient}$ $\text{compliance}$.",
                    "B. $\text{High}$ $\text{cost}$.",
                    "C. **$\text{Septic}$ $\text{shock}$ $\text{and}$ $\text{impaired}$ $\text{GI}$ $\text{absorption}$**.",
                    "D. $\text{Risk}$ $\text{of}$ $\text{GI}$ $\text{side}$ $\text{effects}$.",
                    "E. $\text{Need}$ $\text{for}$ $\text{TDM}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "In critically ill or septic shock patients, **$\text{IV}$ administration is mandatory** because of potential **impaired $\text{GI}$ absorption and lower bioavailability** due to poor perfusion. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "route_of_administration",
                    "sepsis"
                ]
            },
            {
                "id": 1629,
                "question": "The principle of **$\text{Step}$-down $\text{therapy}$** involves:",
                "choices": [
                    "A. $\text{Switching}$ $\text{from}$ $\text{oral}$ $\text{to}$ $\text{IV}$ $\text{route}$.",
                    "B. $\text{Switching}$ $\text{from}$ $\text{monotherapy}$ $\text{to}$ $\text{combination}$ $\text{therapy}$.",
                    "C. $\text{Switching}$ $\text{from}$ $\text{broad}$-spectrum $\text{empiric}$ $\text{to}$ $\text{narrow}$-spectrum $\text{definitive}$ $\text{therapy}$.",
                    "D. **$\text{Switching}$ $\text{from}$ $\text{IV}$ $\text{to}$ $\text{oral}$ $\text{therapy}$ $\text{on}$ $\text{clinical}$ $\text{improvement}$.**",
                    "E. $\text{Increasing}$ $\text{the}$ $\text{dose}$ $\text{of}$ $\text{the}$ $\text{initial}$ $\text{antibiotic}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "**$\text{Step}$-down $\text{therapy}$** is the practice of switching from an **$\text{IV}$ $\text{regimen}$ to a highly $\text{bioavailable}$ $\text{oral}$ $\text{regimen}$** upon clinical improvement, leading to earlier discharge and lower costs. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "step_down_therapy"
                ]
            },
            {
                "id": 1630,
                "question": "A patient with $\text{Gram}$-negative rod bacteremia is on $\text{Gentamicin}$ therapy. Which toxicity requires concurrent monitoring of serum creatinine?",
                "choices": [
                    "A. $\text{Hepatotoxicity}$.",
                    "B. $\text{Ototoxicity}$.",
                    "C. **$\text{Nephrotoxicity}$**.",
                    "D. $\text{Seizures}$.",
                    "E. $\text{Neurotoxicity}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Increased serum $\text{creatinine}$ is the primary indicator of $\text{Gentamicin}$-induced **$\text{nephrotoxicity}$** ($\text{renal}$ $\text{damage}$). (p. 275)",
                "tags": [
                    "antimicrobial_regimen",
                    "side_effects",
                    "aminoglycosides"
                ]
            },
            {
                "id": 1632,
                "question": "A patient's blood culture grows $\text{Staphylococcus}$ $\text{aureus}$, which is sensitive to $\text{Cefazolin}$ and $\text{Vancomycin}$. The patient is currently on $\text{empiric}$ $\text{Cefazolin}$ and $\text{Gentamicin}$. What is the appropriate next step for the antibiotic regimen?",
                "choices": [
                    "A. $\text{Add}$ $\text{Vancomycin}$ $\text{for}$ $\text{synergy}$.",
                    "B. **$\text{De}$-escalate $\text{to}$ $\text{Cefazolin}$ $\text{monotherapy}$**.",
                    "C. $\text{Continue}$ $\text{Cefazolin}$ $\text{and}$ $\text{Gentamicin}$ $\text{combination}$.",
                    "D. $\text{Switch}$ $\text{to}$ $\text{Vancomycin}$ $\text{monotherapy}$.",
                    "E. $\text{Stop}$ $\text{all}$ $\text{antibiotics}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Once definitive culture and sensitivity results are available, the empiric broad-spectrum therapy should be narrowed to a definitive, less toxic, and often single agent. This is called **$\text{De}$-escalation**. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "de_escalation",
                    "definitive_therapy"
                ]
            },
            {
                "id": 1633,
                "question": "The primary goal of $\text{antimicrobial}$ $\text{stewardship}$ is to:",
                "choices": [
                    "A. $\text{Increase}$ $\text{the}$ $\text{average}$ $\text{duration}$ $\text{of}$ $\text{antibiotic}$ $\text{therapy}$.",
                    "B. $\text{Promote}$ $\text{the}$ $\text{use}$ $\text{of}$ $\text{broad}$-spectrum $\text{antibiotics}$.",
                    "C. **$\text{Optimize}$ $\text{antimicrobial}$ $\text{use}$ $\text{to}$ $\text{improve}$ $\text{patient}$ $\text{outcomes}$ $\text{and}$ $\text{reduce}$ $\text{resistance}$.**",
                    "D. $\text{Ensure}$ $\text{all}$ $\text{patients}$ $\text{receive}$ $\text{combination}$ $\text{therapy}$.",
                    "E. $\text{Avoid}$ $\text{all}$ $\text{intravenous}$ $\text{antibiotics}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Antimicrobial stewardship is a core principle aimed at **$\text{optimizing}$ $\text{antimicrobial}$ $\text{use}$** to enhance patient care and limit the emergence of **$\text{resistance}$**. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "stewardship"
                ]
            },
            {
                "id": 1634,
                "question": "A patient with severe $\text{sepsis}$ is given empiric broad-spectrum antibiotics. The patient improves clinically after $72$ hours. Which therapeutic principle should be applied next?",
                "choices": [
                    "A. $\text{Continue}$ $\text{IV}$ $\text{therapy}$ $\text{for}$ $\text{14}$ $\text{days}$.",
                    "B. $\text{Switch}$ $\text{to}$ $\text{prophylactic}$ $\text{dosing}$.",
                    "C. **$\text{Consider}$ $\text{de}$-escalation $\text{and}$ $\text{step}$-down $\text{therapy}$**.",
                    "D. $\text{Switch}$ $\text{to}$ $\text{IV}$ $\text{Vancomycin}$ $\text{for}$ $\text{MRSA}$ $\text{coverage}$.",
                    "E. $\text{Stop}$ $\text{all}$ $\text{antibiotics}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Once a patient is clinically stable, the therapy should be narrowed (de-escalation) and the route should be switched to oral if possible (**step-down $\text{therapy}$**). (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "de_escalation",
                    "step_down_therapy"
                ]
            },
            {
                "id": 1635,
                "question": "A patient with $\text{CKD}$ (Creatinine Clearance $15 \text{ ml/min}$) is prescribed $\text{Gentamicin}$. What is the key principle for dosing this drug in this patient?",
                "choices": [
                    "A. $\text{Dose}$ $\text{should}$ $\text{be}$ $\text{doubled}$.",
                    "B. $\text{Gentamicin}$ $\text{is}$ $\text{contraindicated}$ $\text{in}$ $\text{CKD}$.",
                    "C. **$\text{Dose}$ $\text{must}$ $\text{be}$ $\text{adjusted}$ ($\text{reduced}$ $\text{or}$ $\text{interval}$ $\text{increased}$) $\text{to}$ $\text{prevent}$ $\text{toxicity}$**.",
                    "D. $\text{Only}$ $\text{oral}$ $\text{Gentamicin}$ $\text{should}$ $\text{be}$ $\text{used}$.",
                    "E. $\text{No}$ $\text{dose}$ $\text{adjustment}$ $\text{is}$ $\text{needed}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "For renally excreted drugs like $\text{Gentamicin}$, **$\text{dose}$ $\text{modification}$ $\text{is}$ $\text{required}$** in patients with $\text{CKD}$ to prevent drug accumulation and toxicity (e.g., nephrotoxicity/ototoxicity). (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "renal_adjustment"
                ]
            },
            {
                "id": 1636,
                "question": "A patient with severe intra-abdominal infection is started on combination therapy ($\text{Ceftriaxone}$ and $\text{Metronidazole}$). What is the primary purpose of this combination?",
                "choices": [
                    "A. $\text{To}$ $\text{achieve}$ $\text{synergistic}$ $\text{killing}$ $\text{against}$ $\text{a}$ $\text{single}$ $\text{organism}$.",
                    "B. $\text{To}$ $\text{reduce}$ $\text{the}$ $\text{duration}$ $\text{of}$ $\text{therapy}$.",
                    "C. **$\text{To}$ $\text{broaden}$ $\text{the}$ $\text{spectrum}$ $\text{of}$ $\text{coverage}$** ($\text{Gram}$-negative $\text{and}$ $\text{anaerobes}$).",
                    "D. $\text{To}$ $\text{prevent}$ $\text{drug}$ $\text{resistance}$.",
                    "E. $\text{To}$ $\text{decrease}$ $\text{the}$ $\text{overall}$ $\text{cost}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Combination therapy is most commonly used to **$\text{broaden}$ $\text{the}$ $\text{spectrum}$** of coverage when the causative organism is unknown ($\text{empiric}$ $\text{therapy}$) or when polymicrobial infection is suspected ($\text{e.g}$., $\text{intra}$-abdominal $\text{infection}$). (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "combination_therapy"
                ]
            },
            {
                "id": 1637,
                "question": "A patient is on $\text{Vancomycin}$ therapy for $\text{MRSA}$ bacteremia. Which monitoring is mandatory to ensure safety and efficacy?",
                "choices": [
                    "A. $\text{Serum}$ $\text{Glucose}$ $\text{levels}$.",
                    "B. $\text{Serum}$ $\text{Calcium}$ $\text{levels}$.",
                    "C. **$\text{Therapeutic}$ $\text{Drug}$ $\text{Monitoring}$ ($\text{TDM}$) $\text{of}$ $\text{Vancomycin}$ $\text{Trough}$ $\text{Levels}$**.",
                    "D. $\text{Serum}$ $\text{Lipase}$ $\text{levels}$.",
                    "E. $\text{INR}$ $\text{monitoring}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "**$\text{Vancomycin}$** requires **$\text{TDM}$** ($\text{monitoring}$ $\text{trough}$ $\text{levels}$) to ensure adequate drug concentration for efficacy while minimizing the risk of nephrotoxicity. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "TDM",
                    "Vancomycin"
                ]
            },
            {
                "id": 1638,
                "question": "A patient's blood culture grows $\text{Staphylococcus}$ $\text{aureus}$, which is sensitive to $\text{Cefazolin}$ and $\text{Vancomycin}$. The patient is currently on $\text{empiric}$ $\text{Cefazolin}$ and $\text{Gentamicin}$. What is the appropriate next step for the antibiotic regimen?",
                "choices": [
                    "A. $\text{Add}$ $\text{Vancomycin}$ $\text{for}$ $\text{synergy}$.",
                    "B. **$\text{De}$-escalate $\text{to}$ $\text{Cefazolin}$ $\text{monotherapy}$**.",
                    "C. $\text{Continue}$ $\text{Cefazolin}$ $\text{and}$ $\text{Gentamicin}$ $\text{combination}$.",
                    "D. $\text{Switch}$ $\text{to}$ $\text{Vancomycin}$ $\text{monotherapy}$.",
                    "E. $\text{Stop}$ $\text{all}$ $\text{antibiotics}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Once definitive culture and sensitivity results are available, the empiric broad-spectrum therapy should be narrowed to a definitive, less toxic, and often single agent. This is called **$\text{De}$-escalation**. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "de_escalation",
                    "definitive_therapy"
                ]
            },
            {
                "id": 1639,
                "question": "A patient is prescribed high-dose $\text{Penicillin}$ for $10$ days. Which potential $\text{CNS}$ side effect should the clinician monitor for, especially in the setting of $\text{renal}$ $\text{failure}$?",
                "choices": [
                    "A. $\text{Peripheral}$ $\text{neuropathy}$.",
                    "B. $\text{Optic}$ $\text{neuritis}$.",
                    "C. $\text{Vestibular}$ $\text{toxicity}$.",
                    "D. **$\text{Seizures}$**.",
                    "E. $\text{Hypoglycemia}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "High doses of $\text{Penicillin}$ ($\text{B}$-lactam) antibiotics, particularly in patients with $\text{renal}$ $\text{failure}$ where clearance is reduced, can accumulate in the $\text{CNS}$ and cause **$\text{seizures}$** or encephalopathy. (p. 275)",
                "tags": [
                    "antimicrobial_regimen",
                    "side_effects",
                    "Penicillin"
                ]
            },
            {
                "id": 1640,
                "question": "The definitive diagnosis of a bacterial infection typically requires the performance of:",
                "choices": [
                    "A. $\text{CBC}$ $\text{and}$ $\text{CRP}$ $\text{measurement}$.",
                    "B. $\text{Imaging}$ ($\text{X-ray}$ $\text{or}$ $\text{CT}$ $\text{scan}$).",
                    "C. $\text{Therapeutic}$ $\text{drug}$ $\text{monitoring}$ ($\text{TDM}$).",
                    "D. **$\text{Culture}$ $\text{and}$ $\text{sensitivity}$ $\text{testing}$**.",
                    "E. $\text{A}$ $\text{trial}$ $\text{of}$ $\text{empiric}$ $\text{therapy}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "The definitive diagnosis and guidance for therapy rely on identifying the organism and its sensitivity patterns via **$\text{culture}$ $\text{and}$ $\text{sensitivity}$ $\text{testing}$**. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "diagnosis",
                    "culture"
                ]
            },
            {
                "id": 1641,
                "question": "A patient is admitted with a $\text{severe}$ $\text{infection}$. Which factor mandates the use of $\text{IV}$ $\text{antibiotics}$ $\text{over}$ $\text{oral}$ $\text{route}$?",
                "choices": [
                    "A. $\text{Patient}$ $\text{compliance}$.",
                    "B. $\text{High}$ $\text{cost}$.",
                    "C. **$\text{Septic}$ $\text{shock}$ $\text{and}$ $\text{impaired}$ $\text{GI}$ $\text{absorption}$**.",
                    "D. $\text{Risk}$ $\text{of}$ $\text{GI}$ $\text{side}$ $\text{effects}$.",
                    "E. $\text{Need}$ $\text{for}$ $\text{TDM}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "In critically ill or septic shock patients, **$\text{IV}$ $\text{administration}$ $\text{is}$ $\text{mandatory}$** because of potential **$\text{impaired}$ $\text{GI}$ $\text{absorption}$ $\text{and}$ $\text{lower}$ $\text{bioavailability}$** due to poor perfusion. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "route_of_administration",
                    "sepsis"
                ]
            },
            {
                "id": 1642,
                "question": "The principle of **$\text{Step}$-down $\text{therapy}$** involves:",
                "choices": [
                    "A. $\text{Switching}$ $\text{from}$ $\text{oral}$ $\text{to}$ $\text{IV}$ $\text{route}$.",
                    "B. $\text{Switching}$ $\text{from}$ $\text{monotherapy}$ $\text{to}$ $\text{combination}$ $\text{therapy}$.",
                    "C. $\text{Switching}$ $\text{from}$ $\text{broad}$-spectrum $\text{empiric}$ $\text{to}$ $\text{narrow}$-spectrum $\text{definitive}$ $\text{therapy}$.",
                    "D. **$\text{Switching}$ $\text{from}$ $\text{IV}$ $\text{to}$ $\text{oral}$ $\text{therapy}$ $\text{on}$ $\text{clinical}$ $\text{improvement}$**.",
                    "E. $\text{Increasing}$ $\text{the}$ $\text{dose}$ $\text{of}$ $\text{the}$ $\text{initial}$ $\text{antibiotic}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "**$\text{Step}$-down $\text{therapy}$** is the practice of switching from an **$\text{IV}$ $\text{regimen}$ $\text{to}$ $\text{a}$ $\text{highly}$ $\text{bioavailable}$ $\text{oral}$ $\text{regimen}$** upon clinical improvement, leading to earlier discharge and lower costs. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "step_down_therapy"
                ]
            },
            {
                "id": 1643,
                "question": "A patient with $\text{Gram}$-negative rod bacteremia is on $\text{Gentamicin}$ therapy. Which toxicity requires concurrent monitoring of $\text{serum}$ $\text{creatinine}$?",
                "choices": [
                    "A. $\text{Hepatotoxicity}$.",
                    "B. $\text{Ototoxicity}$.",
                    "C. **$\text{Nephrotoxicity}$**.",
                    "D. $\text{Seizures}$.",
                    "E. $\text{Neurotoxicity}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Increased serum $\text{creatinine}$ is the primary indicator of $\text{Gentamicin}$-induced **$\text{nephrotoxicity}$** ($\text{renal}$ $\text{damage}$). (p. 275)",
                "tags": [
                    "antimicrobial_regimen",
                    "side_effects",
                    "aminoglycosides"
                ]
            },
            {
                "id": 1644,
                "question": "A patient with severe $\text{CAP}$ is given empiric broad-spectrum antibiotics. The patient improves clinically after $72$ hours. Which therapeutic principle should be applied next?",
                "choices": [
                    "A. $\text{Continue}$ $\text{IV}$ $\text{therapy}$ $\text{for}$ $\text{14}$ $\text{days}$.",
                    "B. $\text{Switch}$ $\text{to}$ $\text{prophylactic}$ $\text{dosing}$.",
                    "C. **$\text{Consider}$ $\text{de}$-escalation $\text{and}$ $\text{step}$-down $\text{therapy}$**.",
                    "D. $\text{Switch}$ $\text{to}$ $\text{IV}$ $\text{Vancomycin}$ $\text{for}$ $\text{MRSA}$ $\text{coverage}$.",
                    "E. $\text{Stop}$ $\text{all}$ $\text{antibiotics}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Once a patient is clinically stable, the therapy should be narrowed (de-escalation) and the route should be switched to oral if possible (**step-down $\text{therapy}$**). (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "de_escalation",
                    "step_down_therapy"
                ]
            },
            {
                "id": 1645,
                "question": "A patient with $\text{CKD}$ (Creatinine Clearance $15 \text{ ml/min}$) is prescribed $\text{Gentamicin}$. What is the key principle for dosing this drug in this patient?",
                "choices": [
                    "A. $\text{Dose}$ $\text{should}$ $\text{be}$ $\text{doubled}$.",
                    "B. $\text{Gentamicin}$ $\text{is}$ $\text{contraindicated}$ $\text{in}$ $\text{CKD}$.",
                    "C. **$\text{Dose}$ $\text{must}$ $\text{be}$ $\text{adjusted}$ ($\text{reduced}$ $\text{or}$ $\text{interval}$ $\text{increased}$) $\text{to}$ $\text{prevent}$ $\text{toxicity}$**.",
                    "D. $\text{Only}$ $\text{oral}$ $\text{Gentamicin}$ $\text{should}$ $\text{be}$ $\text{used}$.",
                    "E. $\text{No}$ $\text{dose}$ $\text{adjustment}$ $\text{is}$ $\text{needed}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "For renally excreted drugs like $\text{Gentamicin}$, **$\text{dose}$ $\text{modification}$ $\text{is}$ $\text{required}$** in patients with $\text{CKD}$ to prevent drug accumulation and toxicity (e.g., nephrotoxicity/ototoxicity). (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "renal_adjustment"
                ]
            },
            {
                "id": 1646,
                "question": "A patient with severe intra-abdominal infection is started on combination therapy ($\text{Ceftriaxone}$ and $\text{Metronidazole}$). What is the primary purpose of this combination?",
                "choices": [
                    "A. $\text{To}$ $\text{achieve}$ $\text{synergistic}$ $\text{killing}$ $\text{against}$ $\text{a}$ $\text{single}$ $\text{organism}$.",
                    "B. $\text{To}$ $\text{reduce}$ $\text{the}$ $\text{duration}$ $\text{of}$ $\text{therapy}$.",
                    "C. **$\text{To}$ $\text{broaden}$ $\text{the}$ $\text{spectrum}$ $\text{of}$ $\text{coverage}$** ($\text{Gram}$-negative $\text{and}$ $\text{anaerobes}$).",
                    "D. $\text{To}$ $\text{prevent}$ $\text{drug}$ $\text{resistance}$.",
                    "E. $\text{To}$ $\text{decrease}$ $\text{the}$ $\text{overall}$ $\text{cost}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Combination therapy is most commonly used to **$\text{broaden}$ $\text{the}$ $\text{spectrum}$** of coverage when the causative organism is unknown ($\text{empiric}$ $\text{therapy}$) or when polymicrobial infection is suspected ($\text{e.g}$., $\text{intra}$-abdominal $\text{infection}$). (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "combination_therapy"
                ]
            },
            {
                "id": 1647,
                "question": "A patient is on $\text{Vancomycin}$ therapy for $\text{MRSA}$ bacteremia. Which monitoring is mandatory to ensure safety and efficacy?",
                "choices": [
                    "A. $\text{Serum}$ $\text{Glucose}$ $\text{levels}$.",
                    "B. $\text{Serum}$ $\text{Calcium}$ $\text{levels}$.",
                    "C. **$\text{Therapeutic}$ $\text{Drug}$ $\text{Monitoring}$ ($\text{TDM}$) $\text{of}$ $\text{Vancomycin}$ $\text{Trough}$ $\text{Levels}$**.",
                    "D. $\text{Serum}$ $\text{Lipase}$ $\text{levels}$.",
                    "E. $\text{INR}$ $\text{monitoring}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "**$\text{Vancomycin}$** requires **$\text{TDM}$** ($\text{monitoring}$ $\text{trough}$ $\text{levels}$) to ensure adequate drug concentration for efficacy while minimizing the risk of nephrotoxicity. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "TDM",
                    "Vancomycin"
                ]
            },
            {
                "id": 1648,
                "question": "A patient's blood culture grows $\text{Staphylococcus}$ $\text{aureus}$, which is sensitive to $\text{Cefazolin}$ and $\text{Vancomycin}$. The patient is currently on $\text{empiric}$ $\text{Cefazolin}$ and $\text{Gentamicin}$. What is the appropriate next step for the antibiotic regimen?",
                "choices": [
                    "A. $\text{Add}$ $\text{Vancomycin}$ $\text{for}$ $\text{synergy}$.",
                    "B. **$\text{De}$-escalate $\text{to}$ $\text{Cefazolin}$ $\text{monotherapy}$**.",
                    "C. $\text{Continue}$ $\text{Cefazolin}$ $\text{and}$ $\text{Gentamicin}$ $\text{combination}$.",
                    "D. $\text{Switch}$ $\text{to}$ $\text{Vancomycin}$ $\text{monotherapy}$.",
                    "E. $\text{Stop}$ $\text{all}$ $\text{antibiotics}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Once definitive culture and sensitivity results are available, the empiric broad-spectrum therapy should be narrowed to a definitive, less toxic, and often single agent. This is called **$\text{De}$-escalation**. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "de_escalation",
                    "definitive_therapy"
                ]
            },
            {
                "id": 1649,
                "question": "A patient is prescribed high-dose $\text{Penicillin}$ for $10$ days. Which potential $\text{CNS}$ side effect should the clinician monitor for, especially in the setting of $\text{renal}$ $\text{failure}$?",
                "choices": [
                    "A. $\text{Peripheral}$ $\text{neuropathy}$.",
                    "B. $\text{Optic}$ $\text{neuritis}$.",
                    "C. $\text{Vestibular}$ $\text{toxicity}$.",
                    "D. **$\text{Seizures}$**.",
                    "E. $\text{Hypoglycemia}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "High doses of $\text{Penicillin}$ ($\text{B}$-lactam) antibiotics, particularly in patients with $\text{renal}$ $\text{failure}$ where clearance is reduced, can accumulate in the $\text{CNS}$ and cause **$\text{seizures}$** or encephalopathy. (p. 275)",
                "tags": [
                    "antimicrobial_regimen",
                    "side_effects",
                    "Penicillin"
                ]
            },
            {
                "id": 1650,
                "question": "The definitive diagnosis of a bacterial infection typically requires the performance of:",
                "choices": [
                    "A. $\text{CBC}$ $\text{and}$ $\text{CRP}$ $\text{measurement}$.",
                    "B. $\text{Imaging}$ ($\text{X-ray}$ $\text{or}$ $\text{CT}$ $\text{scan}$).",
                    "C. $\text{Therapeutic}$ $\text{drug}$ $\text{monitoring}$ ($\text{TDM}$).",
                    "D. **$\text{Culture}$ $\text{and}$ $\text{sensitivity}$ $\text{testing}$**.",
                    "E. $\text{A}$ $\text{trial}$ $\text{of}$ $\text{empiric}$ $\text{therapy}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "The definitive diagnosis and guidance for therapy rely on identifying the organism and its sensitivity patterns via **$\text{culture}$ $\text{and}$ $\text{sensitivity}$ $\text{testing}$**. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "diagnosis",
                    "culture"
                ]
            },
            {
                "id": 1651,
                "question": "A patient is admitted with a $\text{severe}$ $\text{infection}$. Which factor mandates the use of $\text{IV}$ $\text{antibiotics}$ $\text{over}$ $\text{oral}$ $\text{route}$?",
                "choices": [
                    "A. $\text{Patient}$ $\text{compliance}$.",
                    "B. $\text{High}$ $\text{cost}$.",
                    "C. **$\text{Septic}$ $\text{shock}$ $\text{and}$ $\text{impaired}$ $\text{GI}$ $\text{absorption}$**.",
                    "D. $\text{Risk}$ $\text{of}$ $\text{GI}$ $\text{side}$ $\text{effects}$.",
                    "E. $\text{Need}$ $\text{for}$ $\text{TDM}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "In critically ill or septic shock patients, **$\text{IV}$ $\text{administration}$ $\text{is}$ $\text{mandatory}$** because of potential **$\text{impaired}$ $\text{GI}$ $\text{absorption}$ $\text{and}$ $\text{lower}$ $\text{bioavailability}$** due to poor perfusion. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "route_of_administration",
                    "sepsis"
                ]
            },
            {
                "id": 1652,
                "question": "The principle of **$\text{Step}$-down $\text{therapy}$** involves:",
                "choices": [
                    "A. $\text{Switching}$ $\text{from}$ $\text{oral}$ $\text{to}$ $\text{IV}$ $\text{route}$.",
                    "B. $\text{Switching}$ $\text{from}$ $\text{monotherapy}$ $\text{to}$ $\text{combination}$ $\text{therapy}$.",
                    "C. $\text{Switching}$ $\text{from}$ $\text{broad}$-spectrum $\text{empiric}$ $\text{to}$ $\text{narrow}$-spectrum $\text{definitive}$ $\text{therapy}$.",
                    "D. **$\text{Switching}$ $\text{from}$ $\text{IV}$ $\text{to}$ $\text{oral}$ $\text{therapy}$ $\text{on}$ $\text{clinical}$ $\text{improvement}$**.",
                    "E. $\text{Increasing}$ $\text{the}$ $\text{dose}$ $\text{of}$ $\text{the}$ $\text{initial}$ $\text{antibiotic}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "**$\text{Step}$-down $\text{therapy}$** is the practice of switching from an **$\text{IV}$ $\text{regimen}$ $\text{to}$ $\text{a}$ $\text{highly}$ $\text{bioavailable}$ $\text{oral}$ $\text{regimen}$** upon clinical improvement, leading to earlier discharge and lower costs. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "step_down_therapy"
                ]
            },
            {
                "id": 1653,
                "question": "A patient with $\text{Gram}$-negative rod bacteremia is on $\text{Gentamicin}$ therapy. Which toxicity requires concurrent monitoring of $\text{serum}$ $\text{creatinine}$?",
                "choices": [
                    "A. $\text{Hepatotoxicity}$.",
                    "B. $\text{Ototoxicity}$.",
                    "C. **$\text{Nephrotoxicity}$**.",
                    "D. $\text{Seizures}$.",
                    "E. $\text{Neurotoxicity}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Increased serum $\text{creatinine}$ is the primary indicator of $\text{Gentamicin}$-induced **$\text{nephrotoxicity}$** ($\text{renal}$ $\text{damage}$). (p. 275)",
                "tags": [
                    "antimicrobial_regimen",
                    "side_effects",
                    "aminoglycosides"
                ]
            },
            {
                "id": 1654,
                "question": "A patient with severe $\text{CAP}$ is given empiric broad-spectrum antibiotics. The patient improves clinically after $72$ hours. Which therapeutic principle should be applied next?",
                "choices": [
                    "A. $\text{Continue}$ $\text{IV}$ $\text{therapy}$ $\text{for}$ $\text{14}$ $\text{days}$.",
                    "B. $\text{Switch}$ $\text{to}$ $\text{prophylactic}$ $\text{dosing}$.",
                    "C. **$\text{Consider}$ $\text{de}$-escalation $\text{and}$ $\text{step}$-down $\text{therapy}$**.",
                    "D. $\text{Switch}$ $\text{to}$ $\text{IV}$ $\text{Vancomycin}$ $\text{for}$ $\text{MRSA}$ $\text{coverage}$.",
                    "E. $\text{Stop}$ $\text{all}$ $\text{antibiotics}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Once a patient is clinically stable, the therapy should be narrowed (de-escalation) and the route should be switched to oral if possible (**step-down $\text{therapy}$**). (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "de_escalation",
                    "step_down_therapy"
                ]
            },
            {
                "id": 1655,
                "question": "A patient with $\text{CKD}$ (Creatinine Clearance $15 \text{ ml/min}$) is prescribed $\text{Gentamicin}$. What is the key principle for dosing this drug in this patient?",
                "choices": [
                    "A. $\text{Dose}$ $\text{should}$ $\text{be}$ $\text{doubled}$.",
                    "B. $\text{Gentamicin}$ $\text{is}$ $\text{contraindicated}$ $\text{in}$ $\text{CKD}$.",
                    "C. **$\text{Dose}$ $\text{must}$ $\text{be}$ $\text{adjusted}$ ($\text{reduced}$ $\text{or}$ $\text{interval}$ $\text{increased}$) $\text{to}$ $\text{prevent}$ $\text{toxicity}$**.",
                    "D. $\text{Only}$ $\text{oral}$ $\text{Gentamicin}$ $\text{should}$ $\text{be}$ $\text{used}$.",
                    "E. $\text{No}$ $\text{dose}$ $\text{adjustment}$ $\text{is}$ $\text{needed}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "For renally excreted drugs like $\text{Gentamicin}$, **$\text{dose}$ $\text{modification}$ $\text{is}$ $\text{required}$** in patients with $\text{CKD}$ to prevent drug accumulation and toxicity (e.g., nephrotoxicity/ototoxicity). (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "renal_adjustment"
                ]
            },
            {
                "id": 1656,
                "question": "A patient with severe intra-abdominal infection is started on combination therapy ($\text{Ceftriaxone}$ and $\text{Metronidazole}$). What is the primary purpose of this combination?",
                "choices": [
                    "A. $\text{To}$ $\text{achieve}$ $\text{synergistic}$ $\text{killing}$ $\text{against}$ $\text{a}$ $\text{single}$ $\text{organism}$.",
                    "B. $\text{To}$ $\text{reduce}$ $\text{the}$ $\text{duration}$ $\text{of}$ $\text{therapy}$.",
                    "C. **$\text{To}$ $\text{broaden}$ $\text{the}$ $\text{spectrum}$ $\text{of}$ $\text{coverage}$** ($\text{Gram}$-negative $\text{and}$ $\text{anaerobes}$).",
                    "D. $\text{To}$ $\text{prevent}$ $\text{drug}$ $\text{resistance}$.",
                    "E. $\text{To}$ $\text{decrease}$ $\text{the}$ $\text{overall}$ $\text{cost}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Combination therapy is most commonly used to **$\text{broaden}$ $\text{the}$ $\text{spectrum}$** of coverage when the causative organism is unknown ($\text{empiric}$ $\text{therapy}$) or when polymicrobial infection is suspected ($\text{e.g}$., $\text{intra}$-abdominal $\text{infection}$). (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "combination_therapy"
                ]
            },
            {
                "id": 1657,
                "question": "A patient is on $\text{Vancomycin}$ therapy for $\text{MRSA}$ bacteremia. Which monitoring is mandatory to ensure safety and efficacy?",
                "choices": [
                    "A. $\text{Serum}$ $\text{Glucose}$ $\text{levels}$.",
                    "B. $\text{Serum}$ $\text{Calcium}$ $\text{levels}$.",
                    "C. **$\text{Therapeutic}$ $\text{Drug}$ $\text{Monitoring}$ ($\text{TDM}$) $\text{of}$ $\text{Vancomycin}$ $\text{Trough}$ $\text{Levels}$**.",
                    "D. $\text{Serum}$ $\text{Lipase}$ $\text{levels}$.",
                    "E. $\text{INR}$ $\text{monitoring}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "**$\text{Vancomycin}$** requires **$\text{TDM}$** ($\text{monitoring}$ $\text{trough}$ $\text{levels}$) to ensure adequate drug concentration for efficacy while minimizing the risk of nephrotoxicity. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "TDM",
                    "Vancomycin"
                ]
            },
            {
                "id": 1658,
                "question": "A patient's blood culture grows $\text{Staphylococcus}$ $\text{aureus}$, which is sensitive to $\text{Cefazolin}$ and $\text{Vancomycin}$. The patient is currently on $\text{empiric}$ $\text{Cefazolin}$ and $\text{Gentamicin}$. What is the appropriate next step for the antibiotic regimen?",
                "choices": [
                    "A. $\text{Add}$ $\text{Vancomycin}$ $\text{for}$ $\text{synergy}$.",
                    "B. **$\text{De}$-escalate $\text{to}$ $\text{Cefazolin}$ $\text{monotherapy}$**.",
                    "C. $\text{Continue}$ $\text{Cefazolin}$ $\text{and}$ $\text{Gentamicin}$ $\text{combination}$.",
                    "D. $\text{Switch}$ $\text{to}$ $\text{Vancomycin}$ $\text{monotherapy}$.",
                    "E. $\text{Stop}$ $\text{all}$ $\text{antibiotics}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "Once definitive culture and sensitivity results are available, the empiric broad-spectrum therapy should be narrowed to a definitive, less toxic, and often single agent. This is called **$\text{De}$-escalation**. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "de_escalation",
                    "definitive_therapy"
                ]
            },
            {
                "id": 1659,
                "question": "A patient is prescribed high-dose $\text{Penicillin}$ for $10$ days. Which potential $\text{CNS}$ side effect should the clinician monitor for, especially in the setting of $\text{renal}$ $\text{failure}$?",
                "choices": [
                    "A. $\text{Peripheral}$ $\text{neuropathy}$.",
                    "B. $\text{Optic}$ $\text{neuritis}$.",
                    "C. $\text{Vestibular}$ $\text{toxicity}$.",
                    "D. **$\text{Seizures}$**.",
                    "E. $\text{Hypoglycemia}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "High doses of $\text{Penicillin}$ ($\text{B}$-lactam) antibiotics, particularly in patients with $\text{renal}$ $\text{failure}$ where clearance is reduced, can accumulate in the $\text{CNS}$ and cause **$\text{seizures}$** or encephalopathy. (p. 275)",
                "tags": [
                    "antimicrobial_regimen",
                    "side_effects",
                    "Penicillin"
                ]
            },
            {
                "id": 1660,
                "question": "The definitive diagnosis of a bacterial infection typically requires the performance of:",
                "choices": [
                    "A. $\text{CBC}$ $\text{and}$ $\text{CRP}$ $\text{measurement}$.",
                    "B. $\text{Imaging}$ ($\text{X-ray}$ $\text{or}$ $\text{CT}$ $\text{scan}$).",
                    "C. $\text{Therapeutic}$ $\text{drug}$ $\text{monitoring}$ ($\text{TDM}$).",
                    "D. **$\text{Culture}$ $\text{and}$ $\text{sensitivity}$ $\text{testing}$**.",
                    "E. $\text{A}$ $\text{trial}$ $\text{of}$ $\text{empiric}$ $\text{therapy}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIAL REGIMEN",
                "explanation": "The definitive diagnosis and guidance for therapy rely on identifying the organism and its sensitivity patterns via **$\text{culture}$ $\text{and}$ $\text{sensitivity}$ $\text{testing}$**. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "diagnosis",
                    "culture"
                ]
            }
        ],
        "Chapter 8.2 PRINCIPLES OF ANTIMICROBIEN REGIMEN": [
            {
                "id": 1622,
                "question": "A patient with $\text{severe}$ $\text{sepsis}$ is given empiric broad-spectrum antibiotics. The general principle for the duration of therapy in most bacterial infections is:",
                "choices": [
                    "A. $\text{A}$ $\text{minimum}$ $\text{of}$ $\text{14}$ $\text{days}$.",
                    "B. $\text{Continue}$ $\text{until}$ $\text{symptoms}$ $\text{fully}$ $\text{resolve}$ $\text{for}$ $\text{7}$ $\text{days}$.",
                    "C. **$\text{7-14}$ $\text{days}$, $\text{adjusted}$ $\text{based}$ $\text{on}$ $\text{clinical}$ $\text{response}$ $\text{and}$ $\text{type}$ $\text{of}$ $\text{infection}$.**",
                    "D. $\text{3}$ $\text{days}$ $\text{post}$-fever $\text{resolution}$.",
                    "E. $\text{3}$ $\text{months}$ $\text{for}$ $\text{all}$ $\text{systemic}$ $\text{infections}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIEN REGIMEN",
                "explanation": "The typical duration of therapy for most bacterial infections is **$7-14$ $\text{days}$**, but this must be **individualized** based on the type of infection and the patient's clinical response. (p. 274)",
                "tags": [
                    "antimicrobial_regimen",
                    "duration_of_therapy"
                ]
            },
            {
                "id": 1623,
                "question": "A patient is on $\text{oral}$ $\text{Ciprofloxacin}$ for complicated urinary tract infection ($\text{UTI}$). What is a crucial $\text{patient}$ $\text{education}$ point regarding drug interaction?",
                "choices": [
                    "A. $\text{Avoid}$ $\text{all}$ $\text{alcohol}$ $\text{consumption}$.",
                    "B. $\text{Avoid}$ $\text{sun}$ $\text{exposure}$ $\text{due}$ $\text{to}$ $\text{risk}$ $\text{of}$ $\text{seizures}$.",
                    "C. **$\text{Avoid}$ $\text{co}$-administration $\text{with}$ $\text{milk}$ $\text{and}$ $\text{antacids}$.**",
                    "D. $\text{Monitor}$ $\text{for}$ $\text{hearing}$ $\text{loss}$.",
                    "E. $\text{Increase}$ $\text{potassium}$-rich $\text{foods}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.2 PRINCIPLES OF ANTIMICROBIEN REGIMEN",
                "explanation": "Fluoroquinolones (e.g., Ciprofloxacin) chelate with **$\text{divalent}$ $\text{cations}$** ($\text{Calcium}$, $\text{Magnesium}$, $\text{Iron}$) found in **milk, dairy products, and antacids**, leading to **impaired absorption**. (p. 275)",
                "tags": [
                    "antimicrobial_regimen",
                    "drug_interaction",
                    "Ciprofloxacin"
                ]
            }
        ]
    },
    "Chapter 8.3": {
        "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)": [
            {
                "id": 1661,
                "question": "A 30-year-old patient is newly diagnosed with $\text{HIV}$ infection. He is asymptomatic and his $\text{CD4}$ count is $550 \text{ cells}/mu l$. According to current guidelines, what is the recommended management regarding $\text{ART}$?",
                "choices": [
                    "A. $\text{Defer}$ $\text{ART}$ $\text{until}$ $\text{CD4}$ $\text{count}$ $\text{drops}$ $\text{below}$ $200 \text{ cells}/mu l$.",
                    "B. $\text{Defer}$ $\text{ART}$ $\text{until}$ $\text{CD4}$ $\text{count}$ $\text{drops}$ $\text{below}$ $350 \text{ cells}/mu l$.",
                    "C. **$\text{Initiate}$ $\text{ART}$ $\text{immediately}$, $\text{regardless}$ $\text{of}$ $\text{CD4}$ $\text{count}$**.",
                    "D. $\text{Initiate}$ $\text{ART}$ $\text{only}$ $\text{if}$ $\text{viral}$ $\text{load}$ $\text{is}$ $\text{very}$ $\text{high}$.",
                    "E. $\text{Start}$ $\text{only}$ $\text{prophylaxis}$ $\text{for}$ $\text{OIs}$ $\text{($\text{PCP}$)} \text{.$"
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "Current $\text{WHO}$ and $\text{Ethiopian}$ guidelines recommend that $\text{ART}$ should be **$\text{initiated}$ $\text{in}$ $\text{all}$ $\text{people}$ $\text{with}$ $\text{HIV}$ $\text{regardless}$ $\text{of}$ $\text{CD4}$ $\text{count}$** or $\text{WHO}$ clinical stage (Treat All). (p. 276)",
                "tags": [
                    "HIV",
                    "ART_initiation",
                    "treat_all"
                ]
            },
            {
                "id": 1662,
                "question": "A patient with $\text{HIV}$ is due to start $\text{First}$-$\text{Line}$ $\text{ART}$. Which drug combination is generally considered the preferred $\text{First}$-$\text{Line}$ $\text{Regimen}$?",
                "choices": [
                    "A. $\text{Zidovudine}$ ($\text{AZT}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Efavirenz}$ ($\text{EFV}$).",
                    "B. $\text{Tenofovir}$ ($\text{TDF}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Lopinavir/Ritonavir}$ ($\text{LPV/r}$).",
                    "C. **$\text{Tenofovir}$ ($\text{TDF}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Dolutegravir}$ ($\text{DTG}$).**",
                    "D. $\text{Abacavir}$ ($\text{ABC}$), $\text{Didanosine}$ ($\text{ddI}$), $\text{and}$ $\text{Efavirenz}$ ($\text{EFV}$).",
                    "E. $\text{Nevirapine}$ ($\text{NVP}$) $\text{and}$ $\text{Zidovudine}$ ($\text{AZT}$) $\text{monotherapy}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The preferred $\text{First}$-$\text{Line}$ $\text{ART}$ $\text{Regimen}$ is **$\text{TDF}$ $\text{+} \text{ 3TC}$ $\text{+} \text{ DTG}$** ($\text{or}$ $\text{FTC}$ $\text{instead}$ $\text{of}$ $\text{3TC}$), replacing $\text{EFV}$ where possible, due to better tolerability and efficacy. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_regimen",
                    "first_line"
                ]
            },
            {
                "id": 1663,
                "question": "A patient on $\text{First}$-$\text{Line}$ $\text{ART}$ is monitored with a $\text{Viral}$ $\text{Load}$ ($\text{VL}$) test at $6$ months. What $\text{VL}$ value is generally considered successful virologic suppression?",
                "choices": [
                    "A. $\text{VL} <1,000 \text{ copies/ml}$.",
                    "B. $\text{VL} <500 \text{ copies/ml}$.",
                    "C. **$\text{VL} <50 \text{ copies/ml}$ ($\text{Undetectable}$) $\text{is}$ $\text{the}$ $\text{goal}$**.",
                    "D. $\text{VL}$ $\text{decrease}$ $\text{by}$ $50%$ $\text{from}$ $\text{baseline}$.",
                    "E. $\text{VL} <10,000 \text{ copies/ml}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The goal of $\text{ART}$ is to achieve **$\text{Undetectable}$ $\text{Viral}$ $\text{Load}$** ($\text{VL} <50 \text{ copies}/\text{ml}$). $\text{VL} <1000 \text{ copies}/\text{ml}$ is generally considered successful virologic suppression in resource-limited settings. However, **undetectable** is the ultimate goal. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_monitoring",
                    "virologic_suppression"
                ]
            },
            {
                "id": 1664,
                "question": "A patient on $\text{TDF/3TC/EFV}$ regimen has a sustained $\text{VL}$ of $5,000 \text{ copies}/\text{ml}$ at $12$ and $18$ months. What is the most appropriate step in management?",
                "choices": [
                    "A. $\text{Counseling}$ $\text{and}$ $\text{continue}$ $\text{First}$-$\text{Line}$.",
                    "B. $\text{Add}$ $\text{an}$ $\text{additional}$ $\text{drug}$ $\text{to}$ $\text{the}$ $\text{current}$ $\text{regimen}$.",
                    "C. **$\text{Switch}$ $\text{to}$ $\text{a}$ $\text{Second}$-$\text{Line}$ $\text{ART}$ $\text{regimen}$**.",
                    "D. $\text{Increase}$ $\text{the}$ $\text{dose}$ $\text{of}$ $\text{EFV}$.",
                    "E. $\text{Stop}$ $\text{ART}$ $\text{and}$ $\text{re}$-start $\text{after}$ $\text{a}$ $\text{drug}$ $\text{holiday}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**Virologic $\text{failure}$** is defined by a sustained $\text{VL} ge 1,000 \text{ copies}/\text{ml}$ despite adherence. After adherence counseling, the patient must be **$\text{switched}$ $\text{to}$ $\text{a}$ $\text{Second}$-$\text{Line}$ $\text{ART}$ $\text{regimen}$**. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_failure",
                    "management"
                ]
            },
            {
                "id": 1665,
                "question": "A patient is on $\text{ART}$. Which laboratory test is the **most effective** way to monitor the long-term efficacy of $\text{ART}$?",
                "choices": [
                    "A. $\text{Complete}$ $\text{Blood}$ $\text{Count}$ ($\text{CBC}$).",
                    "B. $\text{Liver}$ $\text{Function}$ $\text{Tests}$ ($\text{LFTs}$).",
                    "C. **$\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{measurement}$**.",
                    "D. $\text{CD4}$ $\text{count}$ $\text{monitoring}$.",
                    "E. $\text{Serum}$ $\text{Creatinine}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "While $\text{CD4}$ is an important measure of $\text{immune}$ $\text{restoration}$, the **$\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{measurement}$** is the **most $\text{effective}$** method to directly assess the efficacy of $\text{ART}$ in suppressing $\text{HIV}$ replication. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_monitoring",
                    "viral_load"
                ]
            },
            {
                "id": 1666,
                "question": "A patient with $\text{HIV}$ and a $\text{CD4}$ count of $150 \text{ cells}/mu l$ is diagnosed with presumptive $\text{Pneumocystis}$ $\text{Jirovecii}$ $\text{Pneumonia}$ ($\text{PJP}$). What is the necessary prophylactic intervention that should have been started at this $\text{CD4}$ level?",
                "choices": [
                    "A. $\text{Isoniazid}$ $\text{Preventive}$ $\text{Therapy}$ ($\text{IPT}$).",
                    "B. $\text{Fluconazole}$ $\text{prophylaxis}$.",
                    "C. $\text{Acyclovir}$ $\text{prophylaxis}$.",
                    "D. **$\text{Co}$-$\text{trimoxazole}$ $\text{Preventive}$ $\text{Therapy}$ ($\text{CPT}$).**",
                    "E. $\text{Azithromycin}$ $\text{prophylaxis}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**$\text{Co}$-$\text{trimoxazole}$ $\text{Preventive}$ $\text{Therapy}$ ($\text{CPT}$)** is initiated when the $\text{CD4}$ $\text{count}$ $\text{drops}$ $\text{below}$ $200 \text{ cells}/mu l$ to prevent $\text{PJP}$ and other bacterial infections. (p. 276)",
                "tags": [
                    "HIV",
                    "OIs_prophylaxis",
                    "CD4_threshold"
                ]
            },
            {
                "id": 1667,
                "question": "A patient is on $\text{First}$-$\text{Line}$ $\text{ART}$ ($\text{TDF/3TC/DTG}$). Which drug toxicity is a major concern when using $\text{Tenofovir}$ ($\text{TDF}$)?",
                "choices": [
                    "A. $\text{Hepatotoxicity}$.",
                    "B. $\text{Bone}$ $\text{marrow}$ $\text{suppression}$.",
                    "C. **$\text{Renal}$ $\text{toxicity}$ $\text{and}$ $\text{bone}$ $\text{demineralization}$.**",
                    "D. $\text{Peripheral}$ $\text{neuropathy}$.",
                    "E. $\text{Central}$ $\text{nervous}$ $\text{system}$ $\text{side}$ $\text{effects}$ ($\text{e.g}$., $\text{dreams}$)."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**$\text{Tenofovir}$ ($\text{TDF}$)** is associated with dose-related **$\text{renal}$ $\text{toxicity}$** ($\text{Fanconi}$ $\text{syndrome}$) and a decrease in $\text{Bone}$ $\text{Mineral}$ $\text{Density}$ ($\text{bone}$ $\text{demineralization}$). (p. 277)",
                "tags": [
                    "HIV",
                    "ART_toxicity",
                    "TDF"
                ]
            },
            {
                "id": 1668,
                "question": "A patient on $\text{ART}$ experiences $\text{severe}$ $\text{hyperpigmentation}$ of the palms and soles. Which $\text{NRTI}$ component of $\text{ART}$ is the most likely cause?",
                "choices": [
                    "A. $\text{Tenofovir}$ ($\text{TDF}$).",
                    "B. **$\text{Zidovudine}$ ($\text{AZT}$) $\text{or}$ $\text{AZT}$-containing $\text{regimens}$**.",
                    "C. $\text{Lamivudine}$ ($\text{3TC}$).",
                    "D. $\text{Abacavir}$ ($\text{ABC}$).",
                    "E. $\text{Efavirenz}$ ($\text{EFV}$)."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "A key side effect of **$\text{Zidovudine}$ ($\text{AZT}$)** is $\text{Bone}$ $\text{Marrow}$ $\text{Suppression}$ ($\text{anemia}$) $\text{and}$ **$\text{hyperpigmentation}$ $\text{of}$ $\text{nails}$ $\text{and}$ $\text{skin}$** ($\text{especially}$ $\text{palms}$ $\text{and}$ $\text{soles}$). (p. 277)",
                "tags": [
                    "HIV",
                    "ART_toxicity",
                    "AZT"
                ]
            },
            {
                "id": 1669,
                "question": "A patient with $\text{WHO}$ clinical stage $\text{IV}$ $\text{disease}$ is newly diagnosed with $\text{HIV}$. What is the recommended management regarding $\text{ART}$?",
                "choices": [
                    "A. $\text{Defer}$ $\text{ART}$ $\text{until}$ $\text{all}$ $\text{OIs}$ $\text{are}$ $\text{treated}$.",
                    "B. $\text{Defer}$ $\text{ART}$ $\text{until}$ $\text{VL}$ $\text{is}$ $\text{available}$.",
                    "C. **$\text{Initiate}$ $\text{ART}$ $\text{immediately}$ $\text{along}$ $\text{with}$ $\text{OI}$ $\text{treatment}$**.",
                    "D. $\text{Start}$ $\text{ART}$ $\text{with}$ $\text{monotherapy}$ $\text{to}$ $\text{reduce}$ $\text{side}$ $\text{effects}$.",
                    "E. $\text{Start}$ $\text{ART}$ $\text{only}$ $\text{if}$ $\text{CD4}$ $\text{is}$ $\text{below}$ $200 \text{ cells}/mu l$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The $\text{Treat}$ $\text{All}$ policy dictates **$\text{immediate}$ $\text{ART}$ $\text{initiation}$** regardless of $\text{CD4}$ $\text{count}$ or $\text{WHO}$ stage. In the presence of $\text{OIs}$, $\text{ART}$ is started along with $\text{OI}$ $\text{treatment}$. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_initiation",
                    "WHO_stage"
                ]
            },
            {
                "id": 1670,
                "question": "A patient on $\text{TDF/3TC/EFV}$ regimen has a sustained $\text{VL}$ of $5,000 \text{ copies}/\text{ml}$ at $12$ and $18$ months. What is the definition of this condition?",
                "choices": [
                    "A. $\text{Immunological}$ $\text{failure}$.",
                    "B. **$\text{Virologic}$ $\text{failure}$**.",
                    "C. $\text{Clinical}$ $\text{failure}$.",
                    "D. $\text{Treatment}$ $\text{success}$.",
                    "E. $\text{Drug}$ $\text{resistance}$ $\text{only}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**$\text{Virologic}$ $\text{failure}$** is defined by a sustained $\text{VL} ge 1,000 \text{ copies}/\text{ml}$ despite adherence to $\text{ART}$. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_failure",
                    "definition"
                ]
            },
            {
                "id": 1671,
                "question": "The definitive diagnosis and staging of $\text{HIV}$ infection should be followed by $\text{ART}$ initiation. What is the general principle regarding the timing of $\text{ART}$ initiation in all $\text{HIV}$ $\text{patients}$?",
                "choices": [
                    "A. $\text{Start}$ $\text{ART}$ $\text{only}$ $\text{if}$ $\text{CD4}$ $\text{count}$ $\text{is}$ $\text{below}$ $200 \text{ cells}/mu l$.",
                    "B. $\text{Start}$ $\text{ART}$ $\text{only}$ $\text{if}$ $\text{WHO}$ $\text{stage}$ $\text{is}$ $\text{III}$ $\text{or}$ $\text{IV}$.",
                    "C. **$\text{Initiate}$ $\text{ART}$ $\text{immediately}$, $\text{regardless}$ $\text{of}$ $\text{CD4}$ $\text{count}$**.",
                    "D. $\text{Wait}$ $\text{for}$ $\text{CD4}$ $\text{count}$ $\text{to}$ $\text{normalize}$ $\text{before}$ $\text{starting}$.",
                    "E. $\text{Wait}$ $\text{6}$ $\text{months}$ $\text{post}$-diagnosis $\text{to}$ $\text{ensure}$ $\text{adherence}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The **$\text{Treat}$ $\text{All}$** policy recommends **$\text{immediate}$ $\text{ART}$ $\text{initiation}$** regardless of $\text{CD4}$ $\text{count}$ or $\text{WHO}$ clinical stage. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_initiation",
                    "treat_all"
                ]
            },
            {
                "id": 1672,
                "question": "A patient with $\text{HIV}$ is due to start $\text{First}$-$\text{Line}$ $\text{ART}$. Which drug combination is generally considered the preferred $\text{First}$-$\text{Line}$ $\text{Regimen}$?",
                "choices": [
                    "A. $\text{Zidovudine}$ ($\text{AZT}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Efavirenz}$ ($\text{EFV}$).",
                    "B. $\text{Tenofovir}$ ($\text{TDF}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Lopinavir/Ritonavir}$ ($\text{LPV/r}$).",
                    "C. **$\text{Tenofovir}$ ($\text{TDF}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Dolutegravir}$ ($\text{DTG}$).**",
                    "D. $\text{Abacavir}$ ($\text{ABC}$), $\text{Didanosine}$ ($\text{ddI}$), $\text{and}$ $\text{Efavirenz}$ ($\text{EFV}$).",
                    "E. $\text{Nevirapine}$ ($\text{NVP}$) $\text{and}$ $\text{Zidovudine}$ ($\text{AZT}$) $\text{monotherapy}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The preferred $\text{First}$-$\text{Line}$ $\text{ART}$ $\text{Regimen}$ is **$\text{TDF}$ $\text{+} \text{ 3TC}$ $\text{+} \text{ DTG}$** ($\text{or}$ $\text{FTC}$ $\text{instead}$ $\text{of}$ $\text{3TC}$), replacing $\text{EFV}$ where possible, due to better tolerability and efficacy. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_regimen",
                    "first_line"
                ]
            },
            {
                "id": 1673,
                "question": "A patient with $\text{HIV}$ is due for a $\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{test}$ at $6$ months. What $\text{VL}$ value is generally considered successful virologic suppression?",
                "choices": [
                    "A. $\text{VL} <1,000 \text{ copies/ml}$.",
                    "B. $\text{VL} <500 \text{ copies/ml}$.",
                    "C. **$\text{VL} <50 \text{ copies/ml}$ ($\text{Undetectable}$) $\text{is}$ $\text{the}$ $\text{goal}$**.",
                    "D. $\text{VL}$ $\text{decrease}$ $\text{by}$ $50%$ $\text{from}$ $\text{baseline}$.",
                    "E. $\text{VL} <10,000 \text{ copies/ml}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The goal of $\text{ART}$ is to achieve **$\text{Undetectable}$ $\text{Viral}$ $\text{Load}$** ($\text{VL} <50 \text{ copies}/\text{ml}$). $\text{VL} <1000 \text{ copies}/\text{ml}$ is generally considered successful virologic suppression in resource-limited settings. However, **undetectable** is the ultimate goal. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_monitoring",
                    "virologic_suppression"
                ]
            },
            {
                "id": 1674,
                "question": "A patient on $\text{TDF/3TC/EFV}$ regimen has a sustained $\text{VL}$ of $5,000 \text{ copies}/\text{ml}$ at $12$ and $18$ months. What is the most appropriate step in management?",
                "choices": [
                    "A. $\text{Counseling}$ $\text{and}$ $\text{continue}$ $\text{First}$-$\text{Line}$.",
                    "B. $\text{Add}$ $\text{an}$ $\text{additional}$ $\text{drug}$ $\text{to}$ $\text{the}$ $\text{current}$ $\text{regimen}$.",
                    "C. **$\text{Switch}$ $\text{to}$ $\text{a}$ $\text{Second}$-$\text{Line}$ $\text{ART}$ $\text{regimen}$**.",
                    "D. $\text{Increase}$ $\text{the}$ $\text{dose}$ $\text{of}$ $\text{EFV}$.",
                    "E. $\text{Stop}$ $\text{ART}$ $\text{and}$ $\text{re}$-start $\text{after}$ $\text{a}$ $\text{drug}$ $\text{holiday}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**Virologic $\text{failure}$** is defined by a sustained $\text{VL} ge 1,000 \text{ copies}/\text{ml}$ despite adherence. After adherence counseling, the patient must be **$\text{switched}$ $\text{to}$ $\text{a}$ $\text{Second}$-$\text{Line}$ $\text{ART}$ $\text{regimen}$**. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_failure",
                    "management"
                ]
            },
            {
                "id": 1675,
                "question": "A patient is on $\text{ART}$. Which laboratory test is the **most effective** way to monitor the long-term efficacy of $\text{ART}$?",
                "choices": [
                    "A. $\text{Complete}$ $\text{Blood}$ $\text{Count}$ ($\text{CBC}$).",
                    "B. $\text{Liver}$ $\text{Function}$ $\text{Tests}$ ($\text{LFTs}$).",
                    "C. **$\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{measurement}$**.",
                    "D. $\text{CD4}$ $\text{count}$ $\text{monitoring}$.",
                    "E. $\text{Serum}$ $\text{Creatinine}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "While $\text{CD4}$ is an important measure of $\text{immune}$ $\text{restoration}$, the **$\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{measurement}$** is the **most $\text{effective}$** method to directly assess the efficacy of $\text{ART}$ in suppressing $\text{HIV}$ replication. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_monitoring",
                    "viral_load"
                ]
            },
            {
                "id": 1676,
                "question": "A patient with $\text{HIV}$ and a $\text{CD4}$ count of $150 \text{ cells}/mu l$ is diagnosed with presumptive $\text{PJP}$. What is the necessary prophylactic intervention that should have been started at this $\text{CD4}$ level?",
                "choices": [
                    "A. $\text{Isoniazid}$ $\text{Preventive}$ $\text{Therapy}$ ($\text{IPT}$).",
                    "B. $\text{Fluconazole}$ $\text{prophylaxis}$.",
                    "C. $\text{Acyclovir}$ $\text{prophylaxis}$.",
                    "D. **$\text{Co}$-$\text{trimoxazole}$ $\text{Preventive}$ $\text{Therapy}$ ($\text{CPT}$).**",
                    "E. $\text{Azithromycin}$ $\text{prophylaxis}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**$\text{Co}$-$\text{trimoxazole}$ $\text{Preventive}$ $\text{Therapy}$ ($\text{CPT}$)** is initiated when the $\text{CD4}$ $\text{count}$ $\text{drops}$ $\text{below}$ $200 \text{ cells}/mu l$ to prevent $\text{PJP}$ and other bacterial infections. (p. 276)",
                "tags": [
                    "HIV",
                    "OIs_prophylaxis",
                    "CD4_threshold"
                ]
            },
            {
                "id": 1677,
                "question": "A patient is on $\text{First}$-$\text{Line}$ $\text{ART}$ ($\text{TDF/3TC/DTG}$). Which drug toxicity is a major concern when using $\text{Tenofovir}$ ($\text{TDF}$)?",
                "choices": [
                    "A. $\text{Hepatotoxicity}$.",
                    "B. $\text{Bone}$ $\text{marrow}$ $\text{suppression}$.",
                    "C. **$\text{Renal}$ $\text{toxicity}$ $\text{and}$ $\text{bone}$ $\text{demineralization}$.**",
                    "D. $\text{Peripheral}$ $\text{neuropathy}$.",
                    "E. $\text{Central}$ $\text{nervous}$ $\text{system}$ $\text{side}$ $\text{effects}$ ($\text{e.g}$., $\text{dreams}$)."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**$\text{Tenofovir}$ ($\text{TDF}$)** is associated with dose-related **$\text{renal}$ $\text{toxicity}$** ($\text{Fanconi}$ $\text{syndrome}$) $\text{and}$ $\text{a}$ $\text{decrease}$ $\text{in}$ $\text{Bone}$ $\text{Mineral}$ $\text{Density}$ ($\text{bone}$ $\text{demineralization}$). (p. 277)",
                "tags": [
                    "HIV",
                    "ART_toxicity",
                    "TDF"
                ]
            },
            {
                "id": 1678,
                "question": "A patient on $\text{ART}$ experiences $\text{severe}$ $\text{hyperpigmentation}$ $\text{of}$ $\text{the}$ $\text{palms}$ $\text{and}$ $\text{soles}$. Which $\text{NRTI}$ component of $\text{ART}$ is the most likely cause?",
                "choices": [
                    "A. $\text{Tenofovir}$ ($\text{TDF}$).",
                    "B. **$\text{Zidovudine}$ ($\text{AZT}$) $\text{or}$ $\text{AZT}$-containing $\text{regimens}$**.",
                    "C. $\text{Lamivudine}$ ($\text{3TC}$).",
                    "D. $\text{Abacavir}$ ($\text{ABC}$).",
                    "E. $\text{Efavirenz}$ ($\text{EFV}$)."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "A key side effect of **$\text{Zidovudine}$ ($\text{AZT}$)** is $\text{Bone}$ $\text{Marrow}$ $\text{Suppression}$ ($\text{anemia}$) $\text{and}$ **$\text{hyperpigmentation}$ $\text{of}$ $\text{nails}$ $\text{and}$ $\text{skin}$** ($\text{especially}$ $\text{palms}$ $\text{and}$ $\text{soles}$). (p. 277)",
                "tags": [
                    "HIV",
                    "ART_toxicity",
                    "AZT"
                ]
            },
            {
                "id": 1679,
                "question": "A patient with $\text{WHO}$ clinical stage $\text{IV}$ $\text{disease}$ is newly diagnosed with $\text{HIV}$. What is the recommended management regarding $\text{ART}$?",
                "choices": [
                    "A. $\text{Defer}$ $\text{ART}$ $\text{until}$ $\text{all}$ $\text{OIs}$ $\text{are}$ $\text{treated}$.",
                    "B. $\text{Defer}$ $\text{ART}$ $\text{until}$ $\text{VL}$ $\text{is}$ $\text{available}$.",
                    "C. **$\text{Initiate}$ $\text{ART}$ $\text{immediately}$ $\text{along}$ $\text{with}$ $\text{OI}$ $\text{treatment}$**.",
                    "D. $\text{Start}$ $\text{ART}$ $\text{with}$ $\text{monotherapy}$ $\text{to}$ $\text{reduce}$ $\text{side}$ $\text{effects}$.",
                    "E. $\text{Start}$ $\text{ART}$ $\text{only}$ $\text{if}$ $\text{CD4}$ $\text{is}$ $\text{below}$ $200 \text{ cells}/mu l$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The $\text{Treat}$ $\text{All}$ policy dictates **$\text{immediate}$ $\text{ART}$ $\text{initiation}$** regardless of $\text{CD4}$ $\text{count}$ or $\text{WHO}$ stage. In the presence of $\text{OIs}$, $\text{ART}$ is started along with $\text{OI}$ $\text{treatment}$. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_initiation",
                    "WHO_stage"
                ]
            },
            {
                "id": 1680,
                "question": "A patient on $\text{TDF/3TC/EFV}$ regimen has a sustained $\text{VL}$ of $5,000 \text{ copies}/\text{ml}$ at $12$ and $18$ months. What is the definition of this condition?",
                "choices": [
                    "A. $\text{Immunological}$ $\text{failure}$.",
                    "B. **$\text{Virologic}$ $\text{failure}$**.",
                    "C. $\text{Clinical}$ $\text{failure}$.",
                    "D. $\text{Treatment}$ $\text{success}$.",
                    "E. $\text{Drug}$ $\text{resistance}$ $\text{only}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**$\text{Virologic}$ $\text{failure}$** is defined by a sustained $\text{VL} ge 1,000 \text{ copies}/\text{ml}$ despite adherence to $\text{ART}$. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_failure",
                    "definition"
                ]
            },
            {
                "id": 1681,
                "question": "The definitive diagnosis and staging of $\text{HIV}$ infection should be followed by $\text{ART}$ initiation. What is the general principle regarding the timing of $\text{ART}$ initiation in all $\text{HIV}$ $\text{patients}$?",
                "choices": [
                    "A. $\text{Start}$ $\text{ART}$ $\text{only}$ $\text{if}$ $\text{CD4}$ $\text{count}$ $\text{is}$ $\text{below}$ $200 \text{ cells}/mu l$.",
                    "B. $\text{Start}$ $\text{ART}$ $\text{only}$ $\text{if}$ $\text{WHO}$ $\text{stage}$ $\text{is}$ $\text{III}$ $\text{or}$ $\text{IV}$.",
                    "C. **$\text{Initiate}$ $\text{ART}$ $\text{immediately}$, $\text{regardless}$ $\text{of}$ $\text{CD4}$ $\text{count}$**.",
                    "D. $\text{Wait}$ $\text{for}$ $\text{CD4}$ $\text{count}$ $\text{to}$ $\text{normalize}$ $\text{before}$ $\text{starting}$.",
                    "E. $\text{Wait}$ $\text{6}$ $\text{months}$ $\text{post}$-diagnosis $\text{to}$ $\text{ensure}$ $\text{adherence}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The **$\text{Treat}$ $\text{All}$** policy recommends **$\text{immediate}$ $\text{ART}$ $\text{initiation}$** regardless of $\text{CD4}$ $\text{count}$ or $\text{WHO}$ clinical stage. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_initiation",
                    "treat_all"
                ]
            },
            {
                "id": 1682,
                "question": "A patient with $\text{HIV}$ is due to start $\text{First}$-$\text{Line}$ $\text{ART}$. Which drug combination is generally considered the preferred $\text{First}$-$\text{Line}$ $\text{Regimen}$?",
                "choices": [
                    "A. $\text{Zidovudine}$ ($\text{AZT}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Efavirenz}$ ($\text{EFV}$).",
                    "B. $\text{Tenofovir}$ ($\text{TDF}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Lopinavir/Ritonavir}$ ($\text{LPV/r}$).",
                    "C. **$\text{Tenofovir}$ ($\text{TDF}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Dolutegravir}$ ($\text{DTG}$).**",
                    "D. $\text{Abacavir}$ ($\text{ABC}$), $\text{Didanosine}$ ($\text{ddI}$), $\text{and}$ $\text{Efavirenz}$ ($\text{EFV}$).",
                    "E. $\text{Nevirapine}$ ($\text{NVP}$) $\text{and}$ $\text{Zidovudine}$ ($\text{AZT}$) $\text{monotherapy}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The preferred $\text{First}$-$\text{Line}$ $\text{ART}$ $\text{Regimen}$ is **$\text{TDF}$ $\text{+} \text{ 3TC}$ $\text{+} \text{ DTG}$** ($\text{or}$ $\text{FTC}$ $\text{instead}$ $\text{of}$ $\text{3TC}$), replacing $\text{EFV}$ where possible, due to better tolerability and efficacy. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_regimen",
                    "first_line"
                ]
            },
            {
                "id": 1683,
                "question": "A patient with $\text{HIV}$ is due for a $\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{test}$ at $6$ months. What $\text{VL}$ value is generally considered successful virologic suppression?",
                "choices": [
                    "A. $\text{VL} <1,000 \text{ copies/ml}$.",
                    "B. $\text{VL} <500 \text{ copies/ml}$.",
                    "C. **$\text{VL} <50 \text{ copies/ml}$ ($\text{Undetectable}$) $\text{is}$ $\text{the}$ $\text{goal}$**.",
                    "D. $\text{VL}$ $\text{decrease}$ $\text{by}$ $50%$ $\text{from}$ $\text{baseline}$.",
                    "E. $\text{VL} <10,000 \text{ copies/ml}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The goal of $\text{ART}$ is to achieve **$\text{Undetectable}$ $\text{Viral}$ $\text{Load}$** ($\text{VL} <50 \text{ copies}/\text{ml}$). $\text{VL} <1000 \text{ copies}/\text{ml}$ is generally considered successful virologic suppression in resource-limited settings. However, **undetectable** is the ultimate goal. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_monitoring",
                    "virologic_suppression"
                ]
            },
            {
                "id": 1684,
                "question": "A patient on $\text{TDF/3TC/EFV}$ regimen has a sustained $\text{VL}$ of $5,000 \text{ copies}/\text{ml}$ at $12$ and $18$ months. What is the most appropriate step in management?",
                "choices": [
                    "A. $\text{Counseling}$ $\text{and}$ $\text{continue}$ $\text{First}$-$\text{Line}$.",
                    "B. $\text{Add}$ $\text{an}$ $\text{additional}$ $\text{drug}$ $\text{to}$ $\text{the}$ $\text{current}$ $\text{regimen}$.",
                    "C. **$\text{Switch}$ $\text{to}$ $\text{a}$ $\text{Second}$-$\text{Line}$ $\text{ART}$ $\text{regimen}$**.",
                    "D. $\text{Increase}$ $\text{the}$ $\text{dose}$ $\text{of}$ $\text{EFV}$.",
                    "E. $\text{Stop}$ $\text{ART}$ $\text{and}$ $\text{re}$-start $\text{after}$ $\text{a}$ $\text{drug}$ $\text{holiday}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**Virologic $\text{failure}$** is defined by a sustained $\text{VL} ge 1,000 \text{ copies}/\text{ml}$ despite adherence. After adherence counseling, the patient must be **$\text{switched}$ $\text{to}$ $\text{a}$ $\text{Second}$-$\text{Line}$ $\text{ART}$ $\text{regimen}$**. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_failure",
                    "management"
                ]
            },
            {
                "id": 1685,
                "question": "A patient is on $\text{ART}$. Which laboratory test is the **most effective** way to monitor the long-term efficacy of $\text{ART}$?",
                "choices": [
                    "A. $\text{Complete}$ $\text{Blood}$ $\text{Count}$ ($\text{CBC}$).",
                    "B. $\text{Liver}$ $\text{Function}$ $\text{Tests}$ ($\text{LFTs}$).",
                    "C. **$\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{measurement}$**.",
                    "D. $\text{CD4}$ $\text{count}$ $\text{monitoring}$.",
                    "E. $\text{Serum}$ $\text{Creatinine}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "While $\text{CD4}$ is an important measure of $\text{immune}$ $\text{restoration}$, the **$\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{measurement}$** is the **most $\text{effective}$** method to directly assess the efficacy of $\text{ART}$ in suppressing $\text{HIV}$ replication. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_monitoring",
                    "viral_load"
                ]
            },
            {
                "id": 1686,
                "question": "A patient with $\text{HIV}$ and a $\text{CD4}$ count of $150 \text{ cells}/mu l$ is diagnosed with presumptive $\text{PJP}$. What is the necessary prophylactic intervention that should have been started at this $\text{CD4}$ level?",
                "choices": [
                    "A. $\text{Isoniazid}$ $\text{Preventive}$ $\text{Therapy}$ ($\text{IPT}$).",
                    "B. $\text{Fluconazole}$ $\text{prophylaxis}$.",
                    "C. $\text{Acyclovir}$ $\text{prophylaxis}$.",
                    "D. **$\text{Co}$-$\text{trimoxazole}$ $\text{Preventive}$ $\text{Therapy}$ ($\text{CPT}$).**",
                    "E. $\text{Azithromycin}$ $\text{prophylaxis}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**$\text{Co}$-$\text{trimoxazole}$ $\text{Preventive}$ $\text{Therapy}$ ($\text{CPT}$)** is initiated when the $\text{CD4}$ $\text{count}$ $\text{drops}$ $\text{below}$ $200 \text{ cells}/mu l$ to prevent $\text{PJP}$ and other bacterial infections. (p. 276)",
                "tags": [
                    "HIV",
                    "OIs_prophylaxis",
                    "CD4_threshold"
                ]
            },
            {
                "id": 1687,
                "question": "A patient is on $\text{First}$-$\text{Line}$ $\text{ART}$ ($\text{TDF/3TC/DTG}$). Which drug toxicity is a major concern when using $\text{Tenofovir}$ ($\text{TDF}$)?",
                "choices": [
                    "A. $\text{Hepatotoxicity}$.",
                    "B. $\text{Bone}$ $\text{marrow}$ $\text{suppression}$.",
                    "C. **$\text{Renal}$ $\text{toxicity}$ $\text{and}$ $\text{bone}$ $\text{demineralization}$.**",
                    "D. $\text{Peripheral}$ $\text{neuropathy}$.",
                    "E. $\text{Central}$ $\text{nervous}$ $\text{system}$ $\text{side}$ $\text{effects}$ ($\text{e.g}$., $\text{dreams}$)."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**$\text{Tenofovir}$ ($\text{TDF}$)** is associated with dose-related **$\text{renal}$ $\text{toxicity}$** ($\text{Fanconi}$ $\text{syndrome}$) $\text{and}$ $\text{a}$ $\text{decrease}$ $\text{in}$ $\text{Bone}$ $\text{Mineral}$ $\text{Density}$ ($\text{bone}$ $\text{demineralization}$). (p. 277)",
                "tags": [
                    "HIV",
                    "ART_toxicity",
                    "TDF"
                ]
            },
            {
                "id": 1688,
                "question": "A patient on $\text{ART}$ experiences $\text{severe}$ $\text{hyperpigmentation}$ $\text{of}$ $\text{the}$ $\text{palms}$ $\text{and}$ $\text{soles}$. Which $\text{NRTI}$ component of $\text{ART}$ is the most likely cause?",
                "choices": [
                    "A. $\text{Tenofovir}$ ($\text{TDF}$).",
                    "B. **$\text{Zidovudine}$ ($\text{AZT}$) $\text{or}$ $\text{AZT}$-containing $\text{regimens}$**.",
                    "C. $\text{Lamivudine}$ ($\text{3TC}$).",
                    "D. $\text{Abacavir}$ ($\text{ABC}$).",
                    "E. $\text{Efavirenz}$ ($\text{EFV}$)."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "A key side effect of **$\text{Zidovudine}$ ($\text{AZT}$)** is $\text{Bone}$ $\text{Marrow}$ $\text{Suppression}$ ($\text{anemia}$) $\text{and}$ **$\text{hyperpigmentation}$ $\text{of}$ $\text{nails}$ $\text{and}$ $\text{skin}$** ($\text{especially}$ $\text{palms}$ $\text{and}$ $\text{soles}$). (p. 277)",
                "tags": [
                    "HIV",
                    "ART_toxicity",
                    "AZT"
                ]
            },
            {
                "id": 1689,
                "question": "A patient with $\text{WHO}$ clinical stage $\text{IV}$ $\text{disease}$ is newly diagnosed with $\text{HIV}$. What is the recommended management regarding $\text{ART}$?",
                "choices": [
                    "A. $\text{Defer}$ $\text{ART}$ $\text{until}$ $\text{all}$ $\text{OIs}$ $\text{are}$ $\text{treated}$.",
                    "B. $\text{Defer}$ $\text{ART}$ $\text{until}$ $\text{VL}$ $\text{is}$ $\text{available}$.",
                    "C. **$\text{Initiate}$ $\text{ART}$ $\text{immediately}$ $\text{along}$ $\text{with}$ $\text{OI}$ $\text{treatment}$**.",
                    "D. $\text{Start}$ $\text{ART}$ $\text{with}$ $\text{monotherapy}$ $\text{to}$ $\text{reduce}$ $\text{side}$ $\text{effects}$.",
                    "E. $\text{Start}$ $\text{ART}$ $\text{only}$ $\text{if}$ $\text{CD4}$ $\text{is}$ $\text{below}$ $200 \text{ cells}/mu l$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The $\text{Treat}$ $\text{All}$ policy dictates **$\text{immediate}$ $\text{ART}$ $\text{initiation}$** regardless of $\text{CD4}$ $\text{count}$ or $\text{WHO}$ stage. In the presence of $\text{OIs}$, $\text{ART}$ is started along with $\text{OI}$ $\text{treatment}$. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_initiation",
                    "WHO_stage"
                ]
            },
            {
                "id": 1690,
                "question": "A patient on $\text{TDF/3TC/EFV}$ regimen has a sustained $\text{VL}$ of $5,000 \text{ copies}/\text{ml}$ at $12$ and $18$ months. What is the definition of this condition?",
                "choices": [
                    "A. $\text{Immunological}$ $\text{failure}$.",
                    "B. **$\text{Virologic}$ $\text{failure}$**.",
                    "C. $\text{Clinical}$ $\text{failure}$.",
                    "D. $\text{Treatment}$ $\text{success}$.",
                    "E. $\text{Drug}$ $\text{resistance}$ $\text{only}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**$\text{Virologic}$ $\text{failure}$** is defined by a sustained $\text{VL} ge 1,000 \text{ copies}/\text{ml}$ despite adherence to $\text{ART}$. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_failure",
                    "definition"
                ]
            },
            {
                "id": 1691,
                "question": "The definitive diagnosis and staging of $\text{HIV}$ infection should be followed by $\text{ART}$ initiation. What is the general principle regarding the timing of $\text{ART}$ initiation in all $\text{HIV}$ $\text{patients}$?",
                "choices": [
                    "A. $\text{Start}$ $\text{ART}$ $\text{only}$ $\text{if}$ $\text{CD4}$ $\text{count}$ $\text{is}$ $\text{below}$ $200 \text{ cells}/mu l$.",
                    "B. $\text{Start}$ $\text{ART}$ $\text{only}$ $\text{if}$ $\text{WHO}$ $\text{stage}$ $\text{is}$ $\text{III}$ $\text{or}$ $\text{IV}$.",
                    "C. **$\text{Initiate}$ $\text{ART}$ $\text{immediately}$, $\text{regardless}$ $\text{of}$ $\text{CD4}$ $\text{count}$**.",
                    "D. $\text{Wait}$ $\text{for}$ $\text{CD4}$ $\text{count}$ $\text{to}$ $\text{normalize}$ $\text{before}$ $\text{starting}$.",
                    "E. $\text{Wait}$ $\text{6}$ $\text{months}$ $\text{post}$-diagnosis $\text{to}$ $\text{ensure}$ $\text{adherence}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The **$\text{Treat}$ $\text{All}$** policy recommends **$\text{immediate}$ $\text{ART}$ $\text{initiation}$** regardless of $\text{CD4}$ $\text{count}$ or $\text{WHO}$ clinical stage. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_initiation",
                    "treat_all"
                ]
            },
            {
                "id": 1692,
                "question": "A patient with $\text{HIV}$ is due to start $\text{First}$-$\text{Line}$ $\text{ART}$. Which drug combination is generally considered the preferred $\text{First}$-$\text{Line}$ $\text{Regimen}$?",
                "choices": [
                    "A. $\text{Zidovudine}$ ($\text{AZT}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Efavirenz}$ ($\text{EFV}$).",
                    "B. $\text{Tenofovir}$ ($\text{TDF}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Lopinavir/Ritonavir}$ ($\text{LPV/r}$).",
                    "C. **$\text{Tenofovir}$ ($\text{TDF}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Dolutegravir}$ ($\text{DTG}$).**",
                    "D. $\text{Abacavir}$ ($\text{ABC}$), $\text{Didanosine}$ ($\text{ddI}$), $\text{and}$ $\text{Efavirenz}$ ($\text{EFV}$).",
                    "E. $\text{Nevirapine}$ ($\text{NVP}$) $\text{and}$ $\text{Zidovudine}$ ($\text{AZT}$) $\text{monotherapy}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The preferred $\text{First}$-$\text{Line}$ $\text{ART}$ $\text{Regimen}$ is **$\text{TDF}$ $\text{+} \text{ 3TC}$ $\text{+} \text{ DTG}$** ($\text{or}$ $\text{FTC}$ $\text{instead}$ $\text{of}$ $\text{3TC}$), replacing $\text{EFV}$ where possible, due to better tolerability and efficacy. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_regimen",
                    "first_line"
                ]
            },
            {
                "id": 1693,
                "question": "A patient with $\text{HIV}$ is due for a $\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{test}$ at $6$ months. What $\text{VL}$ value is generally considered successful virologic suppression?",
                "choices": [
                    "A. $\text{VL} <1,000 \text{ copies/ml}$.",
                    "B. $\text{VL} <500 \text{ copies/ml}$.",
                    "C. **$\text{VL} <50 \text{ copies/ml}$ ($\text{Undetectable}$) $\text{is}$ $\text{the}$ $\text{goal}$**.",
                    "D. $\text{VL}$ $\text{decrease}$ $\text{by}$ $50%$ $\text{from}$ $\text{baseline}$.",
                    "E. $\text{VL} <10,000 \text{ copies/ml}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The goal of $\text{ART}$ is to achieve **$\text{Undetectable}$ $\text{Viral}$ $\text{Load}$** ($\text{VL} <50 \text{ copies}/\text{ml}$). $\text{VL} <1000 \text{ copies}/\text{ml}$ is generally considered successful virologic suppression in resource-limited settings. However, **undetectable** is the ultimate goal. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_monitoring",
                    "virologic_suppression"
                ]
            },
            {
                "id": 1694,
                "question": "A patient on $\text{TDF/3TC/EFV}$ regimen has a sustained $\text{VL}$ of $5,000 \text{ copies}/\text{ml}$ at $12$ and $18$ months. What is the most appropriate step in management?",
                "choices": [
                    "A. $\text{Counseling}$ $\text{and}$ $\text{continue}$ $\text{First}$-$\text{Line}$.",
                    "B. $\text{Add}$ $\text{an}$ $\text{additional}$ $\text{drug}$ $\text{to}$ $\text{the}$ $\text{current}$ $\text{regimen}$.",
                    "C. **$\text{Switch}$ $\text{to}$ $\text{a}$ $\text{Second}$-$\text{Line}$ $\text{ART}$ $\text{regimen}$**.",
                    "D. $\text{Increase}$ $\text{the}$ $\text{dose}$ $\text{of}$ $\text{EFV}$.",
                    "E. $\text{Stop}$ $\text{ART}$ $\text{and}$ $\text{re}$-start $\text{after}$ $\text{a}$ $\text{drug}$ $\text{holiday}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**Virologic $\text{failure}$** is defined by a sustained $\text{VL} ge 1,000 \text{ copies}/\text{ml}$ despite adherence. After adherence counseling, the patient must be **$\text{switched}$ $\text{to}$ $\text{a}$ $\text{Second}$-$\text{Line}$ $\text{ART}$ $\text{regimen}$**. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_failure",
                    "management"
                ]
            },
            {
                "id": 1695,
                "question": "A patient is on $\text{ART}$. Which laboratory test is the **most effective** way to monitor the long-term efficacy of $\text{ART}$?",
                "choices": [
                    "A. $\text{Complete}$ $\text{Blood}$ $\text{Count}$ ($\text{CBC}$).",
                    "B. $\text{Liver}$ $\text{Function}$ $\text{Tests}$ ($\text{LFTs}$).",
                    "C. **$\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{measurement}$**.",
                    "D. $\text{CD4}$ $\text{count}$ $\text{monitoring}$.",
                    "E. $\text{Serum}$ $\text{Creatinine}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "While $\text{CD4}$ is an important measure of $\text{immune}$ $\text{restoration}$, the **$\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{measurement}$** is the **most $\text{effective}$** method to directly assess the efficacy of $\text{ART}$ in suppressing $\text{HIV}$ replication. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_monitoring",
                    "viral_load"
                ]
            },
            {
                "id": 1696,
                "question": "A patient with $\text{HIV}$ and a $\text{CD4}$ count of $150 \text{ cells}/mu l$ is diagnosed with presumptive $\text{PJP}$. What is the necessary prophylactic intervention that should have been started at this $\text{CD4}$ level?",
                "choices": [
                    "A. $\text{Isoniazid}$ $\text{Preventive}$ $\text{Therapy}$ ($\text{IPT}$).",
                    "B. $\text{Fluconazole}$ $\text{prophylaxis}$.",
                    "C. $\text{Acyclovir}$ $\text{prophylaxis}$.",
                    "D. **$\text{Co}$-$\text{trimoxazole}$ $\text{Preventive}$ $\text{Therapy}$ ($\text{CPT}$).**",
                    "E. $\text{Azithromycin}$ $\text{prophylaxis}$."
                ],
                "correctAnswer": 3,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**$\text{Co}$-$\text{trimoxazole}$ $\text{Preventive}$ $\text{Therapy}$ ($\text{CPT}$)** is initiated when the $\text{CD4}$ $\text{count}$ $\text{drops}$ $\text{below}$ $200 \text{ cells}/mu l$ to prevent $\text{PJP}$ and other bacterial infections. (p. 276)",
                "tags": [
                    "HIV",
                    "OIs_prophylaxis",
                    "CD4_threshold"
                ]
            },
            {
                "id": 1697,
                "question": "A patient is on $\text{First}$-$\text{Line}$ $\text{ART}$ ($\text{TDF/3TC/DTG}$). Which drug toxicity is a major concern when using $\text{Tenofovir}$ ($\text{TDF}$)?",
                "choices": [
                    "A. $\text{Hepatotoxicity}$.",
                    "B. $\text{Bone}$ $\text{marrow}$ $\text{suppression}$.",
                    "C. **$\text{Renal}$ $\text{toxicity}$ $\text{and}$ $\text{bone}$ $\text{demineralization}$.**",
                    "D. $\text{Peripheral}$ $\text{neuropathy}$.",
                    "E. $\text{Central}$ $\text{nervous}$ $\text{system}$ $\text{side}$ $\text{effects}$ ($\text{e.g}$., $\text{dreams}$)."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**$\text{Tenofovir}$ ($\text{TDF}$)** is associated with dose-related **$\text{renal}$ $\text{toxicity}$** ($\text{Fanconi}$ $\text{syndrome}$) $\text{and}$ $\text{a}$ $\text{decrease}$ $\text{in}$ $\text{Bone}$ $\text{Mineral}$ $\text{Density}$ ($\text{bone}$ $\text{demineralization}$). (p. 277)",
                "tags": [
                    "HIV",
                    "ART_toxicity",
                    "TDF"
                ]
            },
            {
                "id": 1698,
                "question": "A patient on $\text{ART}$ experiences $\text{severe}$ $\text{hyperpigmentation}$ $\text{of}$ $\text{the}$ $\text{palms}$ $\text{and}$ $\text{soles}$. Which $\text{NRTI}$ component of $\text{ART}$ is the most likely cause?",
                "choices": [
                    "A. $\text{Tenofovir}$ ($\text{TDF}$).",
                    "B. **$\text{Zidovudine}$ ($\text{AZT}$) $\text{or}$ $\text{AZT}$-containing $\text{regimens}$**.",
                    "C. $\text{Lamivudine}$ ($\text{3TC}$).",
                    "D. $\text{Abacavir}$ ($\text{ABC}$).",
                    "E. $\text{Efavirenz}$ ($\text{EFV}$)."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "A key side effect of **$\text{Zidovudine}$ ($\text{AZT}$)** is $\text{Bone}$ $\text{Marrow}$ $\text{Suppression}$ ($\text{anemia}$) $\text{and}$ **$\text{hyperpigmentation}$ $\text{of}$ $\text{nails}$ $\text{and}$ $\text{skin}$** ($\text{especially}$ $\text{palms}$ $\text{and}$ $\text{soles}$). (p. 277)",
                "tags": [
                    "HIV",
                    "ART_toxicity",
                    "AZT"
                ]
            },
            {
                "id": 1699,
                "question": "A patient with $\text{WHO}$ clinical stage $\text{IV}$ $\text{disease}$ is newly diagnosed with $\text{HIV}$. What is the recommended management regarding $\text{ART}$?",
                "choices": [
                    "A. $\text{Defer}$ $\text{ART}$ $\text{until}$ $\text{all}$ $\text{OIs}$ $\text{are}$ $\text{treated}$.",
                    "B. $\text{Defer}$ $\text{ART}$ $\text{until}$ $\text{VL}$ $\text{is}$ $\text{available}$.",
                    "C. **$\text{Initiate}$ $\text{ART}$ $\text{immediately}$ $\text{along}$ $\text{with}$ $\text{OI}$ $\text{treatment}$**.",
                    "D. $\text{Start}$ $\text{ART}$ $\text{with}$ $\text{monotherapy}$ $\text{to}$ $\text{reduce}$ $\text{side}$ $\text{effects}$.",
                    "E. $\text{Start}$ $\text{ART}$ $\text{only}$ $\text{if}$ $\text{CD4}$ $\text{is}$ $\text{below}$ $200 \text{ cells}/mu l$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The $\text{Treat}$ $\text{All}$ policy dictates **$\text{immediate}$ $\text{ART}$ $\text{initiation}$** regardless of $\text{CD4}$ $\text{count}$ or $\text{WHO}$ stage. In the presence of $\text{OIs}$, $\text{ART}$ is started along with $\text{OI}$ $\text{treatment}$. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_initiation",
                    "WHO_stage"
                ]
            },
            {
                "id": 1700,
                "question": "A patient on $\text{TDF/3TC/EFV}$ regimen has a sustained $\text{VL}$ of $5,000 \text{ copies}/\text{ml}$ at $12$ and $18$ months. What is the definition of this condition?",
                "choices": [
                    "A. $\text{Immunological}$ $\text{failure}$.",
                    "B. **$\text{Virologic}$ $\text{failure}$**.",
                    "C. $\text{Clinical}$ $\text{failure}$.",
                    "D. $\text{Treatment}$ $\text{success}$.",
                    "E. $\text{Drug}$ $\text{resistance}$ $\text{only}$."
                ],
                "correctAnswer": 1,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**$\text{Virologic}$ $\text{failure}$** is defined by a sustained $\text{VL} ge 1,000 \text{ copies}/\text{ml}$ despite adherence to $\text{ART}$. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_failure",
                    "definition"
                ]
            },
            {
                "id": 1701,
                "question": "The definitive diagnosis and staging of $\text{HIV}$ infection should be followed by $\text{ART}$ initiation. What is the general principle regarding the timing of $\text{ART}$ initiation in all $\text{HIV}$ $\text{patients}$?",
                "choices": [
                    "A. $\text{Start}$ $\text{ART}$ $\text{only}$ $\text{if}$ $\text{CD4}$ $\text{count}$ $\text{is}$ $\text{below}$ $200 \text{ cells}/mu l$.",
                    "B. $\text{Start}$ $\text{ART}$ $\text{only}$ $\text{if}$ $\text{WHO}$ $\text{stage}$ $\text{is}$ $\text{III}$ $\text{or}$ $\text{IV}$.",
                    "C. **$\text{Initiate}$ $\text{ART}$ $\text{immediately}$, $\text{regardless}$ $\text{of}$ $\text{CD4}$ $\text{count}$**.",
                    "D. $\text{Wait}$ $\text{for}$ $\text{CD4}$ $\text{count}$ $\text{to}$ $\text{normalize}$ $\text{before}$ $\text{starting}$.",
                    "E. $\text{Wait}$ $\text{6}$ $\text{months}$ $\text{post}$-diagnosis $\text{to}$ $\text{ensure}$ $\text{adherence}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The **$\text{Treat}$ $\text{All}$** policy recommends **$\text{immediate}$ $\text{ART}$ $\text{initiation}$** regardless of $\text{CD4}$ $\text{count}$ or $\text{WHO}$ clinical stage. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_initiation",
                    "treat_all"
                ]
            },
            {
                "id": 1702,
                "question": "A patient with $\text{HIV}$ is due to start $\text{First}$-$\text{Line}$ $\text{ART}$. Which drug combination is generally considered the preferred $\text{First}$-$\text{Line}$ $\text{Regimen}$?",
                "choices": [
                    "A. $\text{Zidovudine}$ ($\text{AZT}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Efavirenz}$ ($\text{EFV}$).",
                    "B. $\text{Tenofovir}$ ($\text{TDF}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Lopinavir/Ritonavir}$ ($\text{LPV/r}$).",
                    "C. **$\text{Tenofovir}$ ($\text{TDF}$), $\text{Lamivudine}$ ($\text{3TC}$), $\text{and}$ $\text{Dolutegravir}$ ($\text{DTG}$).**",
                    "D. $\text{Abacavir}$ ($\text{ABC}$), $\text{Didanosine}$ ($\text{ddI}$), $\text{and}$ $\text{Efavirenz}$ ($\text{EFV}$).",
                    "E. $\text{Nevirapine}$ ($\text{NVP}$) $\text{and}$ $\text{Zidovudine}$ ($\text{AZT}$) $\text{monotherapy}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The preferred $\text{First}$-$\text{Line}$ $\text{ART}$ $\text{Regimen}$ is **$\text{TDF}$ $\text{+} \text{ 3TC}$ $\text{+} \text{ DTG}$** ($\text{or}$ $\text{FTC}$ $\text{instead}$ $\text{of}$ $\text{3TC}$), replacing $\text{EFV}$ where possible, due to better tolerability and efficacy. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_regimen",
                    "first_line"
                ]
            },
            {
                "id": 1703,
                "question": "A patient with $\text{HIV}$ is due for a $\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{test}$ at $6$ months. What $\text{VL}$ value is generally considered successful virologic suppression?",
                "choices": [
                    "A. $\text{VL} <1,000 \text{ copies/ml}$.",
                    "B. $\text{VL} <500 \text{ copies/ml}$.",
                    "C. **$\text{VL} <50 \text{ copies/ml}$ ($\text{Undetectable}$) $\text{is}$ $\text{the}$ $\text{goal}$**.",
                    "D. $\text{VL}$ $\text{decrease}$ $\text{by}$ $50%$ $\text{from}$ $\text{baseline}$.",
                    "E. $\text{VL} <10,000 \text{ copies/ml}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "The goal of $\text{ART}$ is to achieve **$\text{Undetectable}$ $\text{Viral}$ $\text{Load}$** ($\text{VL} <50 \text{ copies}/\text{ml}$). $\text{VL} <1000 \text{ copies}/\text{ml}$ is generally considered successful virologic suppression in resource-limited settings. However, **undetectable** is the ultimate goal. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_monitoring",
                    "virologic_suppression"
                ]
            },
            {
                "id": 1704,
                "question": "A patient on $\text{TDF/3TC/EFV}$ regimen has a sustained $\text{VL}$ of $5,000 \text{ copies}/\text{ml}$ at $12$ and $18$ months. What is the most appropriate step in management?",
                "choices": [
                    "A. $\text{Counseling}$ $\text{and}$ $\text{continue}$ $\text{First}$-$\text{Line}$.",
                    "B. $\text{Add}$ $\text{an}$ $\text{additional}$ $\text{drug}$ $\text{to}$ $\text{the}$ $\text{current}$ $\text{regimen}$.",
                    "C. **$\text{Switch}$ $\text{to}$ $\text{a}$ $\text{Second}$-$\text{Line}$ $\text{ART}$ $\text{regimen}$**.",
                    "D. $\text{Increase}$ $\text{the}$ $\text{dose}$ $\text{of}$ $\text{EFV}$.",
                    "E. $\text{Stop}$ $\text{ART}$ $\text{and}$ $\text{re}$-start $\text{after}$ $\text{a}$ $\text{drug}$ $\text{holiday}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "**Virologic $\text{failure}$** is defined by a sustained $\text{VL} ge 1,000 \text{ copies}/\text{ml}$ despite adherence. After adherence counseling, the patient must be **$\text{switched}$ $\text{to}$ $\text{a}$ $\text{Second}$-$\text{Line}$ $\text{ART}$ $\text{regimen}$**. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_failure",
                    "management"
                ]
            },
            {
                "id": 1705,
                "question": "A patient is on $\text{ART}$. Which laboratory test is the **most effective** way to monitor the long-term efficacy of $\text{ART}$?",
                "choices": [
                    "A. $\text{Complete}$ $\text{Blood}$ $\text{Count}$ ($\text{CBC}$).",
                    "B. $\text{Liver}$ $\text{Function}$ $\text{Tests}$ ($\text{LFTs}$).",
                    "C. **$\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{measurement}$**.",
                    "D. $\text{CD4}$ $\text{count}$ $\text{monitoring}$.",
                    "E. $\text{Serum}$ $\text{Creatinine}$."
                ],
                "correctAnswer": 2,
                "topic": "Chapter 8.3 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",
                "explanation": "While $\text{CD4}$ is an important measure of $\text{immune}$ $\text{restoration}$, the **$\text{Viral}$ $\text{Load}$ ($\text{VL}$) $\text{measurement}$** is the **most $\text{effective}$** method to directly assess the efficacy of $\text{ART}$ in suppressing $\text{HIV}$ replication. (p. 276)",
                "tags": [
                    "HIV",
                    "ART_monitoring",
                    "viral_load"
                ]
            }
        ]
    }
}
    };
})();